PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	DONDERO, TJ; HU, DJ; GEORGE, JR				DONDERO, TJ; HU, DJ; GEORGE, JR			HIV-1 VARIANTS - YET ANOTHER CHALLENGE TO PUBLIC-HEALTH	LANCET			English	Editorial Material											DONDERO, TJ (corresponding author), CTR DIS CONTROL & PREVENT,CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30341, USA.							DELEYS R, 1990, J VIROL, V64, P1207, DOI 10.1128/JVI.64.3.1207-1216.1990; GURTLER LG, 1994, J VIROL, V68, P1581; NKENGASONG JN, 1993, AIDS, V7, P1536, DOI 10.1097/00002030-199311000-00026; SIMON F, IN PRESS REV FR LAB; VANDENHAESEVELDE M, 1994, J VIROL, V68, P1586, DOI 10.1128/JVI.68.3.1586-1596.1994	5	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1376	1376		10.1016/S0140-6736(94)92517-8	http://dx.doi.org/10.1016/S0140-6736(94)92517-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NP955	7910877				2022-12-28	WOS:A1994NP95500003
J	POKHREL, RP; KHATRY, SK; WEST, KP; SHRESTHA, SR; KATZ, J; PRADHAN, EK; LECLERQ, SC; SOMMER, A				POKHREL, RP; KHATRY, SK; WEST, KP; SHRESTHA, SR; KATZ, J; PRADHAN, EK; LECLERQ, SC; SOMMER, A			SUSTAINED REDUCTION IN CHILD-MORTALITY WITH VITAMIN-A IN NEPAL	LANCET			English	Letter									JOHNS HOPKINS UNIV,SCH MED,DANA CTR PREVENT OPHTHALMOL,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH PUBL HLTH,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins University	POKHREL, RP (corresponding author), NEPAL NETRA JYOTI SANGH,KATMANDU,NEPAL.			Katz, Joanne/0000-0002-5997-7823	NCRR NIH HHS [RR04060] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004060] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BEATON GH, 1993, ACC SCN STATE ART SE, V13; PRADHAN EK, IN PRESS CONTROL CLI; WEST KP, 1991, LANCET, V338, P67, DOI 10.1016/0140-6736(91)90070-6	3	10	10	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1368	1369		10.1016/S0140-6736(94)92508-9	http://dx.doi.org/10.1016/S0140-6736(94)92508-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910361				2022-12-28	WOS:A1994NN21700059
J	LOPEZMIRANDA, J; ORDOVAS, JM; ESPINO, A; MARIN, C; SALAS, J; LOPEZSEGURA, F; JIMENEZPEREPEREZ, J; PEREZJIMENEZ, F				LOPEZMIRANDA, J; ORDOVAS, JM; ESPINO, A; MARIN, C; SALAS, J; LOPEZSEGURA, F; JIMENEZPEREPEREZ, J; PEREZJIMENEZ, F			INFLUENCE OF MUTATION IN HUMAN APOLIPOPROTEIN A-1 GENE PROMOTER ON PLASMA LDL CHOLESTEROL RESPONSE TO DIETARY-FAT	LANCET			English	Article							A-I GENE; POLYMORPHISM; REGION; CIII; TRANSCRIPTION; INTERVENTION; ASSOCIATION; CLUSTER; SITES	The plasma lipid response to changes in dietary fat and cholesterol can vary between individuals. At present, responders cannot be identified in advance. An adenine to guanine (A-->G) mutation in the promoter of the apolipoprotein A1 gene (apoA-1) has been suggested as affecting plasma high-density lipoprotein cholesterol. In 50 young men we examined the effect of the same mutation on the responses of both high and low density lipoprotein cholesterol to low-fat diet. The frequency for the A allele was 0.14. Subjects were fed a low-fat diet for 25 days, followed by a diet rich in monounsaturated fatty acid (MUFA, 22% out of 40% fat) for 28 days and lipoproteins were measured at the end of each diet. There were no differences in initial total cholesterol between subjects with the G/G mutation (170 mg/dL: 100 mg/dL= 2.59 mmol/L)) and the G/A mutation (169 mg/dL) genotypes. After consumption of the high monounsaturated fat diet, significant increases were noted in plasma LDL cholesterol (10 mg/dL, p=0.035) in the G/A subjects but not in the G/G subjects (1 mg/dL, p=0.996). These differences showed that a significant diet-gene interaction (p=0.015) existed. No differences were observed on HDL cholesterol between groups. Plasma low-density lipoprotein cholesterol responsiveness to diet may be explained by variation at the apoA-1 gene locus.	TUFTS UNIV,USDA,HUMAN NUTR RES CTR AGING,LIPID METAB LAB,BOSTON,MA 02111; HOSP UNIV REINA SOFIA,CORDOBA,SPAIN	Tufts University; United States Department of Agriculture (USDA); Hospital Universitario Reina Sofia - Cordoba			Jimenez, Francisco Perez/AAJ-9559-2021; Marin Hinojosa, Carmen/AFO-1294-2022; Lopez-Miranda, Jose/Y-8306-2019; Ordovas, Jose/B-8727-2013	Marin Hinojosa, Carmen/0000-0003-2884-4806; Lopez-Miranda, Jose/0000-0002-8844-0718; Perez Jimenez, Francisco/0000-0001-9808-1280; Salas-Coronas, Joaquin/0000-0002-4302-7022; Perez-Jimenez, Francisco/0000-0001-7499-7681; Ordovas, Jose/0000-0002-7581-5680				BLANGERO J, 1990, AM J HUM GENET, V47, P414; CLARKSON TB, 1980, CHILDHOOD PREVENTION, P127; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281; JACOBS DR, 1983, ARTERIOSCLEROSIS, V3, P349, DOI 10.1161/01.ATV.3.4.349; JEENAH M, 1990, MOL BIOL MED, V7, P233; KARATHANASIS SK, 1985, P NATL ACAD SCI USA, V82, P6374, DOI 10.1073/pnas.82.19.6374; KEYS A, 1957, LANCET, V2, P959; MANTTARI M, 1991, METABOLISM, V40, P217, DOI 10.1016/0026-0495(91)90179-Z; MCCALL MR, 1994, ARTERIOSCLER THROMB, V14, P248, DOI 10.1161/01.ATV.14.2.248; PAGANI F, 1990, J LIPID RES, V31, P1371; PAGANI F, 1992, EUR J EPIDEMIOL, V8, P54, DOI 10.1007/BF00145350; PAN XM, 1993, J VASC SURG, V18, P161, DOI 10.1016/0741-5214(93)90595-D; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; PAULHAYASE H, 1992, HUM GENET, V88, P439, DOI 10.1007/BF00215679; REICHL D, 1989, ARTERIOSCLEROSIS, V9, P785, DOI 10.1161/01.ATV.9.6.785; SIGURDSSON G, 1992, ARTERIOSCLER THROMB, V12, P1017, DOI 10.1161/01.ATV.12.9.1017; SMITH JD, 1992, J CLIN INVEST, V89, P1796, DOI 10.1172/JCI115783; TIKKANEN MJ, 1990, CLIN GENET, V37, P327, DOI 10.1111/j.1399-0004.1990.tb03514.x; TUTEJA R, 1992, FEBS LETT, V304, P98, DOI 10.1016/0014-5793(92)80597-A; TYBJAERGHANSEN A, 1993, ATHEROSCLEROSIS, V100, P157, DOI 10.1016/0021-9150(93)90202-6; VONECKARDSTEIN A, 1992, AM J HUM GENET, V50, P1115; WOJCIECHOWSKI AP, 1991, NATURE, V349, P161, DOI 10.1038/349161a0; XU CF, 1990, GENET EPIDEMIOL, V7, P261, DOI 10.1002/gepi.1370070405; 1993, JAMA-J AM MED ASSOC, V269, P3015	25	76	77	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1246	1249		10.1016/S0140-6736(94)92149-0	http://dx.doi.org/10.1016/S0140-6736(94)92149-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910273				2022-12-28	WOS:A1994NM14400007
J	MICHIE, C; HARVEY, D				MICHIE, C; HARVEY, D			CAN EXPRESSION OF CD45RO, A T-CELL SURFACE-MOLECULE, BE USED TO DETECT CONGENITAL INFECTION	LANCET			English	Note							LYMPHOCYTES; ANTIGEN	Exclusion or confirmation of congenital infection can be difficult in newborn infants. The presence of an infective organism in a fetus leads to activation of fetal T lymphocytes. We have examined expression of isoforms of a T-cell surface molecule, CD45RO, in 119 infants, 8 of whom had an intrauterine infection diagnosed antenatally. CD45RO was expressed on fewer than 10% of T cells in control infants and on more than 17% of T cells from infants with known infection (p<0.006). This method allows screening of infants for infection by a range of organisms as a cause of their infection.			MICHIE, C (corresponding author), ROYAL POSTGRAD MED SCH,DEPT PAEDIAT & NEONATAL MED,LONDON W12 0NN,ENGLAND.							AKBAR AN, 1988, J IMMUNOL, V140, P2171; ERBER WN, 1984, LANCET, V1, P1042; ERKELLERYUKSEL FM, 1992, J PEDIATR-US, V120, P216, DOI 10.1016/S0022-3476(05)80430-5; FROEBEL KS, 1991, AIDS, V5, P97, DOI 10.1097/00002030-199101000-00015; MICHIE CA, 1992, PEDIATR INFECT DIS J, V11, P1050, DOI 10.1097/00006454-199211120-00012; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; PARKER DJ, 1988, J IMMUNOL METHODS, V110, P37, DOI 10.1016/0022-1759(88)90080-4; RUDD P, 1988, CLIN OBSTET GYNAECOL, V2, P55; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; UEHARA T, 1992, BLOOD, V80, P452	10	31	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1259	1260		10.1016/S0140-6736(94)92153-9	http://dx.doi.org/10.1016/S0140-6736(94)92153-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910277				2022-12-28	WOS:A1994NM14400011
J	MUSS, HB; THOR, AD; BERRY, DA; KUTE, T; LIU, ET; KOERNER, F; CIRRINCIONE, CT; BUDMAN, DR; WOOD, WC; BARCOS, M; HENDERSON, IC				MUSS, HB; THOR, AD; BERRY, DA; KUTE, T; LIU, ET; KOERNER, F; CIRRINCIONE, CT; BUDMAN, DR; WOOD, WC; BARCOS, M; HENDERSON, IC			C-ERBB-2 EXPRESSION AND RESPONSE TO ADJUVANT THERAPY IN WOMEN WITH NODE-POSITIVE EARLY BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REQUIRING PROLONGED OBSERVATION; THYMIDINE LABELING INDEX; DNA FLOW-CYTOMETRY; PROGNOSTIC-SIGNIFICANCE; PROLIFERATIVE ACTIVITY; CELL-PROLIFERATION; BOWEL PROJECT; PROTEIN; P53; OVEREXPRESSION	Background. The role of molecular markers in predicting the response to treatment of breast cancer is poorly defined. The Cancer and Leukemia Group B (CALGB) conducted a randomized adjuvant-chemotherapy trial (CALGB 8541) comparing three doses (high, moderate, and low) of cyclophosphamide, doxorubicin, and fluorouracil in 1572 women with node-positive breast cancer. This study (CALGB 8869) was designed to determine whether the DNA index, the S-phase fraction, c-erbB-2 expression, or p53 accumulation could be used as a marker to identify a subgroup of patients more likely than others to benefit from high doses of chemotherapy. Methods. Tissue blocks were obtained from 442 patients randomly selected from the larger CALGB trial. Paraffin sections from the primary lesions were analyzed for DNA content, S-phase fraction, c-erbB-2 expression, and p53 accumulation. Results. Patients randomly assigned to the high-dose regimen of adjuvant chemotherapy had significantly longer disease-free and overall survival if their tumors had c-erbB-2 overexpression. No further information was gained by adding the data on S-phase fraction or p53 accumulation to the analysis. There was no clear evidence of a dose-response effect in patients with minimal or no c-erbB-2 expression. Conclusions. There is a significant dose-response effect of adjuvant chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil in patients with overexpression of c-erbB-2 but not in patients with no c-erbB-2 expression or minimal c-erbB-2 expression. Overexpression of c-erbB-2 may be a useful marker to identify the patients who are most likely to benefit from high doses of adjuvant chemotherapy.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,WINSTON SALEM,NC; MASSACHUSETTS GEN HOSP,BOSTON,MA 02114; CANC & LEUKEMIA GRP B,STAT OFF,DURHAM,NC; UNIV N CAROLINA,SCH MED,DEPT MED,CHAPEL HILL,NC; N SHORE UNIV HOSP,NEW YORK HOSP,NEW YORK,NY; EMORY UNIV,ATLANTA,GA 30322; ROSWELL PK MEM INST,DEPT MED,BUFFALO,NY; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143	Wake Forest University; Wake Forest Baptist Medical Center; Harvard University; Massachusetts General Hospital; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; NewYork-Presbyterian Hospital; Northwell Health; North Shore University Hospital; Emory University; Roswell Park Cancer Institute; University of California System; University of California San Francisco			Liu, Edison/C-4141-2008		NATIONAL CANCER INSTITUTE [U10CA031946, U10CA003927, P01CA044768] Funding Source: NIH RePORTER; NCI NIH HHS [CA-44768, CA-31946, CA-03927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLRED DC, 1992, J CLIN ONCOL, V10, P599, DOI 10.1200/JCO.1992.10.4.599; ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200; BAISCH H, 1975, RADIAT ENVIRON BIOPH, V12, P31, DOI 10.1007/BF02339807; BARNES DM, 1991, BREAST CANCER RES TR, V18, P11, DOI 10.1007/BF01975438; BLACK MM, 1955, SURG GYNECOL OBSTET, V100, P543; CALLAHAN R, 1992, CANCER, V69, P1582, DOI 10.1002/1097-0142(19920315)69:6+<1582::AID-CNCR2820691313>3.0.CO;2-Y; CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; CLARK GM, 1989, NEW ENGL J MED, V320, P627, DOI 10.1056/NEJM198903093201003; COX DR, 1972, J R STAT SOC B, V34, P187; DEPPERT W, 1990, ONCOGENE, V5, P1701; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; EDDY DM, 1992, J CLIN ONCOL, V10, P657, DOI 10.1200/JCO.1992.10.4.657; EDDY DM, 1992, J CLIN ONCOL, V10, P1655; FISHER B, 1986, J CLIN ONCOL, V4, P929, DOI 10.1200/JCO.1986.4.6.929; FISHER ER, 1983, CANCER-AM CANCER SOC, V51, P181, DOI 10.1002/1097-0142(19830115)51:2<181::AID-CNCR2820510202>3.0.CO;2-A; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HARRIS AL, 1992, MONOGR NATL CANC I, V11, P181; HEDLEY DW, 1985, CYTOMETRY, V6, P327, DOI 10.1002/cyto.990060409; HEDLEY DW, 1983, J HISTOCHEM CYTOCHEM, V31, P1333, DOI 10.1177/31.11.6619538; HENSON DE, 1991, CANCER-AM CANCER SOC, V68, P2142, DOI 10.1002/1097-0142(19911115)68:10<2142::AID-CNCR2820681010>3.0.CO;2-D; ISOLA J, 1992, J NATL CANCER I, V84, P1109, DOI 10.1093/jnci/84.14.1109; KALLIONIEMI OP, 1991, INT J CANCER, V49, P650, DOI 10.1002/ijc.2910490504; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUTE TE, 1988, CYTOMETRY, V9, P494, DOI 10.1002/cyto.990090515; LIU E, 1992, ONCOGENE, V7, P1027; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MCGUIRE WL, 1992, NEW ENGL J MED, V326, P1756; MONTENARH M, 1992, Critical Reviews in Oncogenesis, V3, P233; MUSS HB, 1989, HIGH RISK BREAST CAN, P103; OREILLY SM, 1991, BRIT J CANCER, V63, P444, DOI 10.1038/bjc.1991.102; OREILLY SM, 1990, EUR J CANCER, V26, P1035, DOI 10.1016/0277-5379(90)90045-U; OREILLY SM, 1992, EUR J CANCER, V28A, P681, DOI 10.1016/S0959-8049(05)80124-8; Osborne CK, 1991, BREAST DIS, P301; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; REMVIKOS Y, 1989, J NATL CANCER I, V81, P1383, DOI 10.1093/jnci/81.18.1383; SALMON DJ, 1987, SCIENCE, V235, P177; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SMITH K, 1993, ONCOGENE, V8, P933; SULKES A, 1979, J NATL CANCER I, V62, P513, DOI 10.1093/jnci/62.3.513; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; TOIKKANEN S, 1992, J CLIN ONCOL, V10, P1044, DOI 10.1200/JCO.1992.10.7.1044; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; WOOD WC, 1994, NEW ENGL J MED, V330, P1253, DOI 10.1056/NEJM199405053301801; ZAMBETTI M, 1992, MONOGR NCI, V11, P77; Zar JH, 1974, BIOSTATISTICAL ANAL; 1978, CANCER, V42, P2809; 1992, LANCET, V339, P71	51	884	909	2	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 5	1994	330	18					1260	1266		10.1056/NEJM199405053301802	http://dx.doi.org/10.1056/NEJM199405053301802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ512	7908410	Bronze			2022-12-28	WOS:A1994NJ51200002
J	EDGREN, E; HEDSTRAND, U; KELSEY, S; SUTTONTYRRELL, K; SAFAR, P; DETRE, KM; MONROE, J; REINMUTH, O; SYNDER, JV; ABRAMSON, NS				EDGREN, E; HEDSTRAND, U; KELSEY, S; SUTTONTYRRELL, K; SAFAR, P; DETRE, KM; MONROE, J; REINMUTH, O; SYNDER, JV; ABRAMSON, NS			ASSESSMENT OF NEUROLOGICAL PROGNOSIS IN COMATOSE SURVIVORS OF CARDIAC-ARREST	LANCET			English	Article							HOPELESSLY ILL PATIENTS; PHYSICIANS RESPONSIBILITY; PREDICTIVE VALUE; SCALE	When a patient resuscitated from cardiac arrest remains unconscious the clinician would like to have a reliable early method for predicting the outcome. The objective of our study was predict cerebral outcome after cardiac arrest by clinical neurological examination. The data were drawn from an international multicentre controlled clinical trial of thiopentone. Twelve hospitals in nine countries took part. 262 comatose cardiac arrest survivors were followed up for one year. These patients were given advanced life support (American Heart Association guidelines) followed by intensive care to a standardised protocol. Glasgow and Glasgow-Pittsburgh coma scores and their constituent signs were recorded at fixed times. Outcome was taken to be the best cerebral performance at any time during follow-up, and for that purpose we used cerebral performance categories (CPC 1-5) of the Glasgow outcome categories. A poor outcome (CPC 3-5) could be predicted immediately after reperfusion (at entry into the study) with an accuracy ranging from 52% to 84% for various signs and scores. On the third day it was possible to identify severely disabled or permanently comatose survivors without false predictions using both coma scores and several of their constituent variables. The best predictor was absence of motor response to pain. This modelling exercise now needs to be repeated on a new series of patients but the results do suggest that, after 3 days, stringent ethical criteria can be met and used in decision-making about termination of care in comatose cardiac arrest survivors.	UNIV PITTSBURGH,INT RESUSCITAT RES CTR,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	EDGREN, E (corresponding author), UNIV UPPSALA HOSP,DEPT ANAESTHESIOL & INTENS CARE,S-75285 UPPSALA,SWEDEN.				NINDS NIH HHS [NS 15295-01-4] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015295] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON NS, 1991, ACTA ANAESTH SCAND, V35, P54; ANDREWS K, 1993, BRIT MED J, V306, P1597, DOI 10.1136/bmj.306.6892.1597; EARNEST MP, 1979, NEUROLOGY, V29, P56, DOI 10.1212/WNL.29.1.56; Edgren E, 1988, Acta Anaesthesiol Belg, V39, P121; EDGREN E, 1989, ACTA ANAESTH SCAND, V33, P265, DOI 10.1111/j.1399-6576.1989.tb02905.x; EDGREN E, 1987, CRIT CARE MED, V15, P820, DOI 10.1097/00003246-198709000-00004; EDGREN E, 1987, ACTA U UPSAL, V89, P1; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; GRENVIK A, 1978, CRIT CARE MED, V6, P284, DOI 10.1097/00003246-197807000-00009; HART RG, 1985, JAMA-J AM MED ASSOC, V254, P1171, DOI 10.1001/jama.1985.03360090061007; JENNETT B, 1975, LANCET, V1, P480; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; LEVY DE, 1985, JAMA-J AM MED ASSOC, V254, P1171, DOI 10.1001/jama.1985.03360090061008; LEVY DE, 1981, ANN INTERN MED, V94, P294; LONGSTRETH WT, 1983, NEW ENGL J MED, V308, P1378, DOI 10.1056/NEJM198306093082302; MULLIE A, 1988, LANCET, V1, P137; NISKANEN M, 1991, CRIT CARE MED, V19, P1465, DOI 10.1097/00003246-199112000-00005; SAFA P, 1988, CARDIOPULMONARY CERE; SHEWMON DA, 1989, NEUROL CLIN, V7, P823, DOI 10.1016/S0733-8619(18)30392-X; TEASDALE G, 1983, LANCET, V2, P678; TEASDALE G, 1974, LANCET, V2, P81; WANZER SH, 1984, NEW ENGL J MED, V310, P955, DOI 10.1056/NEJM198404123101505; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; 1991, CONTR CLIN TRIALS, V12, P525; 1991, NEW ENGL J MED, V324, P1225; 1986, AM J EMERG MED, V4, P72; 1986, NEW ENGL J MED, V314, P397	27	336	342	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 30	1994	343	8905					1055	1059		10.1016/S0140-6736(94)90179-1	http://dx.doi.org/10.1016/S0140-6736(94)90179-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ694	7909098				2022-12-28	WOS:A1994NJ69400007
J	JORGENSEN, JOL; CHRISTIANSEN, JS; ORSKOV, H				JORGENSEN, JOL; CHRISTIANSEN, JS; ORSKOV, H			DEFINING GROWTH-HORMONE DEFICIENCY IN ADULTS - A MATTER OF SPECIFICITY	LANCET			English	Editorial Material							GH				JORGENSEN, JOL (corresponding author), AARHUS KOMMUNE HOSP,DEPT INTERNAL MED ENDORCRINOL & DIABETE,AARHUS,DENMARK.							GOODMAN HG, 1968, NEW ENGL J MED, V278, P57, DOI 10.1056/NEJM196801112780201; IRANMANESH A, 1991, J CLIN ENDOCR METAB, V73, P1081, DOI 10.1210/jcem-73-5-1081; JORGENSEN JOL, 1989, LANCET, V1, P1221; ROSE SR, 1988, NEW ENGL J MED, V319, P201, DOI 10.1056/NEJM198807283190403; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605	5	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 30	1994	343	8905					1050	1051						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ694	7909093				2022-12-28	WOS:A1994NJ69400002
J	KUMAR, S; DURRINGTON, PN; BHATNAGAR, D; LAING, I				KUMAR, S; DURRINGTON, PN; BHATNAGAR, D; LAING, I			SUPPRESSION OF NONESTERIFIED FATTY-ACIDS TO TREAT TYPE-A INSULIN-RESISTANCE SYNDROME	LANCET			English	Note							DIABETES-MELLITUS; GLUCOSE	A patient with type A insulin-resistance syndrome resistance presented with severe hypertriglyceridaemia and diabetes. Fasting insulin and non-esterified fatty acids (NEFA) were very high (41 mU/L and 3.3 mmol/L). A low-fat diet failed to correct hyperlipidaemia and diabetes. Sustained suppression of NEFA with slow-release acipimox for 8 weeks resulted in substantial reduction of serum fasting NEFA (0.31 mmol/L). Glucose tolerance became normal and insulin sensitivity increased from 7% to 32%. The glucose fatty-acid cycle may operate in patients with severe insulin resistance and hyperlipidaemia: high serum NEFA aggravates insulin resistance and hyperglycaemia by inhibiting glucose uptake and utilisation.	UNIV MANCHESTER, DEPT MED, MANCHESTER, ENGLAND; UNIV MANCHESTER, MANCHESTER ROYAL INFIRM, DEPT CLIN BIOCHEM, MANCHESTER M13 9WL, LANCS, ENGLAND	University of Manchester; University of Manchester			kumar, sudhesh/D-6945-2013	kumar, sudhesh/0000-0003-4326-5941				DEAN JD, 1992, DIABETIC MED, V9, P611, DOI 10.1111/j.1464-5491.1992.tb01855.x; DURRINGTON PN, 1989, HYPERLIPIDAEMIA DIAG, P219; FLIER JS, 1993, J CLIN ENDOCR METAB, V76, P1533, DOI 10.1210/jc.76.6.1533; FULCHER GR, 1992, DIABETIC MED, V9, P908, DOI 10.1111/j.1464-5491.1992.tb01730.x; GROOP LC, 1989, J CLIN INVEST, V84, P205, DOI 10.1172/JCI114142; HOSKER JP, 1985, DIABETOLOGIA, V28, P401, DOI 10.1007/BF00280882; KAHN CR, 1976, NEW ENGL J MED, V294, P739, DOI 10.1056/NEJM197604012941401; RANDLE PJ, 1963, LANCET, V1, P785; SALORANTA C, 1993, DIABETIC MED, V10, P950, DOI 10.1111/j.1464-5491.1993.tb00011.x; 1991, DRUG THER B, V29, P57	10	23	23	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 30	1994	343	8905					1073	1074		10.1016/S0140-6736(94)90184-8	http://dx.doi.org/10.1016/S0140-6736(94)90184-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ694	7909102				2022-12-28	WOS:A1994NJ69400012
J	FRERICHS, RR				FRERICHS, RR			PERSONAL SCREENING FOR HIV IN DEVELOPING-COUNTRIES	LANCET			English	Editorial Material											FRERICHS, RR (corresponding author), UNIV CALIF LOS ANGELES,DEPT EPIDEMIOL,LOS ANGELES,CA 90024, USA.							BAMBER SD, 1993, GENITOURIN MED, V69, P148; COHEN J, 1993, SCIENCE, V260, P1254, DOI 10.1126/science.8493564; FRERICHS RR, 1992, LANCET, V340, P1496, DOI 10.1016/0140-6736(92)92755-5; FRERICHS RR, 1993, NEW ENGL J MED, V328, P1717, DOI 10.1056/NEJM199306103282318; FRERICHS RR, 1994, J ACQ IMMUN DEF SYND, V7, P552; KALLINGS LO, 1993, VACCINE, V11, P525, DOI 10.1016/0264-410X(93)90223-K; MASTRO TD, 1994, LANCET, V343, P204, DOI 10.1016/S0140-6736(94)90990-3; NELSON KE, 1993, JAMA-J AM MED ASSOC, V270, P955, DOI 10.1001/jama.270.8.955; NOPKESORN T, 1993, AIDS, V7, P1233, DOI 10.1097/00002030-199309000-00013; TAMASHIRO H, 1993, LANCET, V342, P87, DOI 10.1016/0140-6736(93)91289-X; TAMASHIRO H, IN PRESS B WHO; TRUSSELL J, 1992, FAM PLANN PERSPECT, V24, P20, DOI 10.2307/2135721; WELLER SC, 1993, SOC SCI MED, V36, P1635, DOI 10.1016/0277-9536(93)90352-5; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011	14	21	21	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					960	962		10.1016/S0140-6736(94)90072-8	http://dx.doi.org/10.1016/S0140-6736(94)90072-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909015				2022-12-28	WOS:A1994NF70000016
J	ROSENSTEIN, BJ				ROSENSTEIN, BJ			GENOTYPE-PHENOTYPE CORRELATIONS IN CYSTIC-FIBROSIS	LANCET			English	Editorial Material							DELTA-F508; ASSOCIATION; MUTATIONS; DELETION; DISEASE				ROSENSTEIN, BJ (corresponding author), JOHNS HOPKINS UNIV HOSP,CTR SYST FIBROSIS,BALTIMORE,MD 21205, USA.							CAMPBELL PW, 1991, J PEDIATR-US, V118, P239, DOI 10.1016/S0022-3476(05)80490-1; CURTIS A, 1991, J MED GENET, V28, P34, DOI 10.1136/jmg.28.1.34; DEARCE M, 1992, CLIN GENET, V42, P271; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KEREM E, 1989, J PEDIATR-US, V114, P767, DOI 10.1016/S0022-3476(89)80134-9; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; KUBESCH P, 1993, LANCET, V341, P189, DOI 10.1016/0140-6736(93)90062-L; LESTER LA, 1994, PEDIATRICS, V93, P114; LIECHTIGALLATI S, 1992, PEDIATR RES, V32, P175, DOI 10.1203/00006450-199208000-00010; SANTIS G, 1990, LANCET, V335, P1426, DOI 10.1016/0140-6736(90)91448-J; SANTIS G, 1990, LANCET, V336, P1081, DOI 10.1016/0140-6736(90)92566-Z; TSIU LC, 1992, TRENDS GENET, V8, P392; 1993, NEW ENGL J MED, V329, P1308	13	19	19	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 26	1994	343	8900					746	747		10.1016/S0140-6736(94)91832-5	http://dx.doi.org/10.1016/S0140-6736(94)91832-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907726				2022-12-28	WOS:A1994NC35100004
J	GHOSH, A; CARNAHAN, J; GREENBERG, ME				GHOSH, A; CARNAHAN, J; GREENBERG, ME			REQUIREMENT FOR BDNF IN ACTIVITY-DEPENDENT SURVIVAL OF CORTICAL-NEURONS	SCIENCE			English	Article							NERVE GROWTH-FACTOR; FACTOR MESSENGER-RNA; NEUROTROPHIC FACTOR; SENSORY NEURONS; GANGLION-CELLS; SYMPATHETIC-GANGLION; CILIARY GANGLION; CALCIUM; CULTURE; DEATH	Cultured embryonic cortical neurons from rats were used to explore mechanisms of activity-dependent neuronal survival. Cell survival was increased by the activation of voltage-sensitive calcium channels (VSCCs) but not by activation of N-methyl-D-aspartate receptors. These effects correlated with the expression of brain-derived neurotrophic factor (BDNF) induced by these two classes of calcium channels. Antibodies to BDNF (which block intracellular signaling by BDNF, but not by nerve growth factor, NT3, or NT4/5) reduced the survival of cortical neurons and reversed the VSCC-mediated increase in survival. Thus, endogenous BDNF is a trophic factor for cortical neurons whose expression is VSCC-regulated and that functions in the VSCC-dependent survival of these neurons.	HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; AMGEN INC, THOUSAND OAKS, CA 91320 USA	Harvard University; Harvard Medical School; Amgen					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028829, R37NS028829] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28829] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BARDE YA, 1980, P NATL ACAD SCI-BIOL, V77, P1199, DOI 10.1073/pnas.77.2.1199; Bayer S.A., 1991, NEOCORTICAL DEV; BAYER SA, 1990, EXP NEUROL, V107, P48, DOI 10.1016/0014-4886(90)90062-W; BLACK IB, 1972, J NEUROCHEM, V19, P1367, DOI 10.1111/j.1471-4159.1972.tb01461.x; BONNI A, UNPUB; CASTREN E, 1992, P NATL ACAD SCI USA, V89, P9444, DOI 10.1073/pnas.89.20.9444; CHALAZONITIS A, 1980, DEV BIOL, V78, P173, DOI 10.1016/0012-1606(80)90327-9; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS F, 1989, BRAIN RES, V502, P99, DOI 10.1016/0006-8993(89)90465-4; COLLINS F, 1991, J NEUROSCI, V11, P2582; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; FURBER S, 1987, J NEUROSCI, V7, P1816; GALLI L, 1988, SCIENCE, V242, P90, DOI 10.1126/science.3175637; GALLO V, 1987, J NEUROSCI, V7, P2203; Ghosh A., UNPUB; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GUILLERY RW, 1973, J COMP NEUROL, V149, P423, DOI 10.1002/cne.901490403; HASHISAKI GT, 1989, J COMP NEUROL, V283, P465, DOI 10.1002/cne.902830402; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; KOIKE T, 1991, P NATL ACAD SCI USA, V88, P3892, DOI 10.1073/pnas.88.9.3892; KOKAIA Z, 1993, P NATL ACAD SCI USA, V90, P6711, DOI 10.1073/pnas.90.14.6711; LARMET Y, 1992, NEURON, V9, P563, DOI 10.1016/0896-6273(92)90193-H; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; MADERDRUT JL, 1988, BRAIN RES, V444, P189, DOI 10.1016/0006-8993(88)90928-6; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MIRANDA RC, 1993, P NATL ACAD SCI USA, V90, P6439, DOI 10.1073/pnas.90.14.6439; NISHI R, 1981, DEV BIOL, V87, P301, DOI 10.1016/0012-1606(81)90153-6; PASIC TR, 1989, J COMP NEUROL, V283, P474, DOI 10.1002/cne.902830403; SCOTT BS, 1970, EXP NEUROL, V27, P16, DOI 10.1016/0014-4886(70)90197-4; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; YUSTE R, 1992, SCIENCE, V257, P666, DOI 10.1126/science.1496379; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x; ZAFRA F, 1992, J NEUROSCI, V12, P4793	38	815	835	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 18	1994	263	5153					1618	1623		10.1126/science.7907431	http://dx.doi.org/10.1126/science.7907431			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	7907431				2022-12-28	WOS:A1994NB67300034
J	CRYNS, VL; THOR, A; XU, HJ; HU, SX; WIERMAN, ME; VICKERY, AL; BENEDICT, WF; ARNOLD, A				CRYNS, VL; THOR, A; XU, HJ; HU, SX; WIERMAN, ME; VICKERY, AL; BENEDICT, WF; ARNOLD, A			LOSS OF THE RETINOBLASTOMA TUMOR-SUPPRESSOR GENE IN PARATHYROID CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUSCEPTIBILITY GENE; CELL-CYCLE; EXPRESSION; PROTEIN; CANCER; POLYMORPHISMS; PROGRESSION; DIAGNOSIS; FEATURES; SEQUENCE	Background. The origin and molecular pathogenesis of parathyroid carcinoma are unknown. This life-threatening cause of primary hyperparathyroidism cannot be reliably distinguished from its benign counterpart on the basis of histopathological features alone. Because the PRAD1, or cyclin D1, gene, a cell-cycle regulator, has been implicated in a subgroup of benign parathyroid tumors, we examined the possibility that another cell-cycle regulator with possible functional links to PRAD1, the retinoblastoma tumor-suppressor gene (RB), might be involved in the molecular pathogenesis of parathyroid carcinoma. Methods. Parathyroid carcinomas from 9 patients and adenomas from 21 were studied for evidence of tumor-specific loss of RB gene DNA (allelic loss) by analysis of four DNA polymorphisms and for evidence of altered expression of RB protein by immunohistochemical staining. Results. All of 11 specimens from 5 patients with parathyroid carcinoma and informative DNA patterns and 1 of 19 specimens from 19 patients with parathyroid adenoma and informative DNA patterns lacked an RB allele. Fourteen of 16 specimens (88 percent) from the nine patients with carcinoma had abnormal expression of RB protein (a complete or predominant absence of nuclear staining for the protein). None of the 19 adenomas, including the tumor with loss of an RB allele, had unequivocally abnormal staining for RB protein. Conclusions. Inactivation of the RB gene is common in parathyroid carcinoma and is likely to be an important contributor to its molecular pathogenesis. The presence of such inactivation may help to distinguish benign from malignant parathyroid disease and may have useful diagnostic, prognostic, and therapeutic implications.	MASSACHUSETTS GEN HOSP, DEPT MED, ENDOCRINE ONCOL LAB, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, CTR CANC, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT PATHOL, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; BAYLOR COLL MED, CTR BIOTECHNOL, THE WOODLANDS, TX 77381 USA; VET AFFAIRS MED CTR, ENDOCRINOL SECT, DENVER, CO USA; UNIV COLORADO, HLTH SCI CTR, DENVER, CO USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NCI NIH HHS [1K08 CA-01752-01A1, 1F32 CA-0938101] Funding Source: Medline; NIDDK NIH HHS [5T32 DK-0702817] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001752, F32CA009381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007028] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON BJ, 1983, SURGERY, V94, P906; ARNOLD A, 1988, NEW ENGL J MED, V318, P658, DOI 10.1056/NEJM198803173181102; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; BENEDICT WF, 1990, J CLIN INVEST, V85, P988, DOI 10.1172/JCI114575; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CRYNS VL, 1993, J CLIN ENDOCR METAB, V77, P644, DOI 10.1210/jc.77.3.644; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; IWAMURA Y, 1992, JPN J CLIN ONCOL, V22, P6; KAY S, 1973, ARCH PATHOL, V96, P316; LEVIN KE, 1987, SURGERY, V101, P649; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1256, DOI 10.1093/jnci/84.16.1256; MALLETTE LE, 1992, AM J CLIN PATHOL, V98, P305, DOI 10.1093/ajcp/98.3.305; MATSUO K, 1991, MOL ENDOCRINOL, V5, P1873, DOI 10.1210/mend-5-12-1873; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MCGEE TL, 1990, NUCLEIC ACIDS RES, V18, P207, DOI 10.1093/nar/18.1.207-a; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; ROTH SI, 1962, ARCH PATHOL, V73, P495; SAMBROOK J, 1989, MOL CLONING LABORATO, V2; SANDELIN K, 1992, WORLD J SURG, V16, P724, DOI 10.1007/BF02067369; SCHANTZ A, 1973, CANCER-AM CANCER SOC, V31, P600, DOI 10.1002/1097-0142(197303)31:3<600::AID-CNCR2820310316>3.0.CO;2-0; SHANE E, 1982, ENDOCR REV, V3, P218, DOI 10.1210/edrv-3-2-218; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SMITH JF, 1984, J CLIN PATHOL, V37, P1370, DOI 10.1136/jcp.37.12.1370; SNOVER DC, 1981, AM J CLIN PATHOL, V75, P345; WANG CA, 1985, AM J SURG, V149, P522, DOI 10.1016/S0002-9610(85)80050-7; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; WYNNE AG, 1992, MEDICINE, V71, P197, DOI 10.1097/00005792-199207000-00002; XU HJ, 1991, CANCER RES, V51, P2735; XU HJ, 1991, ONCOGENE, V6, P1139; YANDELL DW, 1989, AM J HUM GENET, V45, P547	35	233	238	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 17	1994	330	11					757	761		10.1056/NEJM199403173301105	http://dx.doi.org/10.1056/NEJM199403173301105			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA742	7906387	Bronze			2022-12-28	WOS:A1994NA74200005
J	HIRAOKA, M; KASUGA, K; HORI, C; SUDO, M				HIRAOKA, M; KASUGA, K; HORI, C; SUDO, M			ULTRASONIC INDICATORS OF URETERAL REFLUX IN THE NEWBORN	LANCET			English	Note							URINARY-TRACT; CHILDREN	There is controversy over the value of ultrasonic screening for detection of vesicoureteric reflux (VUR) in babies. We scanned 300 newborn babies and identified 53 with a dilated renal pelvis or other minor abnormalities. Eventually, 9 of these were investigated by voiding cystourethrography and 3 (5 kidneys) proved to have VUR exceeding grade II, In 3 babies the reason for cystourethrography was persistent renal pelvis dilation; in 3 it was urinary tract infection; and in 3 it was a new ultrasonic sign observed early in the series-ballooning of the renal pelvis during voiding. Whereas persistent dilation of the renal pelvis was a non-specific indicator (absent in 2 of the 5 affected kidneys and present in 5 of those unaffected), ballooning was consistently seen in all 5 affected renal pelvises. This sign, easily obtained in a baby who has been sleeping, deserves prospective assessment for its value in screening.	KASUGA LADLES CLIN,HARUE,FUKUI 91904,JAPAN		HIRAOKA, M (corresponding author), FUKUI MED SCH,DEPT PEDIAT,MATSUOKA,FUKUI 91011,JAPAN.							GORDON AC, 1990, BRIT J UROL, V65, P407, DOI 10.1111/j.1464-410X.1990.tb14766.x; HINCHLIFFE SA, 1992, PEDIATR NEPHROL, V6, P439, DOI 10.1007/BF00874007; SCOTT JES, 1991, LANCET, V338, P1571, DOI 10.1016/0140-6736(91)92385-F; STEELE BT, 1989, J PEDIATR-US, V115, P95, DOI 10.1016/S0022-3476(89)80337-3; STEINHART JM, 1988, PEDIATRICS, V82, P609; TSAI TC, 1989, J CLIN ULTRASOUND, V17, P647, DOI 10.1002/jcu.1870170906; VERBER IG, 1989, ARCH DIS CHILD, V64, P1533, DOI 10.1136/adc.64.11.1533; 1991, LANCET, V338, P1050	8	26	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					519	520		10.1016/S0140-6736(94)91466-4	http://dx.doi.org/10.1016/S0140-6736(94)91466-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906765				2022-12-28	WOS:A1994MX88800014
J	OLIVER, MF; OPIE, LH				OLIVER, MF; OPIE, LH			EFFECTS OF GLUCOSE AND FATTY-ACIDS ON MYOCARDIAL-ISCHEMIA AND ARRHYTHMIAS	LANCET			English	Review							VENTRICULAR ARRHYTHMIAS; ISCHEMIC CONTRACTURE; K+ CHANNELS; RAT-HEART; INFARCTION; REPERFUSION; GLYCOLYSIS; MYOCYTES; HYPOXIA; LIPIDS	Evidence for the utilisation of substrates by the ischaemic myocardium and its dependence for viability on a critical supply of glucose was established many years ago. It was recognised that an excess of free fatty acids (FFA) could increase the severity of ischaemic damage and possibly be arrhythmogenic. But metabolic intervention to improve survival during acute myocardial infarction was not regarded as a priority, perhaps because of uncertainty about its value and the advent of trials of beta-blocker and antiarrhythmic drugs. There has never been an adequate trial of the benefit to the ischaemic or infarcting myocardium of increasing local glucose concentrations or reducing the availability of FFA. We have taken into account new knowledge of the effects of fatty acids on cation channels and brought up to date the arguments for metabolic intervention with glucose-insulin solutions or antilipolytic drugs during sustained ischaemia.	UNIV CAPE TOWN,SCH MED,MRC,HEART RES UNIT,CAPE TOWN 7925,SOUTH AFRICA	University of Cape Town	OLIVER, MF (corresponding author), NATL HEART & LUNG INST,LONDON SW3 6LY,ENGLAND.							ABRAHAM R, 1989, AM J CARDIOL, V63, P269, DOI 10.1016/0002-9149(89)90328-7; ALLISON SP, 1967, LANCET, V1, P478; BELL D, 1990, BRIT HEART J, V63, P82; BRICKNELL OL, 1981, J MOL CELL CARDIOL, V13, P941, DOI 10.1016/0022-2828(81)90292-3; BRODERICK TL, 1993, CIRCULATION, V87, P972, DOI 10.1161/01.CIR.87.3.972; COLEMAN GM, 1989, CIRCULATION, V80, P91; CORR PB, 1982, J MOL CELL CARDIOL, V14, P619, DOI 10.1016/0022-2828(82)90159-6; DELEIRIS J, 1975, NATURE, V153, P746; EBERLI FR, 1991, CIRC RES, V68, P466, DOI 10.1161/01.RES.68.2.466; FERRANNINI E, 1993, AM J PHYSIOL, V264, pE308, DOI 10.1152/ajpendo.1993.264.2.E308; FERRARI R, 1992, MYOCARDIAL RESPONSE, P201; FISCHBACH PS, 1992, CIRCULATION, V86, P1; HUANG JMC, 1992, P NATL ACAD SCI USA, V89, P6452, DOI 10.1073/pnas.89.14.6452; JEREMY RW, 1992, CIRC RES, V70, P1180, DOI 10.1161/01.RES.70.6.1180; KIM DH, 1990, CIRC RES, V67, P1040, DOI 10.1161/01.RES.67.4.1040; KURIEN VA, 1971, EUR J CLIN INVEST, V1, P225, DOI 10.1111/eci.1971.1.4.225; KURIEN VA, 1970, LANCET, V1, P813; LARSEN TS, 1992, MYOCARDIAL RESPONSE, P189; LUXTON MR, 1976, BRIT HEART J, V38, P1204; MAKIGUCHI M, 1991, CARDIOVASC DRUG THER, V5, P753, DOI 10.1007/BF03029751; MANNING AS, 1984, J MOL CELL CARDIOL, V16, P497, DOI 10.1016/S0022-2828(84)80638-0; MAURI F, 1987, Giornale Italiano di Cardiologia, V17, P37; MCLENNAN PL, 1985, CAN J PHYSIOL PHARM, V63, P1411, DOI 10.1139/y85-232; MILLER NE, 1976, CLIN SCI MOL MED, V51, P209, DOI 10.1042/cs0510209; MITTRA B, 1965, LANCET, V2, P607; MJOS OD, 1971, J CLIN INVEST, V50, P1386, DOI 10.1172/JCI106621; OLIVER MF, 1968, LANCET, V1, P710; OLIVER MF, 1981, CURR CONTENTS, V45, P16; OPIE LH, 1971, LANCET, V1, P818; OPIE LH, 1977, LANCET, V2, P890; OPIE LH, 1972, CIRCULATION, V45, P483, DOI 10.1161/01.CIR.45.2.483; OWEN P, 1990, CIRC RES, V66, P344, DOI 10.1161/01.RES.66.2.344; RACKLEY CE, 1981, AM HEART J, V102, P1038, DOI 10.1016/0002-8703(81)90488-9; ROBERTS TL, 1993, BRIT HEART J, V70, P524; ROWE MJ, 1975, LANCET, V2, P295; RUSSELL DC, 1978, BRIT HEART J, V40, P117; SAMAN S, 1988, J MOL CELL CARDIOL, V20, P91, DOI 10.1016/S0022-2828(88)80022-1; SODIPALLARES D, 1969, LANCET, V1, P1315; TANSEY MJB, 1983, LANCET, V2, P419; VALORI C, 1967, AM J CARDIOL, V20, P605, DOI 10.1016/0002-9149(67)90001-X; VETTER N, 1974, LANCET, V2, P284; WEISS JN, 1989, J GEN PHYSIOL, V94, P911, DOI 10.1085/jgp.94.5.911; WOOD DA, 1987, LANCET, V1, P177; 1968, LANCET, V2, P1355	44	413	431	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 15	1994	343	8890					155	158		10.1016/S0140-6736(94)90939-3	http://dx.doi.org/10.1016/S0140-6736(94)90939-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7904009				2022-12-28	WOS:A1994MQ86900015
J	LEUNG, J; BOUVIERDURAND, M; MORRIS, PC; GUERRIER, D; CHEFDOR, F; GIRAUDAT, J				LEUNG, J; BOUVIERDURAND, M; MORRIS, PC; GUERRIER, D; CHEFDOR, F; GIRAUDAT, J			ARABIDOPSIS ABA RESPONSE GENE ABI1 - FEATURES OF A CALCIUM-MODULATED PROTEIN PHOSPHATASE	SCIENCE			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; THALIANA L HEYNH; ABSCISIC-ACID; COLD-ACCLIMATION; GUARD-CELLS; EXPRESSION; ACTIVATOR; MUTATIONS; STOMATA; CLONING	The Arabidopsis ABI1 locus is essential for a wide spectrum of abscisic acid (ABA) responses throughout plant development. Here, ABI1 was shown to regulate stomatal aperture in leaves and mitotic activity in root meristems. The ABI1 gene was cloned and predicted to encode a signaling protein. Although its carboxyl-terminal domain is related to serine-threonine phosphatase 2C, the ABI1 protein has a unique amino-terminal extension containing an EF hand calcium-binding site. These results suggest that the ABI1 protein is a Ca2+-modulated phosphatase and functions to integrate ABA and Ca2+ signals with phosphorylation-dependent response pathways.	INST SCI VEGETALES, CNRS, UPR 40, F-91198 GIF SUR YVETTE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay				Morris, Peter/0000-0003-0919-6305				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BLATT MR, 1993, ANNU REV PLANT PHYS, V44, P543, DOI 10.1146/annurev.pp.44.060193.002551; BOUVIERDURAND M, 1989, PLANT PHYSIOL BIOCH, V27, P511; BOUVIERDURAND M, UNPUB; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DEBLAERE R, 1985, NUCLEIC ACIDS RES, V13, P4777, DOI 10.1093/nar/13.13.4777; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FINKELSTEIN RR, 1990, PLANT PHYSIOL, V94, P1172, DOI 10.1104/pp.94.3.1172; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GILMOUR SJ, 1991, PLANT MOL BIOL, V17, P1233, DOI 10.1007/BF00028738; GILROY S, 1992, CURR PLANT SCI BIOT, V13, P105; GIRAUDAT J, 1992, PLANT CELL, V4, P1251, DOI 10.1105/tpc.4.10.1251; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; HAUGE BM, 1993, PLANT J, V3, P745, DOI 10.1111/j.1365-313X.1993.00745.x; HETHERINGTON AM, 1991, NEW PHYTOL, V119, P9, DOI 10.1111/j.1469-8137.1991.tb01004.x; HORNBERG C, 1984, NATURE, V310, P321, DOI 10.1038/310321a0; JACOBS T, 1992, DEV BIOL, V153, P1, DOI 10.1016/0012-1606(92)90087-W; KOORNNEEF M, 1984, PHYSIOL PLANTARUM, V61, P377, DOI 10.1111/j.1399-3054.1984.tb06343.x; LANG V, 1992, PLANT MOL BIOL, V20, P951, DOI 10.1007/BF00027165; LEE Y, 1991, P NATL ACAD SCI USA, V88, P2127, DOI 10.1073/pnas.88.6.2127; LEUNG J, 1991, J MOL BIOL, V219, P175, DOI 10.1016/0022-2836(91)90560-S; LEUNG J, UNPUB; LEVI M, 1990, PHYSIOL PLANTARUM, V79, P231; LEVI M, 1993, IN VITRO CELL DEV-PL, V29P, P47, DOI 10.1007/BF02632250; LUAN S, 1993, P NATL ACAD SCI USA, V90, P2202, DOI 10.1073/pnas.90.6.2202; MAEDA T, 1993, MOL CELL BIOL, V13, P5408, DOI 10.1128/MCB.13.9.5408; MCAINSH MR, 1991, ABSCISIC ACID PHYSL, P137; MCCARTY DR, 1991, CELL, V66, P895, DOI 10.1016/0092-8674(91)90436-3; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; NORDIN K, 1993, PLANT MOL BIOL, V21, P641, DOI 10.1007/BF00014547; OEDA K, 1991, EMBO J, V10, P1793, DOI 10.1002/j.1460-2075.1991.tb07704.x; PUTNOKY P, 1990, J BACTERIOL, V172, P5450, DOI 10.1128/jb.172.9.5450-5458.1990; SCHNALL JA, 1992, PLANT PHYSIOL, V100, P216, DOI 10.1104/pp.100.1.216; SCHROEDER JI, 1992, PHILOS T R SOC B, V338, P83, DOI 10.1098/rstb.1992.0131; SKRIVER K, 1990, PLANT CELL, V2, P503, DOI 10.1105/tpc.2.6.503; Staiger C, 1993, CURR OPIN CELL BIOL, V5, P226, DOI 10.1016/0955-0674(93)90107-2; TAMURA S, 1989, P NATL ACAD SCI USA, V86, P1796, DOI 10.1073/pnas.86.6.1796; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VARTANIAN N, 1994, PLANT PHYSIOL, V104, P761, DOI 10.1104/pp.104.2.761; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; YAMAGUCHISHINOZAKI K, 1993, MOL GEN GENET, V236, P331, DOI 10.1007/BF00277130; ZEEVAART JAD, 1988, ANNU REV PLANT PHYS, V39, P439, DOI 10.1146/annurev.arplant.39.1.439	44	652	683	4	110	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	1994	264	5164					1448	1452		10.1126/science.7910981	http://dx.doi.org/10.1126/science.7910981			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP221	7910981				2022-12-28	WOS:A1994NP22100039
J	MERINEY, SD; GRAY, DB; PILAR, GR				MERINEY, SD; GRAY, DB; PILAR, GR			SOMATOSTATIN-INDUCED INHIBITION OF NEURONAL CA2+ CURRENT MODULATED BY CGMP-DEPENDENT PROTEIN-KINASE	NATURE			English	Article							RAT SYMPATHETIC NEURONS; CHICK SENSORY NEURONS; CALCIUM CURRENT; GANGLION NEURONS; CILIARY GANGLION; BINDING PROTEIN; CHANNELS; ACTIVATION; PATHWAYS	NEUROTRANSMITTER release is frequently regulated by peptides that modulate neuronal calcium channels. Whole-cell recordings show that the ion permeability(1) and voltage dependence(2) of these channels are controlled by a membrane-associated pathway involving GTP-binding proteins. Here we use perforated-patch recordings to show that, in addition to this pathway, the peptide somatostatin inhibits the calcium current in chick ciliary ganglion neurons by a second soluble pathway involving a cyclic GMP-dependent protein kinase (cGMP-PK). This somatostatin inhibition of Ca2+ current did not desensitize and was not characterized by the slowing of Ca2+-current activation (kinetic slowing) observed in whole-cell recordings. When cGMP-PK was inhibited, somatostatin inhibition of Ca2+ current resembled that observed with whole-cell recordings. cGMP agonists mimic the effect of somatostatin only in perforated patch recordings. An endogenous cGMP-PK therefore forms part of the mechanism by which somatostatin induces a sustained inhibition of neuronal calcium channels.	UNIV CONNECTICUT,DEPT PHYSIOL & NEUROBIOL,STORRS,CT 06269	University of Connecticut								ASHKENAZIE A, 1987, SCIENCE, V238, P272; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BLEY KR, 1990, NEURON, V2, P379; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; DIVERSEPIERLUISSI M, 1993, NEURON, V10, P753, DOI 10.1016/0896-6273(93)90175-Q; DRYER SE, 1991, NEUROSCIENCE, V44, P663, DOI 10.1016/0306-4522(91)90086-4; ELMSLIE KS, 1990, NEURON, V5, P75, DOI 10.1016/0896-6273(90)90035-E; GOLARD A, 1993, J NEUROSCI, V13, P3884; GRASSI F, 1989, NEUROSCI LETT, V105, P113, DOI 10.1016/0304-3940(89)90021-9; GRAY DB, 1990, J NEUROSCI, V10, P2687; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; IKEDA SR, 1989, J PHYSIOL-LONDON, V409, P221, DOI 10.1113/jphysiol.1989.sp017494; KASAI H, 1989, PFLUG ARCH EUR J PHY, V414, P145, DOI 10.1007/BF00580956; KUO CC, 1993, NATURE, V365, P258, DOI 10.1038/365258a0; LEWIS DL, 1986, P NATL ACAD SCI USA, V83, P9035, DOI 10.1073/pnas.83.23.9035; MARCHETTI C, 1986, PFLUG ARCH EUR J PHY, V406, P104, DOI 10.1007/BF00586670; MATTERA R, 1989, SCIENCE, V243, P804, DOI 10.1126/science.2536957; PENINGTON NJ, 1991, J NEUROSCI, V11, P3594, DOI 10.1523/jneurosci.11-11-03594.1991; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; SAH DWY, 1990, J NEUROSCI, V10, P136; SHAPIRO MS, 1993, NEURON, V10, P11, DOI 10.1016/0896-6273(93)90237-L; WANG HL, 1990, NEUROSCIENCE, V38, P335, DOI 10.1016/0306-4522(90)90032-Y; WANKE E, 1987, P NATL ACAD SCI USA, V84, P4313, DOI 10.1073/pnas.84.12.4313; WENTZEK LAF, 1993, J NEUROSCI, V13, P3143; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390	25	126	127	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 26	1994	369	6478					336	339		10.1038/369336a0	http://dx.doi.org/10.1038/369336a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN109	7910377				2022-12-28	WOS:A1994NN10900055
J	GOSPE, SM; OLIN, KL; KEEN, CL				GOSPE, SM; OLIN, KL; KEEN, CL			REDUCED GABA SYNTHESIS IN PYRIDOXINE-DEPENDENT SEIZURES	LANCET			English	Note							GLUTAMIC-ACID DECARBOXYLASE; BRAIN	An abnormality in the pyridoxal-5'-phosphate (PLP) dependent enzyme, glutamic acid decarboxylase (GAD), which synthesises gamma-aminobutyric acid (GABA), may underlie the epileptic syndrome of pyridoxine-dependent seizures. GABA synthesis by shin fibroblasts from an infant with pyridoxine-dependent seizures, and from five controls, was measured. PLP independent GAD activity was similar in control and patient fibroblasts, whereas the patient's PLP dependent GAD activity was reduced compared with controls. These findings support the hypothesis for the expression of this familiar disease.	UNIV CALIF DAVIS,DEPT PEDIAT,SACRAMENTO,CA 95817; UNIV CALIF DAVIS,DEPT INTERNAL MED,SACRAMENTO,CA 95817; UNIV CALIF DAVIS,DEPT NUTR,SACRAMENTO,CA 95817	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	GOSPE, SM (corresponding author), UNIV CALIF DAVIS,DAVIS MED CTR,DEPT NEUROL,DIV CHILD NEUROL,2315 STOCKTON BLVD,SACRAMENTO,CA 95817, USA.		Gospe, Sidney/AAR-4967-2020; Gospe, Sidney M/G-6080-2010	Gospe, Sidney/0000-0002-0099-109X; 				DENNER LA, 1985, J NEUROCHEM, V44, P957, DOI 10.1111/j.1471-4159.1985.tb12910.x; GOHLICH G, 1984, J NEUROL, V231, P50, DOI 10.1007/BF00313653; GOUTIERES F, 1985, ANN NEUROL, V17, P117, DOI 10.1002/ana.410170203; HUNT AD, 1954, PEDIATRICS, V13, P140; KURLEMANN G, 1992, NEUROPEDIATRICS, V23, P257, DOI 10.1055/s-2008-1071353; LOTT IT, 1978, NEUROLOGY, V28, P47, DOI 10.1212/WNL.28.1.47; SCRIVER CR, 1969, ANN NY ACAD SCI, V166, P83; SCRIVER CR, 1960, PEDIATRICS, V26, P62; YOSHIDA T, 1971, TOHOKU J EXP MED, V104, P195, DOI 10.1620/tjem.104.195	9	64	64	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1994	343	8906					1133	1134		10.1016/S0140-6736(94)90236-4	http://dx.doi.org/10.1016/S0140-6736(94)90236-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK730	7910233				2022-12-28	WOS:A1994NK73000010
J	VELLA, S; CHIESI, A; VOLPI, A; GIULIANO, M; FLORIDIA, M; DALLY, LG; BINKIN, N				VELLA, S; CHIESI, A; VOLPI, A; GIULIANO, M; FLORIDIA, M; DALLY, LG; BINKIN, N			DIFFERENTIAL SURVIVAL OF PATIENTS WITH AIDS ACCORDING TO THE 1987 AND 1993 CDC CASE DEFINITIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To evaluate the impact of the 1993 Centers for Disease Control and Prevention (CDC) revised classification system for human immunodeficiency virus and expanded surveillance case definition for acquired immunodeficiency syndrome (AIDS) on the number of cases and on survival of patients with AIDS. Design.-Retrospective analysis of data from a prospective cohort study of patients treated with zidovudine. Patients.-A total of 3515 patients enrolled in the Italian National Registry of Zidovudine-Treated Patients between July 1987 and December 1991 were analyzed. Main Outcome Measures.-Numbers and survival probability estimates (using the Kaplan-Meier method) for patients satisfying the 1993 CDC case definition compared with patients fulfilling the 1987 CDC classification. Multiple regression analysis was also used to analyze the combined effect of independent variables on survival. Results.-According to the new classification system, the number of AIDS cases in the study population would increase by 188%. While the median survival of patients meeting the 1987 definition was 24 months, at the end of 57 months 53% of patients meeting the 1993 definition were still alive. Among the patients meeting the laboratory criteria for AIDS diagnosis using the new definition (CD4+ lymphocyte count <0.20x10(9)/L [200/muL]), the presence of an AIDS-defining illness was a strong independent predictor of death. Conclusions.-The application of the new definition results in a considerable increase in the number of cases. Survival for patients classified according to the 1993 definition is much longer than for those classified with the 1987 definition. Clinical status plays a major role in predicting survival outcome among patients whose CD4+ lymphocyte counts meet the new case definition.	IST SUPER SANITA, BACTERIOL & MED MYCOL LAB, I-00161 ROME, ITALY; IST SUPER SANITA, EPIDEMIOL LAB, I-00161 ROME, ITALY; UNIV TOR VERGATA, DEPT PUBL HLTH, ROME, ITALY	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); University of Rome Tor Vergata	VELLA, S (corresponding author), IST SUPER SANITA, VIROL LAB, VIALE REGINA ELENA 299, I-00161 ROME, ITALY.		Floridia, Marco/Q-6571-2017; Giuliano, Marina/V-8991-2017; VELLA, STEFANO/ABI-3368-2020; Vella, Stefano/GZM-0519-2022; VELLA, STEFANO/D-4912-2015	Floridia, Marco/0000-0003-3971-0141; Giuliano, Marina/0000-0003-2789-7797; Chiesi, Antonio/0000-0002-6892-8142; VELLA, STEFANO/0000-0003-2347-5984; VOLPI, Antonio/0000-0001-9709-4186				BRETTLE RP, 1993, AIDS, V7, P531, DOI 10.1097/00002030-199304000-00013; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P308; Centers for Disease Control Prevention (CDC), 1992, MMWR-MORBID MORTAL W, V41, P1; CHENE G, 1992, LANCET, V339, P1298, DOI 10.1016/0140-6736(92)91629-M; KALBFLEISH JD, 1980, STATISTICAL ANAL FAI, P27; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; PARK RAA, 1992, LANCET, V339, P671, DOI 10.1016/0140-6736(92)90815-K; SHEPPARD HW, 1991, JAMA-J AM MED ASSOC, V266, P2221; VELLA S, 1992, JAMA-J AM MED ASSOC, V267, P1232, DOI 10.1001/jama.267.9.1232; 1985, MMWR MORB MORTAL WKL, V34, P373; 1982, MMWR MORB MORTAL WKL, V31, P507; 1987, MMWR MORB MORTAL WKL, V36, pS3	12	18	18	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 20	1994	271	15					1197	1199		10.1001/jama.271.15.1197	http://dx.doi.org/10.1001/jama.271.15.1197			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF207	7908705				2022-12-28	WOS:A1994NF20700029
J	CASSCELLS, W				CASSCELLS, W			MAGNESIUM AND MYOCARDIAL-INFARCTION	LANCET			English	Editorial Material							SULFATE; HEART		ST LUKES EPISCOPAL HOSP,TEXAS HEART INST,HOUSTON,TX 77030	Saint Lukes Episcopal Hospital; Texas Heart Institute	CASSCELLS, W (corresponding author), UNIV TEXAS,HERMANN HOSP,SCH MED,HOUSTON,TX 77030, USA.							BANAI S, 1990, CIRC RES, V67, P645, DOI 10.1161/01.RES.67.3.645; BELLER GA, 1974, AM J CARDIOL, V33, P225, DOI 10.1016/0002-9149(74)90279-3; CASSCELLS W, 1993, CIRCULATION, V88, P2438, DOI 10.1161/01.CIR.88.5.2438; CHIPPERFIELD B, 1973, LANCET, V2, P709; DESILVA RA, 1981, LANCET, V2, P855; DUTOIT EF, 1992, CIRC RES, V70, P960, DOI 10.1161/01.RES.70.5.960; GERTZ SD, 1987, MAGNESIUM, V6, P225; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; KIYOSUE T, 1932, PFLUGER ARCH, V395, P78; SEELIG M, 1989, AM J CARDIOL, V63, pG4, DOI 10.1016/0002-9149(89)90213-0; SHATTOCK MJ, 1987, J AM COLL NUTR, V6, P27; SUETA CA, 1994, CIRCULATION, V89, P660, DOI 10.1161/01.CIR.89.2.660; TZIVONI D, 1988, CIRCULATION, V77, P392, DOI 10.1161/01.CIR.77.2.392; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WEISS J, 1981, J MOL CELL CARDIOL, V13, P699, DOI 10.1016/0022-2828(81)90277-7; WILLERSON JT, 1993, J AM COLL CARDIOL, V21, P1048, DOI 10.1016/0735-1097(93)90223-N; WOODS KL, 1994, LANCET, V343, P816, DOI 10.1016/S0140-6736(94)92024-9; YUSUF S, 1993, CIRCULATION, V87, P2043, DOI 10.1161/01.CIR.87.6.2043	18	33	33	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					807	809		10.1016/S0140-6736(94)92020-6	http://dx.doi.org/10.1016/S0140-6736(94)92020-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908073				2022-12-28	WOS:A1994ND79200003
J	PERRIMON, N				PERRIMON, N			THE GENETIC-BASIS OF PATTERNED BALDNESS IN DROSOPHILA	CELL			English	Review							SEGMENT POLARITY GENE; MELANOGASTER; EXPRESSION; HEDGEHOG				PERRIMON, N (corresponding author), HARVARD UNIV,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115, USA.			Perrimon, Norbert/0000-0001-7542-472X				BASLER K, 1994, IN PRESS NATURE; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; COUSO JP, 1994, IN PRESS DEVELOPMENT; CUMBERLEDGE S, 1993, NATURE, V363, P549, DOI 10.1038/363549a0; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; FORBES AJ, 1993, IN PRESS DEVELOPME S, V119; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LI XL, 1993, EMBO J, V12, P4499, DOI 10.1002/j.1460-2075.1993.tb06139.x; Martinez Arias Alfonso, 1993, P517; MOHLER J, 1992, DEVELOPMENT, V115, P957; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PEIFER M, 1994, IN PRESS DEVELOPMENT; PERRIMON N, 1989, GENETICS, V121, P333; PREAT T, 1992, GENETICS, V132, P725; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SMITH JC, 1994, CELL, V76, P1934; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x	30	167	178	1	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 11	1994	76	5					781	784		10.1016/0092-8674(94)90351-4	http://dx.doi.org/10.1016/0092-8674(94)90351-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	7907277				2022-12-28	WOS:A1994NA89000002
J	SCHEFFER, IE; BHATIA, KP; LOPESCENDES, I; FISH, DR; MARSDEN, CD; ANDERMANN, F; ANDERMANN, E; DESBIENS, R; CENDES, F; MANSON, JI; BERKOVIC, S				SCHEFFER, IE; BHATIA, KP; LOPESCENDES, I; FISH, DR; MARSDEN, CD; ANDERMANN, F; ANDERMANN, E; DESBIENS, R; CENDES, F; MANSON, JI; BERKOVIC, S			AUTOSOMAL-DOMINANT FRONTAL EPILEPSY MISDIAGNOSED AS SLEEP DISORDER	LANCET			English	Note							NOCTURNAL PAROXYSMAL DYSTONIA; LOBE ORIGIN; SEIZURES	We describe a distinctive epilepsy syndrome in six families, which is the first partial epilepsy syndrome to follow single gene inheritance. The predominant seizure pattern had frontal lobe seizure semiology with clusters of brief motor attacks occurring in sleep. Onset was usually in childhood, often persisting through adult life. Misdiagnosis as night terrors, nightmares, hysteria, or paroxysmal nocturnal dystonia was common, and the inheritance pattern was often not appreciated. This autosomal dominant epilepsy syndrome is ideal for identification of partial epilepsy genes.	AUSTIN HOSP,DEPT NEUROL,HEIDELBERG,VIC 3084,AUSTRALIA; UNIV MELBOURNE,MELBOURNE,VIC,AUSTRALIA; ROYAL CHILDRENS HOSP,MELBOURNE,VIC,AUSTRALIA; UNIV LONDON,NATL HOSP,DEPT CLIN NEUROL,LONDON,ENGLAND; MONTREAL NEUROL HOSP & INST,MONTREAL,PQ,CANADA; WOMENS & CHILDRENS HOSP,ADELAIDE,SA,AUSTRALIA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Royal Children's Hospital Melbourne; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; McGill University; Womens & Childrens Hospital Australia			Cendes, Fernando/C-1301-2012; jiang, yu/HGU-0029-2022; Lopes-Cendes, Iscia/B-9416-2013; Scheffer, Ingrid E/G-1668-2013	Cendes, Fernando/0000-0001-9336-9568; Lopes-Cendes, Iscia/0000-0002-6221-6822; Scheffer, Ingrid E/0000-0002-2311-2174; Berkovic, Samuel/0000-0003-4580-841X				LEE BI, 1985, NEUROLOGY, V35, P1357, DOI 10.1212/WNL.35.9.1357; LEHESJOKI AE, 1991, P NATL ACAD SCI USA, V88, P3696, DOI 10.1073/pnas.88.9.3696; LEPPERT M, 1989, NATURE, V337, P647, DOI 10.1038/337647a0; LUGARESI E, 1986, J NEUROL NEUROSUR PS, V49, P375, DOI 10.1136/jnnp.49.4.375; MEIERKORD H, 1992, MOVEMENT DISORD, V7, P38, DOI 10.1002/mds.870070107; MORRIS HH, 1988, NEUROLOGY, V38, P1075, DOI 10.1212/WNL.38.7.1075; RISE ML, 1991, SCIENCE, V253, P669, DOI 10.1126/science.1871601; TINUPER P, 1990, EPILEPSIA, V31, P549, DOI 10.1111/j.1528-1157.1990.tb06105.x; VIGEVANO F, 1993, EPILEPSIA, V39, P110; WILLIAMSON PD, 1985, ANN NEUROL, V18, P497, DOI 10.1002/ana.410180413	10	279	285	2	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					515	517		10.1016/S0140-6736(94)91463-X	http://dx.doi.org/10.1016/S0140-6736(94)91463-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906762				2022-12-28	WOS:A1994MX88800011
J	LAI, ME; MAZZOLENI, AP; ARGIOLU, F; DEVIRGILIS, S; BALESTRIERI, A; PURCELL, RH; CAO, A; FARCI, P				LAI, ME; MAZZOLENI, AP; ARGIOLU, F; DEVIRGILIS, S; BALESTRIERI, A; PURCELL, RH; CAO, A; FARCI, P			HEPATITIS-C VIRUS IN MULTIPLE EPISODES OF ACUTE HEPATITIS IN POLYTRANSFUSED THALASSEMIC CHILDREN	LANCET			English	Note							NON-B-HEPATITIS; NON-A	We investigated the course of distinct episodes of acute non-A, non-B (NANB) hepatitis in three polytransfused thalassaemic children. In each case, the first episode was associated with the appearance of serum hepatitis C virus (HCV) RNA and anti-HCV seroconversion. The second episode was accompanied by the reappearance of HCV viraemia, which in two patients was due to reinfection with a different HCV strain and in the third could be the result of either reactivation of primary infection or reinfection with a new but closely related strain. Thus HCV infection may not induce protective immunity, which has implications for vaccine development.	UNIV CAGLIARI,INST CLIN & BIOL DEV AGE,CAGLIARI,ITALY; UNIV CAGLIARI,CTR THALASSAEMIA,CAGLIARI,ITALY; NIAID,INFECT DIS LAB,HEPATITIS VIRUSES SECT,BETHESDA,MD 20892	University of Cagliari; University of Cagliari; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	LAI, ME (corresponding author), UNIV CAGLIARI,INST INTERNAL MED,VIA SAN GIORGIO 12,I-09124 CAGLIARI,ITALY.							CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; FARCIP, 1992, SCIENCE, V258, P135; GALBRAITH RM, 1979, LANCET, V1, P951; HRUBY MA, 1978, JAMA-J AM MED ASSOC, V240, P1355; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LAI ME, 1993, J PEDIATR GASTR NUTR, V16, P458, DOI 10.1097/00005176-199305000-00020; MOSLEY JW, 1977, NEW ENGL J MED, V296, P75, DOI 10.1056/NEJM197701132960204; SIMMONDS P, 1993, J GEN VIROL, V74, P661, DOI 10.1099/0022-1317-74-4-661; WEINER AJ, 1991, VIROLOGY, V180, P842, DOI 10.1016/0042-6822(91)90104-J	9	255	260	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					388	390		10.1016/S0140-6736(94)91224-6	http://dx.doi.org/10.1016/S0140-6736(94)91224-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905553				2022-12-28	WOS:A1994MW28300010
J	NORDGAARD, I; HANSEN, BS; MORTENSEN, PB				NORDGAARD, I; HANSEN, BS; MORTENSEN, PB			COLON AS A DIGESTIVE ORGAN IN PATIENTS WITH SHORT-BOWEL	LANCET			English	Article							MALABSORBED CARBOHYDRATE; ABSORPTION; STARCH; CONSERVATION; CALORIE; THERAPY; NEED; DIET	Patients with a short bowel malabsorb dietary nutrients with loss of calories and weight. Malabsorbed carbohydrates are fermented by colonic bacteria to short-chain fatty acids, which are absorbed and supply energy. The maximum energy-consumption capacities in patients with short bowel were individually measured on 40:40% carbohydrate:fat diets. 8 patients with colon in continuity and 6 patients with jejunostomies were placed on isocaloric 60:20% or 20:60% carbohydrate:fat diets and faecal excretions of calories, carbohydrates, fat, nitrogen, and fluids were compared. The high-carbohydrate low-fat diet reduced faecal loss of energy by 2.0 MJ/day compared to the low-carbohydrate high-fat diet in patients with colon in continuity, and absorption of energy increased from 49 to 69% (p < 0.001). Faecal excretions of carbohydrates were low and not influenced by the change in carbohydrate intakes (26 g/day and 28 g/day, respectively) whereas faecal fat (46 g/day and 106 g/day) was highly dependent on dietary intakes and accounted for differences in faecal loss of energy. In contrast, patients with jejunostomies excreted equal amounts of calories on the high-carbohydrate diet(4.8 MJ/day) and the high-fat diet (5.9 MJ/day; p = 0.08); and the percentage of calories absorbed was not different (55% and 48%, respectively; p = 0.21). Furthermore, in patients without colon the excretions of carbohydrates (80 g/day and 42 g/day on high-carbohydrate and low-carbohydrate diets, respectively) and fat(69 g/day and 35 g/day on high-fat and low-fat diets, respectively) were proportional to the amounts ingested. The large intestine is important in the digestion of carbohydrates and hence in the salvage of calories in patients with short bowel and severe malabsorption.			NORDGAARD, I (corresponding author), UNIV COPENHAGEN,RIGSHOSP,DEPT MED A,BLEGDAMSVEJ 9,DK-2100 COPENHAGEN,DENMARK.		Mortensen, Preben B/D-2358-2015	Mortensen, Preben B/0000-0002-5230-9865				ALLARD JP, 1989, GASTROENTEROL CLIN N, V18, P589; ANDERSSON H, 1982, WORLD REV NUTR DIET, V40, P1; BOCHENEK W, 1970, Algerie Medicale, V72, P205; BOND JH, 1980, GASTROENTEROLOGY, V78, P444; BORGSTROM B, 1957, J CLIN INVEST, V36, P1521, DOI 10.1172/JCI103549; CUMMINGS JH, 1991, J APPL BACTERIOL, V70, P443, DOI 10.1111/j.1365-2672.1991.tb02739.x; ENGLYST HN, 1987, AM J CLIN NUTR, V46, P873, DOI 10.1093/ajcn/46.6.873; ENGLYST HN, 1984, ANALYST, V109, P937, DOI 10.1039/an9840900937; HOVERSTAD T, 1986, SCAND J GASTROENTERO, V21, P257, DOI 10.3109/00365528609003073; HYLANDER E, 1978, Scandinavian Journal of Gastroenterology, V13, P423, DOI 10.3109/00365527809181916; Kritchevsky D., 1986, DIETARY FIBER, P131, DOI DOI 10.1007/978-1-4613-2111-8_10; LEVITT MD, 1983, GASTROENTEROLOGY, V85, P769; MCINTYRE PB, 1986, GASTROENTEROLOGY, V91, P25, DOI 10.1016/0016-5085(86)90434-8; MCNEIL NI, 1984, AM J CLIN NUTR, V39, P338, DOI 10.1093/ajcn/39.2.338; MESSING B, 1991, GASTROENTEROLOGY, V100, P1502, DOI 10.1016/0016-5085(91)90645-2; MOLLER A, 1989, FOOD COMPOSITION TAB; NIGHTINGALE JMD, 1992, GUT, V33, P1493, DOI 10.1136/gut.33.11.1493; ROYALL D, 1992, AM J GASTROENTEROL, V87, P751; RUPPIN H, 1980, GASTROENTEROLOGY, V78, P1500; SMITH CJ, 1979, AM J CLIN NUTR, V32, P149, DOI 10.1093/ajcn/32.1.149; SOUTHGATE DA, 1970, BRIT J NUTR, V24, P517, DOI 10.1079/BJN19700050; STEPHEN AM, 1983, GASTROENTEROLOGY, V85, P589; VANAMELSVOORT JMM, 1990, ANN NUTR METAB, V34, P163, DOI 10.1159/000177583; VANDEKAMER JH, 1949, J BIOL CHEM, V177, P347; VOITK AJ, 1973, GASTROENTEROLOGY, V65, P419; Williams S, 1984, AOAC OFFICIAL METHOD; WINAWER SJ, 1966, NEW ENGL J MED, V274, P72, DOI 10.1056/NEJM196601132740204; WOLLAEGER EE, 1973, MAYO CLIN PROC, V48, P833; WOOLF GM, 1987, DIGEST DIS SCI, V32, P8, DOI 10.1007/BF01296681; WOOLF GM, 1983, GASTROENTEROLOGY, V84, P823	30	220	222	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					373	376		10.1016/S0140-6736(94)91220-3	http://dx.doi.org/10.1016/S0140-6736(94)91220-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905549				2022-12-28	WOS:A1994MW28300006
J	HEAGERTY, AM				HEAGERTY, AM			WINNING RHYTHM	LANCET			English	Editorial Material											HEAGERTY, AM (corresponding author), UNIV HOSP S MANCHESTER,DEPT MED,MANCHESTER M20 8LR,LANCS,ENGLAND.			Heagerty, Anthony/0000-0002-9043-2119				BENNET WC, 1935, TARAHUMARA INDIAN TR, P113; EDWARDS RG, 1972, J APPL PHYSIOL, V32, P386, DOI 10.1152/jappl.1972.32.3.386; NICHOLS WW, 1990, MCDONALDS BLOOD FLOW, P270; OROURKE M, 1993, AUST NZ J MED, V23, P703; PALATINI P, 1989, J APPL PHYSIOL, V67, P52, DOI 10.1152/jappl.1989.67.1.52; ROST R, 1983, MUNCHEN MED WOCHEN, V125, P1025; ROWE WJ, 1992, LANCET, V340, P712, DOI 10.1016/0140-6736(92)92243-9; ROWELL LB, 1968, CIRCULATION, V37, P954, DOI 10.1161/01.CIR.37.6.954; VANCITTERS RL, 1969, CIRC RES, V24, P33, DOI 10.1161/01.RES.24.1.33	9	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 5	1994	343	8893					310	310		10.1016/S0140-6736(94)91160-6	http://dx.doi.org/10.1016/S0140-6736(94)91160-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905142				2022-12-28	WOS:A1994MU98500006
J	LISSAU, I; SORENSEN, TIA				LISSAU, I; SORENSEN, TIA			PARENTAL NEGLECT DURING CHILDHOOD AND INCREASED RISK OF OBESITY IN YOUNG ADULTHOOD	LANCET			English	Article							BODY-MASS INDEX; ADOPTION	The association of various features of family life with obesity in childhood is well established, but less is known about the effect of these influences on the risk of later obesity. In this prospective, population-based study, we examined the influence of parental care in childhood on the risk of obesity in the offspring in young adulthood. In 1974, 1258 pupils aged 9-10 years were randomly selected from the third grade of Copenhagen schools. Information on 987 pupils was obtained from the form teachers on family structure and the perceived support from the parents; school medical services reported on the child's general hygiene. 756 (86%) of the 881 eligible participants were followed up 10 years later. The influence of family factors in childhood on the risk of obesity (body-mass index > 95th centile) in young adulthood was estimated by odds ratios with control for age and body-mass index in 1974, sex, and social background. Family structure (biological or other parents and number of siblings) did not significantly affect the risk of adult obesity. Parental neglect greatly increased the risk in comparison with harmonious support (odds ratio 7.1 [95% CI 2.6-19.3]). Dirty and neglected children had a much greater risk of adult obesity than averagely groomed children (9.8 [3.5-28.2]). However, being an only child, receiving overprotective parental support, or being well-groomed had no effect. Parental neglect during childhood predicts a great risk of obesity in young adulthood, independent of age and body-mass index in childhood, sex, and social background.	UNIV COPENHAGEN, RIGSHOSP, DEPT PAEDIAT, DK-2100 COPENHAGEN, DENMARK	Rigshospitalet; University of Copenhagen	LISSAU, I (corresponding author), KOMMUNE HOSP COPENHAGEN, INST PREVENT MED, COPENHAGEN HLTH SERV, DK-1399 COPENHAGEN, DENMARK.		Lissau, Inge/AAJ-3971-2020	Lissau, Inge/0000-0002-2225-9975				BRUCH H, 1957, IMPORTANCE OVERWEIGH; DIETZ WH, 1984, AM J CLIN NUTR, V39, P619, DOI 10.1093/ajcn/39.4.619; DIETZ WH, 1986, PEDIATR CLIN N AM, V33, P823; FRIISASCHE E, 1981, THESIS COPENHAGEN; GARROW JS, 1992, INT J OBESITY, V16, pS59; GARROW JS, 1988, MANAGEMENT PREVENTIO; HERTZEL BS, 1987, CARDIOVASCULAR RISK; JOHNSTON FE, 1985, ANN INTERN MED, V103, P1068, DOI 10.7326/0003-4819-103-6-1068; KINSTON W, 1988, J PSYCHOSOM RES, V32, P513, DOI 10.1016/0022-3999(88)90036-0; LISSAU I, 1993, INT J OBESITY, V17, P125; LISSAU I, 1993, INT J OBESITY, V17, P169; LISSAU I, 1993, THESIS U COPENHAGEN; LISSAULUNDSORENSEN I, 1992, INT J OBESITY, V16, P169; LOADER PJ, 1985, INT J EAT DISORDER, V4, P211, DOI 10.1002/1098-108X(198505)4:2<211::AID-EAT2260040208>3.0.CO;2-P; POWER C, 1988, INT J OBESITY, V12, P445; QUAADE F, 1955, OBESE CHILDREN ANTHR; SILVERMAN WK, 1987, BEHAV THERAPIST, V10, P197; SORENSEN TIA, 1992, INT J OBESITY, V16, P705; SORENSEN TIA, 1992, INT J OBESITY, V16, P227; STUNKARD AJ, 1986, NEW ENGL J MED, V314, P193, DOI 10.1056/NEJM198601233140401; 1985, SAS USERS GUIDE STAT	21	316	320	1	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 5	1994	343	8893					324	327		10.1016/S0140-6736(94)91163-0	http://dx.doi.org/10.1016/S0140-6736(94)91163-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905145				2022-12-28	WOS:A1994MU98500009
J	DARGIE, HJ; MCMURRAY, JJV				DARGIE, HJ; MCMURRAY, JJV			DIAGNOSIS AND MANAGEMENT OF HEART-FAILURE	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ACUTE MYOCARDIAL-INFARCTION; EXERCISE TOLERANCE; DOUBLE-BLIND; ENALAPRIL; MORTALITY; TRIAL; THERAPY; CAPTOPRIL; SURVIVAL; MODERATE		WESTERN GEN HOSP, DEPT CARDIAC, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND	University of Edinburgh	DARGIE, HJ (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP, DEPT CARDIOL, GLASGOW G11 6NT, SCOTLAND.		mcmurray, John/B-2467-2013; Brophy, James/H-6673-2019	mcmurray, John/0000-0002-6317-3975; Brophy, James/0000-0001-8049-6875				[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1990, LANCET, V336, P24; BARNETT DB, 1993, LANCET, V341, P733, DOI 10.1016/0140-6736(93)90498-6; BARNETT DB, 1993, LANCET, V341, P1124, DOI 10.1016/0140-6736(93)93132-K; BOUNOUS EP, 1988, CIRCULATION, V78, P151; CHADDA K, 1986, CIRCULATION, V73, P503, DOI 10.1161/01.CIR.73.3.503; CLELAND J, 1993, CLIN GUIDE ACE INHIB; CLELAND JGF, 1984, BRIT HEART J, V52, P530; CLELAND JGF, 1985, BRIT HEART J, V54, P305; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; COWLEY AJ, 1993, BR HEART J S, V69, pP15; CREAGER MA, 1985, J AM COLL CARDIOL, V6, P163, DOI 10.1016/S0735-1097(85)80269-2; DARGIE HJ, 1987, CIRCULATION, V75, P98; DARGIE HJ, 1992, RECENT ADV CARDIOLOG, V2, P73; DIES F, 1986, CIRCULATION, V74, P38; FELDMAN AM, 1993, NEW ENGL J MED, V329, P149, DOI 10.1056/NEJM199307153290301; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; KLEBER FX, 1992, BRIT HEART J, V67, P289; KRAUS F, 1993, HERZ, V18, P95; KUKIN ML, 1993, CIRCULATION, V88, P47; MASSIE BM, 1992, CIRCULATION S1, V86, P1; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; MCMURRAY J, 1992, European Heart Journal, V13, P350; McMurray J., 1993, European Heart Journal, V14, P133; MCMURRAY J, 1992, LANCET, V340, P1547, DOI 10.1016/0140-6736(92)92803-N; MCMURRAY J, 1991, BMJ-BRIT MED J, V303, P1546, DOI 10.1136/bmj.303.6816.1546-a; MCMURRAY J, 1993, BR HEART J S, V69, pP73; MUJAIS SK, 1992, PROG CARDIOVASC DIS, V35, P221, DOI 10.1016/0033-0620(92)90013-P; MURPHY MB, 1990, CRIT CARE MED, V18, pS14; NADEMANEE K, 1992, J AM COLL CARDIOL, V20, P1063, DOI 10.1016/0735-1097(92)90358-T; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; NOLAN J, 1992, BRIT HEART J, V68, P544; PACHER R, 1993, EUR HEART J, V14, P273, DOI 10.1093/eurheartj/14.2.273; PACKER M, 1993, NEW ENGL J MED, V329, P1, DOI 10.1056/NEJM199307013290101; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PACKER M, 1991, J AM COLL CARDIOL, V17, P740, DOI 10.1016/S0735-1097(10)80193-7; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; RAHIMTOOLA SH, 1989, AM HEART J, V117, P211, DOI 10.1016/0002-8703(89)90685-6; RIEGGER GAJ, 1991, EUR HEART J, V12, P705, DOI 10.1093/eurheartj/12.6.705; SMITH TW, 1993, NEW ENGL J MED, V329, P51, DOI 10.1056/NEJM199307013290111; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; SUTTON GC, 1990, AM HEART J, V120, P1538, DOI 10.1016/0002-8703(90)90055-3; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; URETSKY BF, 1990, CIRCULATION, V82, P774, DOI 10.1161/01.CIR.82.3.774; WAAGSTEIN F, 1975, BRIT HEART J, V37, P1022; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; 1992, LANCET, V239, P278; 1992, EUR HEART J SC, V13, P42; 1992, LANCET, V339, P7753; 1988, LANCET, V2, P1401; 1988, JAMA-J AM MED ASSOC, V259, P530; 1992, AM J CARDIOL S, V70, pC62; 1989, LANCET, V2, P79	57	111	119	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 29	1994	308	6924					321	328		10.1136/bmj.308.6924.321	http://dx.doi.org/10.1136/bmj.308.6924.321			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU492	7907244	Green Published			2022-12-28	WOS:A1994MU49200025
J	CATASSI, C; RATSCH, IM; FABIANI, E; ROSSINI, M; BORDICCHIA, F; CANDELA, F; COPPA, GV; GIORGI, PL				CATASSI, C; RATSCH, IM; FABIANI, E; ROSSINI, M; BORDICCHIA, F; CANDELA, F; COPPA, GV; GIORGI, PL			CELIAC-DISEASE IN THE YEAR 2000 - EXPLORING THE ICEBERG	LANCET			English	Article							SELECTIVE IGA DEFICIENCY; CELIAC-DISEASE; ANTIGLIADIN ANTIBODIES; CHILDREN; MALIGNANCY	lt is now generally believed that subclinical coeliac disease is common in the general population. We have undertaken screening for this disorder in a school district in central Italy. Screening was divided into three levels: first, IgG and IgA antigliadin antibody (AGA) assay on capillary blood obtained by finger prick; second. AGA plus IgA anti-endomysium antibody (AEA) test and measurement of serum immunoglobulins in venous blood: and third, intestinal biopsy. 3351 students (66% of the eligible population) aged 11-15 years attended first level screening. 71 (2%) were recalled because of AGA positivity; 18 of these satisfied second-level criteria and underwent intestinal biopsy. Coeliac disease was diagnosed in 11 subjects, most of whom had no serious symptoms. Selective IgA deficiency was found in 4 subjects, 1 of whom also had coeliac disease. The prevalence of subclinical coeliac disease in the study group was 3.28 per 1000. Coeliac disease screening is feasible and involves only slight discomfort to the general population. Such screening can detect large numbers of cases of coeliac disease, which can be treated with a gluten-free diet. Many subclinical cases of coeliac disease would not be detected by screening only a selected group of at-risk patients.	G SALESI CHILDRENS HOSP, DEPT CLIN CHEM, ANCONA, ITALY		CATASSI, C (corresponding author), UNIV ANCONA, DEPT PEDIAT, VIA CORRIDONI 11, I-60123 ANCONA, ITALY.							BARERA G, 1991, ARCH DIS CHILD, V66, P491, DOI 10.1136/adc.66.4.491; BURGINWOLFF A, 1989, EUR J PEDIATR, V148, P496, DOI 10.1007/BF00441541; BURGINWOLFF A, 1991, ARCH DIS CHILD, V66, P941, DOI 10.1136/adc.66.8.941; CACCIARI E, 1985, LANCET, V1, P1469; COLLIN P, 1992, SCAND J GASTROENTERO, V27, P367, DOI 10.3109/00365529209000089; CORAZZA G, 1992, GASTROENTEROLOGY, V103, P1517, DOI 10.1016/0016-5085(92)91172-Z; CUNNINGHAMRUNDLES C, 1981, CLIN EXP IMMUNOL, V45, P299; FERGUSON MM, 1980, GUT, V21, P223, DOI 10.1136/gut.21.3.223; FERREIRA M, 1992, GUT, V33, P1633, DOI 10.1136/gut.33.12.1633; Greco L., 1992, COMMON FOOD INTOLERA, P25; GRODZINSKY E, 1992, ANN ALLERGY, V69, P66; HOLMES GKT, 1989, GUT, V30, P333, DOI 10.1136/gut.30.3.333; HOLMES GKT, 1992, COMMON FOOD INTOLERA, V1, P105; KOISTINEN J, 1975, VOX SANG, V29, P192, DOI 10.1111/j.1423-0410.1975.tb00494.x; Logan R. F. A., 1992, COMMON FOOD INTOLERA, P14; LOGAN RFA, 1989, GASTROENTEROLOGY, V97, P265, DOI 10.1016/0016-5085(89)90060-7; MAKI M, 1992, COMMON FOOD INTOLERA, V1, P93; MAZZETTI DP, 1992, ITAL J GASTROENTEROL, V24, P352; SAVILAHTI E, 1983, LANCET, V1, P320; SWINSON CM, 1983, LANCET, V1, P111; TRONCONE R, 1991, J PEDIATR GASTR NUTR, V12, P150, DOI 10.1097/00005176-199102000-00002; WALKERSMITH JA, 1990, ARCH DIS CHILD, V65, P909, DOI 10.1136/adc.65.8.909	22	618	641	0	45	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	1994	343	8891					200	203		10.1016/S0140-6736(94)90989-X	http://dx.doi.org/10.1016/S0140-6736(94)90989-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT332	7904667				2022-12-28	WOS:A1994MT33200008
J	EASTWOOD, R; SCHNEIDERMAN, G				EASTWOOD, R; SCHNEIDERMAN, G			COUCH FELLOWS	LANCET			English	Editorial Material											EASTWOOD, R (corresponding author), CLARKE INST PSYCHIAT, TORONTO M5T 1R8, ONTARIO, CANADA.							ANDREWS G, 1989, AM J PSYCHIAT, V146, P881; CAILLARD VF, 1992, INT PSYCHIATRY TODAY, V2, P1; KUPFER DJ, 1993, J CLIN PSYCHIAT, V54, P29; PAYKEL ES, 1993, INT ACAD B, V5, P62; REYNOLDS CF, 1992, AM J PSYCHIAT, V149, P1687; RODENHAUSER P, 1993, INT J GROUP PSYCHOTH, V43, P11, DOI 10.1080/00207284.1994.11491203	6	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	1994	343	8890					131	132		10.1016/S0140-6736(94)90929-6	http://dx.doi.org/10.1016/S0140-6736(94)90929-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7903999				2022-12-28	WOS:A1994MQ86900005
J	GREWE, M; GYUFKO, K; SCHOPF, E; KRUTMANN, J				GREWE, M; GYUFKO, K; SCHOPF, E; KRUTMANN, J			LESIONAL EXPRESSION OF INTERFERON-GAMMA IN ATOPIC ECZEMA	LANCET			English	Note							DERMATITIS	Atopic eczema is thought to be caused by skin-infiltrating CD4 T cells of the Th1-like and/or Th2-like subtype. We assessed expression of the Th1-like cytokine, interferon-gamma, and the Th2-like cytokine, interleukin-4, in lesional atopic skin. Compared with that in normal skin, interferon-gamma and interleukin-4 mRNA expression were increased in eczematous skin lesions in 13 and 4 of 15 patients, respectively. After successful therapy of atopic dermatitis, the increased interferon-gamma mRNA expression but not the increased interleukin-4 mRNA expression was significantly down-regulated. These data indicate that in-situ expression of interferon-gamma is linked to the clinical course of atopic dermatitis.			KRUTMANN, J (corresponding author), UNIV FREIBURG,DEPT DERMATOL,PHOTODERMATOL SECT,D-79104 FREIBURG,GERMANY.							BOS JD, 1992, ARCH DERMATOL, V128, P1509, DOI 10.1001/archderm.128.11.1509; HANIFIN JM, 1984, J ALLERGY CLIN IMMUN, V73, P211, DOI 10.1016/S0091-6749(84)80008-1; HENNINGER HP, 1991, BIOCH BIOPHYS HOPPE, V374, P625; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KRUTMANN J, 1992, J AM ACAD DERMATOL, V26, P225, DOI 10.1016/0190-9622(92)70031-A; KRUTMANN J, 1994, EPIDERMAL CYTOKINES, P4415; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; SZER N, 1992, J ALLERGY CLIN IMMUN, V89, P801	9	345	354	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					25	26		10.1016/S0140-6736(94)90879-6	http://dx.doi.org/10.1016/S0140-6736(94)90879-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905045				2022-12-28	WOS:A1994MN93700015
J	DELORGERIL, M; RENAUD, S; MAMELLE, N; SALEN, P; MARTIN, JL; MONJAUD, I; GUIDOLLET, J; TOUBOUL, P; DELAYE, J				DELORGERIL, M; RENAUD, S; MAMELLE, N; SALEN, P; MARTIN, JL; MONJAUD, I; GUIDOLLET, J; TOUBOUL, P; DELAYE, J			MEDITERRANEAN ALPHA-LINOLENIC ACID-RICH DIET IN SECONDARY PREVENTION OF CORONARY HEART-DISEASE	LANCET			English	Article							MYOCARDIAL-INFARCTION; PLATELET-AGGREGATION; SERUM-LIPIDS; FATTY-ACIDS; RISK; MEN; ANTIOXIDANTS; ARRHYTHMIAS; FRENCH; TRIAL	In a prospective, randomised single-blinded secondary prevention trial we compared the effect of a Mediterranean alpha-linolenic acid-rich diet to the usual post-infarct prudent diet. After a first myocardial infarction, patients were randomly assigned to the experimental (n=302) or control group (n=303). Patients were seen again 8 weeks after randomisation, and each year for 5 years. The experimental group consumed significantly less lipids, saturated fat, cholesterol, and linoleic acid but more oleic and alpha-linolenic acids confirmed by measurements in plasma. Serum lipids, blood pressure, and body mass index remained similar in the 2 groups. In the experimental group, plasma levels of albumin, vitamin E, and vitamin C were increased, and granulocyte count decreased. After a mean follow up of 27 months, there were 16 cardiac deaths in the control and 3 in the experimental group; 17 non-fatal myocardial infarction in the control and 5 in the experimental groups: a risk ratio for these two main endpoints combined of 0.27 (95% CI 0.12-0.59, p=0.001) after adjustment for prognostic variables. Overall mortality was 20 in the control, 8 in the experimental group, an adjusted risk ratio of 0.30 (95% CI 0.11-0.82, p = 0.02). An alpha-linolenic acid-rich Mediterranean diet seems to be more efficient than presently used diets in the secondary prevention of coronary events and death.	INSERM,U265,F-69675 BRON,FRANCE; HOP CARDIOVASC,BIOCHEM LAB,LYON,FRANCE; HOP CARDIOVASC,SERV CARDIOL,LYON,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon; CHU Lyon	DELORGERIL, M (corresponding author), INSERM,U63,LYON DIET HEART STUDY,22 AVE DOYEN LEPINE,CP 18,F-69675 BRON,FRANCE.		Martin, Jean-Louis/X-6588-2019	Martin, Jean-Louis/0000-0002-3426-9601				BURR ML, 1989, LANCET, V2, P757; DELORGERIL M, 1993, J INTERN MED, V233, P343; ELWOOD PC, 1991, CIRCULATION, V83, P38, DOI 10.1161/01.CIR.83.1.38; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; HJERMANN I, 1986, AM J MED, V80, P7, DOI 10.1016/0002-9343(86)90154-3; KAGAWA Y, 1982, J NUTR SCI VITAMINOL, V28, P441, DOI 10.3177/jnsv.28.441; KARDINAAL AFM, 1993, LANCET, V342, P1379, DOI 10.1016/0140-6736(93)92751-E; KEYS A, 1980, 7 COUNTRIES MULTIVAR, P67; LEREN P, 1970, CIRCULATION, V42, P935, DOI 10.1161/01.CIR.42.5.935; LIU TZ, 1982, CLIN CHEM, V28, P2225; MCLENNAN PL, 1993, AM J CLIN NUTR, V57, P207, DOI 10.1093/ajcn/57.2.207; MORRIS JN, 1968, LANCET, V2, P694; PACEASCIAK C, 1968, BIOCHIM BIOPHYS ACTA, V152, P784, DOI 10.1016/0005-2760(68)90126-4; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; REAVEN P, 1993, J CLIN INVEST, V91, P668, DOI 10.1172/JCI116247; RENAUD S, 1986, ATHEROSCLEROSIS, V60, P37, DOI 10.1016/0021-9150(86)90085-7; RENAUD S, 1983, LANCET, V1, P1169; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; RENAUD S, 1990, ATHEROSCLEROSIS, V80, P255, DOI 10.1016/0021-9150(90)90033-F; RENAUD S, 1989, J INTERN MED, V225, P39, DOI 10.1111/j.1365-2796.1989.tb01434.x; RIEMERSMA RA, 1989, J INTERN MED, V225, P111, DOI 10.1111/j.1365-2796.1989.tb01444.x; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SANDKER GW, 1993, EUR J CLIN NUTR, V47, P201; SIMOPOULOS AP, 1992, J AM COLL NUTR, V11, P374; SINGH RB, 1992, AM J CARDIOL, V69, P879, DOI 10.1016/0002-9149(92)90786-X; THAULOW E, 1991, CIRCULATION, V84, P613, DOI 10.1161/01.CIR.84.2.613; VUILLEUMIER JP, 1983, INT J VITAM NUTR RES, V53, P265; Woodhill J M, 1978, Adv Exp Med Biol, V109, P317; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203; 1984, JAMA-J AM MED ASSOC, V251, P351	30	1411	1436	3	147	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1454	1459		10.1016/S0140-6736(94)92580-1	http://dx.doi.org/10.1016/S0140-6736(94)92580-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911176				2022-12-28	WOS:A1994NQ41500007
J	SUBERBIELLE, C; CAILLATZUCMAN, S; LEGENDRE, C; BODEMER, C; NOEL, LH; KREIS, H; BACH, JF				SUBERBIELLE, C; CAILLATZUCMAN, S; LEGENDRE, C; BODEMER, C; NOEL, LH; KREIS, H; BACH, JF			PERIPHERAL MICROCHIMERISM IN LONG-TERM CADAVERIC-KIDNEY ALLOGRAFT RECIPIENTS	LANCET			English	Note							TRANSPLANTATION; CHIMERISM; TOLERANCE	Microchimerism after allogeneic organ transplantation may be a mechanism for induction of donor-specific graft acceptance. However, the frequency of chimerism and its relevance in long-term tolerance are uncertain. We studied 15 long-surviving (more than 20 years) cadaveric-kidney transplant recipients for the systemic presence of donor alleles with allele-specific genomic amplification of DRB1 and H-Y loci. Microchimerism was observed in 1 case in peripheral blood and in 4 cases in shin. Chimerism and number of HLA alleles shared by donor and recipient were not correlated. This low frequency of microchimerism in long-term kidney allograft recipients raises doubts about a major participation of chimerism in donor-specific tolerance.	HOP NECKER ENFANTS MALAD,INSERM,U25,F-75015 PARIS,FRANCE; HOP NECKER ENFANTS MALAD,SERV TRANSPLANTAT RENALE,PARIS,FRANCE; HOP NECKER ENFANTS MALAD,SERV DERMATOL,F-75730 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite				Caillat-Zucman, Sophie/0000-0002-4535-3550				COLLINS RH, 1993, NEW ENGL J MED, V328, P762, DOI 10.1056/NEJM199303183281104; DALLMAN MJ, 1993, IMMUNOL REV, V133, P5, DOI 10.1111/j.1600-065X.1993.tb01507.x; NAKAGOME Y, 1991, AM J MED GENET, V41, P112, DOI 10.1002/ajmg.1320410127; OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x; POSSELT AM, 1990, SCIENCE, V249, P1293, DOI 10.1126/science.2119056; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; STARZL TE, 1993, NEW ENGL J MED, V328, P745, DOI 10.1056/NEJM199303183281101; STARZL TE, 1993, TRANSPLANTATION, V55, P1272, DOI 10.1097/00007890-199306000-00012; STARZL TE, 1992, LANCET, V340, P876, DOI 10.1016/0140-6736(92)93286-V; TIERCY JM, 1991, P NATL ACAD SCI USA, V88, P7121, DOI 10.1073/pnas.88.16.7121	10	115	116	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1468	1469		10.1016/S0140-6736(94)92583-6	http://dx.doi.org/10.1016/S0140-6736(94)92583-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911179				2022-12-28	WOS:A1994NQ41500010
J	CAUL, EO				CAUL, EO			SMALL ROUND STRUCTURED VIRUSES - AIRBORNE TRANSMISSION AND HOSPITAL CONTROL	LANCET			English	Editorial Material											CAUL, EO (corresponding author), PUBL HLTH LAB,REG VIRUS LAB,BRISTOL,AVON,ENGLAND.							Caul E. O., 1993, PHLS Microbiology Digest, V10, P2; CAUL E O, 1988, P139; CHADWICK PR, 1994, LANCET, V343, P171, DOI 10.1016/S0140-6736(94)90959-8; GELLERT GA, 1994, LANCET, V343, P609; GREEN SM, IN PRESS J GEN VIROL; GREENBERG HB, 1979, LANCET, V1, P55; JIANG X, 1993, VIROLOGY, V195, P51, DOI 10.1006/viro.1993.1345; KAPIKIAN AZ, 1994, VIRAL INFECT GASTROI, P471; LAMBDEN PR, 1993, SCIENCE, V259, P516, DOI 10.1126/science.8380940; SAWYER LA, 1988, AM J EPIDEMIOL, V127, P1261, DOI 10.1093/oxfordjournals.aje.a114918; Zahorsky J., 1929, ARCH PEDIAT, V46, P391	11	140	144	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1240	1242		10.1016/S0140-6736(94)92146-6	http://dx.doi.org/10.1016/S0140-6736(94)92146-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910270				2022-12-28	WOS:A1994NM14400004
J	DOMINGUEZORTEGA, L; CUBEDOCERVERA, R; DIAZGALLEGO, E; CORTESFUNES, H				DOMINGUEZORTEGA, L; CUBEDOCERVERA, R; DIAZGALLEGO, E; CORTESFUNES, H			PROTECTION AGAINST CHEMOTHERAPY-INDUCED EMESIS WITH SLEEP	LANCET			English	Letter									HOSP 12 OCTUBRE,SLEEP UNIT,RUBER CLIN,E-28041 MADRID,SPAIN; HOSP 12 OCTUBRE,DEPT CLIN ONCOL,MADRID,SPAIN	Hospital Universitario 12 de Octubre; Hospital Universitario 12 de Octubre	DOMINGUEZORTEGA, L (corresponding author), HOSP 12 OCTUBRE,DEPT INTERNAL MED,CRRA ANDALUCIA KM 5400,E-28041 MADRID,SPAIN.							CARTER SK, 1977, METHODS DEV NEW ANTI; MITCHELL EP, 1992, SEMIN ONCOL, V19, P566; OBRIEN BJ, 1993, CAN MED ASSOC J, V149, P296	3	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1298	1298		10.1016/S0140-6736(94)92188-1	http://dx.doi.org/10.1016/S0140-6736(94)92188-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910307				2022-12-28	WOS:A1994NM14400057
J	MANN, GV				MANN, GV			METABOLIC CONSEQUENCES OF DIETARY TRANS-FATTY-ACIDS	LANCET			English	Review							CORONARY HEART-DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; CARDIOVASCULAR-DISEASE; LINOLEIC-ACID; SERUM-LIPIDS; ATHEROSCLEROSIS; CONSUMPTION; PREVENTION; MORTALITY; ALCOHOL	The epidemic of coronary heart disease in the western world followed the introduction of partially hydrogenated fats in food. Exposure to trans fatty acids (TFA) in those foods can explain the observed sex and age differences in serum cholesterol concentrations and coronary heart disease (CHD), the cholesterolaemic response to pregnancy, and national differences in rates of CHD. There is evidence that TFA can be innocuously used for muscular work. I propose that the TFA in partially hydrogenated fats impair lipoprotein receptors during energy surfeit, leading to hypercholesterolaemia, atherogenesis, obesity, and insulin resistance. A series of feasible experiments is proposed to examine this hypothesis.			MANN, GV (corresponding author), CRAIGHEAD HOUSE,3710 WESTBROOK AVE,NASHVILLE,TN 37205, USA.							BEARD CM, 1992, INT J EPIDEMIOL, V21, P656, DOI 10.1093/ije/21.4.656; BORKMAN M, 1993, NEW ENGL J MED, V328, P238, DOI 10.1056/NEJM199301283280404; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; ENIG MG, 1993, CORONARY HEART DISEASE, P36; ENIG MG, 1990, J AM COLL NUTR, V9, P471, DOI 10.1080/07315724.1990.10720404; FREIS ED, 1969, AM J MED, V46, P735, DOI 10.1016/0002-9343(69)90024-2; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Herrick JB, 1912, J AMER MED ASSOC, V59, P2015; HILL JS, 1991, ARTERIOSCLER THROMB, V11, P290, DOI 10.1161/01.ATV.11.2.290; JEEVANANDAM M, 1991, J CLIN INVEST, V87, P262, DOI 10.1172/JCI114980; KANNEL WB, 1988, NUTR REV, V46, P68, DOI 10.1111/j.1753-4887.1988.tb05389.x; KATAN MB, 1986, PROG LIPID RES, V25, P193, DOI 10.1016/0163-7827(86)90039-1; KEYS A, 1966, AM J CLIN NUTR, V19, P175; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KRITCHEVSKY D, 1989, ATHEROSCLEROSIS, V75, P123, DOI 10.1016/0021-9150(89)90168-8; LIFSHITZ F, 1989, AM J DIS CHILD, V143, P537, DOI 10.1001/archpedi.1989.02150170035015; MANN GV, 1972, AM J EPIDEMIOL, V95, P26, DOI 10.1093/oxfordjournals.aje.a121365; MANN GV, 1993, NEW ENGL J MED, V329, P358; MANN GV, 1955, NEW ENGL J MED, V253, P349, DOI 10.1056/NEJM195509012530901; MANN GV, 1993, CORONARY HEART DISEASE, P61; MANN GV, 1966, JAMA-J AM MED ASSOC, V197, P1070; MARMOT MG, 1984, INT J EPIDEMIOL, V13, P160, DOI 10.1093/ije/13.2.160; MCMURRY MP, 1991, NEW ENGL J MED, V325, P1704, DOI 10.1056/NEJM199112123252405; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MORRIS JN, 1990, BRIT HEART J, V63, P325; NESS RB, 1993, NEW ENGL J MED, V328, P1528, DOI 10.1056/NEJM199305273282104; OLIVER MF, 1955, CLIN SCI, V14, P15; OLIVER MF, 1991, LANCET, V337, P1529, DOI 10.1016/0140-6736(91)93208-Q; PLATT JR, 1966, STRONG INFERENCE STE; Popper K., 1959, LOGIC SCI DISCOVERY; RAVUSSIN E, 1982, AM J CLIN NUTR, V35, P566, DOI 10.1093/ajcn/35.3.566; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; Riepma Siert F., 1970, STORY MARGARINE; ROBBSMITH AHT, 1967, ENIGMA HEART DISEASE; ROSENMAN RH, 1993, HOMEOSTASIS HLTH DIS, V34, P1; SANDERS TAB, 1991, P NUTR SOC, V50, P513, DOI 10.1079/PNS19910064; Scriver C. R., 1989, METABOLIC BASIS INHE, V1; SCRIVER CR, 1989, METABOLIC BASIS INHE, V2; SEFTEL HC, 1980, BRIT MED J, V281, P633, DOI 10.1136/bmj.281.6241.633; SELTZER C C, 1991, Giornale Italiano di Cardiologia, V21, P683; Stary HC, 1989, ARTERIOSCLER, V99, pI19; STEHBENS WE, 1993, CORONARY HEART DISEASE, P18; STRANDBERG TE, 1991, JAMA-J AM MED ASSOC, V266, P1225, DOI 10.1001/jama.266.9.1225; TEXON M, 1993, CORONARY HEART DISEASE, P109; Thom T.J., 1989, INT J EPIDEMIOL S1, V18, P20; THOMAS LH, 1975, BRIT J PREV SOC MED, V29, P82; THOMAS LH, 1992, J EPIDEMIOL COMMUN H, V46, P78, DOI 10.1136/jech.46.1.78; VANHORN L, 1991, AM J PUBLIC HEALTH, V81, P183, DOI 10.2105/AJPH.81.2.183; VERGROESEN AJ, 1972, P NUTR SOC, V31, P323, DOI 10.1079/PNS19720059; WALKER WJ, 1953, AM J MED, V14, P654, DOI 10.1016/0002-9343(53)90383-0; WILLIAMS RR, 1986, JAMA-J AM MED ASSOC, V255, P219, DOI 10.1001/jama.255.2.219; ZOCK PL, 1992, J LIPID RES, V33, P399; 1982, JAMA-J AM MED ASSOC, V248, P1465; 1984, JAMA-J AM MED ASSOC, V251, P355	54	56	61	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1268	1271		10.1016/S0140-6736(94)92157-1	http://dx.doi.org/10.1016/S0140-6736(94)92157-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910281				2022-12-28	WOS:A1994NM14400015
J	ELREFAEY, H; CALDER, L; WHEATLEY, DN; TEMPLETON, A				ELREFAEY, H; CALDER, L; WHEATLEY, DN; TEMPLETON, A			CERVICAL PRIMING WITH PROSTAGLANDIN-E1 ANALOGS, MISOPROSTOL AND GEMEPROST	LANCET			English	Article							1ST TRIMESTER; MIFEPRISTONE RU-486; CURETTAGE ABORTION; DILATATION; SUCTION; LAMICEL	Although it is well established that cervical priming before surgically induced abortion reduces the incidence of complications, its use is infrequent and confined to groups perceived to be at high risk. We compared the effect of prostaglandin E1 analogues, gemeprost and misoprostol, on the cervix. Both induced clinical and histochemical changes that were significantly different from controls and were likely to have therapeutic value. Misoprostol, however, is cheap, easily stored, and associated with few side-effects. Cervical pre-dilation with misoprostol may be considered in all women having surgically induced abortions.	UNIV ABERDEEN,SCH MED,DEPT PATHOL,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen	ELREFAEY, H (corresponding author), UNIV ABERDEEN,SCH MED,DEPT OBSTET & GYNAECOL,ABERDEEN AB9 2ZD,SCOTLAND.							AUBENY G, 1991, CR ACAD SCI III-VIE, V312, P539; COLLINS PW, 1990, MED RES REV, V10, P149, DOI 10.1002/med.2610100202; DIGGORY P, 1989, BRIT J OBSTET GYNAEC, V96, P133; DING JQ, 1990, PROSTAGLANDINS, V39, P281, DOI 10.1016/0090-6980(90)90047-Y; ELREFAEY H, 1994, CONTRACEPTION, V49, P111, DOI 10.1016/0010-7824(94)90085-X; Gore SM, 1992, STAT PRACTICE, P6; GREER IA, 1992, EUR J OBSTET GYN R B, V47, P1, DOI 10.1016/0028-2243(92)90207-F; Grimes D A, 1979, Obstet Gynecol Surv, V34, P177, DOI 10.1097/00006254-197903000-00001; GRIMES DA, 1984, JAMA-J AM MED ASSOC, V251, P2108, DOI 10.1001/jama.251.16.2108; HELM CW, 1988, BRIT J OBSTET GYNAEC, V95, P911, DOI 10.1111/j.1471-0528.1988.tb06579.x; HENSHAW RC, 1991, BRIT J OBSTET GYNAEC, V98, P1025, DOI 10.1111/j.1471-0528.1991.tb15341.x; MARGULIES M, 1992, LANCET, V339, P64, DOI 10.1016/0140-6736(92)90194-8; NORSTROM A, 1988, BRIT J OBSTET GYNAEC, V95, P372, DOI 10.1111/j.1471-0528.1988.tb06608.x; NOSTROM A, 1982, PROSTAGLANDINS, V23, P361; PENNY G, 1994, IN PRESS BR J OBSTET; SAKAMOTO S, 1982, PROSTAGLANDINS LEUKO, V9, P36; SCHULZ KF, 1983, LANCET, V1, P1182; SWEAT F, 1964, ARCH PATHOL, V78, P69; URQUHART DR, 1990, CONTRACEPTION, V42, P191, DOI 10.1016/0010-7824(90)90102-2; 1990, BRIT J OBSTET GYNAEC, V97, P480	20	97	97	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1207	1209		10.1016/S0140-6736(94)92406-6	http://dx.doi.org/10.1016/S0140-6736(94)92406-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909874				2022-12-28	WOS:A1994NL17500015
J	SULLIVAN, P; BEKIR, S; JAFFAR, Z; PAGE, C; JEFFERY, P; COSTELLO, J				SULLIVAN, P; BEKIR, S; JAFFAR, Z; PAGE, C; JEFFERY, P; COSTELLO, J			ANTIINFLAMMATORY EFFECTS OF LOW-DOSE ORAL THEOPHYLLINE IN ATONIC ASTHMA	LANCET			English	Article							AIRWAY INFLAMMATION; EOSINOPHILS	Theophylline, in addition to its bronchodilator effect, may attenuate inflammation in asthma. We did a double-blind placebo-controlled study of the effect of oral theophylline on the inflammatory response of the bronchial mucosa to inhalation of allergen in 19 atopic asthmatic subjects. Bronchoscopy and bronchial biopsy were done 24 hours after allergen inhalation before and after six weeks of treatment with oral slow-release theophylline, 200 mg 12 hourly. The mean serum concentration was 36.6 mu mol/L, which is below the currently-accepted therapeutic range. After treatment with theophylline there was a significant reduction in the number of EG2-positive activated eosinophils (5.9 before and 2.1 after treatment, Wilcoxon signed rank p<0.05) and total eosinophils (16.7 before and 7.6 after treatment, p<0.05) beneath the epithelial basement membrane. We conclude that low-dose oral theophylline attenuates airway inflammatory response to allergen inhalation in atopic asthma.	ROYAL BROMPTON NATL HEART & LUNG INST,DEPT LUNG PATHOL,LONDON,ENGLAND	Imperial College London	SULLIVAN, P (corresponding author), UNIV LONDON KINGS COLL HOSP,SCH MED & DENT,SACKLER INST PULM PHARMACOL,DEPT THORAC MED,LONDON SE5 9PJ,ENGLAND.							[Anonymous], 1993, THORAX, V48, pS1; AZZAWI M, 1992, AM REV RESPIR DIS, V145, P1477, DOI 10.1164/ajrccm/145.6.1477; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; CALHOUN WJ, 1991, J LAB CLIN MED, V117, P514; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; EVANS TW, 1989, CLIN SCI, V76, P479, DOI 10.1042/cs0760479; HENDERSON WR, 1991, AM REV RESPIR DIS, V143, pS86, DOI 10.1164/ajrccm/143.5_Pt_2.S86; KIDNEY JC, 1994, THORAX, V49, P396; LAITINEN LA, 1991, AM REV RESPIR DIS, V143, P423, DOI 10.1164/ajrccm/143.2.423; MOQBEL R, 1992, CLIN EXP ALLERGY, V22, P265, DOI 10.1111/j.1365-2222.1992.tb03082.x; PAUWELS R, 1985, J ALLERGY CLIN IMMUN, V76, P583, DOI 10.1016/0091-6749(85)90779-1; PERSSON CGA, 1986, J ALLERGY CLIN IMMUN, V78, P780, DOI 10.1016/0091-6749(86)90061-8; PIACENTINI GL, 1991, AM REV RESPIR DIS, V143, pS96; SANJAR S, 1990, BRIT J PHARMACOL, V99, P679, DOI 10.1111/j.1476-5381.1990.tb12989.x; VENGE P, 1992, J ALLERGY CLIN IMMUN, V89, pA181; WARD AJM, 1993, AM REV RESPIR DIS, V147, P518, DOI 10.1164/ajrccm/147.3.518; 1972, CLIN PHARMACOL THER, V13, P694	19	332	342	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 23	1994	343	8904					1006	1008		10.1016/S0140-6736(94)90127-9	http://dx.doi.org/10.1016/S0140-6736(94)90127-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909049				2022-12-28	WOS:A1994NG68200010
J	LOEVINSOHN, ME				LOEVINSOHN, ME			CLIMATIC WARMING AND INCREASED MALARIA INCIDENCE IN RWANDA	LANCET			English	Article								Global climatic change is expected to increase the incidence of vector-borne diseases, especially malaria. This study assessed the contribution of climate to a malaria epidemic in Rwanda, focusing on the catchment area of one health centre where diagnosis was consistent and non-climatic variables well monitored. In late 1987 malaria incidence in the area increased by 337% over the 3 previous years. The increase was greatest in groups with little acquired immunity-children under 2 years (564%) and people in high-altitude areas (501%). Case-fatality rose significantly (relative risk = 485, p<0.001). 1987 also saw record high temperatures and rainfall. An autoregressive equation including lagged effects of these two variables explained 80% of the variance in monthly malaria incidence. Temperature (especially mean minimum) predicted incidence best at higher altitudes where malaria had increased most. Empirically derived relations were consistent with the estimated generation time of the disease and with the known sensitivity of the plasmodium parasite to temperature. The patterns of climatic warming between day and night and among seasons will be critical to the effect on malaria. These findings are most relevant to regions near the altitude or latitude limits of the disease, where several epidemics have lately been reported.	INST SCI AGRON RWANDA,BUTARE,RWANDA; APPL ECOL CONSULTANTS,BUTARE,RWANDA									[Anonymous], 1976, TIME SERIES ANAL; AULT SK, 1989, DEMOGRAPHY VECTOR BO, P283; Bennett R., 1979, SPATIAL TIME SERIES; BUGILIMFURA L, 1988, REV MED RWANDAISE, V20, P93; DETINOVA TS, 1962, WHO MONOGR SER, V47; DIETZ K, 1974, B WORLD HEALTH ORGAN, V50, P347; Folland CK, 1990, CLIMATE CHANGE: THE IPCC SCIENTIFIC ASSESSMENT, P195; GASCON J, 1988, T ROY SOC TROP MED H, V82, P222, DOI 10.1016/0035-9203(88)90418-X; LEPERS JP, 1990, B SOC PATHOL EXOT, V83, P330; MALATRE X, 1990, REV MED RWANDAISE, V22, P31; Mitchell JFB, 1990, CLIMATE CHANGE: THE IPCC SCIENTIFIC ASSESSMENT, P131; MOLINEAUX L, 1988, MALARIA PRINCIPLES P, P914; Munyantore S, 1989, REV MED RWANDAISE, V21, P14; MUNYANTORE S, 1993, INFLUENCE RIZICULTUR; ROPELEWSKI CF, 1987, MON WEATHER REV, V115, P1606, DOI 10.1175/1520-0493(1987)115<1606:GARSPP>2.0.CO;2; Wigley TML, 1990, CLIMATE CHANGE: THE IPCC SCIENTIFIC ASSESSMENT, P239; 1991, ELEMENTS ELABORATION; 1983, RECENSEMENT GENERAL; 1990, WORLD HLTH STAT Q, V43, P68; 1990, WHO PEP9010; 1991, RECONSEMENT GENERAL	21	201	209	0	50	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					714	718		10.1016/S0140-6736(94)91586-5	http://dx.doi.org/10.1016/S0140-6736(94)91586-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907685				2022-12-28	WOS:A1994NB80900015
J	WHITE, HD				WHITE, HD			ASPIRIN OR WARFARIN FOR NONRHEUMATIC ATRIAL-FIBRILLATION	LANCET			English	Editorial Material											WHITE, HD (corresponding author), GREEN LANE HOSP,DEPT CARDIOL,AUCKLAND 3,NEW ZEALAND.							CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P406; FEINBERG WM, 1990, ARCH INTERN MED, V150, P2340, DOI 10.1001/archinte.150.11.2340; LAKE FR, 1989, AUST NZ J MED, V19, P321, DOI 10.1111/j.1445-5994.1989.tb00271.x; PETERSEN P, 1989, LANCET, V1, P175; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; 1992, ANN INTERN MED, V116, P6; 1991, CIRCULATION, V84, P527; 1993, LANCET, V342, P1255; 1990, NEW ENGL J MED, V323, P1505; 1992, ANN INTERN MED, V116, P1	11	19	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					683	684		10.1016/S0140-6736(94)91573-3	http://dx.doi.org/10.1016/S0140-6736(94)91573-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907673				2022-12-28	WOS:A1994NB80900002
J	KNOX, KK; CARRIGAN, DR				KNOX, KK; CARRIGAN, DR			DISSEMINATED ACTIVE HHV-6 INFECTIONS IN PATIENTS WITH AIDS	LANCET			English	Note							HUMAN HERPESVIRUS-6	Human herpesvirus 6 (HHV-6) infected cells were detected in all lung, lymph-node, spleen, liver, and kidney tissues obtained at necropsy from an unselected series of nine patients with AIDS. This infection rate was significantly higher than that for cytomegalovirus. Lung infection with HHV-6 was extensive enough in one patient to account for fatal pneumonitis. In other tissues increased numbers of HHV-6 infected cells were related to the presence of lymphocytic infiltrates or residual lymphoid tissue, with lymphocytes being predominantly infected. Thus HHV-6 is an important pathogen in patients with AIDS.			KNOX, KK (corresponding author), MED COLL WISCONSIN,DEPT PATHOL,8700 W WISCONSIN AVE,MILWAUKEE,WI 53226, USA.							CARRIGAN DR, 1990, J INFECT DIS, V162, P844, DOI 10.1093/infdis/162.4.844; CARRIGAN DR, 1991, LANCET, V338, P147, DOI 10.1016/0140-6736(91)90137-E; DROBYSKI WR, 1993, J INFECT DIS, V167, P735, DOI 10.1093/infdis/167.3.735; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAUCI AS, 1993, J ACQ IMMUN DEF SYND, V6, P665; GALLO RC, 1988, J ACQ IMMUN DEF SYND, V1, P521; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; MCKENZIE R, 1991, MEDICINE, V70, P326, DOI 10.1097/00005792-199109000-00004; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PELLETT PE, 1992, ADV VIRUS RES, V41, P1, DOI 10.1016/S0065-3527(08)60034-2	10	115	120	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 5	1994	343	8897					577	578		10.1016/S0140-6736(94)91524-5	http://dx.doi.org/10.1016/S0140-6736(94)91524-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906332				2022-12-28	WOS:A1994MY84300012
J	HENGARTNER, MO; HORVITZ, HR				HENGARTNER, MO; HORVITZ, HR			C-ELEGANS CELL-SURVIVAL GENE CED-9 ENCODES A FUNCTIONAL HOMOLOG OF THE MAMMALIAN PROTOONCOGENE BCL-2	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; FOLLICULAR LYMPHOMA; MOLECULAR-GENETICS; MEMBRANE PROTEIN; B-CELLS; DEATH; CLONING; EXPRESSION; TRANSLOCATION; APOPTOSIS	The activity of the C. elegans gene ced-9 is required to protect cells that normally survive from undergoing programmed cell death. Here we describe the cloning and molecular characterization of this gene. ced-9 is an element of a polycistronic locus that also contains the gene cyt-1, which encodes a protein similar to cytochrome b(560) of complex II of the mitochondrial respiratory chain. ced-9 encodes a 280 amino acid protein showing sequence and structural similarities to the mammalian proto-oncogene bcl-2. Overexpression of bcl-2 can mimic the protective effect of ced-9 on C. elegans cell death and can prevent the ectopic cell deaths that occur in ced-9 loss-of-function mutants. These results suggest that ced-9 and bcl-2 are homologs and that the molecular mechanism of programmed cell death has been conserved from nematodes to mammals.			HENGARTNER, MO (corresponding author), MIT, DEPT BIOL, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA.		Hengartner, Michael O/A-7058-2008; Hengartner, Michael O/E-6235-2011	Hengartner, Michael/0000-0002-7584-596X				ABRAHAM PR, 1992, YEAST, V8, P227, DOI 10.1002/yea.320080309; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BATISTATOU A, 1993, J NEUROSCI, V13, P4422; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BRENNER S, 1974, GENETICS, V77, P71; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; COULSON AR, 1986, P NATL ACAD SCI USA, V85, P4397; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DRISCOLL M, 1992, J NEUROBIOL, V23, P1327, DOI 10.1002/neu.480230919; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FERGUSON EL, 1989, GENETICS, V123, P109; FILES JG, 1983, J MOL BIOL, V164, P355, DOI 10.1016/0022-2836(83)90056-6; FUKUHARA S, 1979, CANCER RES, V39, P3119; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; Gottesman S., 1983, GENE FUNCTION PROKAR, P163; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KORSMEYER SJ, 1992, CANCER SURV, V15, P105; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Lehninger A L, 1982, PRINCIPLES BIOCH; LIN EY, 1993, J IMMUNOL, V151, P1979; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NUNEZ G, 1990, J IMMUNOL, V144, P3602; ODA K, 1992, J MOL BIOL, V223, P1, DOI 10.1016/0022-2836(92)90708-R; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PERRY MD, 1993, GENE DEV, V7, P216, DOI 10.1101/gad.7.2.216; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RUVKUN G, 1989, GENETICS, V121, P501; Sambrook J, 1989, MOL CLONING LABORATO; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SPENCE AM, 1990, CELL, V60, P981, DOI 10.1016/0092-8674(90)90346-G; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; Stryer L., 1988, BIOCHEMISTRY-US; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TANAKA S, 1993, J BIOL CHEM, V268, P10920; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WATERSTON RH, 1981, GENETICS, V97, P307; WHITE JG, 1991, PHILOS T ROY SOC B, V331, P263, DOI 10.1098/rstb.1991.0015; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WOLSTENHOLME DR, 1992, INT REV CYTOL, V141, P173, DOI 10.1016/S0074-7696(08)62066-5; WOOD D, 1984, BIOCHEM J, V222, P519, DOI 10.1042/bj2220519; YU L, 1992, J BIOL CHEM, V267, P24508; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; YUNIS JJ, 1982, NEW ENGL J MED, V307, P1231, DOI 10.1056/NEJM198211113072002; [No title captured]	77	1026	1080	0	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 25	1994	76	4					665	676		10.1016/0092-8674(94)90506-1	http://dx.doi.org/10.1016/0092-8674(94)90506-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	7907274				2022-12-28	WOS:A1994MZ28500009
J	APPLEBY, P; BAIGENT, C; COLLINS, R; FLATHER, M; PARISH, S; PETO, R; BELL, P; HALLS, H; MEAD, G; DIAZ, R; PAOLASSO, E; PAVIOTTI, C; ROMERO, G; CAMPBELL, T; OROURKE, MF; THOMPSON, P; LESAFFRE, E; VANDEWERF, F; VERSTRAETE, M; ARMSTRONG, PW; CAIRNS, JA; MORAN, C; TURPIE, AG; YUSUF, S; GRANDE, P; HEIKKILA, J; KALA, R; BASSAND, JP; BOISSEL, JP; BROCHIER, M; LEIZOROVICZ, A; BRUGGEMANN, T; KARSCH, KR; KASPER, W; LAMMERTS, D; NEUHAUS, KL; MEYER, J; SCHRODER, R; VONESSEN, R; SARAN, RK; ARDISSINO, D; BONADUCE, D; BRUNELLI, C; CERNIGLIARO, C; FORESTI, A; FRANZOSI, MG; GUIDUCCI, D; MAGGIONI, A; MAGNANI, B; MATTIOLI, G; ROSSI, P; SAONTRO, E; TOGNONI, G; VISANI, L; ZENNARO, RG; KANEMOTO, N; KAWAI, C; ARNOLD, AER; BAR, FW; SIMOONS, ML; VERHEUGT, FWA; VERMEER, F; WHITE, HD; SEABRAGOMES, R; FIGUERAS, J; LOPEZSENDON, J; GRIP, L; HERLITZ, J; KARLSSON, JE; WALLENTIN, L; MONNIER, P; ADAMS, PC; BEEN, M; CHAMBERLAIN, DA; DEBONO, D; DOLL, R; DUFF, D; FOX, KAA; SREEHARAN, N; HILLIS, WS; JULIAN, DG; MALCOLM, A; MURRAY, RG; PATTERSON, DLH; POCOCK, S; REID, DS; SANDERCOCK, P; SIGWART, U; SKELDING, J; SKENE, A; SLEIGHT, P; TIMMIS, A; WARLOW, C; WILCOX, RG; ALLEN, A; ANDERSON, J; BRAUNWALD, E; CALIFF, R; GOLD, HK; GRANETT, J; GRAINGER, C; GUERCI, AD; HENNEKENS, C; HONAN, MB; KENNEDY, JW; KNATTERUD, G; LEE, K; LEIMBERGER, J; LENERT, LA; LITTLEJOHN, J; MAYNARD, C; NICKLAS, J; OHMAN, M; OLSON, HG; PASSAMANI, E; RYAN, TJ; SELKER, HP; STUMP, D; TOPOL, EJ; WEAVER, WD; WILLIAMS, DO; WOODLIEF, L				APPLEBY, P; BAIGENT, C; COLLINS, R; FLATHER, M; PARISH, S; PETO, R; BELL, P; HALLS, H; MEAD, G; DIAZ, R; PAOLASSO, E; PAVIOTTI, C; ROMERO, G; CAMPBELL, T; OROURKE, MF; THOMPSON, P; LESAFFRE, E; VANDEWERF, F; VERSTRAETE, M; ARMSTRONG, PW; CAIRNS, JA; MORAN, C; TURPIE, AG; YUSUF, S; GRANDE, P; HEIKKILA, J; KALA, R; BASSAND, JP; BOISSEL, JP; BROCHIER, M; LEIZOROVICZ, A; BRUGGEMANN, T; KARSCH, KR; KASPER, W; LAMMERTS, D; NEUHAUS, KL; MEYER, J; SCHRODER, R; VONESSEN, R; SARAN, RK; ARDISSINO, D; BONADUCE, D; BRUNELLI, C; CERNIGLIARO, C; FORESTI, A; FRANZOSI, MG; GUIDUCCI, D; MAGGIONI, A; MAGNANI, B; MATTIOLI, G; ROSSI, P; SAONTRO, E; TOGNONI, G; VISANI, L; ZENNARO, RG; KANEMOTO, N; KAWAI, C; ARNOLD, AER; BAR, FW; SIMOONS, ML; VERHEUGT, FWA; VERMEER, F; WHITE, HD; SEABRAGOMES, R; FIGUERAS, J; LOPEZSENDON, J; GRIP, L; HERLITZ, J; KARLSSON, JE; WALLENTIN, L; MONNIER, P; ADAMS, PC; BEEN, M; CHAMBERLAIN, DA; DEBONO, D; DOLL, R; DUFF, D; FOX, KAA; SREEHARAN, N; HILLIS, WS; JULIAN, DG; MALCOLM, A; MURRAY, RG; PATTERSON, DLH; POCOCK, S; REID, DS; SANDERCOCK, P; SIGWART, U; SKELDING, J; SKENE, A; SLEIGHT, P; TIMMIS, A; WARLOW, C; WILCOX, RG; ALLEN, A; ANDERSON, J; BRAUNWALD, E; CALIFF, R; GOLD, HK; GRANETT, J; GRAINGER, C; GUERCI, AD; HENNEKENS, C; HONAN, MB; KENNEDY, JW; KNATTERUD, G; LEE, K; LEIMBERGER, J; LENERT, LA; LITTLEJOHN, J; MAYNARD, C; NICKLAS, J; OHMAN, M; OLSON, HG; PASSAMANI, E; RYAN, TJ; SELKER, HP; STUMP, D; TOPOL, EJ; WEAVER, WD; WILLIAMS, DO; WOODLIEF, L			INDICATIONS FOR FIBRINOLYTIC THERAPY IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - COLLABORATIVE OVERVIEW OF EARLY MORTALITY AND MAJOR MORBIDITY RESULTS FROM ALL RANDOMIZED TRIALS OF MORE THAN 1000 PATIENTS	LANCET			English	Article							LEFT-VENTRICULAR FUNCTION; THROMBOLYTIC THERAPY; INTRAVENOUS STREPTOKINASE; INTRACRANIAL HEMORRHAGE; SYSTEMATIC OVERVIEWS; REPERFUSION; SELECTION; STROKE; METAANALYSIS; ANGIOPLASTY	Large randomised trials have demonstrated that fibrinolytic therapy can reduce mortality in patients with suspected acute myocardial infarction (AMI). The indications for, and contraindications to, this treatment in some categories of patient are disputed, examples being late presentation, elderly patients, and those in cardiogenic shock. This overview aims to help resolve some of the remaining uncertainties. From all trials of fibrinolytic therapy versus control that randomised more than 1000 patients with suspected AMI, information was sought and checked on deaths during the first 5 weeks and on major adverse events occurring during hospitalisation. The nine trials included 58 600 patients, among whom 6177 (10.5%) deaths, 564 (1.0%) strokes, and 436 (0.7%) major non-cerebral bleeds were reported. Fibrinolytic therapy was associated with an excess of deaths during days 0-1 (especially among patients presenting more than 1.2 h after symptom onset, and in the elderly) but this was outweighed by a much larger benefit during days 2-35. This ''early hazard'' should not obscure the very clear overall survival advantage that is produced by fibrinolytic therapy. Benefit was observed among patients presenting with ST elevation or bundle-branch block (BBB)-irrespective of age, sex, blood pressure, heart rate, or previous history of myocardial infarction or diabetes and was greater the earlier treatment began. Among the 45 000 patients presenting with ST elevation or BBB the relation between benefit and delay from symptom onset indicated highly significant absolute mortality reductions of about 30 per 1000 for those presenting within 0-6 h and of about 20 per 1600 for those presenting 7-12 h from onset, and a statistically uncertain benefit of about 10 per 1000 for those presenting at 13-18 h (with more randomised evidence needed in this latter group to assess reliably the net effects of treatment). Fibrinolytic therapy was associated with about 4 extra strokes per 1000 during days 0-1: of these, 2 were associated with early death and so were already accounted for in the overall mortality reduction, 1 was moderately or severely disabling, and 1 was not. This overview indicates that fibrinolytic therapy is beneficial in a much wider range of patients than is currently given such treatment routinely.			APPLEBY, P (corresponding author), RADCLIFFE INFIRM, NUFFIELD DEPT CLIN MED,ICRF,MRC,BHF, CLIN TRIAL SERV UNIT, OXFORD OX2 6HE, ENGLAND.		Fox, keith A A/I-3742-2013; sandercock, peter/GQI-3167-2022; Thompson, Peter L/P-1071-2014; Cairns, John/AAI-8744-2021; Verheugt, F.W.A./H-8105-2014; Maynard, Charles/N-3906-2015; Ardissino, Diego/AAC-4041-2022	sandercock, peter/0000-0001-8484-0135; Maynard, Charles/0000-0002-1644-7814; 				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1989, LANCET, V2, P655; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1993, Lancet, V342, P767; [Anonymous], 1986, Lancet, V1, P397; BAIGENT C, 1993, CIRCULATION, V88, P291; BATES ER, 1991, J AM COLL CARDIOL, V18, P1077, DOI 10.1016/0735-1097(91)90770-A; BATES ER, 1988, J AM COLL CARDIOL, V12, pA44, DOI 10.1016/0735-1097(88)92640-X; BATES ER, 1989, J AM COLL CARDIOL, V13, P12, DOI 10.1016/0735-1097(89)90542-1; BRAUNWALD E, 1989, CIRCULATION, V79, P441, DOI 10.1161/01.CIR.79.2.441; BRAUNWALD E, 1985, J CLIN INVEST, V76, P1713, DOI 10.1172/JCI112160; BRAUNWALD E, 1990, CIRCULATION, V82, P1510, DOI 10.1161/01.CIR.82.4.1510; CALIFF RM, 1989, J AM COLL CARDIOL, V13, P1130, DOI 10.1016/0735-1097(89)90274-X; CHAMBERLAIN DA, 1988, LANCET, V1, P545; CHAMBERLAIN DA, 1990, LANCET, V335, P427; CHAPMAN GD, 1993, AM J CARDIOL, V71, P783, DOI 10.1016/0002-9149(93)90824-V; COLLINS R, 1987, STAT MED, V6, P245, DOI 10.1002/sim.4780060308; COLLINS R, 1991, BRIT HEART J, V66, P250; COLLINS R, 1991, CIRCULATION, V84, P230; CRAGG DR, 1991, ANN INTERN MED, V115, P173, DOI 10.7326/0003-4819-115-3-173; DEJAEGERE PP, 1992, J AM COLL CARDIOL, V19, P289, DOI 10.1016/0735-1097(92)90480-B; Early Breast Cancer Trialists' Collaborative Group, 1990, TREATMENT EARLY BREA, V1; EFRON B, 1977, SCI AM, V236, P119, DOI 10.1038/scientificamerican0577-119; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; GRAY D, 1993, LANCET, V341, P654, DOI 10.1016/0140-6736(93)90420-L; GRINES CL, 1990, J AM COLL CARDIOL, V16, P223, DOI 10.1016/0735-1097(90)90482-5; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P1720, DOI 10.1001/jama.265.13.1720; HAMPTON J, 1993, LANCET, V342, P759; HLATKY MA, 1988, AM J CARDIOL, V61, P510, DOI 10.1016/0002-9149(88)90755-2; HONAN MB, 1990, J AM COLL CARDIOL, V16, P359, DOI 10.1016/0735-1097(90)90586-E; HUNT D, 1992, LANCET, V339, P753; HUTTER AM, 1989, J AM COLL CARDIOL, V13, P1127; KETLEY D, 1993, LANCET, V342, P891, DOI 10.1016/0140-6736(93)91945-I; LANGE RA, 1993, NEW ENGL J MED, V328, P726, DOI 10.1056/NEJM199303113281010; LEW AS, 1987, AM J CARDIOL, V59, P1, DOI 10.1016/S0002-9149(87)80059-0; LOUKINEN K L, 1989, Journal of the American College of Cardiology, V13, p94A; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MAGGIONI AP, 1992, NEW ENGL J MED, V327, P1, DOI 10.1056/NEJM199207023270101; MASSEL DR, 1993, BRIT HEART J, V69, P284; MAURI F, 1987, Giornale Italiano di Cardiologia, V17, P37; MIDGETTE AS, 1990, ANN INTERN MED, V113, P961, DOI 10.7326/0003-4819-113-12-961; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; PFEFFER MA, 1991, JAMA-J AM MED ASSOC, V266, P528, DOI 10.1001/jama.266.4.528; ROSSI P, 1991, AM J CARDIOL, V68, P585, DOI 10.1016/0002-9149(91)90348-O; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; SCHRODER R, 1989, AM J CARDIOL, V64, P878, DOI 10.1016/0002-9149(89)90835-7; SLOAN MA, 1992, AM J CARDIOL, V69, pA21, DOI 10.1016/0002-9149(92)91169-5; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1992, NEW ENGL J MED, V327, P45, DOI 10.1056/NEJM199207023270109; WASSERMAN AG, 1989, AM J CARDIOL, V64, pB17, DOI 10.1016/S0002-9149(89)80004-9; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7; WHITE HD, 1992, LANCET, V340, P221, DOI 10.1016/0140-6736(92)90478-L; WILCOX RG, 1988, LANCET, V2, P525; WILCOX RG, 1990, LANCET, V335, P1175; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; 1989, LANCET, V2, P899; 1987, LANCET, V2, P872	58	2181	2249	2	29	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 5	1994	343	8893					311	322		10.1016/S0140-6736(94)91161-4	http://dx.doi.org/10.1016/S0140-6736(94)91161-4			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905143				2022-12-28	WOS:A1994MU98500007
J	BLANCHE, S; MAYAUX, MJ; ROUZIOUX, C; TEGLAS, JP; FIRTION, G; MONPOUX, F; CIRARUVIGNERON, N; MEIER, F; TRICOIRE, J; COURPOTIN, C; VILMER, E; GRISCELLI, C; DELFRAISSY, JF; TARDIEU, M; NOSEDA, G; HURAUX, JM; LEVINE, M; VILMER, E; DECREPY, A; SIMON, F; KRIVINE, A; FRANCOUAL, C; DIMARIA, L; COURPOTIN, C; MONCOMBLE, CC; BURGARD, M; ROUZIOUX, C; GIRAULT, D; STEPHAN, JL; BLANCHE, S; TERRIS, J; VEBER, F; FIRTION, G; HENRION, R; CIRARUVIGNERON, N; BRUNER, C; MATHIEU, FP; HERVE, F; ALLISY, C; DANDINE, M; LABRUNE, P; VIAL, M; LACHASSINE, E; GAUDELUS, J; FLOCH, C; MAZY, F; MEIER, F; ROBIN, M; ALLEMON, MC; TALON, P; BERTEROTTIERE, D; ROUSSET, MC; WIPFF, P; VINAS, A; NARCY, P; ARMENGAUD, D; GUILLOT, F; LEBLANC, A; MAY, A; DOUARD, D; FLEURY, H; BROUARD, J; FREYMUTH, F; VALLE, D; MICHEL, G; TAMALET, C; NICOLAS, J; DEVILLE, A; MONPOUX, F; COTTALORDA, J; HERNANDORENA, X; BROSSARD, V; TRICOIRE, J; ROBERT, A; PUEL, J; MAYAUX, MJ; ROUZIOUX, C; BLANCHE, S; LAURENT, C; DOUSSIN, A; MOUDOUB, Y				BLANCHE, S; MAYAUX, MJ; ROUZIOUX, C; TEGLAS, JP; FIRTION, G; MONPOUX, F; CIRARUVIGNERON, N; MEIER, F; TRICOIRE, J; COURPOTIN, C; VILMER, E; GRISCELLI, C; DELFRAISSY, JF; TARDIEU, M; NOSEDA, G; HURAUX, JM; LEVINE, M; VILMER, E; DECREPY, A; SIMON, F; KRIVINE, A; FRANCOUAL, C; DIMARIA, L; COURPOTIN, C; MONCOMBLE, CC; BURGARD, M; ROUZIOUX, C; GIRAULT, D; STEPHAN, JL; BLANCHE, S; TERRIS, J; VEBER, F; FIRTION, G; HENRION, R; CIRARUVIGNERON, N; BRUNER, C; MATHIEU, FP; HERVE, F; ALLISY, C; DANDINE, M; LABRUNE, P; VIAL, M; LACHASSINE, E; GAUDELUS, J; FLOCH, C; MAZY, F; MEIER, F; ROBIN, M; ALLEMON, MC; TALON, P; BERTEROTTIERE, D; ROUSSET, MC; WIPFF, P; VINAS, A; NARCY, P; ARMENGAUD, D; GUILLOT, F; LEBLANC, A; MAY, A; DOUARD, D; FLEURY, H; BROUARD, J; FREYMUTH, F; VALLE, D; MICHEL, G; TAMALET, C; NICOLAS, J; DEVILLE, A; MONPOUX, F; COTTALORDA, J; HERNANDORENA, X; BROSSARD, V; TRICOIRE, J; ROBERT, A; PUEL, J; MAYAUX, MJ; ROUZIOUX, C; BLANCHE, S; LAURENT, C; DOUSSIN, A; MOUDOUB, Y			RELATION OF THE COURSE OF HIV-INFECTION IN CHILDREN TO THE SEVERITY OF THE DISEASE IN THEIR MOTHERS AT DELIVERY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INFANTS BORN; TYPE-1; WOMEN	Background. Among infants with maternally transmitted human immunodeficiency virus (HIV) infection, there are two patterns of disease progression. In about a fifth of these infants there is a rapid progression to profound immunodeficiency, whereas in the majority the disease progresses much more slowly. Methods. We studied the clinical and biologic characteristics of the mothers of infants infected with HIV type 1 (HIV-1) in the French Prospective Multicenter Cohort. Infection in the children was confirmed by serologic tests at the age of 18 months or by death from the acquired immunodeficiency syndrome at an earlier age. Only the 162 infected infants who could be followed for at least 18 months or until death were included in the analysis. Results. The risk of opportunistic infections or encephalopathy in the first 18 months was 50 percent in the infants of mothers with class IV disease, according to the Centers for Disease Control and Prevention classification, and 14 percent in the infants of mothers with class II or III disease (relative risk, 3.6; 95 percent confidence interval, 1.8 to 7.3; P<0.002). Forty-four percent of the former infants and 9 percent of the latter died before 18 months (relative risk, 4.7; 95 percent confidence interval, 2.1 to 10.4; P<0.002). The risk of death correlated inversely with the mother's CD4+ cell count and directly with her HIV-1 p24 antigen level at delivery. There was also a direct correlation between the mother's CD4+ cell count and that of the infant at one, three, and nine months of age (correlation coefficient at nine months [n = 441, 0.48; P<0.002). HIV-1 p24 antigen was detected more often in the infants whose mothers also had the antigen. Conclusions. In infants whose HIV infection is maternally acquired, the rate of disease progression varies directly with the severity of the disease in the mother at the time of delivery.	HOP NECKER ENFANTS MALAD,VIROL LAB,F-75743 PARIS 15,FRANCE; HOP BICETRE,INSERM,UNITE 292,F-94270 LE KREMLIN BICETR,FRANCE; HOP LA PITIE SALPETRIERE,PARIS,FRANCE; HOP ROBERT DEBRE,PARIS,FRANCE; HOP ST VINCENT,PARIS,FRANCE; HOP TROUSSEAU,F-75571 PARIS 12,FRANCE; HOP CITE UNIV,PARIS,FRANCE; HOP COCHIN,F-75674 PARIS 14,FRANCE; HOP LARIBOISIERE,F-75475 PARIS 10,FRANCE; HOP ST ANTOINE,F-75571 PARIS 12,FRANCE; HOP TENON,F-75970 PARIS 20,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite	BLANCHE, S (corresponding author), HOP NECKER ENFANTS MALAD,INSERM,UNITE 132,UNITE IMMUNOL HEMATOL PEDIAT,F-75743 PARIS 15,FRANCE.		Brouard, Jacques/AAH-3387-2020					ASJO B, 1986, LANCET, V2, P660; AUGER I, 1988, NATURE, V336, P575, DOI 10.1038/336575a0; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BLANCHE S, 1990, AM J DIS CHILD, V144, P1210, DOI 10.1001/archpedi.1990.02150350042021; BURGARD M, 1992, NEW ENGL J MED, V327, P1192, DOI 10.1056/NEJM199210223271702; JONES DS, 1992, PEDIATRICS, V89, P123; KOOT M, 1992, AIDS, V6, P49, DOI 10.1097/00002030-199201000-00006; LYMAN WD, 1990, AIDS, V4, P917, DOI 10.1097/00002030-199009000-00014; PAPIERNIK M, 1992, PEDIATRICS, V89, P297; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; SCOTT GB, 1989, NEW ENGL J MED, V321, P179; TOVO PA, 1992, LANCET, V339, P1249, DOI 10.1016/0140-6736(92)91592-V; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406; 1987, MMWR MORB MORTAL WKL, V36, P225; 1986, ANN INTERN MED, V105, P234; 1992, J ACQ IMMUN DEF SYND, V5, P1019; 1987, MMWR MORB MORTAL WKL, V36, P235	17	182	185	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 3	1994	330	5					308	312		10.1056/NEJM199402033300502	http://dx.doi.org/10.1056/NEJM199402033300502			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU489	7904046	Bronze			2022-12-28	WOS:A1994MU48900002
J	BIGNALL, J				BIGNALL, J			LEARNING AND LOVING	LANCET			English	Editorial Material																		NOVACK DH, 1993, JAMA-J AM MED ASSOC, V269, P2101, DOI 10.1001/jama.269.16.2101; 1993, BRIT MED J, V307, P742	2	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					249	250		10.1016/S0140-6736(94)91107-X	http://dx.doi.org/10.1016/S0140-6736(94)91107-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905091				2022-12-28	WOS:A1994MT44000005
J	AFONSO, LCC; SCHARTON, TM; VIEIRA, LQ; WYSOCKA, M; TRINCHIERI, G; SCOTT, P				AFONSO, LCC; SCHARTON, TM; VIEIRA, LQ; WYSOCKA, M; TRINCHIERI, G; SCOTT, P			THE ADJUVANT EFFECT OF INTERLEUKIN-12 IN A VACCINE AGAINST LEISHMANIA-MAJOR	SCIENCE			English	Article							CELL STIMULATORY FACTOR; CUTANEOUS LEISHMANIASIS; PROTECTIVE IMMUNITY; INTERFERON-GAMMA; MURINE MODEL; INDUCTION; SUBSETS	Protection induced by vaccination depends on the capacity of the vaccine to elicit an appropriate immune response. In leishmaniasis, protection requires leishmanial-specific CD4+ T helper (T(H)) cells. Vaccination of BAL-B/c mice with leishmanial antigens and interleukin-12 (IL-12) promoted the development of leishmanial-specific CD4+ T(H)1 cells These mice were resistant to subsequent infection with Leishmania major. Thus, IL-12 is an effective adjuvant for the initiation of protective cell-mediated immunity against leishmaniasis and may be an important component in other vaccines that need tc induce cell-mediated immunity.	UNIV PENN,SCH VET MED,DEPT PATHOBIOL,PHILADELPHIA,PA 19104; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	University of Pennsylvania; The Wistar Institute			Trinchieri, Giorgio/F-9369-2015; Vieira, Leda Q/G-7487-2014; Vieira, Leda Quercia/AAD-3424-2019; Afonso, Luis C C/C-2224-2013; Afonso, Luis C C/G-5436-2012	Trinchieri, Giorgio/0000-0001-5892-7464; Vieira, Leda Quercia/0000-0001-5481-9618; Afonso, Luis C C/0000-0003-2498-4086; Afonso, Luis C C/0000-0003-2498-4086	NATIONAL CANCER INSTITUTE [R01CA020833, R37CA020833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030073] Funding Source: NIH RePORTER; NCI NIH HHS [CA-20833] Funding Source: Medline; NIAID NIH HHS [AI-30073] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AFONSO LCC, UNPUB; CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; GAZZINELLI RT, 1993, P NATL ACAD SCI USA, V90, P6115, DOI 10.1073/pnas.90.13.6115; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; MACATONIA SE, 1993, INT IMMUNOL, V5, P1119, DOI 10.1093/intimm/5.9.1119; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; SCHARTON TM, 1993, J EXP MED, V178, P567, DOI 10.1084/jem.178.2.567; SCOTT P, 1987, J IMMUNOL, V139, P221; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; SCOTT P, 1991, J IMMUNOL, V147, P3149; SEDER RA, 1993, P NATL ACAD SCI USA, V90, P10188, DOI 10.1073/pnas.90.21.10188; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; TRIPP CS, 1993, P NATL ACAD SCI USA, V90, P3725, DOI 10.1073/pnas.90.8.3725; WARREN HS, 1986, ANNU REV IMMUNOL, V4, P369, DOI 10.1146/annurev.iy.04.040186.002101	18	661	707	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 14	1994	263	5144					235	237		10.1126/science.7904381	http://dx.doi.org/10.1126/science.7904381			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ879	7904381				2022-12-28	WOS:A1994MQ87900038
J	MELKI, J; LEFEBVRE, S; BURGLEN, L; BURLET, P; CLERMONT, O; MILLASSEAU, P; REBOULLET, S; BENICHOU, B; ZEVIANI, M; LEPASLIER, D; COHEN, D; WEISSENBACH, J; MUNNICH, A				MELKI, J; LEFEBVRE, S; BURGLEN, L; BURLET, P; CLERMONT, O; MILLASSEAU, P; REBOULLET, S; BENICHOU, B; ZEVIANI, M; LEPASLIER, D; COHEN, D; WEISSENBACH, J; MUNNICH, A			DE-NOVO AND INHERITED DELETIONS OF THE 5Q13 REGION IN SPINAL MUSCULAR ATROPHIES	SCIENCE			English	Article							WERDNIG-HOFFMANN DISEASE; GENE; CHILDHOOD; CONTIG	Spinal muscular atrophies (SMAs) represent the second most common fatal autosomal recessive disorder after cystic fibrosis. Childhood spinal muscular atrophies are divided into severe (type I) and mild forms (types II and III). By a combination of genetic and physical mapping, a yeast artificial chromosome contig of the 5q13 region spanning the disease locus was constructed that showed the presence of low copy repeats in this region. Allele segregation was analyzed at the closest genetic loci detected by markers C212 and C272 in 201 SMA families. Inherited and de novo deletions were observed in nine unrelated SMA patients. Moreover, deletions were strongly suggested in at least 18 percent of SMA type I patients by the observation of marked heterozygosity deficiency for the loci studied. These results indicate that deletion events are statistically associated with the severe form of spinal muscular atrophy.	HOP NECKER ENFANTS MALAD,INSERM,U393,UNITE RECH HANDICAPS GENET ENFANT,F-75743 PARIS,FRANCE; GENETHON,EVRY,FRANCE; CTR ETUD POLYMORPHISME HUMAIN,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Lefebvre, Suzie/D-5092-2017; Zeviani, Massimo/K-2891-2014; Zeviani, Massimo/AAU-2632-2021	Zeviani, Massimo/0000-0002-9067-5508; BERNARD, BENICHOU/0000-0002-9331-0926; Le Paslier, Denis/0000-0003-4335-9956				BRZUSTOWICZ LM, 1990, NATURE, V344, P540, DOI 10.1038/344540a0; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; CLERMONT O, 1994, AM J HUM GENET, V54, P687; CZEIZEL A, 1989, J MED GENET, V26, P761, DOI 10.1136/jmg.26.12.761; DANIELS RJ, 1992, GENOMICS, V12, P335, DOI 10.1016/0888-7543(92)90382-3; FRANCIS MJ, 1993, HUM MOL GENET, V2, P1161, DOI 10.1093/hmg/2.8.1161; GILLIAM TC, 1990, NATURE, V345, P823, DOI 10.1038/345823a0; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; HAUSMANOWAPETRUSEWICZ I, 1985, J MED GENET, V22, P350, DOI 10.1136/jmg.22.5.350; HAZAN J, 1992, GENOMICS, V12, P183, DOI 10.1016/0888-7543(92)90364-X; KLEYN PW, 1993, P NATL ACAD SCI USA, V90, P6801, DOI 10.1073/pnas.90.14.6801; MELKI J, 1990, LANCET, V336, P271, DOI 10.1016/0140-6736(90)91803-I; MELKI J, 1990, NATURE, V344, P764; Monaco AP, 1988, GENOMICS, V2, P90, DOI 10.1016/0888-7543(88)90113-9; Munsat TL., 1991, NEUROMUSCUL DISORD, V1, P81, DOI [10.1016/0960-8966(91)90052-t, DOI 10.1016/0960-8966(91)90052-T]; PEARN J, 1978, J MED GENET, V15, P403; PEARN JH, 1973, J MED GENET, V10, P260, DOI 10.1136/jmg.10.3.260; ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; ZERRES K, 1988, THESIS U BONN	20	290	299	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 3	1994	264	5164					1474	1477		10.1126/science.7910982	http://dx.doi.org/10.1126/science.7910982			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP221	7910982				2022-12-28	WOS:A1994NP22100047
J	KERR, GS; HALLAHAN, CW; GIORDANO, J; LEAVITT, RY; FAUCI, AS; ROTTEM, M; HOFFMAN, GS				KERR, GS; HALLAHAN, CW; GIORDANO, J; LEAVITT, RY; FAUCI, AS; ROTTEM, M; HOFFMAN, GS			TAKAYASU ARTERITIS	ANNALS OF INTERNAL MEDICINE			English	Article							NORTH-AMERICAN PATIENTS; SURGICAL-TREATMENT; ANGIOGRAPHIC FINDINGS; DISEASE; AORTOARTERITIS; GRANULOMATOSIS; INVOLVEMENT; AORTITIS; METHOTREXATE; SARCOIDOSIS	Objective: To evaluate prospectively the clinical features, angiographic findings, and response to treatment of patients with Takayasu arteritis. Design: 60 patients with Takayasu arteritis were studied at the National Institute of Allergy and Infectious Diseases between 1970 and 1990 and were followed for 6 months to 20 years (median follow-up, 5.3 years). Measurements: Data on clinical features, angiographic and laboratory findings, disease course, and response to therapy were all recorded and stored in a computer-based retrieval system. Setting: The Warren Magnuson Clinical Center of the National Institutes of Health. Results: In our series of patients, Takayasu arteritis was more common in Asian persons compared with persons from other racial groups. Females (97%) were most frequently affected. The median age at disease onset was 25 years. Juveniles had a delay in diagnosis that was about four times that of adults. The clinical presentation ranged from asymptomatic to catastrophic with stroke. The most common clinical finding was a bruit. Hypertension was most often associated with renal artery stenosis. Only 33% of all patients had systemic symptoms on presentation. Sixty-eight percent of patients had extensive vascular disease; stenotic lesions were 3.6-fold more common than were aneurysms (98% compared with 27%). The erythrocyte sedimentation rate was not a consistently reliable surrogate marker of disease activity. Surgical bypass biopsy specimens from clinically inactive patients showed histologically active disease in 44% of patients. Although clinically significant palliation usually occurred after angioplasty or bypass of severely stenotic vessels, restenosis was common. Medical therapy was required for 80% of patients, whereas 20% had monophasic self-limiting disease. Immunosuppressive treatment with glucocorticoids alone or in combination with a cytotoxic agent failed to induce remission in one fourth of patients; about half of those who achieved remission later relapsed. Conclusions: In North America, Takayasu arteritis is a rare disease. It is heterogeneous in presentation, progression, and response to therapy. Current laboratory markers of disease activity are insufficiently reliable to guide management. Most patients require repeated and, at times, prolonged courses of therapy. Although mortality was low, substantial morbidity occurred in most patients.	NIAID, IMMUNOREGULAT LAB, BETHESDA, MD 20892 USA; GEORGE WASHINGTON UNIV HOSP, WASHINGTON, DC 20037 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); George Washington University			Ulatan, Jeffrey/AAM-5560-2020	Ulatan, Jeffrey/0000-0002-3756-0568				ABE K, 1976, JPN HEART J, V17, P1; ACHAR KN, 1986, AM J GASTROENTEROL, V81, P1215; ASKUPMARK E, 1961, ACTA MED SCAND, V169, P467; ASO T, 1992, HEART VESSELS S, V7, P15; CHUGH KS, 1992, AM J NEPHROL, V12, P1, DOI 10.1159/000168409; CIPRIANO PR, 1977, AM J CARDIOL, V39, P744, DOI 10.1016/S0002-9149(77)80139-2; DANARAJ TJ, 1959, CIRCULATION, V20, P856, DOI 10.1161/01.CIR.20.5.856; DEUTSCH V, 1974, AM J ROENTGENOL, V122, P13, DOI 10.2214/ajr.122.1.13; DIGIACOMO V, 1985, ANGIOLOGY, V36, P70, DOI 10.1177/000331978503600202; FRAGA A, 1972, ARTHRITIS RHEUM, V15, P617, DOI 10.1002/art.1780150608; GIORDANO JM, 1991, SURGERY, V109, P252; HALL S, 1985, MEDICINE, V64, P89, DOI 10.1097/00005792-198503000-00002; HE NS, 1990, CHINESE MED J-PEKING, V103, P666; HOFFMAN GS, 1992, ARTHRITIS RHEUM, V35, P1322, DOI 10.1002/art.1780351113; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; HOFFMAN GS, 1994, ARTHRITIS RHEUM, V37, P578, DOI 10.1002/art.1780370420; ISAACSON C, 1961, J PATHOL BACTERIOL, V81, P69, DOI 10.1002/path.1700810109; ISHIKAWA K, 1988, J AM COLL CARDIOL, V12, P964, DOI 10.1016/0735-1097(88)90462-7; ISHIKAWA K, 1982, AM J CARDIOL, V50, P1293, DOI 10.1016/0002-9149(82)90466-0; JUDGE RD, 1962, AM J MED, V32, P379, DOI 10.1016/0002-9343(62)90128-6; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KHRAISHI MM, 1992, ARTHRITIS RHEUM, V35, P573, DOI 10.1002/art.1780350514; KUMAR S, 1989, CARDIOVASC INTER RAD, V12, P321, DOI 10.1007/BF02575430; LAGNEAU P, 1987, ANN SURG, V205, P157, DOI 10.1097/00000658-198702000-00010; LANDE A, 1976, NEW YORK STATE J MED, V76, P1477; LEE J, 1990, HLA SYSTEM; LEE KS, 1967, ACTA PAEDIATR SCAND, V56, P526, DOI 10.1111/j.1651-2227.1967.tb15418.x; LENHOFF SJ, 1982, POSTGRAD MED J, V58, P386, DOI 10.1136/pgmj.58.680.386; LUPIH E, 1975, CHEST, V67, P69, DOI 10.1378/chest.67.1.69; LUPIHERRERA E, 1977, AM HEART J, V93, P94, DOI 10.1016/S0002-8703(77)80178-6; MAEDA S, 1983, ACTA PATHOL JAPON, V33, P183; Matsumura A, 1992, Heart Vessels Suppl, V7, P120, DOI 10.1007/BF01744557; MENDELOFF AI, 1980, INFLAMM BOWEL DIS, P5; MEVORACH D, 1992, ANN RHEUM DIS, V51, P904, DOI 10.1136/ard.51.7.904; MORIUCHI J, 1982, HUM IMMUNOL, V4, P87, DOI 10.1016/0198-8859(82)90054-4; NAKAO K, 1967, CIRCULATION, V35, P1141, DOI 10.1161/01.CIR.35.6.1141; NUMANO F, 1982, JPN CIRC J, V46, P184, DOI 10.1253/jcj.46.184; NUSINOW SR, 1984, ARTHRITIS RHEUM, V27, P1405, DOI 10.1002/art.1780271211; PAJARI R, 1986, THORAC CARDIOV SURG, V34, P176, DOI 10.1055/s-2007-1020404; ROSE AG, 1980, ARCH PATHOL LAB MED, V104, P231; ROSE CD, 1990, J RHEUMATOL, V17, P102; Sabba C, 1990, Am J Cardiovasc Pathol, V3, P95; SEN PK, 1973, MONOGRAPH BASED STUD; SHARMA S, 1991, BRIT J RADIOL, V64, P690, DOI 10.1259/0007-1285-64-764-690; SHARMA S, 1990, CLIN RADIOL, V42, P177, DOI 10.1016/S0009-9260(05)81929-4; SHARMA S, 1992, AM J ROENTGENOL, V158, P417, DOI 10.2214/ajr.158.2.1346073; SIMES RJ, 1986, BIOMETRIKA, V73, P751, DOI 10.2307/2336545; SUBRAMANYAN R, 1989, CIRCULATION, V80, P429, DOI 10.1161/01.CIR.80.3.429; TAKAGI A, 1989, J CARDIOVASC SURG, V30, P553; VINIJCHAIKUL K, 1967, AM J MED, V43, P15, DOI 10.1016/0002-9343(67)90145-3; VOLKMAN DJ, 1982, NEW ENGL J MED, V306, P464, DOI 10.1056/NEJM198202253060806; WAERN AU, 1983, ANGIOLOGY, V34, P311; Weaver F A, 1992, Heart Vessels Suppl, V7, P154, DOI 10.1007/BF01744562; WEAVER RL, 1990, WAVE MOTION, V12, P129, DOI 10.1016/0165-2125(90)90034-2; WONG VCW, 1983, AM J MED, V75, P597, DOI 10.1016/0002-9343(83)90439-4; WOOLF AD, 1987, ANN RHEUM DIS, V46, P441, DOI 10.1136/ard.46.6.441; YAMADA I, 1992, AM J ROENTGENOL, V159, P263, DOI 10.2214/ajr.159.2.1352939; YAMATO M, 1986, RADIOLOGY, V161, P329, DOI 10.1148/radiology.161.2.2876459; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZHENG DY, 1990, CHINESE MED J-PEKING, V103, P536; 1990, AM SOC HISTOCOMPATIB; 1992, HEART VESSELS S, V7, P1; 1990, NATIONAL DATA BOOK, P77	63	1304	1429	2	37	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1994	120	11					919	929		10.7326/0003-4819-120-11-199406010-00004	http://dx.doi.org/10.7326/0003-4819-120-11-199406010-00004			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN110	7909656				2022-12-28	WOS:A1994NN11000004
J	GODDARD, CJR; WARNES, TW				GODDARD, CJR; WARNES, TW			PRIMARY BILIARY-CIRRHOSIS - HOW SHOULD WE EVALUATE NEW TREATMENTS	LANCET			English	Editorial Material							CONTROLLED TRIAL; PROGNOSIS; COLCHICINE; MODEL				GODDARD, CJR (corresponding author), MANCHESTER ROYAL INFIRM,LIVER UNIT,MANCHESTER,LANCS,ENGLAND.							BABBS C, 1988, LANCET, V1, P1021; BIRCHER J, 1983, SEMIN LIVER DIS, V3, P275, DOI 10.1055/s-2008-1040780; CHRISTENSEN E, 1993, GASTROENTEROLOGY, V105, P1865, DOI 10.1016/0016-5085(93)91086-W; DICKSON ER, 1989, HEPATOLOGY, V10, P1, DOI 10.1002/hep.1840100102; HEATHCOTE EJ, 1994, HEPATOLOGY, V10, P1149; KAPLAN MM, 1986, NEW ENGL J MED, V315, P1448, DOI 10.1056/NEJM198612043152304; KAPLAN MM, 1991, GASTROENTEROLOGY, V101, P1332, DOI 10.1016/0016-5085(91)90085-Y; LINDOR KD, 1994, GASTROENTEROLOGY, V106, P1284, DOI 10.1016/0016-5085(94)90021-3; LOMBARD M, 1993, GASTROENTEROLOGY, V104, P519, DOI 10.1016/0016-5085(93)90422-9; POUPON RE, 1994, NEW ENGL J MED, V330, P1342, DOI 10.1056/NEJM199405123301903; POUPON RE, 1994, HEPATOLOGY, V19, P635, DOI 10.1002/hep.1840190314; ROLL J, 1983, NEW ENGL J MED, V308, P1, DOI 10.1056/NEJM198301063080101; WARNES TW, 1987, J HEPATOL, V5, P1, DOI 10.1016/S0168-8278(87)80053-3; WIESNER RH, 1988, HEPATOLOGY, V8, P668, DOI 10.1002/hep.1840080339	14	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1305	1306		10.1016/S0140-6736(94)92461-9	http://dx.doi.org/10.1016/S0140-6736(94)92461-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910318				2022-12-28	WOS:A1994NN21700004
J	SKRABANEK, P				SKRABANEK, P			THE COERCIVE ALTRUISM OF SAVING LIVES ON ROADS	LANCET			English	Editorial Material											SKRABANEK, P (corresponding author), UNIV DUBLIN TRINITY COLL,DEPT COMMUNITY HLTH & GEN PRACTICE,DUBLIN 2,IRELAND.							EASON K, 1991, TIMES           0514; EVANS L, 1994, AM J PUBLIC HEALTH, V84, P33, DOI 10.2105/AJPH.84.1.33; HANNON BM, 1978, AM J PUBLIC HEALTH, V68, P765, DOI 10.2105/AJPH.68.8.765; HOFSTADTER D, 1985, MATH THEMES; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; Leichter H.M., 1991, FREE BE FOOLISH POLI; MCCARTHY M, 1992, BRIT MED J, V305, P881, DOI 10.1136/bmj.305.6858.881; MCCARTHY M, 1989, J EPIDEMIOL COMMUN H, V43, P218, DOI 10.1136/jech.43.3.218; 1986, LANCET, V1, P75; 1983, JAMA-J AM MED ASSOC, V249, P3216; 1988, LANCET, V1, P159	11	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1176	1176		10.1016/S0140-6736(94)92397-3	http://dx.doi.org/10.1016/S0140-6736(94)92397-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NL175	7909865				2022-12-28	WOS:A1994NL17500006
J	WOO, DDL; MIAO, SYP; PELAYO, JC; WOOLF, AS				WOO, DDL; MIAO, SYP; PELAYO, JC; WOOLF, AS			TAXOL INHIBITS PROGRESSION OF CONGENITAL POLYCYSTIC KIDNEY-DISEASE	NATURE			English	Article							PROTOONCOGENE EXPRESSION; CYST FORMATION; CYCLIC-AMP; MICROTUBULES; CELLS; SECRETION; MEMBRANE; GROWTH; MOUSE; EPITHELIA	POLYCYSTIC kidney diseases (PKD) are the most common hereditary diseases of the human kidney and account for ten per cent of patients requiring renal transplantation or dialysis. Renal cyst formation has been attributed to enhanced cell proliferation, unbalanced cell death, abnormal targeting of membrane proteins; aberrant kidney development and tubular obstruction, but there is no treatment that blocks the formation and enlargement of renal cysts. We have now developed an in vitro model of spontaneous cyst formation that distinguishes polycystic kidney epithelium from its normal counterpart. Inhibitors of DNA, RNA and protein synthesis did not prevent in vitro cyst formation, but this was reversibly inhibited by ouabain, amiloride and the microtubule-specific agents colchicine, vinblastine and taxol. The cpk mouse is a well-characterized recessive PKD model(1-3) and we find that cpk/cpk mice develop PKD and die from uraemia by 4-5 weeks of age, but when treated weekly with taxol they survive for more than 200 days with minimal loss of renal function, show limited collecting-dust cyst enlargement, and attain adult size. Our results indicate that the microtubule cytoskeleton has a central role in the pathogenesis of PKD in cpk mice and that taxol may also be useful in treating human PKD.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PAEDIAT,LOS ANGELES,CA 90024; INST CHILD HLTH,DEV BIOL UNIT,LONDON WC1N 1EH,ENGLAND	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of London; University College London	WOO, DDL (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,7-155 FACTOR BLDG,LOS ANGELES,CA 90024, USA.		Woolf, Adrian S./AAZ-1075-2020	Woolf, Adrian S./0000-0001-5541-1358				AVNER ED, 1988, PEDIATR NEPHROL, V2, P210, DOI 10.1007/BF00862593; AVNER ED, 1987, PEDIATR NEPHROL, V1, P587, DOI 10.1007/BF00853593; AVNER ED, 1992, P NATL ACAD SCI USA, V89, P7447, DOI 10.1073/pnas.89.16.7447; BLOOM TL, 1989, DEVELOPMENT, V106, P159; BRENNER BM, 1983, KIDNEY INT, V23, P647, DOI 10.1038/ki.1983.72; CARONE FA, 1989, KIDNEY INT, V35, P1351, DOI 10.1038/ki.1989.134; COWLEY BD, 1987, P NATL ACAD SCI USA, V84, P8394, DOI 10.1073/pnas.84.23.8394; COWLEY BD, 1991, J AM SOC NEPHROL, V1, P1048; DEALMEIDA JB, 1991, AM J PHYSIOL, V260, pC691, DOI 10.1152/ajpcell.1991.260.4.C691; FLEMING TP, 1988, ANNU REV CELL BIOL, V4, P459, DOI 10.1146/annurev.cellbio.4.1.459; GATTONE VH, 1988, LAB INVEST, V59, P231; KELLY R, 1990, CELL, V60, P5; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MANGOOKARIM R, 1989, FASEB J, V3, P2629, DOI 10.1096/fasebj.3.14.2480260; MARO R, 1991, DEVELOPMENT S1, V1, P17; PARCZYK K, 1989, J BIOL CHEM, V264, P16837; PREMINGER GM, 1982, J UROLOGY, V127, P556, DOI 10.1016/S0022-5347(17)53911-7; ROGALSKI AA, 1984, J CELL BIOL, V99, P1101, DOI 10.1083/jcb.99.3.1101; Russell E, 1977, MOUSE NEWSLETTER, V56, P40; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SLOT C, 1965, SCAND J CLIN LAB INV, V17, P381, DOI 10.3109/00365516509077065; THYBERG J, 1985, EXP CELL RES, V159, P1, DOI 10.1016/S0014-4827(85)80032-X; VALENTICH JD, 1979, J CELL PHYSIOL, V100, P291, DOI 10.1002/jcp.1041000210; WILSON PD, 1991, AM J PHYSIOL, V260, pF420, DOI 10.1152/ajprenal.1991.260.3.F420; WILSON PD, 1986, KIDNEY INT, V30, P371, DOI 10.1038/ki.1986.194; YANG AH, 1987, IN VITRO CELL DEV B, V23, P34	26	129	147	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 21	1994	368	6473					750	753		10.1038/368750a0	http://dx.doi.org/10.1038/368750a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	7908721				2022-12-28	WOS:A1994NG55300061
J	OZEL, M; DIRINGER, H				OZEL, M; DIRINGER, H			SMALL VIRUS-LIKE STRUCTURE IN FRACTIONS FROM SCRAPIE HAMSTER BRAIN	LANCET			English	Note							PROTEIN	The scrapie model in hamsters has been used to search for the agents that cause Creutzfeldt-Jakob disease in man and similar transmissible encephalopathies in animals. We found structures that are extraordinarily small for a virus, but exhibit viral structural properties in negatively stained samples, by electron microscopy in fractions containing scrapie-associated fibrils.	BUNDESGESUNDHEITSAMT,ROBERT KOCH INST,D-13353 BERLIN,GERMANY	Robert Koch Institute								DIRINGER H, 1992, EXP CLIN IMMUNOGENET, V9, P212; DIRINGER H, 1983, EUR J BIOCHEM, V134, P550; HILMERT H, 1984, BIOSCIENCE REP, V4, P165, DOI 10.1007/BF01120313; MERZ PA, 1983, NATURE, V306, P474, DOI 10.1038/306474a0; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Rohwer R G, 1991, Curr Top Microbiol Immunol, V172, P195; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; TISCHER I, 1982, NATURE, V295, P64, DOI 10.1038/295064a0	8	34	34	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 9	1994	343	8902					894	895		10.1016/S0140-6736(94)90010-8	http://dx.doi.org/10.1016/S0140-6736(94)90010-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF213	7908360				2022-12-28	WOS:A1994NF21300010
J	WILSON, APR				WILSON, APR			DONOR SERUM FOR PERITONITIS	LANCET			English	Editorial Material											WILSON, APR (corresponding author), UNIV COLL HOSP LONDON,DEPT CLIN MICROBIOL,WC1 LONDON,ENGLAND.							BILLING AG, 1994, EUR J CLIN INVEST, V24, P28, DOI 10.1111/j.1365-2362.1994.tb02056.x; BOHNEN J, 1983, ARCH SURG-CHICAGO, V118, P285; BOHNEN JMA, 1988, ARCH SURG-CHICAGO, V123, P225; DUNN DL, 1987, ARCH SURG-CHICAGO, V122, P105; EDMONISTON CE, 1990, WORLD J SURG, V14, P176; ROTSTEIN OD, 1990, WORLD J SURG, V14, P159, DOI 10.1007/BF01664868; SCHEIN M, 1988, SURG GYNECOL OBSTET, V166, P187; SKAU T, 1986, J SURG RES, V40, P13, DOI 10.1016/0022-4804(86)90139-3	8	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					807	807		10.1016/S0140-6736(94)92019-2	http://dx.doi.org/10.1016/S0140-6736(94)92019-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908072				2022-12-28	WOS:A1994ND79200002
J	LYNCH, JW; KAPLAN, GA; COHEN, RD; KAUHANEN, J; WILSON, TW; SMITH, NL; SALONEN, JT				LYNCH, JW; KAPLAN, GA; COHEN, RD; KAUHANEN, J; WILSON, TW; SMITH, NL; SALONEN, JT			CHILDHOOD AND ADULT SOCIOECONOMIC-STATUS AS PREDICTORS OF MORTALITY IN FINLAND	LANCET			English	Article							EARLY LIFE EXPERIENCE; CARDIOVASCULAR-DISEASE; HEART-DISEASE; MOBILITY; CHILDREN; HEALTH	Research has suggested that social-class differences in adult health may be at least partly determined by conditions earlier in life. In 2636 Finnish men, we assessed impact of childhood and adult socioeconomic conditions on adult mortality risk by examining whether differing socioeconomic lifecourses from early childhood to adulthood were associated with different risks of all-cause and cardiovascular mortality. Compared with high-income adults, those with low income had increased relative risks of all-cause (2.54, 95% CI 1.83-3.53) and cardiovascular (2.37, 1.51-3.7) mortality, but these increased risks were not related in either adult group to childhood socioeconomic conditions. Men who went from low-income childhood to high-income adulthood had the same mortality risks as those whose socioeconomic circumstances were good in both childhood and adulthood (1.14, 0.56-2.31, all causes; 0.99, 0.39-2.51, cardiovascular). By contrast, men who experienced poor socioeconomic circumstances as both children and adults were about twice as likely to die as those whose position improved (2.39, 1.28-4.44, all causes; 2.02, 0.9-4.54, cardiovascular). Our findings suggest that socioeconomic conditions in childhood are not important determinants of adult health. We caution against this interpretation-a lifecourse approach to socioeconomic differences in adult health requires understanding of the social and economic context in which individual lifecourses are determined.	CALIF DEPT COMMUNITY HLTH SERV, HUMAN POPULAT LAB, BERKELEY, CA 94704 USA; UNIV KUOPIO, PUBL HLTH RES INST, DEPT HLTH & GEN PRACTICE, KUOPIO, FINLAND	University of Eastern Finland			Kauhanen, Jussi/ABC-4064-2021; Kaplan, George/AAJ-2398-2020; Lynch, John W/A-4797-2008	Lynch, John W/0000-0003-2781-7902	NHLBI NIH HHS [HL44199] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BARKER DJP, 1992, CORONARY HEART DISEA, P83; Barker DJP, 1992, FETAL INFANT ORIGINS; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; Cox D. R., 1984, ANAL SURVIVAL DATA; DUBOS R, 1966, PEDIATRICS, V38, P789; DUNCAN OD, 1979, AM J SOCIOL, V84, P793, DOI 10.1086/226861; ELFORD J, 1991, INT J EPIDEMIOL, V20, P833, DOI 10.1093/ije/20.4.833; ELFORD J, 1992, J EPIDEMIOL COMMUN H, V46, P1, DOI 10.1136/jech.46.1.1-a; ELO IT, 1992, POPUL INDEX, V58, P186, DOI 10.2307/3644718; FORSDAHL A, 1966, PEDIATRICS, V38, P789; HASLE H, 1990, BRIT MED J, V300, P512, DOI 10.1136/bmj.300.6723.512; HOGUE CJR, 1993, AM J PUBLIC HEALTH, V83, P9, DOI 10.2105/AJPH.83.1.9; KAPLAN GA, 1990, BRIT MED J, V301, P1121, DOI 10.1136/bmj.301.6761.1121; KENT G, 1992, POLITICS CHILDRENS S; LAKKA TA, 1992, AM J EPIDEMIOL, V136, P806, DOI 10.1093/aje/136.7.806; LICHTENSTEIN P, 1993, SOC SCI MED, V36, P441, DOI 10.1016/0277-9536(93)90406-T; LUNDBERG O, 1993, SOC SCI MED, V36, P1047, DOI 10.1016/0277-9536(93)90122-K; LUNDBERG O, 1991, SOC SCI MED, V32, P385, DOI 10.1016/0277-9536(91)90339-E; MARE RD, 1990, MEASUREMENT ANAL MOR, P362; NAJMAN JM, 1992, SOC SCI MED, V34, P829, DOI 10.1016/0277-9536(92)90252-L; NELSON MD, 1992, AM J PUBLIC HEALTH, V82, P1131, DOI 10.2105/AJPH.82.8.1131; NORDSTROM ML, 1993, AM J PUBLIC HEALTH, V83, P26, DOI 10.2105/AJPH.83.1.26; NOTKOLA V, 1985, SOC SCI MED, V21, P517, DOI 10.1016/0277-9536(85)90035-8; OSTBERG V, 1991, SOC SCI MED, V32, P403, DOI 10.1016/0277-9536(91)90341-9; PECK AMN, 1992, J EPIDEMIOL COMMUN H, V46, P71, DOI 10.1136/jech.46.1.71; SALONEN JT, 1988, ANN CLIN RES, V20, P46; SINGLETON F, 1986, EC FINLAND 20TH CENT; VAGERO D, 1989, J EPIDEMIOL COMMUN H, V43, P280, DOI 10.1136/jech.43.3.280; WILSON TW, 1993, AM J EPIDEMIOL, V137, P292, DOI 10.1093/oxfordjournals.aje.a116676	30	237	244	1	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 26	1994	343	8896					524	527		10.1016/S0140-6736(94)91468-0	http://dx.doi.org/10.1016/S0140-6736(94)91468-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906766	Green Submitted			2022-12-28	WOS:A1994MX88800016
J	TAMBYAH, PA; HUI, KP; GOPALAKRISHNAKONE, P; CHIN, NK; CHAN, TB				TAMBYAH, PA; HUI, KP; GOPALAKRISHNAKONE, P; CHIN, NK; CHAN, TB			CENTRAL-NERVOUS-SYSTEM EFFECTS OF TETRODOTOXIN POISONING	LANCET			English	Letter									NATL UNIV SINGAPORE,DEPT ANAT,VENOM & TOXIN RES GRP,SINGAPORE,SINGAPORE	National University of Singapore	TAMBYAH, PA (corresponding author), NATL UNIV SINGAPORE HOSP,DEPT MED,SINGAPORE 0511,SINGAPORE.							CHEW SK, 1984, LANCET, V2, P108; KAO CY, 1966, PHARMACOL REV, V18, P997; KEREN G, 1982, CRIT CARE MED, V10, P798, DOI 10.1097/00003246-198211000-00027; ODA K, 1989, NEUROLOGY, V39, P743, DOI 10.1212/WNL.39.5.743; TIBBALLS J, 1988, ANAESTH INTENS CARE, V16, P215, DOI 10.1177/0310057X8801600216	5	16	17	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					538	539		10.1016/S0140-6736(94)91489-3	http://dx.doi.org/10.1016/S0140-6736(94)91489-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906776				2022-12-28	WOS:A1994MX88800039
J	DZUBOW, LM				DZUBOW, LM			MOHS SURGERY	LANCET			English	Editorial Material							BASAL-CELL CARCINOMA; RECURRENCE; RATES; SKIN				DZUBOW, LM (corresponding author), UNIV PENN, DEPT DERMATOL, PHILADELPHIA, PA 19104 USA.							CLOUSTON PD, 1990, ARCH NEUROL-CHICAGO, V47, P73, DOI 10.1001/archneur.1990.00530010091025; Mohs FE, 1991, MOHS MICROGRAPHIC SU, P1; ROBINSON JK, 1993, CLIN PLAST SURG, V20, P149; ROWE DE, 1989, J DERMATOL SURG ONC, V15, P315, DOI 10.1111/j.1524-4725.1989.tb03166.x; ROWE DE, 1992, J AM ACAD DERMATOL, V26, P976, DOI 10.1016/0190-9622(92)70144-5; ROWE DE, 1989, J DERMATOL SURG ONC, V15, P424, DOI 10.1111/j.1524-4725.1989.tb03249.x; TROMOVITCH TA, 1974, ARCH DERMATOL, V110, P231, DOI 10.1001/archderm.110.2.231	7	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	1994	343	8895					433	434		10.1016/S0140-6736(94)92687-5	http://dx.doi.org/10.1016/S0140-6736(94)92687-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905951	hybrid			2022-12-28	WOS:A1994MW69000005
J	EBERS, GC				EBERS, GC			TREATMENT OF MULTIPLE-SCLEROSIS	LANCET			English	Article							INTRAVENOUS METHYLPREDNISOLONE; CONTROLLED TRIAL; NATURAL-HISTORY; DOUBLE-BLIND; PILOT TRIAL; CYCLOPHOSPHAMIDE; RELAPSE; MICE				EBERS, GC (corresponding author), UNIV WESTERN ONTARIO,UNIV HOSP,DEPT CLIN NEUROL SCI,LONDON N6A 5A5,ONTARIO,CANADA.			Ebers, George/0000-0003-4771-4177				[Anonymous], 1990, ANN NEUROL, V27, P591; ARCHAMBAULT A, 1993, GASTROENTEROLOGY S2, V104, P4; BARNES MP, 1985, J NEUROL NEUROSUR PS, V48, P157, DOI 10.1136/jnnp.48.2.157; BECK RW, 1993, NEW ENGL J MED, V329, P1764, DOI 10.1056/NEJM199312093292403; BECK RW, 1992, NEW ENGL J MED, V326, P581, DOI 10.1056/NEJM199202273260901; BELL RB, 1992, TREATMENT MULTIPLE S, P281; BORNSTEIN MB, 1991, NEUROLOGY, V41, P533, DOI 10.1212/WNL.41.4.533; BORNSTEIN MB, 1987, NEW ENGL J MED, V317, P408, DOI 10.1056/NEJM198708133170703; COOK SD, 1986, LANCET, V1, P1405; DURELLI L, 1986, NEUROLOGY, V36, P238, DOI 10.1212/WNL.36.2.238; FILIPPI M, IN PRESS J NEUROL NE; HAFLER DA, 1992, TREATMENT MULTIPLE S, P301; HARADA M, 1984, DIABETOLOGIA, V27, P604, DOI 10.1007/BF00276978; HAUSER SL, 1983, NEW ENGL J MED, V308, P173, DOI 10.1056/NEJM198301273080401; KOOPMANS RA, 1989, ANN NEUROL, V26, P248, DOI 10.1002/ana.410260211; LANDO Z, 1979, J IMMUNOL, V123, P2156; LIKOSKY WH, 1991, J NEUROL NEUROSUR PS, V54, P1055, DOI 10.1136/jnnp.54.12.1055; LUBLIN FD, 1992, CURR OPIN NEUROL NEU, V5, P182; MCDONALD WI, 1992, NEUROPATH APPL NEURO, V18, P319, DOI 10.1111/j.1365-2990.1992.tb00794.x; MILLER DH, 1993, BRAIN, V116, P1077, DOI 10.1093/brain/116.5.1077; MILLER DH, 1993, CAN J NEUROL SCI, V20, pS193; MILLIGAN NM, 1988, J NEUROL NEUROSUR PS, V51, P597; NOSEWORTHY JH, 1989, NEUROLOGY, V39, P977, DOI 10.1212/WNL.39.7.977; NOSEWORTHY JH, IN PRESS NEUROLOGY; OLSSON T, 1992, CURR OPIN NEUROL NEU, V5, P195; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; POLAK L, 1974, NATURE, V249, P254; RUDGE P, 1989, J NEUROL NEUROSUR PS, V52, P559, DOI 10.1136/jnnp.52.5.559; RUDICK RA, 1992, TREATMENT MULTIPLE S; The IFNB Multiple Sclerosis Study Group, 1993, NEUROLOGY, V43, P655; THOMPSON AJ, 1989, NEUROLOGY, V39, P969, DOI 10.1212/WNL.39.7.969; WANG WZ, 1992, CLIN EXP IMMUNOL, V88, P157; WEINER HL, 1993, NEUROLOGY, V43, P910, DOI 10.1212/WNL.43.5.910; WEINSHENKER BG, 1991, BRAIN, V114, P1057, DOI 10.1093/brain/114.2.1057; WEINSHENKER BG, 1989, BRAIN, V112, P1419, DOI 10.1093/brain/112.6.1419; YUDKIN PL, 1991, LANCET, V338, P1051, DOI 10.1016/0140-6736(91)91909-E; 1988, LANCET, V2, P179; 1991, LANCET, V337, P441	38	31	31	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					275	279		10.1016/S0140-6736(94)91119-3	http://dx.doi.org/10.1016/S0140-6736(94)91119-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905103				2022-12-28	WOS:A1994MT44000017
J	HEAGERTY, AHM; FITZGERALD, D; SMITH, A; BOWERS, B; JONES, P; FRYER, AA; ZHAO, L; ALLDERSEA, J; STRANGE, RC				HEAGERTY, AHM; FITZGERALD, D; SMITH, A; BOWERS, B; JONES, P; FRYER, AA; ZHAO, L; ALLDERSEA, J; STRANGE, RC			GLUTATHIONE-S-TRANSFERASE GSTM1 PHENOTYPES AND PROTECTION AGAINST CUTANEOUS TUMORS	LANCET			English	Note							SQUAMOUS-CELL CARCINOMA; CANCER SUSCEPTIBILITY; RISK; SKIN	Multiple allelism at loci encoding detoxicating enzymes is associated with cancer risk. We have studied genetic variation at the glutathione S-transferase GSTM1 locus to see whether phenotypes confer altered susceptibility to basal cell carcinoma (BCC), squamous cell carcinoma (SCC), malignant melanoma (MM), or multiple skin tumours of different histological types. The frequency of GSTM1 null in cases and controls (52%) was similar, except for patients with two or more tumours of different types (71%, p = 0.033). GSTM1 A/B was reduced in frequency (p < 0.05) in patients with single or multiple BCC. Thus GSTM1 A/B may be protective, and effectiveness of detoxication may be a factor determining susceptibility to skin cancer.	ROYAL CORNWALL HOSP,DEPT DERMATOL,TRURO,CORNWALL,ENGLAND; UNIV KEELE,DEPT MATH,KEELE ST5 5BG,STAFFS,ENGLAND; KEELE UNIV,N STAFFORDSHIRE HOSP,SCH POSTGRAD MED,CTR PATHOL & MOLEC MED,STOKE ON TRENT,STAFFS,ENGLAND	Royal Cornwall Hospital; Keele University; Keele University; University Hospital of North Staffordshire NHS Trust	HEAGERTY, AHM (corresponding author), N STAFFORDSHIRE HOSP,DEPT DERMATOL,STOKE ON TRENT ST4 7BQ,STAFFS,ENGLAND.			Fryer, Anthony/0000-0001-8678-0404				AUBRY F, 1985, CANCER-AM CANCER SOC, V55, P907, DOI 10.1002/1097-0142(19850215)55:4<907::AID-CNCR2820550433>3.0.CO;2-5; FRYER AA, 1993, BIOCHEM J, V295, P313, DOI 10.1042/bj2950313; KARAGAS MR, 1992, JAMA-J AM MED ASSOC, V267, P3305, DOI 10.1001/jama.267.24.3305; KETTERER B, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P97; MUKHTAR H, 1993, CANCER RES, V53, P3439; SEIDEGARD J, 1988, P NATL ACAD SCI USA, V85, P7293, DOI 10.1073/pnas.85.19.7293; STRANGE RC, 1991, CARCINOGENESIS, V12, P25, DOI 10.1093/carcin/12.1.25; STRANGE RC, 1993, STRUCTURE FUNCTION G, P160; WOLF CR, 1992, CARCINOGENESIS, V13, P1035, DOI 10.1093/carcin/13.6.1035; ZHONG S, 1991, CARCINOGENESIS, V12, P1533, DOI 10.1093/carcin/12.9.1533	10	161	163	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					266	268		10.1016/S0140-6736(94)91115-0	http://dx.doi.org/10.1016/S0140-6736(94)91115-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905099				2022-12-28	WOS:A1994MT44000013
J	WILCOCK, GK; SCOTT, M; PEARSALL, T				WILCOCK, GK; SCOTT, M; PEARSALL, T			LONG-TERM USE OF TACRINE	LANCET			English	Letter							ALZHEIMERS-DISEASE				WILCOCK, GK (corresponding author), FRENCHAY HOSP,DEPT CARE ELDERLY,BRISTOL BS16 1LE,AVON,ENGLAND.							DAVIS KL, 1992, NEW ENGL J MED, V327, P1253, DOI 10.1056/NEJM199210293271801; EAGGER SA, 1991, LANCET, V337, P989, DOI 10.1016/0140-6736(91)92656-M; FARLOW M, 1992, JAMA-J AM MED ASSOC, V268, P2523, DOI 10.1001/jama.268.18.2523; ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698; WILCOCK GK, 1993, AGE AGEING, V22, P316, DOI 10.1093/ageing/22.5.316	5	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					294	294		10.1016/S0140-6736(94)91140-1	http://dx.doi.org/10.1016/S0140-6736(94)91140-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905118				2022-12-28	WOS:A1994MT44000039
J	PAUL, WE; SEDER, RA				PAUL, WE; SEDER, RA			LYMPHOCYTE-RESPONSES AND CYTOKINES	CELL			English	Review							T-CELL SUBSETS; HUMAN INTERLEUKIN-4; INTERFERON-GAMMA; MURINE LEISHMANIASIS; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; GROWTH-HORMONE; ACTIVATION; IL-4; MICE		NIAID,CLIN INVEST LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	PAUL, WE (corresponding author), NIAID,IMMUNOL LAB,BETHESDA,MD 20892, USA.							ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ABE E, 1992, P NATL ACAD SCI USA, V89, P2864, DOI 10.1073/pnas.89.7.2864; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARASE H, 1993, EUR J IMMUNOL, V23, P307, DOI 10.1002/eji.1830230151; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BANCHEREAU J, 1991, NATURE, V353, P678, DOI 10.1038/353678a0; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; BETZ M, 1990, J IMMUNOL, V145, P1046; BOULAY JL, 1993, CURR BIOL, V3, P573, DOI 10.1016/0960-9822(93)90002-6; BOULAY JL, 1992, CURR OPIN IMMUNOL, V4, P294, DOI 10.1016/0952-7915(92)90079-T; BOULAY JL, 1992, J BIOL CHEM, V267, P20525; BRADLEY LM, 1993, J IMMUNOL, V150, P3119; BRUHN KW, 1993, P NATL ACAD SCI USA, V90, P9707, DOI 10.1073/pnas.90.20.9707; CHATELAIN R, 1992, J IMMUNOL, V148, P1182; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FLAMAND V, 1990, J IMMUNOL, V144, P2875; GROSS A, 1993, J IMMUNOL, V150, P2112; GUBLER U, 1991, P NATL ACAD SCI USA, V88, P4143, DOI 10.1073/pnas.88.10.4143; HAMAOKA T, 1986, ANNU REV IMMUNOL, V4, P167, DOI 10.1146/annurev.immunol.4.1.167; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; KAMOGAWA Y, 1993, CELL, V75, P985, DOI 10.1016/0092-8674(93)90542-X; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LIEW FY, 1989, EUR J IMMUNOL, V19, P1227, DOI 10.1002/eji.1830190712; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; MACCHIA D, 1993, NATURE, V363, P464, DOI 10.1038/363464a0; MANDLER R, 1993, J EXP MED, V178, P1577, DOI 10.1084/jem.178.5.1577; MCKAY DB, 1992, SCIENCE, V257, P412, DOI 10.1126/science.257.5068.412; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MURRAY JS, 1992, EUR J IMMUNOL, V22, P559, DOI 10.1002/eji.1830220239; PARISH CR, 1972, J EXP MED, V135, P298, DOI 10.1084/jem.135.2.298; PAUL WE, 1992, ADV IMMUNOL, V53, P1; POO WJ, 1988, NATURE, V332, P378, DOI 10.1038/332378a0; POWERS R, 1992, SCIENCE, V256, P1673, DOI 10.1126/science.256.5064.1673; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RAPOPORT MJ, 1993, J EXP MED, V178, P87, DOI 10.1084/jem.178.1.87; REDFIELD C, 1991, BIOCHEMISTRY-US, V30, P11029, DOI 10.1021/bi00110a004; ROCKEN M, 1992, J IMMUNOL, V148, P1031; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SCOTT DE, 1990, J IMMUNOL, V145, P2183; SEDER RA, 1991, EUR J IMMUNOL, V21, P1241, DOI 10.1002/eji.1830210522; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SEDER RA, 1993, P NATL ACAD SCI USA, V90, P10188, DOI 10.1073/pnas.90.21.10188; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; STREET NE, 1990, J IMMUNOL, V144, P1629; SWAIN SL, 1991, IMMUNOL REV, V123, P115, DOI 10.1111/j.1600-065X.1991.tb00608.x; SWAIN SL, 1990, J IMMUNOL, V145, P3796; SZABO SJ, 1993, MOL CELL BIOL, V13, P4293; TARA D, 1993, IN PRESS J IMMUNOL; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; URBAN JF, 1991, P NATL ACAD SCI USA, V88, P5513, DOI 10.1073/pnas.88.13.5513; WALTER MR, 1992, J BIOL CHEM, V267, P20371; WLODAVER A, 1992, FEBS LETT, V309, P59, DOI 10.1016/0014-5793(92)80739-4; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145	73	1701	1770	3	82	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 28	1994	76	2					241	251		10.1016/0092-8674(94)90332-8	http://dx.doi.org/10.1016/0092-8674(94)90332-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	7904900				2022-12-28	WOS:A1994MU67800008
J	WEST, LJ; MORRIS, PJ; WOOD, KJ				WEST, LJ; MORRIS, PJ; WOOD, KJ			FETAL LIVER HEMATOPOIETIC-CELLS AND TOLERANCE TO ORGAN ALLOGRAFTS	LANCET			English	Note							TRANSPLANTATION	Fetal liver haematopoietic cells were used to induce neonatal tolerance to cardiac allografts. Newborn mice were injected with fetal or newborn haematopoietic liver cells in two fully allogeneic strain combinations. There was no clinical evidence of graft-versus-host disease. Long-term survival of subsequent cardiac allografts occurred in both strains without immunosuppressants. Unresponsiveness was found not to be donor-specific with prolongation of third-party allografts as well as donor-type grafts. These findings have important implications for inducing tolerance in paediatric organ transplantation.	UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT SURG,OXFORD OX3 9DU,ENGLAND	University of Oxford				West, Lori/0000-0002-1990-3651				BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; FLAKE AW, 1986, SCIENCE, V233, P76; HARRISON MR, 1989, LANCET, V2, P1425; ROYO C, 1987, THYMUS, V10, P57; SANHADJI K, 1992, BONE MARROW TRANSPL, V9, P77; STREILEIN JW, 1991, TRANSPLANTATION, V252, P1; SUPERINA RA, 1986, TRANSPLANTATION, V42, P227; TOURAINE JL, 1992, BONE MARROW TRANSPL, V9, P121; TOURAINE JL, 1989, TRANSPLANT P, V21, P3112	9	30	30	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 15	1994	343	8890					148	149		10.1016/S0140-6736(94)90936-9	http://dx.doi.org/10.1016/S0140-6736(94)90936-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7904006				2022-12-28	WOS:A1994MQ86900012
J	MAXWELL, DL; POLKEY, MI; HENRY, JA				MAXWELL, DL; POLKEY, MI; HENRY, JA			HYPONATREMIA AND CATATONIC STUPOR AFTER TAKING ECSTASY	BRITISH MEDICAL JOURNAL			English	Article							DEATHS; MDMA		GUYS HOSP,DEPT MED,LONDON SE1 9RT,ENGLAND; GUYS HOSP,NATL POISONS UNIT,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust								ALGRA A, 1991, CIRCULATION, V83, P1888, DOI 10.1161/01.CIR.83.6.1888; Chambers J, 1991, Health Trends, V23, P122; DOWLING GP, 1987, JAMA-J AM MED ASSOC, V257, P1615, DOI 10.1001/jama.257.12.1615; HENRY JA, 1992, LANCET, V340, P384, DOI 10.1016/0140-6736(92)91469-O; SIEGEL RK, 1986, J PSYCHOACTIVE DRUGS, V18, P349, DOI 10.1080/02791072.1986.10472368	5	100	100	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1993	307	6916					1399	1399		10.1136/bmj.307.6916.1399	http://dx.doi.org/10.1136/bmj.307.6916.1399			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MK420	7903884	Bronze, Green Published			2022-12-28	WOS:A1993MK42000023
J	SHERMAN, DIN; WARD, RJ; WARRENPERRY, M; WILLIAMS, R; PETERS, TJ				SHERMAN, DIN; WARD, RJ; WARRENPERRY, M; WILLIAMS, R; PETERS, TJ			ASSOCIATION OF RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISM IN ALCOHOL DEHYDROGENASE-2 GENE WITH ALCOHOL-INDUCED LIVER-DAMAGE	BRITISH MEDICAL JOURNAL			English	Article							ALDEHYDE DEHYDROGENASE; DISEASE; PREDISPOSITION; SENSITIVITY; CIRRHOSIS; GENOTYPES; WOMEN	Objective-To investigate the role of genetically determined differences in the enzymes of alcohol metabolism in susceptibility to liver damage from misusing alcohol. Design-Use of pADH36 probe to study PVU II restriction length fragment polymorphism in alcohol dehydrogenase 2 gene in white alcohol misusers and controls. Setting-Teaching hospital referral centres for fiver disease and alcohol misuse. Subjects-45 white alcohol misusers (38 with alcoholic liver disease) and 23 healthy controls. Main outcome measures-Alcohol misuse, the presence and severity of alcoholic liver disease, alcohol dependency, and family history of alcohol misuse. Results-A two allele polymorphism (A and B) was identified. In control subjects the allele frequencies were 85% for A and 15% for B compared with 37% and 63% respectively in alcohol misusers (p < 0.001). B allele was significantly associated with severe liver damage (p < 0.05) as well as alcohol dependency and family history of alcohol misuse compared with controls. Conclusion-Inherited variation in enzymes of ethanol metabolism may contribute to the pathogenesis of alcohol induced liver damage. This supports the presence of a genetic component in alcohol misuse.	KINGS COLL,SCH MED & DENT,DEPT CLIN BIOCHEM,LONDON SE5 9PJ,ENGLAND	University of London; King's College London	SHERMAN, DIN (corresponding author), KINGS COLL,SCH MED & DENT,INST LIVER STUDIES,LONDON SE5 9PJ,ENGLAND.			Ward, Roberta J/0000-0002-5671-784X; opoku, anita/0000-0001-7243-8157				AGARWAL D, PHARMACOL THERAPEUT, V45, P69; BOHMAN M, 1981, ARCH GEN PSYCHIAT, V38, P965; BOSRON WF, 1986, HEPATOLOGY, V6, P502, DOI 10.1002/hep.1840060330; BOSRON WF, 1983, BIOCHEMISTRY-US, V22, P1852, DOI 10.1021/bi00277a017; CLONINGER CR, 1990, BANB REPORT, V33, P105; COLLINS MA, 1979, SCIENCE, V206, P1184, DOI 10.1126/science.505002; COUZIGOU P, 1990, ALCOHOL ALCOHOLISM, V25, P623, DOI 10.1093/oxfordjournals.alcalc.a045058; CRABB DW, 1989, J CLIN INVEST, V83, P314, DOI 10.1172/JCI113875; DAY CP, 1991, HEPATOLOGY, V14, P798, DOI 10.1002/hep.1840140509; DUESTER G, 1986, J BIOL CHEM, V261, P2027; ENOMOTO N, 1991, HEPATOLOGY, V13, P1071, DOI 10.1002/hep.1840130611; GOEDDE HW, 1987, ENZYME, V37, P29, DOI 10.1159/000469239; HITTLE JB, 1988, J LAB CLIN MED, V112, P7; HRUBEC Z, 1981, ALCOHOL CLIN EXP RES, V5, P207, DOI 10.1111/j.1530-0277.1981.tb04890.x; Lelbach W K, 1976, Prog Liver Dis, V5, P494; MARTIN NG, 1985, BEHAV GENET, V15, P93, DOI 10.1007/BF01065891; Peters T J, 1987, Prog Clin Biol Res, V241, P215; SAUNDERS JB, 1981, BMJ-BRIT MED J, V282, P1140, DOI 10.1136/bmj.282.6270.1140; SHIBUYA A, 1988, AM J HUM GENET, V43, P744; SMITH M, 1986, ADV HUM GENET, V15, P249; SORRELL MF, 1985, ALCOHOL CLIN EXP RES, V9, P306, DOI 10.1111/j.1530-0277.1985.tb05549.x; 1987, GREAT GROWING EVIL M	22	31	31	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1993	307	6916					1388	1390		10.1136/bmj.307.6916.1388	http://dx.doi.org/10.1136/bmj.307.6916.1388			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK420	7903883	Green Published, Bronze			2022-12-28	WOS:A1993MK42000019
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW RULE ON LABELING FOODS AS HEALTHY ISSUED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	1994	271	23					1818	1818						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP959	7910857				2022-12-28	WOS:A1994NP95900004
J	WAGA, S; STILLMAN, B				WAGA, S; STILLMAN, B			ANATOMY OF A DNA-REPLICATION FORK REVEALED BY RECONSTITUTION OF SV40 DNA-REPLICATION IN-VITRO	NATURE			English	Article							SIMIAN VIRUS-40 DNA; POLYMERASE-ALPHA-PRIMASE; LAGGING STRAND SYNTHESIS; CELL NUCLEAR ANTIGEN; T-ANTIGEN; SACCHAROMYCES-CEREVISIAE; FACTOR-C; INVITRO REPLICATION; ACCESSORY PROTEINS; INITIATION	Complete enzymatic replication of DNA from the simian virus 40 origin has been reconstituted with T antigen and highly purified cellular proteins. DNA polymerase-alpha/primase functions primarily to synthesize RNA-DNA primers for initiation of DNA replication at the origin and for priming each Okazaki fragment. A polymerase switching mechanism requiring replication factor C and the proliferating cell nuclear antigen allows two molecules of DNA polymerase-delta to replicate both strands of the double helix conjointly.			WAGA, S (corresponding author), COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724, USA.			Waga, Shou/0000-0003-4986-8735; Stillman, Bruce/0000-0002-9453-4091				ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BULLOCK PA, 1991, MOL CELL BIOL, V11, P2350, DOI 10.1128/MCB.11.5.2350; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CHA TA, 1988, CANCER CELL, V6, P1; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; DEAN FB, 1992, J BIOL CHEM, V267, P14129; DENIS D, 1993, MOL CELL BIOL, V13, P2882, DOI 10.1128/MCB.13.5.2882; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; EKI T, 1992, J BIOL CHEM, V267, P7284; ELIASSON R, 1978, J BIOL CHEM, V253, P7469; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KONRAD EB, 1974, P NATL ACAD SCI USA, V71, P2048, DOI 10.1073/pnas.71.5.2048; Kornberg A., 1992, DNA REPLICATION; LEE SH, 1991, J BIOL CHEM, V266, P594; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MELENDY T, 1992, NUCLEIC ACIDS MOL BI, V6, P129; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11018; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P952, DOI 10.1073/pnas.89.3.952; NETHANEL T, 1990, J VIROL, V64, P5912, DOI 10.1128/JVI.64.12.5912-5918.1990; NISHIDA C, 1988, J BIOL CHEM, V263, P501; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; ROBERTS JD, 1991, P NATL ACAD SCI USA, V88, P3465, DOI 10.1073/pnas.88.8.3465; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; VEAUTE X, 1993, SCIENCE, V261, P598, DOI 10.1126/science.8342022; WAGA S, IN PRESS J BIOL CHEM; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	50	511	517	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 19	1994	369	6477					207	212		10.1038/369207a0	http://dx.doi.org/10.1038/369207a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM067	7910375				2022-12-28	WOS:A1994NM06700048
J	NORTHRIDGE, DB; HALL, RJC				NORTHRIDGE, DB; HALL, RJC			POST-MYOCARDIAL-INFARCTION EXERCISE TESTING IN THE THROMBOLYTIC ERA	LANCET			English	Editorial Material							PROGNOSTIC VALUE; SOON; RISK				NORTHRIDGE, DB (corresponding author), UNIV WALES HOSP,DEPT CARDIOL,CARDIFF,WALES.							ARNOLD AER, 1993, EUR HEART J, V14, P306, DOI 10.1093/eurheartj/14.3.306; DEBELDER MA, 1988, BRIT HEART J, V60, P377; DEFEYTER PJ, 1982, CIRCULATION, V66, P527, DOI 10.1161/01.CIR.66.3.527; ELLIS SG, 1989, CIRCULATION, V80, P1159, DOI 10.1161/01.CIR.80.5.1159; PATERSON RE, 1983, AM J CARDIOL, V51, P361; PEART I, 1989, BRIT HEART J, V61, P231; PICCALO G, 1992, AM J CARDIOL, V70, P31, DOI 10.1016/0002-9149(92)91385-H; STEVENSON R, 1993, BRIT HEART J, V70, P415; THEROUX P, 1979, NEW ENGL J MED, V301, P341, DOI 10.1056/NEJM197908163010701	9	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1175	1176		10.1016/S0140-6736(94)92396-5	http://dx.doi.org/10.1016/S0140-6736(94)92396-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909864				2022-12-28	WOS:A1994NL17500005
J	GRECH, ED; BAINES, M; STEYN, R; FARAGHER, EB; PAGE, RD; FABRI, BM; RAMSDALE, DR; RASHID, A				GRECH, ED; BAINES, M; STEYN, R; FARAGHER, EB; PAGE, RD; FABRI, BM; RAMSDALE, DR; RASHID, A			NORMOTHERMIC VERSUS HYPOTHERMIC CORONARY-BYPASS SURGERY	LANCET			English	Letter							STRESS		BROADGREEN HOSP,DEPT PATHOL,LIVERPOOL,MERSEYSIDE,ENGLAND; WITHINGTON HOSP,DEPT STAT,MANCHESTER,LANCS,ENGLAND	Royal Liverpool & Broadgreen University Hospitals NHS Trust; University of Liverpool	GRECH, ED (corresponding author), CARDIOTHORAC CTR,LIVERPOOL L14 3PE,MERSEYSIDE,ENGLAND.							ABDALLA EK, 1990, J SURG RES, V48, P291, DOI 10.1016/0022-4804(90)90061-6; FERRARI R, 1990, CIRCULATION, V81, P201, DOI 10.1161/01.CIR.81.1.201; Randomised trial of normothermic versus hypothermic coronary bypass surgery, 1994, LANCET, V343, P559; SIES H, 1984, METHOD ENZYMOL, V105, P445	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1994	343	8906					1155	1156		10.1016/S0140-6736(94)90258-5	http://dx.doi.org/10.1016/S0140-6736(94)90258-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK730	7910240				2022-12-28	WOS:A1994NK73000030
J	ROBERTS, CWM; SHUTTER, JR; KORSMEYER, SJ				ROBERTS, CWM; SHUTTER, JR; KORSMEYER, SJ			HOX11 CONTROLS THE GENESIS OF THE SPLEEN	NATURE			English	Article							T-CELL LEUKEMIA; HOMEOBOX GENE; DEVELOPMENTAL DEFECTS; TARGETED DISRUPTION; EXPRESSION; MURINE; ORGANIZATION; HOX-1.6; CODES	MANY homeobox genes are clustered in a linear array along a chromosome, reflecting their ordered expression along the anterior-posterior axis of the embryo(1). Expression patterns(2,3) as well as grafting(4), ectopic expression(5,6) and loss-of-function experiments(7-11) suggest that the Hox genes encode a combinatorial system of positional specification along that axis. In contrast, the function of orphan homeobox genes(12) located at sites outside the four mammalian Hox clusters is less well understood. To assess the functional role of the orphan homeobox gene Hox11, we have generated Hox11-deficient mice through gene targeting. Hox11(-/-) mice have no spleen, but otherwise appear normal. Hox11 is normally expressed in the splenic anlage arising from the splanchnic mesoderm. Hox11(-/-) embryos have no cellular organization at the site of splenic development but all other splanchnic derivatives develop normally. Hox11 controls the genesis of a single organ, providing new insight into the genetic regulation of morphogenesis.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	ROBERTS, CWM (corresponding author), WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110, USA.		Roberts, Charles/N-2541-2018	Roberts, Charles/0000-0003-1135-1896				BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; CARTER TC, 1954, MOUSE NEWS LETT, V11, P16; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DUBE ID, 1991, BLOOD, V78, P2996; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GREEN MC, 1967, DEV BIOL, V15, P62, DOI 10.1016/0012-1606(67)90006-1; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HATANO M, 1992, BLOOD S, V80, pA355; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KOYAMA A, 1960, ACTA HAEMATOL JPN, V23, P20; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MANSEAU LJ, 1989, TRENDS GENET, V5, P400, DOI 10.1016/0168-9525(89)90198-4; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; NIEHRS C, 1990, CURR OPIN GENET DEV, V2, P550; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAJU R, 1993, MECH DEVELOP, V44, P51; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RUGH R, 1990, MOUSE ITS REPRODUCTI; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; STERN CD, 1990, CURR OPIN GENET DEV, V2, P556; WALDMAN JD, 1977, J PEDIATR-US, V90, P555, DOI 10.1016/S0022-3476(77)80365-X; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75	30	240	248	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 21	1994	368	6473					747	749		10.1038/368747a0	http://dx.doi.org/10.1038/368747a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	7908720				2022-12-28	WOS:A1994NG55300060
J	STEEL, M				STEEL, M			CYCLINS AND CANCER - WHEELS WITHIN WHEELS	LANCET			English	Editorial Material							CELL-CYCLE				STEEL, M (corresponding author), UNIV ST ANDREWS,SCH BIOL & MED SCI,ST ANDREWS KY16 9ST,FIFE,SCOTLAND.							COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Hagan Iain, 1992, Trends in Cell Biology, V2, P245, DOI 10.1016/0962-8924(92)90313-C; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KEYOMARSI K, 1994, CANCER RES, V54, P380; MARX J, 1994, SCIENCE, V263, P319, DOI 10.1126/science.8278804; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; STURZBECHER HW, 1990, ONCOGENE, V5, P795	13	9	11	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					931	932		10.1016/S0140-6736(94)90062-0	http://dx.doi.org/10.1016/S0140-6736(94)90062-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909007				2022-12-28	WOS:A1994NF70000006
J	BERGQVIST, D; KARACAGIL, S				BERGQVIST, D; KARACAGIL, S			FEMORAL-ARTERY DISEASE	LANCET			English	Article							TRANS-LUMINAL ANGIOPLASTY; INTERMITTENT CLAUDICATION; SAPHENOUS-VEIN; FEMOROPOPLITEAL BYPASS; DRUG-TREATMENT; RISK-FACTORS; FOLLOW-UP; POLYTETRAFLUOROETHYLENE; MANAGEMENT; REVASCULARIZATION				BERGQVIST, D (corresponding author), UNIV HOSP UPPSALA, DEPT SURG, S-75598 UPPSALA, SWEDEN.							BEVAN EG, 1992, DRUG AGING, V2, P125, DOI 10.2165/00002512-199202020-00006; Blankensteijn J D, 1988, Eur J Vasc Surg, V2, P183, DOI 10.1016/S0950-821X(88)80073-2; BOTHIG S, 1976, Cor et Vasa, V18, P104; CAMERON HA, 1988, BRIT J CLIN PHARMACO, V26, P569, DOI 10.1111/j.1365-2125.1988.tb05297.x; COX GS, 1993, J VASC SURG, V17, P172, DOI 10.1016/0741-5214(93)90021-D; CRANLEY JJ, 1982, ARCH SURG-CHICAGO, V117, P1543; Creasy T S, 1990, Eur J Vasc Surg, V4, P135, DOI 10.1016/S0950-821X(05)80427-X; CRONENWETT JL, 1984, ARCH SURG-CHICAGO, V119, P430; DO BD, 1992, CARDIOVASC INTERVENT, V15, P306; Dormandy J A, 1991, Eur J Vasc Surg, V5, P131, DOI 10.1016/S0950-821X(05)80676-0; GYNTELBERG F, 1973, DAN MED BULL, V20, P1; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; HIATT WR, 1990, CIRCULATION, V81, P602, DOI 10.1161/01.CIR.81.2.602; HOUSLEY E, 1988, BRIT MED J, V296, P1483, DOI 10.1136/bmj.296.6635.1483; HUGHSON WG, 1978, BRIT MED J, V1, P1379, DOI 10.1136/bmj.1.6124.1379; ISACSSON SO, 1972, ACTA MED SCAND, P1; JANZON L, 1990, J INTERN MED, V227, P301, DOI 10.1111/j.1365-2796.1990.tb00164.x; KLIMACH O, 1984, BRIT J SURG, V71, P821, DOI 10.1002/bjs.1800711103; KREPEL VM, 1985, RADIOLOGY, V156, P325, DOI 10.1148/radiology.156.2.3160061; Leng G., 1993, VASC MED REV, V4, P5, DOI [10.1177/1358863X9300400102, DOI 10.1177/1358863X9300400102]; LINDGARDE F, 1989, CIRCULATION, V80, P1549, DOI 10.1161/01.CIR.80.6.1549; MYHRE HO, 1990, ACTA CHIR SCAND, P39; OGREN M, 1993, EUR J VASCULAR SURG, V7, P500, DOI 10.1016/S0950-821X(05)80360-3; OURIEL K, 1986, J VASC SURG, V3, P531, DOI 10.1067/mva.1986.avs0030531; QUINONESBALDRICH WJ, 1992, J VASC SURG, V16, P209, DOI 10.1016/0741-5214(92)90109-L; RADACK K, 1990, ANN INTERN MED, V113, P135, DOI 10.7326/0003-4819-113-2-135; REID DD, 1974, LANCET, V1, P469; REUNANEN A, 1982, ACTA MED SCAND, V211, P249; RICHARD JL, 1972, REV EPIDEMIOL SANTE, V20, P735; ROSE G, 1977, BRIT J PREV SOC MED, V31, P42; RUCKLEY CV, 1991, EPIDEMIOLOGY PERIPHE, P97; SAPOVAL MR, 1992, RADIOLOGY, V184, P833, DOI 10.1148/radiology.184.3.1509075; SKAU T, 1993, EUR J VASCULAR SURG, V7, P432, DOI 10.1016/S0950-821X(05)80262-2; SMITH GD, 1990, CIRCULATION, V82, P1925, DOI 10.1161/01.CIR.82.6.1925; STERPETTI AV, 1985, J VASC SURG, V2, P907, DOI 10.1067/mva.1985.avs0020907; TROENG T, 1993, EUR J VASCULAR SURG, V7, P438, DOI 10.1016/S0950-821X(05)80263-4; VANDERHEIJDEN FHWM, 1992, EUR J VASCULAR SURG, V6, P651, DOI 10.1016/S0950-821X(05)80845-X; VANRIJ AM, 1991, J CARDIOVASC SURG, V32, P34; VERSTRAETE M, 1989, CIRCULATION, V80, P1544; VROEGINDEWEIJ D, 1992, EUR J VASCULAR SURG, V6, P164, DOI 10.1016/S0950-821X(05)80235-X; WALSH DB, 1991, J VASC SURG, V14, P299, DOI 10.1016/0741-5214(91)90080-E; WHYMAN MR, 1993, EUR J VASCULAR SURG, V7, P444, DOI 10.1016/S0950-821X(05)80264-6; YASHAR JJ, 1981, ARCH SURG-CHICAGO, V116, P1037; ZEITLER E, 1989, HERZ, V14, P22; 1988, ARCH SURG-CHICAGO, V123, P434	45	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 26	1994	343	8900					773	778		10.1016/S0140-6736(94)91844-9	http://dx.doi.org/10.1016/S0140-6736(94)91844-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907736				2022-12-28	WOS:A1994NC35100016
J	FORD, D; EASTON, DF; BISHOP, DT; NAROD, SA; GOLDGAR, DE; HAITES, N; MILNER, B; ALLAN, L; PONDER, BAJ; PETO, J; SMITH, S; STRATTON, M; LENOIR, GM; FEUNTEUN, J; LYNCH, H; ARASON, A; BARKARDOTTIR, R; EGILSSON, V; BLACK, DM; KELSELL, D; SPURR, N; DEVILEE, P; CORNELISSE, CJ; VARSEN, H; BIRCH, JM; SKOLNICK, M; SANTIBANEZKOREF, MS; TEARE, D; STEEL, M; PORTER, D; COHEN, BB; CAROTHERS, A; SMYTH, E; WEBER, B; NEWBOLD, B; BOEHNKE, M; COLLINS, FS; CANNONALBRIGHT, LA; GOLDGAR, D				FORD, D; EASTON, DF; BISHOP, DT; NAROD, SA; GOLDGAR, DE; HAITES, N; MILNER, B; ALLAN, L; PONDER, BAJ; PETO, J; SMITH, S; STRATTON, M; LENOIR, GM; FEUNTEUN, J; LYNCH, H; ARASON, A; BARKARDOTTIR, R; EGILSSON, V; BLACK, DM; KELSELL, D; SPURR, N; DEVILEE, P; CORNELISSE, CJ; VARSEN, H; BIRCH, JM; SKOLNICK, M; SANTIBANEZKOREF, MS; TEARE, D; STEEL, M; PORTER, D; COHEN, BB; CAROTHERS, A; SMYTH, E; WEBER, B; NEWBOLD, B; BOEHNKE, M; COLLINS, FS; CANNONALBRIGHT, LA; GOLDGAR, D			RISKS OF CANCER IN BRCA1-MUTATION CARRIERS	LANCET			English	Article							BREAST-CANCER; OVARIAN	Germline mutations in a gene on chromosome 17q known as BRCA1 are responsible for a large proportion of inherited predispositions to breast and ovarian cancer. In 33 families with evidence of linkage to BRCA1, we estimated the risks of breast and ovarian cancer from the occurrence of second cancers in individuals with breast cancer, and examined the risks of other cancers in BRCA1 carriers. 26 contralateral primary breast cancers occurring more than 3 years after a first breast cancer were observed before age 70, giving an estimated cumulative risk of breast cancer in gene carriers of 87% by age 70. 23 primary ovarian cancers occurred in women with a previous breast cancer, resulting in an estimated cumulative risk of ovarian cancer of 44% by age 70. 87 cancers other than breast or ovarian cancer were observed in individuals with breast or ovarian cancer and their first-degree relatives compared with 69.3 expected, based on national incidence rates. Significant excesses were observed for colon cancer (estimated relative risk [RR] to gene carriers 4.11 [95% Cl 2.36-7.15]) and prostate cancer(3.33 [1.78-6.20]). No significant excesses (or deficits) were noted for cancers of other sites. Our study provides estimates of breast and ovarian cancer risks which are useful for counselling BRCA1-mutation carriers. It also shows that carriers are at increased risk of colon and prostate cancer, which may be of clinical significance in certain families if the risks are associated with specific mutations.	ST JAMES HOSP,ICRF,GENET EPIDEMIOL UNIT,LEEDS,ENGLAND; MONTREAL GEN HOSP,MONTREAL,PQ,CANADA; UNIV UTAH,DEPT MED INFORMAT,SALT LAKE CITY,UT 84112; UNIV ABERDEEN,ABERDEEN,SCOTLAND; CANC RES CAMPAIGN,LONDON,ENGLAND; INST CANC RES,LONDON,ENGLAND; INT AGCY RES CANC,LYON,FRANCE; UNIV ICELAND,REYKJAVIK,ICELAND; IMPERIAL CANC RES FUND,LEEDS,W YORKSHIRE,ENGLAND; LEIDEN UNIV,LEIDEN,NETHERLANDS; FDN DETECT HEREDITARY TUMOURS,LEIDEN,NETHERLANDS; CHRISTIE HOSP & HOLT RADIUM INST,MANCHESTER M20 9BX,LANCS,ENGLAND; IMPERIAL CANC RES FUND,LONDON,ENGLAND; MRC,HUMAN GENET UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND; UNIV MICHIGAN,ANN ARBOR,MI 48109; INST CANC RES,CAMBRIDGE,CAMBS,ENGLAND	Saint James's University Hospital; McGill University; Utah System of Higher Education; University of Utah; University of Aberdeen; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; World Health Organization; International Agency for Research on Cancer (IARC); University of Iceland; Leiden University; Leiden University - Excl LUMC; Christie NHS Foundation Trust; Christie Hospital; Cancer Research UK; University of Edinburgh; University of Michigan System; University of Michigan; University of London; Institute of Cancer Research - UK	FORD, D (corresponding author), INST CANC RES,EPIDEMIOL SECT,BLOCK D,BELMONT SM2 5NG,SURREY,ENGLAND.		Feunteun, Jean/AAZ-1267-2020; Narod, Steven A/AAA-6112-2022; DEVILEE, PETER/ABR-2140-2022; Kelsell, David P/F-8767-2011	Bishop, Tim/0000-0002-8752-8785	NCI NIH HHS [CA57601] Funding Source: Medline; NHGRI NIH HHS [HG00209] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057601] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARASON A, 1993, AM J HUM GENET, V52, P711; BOWCOCK AM, 1993, AM J HUM GENET, V52, P718; Cannon L., 1982, CANCER SURV, V1, P47; EASTON DF, 1993, AM J HUM GENET, V52, P678; EASTON DF, 1992, THESIS U LONDON; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HALL JM, 1992, AM J HUM GENET, V53, P678; MUIR C, 1987, CANCER INCIDENCE 5 C, V5; NAROD SA, 1991, LANCET, V338, P82; TOBACMAN JK, 1982, LANCET, V2, P795; TULINIUS H, 1992, BRIT MED J, V305, P855, DOI 10.1136/bmj.305.6858.855; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a	12	1464	1494	4	107	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					692	695		10.1016/S0140-6736(94)91578-4	http://dx.doi.org/10.1016/S0140-6736(94)91578-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907678				2022-12-28	WOS:A1994NB80900007
J	BAKER, PN; JOHNSON, IR; GOWLAND, PA; HYKIN, J; HARVEY, PR; FREEMAN, A; ADAMS, V; WORTHINGTON, BS; MANSFIELD, P				BAKER, PN; JOHNSON, IR; GOWLAND, PA; HYKIN, J; HARVEY, PR; FREEMAN, A; ADAMS, V; WORTHINGTON, BS; MANSFIELD, P			FETAL WEIGHT ESTIMATION BY ECHO-PLANAR MAGNETIC-RESONANCE-IMAGING	LANCET			English	Note							NMR	Fetal weight was estimated in utero in eleven singleton pregnancies by measurement of fetal volume with echo-planar imaging (EPI), a form of magnetic resonance imaging, and by ultrasound measurements. EPI estimates of fetal volume were closely correlated with actual birthweight (R = 0.97). The median difference (expressed as a percentage of actual birthweight) between actual and EPI-estimated birthweights was 3.0% (range 0.6-9.9); this discrepancy was significantly smaller than that found for ultrasonographic estimates (6.5%[1.7-17.8]; p < 0.01).	CITY HOSP,DEPT OBSTET & GYNAECOL,NOTTINGHAM NG5 1PB,ENGLAND; UNIV NOTTINGHAM,CTR MAGNET RESONANCE,NOTTINGHAM,ENGLAND; UNIV NOTTINGHAM,DEPT RADIOL,NOTTINGHAM,ENGLAND	University of Nottingham; University of Nottingham; University of Nottingham			Harvey, Paul R./U-7778-2019; Gowland, Penny A./I-9016-2012	Gowland, Penny A./0000-0002-4900-4817; Baker, Philip/0000-0002-4592-6427				BAKER PN, IN PRESS AM J OBSTET; BAKER PN, IN PRESS CLIN SCI; BUDINGER TF, 1981, J COMPUT ASSIST TOMO, V5, P800, DOI 10.1097/00004728-198112000-00003; CHAPMAN B, 1987, MAGNET RESON MED, V5, P246, DOI 10.1002/mrm.1910050305; JOHNSON IR, 1990, AM J OBSTET GYNECOL, V163, P601, DOI 10.1016/0002-9378(90)91209-U; MANSFIELD P, 1982, NMR IMAGING BIOMEDIC, P143; MAYHEW TM, 1991, J ANAT, V178, P133; SHEPARD MJ, 1982, AM J OBSTET GYNECOL, V142, P47; WATSON WJ, 1988, J REPROD MED, V33, P369; 1991, NRPB1 NAT RAD PROT B, V2	10	99	102	2	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 12	1994	343	8898					644	645		10.1016/S0140-6736(94)92638-7	http://dx.doi.org/10.1016/S0140-6736(94)92638-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906814				2022-12-28	WOS:A1994NA09300011
J	BEROYZ, G; CASALE, R; FARREIROS, A; PALERMO, M; MARGULIES, M; VOTO, L; FABREGUES, G; RAMALINGAM, R; DAVIES, T; BRYCE, R; BOYD, W; CARMODY, F; KING, J; VACCA, A; FAY, R; WALTERS, W; ANTONAS, B; BENNETT, P; BROOM, T; CROWTHER, C; DERHAM, R; GEORGE, K; HAGUE, W; HASENHOHR, G; HEYSEN, D; KORNMAN, L; OLOUGHLIN, S; MORRIS, D; PRIDMORE, B; ROBINSON, J; SVIGOS, D; SWEET, R; BEALE, M; BENNETT, M; BOSCH, E; FISHER, C; HORRAUTZ, S; SYMINGTON, I; SZIRT, A; FORBES, K; FREEMAN, A; POPPER, E; WILSON, J; PERMEZEL, M; BOWDITCH, J; REYNOLDS, G; MOULINASSE, R; BIETLOT, Y; KIRKPATRICK, C; COULON, R; DELVOYE, P; DEMATOS, CF; SIMONINI, S; LEJEUNE, B; NEERDAELS, C; ALEXANDER, S; GOESSENS, L; HANSSENS, M; SPITZ, B; VANASSCHE, A; WECKHUYSEN, R; PARBOOSINGH, J; HARMAN, C; REY, E; BURROWS, R; BELCHER, J; GARNER, P; SYLVAIN, J; NIMROD, C; THOMAS, B; DEININGER, F; LAO, T; LI, C; FRIEDMAN, S; BORNSTEIN, J; SHALIT, A; MATZKEL, A; POMERANZ, M; GELSNER, M; MANKUTA, D; WIZNITZER, A; LEVINE, S; ADEEB, N; CHANDRAN, R; NASRI, N; SHARIFF, J; ANSELL, D; LAKE, Y; GOROCHOVA, L; MERIAKRI, V; ROMANUGA, N; DOTZ, I; SHEUV, B; VIKHLYAEVA, E; ANDREEV, K; GOLUBEVA, L; GORODCOV, V; ADELANTADO, J; SANTONJA, J; HOLMBERG, H; BUCHHAVE, P; LEANDERSSON, U; LILJESTRAND, J; RYDHSTROEM, H; SWEDIN, G; BJORKLUND, A; GENNSER, G; SANDEN, MC; DAHLGREN, S; HAMMARBACK, S; SMEDS, A; SIDENVALL, M; ENEROTH, E; SZABOLCS, A; DANIELSSON, I; LINDQVIST, P; HOGSTEDT, S; WALLENBURG, H; BREMER, H; BRIET, J; DEBIEMEYERINK, A; DONKERS, B; LAMPING, P; SCHIERBEEK, J; VANDERLEEUWHARMSEN, L; THE, H; VANBODEGOM, F; VANEGMONDLINDEN, A; FLU, P; KUIJKEN, J; MORREL, B; STRAUB, M; VIERHOUT, M; KEIRSE, M; VANROOSMALEN, J; HOHNER, C; HUTTEN, J; BENNEN, J; ROEX, A; WIJFFELS, T; OOSTERHOFF, H; OTTEN, J; VANDERKLEI, T; RAMONDT, J; VANDERMOER, P; DEGRAAFF, J; SIJSMA, E; DEGREVE, O; SMIT, D; SMULDERS, P; NIJHUIS, J; ZONDERVAN, H; LIND, J; SCHOOT, B; MONKHORST, M; STUT, J; VANDAM, L; VANOTTERLO, L; VLAANDEREN, W; EGGENS, J; SANTEMA, J; VERHOEFF, A; HAMID, S; JOHN, I; KHAN, G; SHAH, S; SHEIKH, E; SINHA, C; ABRAMOVICH, D; CAMPBELL, D; FISHER, P; GALL, S; HALL, M; JANDIAL, V; PARKIN, D; SMITH, N; SUTHERLAND, H; SWAPP, G; TEMPLETON, A; TERRY, P; KALAM, A; MAGEE, S; MARTIN, D; SPEARING, G; ALDERMAN, B; MURRAY, A; SUTHERST, J; HYATT, D; SAUNDERS, P; BURGESS, S; COCHRANE, G; WHITE, A; ARMSTRONG, M; MCNICHOL, E; OSBOURNE, G; PRICE, J; CRICHTON, J; EVANS, D; ANDERSON, R; HULL, M; JAMES, D; NIVEN, P; STIRRAT, G; WARDLE, P; GARDNER, P; PADGETT, L; ALAILY, A; NASH, G; GINZ, B; SMITH, M; RICHARDS, C; ARMAR, A; ARMSTRONG, N; MANNING, E; PERSAD, K; COLLINGWOOD, M; COLLINS, R; CROWTHER, J; FARRELL, B; HAFNER, B; HANDOLL, H; HEINEMAN, J; KNIGHT, S; MEAD, G; RADLEY, A; SPENCE, S; REID, W; TREHARNE, I; HEASLEY, R; LOWRY, D; MYLES, T; WALLACE, R; GEALS, M; GORDON, G; TRAIN, T; HUTCHON, D; MACDONALD, J; STOREY, R; ANDERSON, G; WORTH, R; ERIAN, J; MCQUEEN, J; TATFORD, E; TERRY, M; NEALE, R; HOWAT, R; KENNEDY, J; MACNAUGHTON, M; MCEWAN, H; WALKER, J; HUTCHESON, R; KEMP, V; READ, M; SIMMS, M; SWINGLER, G; HUSEMEYER, R; CHAPMAN, M; MAXWELL, D; ELDER, M; FUSI, L; HAWKINS, D; NICOLINI, U; WINSTON, R; BURTON, E; FAIRBANK, J; SIMMONS, S; SPING, J; TRICKEY, N; EVANS, D; GILLARD, M; HUDSON, C; SETCHELL, M; WATHEN, N; CANTY, S; WHITELEY, P; CAMPBELL, J; FEENEY, J; HAY, D; IMRIE, A; PALMER, A; PURDIE, D; SPECK, E; TYRRELL, S; MCLEAN, J; BROWN, V; DUNCAN, S; JOHNSON, D; MILLAR, D; BUCKLEY, D; CHARNOCK, M; DOVE, P; ELLIS, J; GILLMER, M; MCVITTIE, J; MANNION, V; REDMAN, CWG; SELLERS, S; TURNBULL, A; NEWMAN, M; CAMPBELL, S; CARDOSO, L; GIBB, D; HARRINGTON, K; PARSONS, J; NICOLAIDES, K; STUDD, J; DIXON, R; GIE, C; PICKLES, C; SEAR, R; GRAHAM, R; KIRWAN, P; SMITH, G; ANWAR, M; ALAZZAWI, F; DAVIDSON, A; DECHAZEL, R; DRIFE, J; GILL, F; LANG, G; MACAFEE, J; MACVICAR, J; NAFTALIN, N; NEUBERG, R; TAYLOR, D; LEAVER, E; TIMOTHY, I; CRICHTON, J; BREESON, A; LAMB, M; VELACOTT, I; VERNER, V; HORWELL, D; LOBB, M; SELIGMAN, S; SCOTT, A; HALL, S; MACKENZIE, W; SMITH, E; VETHANAVAGAN, S; VERZIN, J; WEIR, P; WHITE, R; CLARK, H; FAWDRY, R; LYNCH, C; MCCUNE, G; BOWENSIMPKINS, P; CALVERT, J; EMERY, S; JACKSON, W; STOKES, I; WARD, A; BROWNING, A; COX, C; LITTLE, D; STIBBE, H; MCINTOSH, A; SNODGRASS, C; WAGSTAFF, T; HOWIE, P; TAYLOR, D; BIBBY, J; DAVIES, W; ELLIOTT, B; SHAXTED, E; MCGARRY, J; DAW, E; BAKER, K; CLUBB, A; GOUGH, J; GRANT, M; MENON, V; OBHARI, M; OBRIEN, P; REDMAN, C; BROWN, R; RYALL, A; WALTON, S; BAKER, J; BRUCE, J; LIU, D; JOHNSON, I; TYACK, A; COWIE, D; NYSENBAUM, A; BAMFORD, P; GARRIOCH, D; HILL, J; GRANT, A; FELTON, D; HACKMAN, B; FALCONER, A; FREEMAN, F; GREENE, K; JACKSON, J; HUNTER, G; GRATTON, D; MAULIK, T; YOUSSEF, H; BANWELL, G; HARTWELL, R; WILSON, P; BOND, A; FORBESSMITH, P; BARRON, L; DAVISON, J; DUNLOP, W; LIND, T; TACCHI, D; BALFOUR, R; MUTCH, L; COLTART, T; DESWIET, M; EDMONDS, D; LOEFFLER, F; MALVERN, J; MORRIS, D; OSBOURNE, J; RODECK, C; SIMS, C; SPENCER, J; BONE, C; MACDONALD, A; DREW, N; BALLARD, R; THONET, R; WORTH, R; HANNA, L; MORCOS, S; HOLT, E; COOPER, J; CALLEN, P; FOZZARD, C; GRUNDY, M; STANLEY, S; DANIEL, D; GOLDING, R; WIENER, J; BUCKINGHAM, M; HEARD, M; LETCHWORTH, A; BOOMLA, K; CLARK, A; GRUDZINSKAS, J; HARTGILL, J; ORAM, D; ROBSON, J; SAVAGE, W; BLUNT, V; LANE, J; OWEN, A; REDFORD, D; BEARD, R; BOSTOCK, J; MEASDAY, B; MELVILLE, H; DORNAN, J; TRAUB, A; UTIDJIAN, M; AULD, A; KRASZEWSKI, A; MACK, D; MCDOUGALL, N; MOWAT, J; DOCHERTY, P; MCKENNA, D; SMEDLEY, G; WILDE, J; SMITH, R; WATNEY, P; MCDONNELL, J; TROMAMS, P; CALDER, A; GLASIER, A; GREER, I; JOHNSTONE, F; LISTON, W; LIVINGSTONE, J; NEILSON, J; SMITH, S; WEST, C; BULLOUGH, C; JONES, A; MACKAY, G; COOPER, K; RUOSS, C; JAMES, D; JOYCE, D; MCCOY, D; MCLEOD, F; SAVAGE, P; SMITH, P; TURNER, G; KANE, L; ROSENBERG, D; SHANNON, R; BROMHAM, D; BUCHAN, P; CROMPTON, A; JARVIS, G; LILFORD, R; MACDONALD, H; THORNTON, J; PINKER, G; BEVAN, J; CLARK, A; FRANCIS, J; KETTLE, M; HOLMES, H; KERRWILSON, R; SUTTON, M; BEYNON, J; HOOKER, J; FERGUSSON, I; MORTON, K; TAYLOR, R; DAVIS, J; LOW, R; STEWART, J; ASHWORTH, F; SOONAWALLA, K; TEBBUTT, I; USHERWOOD, M; VOIGT, J; COHEN, S; GODFREY, K; MCNAB, G; MURRAY, B; GUDGEON, D; FOULKES, J; STANNARD, P; JAMSHIDI, R; MULHOLLAND, J; BOND, E; DUNLOP, J; FOGARTY, P; BRANT, H; LACHELIN, L; LLOYDJONES, R; SIDDLE, N; SILVERSTONE, A; STEELE, S; WARD, R; EDDIE, D; VERNONPARRY, J; CIETAK, K; KENNEDY, C; REED, M; SANTCASSIA, L; BEGG, H; FRAMPTON, J; GRIFFIN, D; LEWIS, B; NESTROP, A; SHERIDAN, R; TIPTON, R; BOBER, S; BROUGH, F; STAFFORD, J; HOUSE, M; PAWSON, M; REES, D; VENN, R; ANDERSON, T; HUGHES, J; REGINALD, P; HENSON, G; MORGAN, H; ALLEN, I; HANNAY, W; LENNOX, C; CALLENDER, R; MCLEAN, R; GOLDKRAND, J; FIDALGO, C				BEROYZ, G; CASALE, R; FARREIROS, A; PALERMO, M; MARGULIES, M; VOTO, L; FABREGUES, G; RAMALINGAM, R; DAVIES, T; BRYCE, R; BOYD, W; CARMODY, F; KING, J; VACCA, A; FAY, R; WALTERS, W; ANTONAS, B; BENNETT, P; BROOM, T; CROWTHER, C; DERHAM, R; GEORGE, K; HAGUE, W; HASENHOHR, G; HEYSEN, D; KORNMAN, L; OLOUGHLIN, S; MORRIS, D; PRIDMORE, B; ROBINSON, J; SVIGOS, D; SWEET, R; BEALE, M; BENNETT, M; BOSCH, E; FISHER, C; HORRAUTZ, S; SYMINGTON, I; SZIRT, A; FORBES, K; FREEMAN, A; POPPER, E; WILSON, J; PERMEZEL, M; BOWDITCH, J; REYNOLDS, G; MOULINASSE, R; BIETLOT, Y; KIRKPATRICK, C; COULON, R; DELVOYE, P; DEMATOS, CF; SIMONINI, S; LEJEUNE, B; NEERDAELS, C; ALEXANDER, S; GOESSENS, L; HANSSENS, M; SPITZ, B; VANASSCHE, A; WECKHUYSEN, R; PARBOOSINGH, J; HARMAN, C; REY, E; BURROWS, R; BELCHER, J; GARNER, P; SYLVAIN, J; NIMROD, C; THOMAS, B; DEININGER, F; LAO, T; LI, C; FRIEDMAN, S; BORNSTEIN, J; SHALIT, A; MATZKEL, A; POMERANZ, M; GELSNER, M; MANKUTA, D; WIZNITZER, A; LEVINE, S; ADEEB, N; CHANDRAN, R; NASRI, N; SHARIFF, J; ANSELL, D; LAKE, Y; GOROCHOVA, L; MERIAKRI, V; ROMANUGA, N; DOTZ, I; SHEUV, B; VIKHLYAEVA, E; ANDREEV, K; GOLUBEVA, L; GORODCOV, V; ADELANTADO, J; SANTONJA, J; HOLMBERG, H; BUCHHAVE, P; LEANDERSSON, U; LILJESTRAND, J; RYDHSTROEM, H; SWEDIN, G; BJORKLUND, A; GENNSER, G; SANDEN, MC; DAHLGREN, S; HAMMARBACK, S; SMEDS, A; SIDENVALL, M; ENEROTH, E; SZABOLCS, A; DANIELSSON, I; LINDQVIST, P; HOGSTEDT, S; WALLENBURG, H; BREMER, H; BRIET, J; DEBIEMEYERINK, A; DONKERS, B; LAMPING, P; SCHIERBEEK, J; VANDERLEEUWHARMSEN, L; THE, H; VANBODEGOM, F; VANEGMONDLINDEN, A; FLU, P; KUIJKEN, J; MORREL, B; STRAUB, M; VIERHOUT, M; KEIRSE, M; VANROOSMALEN, J; HOHNER, C; HUTTEN, J; BENNEN, J; ROEX, A; WIJFFELS, T; OOSTERHOFF, H; OTTEN, J; VANDERKLEI, T; RAMONDT, J; VANDERMOER, P; DEGRAAFF, J; SIJSMA, E; DEGREVE, O; SMIT, D; SMULDERS, P; NIJHUIS, J; ZONDERVAN, H; LIND, J; SCHOOT, B; MONKHORST, M; STUT, J; VANDAM, L; VANOTTERLO, L; VLAANDEREN, W; EGGENS, J; SANTEMA, J; VERHOEFF, A; HAMID, S; JOHN, I; KHAN, G; SHAH, S; SHEIKH, E; SINHA, C; ABRAMOVICH, D; CAMPBELL, D; FISHER, P; GALL, S; HALL, M; JANDIAL, V; PARKIN, D; SMITH, N; SUTHERLAND, H; SWAPP, G; TEMPLETON, A; TERRY, P; KALAM, A; MAGEE, S; MARTIN, D; SPEARING, G; ALDERMAN, B; MURRAY, A; SUTHERST, J; HYATT, D; SAUNDERS, P; BURGESS, S; COCHRANE, G; WHITE, A; ARMSTRONG, M; MCNICHOL, E; OSBOURNE, G; PRICE, J; CRICHTON, J; EVANS, D; ANDERSON, R; HULL, M; JAMES, D; NIVEN, P; STIRRAT, G; WARDLE, P; GARDNER, P; PADGETT, L; ALAILY, A; NASH, G; GINZ, B; SMITH, M; RICHARDS, C; ARMAR, A; ARMSTRONG, N; MANNING, E; PERSAD, K; COLLINGWOOD, M; COLLINS, R; CROWTHER, J; FARRELL, B; HAFNER, B; HANDOLL, H; HEINEMAN, J; KNIGHT, S; MEAD, G; RADLEY, A; SPENCE, S; REID, W; TREHARNE, I; HEASLEY, R; LOWRY, D; MYLES, T; WALLACE, R; GEALS, M; GORDON, G; TRAIN, T; HUTCHON, D; MACDONALD, J; STOREY, R; ANDERSON, G; WORTH, R; ERIAN, J; MCQUEEN, J; TATFORD, E; TERRY, M; NEALE, R; HOWAT, R; KENNEDY, J; MACNAUGHTON, M; MCEWAN, H; WALKER, J; HUTCHESON, R; KEMP, V; READ, M; SIMMS, M; SWINGLER, G; HUSEMEYER, R; CHAPMAN, M; MAXWELL, D; ELDER, M; FUSI, L; HAWKINS, D; NICOLINI, U; WINSTON, R; BURTON, E; FAIRBANK, J; SIMMONS, S; SPING, J; TRICKEY, N; EVANS, D; GILLARD, M; HUDSON, C; SETCHELL, M; WATHEN, N; CANTY, S; WHITELEY, P; CAMPBELL, J; FEENEY, J; HAY, D; IMRIE, A; PALMER, A; PURDIE, D; SPECK, E; TYRRELL, S; MCLEAN, J; BROWN, V; DUNCAN, S; JOHNSON, D; MILLAR, D; BUCKLEY, D; CHARNOCK, M; DOVE, P; ELLIS, J; GILLMER, M; MCVITTIE, J; MANNION, V; REDMAN, CWG; SELLERS, S; TURNBULL, A; NEWMAN, M; CAMPBELL, S; CARDOSO, L; GIBB, D; HARRINGTON, K; PARSONS, J; NICOLAIDES, K; STUDD, J; DIXON, R; GIE, C; PICKLES, C; SEAR, R; GRAHAM, R; KIRWAN, P; SMITH, G; ANWAR, M; ALAZZAWI, F; DAVIDSON, A; DECHAZEL, R; DRIFE, J; GILL, F; LANG, G; MACAFEE, J; MACVICAR, J; NAFTALIN, N; NEUBERG, R; TAYLOR, D; LEAVER, E; TIMOTHY, I; CRICHTON, J; BREESON, A; LAMB, M; VELACOTT, I; VERNER, V; HORWELL, D; LOBB, M; SELIGMAN, S; SCOTT, A; HALL, S; MACKENZIE, W; SMITH, E; VETHANAVAGAN, S; VERZIN, J; WEIR, P; WHITE, R; CLARK, H; FAWDRY, R; LYNCH, C; MCCUNE, G; BOWENSIMPKINS, P; CALVERT, J; EMERY, S; JACKSON, W; STOKES, I; WARD, A; BROWNING, A; COX, C; LITTLE, D; STIBBE, H; MCINTOSH, A; SNODGRASS, C; WAGSTAFF, T; HOWIE, P; TAYLOR, D; BIBBY, J; DAVIES, W; ELLIOTT, B; SHAXTED, E; MCGARRY, J; DAW, E; BAKER, K; CLUBB, A; GOUGH, J; GRANT, M; MENON, V; OBHARI, M; OBRIEN, P; REDMAN, C; BROWN, R; RYALL, A; WALTON, S; BAKER, J; BRUCE, J; LIU, D; JOHNSON, I; TYACK, A; COWIE, D; NYSENBAUM, A; BAMFORD, P; GARRIOCH, D; HILL, J; GRANT, A; FELTON, D; HACKMAN, B; FALCONER, A; FREEMAN, F; GREENE, K; JACKSON, J; HUNTER, G; GRATTON, D; MAULIK, T; YOUSSEF, H; BANWELL, G; HARTWELL, R; WILSON, P; BOND, A; FORBESSMITH, P; BARRON, L; DAVISON, J; DUNLOP, W; LIND, T; TACCHI, D; BALFOUR, R; MUTCH, L; COLTART, T; DESWIET, M; EDMONDS, D; LOEFFLER, F; MALVERN, J; MORRIS, D; OSBOURNE, J; RODECK, C; SIMS, C; SPENCER, J; BONE, C; MACDONALD, A; DREW, N; BALLARD, R; THONET, R; WORTH, R; HANNA, L; MORCOS, S; HOLT, E; COOPER, J; CALLEN, P; FOZZARD, C; GRUNDY, M; STANLEY, S; DANIEL, D; GOLDING, R; WIENER, J; BUCKINGHAM, M; HEARD, M; LETCHWORTH, A; BOOMLA, K; CLARK, A; GRUDZINSKAS, J; HARTGILL, J; ORAM, D; ROBSON, J; SAVAGE, W; BLUNT, V; LANE, J; OWEN, A; REDFORD, D; BEARD, R; BOSTOCK, J; MEASDAY, B; MELVILLE, H; DORNAN, J; TRAUB, A; UTIDJIAN, M; AULD, A; KRASZEWSKI, A; MACK, D; MCDOUGALL, N; MOWAT, J; DOCHERTY, P; MCKENNA, D; SMEDLEY, G; WILDE, J; SMITH, R; WATNEY, P; MCDONNELL, J; TROMAMS, P; CALDER, A; GLASIER, A; GREER, I; JOHNSTONE, F; LISTON, W; LIVINGSTONE, J; NEILSON, J; SMITH, S; WEST, C; BULLOUGH, C; JONES, A; MACKAY, G; COOPER, K; RUOSS, C; JAMES, D; JOYCE, D; MCCOY, D; MCLEOD, F; SAVAGE, P; SMITH, P; TURNER, G; KANE, L; ROSENBERG, D; SHANNON, R; BROMHAM, D; BUCHAN, P; CROMPTON, A; JARVIS, G; LILFORD, R; MACDONALD, H; THORNTON, J; PINKER, G; BEVAN, J; CLARK, A; FRANCIS, J; KETTLE, M; HOLMES, H; KERRWILSON, R; SUTTON, M; BEYNON, J; HOOKER, J; FERGUSSON, I; MORTON, K; TAYLOR, R; DAVIS, J; LOW, R; STEWART, J; ASHWORTH, F; SOONAWALLA, K; TEBBUTT, I; USHERWOOD, M; VOIGT, J; COHEN, S; GODFREY, K; MCNAB, G; MURRAY, B; GUDGEON, D; FOULKES, J; STANNARD, P; JAMSHIDI, R; MULHOLLAND, J; BOND, E; DUNLOP, J; FOGARTY, P; BRANT, H; LACHELIN, L; LLOYDJONES, R; SIDDLE, N; SILVERSTONE, A; STEELE, S; WARD, R; EDDIE, D; VERNONPARRY, J; CIETAK, K; KENNEDY, C; REED, M; SANTCASSIA, L; BEGG, H; FRAMPTON, J; GRIFFIN, D; LEWIS, B; NESTROP, A; SHERIDAN, R; TIPTON, R; BOBER, S; BROUGH, F; STAFFORD, J; HOUSE, M; PAWSON, M; REES, D; VENN, R; ANDERSON, T; HUGHES, J; REGINALD, P; HENSON, G; MORGAN, H; ALLEN, I; HANNAY, W; LENNOX, C; CALLENDER, R; MCLEAN, R; GOLDKRAND, J; FIDALGO, C			CLASP - A RANDOMIZED TRIAL OF LOW-DOSE ASPIRIN FOR THE PREVENTION AND TREATMENT OF PREECLAMPSIA AMONG 9364 PREGNANT-WOMEN	LANCET			English	Article							CLASSIFYING PERINATAL DEATH; INDUCED HYPERTENSION; FETAL; PREECLAMPSIA; RISK; PROSTACYCLIN; PLATELETS	Pre-eclampsia is a common and serious complication of pregnancy that affects both mother and child. Review of previous small trials of antiplatelet therapy, particularly low-dose aspirin, suggested reductions of about three-quarters in the incidence of pre-eclampsia and some avoidance of intrauterine growth retardation (IUGR), but larger trials have not confirmed these results. In our multicentre study 9364 women were randomly assigned 60 mg aspirin daily or matching placebo. 74% were entered for prophylaxis of pre-eclampsia, 12% for prophylaxis of IUGR, 12% for treatment of pre-eclampsia, and 3% for treatment of IUGR. Overall, the use of aspirin was associated with a reduction of only 12% in the incidence of proteinuric pre-eclampsia, which was not significant. Nor was there any significant effect on the incidence of IUGR or of stillbirth and neonatal death. Aspirin did, however, significantly reduce the likelihood of preterm delivery (19.7% aspirin vs 22.2% control; absolute reduction of 2.5 [SD 0.9] per 100 women treated; 2p = 0.003). There was a significant trend (p = 0.004) towards progressively greater reductions in proteinuric preeclampsia the more preterm the delivery. Aspirin was not associated with a significant increase in placental haemorrhages or in bleeding during preparation for epidural anaesthesia, but there was a slight increase in use of blood transfusion after delivery. Low-dose aspirin was generally safe for the fetus and newborn infant, with no evidence of an increased likelihood of bleeding. Our findings do not support routine prophylactic or therapeutic administration of antiplatelet therapy in pregnancy to all women at increased risk of pre-eclampsia or IUGR. Low-dose aspirin may be justified in women judged to be especially liable to early-onset pre-eclampsia severe enough to need very preterm delivery. In such women it seems appropriate to start low-dose aspirin prophylactically early in the second trimester.	HOSP NACL ALEJANDROS POSADAS, BUENOS AIRES, ARGENTINA; JUAN A FERNANDEZ HOSP, BUENOS AIRES, ARGENTINA; POLICLIN BANCARIA, BUENOS AIRES, ARGENTINA; BROKEN HILL BASE HOSP, BROKEN HILL, NSW, AUSTRALIA; BUNDABERG HOSP, BUNDABERG, QLD, AUSTRALIA; FLINDERS MED CTR, BEDFORD PK, SA, AUSTRALIA; MACKAY BASE HOSP, MACKAY, QLD, AUSTRALIA; MATER MOTHERS HOSP, BRISBANE, QLD, AUSTRALIA; NEPEAN HOSP, PENRITH, NSW, AUSTRALIA; NEWCASTLE MATER HOSP, WARATAH, AUSTRALIA; QUEEN VICTORIA HOSP, ADELAIDE, SA, AUSTRALIA; ROYAL HOSP WOMEN, PADDINGTON, AUSTRALIA; ROYAL HOSP WOMEN, HERSTON, QLD, AUSTRALIA; ROYAL WOMENS HOSP, PARKVILLE, VIC, AUSTRALIA; ST GEORGE HOSP, MILDURA, VIC, AUSTRALIA; CLIN NOTRE DAME, TOURNAI, BELGIUM; CLIN ST PIERRE, WAVRE, BELGIUM; HOP ERASME, BRUSSELS, BELGIUM; HOP MADELEINE, ATH, BELGIUM; HOP ST PIERRE & ERASME, BRUSSELS, BELGIUM; INST MEDICOCHIRURG, TOURNAI, BELGIUM; MATERN IXLLES, BRUSSELS, BELGIUM; UNIV ZIEKENHUIS GASTHUISBERG LEUVEN HOSP GRP, LOUVAIN, BELGIUM; FOOTHILLS PROV GEN HOSP, CALGARY, AB, CANADA; HLTH SCI CTR, WINNIPEG, MB, CANADA; HOP ST JUSTINE, MONTREAL, PQ, CANADA; MCMASTER UNIV, HAMILTON, ON, CANADA; OTTAWA CIVIC HOSP, OTTAWA, ON, CANADA; OTTAWA GEN HOSP, OTTAWA, ON, CANADA; WOMENS COLL HOSP, TORONTO, ON, CANADA; UNIV MUNICH, FRAUENKLIN, MUNICH, GERMANY; PRINCE WALES HOSP, SHA TIN, HONG KONG; BEILINSON MED CTR, PETAH TIQWA, ISRAEL; CARMEL HOSP, HAIFA, ISRAEL; HILLEL JAFFE HOSP, HADERA, ISRAEL; KAPLAN HOSP, REHOVOT, ISRAEL; MEIR HOSP, KEFAR SAVA, ISRAEL; SOROKA MED CTR, BEER SHEVA, ISRAEL; WOLFSON MED CTR, HOLON, ISRAEL; MATERN HOSP, KUALA LUMPUR, MALAYSIA; MIDDLEMORE HOSP, AUCKLAND, NEW ZEALAND; MATERN HOSP, IRKUTSK, RUSSIA; CHELYABINSK MED INST, CHELYABINSK, RUSSIA; RUSSIAN SCI CTR, MOSCOW, RUSSIA; SCI RES CTR, IVANOVO, RUSSIA; HOSP SANTA CRUZ & SAN PABLO, BARCELONA, SPAIN; UNIV VALENCIA, VALENCIA, SPAIN; CENT HOSP, KALMAR, SWEDEN; CENT HOSP KARLSKRONA, KARLSKRONA, SWEDEN; CITY HOSP, OSTERSUND, SWEDEN; DANDERYD HOSP, DANDERYD, SWEDEN; ESKILSTUNA CTY HOSP, STOCKHOLM, SWEDEN; HUDIKSVALLS SJUKHUS, HUDIKSVALL, SWEDEN; SODER SJUKHUSET, STOCKHOLM, SWEDEN; SODERTALJE SJUKHUS, SODERTALJE, SWEDEN; SUNDSVALLS SJUKHUS KK, SUNDSVALL, SWEDEN; VASTERAS HOSP, VASTERAS, SWEDEN; DIJKZIGT ACAD HOSP, ROTTERDAM, NETHERLANDS; GEERTRUIDEN ZIEKENHUIS, DEVENTER, NETHERLANDS; GEMINI ZIEKENHUIS, DEN HELDER, NETHERLANDS; HOFPOORT ZIEKENHUIS, WOERDEN, NETHERLANDS; IKAZIA ZIEKENHUIS, ROTTERDAM, NETHERLANDS; LEIDEN UNIV HOSP, LEIDEN, NETHERLANDS; LIEVENSBERG ZIEKENHUIS, BERGEN OP ZOO, NETHERLANDS; MED CTR ALKMAAR, ALKMAAR, NETHERLANDS; PASTEUR ZIEKENHUIS, OOSTERHOUT, NETHERLANDS; RODE KRUIS ZIEKENHUIS, HEEMSKERK, NETHERLANDS; ST CLARA HOSP, ROTTERDAM, NETHERLANDS; ST ELIZABETH HOSP, TILBURG, NETHERLANDS; ST JANSDAL ZIEKENHUIS, HARDERWIJK, NETHERLANDS; TWENTEBORG ZIEKENHUIS, ALMELO, NETHERLANDS; UNIV HOSP NIJMEGEN, NIJMEGEN, NETHERLANDS; UNIV AMSTERDAM, AMSTERDAM, NETHERLANDS; WESTEINDE ZIEKENHUIS, THE HAGUE, NETHERLANDS; ZIEKENHUIS CTR, APELDOORN, NETHERLANDS; ZIEKENHUZEN RYNSTAETE & VELP, ARNHEM, NETHERLANDS; ZUIDER ZIEKENHUIS, ROTTERDAM, NETHERLANDS; CORNICHE HOSP, ABU DHABI, U ARAB EMIRATES; ABERDEEN MATERN HOSP, ABERDEEN, ABERDEEN, SCOTLAND; ALTNAGELVIN HOSP, LONDONDERRY, LONDONDERRY, NORTH IRELAND; ARROWE PK HOSP, WIRRAL, MERSEYSIDE, ENGLAND; ASHFORD HOSP, ASHFORD, KENT, ENGLAND; BARKING HOSP, BARKING, ENGLAND; BELFAST CITY HOSP, BELFAST, ANTRIM, NORTH IRELAND; BELLSHILL MATERN HOSP, BELLSHILL, SCOTLAND; BORDERS GEN HOSP, MELROSE, SCOTLAND; BRISTOL ST MICHAELS HOSP, BRISTOL, AVON, ENGLAND; BRONGLAIS GEN HOSP, ABERYSTWYTH, DYFED, WALES; BUCHANAN HOSP, ST LEONARDS ON SEA, ENGLAND; BURTON DIST HOSP CTR, BURTON UPON TRENT, STAFFS, ENGLAND; CAERPHILLY DIST MINERS HOSP, CAERPHILLY, M GLAM, WALES; CENT MIDDLESEX HOSP, LONDON, ENGLAND; RADCLIFFE INFIRM, CLIN TRIAL SERV UNIV, OXFORD, OXON, ENGLAND; CITY MATERN HOSP, CARLISLE, CUMBRIA, ENGLAND; COLCHESTER MATERN HOSP, COLCHESTER, ESSEX, ENGLAND; CRAIGAVON AREA HOSP, CRAIGAVON, NORTH IRELAND; CRESSWELL MATERN HOSP, DUMFRIES, DUMFRIES, SCOTLAND; DARLINGTON MEM HOSP, DARLINGTON, DURHAM, ENGLAND; DOWNPATRICK MATERN HOSP, DOWNPATRICK, DOWN, NORTH IRELAND; DRYBURN HOSP, DURHAM, DURHAM, ENGLAND; EPSOM DIST HOSP, EPSOM, SURREY, ENGLAND; FARNBOROUGH HOSP, ORPINGTON, ENGLAND; FRIARAGE HOSP, NORTHALLERTON, N YORKSHIRE, ENGLAND; GLASGOW ROYAL MATERN HOSP, GLASGOW, LANARK, SCOTLAND; GLOUCESTERSHIRE ROYAL HOSP, GLOUCESTER, GLOS, ENGLAND; GRANTHAM & KESTEVEN GEN HOSP, GRANTHAM, LINCS, ENGLAND; GUYS HOSP, LONDON, ENGLAND; HAMMERSMITH HOSP, LONDON, ENGLAND; HAROLD WOOD HOSP, ROMFORD, ESSEX, ENGLAND; HEATHERWOOD HOSP, ASCOT, BERKS, ENGLAND; HOMERTON HOSP, LONDON, ENGLAND; HORTON GEN HOSP, BANBURY, OXON, ENGLAND; HUDDERSFIELD ROYAL INFIRM, HUDDERSFIELD, W YORKSHIRE, ENGLAND; HULL MATERN HOSP, Kingston Upon Hull, N HUMBERSIDE, ENGLAND; JAMES PAGET HOSP, GREAT YARMOUTH, NORFOLK, ENGLAND; JESSOP HOSP WOMEN, SHEFFIELD, S YORKSHIRE, ENGLAND; JOHN RADCLIFFE HOSP, OXFORD, OXON, ENGLAND; KETTERING & DIST GEN HOSP, KETTERING, NORTHANTS, ENGLAND; KINGS COLL HOSP, LONDON, ENGLAND; KINGS MILL HOSP, SUTTON IN ASHFIELD, NOTTS, ENGLAND; LEICESTER GEN HOSP, LEICESTER, LEICS, ENGLAND; LEICESTER MATERN HOSP, LEICESTER, LEICS, ENGLAND; LEIGHTON HOSP, CREWE, CHESHIRE, ENGLAND; LEWIS HOSP, LEWIS, SCOTLAND; LINCOLN CTY HOSP, LINCOLN, LINCS, ENGLAND; LUTON & DUNSTABLE HOSP, LUTON, BEDS, ENGLAND; MACCLESFIELD HOSP, MACCLESFIELD, CHESHIRE, ENGLAND; MARSTON GREEN HOSP, BIRMINGHAM, W MIDLANDS, ENGLAND; MATER INFIRMORUM GEN HOSP, BELFAST, ANTRIM, NORTH IRELAND; MID ULSTER HOSP, MAGHERAFELT, NORTH IRELAND; MILTON KEYNES DIST GEN HOSP, MILTON KEYNES, BUCKS, ENGLAND; MORRISTON HOSP, SWANSEA, W GLAM, WALES; NEVILL HALL HOSP, ABERGAVENNY, WALES; NEW CROSS HOSP, WOLVERHAMPTON, W MIDLANDS, ENGLAND; NEWCASTLE GEN HOSP, TYNE & WEAR, NEWCASTLE UPON TYNE, ENGLAND; NINEWELLS HOSP, DUNDEE, SCOTLAND; NORTHAMPTON GEN HOSP, NORTHAMPTON, ENGLAND; N MANCHESTER GRP HOSP, MANCHESTER, LANCS, ENGLAND; N STAFFS MATERN HOSP, STOKE ON TRENT, ENGLAND; N TEES GEN HOSP, STOCKTON ON TEES, ENGLAND; NOTTINGHAM CITY HOSP, NOTTINGHAM, ENGLAND; TRAFFORD GEN HOSP, MANCHESTER, LANCS, ENGLAND; PEMBURY HOSP, TUNBRIDGE WELLS, ENGLAND; PERINATAL TRIALS SERV, NATL PERINATAL EPIDEMIOL UNIT, OXFORD, ENGLAND; PETERBOROUGH MATERN UNIT, PETERBOROUGH, CAMBS, ENGLAND; PLYMOUTH GEN HOSP, PLYMOUTH, ENGLAND; PONTEFRACT DIST GEN HOSP, PONTEFRACT, W YORKSHIRE, ENGLAND; PRINCE CHARLES HOSP, MERTHYR TYDFIL, ENGLAND; PRINCESS ALEXANDRA HOSP, HARLOW, ENGLAND; PRINCESS MARGARET HOSP, SWINDON, ENGLAND; PPRINCESS MARY MATERN HOSP, NEWCASTLE UPON TYNE, ENGLAND; PRINCESS WALES HOSP, BRIDGEND, WALES; PUBL HLTH RES UNIT, GLASGOW, SCOTLAND; QUEEN CHARLOTTES MATERN HOSP, LONDON, ENGLAND; QUEEN ELIZABETH HOSP, KINGS LYNN, ENGLAND; QUEEN ELIZABETH 2 HOSP, WELWYN GARDEN CITY, ENGLAND; QUEEN MARYS HOSP, LONDON, ENGLAND; QUEEN MARYS HOSP, SIDCUP, ENGLAND; ROYAL BERKSHIRE HOSP, READING, ENGLAND; ROYAL CORNWALL HOSP, TRELISKE, ENGLAND; ROYAL GWENT HOSP, NEWPORT, WALES; ROYAL HAMPSHIRE CTY HOSP, WINCHESTER, ENGLAND; ROYAL LONDON HOSP, LONDON, ENGLAND; ROYAL SHREWSBURY HOSP, SHREWSBURY, SALOP, ENGLAND; ROYAL SUSSEX CTY HOSP, BRIGHTON, ENGLAND; ROYAL VICTORIA HOSP, BELFAST, NORTH IRELAND; RUSH GREEN HOSP, ROMFORD, ENGLAND; RUTHERGLEN MATERN HOSP, GLASGOW, SCOTLAND; SALISBURY DIST HOSP, SALISBURY, WILTS, ENGLAND; SANDWELL DIST GEN HOSP, W BROMWICH, ENGLAND; SCARSDALE HOSP, CHESTERFIELD, ENGLAND; SIMPSON MEM MATERN PAVIL, EDINBURGH, SCOTLAND; S SHIELDS GEN HOSP, S SHIELDS, TYNE & WEAR, ENGLAND; SOUTHLANDS HOSP, SHOREHAM BY SEA, ENGLAND; SOUTHMEAD GEN HOSP, WESTBURY ON TRYM, ENGLAND; ST ALBANS HOSP, ST ALBANS, HERTS, ENGLAND; HEMEL HEMPSTEAD HOSP, HEMEL HEMPSTEAD, HERTS, ENGLAND; ST JAMES UNIV HOSP, LEEDS, ENGLAND; ST MARYS HOSP, LONDON, ENGLAND; ST MARYS HOSP, PORTSMOUTH, ENGLAND; ST PAULS HOSP, CHELTENHAM, ENGLAND; ST RICHARDS HOSP, CHICHESTER, ENGLAND; ST THOMAS HOSP, LONDON, ENGLAND; STOBHILL GEN HOSP, GLASGOW, SCOTLAND; STOKE MANDEVILLE HOSP, AYLESBURY, ENGLAND; SUNDERLAND DIST GEN HOSP, SUNDERLAND, DURHAM, ENGLAND; TORBAY HOSP, PLYMOUTH, DEVON, ENGLAND; TYRONE CTY HOSP, OMAGH, NORTH IRELAND; ULSTER HOSP, BELFAST, NORTH IRELAND; UNIV COLL OBSTET HOSP, LONDON, ENGLAND; VICTORIA HOSP, BLACKPOOL, ENGLAND; VICTORIA HOSP, WORKSOP, ENGLAND; WALSGRAVE GEN HOSP, COVENTRY, ENGLAND; WARNEFORD GEN HOSP, ROYAL LEAMINGTON SPA, ENGLAND; WATFORD DIST GEN HOSP, WATFORD, HERTS, ENGLAND; W CUMBERLAND DIST GEN HOSP, WHITEHAVEN, ENGLAND; W LONDON HOSP, LONDON, ENGLAND; W SUFFOLK HOSP, BURY ST EDMUNDS, ENGLAND; WEXHAM PK HOSP, SLOUGH, ENGLAND; WHITTINGTON HOSP, LONDON, ENGLAND; WORDSLEY HOSP, STOURBRIDGE, ENGLAND; MEM MED CTR, SAVANNAH, GA USA	University of Buenos Aires; Flinders Medical Centre; Nepean Hospital; University of Sydney; Calvary Mater Newcastle Hospital; Royal Brisbane & Women's Hospital; St George Hospital; Universite Libre de Bruxelles; Universite Libre de Bruxelles; KU Leuven; University Hospital Leuven; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; Universite de Montreal; McMaster University; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Munich; Chinese University of Hong Kong; Prince of Wales Hospital; Rabin Medical Center; Clalit Health Services; Carmel Medical Center; Hebrew University of Jerusalem; Kaplan Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Ben Gurion University; Soroka Medical Center; South Ural State Medical University; University of Valencia; Danderyds Hospital; Sodersjukhuset Hospital; Vasteras Central Hospital; Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Medical Center Of Alkmaar; Elisabeth-TweeSteden Ziekenhuis (ETZ); Radboud University Nijmegen; University of Amsterdam; Rijnstate Hospital; University of Aberdeen; Belfast City Hospital; Imperial College London; Radcliffe Infirmary; Gloucestershire Royal Hospital; Guy's & St Thomas' NHS Foundation Trust; Imperial College London; University of Oxford; King's College Hospital NHS Foundation Trust; King's College Hospital; University Hospitals of Leicester NHS Trust; Leicester General Hospital; Morriston Hospital; New Cross Hospital; Newcastle General Hospital; University of Dundee; University Hospital of North Tees; Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Oxford; University of Plymouth; Princess Alexandra Hospital NHS Trust; University of Glasgow; Imperial College London; University of London; Queen Mary University London; Royal Berkshire Hospital; Royal Cornwall Hospital; Royal Gwent Hospital; Barts Health NHS Trust; Royal London Hospital; University of Brighton; Salisbury District Hospital; Southmead Hospital; Saint James's University Hospital; Imperial College London; Guy's & St Thomas' NHS Foundation Trust; Watford General Hospital; University of London; University College London	BEROYZ, G (corresponding author), RADCLIFFE INFIRM, CLASP COORDINATING CTR, HARKNESS BLDG, OXFORD OX2 6HE, ENGLAND.		Voto, Liliana Susana/AAC-4923-2020; Thornton, Jim/B-8336-2008; Saunders, Philippa TK/C-7489-2013; Robson, John/H-3904-2014; Vierhout, M.E./H-8109-2014; surname, name s/A-2183-2010; Fairbank, Jeremy/AAA-3411-2019; Lindqvist, Pelle G/N-9205-2013; Khan, Gulfaraz/AAC-2859-2022	Thornton, Jim/0000-0001-9764-6876; Saunders, Philippa TK/0000-0001-9051-9380; Robson, John/0000-0001-6889-0415; Lindqvist, Pelle G/0000-0002-1652-8235; Khan, Gulfaraz/0000-0001-6836-1783; Bennett, Phillip/0000-0002-6253-4919				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1993, Lancet, V341, P396; BEAUFILS M, 1985, LANCET, V1, P840, DOI 10.1016/S0140-6736(85)92207-X; BENIGNI A, 1989, NEW ENGL J MED, V321, P357, DOI 10.1056/NEJM198908103210604; BUSSOLINO F, 1980, LANCET, V2, P702; COLE SK, 1986, BRIT J OBSTET GYNAEC, V93, P1204, DOI 10.1111/j.1471-0528.1986.tb07853.x; COLLINS E, 1981, OBSTET GYNECOL, V58, pS57; COLLINS R, 1994, PREGANCY CHILDBIRTH; DESWIET M, 1990, J OBSTET GYNECOL, V10, P467; GOODLIN RC, 1978, LANCET, V2, P51; HAUTH JC, 1993, AM J OBSTET GYNECOL, V168, P1083, DOI 10.1016/0002-9378(93)90351-I; HEY EN, 1986, BRIT J OBSTET GYNAEC, V93, P1213, DOI 10.1111/j.1471-0528.1986.tb07854.x; IHLE BU, 1987, BRIT MED J, V294, P79, DOI 10.1136/bmj.294.6564.79; IMPERIALE T F, 1991, Journal of the American Medical Association, V266, P260, DOI 10.1001/jama.266.2.260; MACDONALD R, 1991, BRIT J ANAESTH, V66, P1, DOI 10.1093/bja/66.1.1; MOLLER B, 1986, ACTA OBSTET GYN SCAN, V65, P307; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; REDMAN CWG, 1990, NEW ENGL J MED, V323, P478, DOI 10.1056/NEJM199008163230710; REDMAN CWG, 1978, BRIT MED J, V1, P467, DOI 10.1136/bmj.1.6111.467; REDMAN CWG, 1991, PLACENTA, V12, P301, DOI 10.1016/0143-4004(91)90339-H; REDMAN CWG, 1988, LANCET, V1, P809; SCHIFF E, 1989, NEW ENGL J MED, V321, P351, DOI 10.1056/NEJM198908103210603; SIBAI BM, 1991, AM J OBSTET GYNECOL, V165, P1408; SIBAI BM, 1993, NEW ENGL J MED, V329, P1213, DOI 10.1056/NEJM199310213291701; UZAN S, 1991, LANCET, V337, P1427, DOI 10.1016/0140-6736(91)93124-R; VIINIKKA L, 1993, BRIT J OBSTET GYNAEC, V100, P809, DOI 10.1111/j.1471-0528.1993.tb14304.x; WALLENBURG HCS, 1986, LANCET, V1, P1; WHITE SJ, 1978, BRIT J CANCER, V37, P849, DOI 10.1038/bjc.1978.124; YUDKIN PL, 1987, EARLY HUM DEV, V15, P45, DOI 10.1016/0378-3782(87)90099-5	29	673	692	1	57	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 12	1994	343	8898					619	629						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906809				2022-12-28	WOS:A1994NA09300006
J	ENGLEMAN, HM; MARTIN, SE; DEARY, IJ; DOUGLAS, NJ				ENGLEMAN, HM; MARTIN, SE; DEARY, IJ; DOUGLAS, NJ			EFFECT OF CONTINUOUS POSITIVE AIRWAY PRESSURE TREATMENT ON DAYTIME FUNCTION IN SLEEP APNOEA/HYPOPNOEA SYNDROME	LANCET			English	Article							APNEA HYPOPNEA SYNDROME; PERFORMANCE; DEPRESSION; HEALTH	Continuous positive airway pressure (CPAP) is the treatment of choice for the sleep apnoea/hypopnoea syndrome (SAHS); it is usually given with the aim of improving daytime cognitive function, mood, and sleepiness. However, its efficacy has not been validated by controlled trials. We have carried out a randomised, placebo-controlled, crossover study of objective daytime sleepiness, symptoms, cognitive function, and mood in a consecutive series of 32 SAHS patients with a median apnoea plus hypopnoea frequency of 28 (range 7-129) per hour slept. Patients were treated with 4 weeks each of CPAP and an oral placebo, which they were told might improve upper airway muscle function during sleep. Assessments on the last day of each treatment included a multiple sleep latency test and tests of symptom scores, mood profiles, and cognitive performance. The patients had significantly less daytime sleepiness on CPAP than during the placebo period (mean sleep latency 7.2 [SE 0.7] vs 6.1 [0.7] min, p = 0.03). There were also improvements with CPAP in symptom ratings (2.1 [0.2] vs 4.3 [0.3], p < 0.001), mood (p < 0.05 for several measures), and cognitive performance, which showed improved vigilance (obstacles hit in Steer Clear ''driving'' test 76 [5] vs 81 [6], p < 0.01), mental flexibility (trail-making B time 66 [5] vs 75 [5] vs p < 0.05), and attention (p < 0.05). Objectively monitored CPAP use averaged only 3.4 (0.4) hours per night, but this study provides evidence of improved cognitive performance even at this low revel of CPAP compliance.	UNIV EDINBURGH,DEPT MED,RESP MED UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT PSYCHOL,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh			Deary, Ian J/C-6297-2009; Douglas, Neil/B-1491-2013	Deary, Ian J/0000-0002-1733-263X; 				BEARPARK H, 1987, SLEEP RES, V16, P303; CHARBONNEAU M, 1992, American Review of Respiratory Disease, V145, pA168; CHESHIRE K, 1992, ARCH INTERN MED, V152, P538, DOI 10.1001/archinte.152.3.538; Dement WC, 1978, SLEEP APNEA SYNDROME, P23; DERDERIAN SS, 1988, CHEST, V94, P1023, DOI 10.1378/chest.94.5.1023; DOUGLAS NJ, 1992, LANCET, V339, P347, DOI 10.1016/0140-6736(92)91660-Z; ENGLEMAN HM, 1993, THORAX, V48, P911, DOI 10.1136/thx.48.9.911; ENGLEMAN HM, IN PRESS THORAX; FINDLEY LJ, 1989, AM REV RESPIR DIS, V140, P529, DOI 10.1164/ajrccm/140.2.529; FINDLEY LJ, 1988, AM REV RESPIR DIS, V138, P337, DOI 10.1164/ajrccm/138.2.337; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GREENBERG GD, 1987, SLEEP, V10, P254, DOI 10.1093/sleep/10.3.254; HUNT SM, 1984, J EPIDEMIOL COMMUN H, V38, P156, DOI 10.1136/jech.38.2.156; Jennum, 1992, J Sleep Res, V1, P240; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P887, DOI 10.1164/ajrccm/147.4.887; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P1162, DOI 10.1164/ajrccm/147.5.1162; LAMPHERE J, 1989, CHEST, V96, P1364, DOI 10.1378/chest.96.6.1364; LANGAN SJ, 1991, DIABETOLOGIA, V34, P337, DOI 10.1007/BF00405006; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MATHEWS G, 1990, BRIT J PSYCHOL, V81, P17; MILLMAN RP, 1989, J CLIN PSYCHIAT, V50, P348; PARTINEN M, 1988, CHEST, V94, P1200, DOI 10.1378/chest.94.6.1200; PETRIE RXA, 1989, PSYCHOPHARMACOLOGY, V99, P393, DOI 10.1007/BF00445565; REEVES-HOCHE M K, 1992, American Review of Respiratory Disease, V145, pA169; REYNOLDS CF, 1984, J CLIN PSYCHIAT, V45, P287; SANGAL RB, 1992, CHEST, V102, P699, DOI 10.1378/chest.102.3.699; THORPY MJ, 1992, SLEEP, V15, P268; WHYTE KF, 1989, Q J MED, V72, P659; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	30	450	460	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 5	1994	343	8897					572	575		10.1016/S0140-6736(94)91522-9	http://dx.doi.org/10.1016/S0140-6736(94)91522-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906330				2022-12-28	WOS:A1994MY84300010
J	NICOLAOU, KC; YANG, Z; LIU, JJ; UENO, H; NANTERMET, PG; GUY, RK; CLAIBORNE, CF; RENAUD, J; COULADOUROS, EA; PAULVANNAN, K; SORENSEN, EJ				NICOLAOU, KC; YANG, Z; LIU, JJ; UENO, H; NANTERMET, PG; GUY, RK; CLAIBORNE, CF; RENAUD, J; COULADOUROS, EA; PAULVANNAN, K; SORENSEN, EJ			TOTAL SYNTHESIS OF TAXOL	NATURE			English	Article							SYSTEM; AGENT	TAXOL(1-4), a substance originally isolated from the Pacific yew tree (Taxus brevifolia) more than two decades ago, has recently been approved for the clinical treatment of cancer patients. Hailed as having provided one of the most significant advances in cancer therapy(5), this molecule exerts its anticancer activity by inhibiting mitosis through enhancement of the polymerization of tubulin and consequent stabilization of microtubules(6). The scarcity of taxol and the ecological impact of harvesting it have prompted extensive searches for alternative sources including semisynthesis, cellular culture production and chemical synthesis(2,3). The latter has been attempted for almost two decades, but these attempts have been thwarted by the magnitude of the synthetic challenge. Here we report the total synthesis of taxol by a convergent strategy, which opens a chemical pathway for the production of both the natural product itself and a variety of designed taxoids.	UNIV CALIF SAN DIEGO, DEPT CHEM, SAN DIEGO, CA 92093 USA	University of California System; University of California San Diego	NICOLAOU, KC (corresponding author), SCRIPPS RES INST, DEPT CHEM, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Yang, Zhen/GWQ-4960-2022; Guy, Rodney/J-7107-2013; Yang, Zhen/J-6306-2015	Guy, Rodney/0000-0002-9638-2060; Yang, Zhen/0000-0001-8036-934X				Chamberlin A.R., 1990, ORG REACT, V39, P1; Griffith W. P., 1990, ALDRICHIM ACTA, V23, P13; GUENARD D, 1993, ACCOUNTS CHEM RES, V26, P160, DOI 10.1021/ar00028a005; MAGEE TV, 1992, J ORG CHEM, V57, P3274, DOI 10.1021/jo00038a008; MCMURRY JE, 1989, CHEM REV, V89, P1513, DOI 10.1021/cr00097a007; NICOLAOU KC, 1992, J CHEM SOC CHEM COMM, P1117, DOI 10.1039/c39920001117; NICOLAOU KC, 1993, J CHEM SOC CHEM COMM, P1024, DOI 10.1039/c39930001024; NICOLAOU KC, 1994, J CHEM SOC CHEM COMM, P295, DOI 10.1039/c39940000295; NICOLAOU KC, 1994, ANGEW CHEM INT EDIT, V33, P15, DOI 10.1002/anie.199400151; NICOLAOU KC, 1992, J CHEM SOC CHEM COMM, P1118, DOI 10.1039/c39920001118; OJIMA I, 1992, TETRAHEDRON, V48, P6985, DOI 10.1016/S0040-4020(01)91210-4; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Sharpless K. B., 1979, ALDRICHIM ACTA, V12, P63; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; 1993, PACLITAXEL TAXOF S3, V20, P1	16	979	1099	19	700	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 17	1994	367	6464					630	634		10.1038/367630a0	http://dx.doi.org/10.1038/367630a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	MW688	7906395				2022-12-28	WOS:A1994MW68800049
J	OFFERHAUS, GJA				OFFERHAUS, GJA			GASTRIC STUMP CANCER - LESSONS FROM OLD SPECIMENS	LANCET			English	Editorial Material											OFFERHAUS, GJA (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT PATHOL,1105 AZ AMSTERDAM,NETHERLANDS.							ALEXANDERWILLIAMS J, 1991, BRIT MED J, V302, P547, DOI 10.1136/bmj.302.6776.547; CORREA P, 1992, CANCER RES, V52, P6735; DUBROW R, 1993, J NATL CANCER I, V85, P1268, DOI 10.1093/jnci/85.16.1268; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHER SG, 1993, JNCI-J NATL CANCER I, V85, P1303, DOI 10.1093/jnci/85.16.1303; LEE S, 1990, SCAND J GASTROENTERO, V25, P1223, DOI 10.3109/00365529008998557; OFFERHAUS GJA, 1985, EUR J CANCER CLIN ON, V21, P73, DOI 10.1016/0277-5379(85)90203-2; OFFERHAUS GJA, 1992, LANCET, V340, P33, DOI 10.1016/0140-6736(92)92433-G; VONHOLSTEIN CS, 1993, CANCER, V72, P1532; WRIGHT PA, 1993, GUT, V34, P145, DOI 10.1136/gut.34.2.145	10	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					66	67		10.1016/S0140-6736(94)90807-9	http://dx.doi.org/10.1016/S0140-6736(94)90807-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903770				2022-12-28	WOS:A1994MQ09200002
J	CROTTY, B				CROTTY, B			ULCERATIVE-COLITIS AND XENOBIOTIC METABOLISM	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; CROHNS-DISEASE; HUMAN LIVER; JEWISH POPULATION; DRUG-METABOLISM; SMOKING; INACTIVATION; ASSOCIATION; GENES; RISK	Any hypothesis on the cause of ulcerative colitis must account for genetic influences, geographic and ethnic variations, effects of smoking and oral contraception, anatomical distribution, the relapsing and remitting nature of the disease, and association with primary sclerosing cholangitis. This hypothesis proposes that ulcerative colitis is caused by a reactive xenobiotic metabolite which is conjugated before excretion into bile. The amount of metabolite produced is determined by exposure to its parent compound, by the inherited pattern of metabolism, and by inhibition and induction of enzymes catalysing alternative pathways. Deconjugation by bacteria within the colonic lumen releases the reactive metabolite, damaging the colonic epithelial barrier and exposing the mucosal immune system to luminal contents. Biliary epithelial damage by the metabolite leads to an immune response in those individuals carrying appropriate HLA molecules, thereby initiating an inflammatory process within the biliary tree.			CROTTY, B (corresponding author), UNIV MELBOURNE,HEIDELBERG REPATRIAT HOSP,DEPT MED,BANKSIA ST,W HEIDELBERG,VIC 3081,AUSTRALIA.							ARMSTRONG M, 1992, LANCET, V339, P1017, DOI 10.1016/0140-6736(92)90537-D; AUANSAKUL AC, 1982, DRUG METAB DISPOS, V10, P344; BOYKO EJ, 1987, NEW ENGL J MED, V316, P707, DOI 10.1056/NEJM198703193161202; CAPORASO N, 1989, CANCER RES, V49, P3675; CHAPMAN RW, 1990, INFLAMMATORY BOWEL D, P513; FORRESTER LM, 1992, BIOCHEM J, V281, P359, DOI 10.1042/bj2810359; GEORGE J, 1991, AUST NZ J MED, V21, P356, DOI 10.1111/j.1445-5994.1991.tb04708.x; GILAT T, 1974, GASTROENTEROLOGY, V66, P335; GOLDIN BR, 1986, ANNU REV MICROBIOL, V40, P367, DOI 10.1146/annurev.mi.40.100186.002055; GUDJONSSON H, 1988, TISSUE ANTIGENS, V31, P243, DOI 10.1111/j.1399-0039.1988.tb02090.x; GUENGERICH FP, 1990, ASIA PAC J PHARMACOL, V5, P327; GUENGERICH FP, 1990, CHEM RES TOXICOL, V3, P363, DOI 10.1021/tx00016a015; KATAKURA S, 1989, SCAND J GASTROENTERO, V24, P381, DOI 10.3109/00365528909093063; KNODELL RG, 1991, GASTROENTEROLOGY, V101, P1680, DOI 10.1016/0016-5085(91)90408-D; LANGMAN MJS, 1990, INFLAMM BOWEL DIS, P25; Levine W G, 1981, Prog Drug Res, V25, P361; LINDBERG E, 1992, GUT, V33, P779, DOI 10.1136/gut.33.6.779; LOOCK W, 1988, J CLIN PHARMACOL, V28, P216, DOI 10.1002/j.1552-4604.1988.tb03135.x; MATHAN VI, 1989, GUT, V30, P971, DOI 10.1136/gut.30.7.971; MERRETT MN, 1992, GUT, V33, P1254; MEYER UA, 1990, ADV DRUG RES, V19, P197; MUCKLOW JC, 1988, PHARMACOL THERAPEUT, V36, P105, DOI 10.1016/0163-7258(88)90113-1; PORTER TD, 1991, J BIOL CHEM, V266, P13469; PROBERT CSJ, 1992, GUT, V33, P687, DOI 10.1136/gut.33.5.687; PULLAN RD, 1993, GUT, V34, P676, DOI 10.1136/gut.34.5.676; PULLAN RD, 1993, GASTROENTEROLOGY, V104, pA765; ROZEN P, 1979, GASTROENTEROLOGY, V76, P25; RUTGEERTS P, 1991, LANCET, V338, P771, DOI 10.1016/0140-6736(91)90663-A; SHEPHERD HA, 1983, Q J MED, V52, P503; SIMMONDS NJ, 1993, GUT, V34, P865, DOI 10.1136/gut.34.7.865; TOYODA H, 1993, GASTROENTEROLOGY, V104, P741, DOI 10.1016/0016-5085(93)91009-7; TRUELOVE SC, 1965, BMJ-BRIT MED J, V1, P150, DOI 10.1136/bmj.1.5428.150; TYSK C, 1988, GUT, V29, P990, DOI 10.1136/gut.29.7.990; VESSEY M, 1986, BRIT MED J, V292, P1101, DOI 10.1136/bmj.292.6528.1101; WAKEFIELD AJ, 1989, LANCET, V2, P773; YAMAMOTO I, 1966, JPN J PHARMACOL, V16, P183, DOI 10.1254/jjp.16.183; [No title captured]	37	23	28	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					35	38		10.1016/S0140-6736(94)90882-6	http://dx.doi.org/10.1016/S0140-6736(94)90882-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905049				2022-12-28	WOS:A1994MN93700018
J	GENDRONMAGUIRE, M; MALLO, M; ZHANG, M; GRIDLEY, T				GENDRONMAGUIRE, M; MALLO, M; ZHANG, M; GRIDLEY, T			HOXA-2 MUTANT MICE EXHIBIT HOMEOTIC TRANSFORMATION OF SKELETAL ELEMENTS DERIVED FROM CRANIAL NEURAL CREST	CELL			English	Article							HOMEOBOX GENE; RETINOIC ACID; TARGETED DISRUPTION; DEVELOPMENTAL DEFECTS; DROSOPHILA EMBRYO; EXPRESSION; CELLS; HINDBRAIN; PATTERN; HOX-1.6	Mice homozygous for a targeted mutation of the Hoxa-2 (Hox 1.11) gene are born with cleft palates and die within 24 hr of birth. Analysis of stained skeletons revealed that homozygous mutant animals contained multiple cranial skeletal defects, including a duplication of the ossification centers of the bones of the middle ear. Histological analysis suggested that this duplication resulted from the transformation of skeletal elements derived from the second branchial arch into more anterior structures, resulting in a duplication of Meckel's cartilage adjacent to the otic capsule. Skeletal elements normally derived from the second arch were absent in the mutants. These data provide direct experimental evidence for the existence of a branchial Hox code.	HOFFMANN LA ROCHE INC, DEPT TOXICOL & PATHOL, NUTLEY, NJ 07110 USA	Roche Holding	GENDRONMAGUIRE, M (corresponding author), ROCHE INST MOLEC BIOL, ROCHE RES CTR, NUTLEY, NJ 07110 USA.		Mallo, Moises/D-5907-2016	Mallo, Moises/0000-0002-9744-0912				AKAM M, 1987, DEVELOPMENT, V101, P1; ALTMAN J, 1982, ADV ANAT EMBRYOL CEL, V74, P1; BARON A, 1987, EMBO J, V6, P2977, DOI 10.1002/j.1460-2075.1987.tb02603.x; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; COULY GF, 1993, DEVELOPMENT, V117, P409; DAMICOMARTEL A, 1983, AM J ANAT, V166, P445, DOI 10.1002/aja.1001660406; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DOLLE P, 1993, P NATL ACAD SCI USA, V90, P7666, DOI 10.1073/pnas.90.16.7666; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; HOGAN B, 1992, NATURE, V355, P494, DOI 10.1038/355494a0; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; JEGALIAN BG, 1992, CELL, V71, P901, DOI 10.1016/0092-8674(92)90387-R; Kaufman M.H., 1992, ATLAS MOUSE DEV; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KRUMLAUF R, 1993, TRENDS GENET, V9, P106, DOI 10.1016/0168-9525(93)90203-T; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MOORE KL, 1993, DEV HUMAN CLIN ORIEN, P186; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; NODEN DM, 1983, DEV BIOL, V96, P144, DOI 10.1016/0012-1606(83)90318-4; NODEN DM, 1993, J NEUROBIOL, V24, P248, DOI 10.1002/neu.480240210; NODEN DM, 1988, DEVELOPMENT, V103, P121; NODEN DM, 1986, J CRAN GENET DEV BIO, P15; Paxinos G., 1991, ATLAS DEV RAT BRAIN; POLLOCK RA, 1992, CELL, V71, P911, DOI 10.1016/0092-8674(92)90388-S; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; Sambrook J, 1989, MOL CLONING LABORATO; SHAM MH, 1992, EMBO J, V11, P1825, DOI 10.1002/j.1460-2075.1992.tb05234.x; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; SMITH DE, 1992, DEVELOPMENT, V116, P555; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STJOHNSTON D, 1992, CELL, V68, P201; STONER CM, 1989, CANCER RES, V49, P1497; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TAN DP, 1992, P NATL ACAD SCI USA, V89, P6280, DOI 10.1073/pnas.89.14.6280; Van de Water T R, 1980, Birth Defects Orig Artic Ser, V16, P147	51	460	465	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 31	1993	75	7					1317	1331		10.1016/0092-8674(93)90619-2	http://dx.doi.org/10.1016/0092-8674(93)90619-2			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	7903600				2022-12-28	WOS:A1993MP86900011
J	LIN, JP; BROWN, JK; WALSH, EG				LIN, JP; BROWN, JK; WALSH, EG			PHYSIOLOGICAL MATURATION OF MUSCLES IN CHILDHOOD	LANCET			English	Article								Little is known about the motor muscle physiology of growing children and it has been assumed that increasing motor dexterity and speed correspond solely to brain maturation, although there is evidence that muscles mature from studies of other mammalian species. Such a finding in children would throw light on the possible mechanics of motor delays in speech, hand function, athletic, and musical skills as well as helping towards a better understanding of pathological motor disorders such as the cerebral palsies. Our non-invasive observations of soleus-muscle relaxation times in healthy children suggest that a child's muscles are initially slow to relax but relaxation doubles in speed up to adult rates by early adolescence. Half-relaxation times halved from about 90 ms at age 3 to about 40 ms at age 10. On the basis of these studies, we suggest that muscle maturation rate-limits motor tasks; which should be borne in mind when considering motor development in muscles and when attempting to determine the effects of early brain or spinal cord damage. Such methods of measuring the dynamics of muscle open up new areas of research and offer the possibility of developing operationally-defined in-vivo measurements for use in motor assessment and for following up the effects on muscle or treatments such as physiotherapy, orthotics, surgery, and drugs.	ROYAL HOSP SICK CHILDREN, EDINBURGH, MIDLOTHIAN, SCOTLAND; UNIV EDINBURGH, DEPT PHYSIOL, EDINBURGH, SCOTLAND	University of Edinburgh			Lin, Jean-Pierre/R-3779-2019	Lin, Jean-Pierre/0000-0001-9314-2259				BARRY JA, 1994, EXP PHYSIOL, V79, P515, DOI 10.1113/expphysiol.1994.sp003784; BROOKE MH, 1969, NEUROLOGY, V19, P591, DOI 10.1212/WNL.19.6.591; BULLER AJ, 1960, J PHYSIOL-LONDON, V150, P417, DOI 10.1113/jphysiol.1960.sp006395; DAVIES CTM, 1983, J APPL PHYSIOL, V55, P191, DOI 10.1152/jappl.1983.55.1.191; EYRE JA, 1991, J PHYSIOL-LONDON, V434, P441, DOI 10.1113/jphysiol.1991.sp018479; GARNETT RAF, 1979, J PHYSIOL-LONDON, V287, P33, DOI 10.1113/jphysiol.1979.sp012643; KALVERBOER AF, 1993, MOTOR DEV EARLY LATE; MALINA RM, 1991, GROWTH MATURATION PH, P115; MARGRETH A, 1980, PLASTICITY MUSCLE, P193; PARKER DF, 1990, ANN HUM BIOL, V17, P199, DOI 10.1080/03014469000000962; PETTE D, 1980, PLASTICITY MUSCLE; SALE D, 1982, J APPL PHYSIOL, V52, P1636, DOI 10.1152/jappl.1982.52.6.1636; SALMONS S, 1976, NATURE, V263, P30, DOI 10.1038/263030a0; WALSH EG, 1993, EXP PHYSIOL, V78, P531, DOI 10.1113/expphysiol.1993.sp003704; WALSH EG, 1992, CLIN DEV MED SERIES, V125, P26; WATTS C, 1992, J PHYSIOL-LONDON, V452, pP273	16	14	14	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 4	1994	343	8910					1386	1389		10.1016/S0140-6736(94)92522-4	http://dx.doi.org/10.1016/S0140-6736(94)92522-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910882				2022-12-28	WOS:A1994NP95500008
J	EGGER, M; SMITH, GD				EGGER, M; SMITH, GD			MAGNESIUM AND MYOCARDIAL-INFARCTION	LANCET			English	Letter									UNIV GLASGOW, DEPT PUBL HLTH, GLASGOW G8 8RZ, LANARK, SCOTLAND	University of Glasgow	EGGER, M (corresponding author), UNIV BERN, DEPT SOCIAL & PREVENT MED, BERN, SWITZERLAND.		Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Egger, Matthias/0000-0001-7462-5132				DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; HORTON R, 1993, LANCET, V342, P1291, DOI 10.1016/0140-6736(93)92375-4; KETLEY D, 1993, LANCET, V342, P891, DOI 10.1016/0140-6736(93)91945-I; Oakes M, 1993, Stat Methods Med Res, V2, P147; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V; 1993, CIRCULATION S1, V88, P292	6	7	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 21	1994	343	8908					1285	1285		10.1016/S0140-6736(94)92175-X	http://dx.doi.org/10.1016/S0140-6736(94)92175-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910286				2022-12-28	WOS:A1994NM14400031
J	RIETHMULLER, G; SCHNEIDERGADICKE, E; SCHLIMOK, G; SCHMIEGEL, W; RAAB, R; HOFFKEN, K; GRUBER, R; PICHLMAIER, H; HIRCHE, H; PICHLMAYR, R; BUGGISCH, P; WITTE, J; EIGLER, FW; FACKLERSCHWALBE, I; FUNKE, I; SCHMIDT, CG; SCHREIBER, H; SCHWEIBERER, L; EIBLEIBESFELDT, B				RIETHMULLER, G; SCHNEIDERGADICKE, E; SCHLIMOK, G; SCHMIEGEL, W; RAAB, R; HOFFKEN, K; GRUBER, R; PICHLMAIER, H; HIRCHE, H; PICHLMAYR, R; BUGGISCH, P; WITTE, J; EIGLER, FW; FACKLERSCHWALBE, I; FUNKE, I; SCHMIDT, CG; SCHREIBER, H; SCHWEIBERER, L; EIBLEIBESFELDT, B			RANDOMIZED TRIAL OF MONOCLONAL-ANTIBODY FOR ADJUVANT THERAPY OF RESECTED DUKES-C COLORECTAL-CARCINOMA	LANCET			English	Article							MOLECULAR-CLONING; CLINICAL-TRIALS; TUMOR-GROWTH; NUDE-MICE; T-CELLS; ANTIGENS; CANCER; CDNA	Over the past decade various clinical trials have used monoclonal antibodies as therapeutic agents against solid tumours. No consistent pattern of response or improved survival has yet emerged although antigenic heterogeneity and insufficient accessibility of cells in advanced tumours have been offered as explanations for these failures. We designed a study in which a monoclonal antibody was used to target minimal residual disease in an early stage of tumour cell dissemination in patients with colorectal cancer. Only patients in Dukes' stage C who had undergone curative surgery and were free of manifest residual tumour were admitted. 189 patients with colorectal cancer of stage Dukes' C were randomly assigned to an observation regimen or to postoperative treatment with 500 mg of 17-1A antibody, followed by four 100 mg infusions each month. A balance of risk factors in the two groups was achieved by dynamic randomisation procedure. After a median follow-up of 5 years, antibody treatment reduced the overall death rate by 30% (Cox's proportional hazard, p = 0.04, log-rank p = 0.05) and decreased the recurrence rate by 27% (p = 0.03, p = 0.05). The effect of antibody was most pronounced in patients who had distant metastasis as first sign of a relapse (p = 0.0014, p = 0.002), an effect that was not seen for local relapses (p = 0.74, p = 0.67). Toxic effects of 17-1A antibody were infrequent, consisting mainly of mild constitutional and gastrointestinal symptoms. During 371 infusions four anaphylactic reactions were seen, all controllable by intravenous steroids and none necessitated admission to hospital. Adjuvant therapy with 17-1A antibody extends life and prolongs remission in patients with colorectal cancer of Dukes' stage C.	UNIV MUNICH, FAK MED, TUMORZENTRUM MUNCHEN, MUNICH, GERMANY; TECH UNIV MUNICH, MUNICH, GERMANY; ZENT KLINIKUM, AUGSBURG, GERMANY; HANNOVER MED SCH, CHIRURG KLIN, HANNOVER, GERMANY; UNIV COLOGNE, CHIRURG KLIN, COLOGNE, GERMANY; UNIV HAMBURG, KRANKENHAUS EPPENDORF, MED KLIN, W-2000 HAMBURG, GERMANY; UNIV ESSEN GESAMTHSCH, INNERE KLIN, ESSEN, GERMANY; UNIV ESSEN GESAMTHSCH, INST MED INFORMAT & BIOMATH, ESSEN, GERMANY; UNIV ESSEN GESAMTHSCH, CHIRURG KLIN, ESSEN, GERMANY; UNIV MUNICH, KLINIKUM GROSSHADERN, CHIRURG KLIN, W-8000 MUNICH, GERMANY; UNIV ESSEN GESAMTHSCH, TUMOR KLIN, ESSEN, GERMANY; UNIV HAMBURG, KRANKENHAUS EPPENDORF, CHIRURG KLIN, W-2000 HAMBURG, GERMANY	University of Munich; Technical University of Munich; Hannover Medical School; University of Cologne; University of Hamburg; University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen; University of Munich; University of Duisburg Essen; University of Hamburg	RIETHMULLER, G (corresponding author), UNIV MUNICH, INST IMMUNOL, GOETHESTR 31, W-8000 MUNICH, GERMANY.							AUGUST DA, 1984, CANCER METAST REV, V3, P303, DOI 10.1007/BF00051457; FISHER B, 1988, JNCI-J NATL CANCER I, V80, P21, DOI 10.1093/jnci/80.1.21; FOGLER WE, 1988, CANCER RES, V48, P6303; GOTTLINGER HG, 1986, INT J CANCER, V38, P47; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HERLYN D, 1982, P NATL ACAD SCI-BIOL, V79, P4761, DOI 10.1073/pnas.79.15.4761; HERLYN DM, 1980, CANCER RES, V40, P717; HERLYN M, 1979, P NATL ACAD SCI USA, V76, P1438, DOI 10.1073/pnas.76.3.1438; JAIN RK, 1990, CANCER RES, V50, P2741; JOHANSSON C, 1991, INT J CANCER, V48, P297, DOI 10.1002/ijc.2910480224; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOPROWSKI H, 1979, SOMAT CELL GENET, V5, P957, DOI 10.1007/BF01542654; KOSMAS C, 1991, BRIT J CANCER, V64, P494, DOI 10.1038/bjc.1991.337; KROOK JE, 1991, NEW ENGL J MED, V324, P709, DOI 10.1056/NEJM199103143241101; LANZAVECCHIA A, 1988, J EXP MED, V167, P345, DOI 10.1084/jem.167.2.345; LINDEMANN F, 1992, LANCET, V340, P685, DOI 10.1016/0140-6736(92)92230-D; LOBUGLIO AF, 1989, P NATL ACAD SCI USA, V86, P4220, DOI 10.1073/pnas.86.11.4220; MELLSTEDT H, 1991, SEMIN ONCOL, V18, P462; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; PANTEL K, 1993, JNCI-J NATL CANCER I, V85, P1419, DOI 10.1093/jnci/85.17.1419; PANTEL K, 1993, LANCET, V341, P501, DOI 10.1016/0140-6736(93)90262-F; PEREZ MS, 1989, J IMMUNOL, V142, P3662; RIETHMULLER G, 1992, CURR OPIN IMMUNOL, V4, P647, DOI 10.1016/0952-7915(92)90041-C; RIETHMULLER G, 1989, PROGR IMMUNOLOGY, V7, P1079; SCHEINBERG DA, 1991, CURR OPIN IMMUNOL, V3, P679, DOI 10.1016/0952-7915(91)90096-J; SEARS HF, 1984, GENES ANTIGENS CANCE, V19, P180; SIMON B, 1990, P NATL ACAD SCI USA, V87, P2755, DOI 10.1073/pnas.87.7.2755; STEPLEWSKI Z, 1981, CANCER RES, V41, P2723; STRNAD J, 1989, CANCER RES, V49, P314; SZALA S, 1990, P NATL ACAD SCI USA, V87, P3542, DOI 10.1073/pnas.87.9.3542; ZELEN M, 1974, J CHRON DIS, V27, P365, DOI 10.1016/0021-9681(74)90015-0; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203	32	638	673	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 14	1994	343	8907					1177	1183		10.1016/S0140-6736(94)92398-1	http://dx.doi.org/10.1016/S0140-6736(94)92398-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909866				2022-12-28	WOS:A1994NL17500007
J	SINGH, N; YU, VL				SINGH, N; YU, VL			POTABLE WATER AND MYCOBACTERIUM-AVIUM COMPLEX IN HIV PATIENTS - IS PREVENTION POSSIBLE	LANCET			English	Editorial Material							INFECTION; SYSTEMS; COLONIZATION		UNIV PITTSBURGH,PITTSBURGH,PA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	SINGH, N (corresponding author), VET ADM MED CTR,PITTSBURGH,PA, USA.							BERMUDEZ LE, 1992, J INFECT DIS, V165, P75, DOI 10.1093/infdis/165.1.75; DUMOULIN GC, 1988, JAMA-J AM MED ASSOC, V260, P1599, DOI 10.1001/jama.260.11.1599; GLEW RH, 1994, NEW ENGL J MED, V330, P557; HAMPSON SJ, 1989, LANCET, V1, P65; HELLYER TJ, 1993, J INFECTION, V26, P55, DOI 10.1016/0163-4453(93)96840-M; LEE TC, 1988, ARCH ENVIRON HEALTH, V43, P59, DOI 10.1080/00039896.1988.9934375; MAPOTHER ME, 1984, INFECT IMMUN, V45, P67, DOI 10.1128/IAI.45.1.67-73.1984; MEISSNER PS, 1986, J INFECT DIS, V153, P325, DOI 10.1093/infdis/153.2.325; PRINCE DS, 1989, NEW ENGL J MED, V321, P863, DOI 10.1056/NEJM198909283211304; VICKERS RM, 1987, INFECT CONT HOSP EP, V8, P357, DOI 10.1017/S0195941700067412; VONREYN CF, 1993, J INFECT DIS, V168, P1553, DOI 10.1093/infdis/168.6.1553; WALLACE JM, 1988, CHEST, V93, P926, DOI 10.1378/chest.93.5.926; WAYNE LG, 1986, EUR J CLIN MICROBIOL, V5, P363, DOI 10.1007/BF02017802; WENDT SL, 1980, AM REV RESPIR DIS, V122, P259	14	12	12	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1994	343	8906					1110	1111		10.1016/S0140-6736(94)90228-3	http://dx.doi.org/10.1016/S0140-6736(94)90228-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK730	7910225				2022-12-28	WOS:A1994NK73000002
J	LANGMAN, MJS; WEIL, J; WAINWRIGHT, P; LAWSON, DH; RAWLINS, MD; LOGAN, RFA; MURPHY, M; VESSEY, MP; COLINJONES, DG				LANGMAN, MJS; WEIL, J; WAINWRIGHT, P; LAWSON, DH; RAWLINS, MD; LOGAN, RFA; MURPHY, M; VESSEY, MP; COLINJONES, DG			RISKS OF BLEEDING PEPTIC-ULCER ASSOCIATED WITH INDIVIDUAL NONSTEROIDAL ANTIINFLAMMATORY DRUGS	LANCET			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS	Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of peptic ulcer complications, but it is not clear whether some drugs are more likely than others to cause such complications. We compared previous use of NSAIDs in 1144 patients aged 60 and older admitted to hospitals in five large cities with peptic ulcer bleeding and in 1126 hospital controls and 989 community controls matched for age and sex. Peptic ulcer bleeding was strongly associated with use of non-aspirin NSAIDs of any type during the 3 months before admission (411 cases, 351 controls; odds ratio 4.5 [95% Cl 3.6 to 5.6]). The odds ratios for peptic ulcer bleeding were lowest for ibuprofen (2.0 [1.4-2.8]) and diclofenac (4.2 [2.6-6.8]), and intermediate for indomethacin, naproxen, and piroxicam (11.3 [6.3-20.3], 9.1 [5.5-15.1], and 13.7 [7.1-26.3]). Azapropazone and ketoprofen carried the highest risks (31.5 [10.3-96.9] and 23.7 [7.6-74.2]). Risks also increased with drug dose (low dose 2.5 [1.7-3.8], intermediate 4.5 [3.3-6.0], and high 8.6 [5.8-12.6]) for all drugs combined. Appropriate clinical strategies could prevent many episodes of peptic ulcer bleeding: NSAIDs should be used only in patients who do not respond to other analgesics; the lowest possible doses should be used; and the least toxic NSAIDs should be selected.	UNIV BIRMINGHAM,BIRMINGHAM,ENGLAND; GLASGOW ROYAL INFIRM,GLASGOW,SCOTLAND; UNIV NEWCASTLE UPON TYNE,NEWCASTLE TYNE,ENGLAND; UNIV NOTTINGHAM,NOTTINGHAM,ENGLAND; UNIV OXFORD,OXFORD,ENGLAND; QUEEN ALEXANDRA HOSP,PORTSMOUTH,ENGLAND	University of Birmingham; University of Glasgow; Newcastle University - UK; University of Nottingham; University of Oxford; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital								BEARD K, 1987, ARCH INTERN MED, V147, P1621, DOI 10.1001/archinte.147.9.1621; CARSON JL, 1987, ARCH INTERN MED, V147, P1054, DOI 10.1001/archinte.147.6.1054; CARSON JL, 1987, ARCH INTERN MED, V147, P85, DOI 10.1001/archinte.147.1.85; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; HENRY D, 1993, GASTROENTEROLOGY, V105, P1978; HOLVOET J, 1991, GUT, V32, P730, DOI 10.1136/gut.32.7.730; KAUFMAN DW, 1993, CLIN PHARMACOL THER, V53, P485, DOI 10.1038/clpt.1993.55; LAPORTE JR, 1991, LANCET, V337, P85, DOI 10.1016/0140-6736(91)90744-A; NOBILI A, 1992, PHARMACOEPIDEM DR S, V1, P65; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; RODRIGUEZ LAG, 1992, EPIDEMIOLOGY, V3, P337, DOI 10.1097/00001648-199207000-00008; ROSSI AC, 1987, BRIT MED J, V294, P147, DOI 10.1136/bmj.294.6565.147; SAVAGE RL, 1993, ARTHRITIS RHEUM, V36, P84, DOI 10.1002/art.1780360114; SOMERVILLE K, 1986, LANCET, V1, P452; SOMERVILLE KW, 1992, EUR J GASTROEN HEPAT, V4, P645; 1985, BRIT MED J, V292, P614	16	681	707	2	21	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 30	1994	343	8905					1075	1078		10.1016/S0140-6736(94)90185-6	http://dx.doi.org/10.1016/S0140-6736(94)90185-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ694	7909103				2022-12-28	WOS:A1994NJ69400013
J	BROWN, KE; GREEN, SW; DEMAYOLO, JA; BELLANTI, JA; SMITH, SD; SMITH, TJ; YOUNG, NS				BROWN, KE; GREEN, SW; DEMAYOLO, JA; BELLANTI, JA; SMITH, SD; SMITH, TJ; YOUNG, NS			CONGENITAL ANEMIA AFTER TRANSPLACENTAL B19 PARVOVIRUS INFECTION	LANCET			English	Note								We report three children with congenital anaemia after intrauterine infection with B19 parvovirus. All the fetuses developed hydrops fetails that was treated by blood transfusion. After delivery the infants had hypo-gammaglobulinaemia. In three, sera lacked B19 but viral DNA was found in bone marrow. All were treated with immunoglobulin. One child died and B19 was found in various tissues. In the other two cases, virus could no longer be detected after therapy but the patients remain persistently anaemic. Persistent B19 infection should be suspected in infants with congenital red-cell aplasia.	GEORGETOWN UNIV,SCH MED,INT CTR INTERDISCIPLINARY STUDIES IMMUNOL,WASHINGTON,DC; UNIV CHICAGO,MED CTR,PEDIAT HEMATOL ONCOL SECT,CHICAGO,IL 60637; CLIN HEMATOL ONCOL ASSOCIATES,DENVER,CO; PRESBYTERIAN ST LUKES HOSP,ROCKY MT CHILDRENS CANC CTR,DENVER,CO	Georgetown University; University of Chicago; University of Chicago Medical Center	BROWN, KE (corresponding author), NHLBI,HEMATOL BRANCH,10-7C218,BETHESDA,MD 20892, USA.			Bellanti, Joseph/0000-0002-5038-7202; Brown, Kevin/0000-0002-1568-683X				BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; BROWN KE, 1993, SCIENCE, V262, P114, DOI 10.1126/science.8211117; BROWN KE, IN PRESS CRIT REV ON; COHEN BJ, 1983, J HYG-CAMBRIDGE, V91, P113, DOI 10.1017/S0022172400060095; Maniatis T., 1982, MOL CLONING; MILLER DR, 1990, BLOOD DISEASES INFAN, P144; MOREY AL, 1991, LANCET, V337, P496, DOI 10.1016/0140-6736(91)93435-C; OSULLIVAN MG, 1994, J CLIN INVEST, V93, P1571, DOI 10.1172/JCI117136; OZAWA K, 1987, BLOOD, V70, P384, DOI 10.1182/blood.V70.2.384.384	9	106	109	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 9	1994	343	8902					895	896		10.1016/S0140-6736(94)90011-6	http://dx.doi.org/10.1016/S0140-6736(94)90011-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF213	7908361	hybrid			2022-12-28	WOS:A1994NF21300011
J	SAVARINO, V; VIGNERI, S; MELA, GS; TERMINI, R; CELLE, G				SAVARINO, V; VIGNERI, S; MELA, GS; TERMINI, R; CELLE, G			DUODENAL-ULCER HEALING DRUGS	LANCET			English	Letter							HELICOBACTER-PYLORI		UNIV PALERMO,INST INTERNAL MED & GERIATR,PALERMO,ITALY	University of Palermo	SAVARINO, V (corresponding author), UNIV GENOA,DEPT GASTROENTEROL,I-16132 GENOA,ITALY.							BAYERDORFFER E, 1992, EUR J GASTROEN HEPAT, V4, P697; GOODWIN CS, 1992, HELICOBACTER PYLORI, P224; JONES DB, 1987, GUT, V28, P1120, DOI 10.1136/gut.28.9.1120; LABENZ J, 1993, GUT, V34, P1167, DOI 10.1136/gut.34.9.1167; LOGAN RPH, 1992, BRIT MED J, V305, P1094, DOI 10.1136/bmj.305.6861.1094-c	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 9	1994	343	8902					915	916						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF213	7908374				2022-12-28	WOS:A1994NF21300034
J	STUART, AE				STUART, AE			TAKING THE TENSION OUT OF HERNIA REPAIR	LANCET			English	Editorial Material											STUART, AE (corresponding author), OLDCHURCH HOSP,ROMFORD RM7 0BE,ESSEX,ENGLAND.							LICHTENSTEIN IL, 1989, AM J SURG, V157, P188, DOI 10.1016/0002-9610(89)90526-6; LICHTENSTEIN IL, 1993, SURG CLIN N AM, V73, P529; SAILORS DM, 1993, AM SURGEON, V59, P85	3	8	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 26	1994	343	8900					748	748		10.1016/S0140-6736(94)91834-1	http://dx.doi.org/10.1016/S0140-6736(94)91834-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907728				2022-12-28	WOS:A1994NC35100006
J	SILAGY, C; MANT, D; FOWLER, G; LODGE, M				SILAGY, C; MANT, D; FOWLER, G; LODGE, M			METAANALYSIS ON EFFICACY OF NICOTINE REPLACEMENT THERAPIES IN SMOKING CESSATION	LANCET			English	Article							PHYSICAL-DEPENDENCE; CHEWING-GUM; TRIALS	Nicotine-replacement therapy (NRT) by gum, transdermal patch, intranasal spray, or inhalation is expensive but how effective is it? We have done a meta-analysis of controlled trials to see how effects on abstinence rates are influenced by the clinical setting, the level of nicotine dependency, the dosage of NRT, and the intensity of additional advice and support offered. Published or unpublished randomised controlled trials of NRT that have assessed abstinence at least 6 months after the start of NRT were identified and 53 trials (42 gum, 9 patch, 1 intranasal spray, 1 inhaler), with data from 17 703 subjects, were included in the analyses. Use of NRT increased the odds ratio (OR) of abstinence to 1.71 (95% confidence interval 1.56-1.87) compared with those allocated to the control interventions. The ORs for the different forms of NRT were 1.61 for gum, 2.07 for transdermal patch, 2.92 for nasal spray, and 3.05 for inhaled nicotine. These odds were non-significantly higher in subjects with higher levels of nicotine dependence but they were largely independent of the intensity of additional support provided or the setting in which NRT was offered. We conclude that the currently available forms of NRT are effective therapies to aid smoking cessation.	UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary; University of Oxford			Mant, David CA/C-7763-2009					CHALMERS I, 1985, EFFECTIVE CARE PREGN; COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666; FAGERSTROM KO, 1978, ADDICT BEHAV, V3, P235, DOI 10.1016/0306-4603(78)90024-2; FIORE MC, 1992, JAMA-J AM MED ASSOC, V268, P2687, DOI 10.1001/jama.268.19.2687; GOURLAY SG, 1990, MED J AUSTRALIA, V153, P699, DOI 10.5694/j.1326-5377.1990.tb126327.x; HENNINGFIELD JE, 1990, JAMA-J AM MED ASSOC, V264, P1560, DOI 10.1001/jama.264.12.1560; HUGHES JR, 1986, JAMA-J AM MED ASSOC, V255, P3277, DOI 10.1001/jama.255.23.3277; LAM W, 1987, LANCET, V2, P27; PALMER KJ, 1992, DRUGS, V44, P498, DOI 10.2165/00003495-199244030-00011; RAW M, 1985, BRIT MED J, V290, P1231, DOI 10.1136/bmj.290.6477.1231; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P186; SAUL H, 1993, NEW SCI, V137, P12; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	13	372	373	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 15	1994	343	8890					139	142		10.1016/S0140-6736(94)90933-4	http://dx.doi.org/10.1016/S0140-6736(94)90933-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7904003				2022-12-28	WOS:A1994MQ86900009
J	SAATCIOGLU, F; DENG, TL; KARIN, M				SAATCIOGLU, F; DENG, TL; KARIN, M			A NOVEL CIS-ELEMENT MEDIATING LIGAND-INDEPENDENT ACTIVATION BY C-ERBA - IMPLICATIONS FOR HORMONAL-REGULATION	CELL			English	Article							RETINOIC ACID RECEPTORS; THYROID-HORMONE; GLUCOCORTICOID RECEPTOR; DNA-BINDING; PROGESTERONE-RECEPTOR; NEGATIVE REGULATION; RESPONSE ELEMENTS; AP-1-RESPONSIVE GENES; TRANSCRIPTION FACTOR; TRANS-ACTIVATION	A novel type of hormone-responsive element (HRE) is described. Unlike classical HREs, this element, RSV-T3RE (found in Rous sarcoma virus-long terminal repeat), mediates strong activation by the c-ErbAalpha thyroid hormone (T3) receptor in the absence of T3, and addition of T3 reverses this response. Whereas both c-ErbAalpha and v-ErbA are potent ligand-independent activators through the RSV-T3RE, c-ErbAbeta is not. The RSV-T3RE is recognized and activated by either c-ErbAalpha homodimers or c-ErbAalpha/retinoid X receptor (RXR) heterodimers. Ligand-independent activation by c-ErbAalpha depends on a unique N-terminal activation domain, while the C-terminal activation domain is not absolutely required. Ligand-dependent activation, on the other hand, requires the C-terminal but not the N-terminal activation domain. Upon binding to the RSV-T3RE, c-ErbAalpha assumes a different conformation than when bound to a classical T3RE. c-ErbAalpha is therefore capable of selective deployment of activation domains, dictated both by the HRE with which it interacts and by T3 binding.	UNIV CALIF SAN DIEGO,SCH MED,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego	SAATCIOGLU, F (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,LA JOLLA,CA 92093, USA.				NCI NIH HHS [CA50528] Funding Source: Medline; NHLBI NIH HHS [HL35018] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050528] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL035018] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ALLAN GF, 1992, P NATL ACAD SCI USA, V89, P11750, DOI 10.1073/pnas.89.24.11750; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DEBOIS C, 1991, CELL, V67, P731; DENG TL, 1992, P NATL ACAD SCI USA, V89, P8572, DOI 10.1073/pnas.89.18.8572; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FLINK IL, 1990, J BIOL CHEM, V265, P11233; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1989, CELL, V59, P597; GLASS CK, 1991, MOL ASPECTS CELLULAR, V6, P229; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GODOWSKI PJ, 1989, BIOCHEM PHARMACOL, V38, P3135, DOI 10.1016/0006-2952(89)90605-9; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GROYER A, 1987, NATURE, V328, P624, DOI 10.1038/328624a0; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Ivarie R D, 1980, Recent Prog Horm Res, V36, P195; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; SAKAI DD, 1988, GENE DEV, V2, P114; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SPORN MB, 1991, MOL ENDOCRINOL, V5, P3, DOI 10.1210/mend-5-1-3; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TONEY JH, 1993, BIOCHEMISTRY-US, V32, P2, DOI 10.1021/bi00052a001; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WIELAND S, 1991, EMBO J, V10, P2513, DOI 10.1002/j.1460-2075.1991.tb07791.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	61	121	121	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 17	1993	75	6					1095	1105		10.1016/0092-8674(93)90319-L	http://dx.doi.org/10.1016/0092-8674(93)90319-L			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	7903219				2022-12-28	WOS:A1993MM89300008
J	SKAKKEBAEK, NE; GIWERCMAN, A; DEKRETSER, D				SKAKKEBAEK, NE; GIWERCMAN, A; DEKRETSER, D			PATHOGENESIS AND MANAGEMENT OF MALE-INFERTILITY	LANCET			English	Review							GERM-CELL TUMORS; CARCINOMA-INSITU; INVITRO FERTILIZATION; SPERM FUNCTION; VAS-DEFERENS; MEN; FERTILITY; SPERMATOZOA; TESTIS; EPIDEMIOLOGY		MONASH UNIV,MONASH MED CTR,INST REPROD & DEV,CLAYTON,VIC 3168,AUSTRALIA	Monash University	SKAKKEBAEK, NE (corresponding author), UNIV COPENHAGEN,RIGSHOSP,DEPT GROWTH & REPROD,DK-2100 COPENHAGEN,DENMARK.							AITKEN RJ, 1992, J REPROD FERTIL, V94, P451; AITKEN RJ, 1987, J REPROD FERTIL, V81, P459; ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; [Anonymous], 1992, FERTIL STERIL, V57, P1289; BAKER HWG, 1985, BRIT MED J, V291, P1678, DOI 10.1136/bmj.291.6510.1678; BARRAT CLR, IN PRESS REPROD MED; BERTHELSEN JG, 1983, FERTIL STERIL, V39, P68; BICK D, 1992, NEW ENGL J MED, V326, P1752, DOI 10.1056/NEJM199206253262606; BONDE JPE, 1993, INT J ANDROL, V16, P1, DOI 10.1111/j.1365-2605.1993.tb01367.x; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; COMHAIRE F, 1991, ADV EXP MED BIOL, V286, P281; CROWLEY WF, 1990, AM J OBSTET GYNECOL, V163, P1752, DOI 10.1016/0002-9378(90)91440-N; DAMEWOOD MD, 1986, FERTIL STERIL, V45, P443; DEKRETSE.DM, 1972, J CLIN ENDOCR METAB, V35, P392, DOI 10.1210/jcem-35-3-392; DEKRETSER DM, 1985, CLIN OBSTET GYNAECOL, V12, P767; GIWERCMAN A, 1989, J UROLOGY, V142, P998, DOI 10.1016/S0022-5347(17)38967-X; GIWERCMAN A, 1993, EUR UROL, V23, P104; HENDRY WF, 1990, LANCET, V335, P85, DOI 10.1016/0140-6736(90)90548-J; KRUGER TF, 1988, FERTIL STERIL, V49, P112; KRUGER TF, 1986, FERTIL STERIL, V46, P1118; KUN MA, 1993, CELL, V75, P1287; KUNNEN M, 1992, INT RADIOLOGY, P72; LIU DY, 1992, FERTIL STERIL, V58, P465; MALLIDIS C, 1994, LANCET, V343, P1072, DOI 10.1016/S0140-6736(94)90183-X; MEACHAM RB, 1993, FERTIL STERIL, V59, P393; MEINERTZ H, 1990, FERTIL STERIL, V54, P315; MOLLER H, 1993, EUR UROL, V23, P8; MOSHER W, 1990, FECUNDITY INFERTILIT; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SILBER S, IN PRESS 7TH P WORLD; SILBER SJ, 1990, NEW ENGL J MED, V323, P1788, DOI 10.1056/NEJM199012273232602; SIMPSON E, 1993, HUM MOL GENET, V2, P469, DOI 10.1093/hmg/2.4.469; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; SOUTHWICK G J, 1988, Microsurgery, V9, P266, DOI 10.1002/micr.1920090412; TEMPLE-SMITH P D, 1985, Journal of In Vitro Fertilization and Embryo Transfer, V2, P119, DOI 10.1007/BF01131497; TEMPLETON A, 1990, BRIT MED J, V301, P148, DOI 10.1136/bmj.301.6744.148; VANDUIN M, 1992, GENOMICS, V14, P1064, DOI 10.1016/S0888-7543(05)80130-2; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1061, DOI 10.1093/oxfordjournals.humrep.a138192; VERMEULEN A, 1993, ENVIRON HEALTH PERSP, V101, P91, DOI 10.2307/3431381; WASSARMAN PM, 1992, BIOL REPROD, V46, P186, DOI 10.1095/biolreprod46.2.186; YATES CA, 1992, THESIS MONASH U MELB; 1992, WHO LABORATORY MANUA; 1986, BRIT MED J, V293, P1401; 1992, LANCET, V339, P1328	44	145	157	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1473	1479		10.1016/S0140-6736(94)92586-0	http://dx.doi.org/10.1016/S0140-6736(94)92586-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911182				2022-12-28	WOS:A1994NQ41500013
J	PALMER, JP				PALMER, JP			WHAT IS THE BEST WAY TO PREDICT IDDM	LANCET			English	Editorial Material							GLUTAMIC-ACID DECARBOXYLASE; INSULIN; RELATIVES; AUTOANTIBODIES; ASSAY		UNIV WASHINGTON,DEPT MED,SEATTLE,WA	University of Washington; University of Washington Seattle	PALMER, JP (corresponding author), VET AFFAIRS MED CTR,SEATTLE,WA 98108, USA.							ATKINSON MA, 1993, J CLIN INVEST, V91, P350, DOI 10.1172/JCI116192; BJORK E, 1994, DIABETES, V43, P161, DOI 10.2337/diabetes.43.1.161; GIANANI R, 1992, DIABETES, V41, P347, DOI 10.2337/diabetes.41.3.347; GREENBAUM CJ, 1992, J CLIN ENDOCR METAB, V74, P1040, DOI 10.1210/jc.74.5.1040; HAGOPIAN WA, 1993, J CLIN INVEST, V91, P368, DOI 10.1172/JCI116195; HARRISON LC, 1993, LANCET, V341, P1365, DOI 10.1016/0140-6736(93)90940-I; KRISCHER JP, 1993, J CLIN ENDOCR METAB, V77, P743, DOI 10.1210/jc.77.3.743; PALMER JP, 1993, DIABETES REV, V1, P104; ROBERT JJ, 1991, DIABETES CARE, V14, P718, DOI 10.2337/diacare.14.8.718	9	9	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1377	1378		10.1016/S0140-6736(94)92519-4	http://dx.doi.org/10.1016/S0140-6736(94)92519-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910879				2022-12-28	WOS:A1994NP95500005
J	BOS, JD; KAPSENBERG, ML; SMITT, JHS				BOS, JD; KAPSENBERG, ML; SMITT, JHS			PATHOGENESIS OF ATOPIC ECZEMA	LANCET			English	Article							FC-EPSILON-RI; T-CELLS; LYMPHOCYTES-T; FUNCTIONAL SUBSETS; SKIN; RESPONSES; INTERLEUKIN-4; DERMATITIS; TYPE-1; CHROMOSOME-11Q				BOS, JD (corresponding author), UNIV AMSTERDAM, ACAD MED CENTRUM, DEPT DERMATOL, MEIBERGDROEF 9, 1105 AZ AMSTERDAM, NETHERLANDS.							BARKER JNWN, 1991, LANCET, V337, P211, DOI 10.1016/0140-6736(91)92168-2; BIEBER T, 1992, INT ARCH ALLERGY IMM, V99, P204, DOI 10.1159/000236249; BJORKSTEN B, 1987, CLIN REV ALLERG, V5, P339; BOS JD, 1992, ARCH DERMATOL, V128, P1509, DOI 10.1001/archderm.128.11.1509; BOS JD, 1993, IMMUNOL TODAY, V14, P75, DOI 10.1016/0167-5699(93)90062-P; BRUIJNZEELKOOME.C, 1986, ARCH DERMATOL RES, V278, P199; BURTON JL, 1989, LANCET, V1, P27; CHAN SC, 1993, J INVEST DERMATOL, V100, P681, DOI 10.1111/1523-1747.ep12472344; COLEMAN R, 1993, LANCET, V341, P1121, DOI 10.1016/0140-6736(93)93130-S; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; COOKSON WOCM, 1989, LANCET, V1, P1292; DAYNES RA, 1989, EUR J IMMUNOL, V19, P2319, DOI 10.1002/eji.1830191221; FARGEAS C, 1992, EUR J IMMUNOL, V22, P2173, DOI 10.1002/eji.1830220833; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; ISHIZAKA K, 1966, J IMMUNOL, V97, P75; KAPSENBERG ML, 1992, SPRINGER SEMIN IMMUN, V13, P303; KAPSENBERG ML, 1991, IMMUNOL TODAY, V12, P392, DOI 10.1016/0167-5699(91)90137-I; MAGGI E, 1992, J IMMUNOL, V148, P2142; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MELNIK BC, 1989, J AM ACAD DERMATOL, V21, P557, DOI 10.1016/S0190-9622(89)70226-7; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RAMBLINDHAUER C, 1991, ARCH DERMATOL RES, V283, P71, DOI 10.1007/BF00371611; ROOK AH, 1993, ARCH DERMATOL, V129, P486, DOI 10.1001/archderm.129.4.486; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; SNIJDEWINT FGM, 1993, J IMMUNOL, V150, P5321; SVENTIVANYI A, 1968, J ALLERGY, V42, P203; TURTON JA, 1976, LANCET, V2, P686; VANDERHEIJDEN FL, 1993, J IMMUNOL, V150, P3643; VANDERHEIJDEN FL, 1991, J INVEST DERMATOL, V97, P389, DOI 10.1111/1523-1747.ep12480966; WERNER Y, 1985, ACTA DERM-VENEREOL, V65, P102; WIERENGA EA, 1993, BLOOD, V82, P1471; WIERENGA EA, 1991, J IMMUNOL, V147, P2942; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; WILLIAMS HC, 1992, CLIN EXP DERMATOL, V17, P385, DOI 10.1111/j.1365-2230.1992.tb00244.x; YOUNG RP, 1992, J MED GENET, V29, P236, DOI 10.1136/jmg.29.4.236	36	91	92	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 28	1994	343	8909					1338	1341		10.1016/S0140-6736(94)92473-2	http://dx.doi.org/10.1016/S0140-6736(94)92473-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910330				2022-12-28	WOS:A1994NN21700016
J	HULL, HF; WARD, NA; HULL, BP; MILSTIEN, JB; DEQUADROS, C				HULL, HF; WARD, NA; HULL, BP; MILSTIEN, JB; DEQUADROS, C			PARALYTIC POLIOMYELITIS - SEASONED STRATEGIES, DISAPPEARING DISEASE	LANCET			English	Article							ORAL POLIO VACCINE; ERADICATION; EFFICACY; PROGRESS; COUNTRIES; BRAZIL	With more than 2 years having elapsed since the last case of paralytic poliomyelitis occurred in the Western Hemisphere, significant progress has been made towards the global eradication of wild polioviruses. Poliomyelitis is disappearing from Europe, North Africa, Southern Africa, the Middle East, China, and the Pacific. Reported poliomyelitis cases declined to 15 587 cases in 1992. Current eradication strategies recommended by the World Health Organization include national mass campaigns administering oral poliovaccine to all children under 5 years of age, enhanced surveillance to detect cases of acute flaccid paralysis, creating a network of laboratories for viral diagnosis, and targeted immunisation to areas and populations where poliovirus transmission is likely to persist. The major obstacles to eradication include inadequate political support for eradication and insufficient funding, especially for the purchase of vaccine. With additional support for the international eradication effort, epidemics of poliomyelitis will cease in developing countries, and industrialised countries will be able to save the large sums spent each year on poliovaccine and rehabilitation.	CTR DIS CONTROL & PREVENT, NATL IMMUNIZAT PROGRAM, ATLANTA, GA 30341 USA; WHO, BIOL UNIT, CH-1211 GENEVA, SWITZERLAND; PAN AMER HLTH ORG, EXPANDED PROGRAMME IMMUNIZAT, WASHINGTON, DC USA	Centers for Disease Control & Prevention - USA; World Health Organization; Pan American Health Organization	HULL, HF (corresponding author), WHO, EXPANDED PROGRAMME IMMUNIZAT, CH-1211 GENEVA 4, SWITZERLAND.							ANDRUS JK, 1992, B WORLD HEALTH ORGAN, V70, P591; [Anonymous], 1992, Wkly Epidemiol Rec, V67, P341; BIELLIK RJ, 1992, B WORLD HEALTH ORGAN, V70, P79; CHOPRA K, 1989, J TROP PEDIATRICS, V35, P19, DOI 10.1093/tropej/35.1.19; CRUZ RR, 1984, REV INFECT DIS, V6, pS408; DEMING MS, 1992, AM J EPIDEMIOL, V135, P393, DOI 10.1093/oxfordjournals.aje.a116300; DEQUADROS CA, 1991, PEDIATR INFECT DIS J, V10, P222, DOI 10.1097/00006454-199103000-00011; Expanded programme on immunization, 1993, WKLY EPIDEMIOL REC, V68, P297; FOX JP, 1984, REV INFECT DIS, V6, pS352; GEAR JHS, 1984, REV INFECT DIS, V6, pS379; JOHN TJ, 1976, BRIT MED J, V1, P812, DOI 10.1136/bmj.1.6013.812; LEMON SM, 1991, PROG MED VIROL, V38, P42; Mandke B V, 1990, Indian J Public Health, V34, P200; MCBEAN AM, 1988, AM J EPIDEMIOL, V128, P615, DOI 10.1093/oxfordjournals.aje.a115009; MELNICK JL, 1984, REV INFECT DIS, V6, pS387; MELNICK JL, 1992, EPIDEMIOL INFECT, V108, P1; MODLIN JF, 1991, PEDIATR INFECT DIS J, V10, P976, DOI 10.1097/00006454-199112000-00031; ONORATO IM, 1991, J INFECT DIS, V163, P1, DOI 10.1093/infdis/163.1.1; ORENSTEIN WA, 1985, B WORLD HEALTH ORGAN, V63, P1055; PATRIARCA PA, 1988, LANCET, V1, P429; PATRIARCA PA, 1993, LANCET, V342, P1461, DOI 10.1016/0140-6736(93)92936-N; PATRIARCA PA, 1991, REV INFECT DIS, V13, P926; PLOTKIN SA, 1991, PEDIATR INFECT DIS J, V10, P979, DOI 10.1097/00006454-199112000-00032; RICHARDSON G, 1993, RD P ICAAC WASH; RISI JB, 1984, REV INFECT DIS, V6, pS400; SABIN AB, 1980, B WORLD HEALTH ORGAN, V58, P141; SABIN AB, 1960, JAMA-J AM MED ASSOC, V173, P1521, DOI 10.1001/jama.1960.03020320001001; SATTAR SA, 1991, VIRUSES WASTEWATER T, P91; STREBEL PM, 1992, CLIN INFECT DIS, V14, P568, DOI 10.1093/clinids/14.2.568; SUTTER RW, 1991, LANCET, V338, P715, DOI 10.1016/0140-6736(91)91442-W; TULCHINSKY T, 1989, AM J PUBLIC HEALTH, V79, P1648, DOI 10.2105/AJPH.79.12.1648; 1984, 1984 BELL C NEW YORK; 1993, WKLY EPIDEMIOL REC, V68, P222; 1993, CAN COMMUN DIS REP, V19, P57; 1993, B PAHO, V27, P287; 1992, WKLY EPIDEMIOL REC, V67, P336	36	167	169	0	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 28	1994	343	8909					1331	1337		10.1016/S0140-6736(94)92472-4	http://dx.doi.org/10.1016/S0140-6736(94)92472-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910329				2022-12-28	WOS:A1994NN21700015
J	KATAMINE, S; MORIUCHI, R; YAMAMOTO, T; TERADA, K; EGUCHI, K; TSUJI, Y; YAMABE, T; MIYAMOTO, T; HINO, S				KATAMINE, S; MORIUCHI, R; YAMAMOTO, T; TERADA, K; EGUCHI, K; TSUJI, Y; YAMABE, T; MIYAMOTO, T; HINO, S			HTLV-I PROVIRAL DNA IN UMBILICAL-CORD BLOOD OF BABIES BORN TO CARRIER MOTHERS	LANCET			English	Note							CELL LEUKEMIA-VIRUS; POLYMERASE CHAIN-REACTION; TO-CHILD TRANSMISSION; ANTIBODY; ANTIGEN; MILK	Human T-lymphotropic virus type I (HTLV-I) in cord blood raises the possibility of intrauterine transmission as an alternative pathway to transmission via breast milk. However, none of 7 children with HTLV-I proviral DNA positive cord blood had seroconverted by 24-48 months. Contamination of cord blood by maternal blood was precluded on the basis of viral load and IgA concentration. Thus cord blood proviral DNA is not a hallmark of intrauterine infection. Moreover, none of the cord blood samples of 9 formula-fed children later confirmed to be infected was positive for HTLV-I, indicating that intrauterine infection is not a likely candidate as an alternative pathway.	NAGASAKI UNIV,SCH MED,DEPT INTERNAL MED 1,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT PAEDIAT,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT OBSTET & GYNAECOL,NAGASAKI 852,JAPAN; TOTTORI UNIV,FAC MED,DEPT VIROL,YONAGO,TOTTORI 683,JAPAN	Nagasaki University; Nagasaki University; Nagasaki University; Tottori University	KATAMINE, S (corresponding author), NAGASAKI UNIV,SCH MED,DEPT BACTERIOL,1-12-4 SAKAMOTO,NAGASAKI 852,JAPAN.							HINO S, 1987, LANCET, V2, P158; HINO S, 1985, JPN J CANCER RES, V76, P474; KAWASE K, 1992, JPN J CANCER RES, V83, P968, DOI 10.1111/j.1349-7006.1992.tb02009.x; KUGA T, 1988, JPN J CANCER RES, V79, P1168, DOI 10.1111/j.1349-7006.1988.tb01541.x; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; SAITO S, 1990, JPN J CANCER RES, V81, P890, DOI 10.1111/j.1349-7006.1990.tb02663.x; SATOW YI, 1991, LANCET, V338, P915, DOI 10.1016/0140-6736(91)91775-P; TAKAHASHI K, 1991, INT J CANCER, V49, P673, DOI 10.1002/ijc.2910490508	8	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1326	1327		10.1016/S0140-6736(94)92469-4	http://dx.doi.org/10.1016/S0140-6736(94)92469-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910326				2022-12-28	WOS:A1994NN21700012
J	STOKER, D; SPIEGELHALTER, DJ; SINGH, R; WELLWOOD, JM				STOKER, D; SPIEGELHALTER, DJ; SINGH, R; WELLWOOD, JM			LAPAROSCOPIC VERSUS OPEN INGUINAL-HERNIA REPAIR - RANDOMIZED PROSPECTIVE TRIAL	LANCET			English	Article								Laparoscopic surgery benefits patients because it reduces pain and enables earlier mobilisation. There is concern that laparoscopic hernia repair may enter surgical practice without proper evaluation. We have done a randomised, prospective study comparing laparoscopic and open inguinal hernia repair performed under day-case general anaesthesia. 150 patients were randomised to have laparoscopic (group L) or open (group O) herniorrhaphy. Group L underwent transabdominal stapling of preperitoneal Prolene mesh. Group O underwent open repair, with a tension-free nylon darn. Postoperatively patients completed pain analogue scales eight times over 7 days, and use of analgesia was recorded. Time of return to normal domestic activity and to work was assessed. The groups were similar in age, sex, and body surface area. Self-administered co-proxamol was a median of 18 tablets (1 tablet=325 mg) in group O (n=75) and 6 in group L (n=75, p<0.001). Overall mean pain analogue score was 3.1 (SD 1.8, n=70) in group O and 1.8 (SD 1.1, n=71) in group L (p<0.0001). Return to normal domestic activity was a median of 7 days in group O (n=72) and 3 days in group L (n=73) (p<0.001). Return to work was a median of 28 days in group O (n=39) and 14 days in group L (n=40) (p<0.002). These data suggest that laparoscopic hernia repair induces less pain than open hernia repair, and enables patients to return to normal activity and work more quickly.	WHIPPS CROSS HOSP & CHEST CLIN,DEPT SURG,LONDON,ENGLAND; ST BARTHOLOMEWS HOSP,PROFESSORIAL SURG UNIT,LONDON EC1A 7BE,ENGLAND; UNIV FORVIE SITE,MRC,BIOSTAT UNIT,CAMBRIDGE,CAMBS,ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London; MRC Biostatistics Unit; University of Cambridge								CORBITT JD, 1993, SURG LAPAROSC ENDOSC, V3, P328; CORSON RJ, 1993, ANN R COLL SURG EN S, V75, P125; MACINTYRE IMC, 1992, BRIT J SURG, V79, P1123, DOI 10.1002/bjs.1800791103; MCMAHON AJ, 1993, BRIT J SURG, V80, P1593, DOI 10.1002/bjs.1800801233; RUTKOW IM, 1992, ARCH SURG-CHICAGO, V127, P1271; STOKER DL, 1993, BRIT J SURG, V80, P1354, DOI 10.1002/bjs.1800801059; 1993, LANCET, V342, P187; 1993, CLIN GUIDELINES MANA	8	251	252	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1243	1245		10.1016/S0140-6736(94)92148-2	http://dx.doi.org/10.1016/S0140-6736(94)92148-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910272				2022-12-28	WOS:A1994NM14400006
J	NOSSAL, GJV				NOSSAL, GJV			MINIMAL RESIDUAL DISEASE AS THE TARGET FOR IMMUNOTHERAPY OF CANCER	LANCET			English	Editorial Material											NOSSAL, GJV (corresponding author), WALTER & ELIZA HALL INST MED RES,MELBOURNE,AUSTRALIA.							AMLOT PL, 1993, BLOOD, V82, P2624; BOON T, 1993, INT J CANCER, V54, P177, DOI 10.1002/ijc.2910540202; BYSTRYN JC, 1993, ANN NY ACAD SCI, V690; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; HARDINGHAM JE, 1993, CANCER RES, V53, P3455; KLEIN G, 1993, CURR OPIN IMMUNOL, V5, P687, DOI 10.1016/0952-7915(93)90122-9; PANTEL K, 1993, JNCI-J NATL CANCER I, V85, P1419, DOI 10.1093/jnci/85.17.1419; SCHLIMOK G, 1990, J CLIN ONCOL, V8, P831, DOI 10.1200/JCO.1990.8.5.831; WELT S, 1990, J CLIN ONCOL, V8, P1894, DOI 10.1200/JCO.1990.8.11.1894	10	15	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1172	1174		10.1016/S0140-6736(94)92394-9	http://dx.doi.org/10.1016/S0140-6736(94)92394-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909862				2022-12-28	WOS:A1994NL17500003
J	SHAH, NM; MARCHIONNI, MA; ISAACS, I; STROOBANT, P; ANDERSON, DJ				SHAH, NM; MARCHIONNI, MA; ISAACS, I; STROOBANT, P; ANDERSON, DJ			GLIAL GROWTH-FACTOR RESTRICTS MAMMALIAN NEURAL CREST STEM-CELLS TO A GLIAL FATE	CELL			English	Article							RAT SCHWANN-CELLS; NEURONAL DIFFERENTIATION; DORSAL-ROOT; COMMITMENT; LINEAGE; GLUCOCORTICOIDS; IDENTIFICATION; DERIVATIVES; POPULATIONS; SEGREGATION	Growth factors and cytokines are thought to influence the development of uncommitted progenitor cell populations, but the issue of how these factors act on individual cells remains controversial. Such factors may act simply as selective mitogens or survival factors for cells that undergo lineage restrictions stochastically. Alternatively, they may instruct or bias multipotent cells to choose one lineage at the expense of others. Here we show that glial growth factor (GGF), previously defined as a Schwann cell mitogen, strongly suppresses neuronal differentiation of rat neural crest stem cells while promoting or allowing glial differentiation. Quantitative clonal analysis suggests that the action of GGF is likely to be instructive rather than selective. Taken together with the expression pattern of GGF, these data suggest a lateral signaling model for the diversification of cell types within developing peripheral ganglia.	CAMBRIDGE NEUROSCI INC, CAMBRIDGE, MA 02139 USA; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Ludwig Institute for Cancer Research	SHAH, NM (corresponding author), CALTECH, HOWARD HUGHES MED INST, DIV BIOL 216-76, PASADENA, CA 91125 USA.							Anderson D J, 1993, Curr Opin Neurobiol, V3, P8, DOI 10.1016/0959-4388(93)90028-W; ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; BAROFFIO A, 1992, J CELL SCI, V103, P581; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIMENT G, 1990, COMMENTS DEV NEUROBI, V1, P207; DAVIS JB, 1990, J CELL BIOL, V110, P1353, DOI 10.1083/jcb.110.4.1353; DEXTER TM, 1990, PHILOS T ROY SOC B, V327, P85, DOI 10.1098/rstb.1990.0045; DOUPE AJ, 1985, J NEUROSCI, V5, P2143; DOUPE AJ, 1985, J NEUROSCI, V5, P2119; DUFF RS, 1991, DEV BIOL, V147, P451, DOI 10.1016/0012-1606(91)90303-K; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FRANK E, 1991, DEVELOPMENT, V111, P895; FRASER SE, 1991, DEVELOPMENT, V112, P913; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOLTON B, 1982, DEV BIOL, V89, P72, DOI 10.1016/0012-1606(82)90295-0; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; JESSEN KR, 1991, GLIA, V4, P185, DOI 10.1002/glia.440040210; JIN JJ, 1993, CELL GROWTH DIFFER, V4, P227; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; JUST U, 1991, CELL, V64, P1163, DOI 10.1016/0092-8674(91)90271-Y; Le Douarin N.M., 1982, NEURAL CREST; LEDOUARIN NM, 1986, SCIENCE, V231, P1515, DOI 10.1126/science.3952494; LEDOUARIN NM, 1993, DEV BIOL, V159, P24, DOI 10.1006/dbio.1993.1219; LEMKE GE, 1984, J NEUROSCI, V4, P75; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; LO LC, 1991, DEV BIOL, V145, P139, DOI 10.1016/0012-1606(91)90220-W; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; METCALF D, 1991, P NATL ACAD SCI USA, V88, P11310, DOI 10.1073/pnas.88.24.11310; METCALF D, 1980, P NATL ACAD SCI-BIOL, V77, P5327, DOI 10.1073/pnas.77.9.5327; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; NAWA H, 1990, COLD SH Q B, V55, P247; OGAWA M, 1993, BLOOD, V81, P2844; PATTERSON PH, 1977, DEV BIOL, V56, P263, DOI 10.1016/0012-1606(77)90269-X; PATTERSON PH, 1993, CELL, V72, P123, DOI 10.1016/S0092-8674(05)80032-7; PATTERSON PH, 1990, CELL, V62, P1035, DOI 10.1016/0092-8674(90)90379-S; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RIDLEY AJ, 1989, J CELL BIOL, V109, P3419, DOI 10.1083/jcb.109.6.3419; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SELLECK MAJ, 1993, DEV BIOL, V159, P1, DOI 10.1006/dbio.1993.1217; SIEBERBLUM M, 1991, NEURON, V6, P949, DOI 10.1016/0896-6273(91)90235-R; STEMPLE DL, 1988, NEURON, V1, P517, DOI 10.1016/0896-6273(88)90182-1; STEMPLE DL, 1993, DEV BIOL, V159, P12, DOI 10.1006/dbio.1993.1218; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WESTON JA, 1991, CURR TOP DEV BIOL, V25, P133; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641	58	445	455	0	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 6	1994	77	3					349	360		10.1016/0092-8674(94)90150-3	http://dx.doi.org/10.1016/0092-8674(94)90150-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NK970	7910115				2022-12-28	WOS:A1994NK97000006
J	SAVEN, A; PIRO, LD				SAVEN, A; PIRO, LD			2-CHLORODEOXYADENOSINE - A NEWER PURINE ANALOG ACTIVE IN THE TREATMENT OF INDOLENT LYMPHOID MALIGNANCIES	ANNALS OF INTERNAL MEDICINE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; HAIRY-CELL LEUKEMIA; FLUDARABINE PHOSPHATE; DEAMINASE DEFICIENCY; 2-CHLORO-2'-DEOXYADENOSINE; DEOXYADENOSINE; TOXICITY; AGENT; APOPTOSIS; INFUSION	Objective: To review the structure, mechanism of action, pharmacologic features, and clinical trial results of the newer purine analog, 2-chlorodeoxyadenosine (2-CdA). Data Sources and Study Selection: English-language medical literature review of more than 70 articles. Data Synthesis: 2-Chlorodeoxyadenosine is unique compared with traditional antimetabolite drugs in that it is equally active against dividing and resting lymphocytes, which may be especially important in indolent lymphoid malignancies, such as chronic lymphocytic leukemia, because most cells in these disorders are in the resting phase. In patients with alkylator-refractory chronic lymphocytic leukemia who were treated with 2-CdA, 44% achieved a response (4% complete responses, 40% partial responses), and 54%, scored as nonresponders, had a sustained reduction in their peripheral lymphocytosis. Patients with untreated chronic lymphocytic leukemia had an 85% response rate (25% complete responses, 60% partial responses). Patients with previously treated low-grade lymphoma achieved an overall response rate of 43%. The most striking clinical effects of this drug have been seen in hairy cell leukemia, in which a single course of therapy induces complete remissions in 85% of partial remissions in 12%. Activity has also been shown in cutaneous T-cell lymphoma and the myeloid leukemias. Conclusions: 2-Chlorodeoxyadenosine is a newer purine analog with potent activity in the treatment of indolent lymphoproliferative diseases and illustrates the model for rational drug development.			SAVEN, A (corresponding author), SCRIPPS CLIN & RES FDN, IDA M & CECIL H GREEN CANC CTR, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							AVERY TL, 1989, CANCER RES, V49, P4972; BARTON K, 1992, J CLIN ONCOL, V10, P1821, DOI 10.1200/JCO.1992.10.11.1821; BEUTLER E, 1992, LANCET, V340, P952, DOI 10.1016/0140-6736(92)92826-2; BEUTLER E, 1991, LEUKEMIA LYMPHOMA, V5, P1, DOI 10.3109/10428199109068099; BOURONCLE BA, 1979, BLOOD, V53, P412; CARRERA CJ, 1990, J CLIN INVEST, V86, P1480, DOI 10.1172/JCI114865; CARRERA CJ, 1987, CLIN RES, V35, pA597; CARRERA CJ, 1991, ADV EXP MED BIOL, V309, P15; CARRERA CJ, 1987, MOL BASIS BLOOD DISE, P407; CARRERA CJ, 1990, BLOOD S, V76, pA260; CARSON DA, 1984, P NATL ACAD SCI-BIOL, V81, P2232, DOI 10.1073/pnas.81.7.2232; CARSON DA, 1992, P NATL ACAD SCI USA, V89, P2970, DOI 10.1073/pnas.89.7.2970; CARSON DA, 1980, P NATL ACAD SCI-BIOL, V77, P6865, DOI 10.1073/pnas.77.11.6865; CARSON DA, 1983, BLOOD, V62, P737; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; CHRISTENSEN LF, 1972, J MED CHEM, V15, P735, DOI 10.1021/jm00277a010; CHUN HG, 1991, J CLIN ONCOL, V9, P175, DOI 10.1200/JCO.1991.9.1.175; CHUNDURU SK, 1991, P AM ASSOC CANC RES, V97, P17; COHEN A, 1978, P NATL ACAD SCI USA, V75, P472, DOI 10.1073/pnas.75.1.472; DIMOPOULOS MA, 1992, BLOOD, V80, P1626; DIMOPOULOS MA, 1993, ANN INTERN MED, V118, P195, DOI 10.7326/0003-4819-118-3-199302010-00007; ESTEY EH, 1992, BLOOD, V79, P882; FIGUEROA M, 1993, BLOOD, V81, P3484; FILLEUL B, 1993, BLOOD, V82, pA142; FOON KA, 1990, ANN INTERN MED, V113, P525, DOI 10.7326/0003-4819-113-7-525; FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219; GIBLETT ER, 1972, LANCET, V2, P1067; GREVER MR, 1988, NOUV REV FR HEMATOL, V30, P457; HAKIMIAN D, 1993, BLOOD, V82, P1798; HICKISH T, 1993, BRIT J CANCER, V67, P139, DOI 10.1038/bjc.1993.24; HIDDEMANN W, 1991, ANN HEMATOL, V63, P1, DOI 10.1007/BF01714952; HOFFMAN M, 1991, BLOOD S, V78, pA454; JULIUSSON G, 1992, BLOOD, V79, P888; JULIUSSON G, 1993, LANCET, V341, P54, DOI 10.1016/0140-6736(93)92530-7; JULIUSSON G, 1993, J CLIN ONCOL, V11, P679, DOI 10.1200/JCO.1993.11.4.679; JULIUSSON G, 1992, NEW ENGL J MED, V327, P1056, DOI 10.1056/NEJM199210083271504; JULIUSSON G, 1993, BLOOD, V82, pA568; JULIUSSON G, 1992, BLOOD, V80, P1427; KAWASAKI H, 1993, BLOOD, V81, P597; KAY AC, 1992, J CLIN ONCOL, V10, P371, DOI 10.1200/JCO.1992.10.3.371; KEATING MJ, 1989, BLOOD, V74, P19; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KUZEL TM, 1992, P AN M AM SOC CLIN, V11, pA1089; LAURIA F, 1991, BLOOD S, V78, pA34; LILIEMARK J, 1992, J CLIN ONCOL, V10, P1514, DOI 10.1200/JCO.1992.10.10.1514; LILIEMARK J, 1991, CANCER RES, V51, P5570; LILIEMARK J, 1991, BLOOD S, V78, pA33; LILIEMARK J, 1992, BLOOD, V80, P1874; MIYASHITA T, 1993, BLOOD, V81, P151; OBRIEN S, 1994, NEW ENGL J MED, V330, P319, DOI 10.1056/NEJM199402033300504; OBRIEN S, 1993, BLOOD, V82, pA141; ODWYER PJ, 1988, ANN INTERN MED, V108, P733, DOI 10.7326/0003-4819-108-5-733; PARSONS PG, 1986, BIOCHEM PHARMACOL, V35, P4025, DOI 10.1016/0006-2952(86)90022-5; PETZER AL, 1991, BLOOD, V78, P2583; PIRO LD, 1990, NEW ENGL J MED, V322, P1117, DOI 10.1056/NEJM199004193221605; PIRO LD, 1988, BLOOD, V72, P1069; PIRO LD, 1992, P AN M AM SOC CLIN, V11, P846; PUCCIO CA, 1991, J CLIN ONCOL, V9, P1562, DOI 10.1200/JCO.1991.9.9.1562; ROBERTSON LE, 1993, BLOOD, V81, P143; SANTANA VM, 1992, J CLIN ONCOL, V10, P364, DOI 10.1200/JCO.1992.10.3.364; SANTANA VM, 1991, J CLIN ONCOL, V9, P416, DOI 10.1200/JCO.1991.9.3.416; SAVEN A, 1992, BLOOD, V80, P587; SAVEN A, 1993, NEW ENGL J MED, V328, P812; SAVEN A, 1993, NEW ENGL J MED, V329, P734, DOI 10.1056/NEJM199309023291013; SAVEN A, 1993, ANN INTERN MED, V119, P278, DOI 10.7326/0003-4819-119-4-199308150-00005; SAVEN A, 1993, J CLIN ONCOL, V11, P671, DOI 10.1200/JCO.1993.11.4.671; SAVEN A, 1991, LEUKEMIA LYMPHOMA, V5, P133, DOI 10.3109/10428199109103394; SAVEN A, 1993, P AN M AM SOC CLIN, V12, P310; SAVNE A, 1993, BLOOD S, V82, P1764; SETO S, 1985, J CLIN INVEST, V75, P377, DOI 10.1172/JCI111710; SETO S, 1986, J IMMUNOL, V136, P2839; SEYMOUR JF, 1993, BLOOD, V82, pA142; SIPE JC, 1994, IN PRESS NEUROLOGY; SORENSEN JM, 1992, P AN M AM SOC CLIN, V11, pA867; SPIELBERGER RT, 1993, P AN M AM SOC CLIN, V12, P140; TALLMAN MS, 1992, BLOOD, V80, P2203; VAHDAT L, 1993, BLOOD, V82, pA129; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	78	93	94	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1994	120	9					784	791		10.7326/0003-4819-120-9-199405010-00010	http://dx.doi.org/10.7326/0003-4819-120-9-199405010-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH251	7908507				2022-12-28	WOS:A1994NH25100010
J	HARRINGTON, CR; WISCHIK, CM; MCARTHUR, FK; TAYLOR, GA; EDWARDSON, JA; CANDY, JM				HARRINGTON, CR; WISCHIK, CM; MCARTHUR, FK; TAYLOR, GA; EDWARDSON, JA; CANDY, JM			ALZHEIMERS-DISEASE-LIKE CHANGES IN TAN PROTEIN PROCESSING - ASSOCIATION WITH ALUMINUM ACCUMULATION IN BRAINS OF RENAL DIALYSIS PATIENTS	LANCET			English	Article							PAIRED HELICAL FILAMENTS; NEUROFIBRILLARY TANGLES; MICROPROBE; ISOFORMS; ABSENCE; PLAQUE	Tau protein is a major structural protein of the paired helical filaments (PHFs) found in both neuritic senile plaques and neurofibrillary tangles in Alzheimer's disease (AD). Senile plaques also contain amyloid beta protein (A beta). We did an immunochemical analysis of frontal cortex from 15 dialysis cases, 5 Alzheimer's disease patients, and 6 control cases to see whether AD-like changes in A beta deposition and tau protein were linked to aluminium accumulation. Dialysis patients were used because they are frequently exposed to increased levels of aluminium. 8 of the 15 dialysis cases had insoluble A beta, but there was no association between its presence and the accumulation of aluminium. However, we found AD-like changes in the processing of tau protein. In white matter, truncated tau protein in the PHF-core fraction and endogenously truncated tau in the supernatant fraction were both increased in association with aluminium accumulation in the brain. In grey matter, normal tau protein was depleted and insoluble hyperphosphorylated tau increased in association with aluminium concentration. Protease-resistant PHFs were present in grey matter in 2 dialysis cases, a frequency above that expected for AD in this age group. PHF-core tau in both grey and white matter correlated with decreased levels of normal tau protein in white matter. These findings are consistent with a role for aluminium in the development of AD-like pathology in patients subjected to prolonged aluminium exposure.	NEWCASTLE GEN HOSP, MRC, NEUROCHEM PATHOL UNIT, NEWCASTLE UPON TYNE, TYNE & WEAR, ENGLAND	Newcastle General Hospital	HARRINGTON, CR (corresponding author), UNIV CAMBRIDGE, CTR MRC, DEPT PSYCHIAT, CAMBRIDGE BRAIN BANK LAB, HILLS RD, CAMBRIDGE CB2 2QH, CAMBS, ENGLAND.			Harrington, Charles/0000-0003-2250-3920				ABDELGHANY M, 1993, J BIOL CHEM, V268, P11976; CANDY JM, 1992, J NEUROL SCI, V107, P210, DOI 10.1016/0022-510X(92)90291-R; CANDY JM, 1986, LANCET, V1, P354; CHAFI AH, 1991, NEUROSCI LETT, V123, P61, DOI 10.1016/0304-3940(91)90158-P; DOLL R, 1993, AGE AGEING, V22, P138, DOI 10.1093/ageing/22.2.138; EDWARDSON JA, 1991, ALUMINUM CHEM BIOL M, P85; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GUY SP, 1991, NEUROSCI LETT, V121, P166, DOI 10.1016/0304-3940(91)90676-K; HARRINGTON CR, 1991, P NATL ACAD SCI USA, V88, P5842, DOI 10.1073/pnas.88.13.5842; JACOBS RW, 1989, CAN J NEUROL SCI, V16, P498, DOI 10.1017/S0317167100029838; KAWAHARA M, 1992, BIOCHEM BIOPH RES CO, V189, P1317, DOI 10.1016/0006-291X(92)90217-9; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; LANDSBERG JP, 1992, NATURE, V360, P65, DOI 10.1038/360065a0; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; MATTSON MP, 1993, BRAIN RES, V602, P21, DOI 10.1016/0006-8993(93)90236-G; MORRIS CM, 1989, J NEUROL SCI, V94, P295, DOI 10.1016/0022-510X(89)90238-4; MUKAETOVALADINSKA EB, 1993, AM J PATHOL, V143, P565; MULLAN M, 1993, TRENDS NEUROSCI, V16, P398, DOI 10.1016/0166-2236(93)90007-9; NOVAK M, 1993, EMBO J, V12, P365, DOI 10.1002/j.1460-2075.1993.tb05665.x; PERL DP, 1980, SCIENCE, V208, P297, DOI 10.1126/science.7367858; ROCCA WA, 1991, ANN NEUROL, V30, P381, DOI 10.1002/ana.410300310; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SHIGEMATSU K, 1992, BRAIN RES, V593, P117, DOI 10.1016/0006-8993(92)91272-G; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506	27	121	128	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 23	1994	343	8904					993	997		10.1016/S0140-6736(94)90124-4	http://dx.doi.org/10.1016/S0140-6736(94)90124-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909090				2022-12-28	WOS:A1994NG68200007
J	PFISTER, HW; WILSKE, B; WEBER, K				PFISTER, HW; WILSKE, B; WEBER, K			LYME BORRELIOSIS - BASIC SCIENCE AND CLINICAL ASPECTS	LANCET			English	Article							CEREBROSPINAL-FLUID; BURGDORFERI; DISEASE; NEUROBORRELIOSIS; ANTIBODIES		MAX VON PETTENKOFER INST HYG & MED MICROBIOL, D-80366 MUNICH, GERMANY	University of Munich	PFISTER, HW (corresponding author), UNIV MUNICH, NEUROL KLIN GROSSHADERN, MARCHIONINISTR 15, D-81377 MUNICH, GERMANY.							ACKERMANN R, 1985, DEUT MED WOCHENSCHR, V110, P1039, DOI 10.1055/s-2008-1068956; ANDERSON CE, 1991, ABA J, V77, P23; Asbrink E., 1993, Aspects of Lyme borreliosis., P193; BARANTON G, 1992, INT J SYST BACTERIOL, V42, P378, DOI 10.1099/00207713-42-3-378; BARBOUR AG, 1986, MICROBIOL REV, V50, P381, DOI 10.1128/MMBR.50.4.381-400.1986; BARBOUR AG, 1986, ZBL BAKT-INT J MED M, V263, P83; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; BURGDORFER W, 1991, SCAND J INFECT DIS, P35; COMSTOCK LE, 1989, INFECT IMMUN, V57, P1626, DOI 10.1128/IAI.57.5.1626-1628.1989; CRAFT JE, 1984, J INFECT DIS, V149, P789, DOI 10.1093/infdis/149.5.789; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; FAHRER H, 1988, SCHWEIZ MED WSCHR, V118, P65; GARCIAMONCO JC, 1990, J INFECT DIS, V161, P1187, DOI 10.1093/infdis/161.6.1187; GOLIGHTLY MG, 1993, AM J CLIN PATHOL, V99, P168, DOI 10.1093/ajcp/99.2.168; GRODZICKI RL, 1988, J INFECT DIS, V157, P790, DOI 10.1093/infdis/157.4.790; HABICHT GS, 1991, J INFECT DIS, V164, P568, DOI 10.1093/infdis/164.3.568; HANSEN K, 1988, J CLIN MICROBIOL, V26, P338, DOI 10.1128/JCM.26.2.338-346.1988; Hayes S. F., 1993, Aspects of Lyme borreliosis., P29; Herzer P., 1993, Aspects of Lyme borreliosis., P168; KLEMPNER MS, 1993, J INFECT DIS, V167, P1074, DOI 10.1093/infdis/167.5.1074; KRISTOFERITSCH W, 1988, ANN NY ACAD SCI, V539, P35, DOI 10.1111/j.1749-6632.1988.tb31836.x; MARTIN R, 1988, ANN NEUROL, V24, P509, DOI 10.1002/ana.410240406; MUNCHHOFF P, 1986, ZBL BAKT HYG A, V263, P412; PAUL H, 1989, ZBL BAKT P, V18, P44; PFISTER HW, 1989, NEUROLOGY, V39, P1118, DOI 10.1212/WNL.39.8.1118; PIESMAN J, 1993, J INFECT DIS, V167, P1082, DOI 10.1093/infdis/167.5.1082; PREACMURSIC V, 1992, INFECTION, V20, P342, DOI 10.1007/BF01710681; SCHAIBLE UE, 1990, P NATL ACAD SCI USA, V87, P3768, DOI 10.1073/pnas.87.10.3768; SCHUTZER SE, 1990, LANCET, V335, P312, DOI 10.1016/0140-6736(90)90606-6; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1991, SCAND J INFECT DIS, P51; Weber K., 1993, Aspects of Lyme borreliosis., P93; WILSKE B, 1993, INFECT IMMUN, V61, P2182, DOI 10.1128/IAI.61.5.2182-2191.1993; WILSKE B, 1987, DEUT MED WOCHENSCHR, V112, P1730, DOI 10.1055/s-2008-1068320; WILSKE B, 1993, MED MICROBIOL IMMUN, V182, P255, DOI 10.1007/BF00579624; WILSKE B, 1993, J CLIN MICROBIOL, V31, P340, DOI 10.1128/JCM.31.2.340-350.1993; Wilske B., 1993, Aspects of Lyme borreliosis., P267	37	73	78	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 23	1994	343	8904					1013	1016		10.1016/S0140-6736(94)90130-9	http://dx.doi.org/10.1016/S0140-6736(94)90130-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909052				2022-12-28	WOS:A1994NG68200013
J	LIENS, D; DELMAS, PD; MEUNIER, PJ				LIENS, D; DELMAS, PD; MEUNIER, PJ			LONG-TERM EFFECTS OF INTRAVENOUS PAMIDRONATE IN FIBROUS DYSPLASIA OF BONE	LANCET			English	Note								Nine patients with symptomatic and severe fibrous dysplasia were treated with intravenous pamidronate (60 mg per day over 3 days every sixth month), and were followed up for 18-48 months. The major effect was decreased bone pain (complete remission in 12 of 14 sites). Radiological changes were seen in four patients, with thickening of cortices, refilling of osteolytic lesions, or both. The initial increased bone remodelling was reduced, as shown by decrease of raised serum alkaline phosphatase and urinary hydroxyproline. The treatment was well tolerated, but a 13-year-old patient showed widening of knee growth-plates which is consistent with a transient mineralisation defect.	HOP EDOUARD HERRIOT,INSERM,U403,PAVILLON F,F-69437 LYON,FRANCE	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm)								ADAMSON BB, 1993, LANCET, V342, P1459, DOI 10.1016/0140-6736(93)92935-M; BELL NH, 1970, J CLIN ENDOCR METAB, V31, P283, DOI 10.1210/jcem-31-3-283; COLE DEC, 1983, AM J MED GENET, V14, P725, DOI 10.1002/ajmg.1320140414; Fleisch H, 1989, Recent Results Cancer Res, V116, P1; HJELMSTEDT A, 1979, ACTA ORTHOP SCAND, V50, P251, DOI 10.3109/17453677908989764; JIANG Y, 1993, CALCIF TISSUE INT S2, V52, pS44; LONG A, 1988, IRISH J MED SCI, V157, P229, DOI 10.1007/BF02949307; MORII H, 1971, ENDOCRINOL JAPON, V18, P81; YAMAMOTO K, 1983, ENDOCRINOL JAPON, V30, P651	9	156	160	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					953	954		10.1016/S0140-6736(94)90069-8	http://dx.doi.org/10.1016/S0140-6736(94)90069-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909013				2022-12-28	WOS:A1994NF70000013
J	MCNAMEE, D				MCNAMEE, D			WORKING TO SURVIVE	LANCET			English	Editorial Material																		ARRIGHI HM, 1994, EPIDEMIOLOGY, V5, P189, DOI 10.1097/00001648-199403000-00009	1	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					930	930		10.1016/S0140-6736(94)90060-4	http://dx.doi.org/10.1016/S0140-6736(94)90060-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909005				2022-12-28	WOS:A1994NF70000004
J	MCNULTY, A; KALDOR, JM; MCDONALD, AM; BAUMGART, K; COOPER, DA				MCNULTY, A; KALDOR, JM; MCDONALD, AM; BAUMGART, K; COOPER, DA			ACQUIRED IMMUNODEFICIENCY WITHOUT EVIDENCE OF HIV-INFECTION - NATIONAL RETROSPECTIVE SURVEY	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEW S WALES,NATL CTR HIV EPIDEMIOL & CLIN RES,SYDNEY,NSW,AUSTRALIA; UNIV SYDNEY,CENTENARY INST CANC MED & CELL BIOL,SYDNEY,NSW 2006,AUSTRALIA; TAYLOR SQ PRIVATE CLIN,DARLINGHURST,NSW,AUSTRALIA	University of New South Wales Sydney; Kirby Institute; University of Sydney; Centenary Institute			Kaldor, John M/D-4545-2011					GATENBY PA, 1989, LANCET, V1, P1027, DOI 10.1016/S0140-6736(89)92677-9; KALDOR J, 1993, MED J AUSTRALIA, V158, P10, DOI 10.5694/j.1326-5377.1993.tb121640.x; LAURENCE J, 1993, ANN INTERN MED, V119, P55, DOI 10.7326/0003-4819-119-1-199307010-00010; MULLER J, 1990, MYCOSES IN AIDS PATIENTS, P123; 1992, MMWR, V41, P541	5	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 26	1994	308	6932					825	826		10.1136/bmj.308.6932.825	http://dx.doi.org/10.1136/bmj.308.6932.825			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND243	7909464	Green Published			2022-12-28	WOS:A1994ND24300024
J	BENDELAC, A; KILLEEN, N; LITTMAN, DR; SCHWARTZ, RH				BENDELAC, A; KILLEEN, N; LITTMAN, DR; SCHWARTZ, RH			A SUBSET OF CD4(+) THYMOCYTES SELECTED BY MHC CLASS-I MOLECULES	SCIENCE			English	Article							CD8+ T-CELLS; CYTOPLASMIC TAIL; BINDING-SITE; IMMATURE THYMOCYTES; THYMIC SELECTION; ALPHA-3 DOMAIN; DEFICIENT MICE; GENE FAMILY; LINEAGE; CD4+	To complete their maturation, most immature thymocytes depend on the simultaneous engagement of their antigen receptor [alpha beta T cell receptor (TCR)] and their CD4 or CD8 coreceptors with major histocompatibility complex class II or I ligands, respectively. However, a normal subset of mature alpha beta TCR(+) thymocytes did not follow these rules. These thymocytes expressed NK1.1 and a restricted set of alpha beta TCRs that are intrinsically class I-reactive because their positive selection was class I-dependent but CD8-independent. These cells were CD4(+) and CD4(-)8(-) but never CD8(+), because the presence of CD8 caused negative selection. Thus, neither CD4 nor CD8 contributes signals that direct their maturation into the CD4(+) and CD4(-)8(-) lineages.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	BENDELAC, A (corresponding author), NIAID,CELLULAR & MOLEC IMMUNOL LAB,BETHESDA,MD 20892, USA.							ARASE H, 1992, P NATL ACAD SCI USA, V89, P6506, DOI 10.1073/pnas.89.14.6506; AUPHAN N, 1992, INT IMMUNOL, V4, P1419, DOI 10.1093/intimm/4.12.1419; BENDELAC A, 1991, NATURE, V353, P68, DOI 10.1038/353068a0; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; Bendelac A, 1992, Semin Immunol, V4, P187; BENDELAC A, UNPUB; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BIX M, 1993, J EXP MED, V178, P901, DOI 10.1084/jem.178.3.901; BIX M, 1992, NATURE, V359, P330, DOI 10.1038/359330a0; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; BUDD RC, 1987, J EXP MED, V166, P577, DOI 10.1084/jem.166.2.577; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CHAN IT, 1993, SCIENCE, V261, P1581, DOI 10.1126/science.8372352; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; FISCHER M, 1991, J IMMUNOL, V146, P3452; FOWLKES BJ, 1987, NATURE, V329, P251, DOI 10.1038/329251a0; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; HAYAKAWA K, 1992, J EXP MED, V176, P269, DOI 10.1084/jem.176.1.269; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KATIV I, 1993, J EXP MED, V177, P1429; KILLEEN N, 1993, NATURE, V364, P729, DOI 10.1038/364729a0; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; KRUISBEEK AM, 1985, J EXP MED, V161, P1029, DOI 10.1084/jem.161.5.1029; LANTZ O, UNPUB; LEVITSKY HI, 1991, J IMMUNOL, V146, P1113; LOCKSLEY RM, 1993, SCIENCE, V261, P1448, DOI 10.1126/science.8367726; MARUSICGALESIC S, 1988, NATURE, V333, P180, DOI 10.1038/333180a0; MATZINGER P, 1993, IMMUNOL REV, V135, P81, DOI 10.1111/j.1600-065X.1993.tb00645.x; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; MOZES E, 1993, SCIENCE, V261, P91, DOI 10.1126/science.8316860; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; RAMSDELL F, 1989, J IMMUNOL, V143, P1467; RAPOPORT MJ, 1993, J EXP MED, V178, P87, DOI 10.1084/jem.178.1.87; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SAWADA S, UNPUB; SEONG RH, 1992, NATURE, V356, P718, DOI 10.1038/356718a0; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SYKES M, 1990, J IMMUNOL, V145, P3209; TAKAHAMA Y, 1992, SCIENCE, V258, P1456, DOI 10.1126/science.1439838; TAKAHAMA Y, 1991, J IMMUNOL, V147, P2883; TAKEDA K, 1993, J EXP MED, V177, P155, DOI 10.1084/jem.177.1.155; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VANMEERWIJK JPM, 1993, SCIENCE, V261, P911, DOI 10.1126/science.8102208; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; VONBOEHMER H, 1991, J EXP MED, V176, P699; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZUNIGAPFLUCKER JC, 1989, J EXP MED, V169, P2085, DOI 10.1084/jem.169.6.2085	56	461	461	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 25	1994	263	5154					1774	1778		10.1126/science.7907820	http://dx.doi.org/10.1126/science.7907820			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NC040	7907820				2022-12-28	WOS:A1994NC04000039
J	WILLIAMS, G				WILLIAMS, G			IDDM - LONG HONEYMOON, SWEET ENDING	LANCET			English	Editorial Material							PROTEIN; MOUSE; MICE				WILLIAMS, G (corresponding author), UNIV LIVERPOOL, DEPT MED, DIABET & ENDOCRINOL RES GRP, LIVERPOOL, ENGLAND.							[Anonymous], 1988, DIABETES, V37, P1574, DOI 10.2337/diabetes.37.11.15742903105; BINGLEY PJ, 1993, DIABETES, V42, P213, DOI 10.2337/diabetes.42.2.213; BRUDZYNSKI K, 1992, DIABETOLOGIA, V35, P316, DOI 10.1007/BF00401198; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; ELIAS D, 1991, P NATL ACAD SCI USA, V88, P3088, DOI 10.1073/pnas.88.8.3088; GUYTINGCO R, 1991, DIABETES, V40, pA152; KOIVISTO VA, 1984, DIABETOLOGIA, V27, P193; MCINERNEY MF, 1991, DIABETES, V40, P715, DOI 10.2337/diabetes.40.6.715; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; Tochino Y, 1987, Crit Rev Immunol, V8, P49; YKIJARVINEN H, 1992, ENDOCR REV, V13, P415, DOI 10.1210/er.13.3.415	11	2	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 19	1994	343	8899					684	685		10.1016/S0140-6736(94)91574-1	http://dx.doi.org/10.1016/S0140-6736(94)91574-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907674				2022-12-28	WOS:A1994NB80900003
J	GERLACH, H; ROSSAINT, R; PAPPERT, D; KNORR, M; FALKE, KJ				GERLACH, H; ROSSAINT, R; PAPPERT, D; KNORR, M; FALKE, KJ			AUTOINHALATION OF NITRIC-OXIDE AFTER ENDOGENOUS SYNTHESIS IN NASOPHARYNX	LANCET			English	Note								Exogenous nitric oxide (NO) reduces pulmonary vascular resistance after low-dose inhalation in patients. To estimate endogenous NO synthesis in the upper respiratory tract, we measured inhaled and exhaled NO in volunteers and patients during spontaneous or controlled ventilation, respectively. 20.3 nmol per min NO was synthesised in the nasopharnyx of non-smoking volunteers, leading to autoinhalation of 0.07-0.13 NO parts per million during inspiration; smokers had reduced NO synthesis. In volunteers, 50-70% of the NO was resorbed by the lungs; ventilated patients were deprived of NO autoinhalation. Bacteria in the nose may take part in endogenous NO synthesis.			GERLACH, H (corresponding author), FREE UNIV BERLIN,CLIN RUDOLF VIRCHOW,ANAESTHESIOL & INTENS CARE MED CLIN,D-13353 BERLIN,GERMANY.		Knorr, Michael/Q-3109-2019					CANNONS AC, 1993, J BIOL CHEM, V268, P3268; GERLACH H, 1993, INTENS CARE MED, V19, P443, DOI 10.1007/BF01711084; GERLACH H, 1993, EUR J CLIN INVEST, V23, P499, DOI 10.1111/j.1365-2362.1993.tb00797.x; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; SUTTORP N, 1993, J EXP MED, V178, P337, DOI 10.1084/jem.178.1.337	7	221	225	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					518	519		10.1016/S0140-6736(94)91465-6	http://dx.doi.org/10.1016/S0140-6736(94)91465-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906764				2022-12-28	WOS:A1994MX88800013
J	JAKEMAN, P; SMITH, WCS				JAKEMAN, P; SMITH, WCS			THALIDOMIDE IN LEPROSY REACTION	LANCET			English	Editorial Material											JAKEMAN, P (corresponding author), LEPROSY MISSION EVALUAT UNIT,SINGAPORE,SINGAPORE.							GHIGLIOTTI G, 1993, J AM ACAD DERMATOL, V28, P271, DOI 10.1016/S0190-9622(08)81153-X; GUTIERREZRODRIGUEZ O, 1989, J RHEUMATOL, V16, P158; HASTINGS R C, 1980, Ethiopian Medical Journal, V18, P65; Jadhav V H, 1990, Indian J Lepr, V62, P316; MAKONKAWKEYOON S, 1993, P NATL ACAD SCI USA, V90, P5974, DOI 10.1073/pnas.90.13.5974; REA TH, 1978, ARCH DERMATOL, V114, P1023, DOI 10.1001/archderm.114.7.1023; SAGHER F, 1969, LEPROSY REV, V40, P126; Sheskin J, 1975, Med Cutan Ibero Lat Am, V3, P81; SHESKIN J, 1968, ISRAEL J MED SCI, V4, P901; TAMURA F, 1990, TRANSPLANTATION, V49, P20, DOI 10.1097/00007890-199001000-00005; 1993, THALIDOMIDE DRUG CAM; 1988, WHO TECH REP SER, V768	12	28	28	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 19	1994	343	8895					432	433		10.1016/S0140-6736(94)92686-7	http://dx.doi.org/10.1016/S0140-6736(94)92686-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905950				2022-12-28	WOS:A1994MW69000004
J	BARR, CS; NAAS, A; FREEMAN, M; LANG, CC; STRUTHERS, AD				BARR, CS; NAAS, A; FREEMAN, M; LANG, CC; STRUTHERS, AD			QT DISPERSION AND SUDDEN UNEXPECTED DEATH IN CHRONIC HEART-FAILURE	LANCET			English	Article							PLASMA NOREPINEPHRINE; INTERVAL PROLONGATION; PROGNOSTIC IMPORTANCE; MORTALITY; PREDICTORS; RISK	Death in chronic heart failure (CHF) can be from progression of disease or sudden and unexpected. We have attempted to identify factors that predict sudden death in CHF. We followed up 44 patients with CHF for 12-50 (mean 36) months. 4 patients died of non-cardiovascular causes and were excluded from analysis. There were 7 sudden deaths (symptoms for less than 1 h in a previously stable patient) and 12 from progressive CHF. Patients who died of progressive CHF had lower left-ventricular ejection fractions and higher concentrations of atrial natriuretic factor than the 21 survivors, but there were no differences in these variables between survivors and those who died suddenly. However, the sudden death group had significantly (p<0.05) greater inter-lead variability in the QT interval on the electrocardiogram (QT dispersion; 98.6 [95% CI 79.1-118] ms1/2) than survivors (53.1 [41.9-64.3] ms1/2) or the group who died from progressive CHF (66.7 [51.8-81.6] ms%). QT dispersion is a marker of myocardial electrical instability. The association of increased QT dispersion with sudden death suggests that patients at high risk of such death could be identified by means of this simple, reproducible test. This group might benefit from more intensive treatment.			BARR, CS (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT CLIN PHARMACOL,DUNDEE DD1 9SY,SCOTLAND.			Lang, Chim/0000-0002-4530-3078; Struthers, Allan/0000-0002-2926-2528				ALGRA A, 1991, CIRCULATION, V83, P1888, DOI 10.1161/01.CIR.83.6.1888; BUJA G, 1993, AM J CARDIOL, V72, P973, DOI 10.1016/0002-9149(93)91118-2; CLELAND JGF, 1987, BRIT HEART J, V58, P572; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; COHN JN, 1988, AM J CARDIOL, V62, pA25, DOI 10.1016/S0002-9149(88)80081-X; DAY CP, 1990, BRIT HEART J, V63, P342; DAY CP, 1993, LANCET, V341, P1423; FRANCIS GS, 1990, CARDIOSCIENCE, V1, P29; GOTTLIEB SS, 1990, J AM COLL CARDIOL, V16, P827, DOI 10.1016/S0735-1097(10)80329-8; GOTTLIEB SS, 1989, J AM COLL CARDIOL, V13, P1534, DOI 10.1016/0735-1097(89)90344-6; GRADMAN A, 1989, J AM COLL CARDIOL, V14, P564, DOI 10.1016/0735-1097(89)90093-4; Higham P. D., 1993, European Heart Journal, V14, P86; HINKLE LE, 1982, CIRCULATION, V65, P457, DOI 10.1161/01.CIR.65.3.457; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; MERX W, 1977, AM HEART J, V94, P603, DOI 10.1016/S0002-8703(77)80130-0; PACKER M, 1987, AM J MED, V82, P4, DOI 10.1016/0002-9343(87)90126-4; Potratz J., 1993, European Heart Journal, V14, P254; PUDDU PE, 1986, J ELECTROCARDIOL, V19, P203, DOI 10.1016/S0022-0736(86)80030-9; PUDDU PE, 1982, J ELECTROCARDIOL, V15, P15, DOI 10.1016/S0022-0736(82)80040-X; SCHOUTEN EG, 1991, CIRCULATION, V84, P1516, DOI 10.1161/01.CIR.84.4.1516; STEVENSON WG, 1988, AM HEART J, V116, P1447, DOI 10.1016/0002-8703(88)90727-2	21	641	646	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 5	1994	343	8893					327	329		10.1016/S0140-6736(94)91164-9	http://dx.doi.org/10.1016/S0140-6736(94)91164-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905146				2022-12-28	WOS:A1994MU98500010
J	MOORE, MJ; CLIPP, EC				MOORE, MJ; CLIPP, EC			ALZHEIMERS-DISEASE AND CAREGIVER TIME	LANCET			English	Letter									DUKE UNIV,VET ADM MED CTR,DEPT MED,CTR GERIAT RES EDUC & CLIN,DURHAM,NC 27706	Duke University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	MOORE, MJ (corresponding author), DUKE UNIV,FUQUA SCH BUSINESS,DURHAM,NC 27708, USA.								0	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 22	1994	343	8891					239	240		10.1016/S0140-6736(94)91027-8	http://dx.doi.org/10.1016/S0140-6736(94)91027-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MT332	7904698				2022-12-28	WOS:A1994MT33200051
J	CHAZOUILLERES, O; MAMISH, D; KIM, M; CAREY, K; FERRELL, L; ROBERTS, JP; ASCHER, NL; WRIGHT, TL				CHAZOUILLERES, O; MAMISH, D; KIM, M; CAREY, K; FERRELL, L; ROBERTS, JP; ASCHER, NL; WRIGHT, TL			OCCULT HEPATITIS-B VIRUS AS SOURCE OF INFECTION IN LIVER-TRANSPLANT RECIPIENTS	LANCET			English	Article							CLINICAL IMPLICATIONS; VIRAL-INFECTION; NON-A; DNA; SEQUENCES; DISEASE; SERUM	Hepatitis B virus (HBV) infection almost always recurs after liver transplantation in patients who were surface antigen (HBsAg) positive before surgery but apparent de novo acquisition of infection in a transplant setting has not previously been reported. We have used sensitive techniques to elucidate the origin of such infections in patients in a Californian transplantation programme. We tested post-transplant serum from 207 patients who had been HBsAg negative and found 20 to be HBsAg positive. The origin of infection was identified in 7 patients, being occult pre-transplant infection in 5 and occult infection in the donor in 2. No pre-transplant patient nor donor with demonstrable HBV DNA had serological markers of hepatitis B. Post-transplant HBV DNA was present in serum from 19 patients. Analysis of the variable pre-S region of HBV demonstrated 100% sequence homology between recipient liver and post-transplant serum (2 patients) and between donor serum and recipient post-transplant serum (2). There was only 84% homology between the 2 different patients infected with subtype adw. 19 patients are alive, 9 without histological evidence of hepatitis (mean follow-up 33 months), and survival was significantly greater than that of a group with recurrent HBV infection. Apparent acquisition of HBV infection with liver transplantation is not rare, and may be due to occult pre-transplant infection or occult infection in the donor. The post-transplant outcome of this infection tends to be benign but our findings do underscore the clinical relevance of HBV infection in the absence of serological markers.	DEPT VET AFFAIRS MED CTR,DEPT MED,4150 CLEMENT ST,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIAID NIH HHS [R29AI32242-01] Funding Source: Medline; NIDDK NIH HHS [P30DK26743] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLUM HE, 1991, HEPATOLOGY, V14, P56, DOI 10.1002/hep.1840140110; BRECHOT C, 1991, J HEPATOL, V13, pS49, DOI 10.1016/0168-8278(91)90023-5; BROWN J L, 1992, Hepatology, V15, P144, DOI 10.1002/hep.1840150124; CADRANEL JF, 1991, TRANSPLANTATION, V52, P645, DOI 10.1097/00007890-199110000-00013; DEGOS F, 1988, GASTROENTEROLOGY, V94, P151, DOI 10.1016/0016-5085(88)90623-3; DEMETRIS AJ, 1990, AM J PATHOL, V137, P667; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; HOOFNAGLE JH, 1978, NEW ENGL J MED, V298, P1379, DOI 10.1056/NEJM197806222982502; LAVINE JE, 1991, GASTROENTEROLOGY, V100, P263, DOI 10.1016/0016-5085(91)90611-N; LIANG TJ, 1991, HEPATOLOGY, V13, P1044, DOI 10.1002/hep.1840130607; LUGASSY C, 1987, J INFECT DIS, V155, P64, DOI 10.1093/infdis/155.1.64; MALTER JM, 1991, HEPATOLOGY, V13, P188, DOI 10.1002/hep.1840130127; OGRADY JG, 1992, J HEPATOL, V14, P104, DOI 10.1016/0168-8278(92)90138-F; ONO Y, 1983, NUCLEIC ACIDS RES, V11, P1747, DOI 10.1093/nar/11.6.1747; PETERS M, 1991, HEPATOLOGY, V13, P977, DOI 10.1016/0270-9139(91)90273-X; Sambrook J, 1989, MOL CLONING LABORATO; THIERS V, 1988, LANCET, V2, P1273; WRIGHT TL, 1992, LANCET, V339, P952, DOI 10.1016/0140-6736(92)91530-L; WRIGHT TL, 1992, GASTROENTEROLOGY, V103, P317, DOI 10.1016/0016-5085(92)91129-R; YOFFE B, 1990, HEPATOLOGY, V12, P187, DOI 10.1002/hep.1840120202; ZELDIS JB, 1989, J CLIN INVEST, V84, P1503, DOI 10.1172/JCI114326	21	266	275	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 15	1994	343	8890					142	146		10.1016/S0140-6736(94)90934-2	http://dx.doi.org/10.1016/S0140-6736(94)90934-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7904004				2022-12-28	WOS:A1994MQ86900010
J	YKIJARVINEN, H				YKIJARVINEN, H			PATHOGENESIS OF NON-INSULIN-DEPENDENT DIABETES-MELLITUS	LANCET			English	Article							IMPAIRED GLUCOSE-TOLERANCE; FOLLOW-UP; OBESITY				YKIJARVINEN, H (corresponding author), UNIV HELSINKI, DEPT MED 3, HAARTMANINKATU 4, SF-00290 HELSINKI 29, FINLAND.							BELL GI, 1993, TRENDS ENDOCRIN MET, V4, P86, DOI 10.1016/1043-2760(93)90084-R; Bennett PH, 1990, ELLENBERG RIFKINS DI, P363; BJORNTORP P, 1988, DIABETES METAB REV, V4, P615, DOI 10.1002/dmr.5610040607; BOWDEN DW, 1992, DIABETES, V41, P88, DOI 10.2337/diabetes.41.1.88; Daweke H, 1968, Diabetologia, V4, P349, DOI 10.1007/BF01211771; ERIKSSON KF, 1991, DIABETOLOGIA, V34, P891, DOI 10.1007/BF00400196; GERBITZ KD, 1992, DIABETOLOGIA, V35, P1181, DOI 10.1007/BF00401375; HAFFNER SM, 1990, DIABETES, V39, P283, DOI 10.2337/diabetes.39.3.283; HAFFNER SM, 1988, NEW ENGL J MED, V319, P1297, DOI 10.1056/NEJM198811173192001; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; HARING HU, 1993, DIABETOLOGIA, V36, P176, DOI 10.1007/BF00399946; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; LAAKSO M, 1992, DIABETES, V41, P1076, DOI 10.2337/diabetes.41.9.1076; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; MITRAKOU A, 1992, NEW ENGL J MED, V326, P22, DOI 10.1056/NEJM199201023260104; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; SKARFORS ET, 1991, BRIT MED J, V303, P755, DOI 10.1136/bmj.303.6805.755; SONKSEN PH, 1973, DIABETOLOGIA, V9, P426, DOI 10.1007/BF01239440; TUOMI T, 1993, DIABETES, V42, P359, DOI 10.2337/diabetes.42.2.359; WESTERMARK P, 1992, DIABETOLOGIA, V35, P297, DOI 10.1007/BF00401195; YKIJARVINEN H, 1992, ENDOCR REV, V13, P415, DOI 10.1210/er.13.3.415	22	162	166	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 8	1994	343	8889					91	95		10.1016/S0140-6736(94)90821-4	http://dx.doi.org/10.1016/S0140-6736(94)90821-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903784				2022-12-28	WOS:A1994MQ09200016
J	WANG, SX; HAZELRIGG, T				WANG, SX; HAZELRIGG, T			IMPLICATIONS FOR BCD MESSENGER-RNA LOCALIZATION FROM SPATIAL-DISTRIBUTION OF EXU PROTEIN IN DROSOPHILA OOGENESIS	NATURE			English	Article							MESSENGER-RNA LOCALIZATION; BICOID RNA; GENE; MICROTUBULES; DIFFERENTIATION; MORPHOGEN; TRANSPORT; GRADIENT; PATTERN; EMBRYOS	SUBCELLULAR RNA localization in different cell types leads to asymmetric distribution of proteins in these cells(1,2). The localization of bicoid (bcd) messenger RNA to the anterior pole of the developing Drosophila oocyte gives rise in embryogenesis to a steep concentration gradient of the bcd protein(3-6), a transcription factor that activates expression of zygotic genes needed for anterior development(7-9). The exuperantia (exu) gene is necessary for this localization of bcd mRNA(3,4). Here we express a chimaeric gene encoding a fusion between the Acquorea victoria green fluorescent protein (GPP)(10) and the exu protein (Exu) in female germ cells, and find that the fusion protein fluoresces strongly in both live and fixed cells during Drosophila oogenesis. The fusion protein rescues an exu null allele, restoring full fertility to females, and is expressed and localized in a temporal and spatial pattern similar to native Exu. The high sensitivity of the GFP tag provides important ne,v details on the subcellular localization of Exu. The fusion protein is found in particles concentrated at ring canals, where transport occurs between nurse cells and the oocyte. Drugs such as colchicine and taxol that affect microtubule stability alter localization of the particles. We propose that the particles are ribonucleoprotein complexes or vesicles which transport bcd mRNA along microtubules and target it to the anterior oocyte cortex.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University								AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; GUTZEIT H, 1986, ROUX ARCH DEV BIOL, V195, P173, DOI 10.1007/BF02439435; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; MACDONALD PM, 1991, GENE DEV, V5, P2455, DOI 10.1101/gad.5.12b.2455; MARCEY D, 1991, EMBO J, V10, P4259, DOI 10.1002/j.1460-2075.1991.tb05004.x; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRODER C, 1988, EMBO J, V7, P2881, DOI 10.1002/j.1460-2075.1988.tb03145.x; SCHUEPBACH T, 1986, Wilhelm Roux's Archives of Developmental Biology, V195, P302; SINGER R H, 1992, Current Opinion in Cell Biology, V4, P15, DOI 10.1016/0955-0674(92)90053-F; Spradling Allan C., 1993, P1; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; Thummel CS, 1992, DROS INF SERV, V71, P150; WAM RM, 1986, EXP CELL RES, V157, P355; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269	25	424	474	3	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 2	1994	369	6479					400	403		10.1038/369400a0	http://dx.doi.org/10.1038/369400a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP174	7910952				2022-12-28	WOS:A1994NP17400057
J	WHITMORE, WF				WHITMORE, WF			LOCALIZED PROSTATIC-CANCER - MANAGEMENT AND DETECTION ISSUES	LANCET			English	Article							NATURAL-HISTORY; ADENOCARCINOMA; CARCINOMA; ANTIGEN				WHITMORE, WF (corresponding author), MEM SLOAN KETTERING CANC CTR, DEPT SURG, UROL SERV, 1275 YORK AVE, NEW YORK, NY 10021 USA.							ADAMI HO, 1994, LANCET, V343, P958, DOI 10.1016/S0140-6736(94)90071-X; ADOLFSSON J, 1993, CANCER-AM CANCER SOC, V72, P310, DOI 10.1002/1097-0142(19930715)72:2<310::AID-CNCR2820720203>3.0.CO;2-T; BENSON MC, 1992, J UROLOGY, V147, P817, DOI 10.1016/S0022-5347(17)37394-9; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; CARTER HB, 1990, J UROLOGY, V143, P742, DOI 10.1016/S0022-5347(17)40078-4; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; CATALONA WJ, 1993, UROLOGY, V42, P113, DOI 10.1016/0090-4295(93)90632-K; CHENG WS, 1993, UROLOGY, V42, P283, DOI 10.1016/0090-4295(93)90617-J; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; CHODAK GW, 1993, UROLOGY, V42, P116, DOI 10.1016/0090-4295(93)90633-L; COWEN ME, 1994, J CLIN EPIDEMIOL, V47, P3, DOI 10.1016/0895-4356(94)90029-9; EPSTEIN JI, 1994, JAMA-J AM MED ASSOC, V271, P368, DOI 10.1001/jama.271.5.368; EPSTEIN JI, 1993, J UROLOGY, V150, P135, DOI 10.1016/S0022-5347(17)35415-0; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; FUKS Z, 1991, INT J RADIAT ONCOL, V21, P537, DOI 10.1016/0360-3016(91)90668-T; Gleason D F, 1988, NCI Monogr, P15; HINMAN F, 1991, J UROLOGY, V145, P126, DOI 10.1016/S0022-5347(17)38267-8; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; LUYAO GL, 1994, LANCET, V343, P251, DOI 10.1016/S0140-6736(94)91109-6; Madsen P O, 1988, Scand J Urol Nephrol Suppl, V110, P95; MCNEAL JE, 1990, AM J SURG PATHOL, V14, P240, DOI 10.1097/00000478-199003000-00005; MCNEAL JE, 1986, LANCET, V1, P60; MCNEAL JE, 1988, J UROLOGY, V139, P61, DOI 10.1016/S0022-5347(17)42293-2; OESTERLING JE, 1993, UROL CLIN N AM, V20, P687; OESTERLING JE, 1993, JAMA-J AM MED ASSOC, V270, P860, DOI 10.1001/jama.270.7.860; PARK WW, 1951, SURG GYNECOL OBSTET, V93, P129; PAULSON DF, 1982, J UROLOGY, V128, P502, DOI 10.1016/S0022-5347(17)53016-5; RUTQVIST LE, 1985, CANCER-AM CANCER SOC, V55, P658, DOI 10.1002/1097-0142(19850201)55:3<658::AID-CNCR2820550331>3.0.CO;2-P; SCARDINO PT, 1992, HUM PATHOL, V23, P211, DOI 10.1016/0046-8177(92)90102-9; SCHELLHAMMER PF, 1993, J UROLOGY, V150, P1851, DOI 10.1016/S0022-5347(17)35913-X; SCHRODER FH, 1992, PROSTATE, P129; STAMEY TA, 1993, J UROLOGY, V149, P787, DOI 10.1016/S0022-5347(17)36208-0; STAMEY TA, 1993, CANCER, V71, P933, DOI 10.1002/1097-0142(19930201)71:3+<933::AID-CNCR2820711408>3.0.CO;2-L; Tribukait B., 1993, European Urology, V23, P64; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487; WHITMORE WF, 1993, JAMA-J AM MED ASSOC, V269, P2676, DOI 10.1001/jama.269.20.2676; WHITMORE WF, 1984, UROL CLIN N AM, V11, P205; WHITMORE WF, 1988, NATL CANCER I MONOGR, V7, P7; WHITTEMORE AS, 1991, J NATL CANCER I, V83, P1231, DOI 10.1093/jnci/83.17.1231; ZINCKE H, 1991, J UROLOGY, V146, P1053, DOI 10.1016/S0022-5347(17)37999-5; 1992, NCI MONOGRAPH	42	60	61	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 21	1994	343	8908					1263	1267		10.1016/S0140-6736(94)92156-3	http://dx.doi.org/10.1016/S0140-6736(94)92156-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910280				2022-12-28	WOS:A1994NM14400014
J	DALONZO, GE; NATHAN, RA; HENOCHOWICZ, S; MORRIS, RJ; RATNER, P; RENNARD, SI				DALONZO, GE; NATHAN, RA; HENOCHOWICZ, S; MORRIS, RJ; RATNER, P; RENNARD, SI			SALMETEROL XINAFOATE AS MAINTENANCE THERAPY COMPARED WITH ALBUTEROL IN PATIENTS WITH ASTHMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACTING BETA-2-ADRENOCEPTOR AGONIST; INHALED SALMETEROL; SALBUTAMOL; EXACERBATIONS; SYMPTOMS; CELLS	Objective.-To compare the efficacy and safety of inhaled salmeterol xinafoate, a long-acting beta(2)-adrenoceptor agonist, with that of albuterol, a short-acting inhaled beta(2)-agonist, in the treatment of asthma. Design.-Randomized, double-blind, placebo-controlled, parallel-group study. Setting.-Eleven outpatient clinical centers. Subjects.-A total of 322 male and female patients at least 12 years of age with chronic symptomatic asthma requiring daily therapy. Intervention.-Patients were treated with salmeterol xinafoate (42 mu g inhaled twice daily), albuterol (180 mu g inhaled four times daily), or placebo (four times a day) for 12 weeks; patients in all three groups could use inhaled albuterol as backup medication for breakthrough symptoms. Main Outcome Measures.-Serial 12-hour forced expiratory flow in 1 second (FEV(1)), peak expiratory flow (PEF), asthma symptoms, nocturnal awakenings due to asthma, episodes of asthma exacerbations, and electrocardiography. Results.-The mean area under the curve for FEV(1) throughout each 12-hour period was consistently greater after a single dose of salmeterol than after two doses of albuterol administered 6 hours apart (P<.001), with the difference ranging from 3.1 to 4.3 L.h. Salmeterol produced an average increase in morning and evening PEF of 26 and 29 L/min, respectively, over pretreatment values compared with decreases of -13 and -3 L/min, respectively, in the albuterol group and -2 L/min both in the morning and evening in the placebo group (P<.001). Patients in the salmeterol group had significantly fewer days and nights with symptoms than did either the albuterol or placebo group (P<.001). Responses to salmeterol were similar at day 1 and at week 12. Adverse events in all treatment groups were equally infrequent, and no clinically significant change in cardiac rhythm was observed with salmeterol treatment. Conclusion.-Salmeterol inhaled twice daily is more effective than albuterol inhaled four times a day (or as needed) in patients with asthma requiring maintenance therapy. No deterioration of asthma control was observed with the use of salmeterol over a 3-month period.	UNIV TEXAS, HLTH SCI CTR, HOUSTON, TX USA; UNIV NEBRASKA, MED CTR, OMAHA, NE USA	University of Texas System; University of Texas Health Science Center Houston; University of Nebraska System; University of Nebraska Medical Center								AYRES JG, 1993, AM REV RESPIR DIS, V147, pA61; BALL DI, 1991, BRIT J PHARMACOL, V104, P665, DOI 10.1111/j.1476-5381.1991.tb12486.x; BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BRITTON MG, 1992, EUR RESPIR J, V5, P1062; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; CHURCH MK, 1987, BRIT J PHARMACOL, V90, P421, DOI 10.1111/j.1476-5381.1987.tb08972.x; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; FITZPATRICK MF, 1990, BRIT MED J, V301, P1365, DOI 10.1136/bmj.301.6765.1365; JACK D, 1991, BRIT J CLIN PHARMACO, V31, P501, DOI 10.1111/j.1365-2125.1991.tb05571.x; JENKINS MM, 1991, LANCET, V337, P913, DOI 10.1016/0140-6736(91)90242-H; KEMP JP, 1993, ANN ALLERGY, V70, P316; LOTVALL J, 1992, ALLERGY, V47, P477, DOI 10.1111/j.1398-9995.1992.tb00668.x; MACKOWIAK JI, 1993, AM REV RESPIR DIS, V147, pA60; NICKLAS RA, 1990, J ALLERGY CLIN IMMUN, V85, P959, DOI 10.1016/0091-6749(90)90084-H; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; Polgar G, 1971, PULMONARY FUNCTION T; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SHEPHERD GL, 1991, LANCET, V337, P1424, DOI 10.1016/0140-6736(91)93118-S; ULLMAN A, 1988, THORAX, V43, P674, DOI 10.1136/thx.43.9.674; ULLMAN A, 1990, AM REV RESPIR DIS, V142, P571, DOI 10.1164/ajrccm/142.3.571; van Elteren PH, 1960, B INT STAT I, V37, P351; WILKINSONJRW, 1992, BRIT MED J, V305, P931; 1987, AM REV RESPIR DIS, V136, P225; 1991, NIH913042 PUBL	24	152	153	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	1994	271	18					1412	1416		10.1001/jama.271.18.1412	http://dx.doi.org/10.1001/jama.271.18.1412			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ693	7909853				2022-12-28	WOS:A1994NJ69300028
J	SPRAY, DC				SPRAY, DC			CMTX1 - A GAP JUNCTION GENETIC-DISEASE	LANCET			English	Editorial Material							GROWTH; CELLS; INVIVO; CDNA		ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY	Yeshiva University; Albert Einstein College of Medicine	SPRAY, DC (corresponding author), ALBERT EINSTEIN COLL MED,DEPT NEUROSCI,BRONX,NY, USA.			Spray, David/0000-0001-8368-5073				BAI S, 1993, BIOCHIM BIOPHYS ACTA, V1216, P197, DOI 10.1016/0167-4781(93)90145-4; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; CHANSON M, 1993, J GEN PHYSIOL, V102, P925, DOI 10.1085/jgp.102.5.925; DERMIETZEL R, 1993, TRENDS NEUROSCI, V16, P185; EGHBALI B, 1991, P NATL ACAD SCI USA, V88, P10701, DOI 10.1073/pnas.88.23.10701; FAIRWEATHER N, 1994, HUM MOL GENET, V3, P29, DOI 10.1093/hmg/3.1.29; IONASESCU V, 1994, HUM MOL GENET, V3, P355, DOI 10.1093/hmg/3.2.355; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; MESNIL M, 1993, PROG CELL R, V3, P311; NAUS CCG, 1992, CANCER RES, V52, P4208; SAFFITZ JE, 1993, CIRCULATION, V87, P1742, DOI 10.1161/01.CIR.87.5.1742; SPRAY DC, 1992, BIOPHYS J, V62, P48, DOI 10.1016/S0006-3495(92)81774-5; SPRAY DC, 1994, ION CHANNELS CARDIOV, P185; SU Y, 1993, P NATL ACAD SCI USA, V90, P10856, DOI 10.1073/pnas.90.22.10856; SUTER U, 1993, TRENDS NEUROSCI, V16, P50, DOI 10.1016/0166-2236(93)90015-E; TETZLAFF W, 1982, J NEUROCYTOL, V11, P839, DOI 10.1007/BF01153522; Warner A., 1992, Seminars in Cell Biology, V3, P81	18	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1994	343	8906					1111	1112		10.1016/S0140-6736(94)90229-1	http://dx.doi.org/10.1016/S0140-6736(94)90229-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK730	7910226				2022-12-28	WOS:A1994NK73000003
J	MAYANS, MV; HALL, AJ; INSKIP, HM; LINDSAY, SW; CHOTARD, J; MENDY, M; WHITTLE, HC				MAYANS, MV; HALL, AJ; INSKIP, HM; LINDSAY, SW; CHOTARD, J; MENDY, M; WHITTLE, HC			DO BEDBUGS TRANSMIT HEPATITIS-B	LANCET			English	Article							ANTIGEN	An intervention study was done over two years in seven Gambian villages to determine the contribution of bedbugs to hepatitis B transmission. In addition, fortnightly questionnaires were completed for each child to assess other possible routes of transmission. The intervention, insecticide spraying of the child's dwelling, was highly effective in reducing exposure to bedbugs but there was no effect on hepatitis B infection. No other risk factor for transmission was identified despite a consistent village-to-village variation in the rate of childhood infection. The major mode of transmission of hepatitis B in childhood remains unknown.	LONDON SCH HYG & TROP MED, COMMUNICABLE DIS EPIDEMIOL UNIT, LONDON WC1E 7HT, ENGLAND; MRC LABS, BANJUL, GAMBIA; WHO, INT AGCY RES CANC, BANJUL, GAMBIA	University of London; London School of Hygiene & Tropical Medicine; MRC Laboratory Molecular Biology; World Health Organization; International Agency for Research on Cancer (IARC)			Mendy, Maimuna/ABD-5038-2021; Inskip, Hazel/L-5467-2018	Inskip, Hazel/0000-0001-8897-1749				Barin F, 1981, Prog Med Virol, V27, P148; FORTUIN M, 1993, LANCET, V341, P1129, DOI 10.1016/0140-6736(93)93137-P; JUPP PG, 1979, S AFR MED J, V56, P54; MAYANS MV, 1990, LANCET, V336, P1107, DOI 10.1016/0140-6736(90)92580-B; NEWKIRK MM, 1975, GASTROENTEROLOGY, V69, P982; OGSTON CW, 1979, J INFECT DIS, V140, P411, DOI 10.1093/infdis/140.3.411; WHITTLE H, 1990, J INFECT DIS, V161, P1112, DOI 10.1093/infdis/161.6.1112	7	27	27	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 26	1994	343	8900					761	763		10.1016/S0140-6736(94)91838-4	http://dx.doi.org/10.1016/S0140-6736(94)91838-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907732				2022-12-28	WOS:A1994NC35100010
J	LENDERKING, WR; GELBER, RD; COTTON, DJ; COLE, BF; GOLDHIRSCH, A; VOLBERDING, PA; TESTA, MA				LENDERKING, WR; GELBER, RD; COTTON, DJ; COLE, BF; GOLDHIRSCH, A; VOLBERDING, PA; TESTA, MA			EVALUATION OF THE QUALITY-OF-LIFE ASSOCIATED WITH ZIDOVUDINE TREATMENT IN ASYMPTOMATIC HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLACEBO-CONTROLLED TRIAL; ADJUSTED SURVIVAL ANALYSIS; AIDS-RELATED COMPLEX; OF-LIFE; HIV-INFECTION; BREAST-CANCER; DOUBLE-BLIND; THERAPY; AZT	Background. Zidovudine therapy is recommended for asymptomatic patients infected with the human immunodeficiency virus (HIV) who have fewer than 500 CD4+ cells per cubic millimeter. An analysis of the quality of life associated with therapy that integrated both the effects of adverse events and the benefits of delayed disease progression might influence this recommendation. Methods. We applied a survival analysis adjusted for the quality of life to data from a randomized trial conducted by the AIDS Clinical Trials Group, The trial compared treatment with 500 mg of zidovudine per day, 1500 mg of zidovudine per day, and placebo (Protocol 019) in 1338 asymptomatic HIV-infected patients. Results. The average time with neither a progression of disease nor an adverse event (symptom or laboratory finding) was 15.7, 15.6, and 14.8 months for patients receiving placebo, 500 mg of zidovudine, and 1500 mg of zidovudine, respectively. The incidence of severe symptoms was 13.8 percent in the placebo group, 15.2 percent in the 500-mg group, and 19.9 percent in the 1500-mg group (P = 0.038). After 18 months, the 500-mg group gained an average of 0.5 month without disease progression, as compared with the placebo group, but had severe adverse events an average of 0.6 month sooner. The 500-mg group had more quality-of-life-adjusted time than the placebo group only if the time lived after the progression of disease was considered by a patient to have less value than the time after the occurrence of a severe symptom. Conclusions. For asymptomatic patients treated with 500 mg of zidovudine, a reduction in the quality of life due to severe side effects of therapy approximately equals the increase in the quality of life associated with a delay in the progression of HIV disease.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; BETH ISRAEL HOSP,BOSTON,MA; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,SAN FRANCISCO,CA 94110	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center	LENDERKING, WR (corresponding author), HARVARD UNIV,SCH PUBL HLTH,CTR STAT DATA & ANAL,DEPT BIOSTAT AIDS CLIN TRIALS GRP,BOSTON,MA 02115, USA.		Testa, Marianna/L-9768-2019; Cole, Bernard/I-3775-2012		AHRQ HHS [R01 HS07767-01] Funding Source: Medline; PHS HHS [N0-A1-95030] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; ALTMAN LK, 1993, NY TIMES        0627, P23; Altman LK, 1993, NY TIMES, P1; COHEN J, 1993, SCIENCE, V260, P157, DOI 10.1126/science.8469966; COLE BF, 1993, STAT MED, V12, P975, DOI 10.1002/sim.4780121009; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; GELBER RD, 1991, ANN INTERN MED, V114, P621, DOI 10.7326/0003-4819-114-8-621; GELBER RD, 1992, ANN INTERN MED, V116, P961, DOI 10.7326/0003-4819-116-12-961; GLASZIOU PP, 1990, STAT MED, V9, P1259, DOI 10.1002/sim.4780091106; GOLDHIRSCH A, 1989, J CLIN ONCOL, V7, P36, DOI 10.1200/JCO.1989.7.1.36; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; KAHN J, 1993, J ACQ IMMUN DEF SYND, V6, pS47; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; MERIGAN TC, 1991, BLOOD, V78, P900; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; Rosner B., 2010, FUNDAMENTALS BIOSTAT; SANDE MA, 1993, JAMA-J AM MED ASSOC, V270, P2583, DOI 10.1001/jama.270.21.2583; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WACHTEL T, 1992, ANN INTERN MED, V116, P129, DOI 10.7326/0003-4819-116-2-129; WU AW, 1990, J ACQ IMMUN DEF SYND, V3, P683	20	135	135	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 17	1994	330	11					738	743		10.1056/NEJM199403173301102	http://dx.doi.org/10.1056/NEJM199403173301102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA742	7906386				2022-12-28	WOS:A1994NA74200002
J	FORBES, GM; GLASER, ME; CULLEN, DJE; WARREN, JR; CHRISTIANSEN, KJ; MARSHALL, BJ; COLLINS, BJ				FORBES, GM; GLASER, ME; CULLEN, DJE; WARREN, JR; CHRISTIANSEN, KJ; MARSHALL, BJ; COLLINS, BJ			DUODENAL-ULCER TREATED WITH HELICOBACTER-PYLORI ERADICATION - 7-YEAR FOLLOW-UP	LANCET			English	Article								The long-term benefits of Helicobacter pylori-eradication treatment (HET) in H pylori-associated duodenal ulcer are unclear. We followed up patients with duodenal ulcers from a trial of H pylori eradication in 1985-86. 63 of 78 patients (81%) were reviewed clinically and had upper gastrointestinal endoscopy with gastric antral biopsy. Of 35 patients previously rendered H pylori negative, 32 (92%) remained H pylori negative after 7.1 years (mean). All patients initially H pylori positive remained infected, unless HET was given in the interim. Duodenal ulceration was found in 20% (5 out of 25) of patients remaining H pylori-positive, compared with 3% (1 of 38) of H pylori-negative patients (p < 0 05). The reduction of duodenal ulcer relapse obtained from H pylori eradicaton in H pylori-associated duodenal ulcer extends to at least 7 years after treatment, and is likely to be due to freedom from H pylori infection. However, duodenal ulcer may recur in patients rendered H pylori negative, due to factors other than reinfection with H pylori.	ROYAL PERTH HOSP,DEPT PATHOL,PERTH,WA 6001,AUSTRALIA; ROYAL PERTH HOSP,DEPT MICROBIOL,PERTH,WA 6001,AUSTRALIA; UNIV VIRGINIA,DEPT MED,CHARLOTTESVILLE,VA 22903	Royal Perth Hospital; University of Western Australia; Royal Perth Hospital; University of Western Australia; University of Virginia	FORBES, GM (corresponding author), ROYAL PERTH HOSP,DEPT GASTROENTEROL,BOX X2213,PERTH,WA 6001,AUSTRALIA.			Marshall, Barry/0000-0003-4853-5015				BORODY T, 1992, LANCET, V339, P1295, DOI 10.1016/0140-6736(92)91622-F; CHIBA N, 1992, AM J GASTROENTEROL, V87, P1716; GEORGE LL, 1990, MED J AUSTRALIA, V153, P145, DOI 10.5694/j.1326-5377.1990.tb136833.x; MARSHALL BJ, 1988, LANCET, V2, P1437; PARSONNET J, 1992, GASTROENTEROLOGY, V102, P41, DOI 10.1016/0016-5085(92)91782-Y; PETERSON WL, 1991, NEW ENGL J MED, V324, P1043, DOI 10.1056/NEJM199104113241507; TRUESDALE R A, 1990, Gastroenterology, V98, pA140; TYTGAT GNJ, 1993, GASTROENTEROL CLIN N, V22, P127; VANZANTEN SV, 1992, GASTROENTEROLOGY, V102, pA184	9	338	346	3	18	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					258	260		10.1016/S0140-6736(94)91111-8	http://dx.doi.org/10.1016/S0140-6736(94)91111-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905095				2022-12-28	WOS:A1994MT44000009
J	SANDERSON, F; FERVENZA, F; WINEARLS, CG				SANDERSON, F; FERVENZA, F; WINEARLS, CG			TREATMENT OF IDIOPATHIC MEMBRANOUS NEPHROPATHY	LANCET			English	Letter									CHURCHILL JOHN RADCLIFFE HOSP,OXFORD REG RENAL UNIT,OXFORD,ENGLAND		SANDERSON, F (corresponding author), IMPERIAL CANC RES FUND,HUMAN GENET LAB,LONDON WC2A 3PX,ENGLAND.							CAMERON JS, 1990, Q J MED, V74, P1313; MATHIESON PW, 1988, LANCET, V2, P869; SHIEPPATI, 1993, LANCET, V342, P1277; WARWICK G, 1993, IN PRESS NEPHROL DIA	4	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					290	290		10.1016/S0140-6736(94)91135-5	http://dx.doi.org/10.1016/S0140-6736(94)91135-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905110				2022-12-28	WOS:A1994MT44000031
J	SILVA, JM; SILVA, PS				SILVA, JM; SILVA, PS			SEXLESS HDL	LANCET			English	Editorial Material											SILVA, JM (corresponding author), UNIV HOSP COIMBRA,DEPT MED 2,COIMBRA,PORTUGAL.							AILHAUD G, 1993, ANN BIOL CLIN-PARIS, V51, P267; ASSMANN G, 1993, CIRCULATION, V87, P28; DEMIROVIC J, 1992, AM J EPIDEMIOL, V136, P155, DOI 10.1093/oxfordjournals.aje.a116482; HUNNINGHAKE DB, 1993, NEW ENGL J MED, V328, P1213, DOI 10.1056/NEJM199304293281701; KUSHWAHA RS, 1992, CURR OPIN LIPIDOL, V3, P167; WALLDIUS G, 1992, CURR OPIN LIPIDOL, V3, P34; WILSON PWF, 1990, AM J CARDIOL, V66, pA7, DOI 10.1016/0002-9149(90)90562-F; 1992, NUTR META CARDIOVASC, V2, P113; 1988, EUROPEAN HEART J, V9, P571	9	1	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 15	1994	343	8890					129	130		10.1016/S0140-6736(94)90927-X	http://dx.doi.org/10.1016/S0140-6736(94)90927-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7903997				2022-12-28	WOS:A1994MQ86900003
J	BERNSTEIN, CN; SHANAHAN, F; WEINSTEIN, WM				BERNSTEIN, CN; SHANAHAN, F; WEINSTEIN, WM			ARE WE TELLING PATIENTS THE TRUTH ABOUT SURVEILLANCE COLONOSCOPY IN ULCERATIVE-COLITIS	LANCET			English	Article							CANCER SURVEILLANCE; COLORECTAL-CANCER; COLON CANCER; DYSPLASIA; CARCINOMA; ESOPHAGUS; COHORT	The recommended approach to the increased risk of colorectal carcinoma in Ulcerative colitis has been colonoscopic surveillance rather than prophylactic colectomy. This strategy is based on the assumption that dysplastic lesions can be detected before invasive cancer has developed. We have analysed published reports on dysplasia surveillance to find out whether this assumption is valid. Ten prospective studies (1225 patients) satisfied our criteria. Of 40 patients with dysplasia-associated mass or lesion (DALM) detected, 17 (43%) already had cancer at immediate colectomy. The risks of cancer at immediate colectomy were 42% (10 of 24 patients) for high-grade and 19% (3 of 16) for low-grade dysplasia. Of 47 patients found to have high-grade dysplasia after the initial colonoscopy, 15 (32%) had cancer. 16-29% of patients with untreated low-grade dysplasia progressed to DALM, high-grade dysplasia, or cancer. Of patients with indefinite results, 28% progressed to high-grade dysplasia and 9% to cancer, so continued surveillance is essential. The risk of progression to dysplasia was only 2.4% for patients whose initial result was negative, so surveillance could perhaps be less frequent for these patients. Immediate colectomy is essential for all patients diagnosed with high-grade or low-grade dysplasia. A diagnosis of dysplasia does not preclude the presence of invasive cancer. We believe that patients should be informed about the limitations of colonoscopic surveillance so that they can take part rationally in decision-making about their management.	UNIV MANITOBA, DEPT MED, DIV GASTROENTEROL, WINNIPEG R3T 2N2, MANITOBA, CANADA; NATL UNIV IRELAND UNIV COLL CORK, DEPT MED, DIV GASTROENTEROL, CORK, IRELAND; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV GASTROENTEROL, LOS ANGELES, CA USA	University of Manitoba; University College Cork; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA				Shanahan, Fergus/0000-0003-0467-0936				BLACKSTONE MO, 1981, GASTROENTEROLOGY, V80, P366; BROSTROM O, 1986, GUT, V27, P1408, DOI 10.1136/gut.27.12.1408; CELLO JP, 1989, GASTROINTESTINAL DIS, P1435; COLLINS RH, 1987, NEW ENGL J MED, V316, P1654, DOI 10.1056/NEJM198706253162609; CROWSON TD, 1976, JAMA-J AM MED ASSOC, V236, P2651, DOI 10.1001/jama.236.23.2651; EKBOM A, 1990, NEW ENGL J MED, V323, P1228, DOI 10.1056/NEJM199011013231802; GYDE SN, 1988, GUT, V29, P206, DOI 10.1136/gut.29.2.206; HAMEETEMAN W, 1989, GASTROENTEROLOGY, V96, P1249, DOI 10.1016/S0016-5085(89)80011-3; KORELITZ BI, 1985, BOCKUS GASTROENTEROL, V4, P2346; LASHNER BA, 1990, AM J GASTROENTEROL, V85, P1083; LASHNER BA, 1989, DIGEST DIS SCI, V34, P1536, DOI 10.1007/BF01537106; LEIDENIUS M, 1991, GUT, V32, P1521, DOI 10.1136/gut.32.12.1521; LENNARDJONES JE, 1990, GUT, V31, P800, DOI 10.1136/gut.31.7.800; LEWIN KJ, 1992, GASTROINTESTINAL PAT, P22; LOFBERG R, 1990, GASTROENTEROLOGY, V99, P1021; LYNCH DAF, 1993, GUT, V34, P1075, DOI 10.1136/gut.34.8.1075; MACDOUGALL I, 1964, LANCET, V2, P65; MCARDLE JE, 1992, HUM PATHOL, V23, P479, DOI 10.1016/0046-8177(92)90123-K; MELVILLE DM, 1989, HUM PATHOL, V20, P1008, DOI 10.1016/0046-8177(89)90273-6; NUGENT FW, 1991, GASTROENTEROLOGY, V100, P1241, DOI 10.1016/0016-5085(91)70010-U; RANSOHOFF DF, 1985, DIS COLON RECTUM, V28, P383, DOI 10.1007/BF02560215; RIDDELL RH, 1983, HUM PATHOL, V14, P931, DOI 10.1016/S0046-8177(83)80175-0; ROSENSTOCK E, 1985, GASTROENTEROLOGY, V89, P1342, DOI 10.1016/0016-5085(85)90653-5; RUTEGARD J, 1988, SCAND J GASTROENTERO, V23, P139, DOI 10.3109/00365528809103958; TAYLOR BA, 1992, DIS COLON RECTUM, V35, P950, DOI 10.1007/BF02253497; VILIEN M, 1991, J INTERN MED, V230, P259, DOI 10.1111/j.1365-2796.1991.tb00440.x; WAYE JD, 1983, SCAND J GASTROENTERO, V18, P44; WOOLRICH AJ, 1992, GASTROENTEROLOGY, V103, P431, DOI 10.1016/0016-5085(92)90831-I	28	433	442	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					71	74						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903776				2022-12-28	WOS:A1994MQ09200008
J	CUI, KH; WARNES, GM; JEFFREY, R; MATTHEWS, CD				CUI, KH; WARNES, GM; JEFFREY, R; MATTHEWS, CD			SEX DETERMINATION OF PREIMPLANTATION EMBRYOS BY HUMAN TESTIS-DETERMINING-GENE AMPLIFICATION	LANCET			English	Article							DNA AMPLIFICATION; SPERM RECEPTOR; INVITRO; FERTILIZATION; PROTEIN; BIOPSY; ZP3	When there is a risk of inherited disease, preimplantation diagnosis gives couples an opportunity to avoid having a child with the disease. Sex determination can be used to exclude the likelihood of a sex-linked disorder. Accuracy of the diagnosis is important. We have tested the reliability of sex determination based on the recognition of a testis-determining gene (SRY) sequence. DNA from the blood of 120 men and women and from 38 single lymphocytes was amplified by polymerase chain reaction (PCR) with the SRY and control (ZP3) gene primers. All results confirmed the correct sex of origin (100%). The test was then used to determine the sex of 21 single embryo cells biopsied from 21 (4-8 cell) human polyspermic embryos. 2 embryo cells recognised at biopsy to have degenerated produced negative results. The other 19 single embryo cells showed 100% PCR amplification. 11 (58%) of the embryos were judged to be ''male'' and 8 (42%) ''female''. The SRY and ZP3 gene primers selected are highly specific and give accurate results in sex determination and their use provides a new reliable method for routine preimplantation and general prenatal sex determination in man.			CUI, KH (corresponding author), UNIV ADELAIDE,QUEEN ELIZABETH HOSP,DEPT OBSTET & GYNAECOL,WOODVILLE,SA 5011,AUSTRALIA.							BISHOP CE, 1987, NUCLEIC ACIDS RES, V15, P2959, DOI 10.1093/nar/15.7.2959; BRADBURY MW, 1990, P NATL ACAD SCI USA, V87, P4053, DOI 10.1073/pnas.87.11.4053; CHAMBERLIN ME, 1990, P NATL ACAD SCI USA, V87, P6014, DOI 10.1073/pnas.87.16.6014; CUI KH, 1993, HUM REPROD, V8, P621, DOI 10.1093/oxfordjournals.humrep.a138107; CUI KH, 1993, NATURE, V366, P117, DOI 10.1038/366117b0; HANDYSIDE AH, 1989, LANCET, V1, P347; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; HARDY K, 1990, HUM REPROD, V5, P708, DOI 10.1093/oxfordjournals.humrep.a137173; Kawasaki E.S., 1990, PCR PROTOCOLS GUIDE, P146; LO YMD, 1989, LANCET, V2, P1363; NAKAGOME Y, 1990, LANCET, V335, P291, DOI 10.1016/0140-6736(90)90109-I; NAKAHORI Y, 1986, NUCLEIC ACIDS RES, V14, P7569, DOI 10.1093/nar/14.19.7569; PAYNE D, 1991, HUM REPROD, V6, P423, DOI 10.1093/oxfordjournals.humrep.a137352; QUINN P, 1985, ANN NY ACAD SCI, V442, P195, DOI 10.1111/j.1749-6632.1985.tb37520.x; RINGUETTE MJ, 1988, DEV BIOL, V127, P287, DOI 10.1016/0012-1606(88)90315-6; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; STROM CM, 1991, J IN VITRO FERTIL EM, V8, P225, DOI 10.1007/BF01130810; TROUNSON AL, 1992, HUM REPROD, V7, P583; VANDUIN M, 1991, CYTOGENET CELL GENET, V58, P1927; WINSTON RML, 1991, HUM REPROD, V6, P281	20	54	53	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					79	82		10.1016/S0140-6736(94)90815-X	http://dx.doi.org/10.1016/S0140-6736(94)90815-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903778				2022-12-28	WOS:A1994MQ09200010
J	LIFSON, AR				LIFSON, AR			PREVENTING HIV - HAVE WE LOST OUR WAY	LANCET			English	Editorial Material							RISK-FACTORS; DRUG-USERS; AIDS; TRANSMISSION; PROSTITUTES				LIFSON, AR (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,MINNEAPOLIS,MN 55455, USA.							[Anonymous], 1990, Wkly Epidemiol Rec, V65, P221; [Anonymous], 1993, MMWR, V42, P869; BINSON D, 1993, FAM PLANN PERSPECT, V25, P268, DOI 10.2307/2136144; DESJARLAIS DC, 1992, AIDS, V6, P1053, DOI 10.1097/00002030-199210000-00001; HAYS RB, 1990, AIDS, V4, P901, DOI 10.1097/00002030-199009000-00011; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; MANN JM, 1992, AIDS WORLD CAMBRIDGE; MICHAELS D, 1992, JAMA-J AM MED ASSOC, V268, P3456, DOI 10.1001/jama.268.24.3456; NICOLOSI A, 1992, AM J EPIDEMIOL, V135, P225, DOI 10.1093/oxfordjournals.aje.a116275; SIMOES EAF, 1993, J ACQ IMMUN DEF SYND, V6, P1030; SIRAPRAPASIRI T, 1991, AIDS, V5, P579, DOI 10.1097/00002030-199105000-00017; STALL R, 1990, J ACQ IMMUN DEF SYND, V3, P1181; 1993, SOCIAL IMPACT AIDS U; 1992, MMWR, V41, P1; 1994, MMWR, V43, P155	15	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1306	1308		10.1016/S0140-6736(94)92462-7	http://dx.doi.org/10.1016/S0140-6736(94)92462-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910319				2022-12-28	WOS:A1994NN21700005
J	SCHINKEL, AH; SMIT, JJM; VANTELLINGEN, O; BEIJNEN, JH; WAGENAAR, E; VANDEEMTER, L; MOL, CAAM; VANDERVALK, MA; ROBANUSMAANDAG, EC; TERIELE, HPJ; BERNS, AJM; BORST, P				SCHINKEL, AH; SMIT, JJM; VANTELLINGEN, O; BEIJNEN, JH; WAGENAAR, E; VANDEEMTER, L; MOL, CAAM; VANDERVALK, MA; ROBANUSMAANDAG, EC; TERIELE, HPJ; BERNS, AJM; BORST, P			DISRUPTION OF THE MOUSE MDR1A P-GLYCOPROTEIN GENE LEADS TO A DEFICIENCY IN THE BLOOD-BRAIN-BARRIER AND TO INCREASED SENSITIVITY TO DRUGS	CELL			English	Article							MULTIDRUG-RESISTANCE GENE; PERFORMANCE LIQUID-CHROMATOGRAPHY; BACTERIAL TRANSPORT PROTEINS; MONOCLONAL-ANTIBODIES; CHINESE-HAMSTER; CELLS; EXPRESSION; VINBLASTINE; VINCRISTINE; FAMILY	We have generated mice homozygous for a disruption of the mdr1a (also called mdr3) gene, encoding a drug-transporting P-glycoprotein. The mice were viable and fertile and appeared phenotypically normal, but they displayed an increased sensitivity to the centrally neurotoxic pesticide ivermectin (100-fold) and to the carcinostatic drug vinblastine (3-fold). By comparison of mdr1a (+/+) and (-/-) mice, we found that the mdr1a P-glycoprotein is the major P-glycoprotein in the blood-brain barrier and that its absence results in elevated drug levels in many tissues (especially in brain) and in decreased drug elimination. Our findings explain some of the side effects in patients treated with a combination of carcinostatics and P-glycoprotein inhibitors and indicate that these inhibitors might be useful in selectively enhancing the access of a range of drugs to the brain.	NETHERLANDS CANC INST,DEPT CLIN CHEM,1066 CX AMSTERDAM,NETHERLANDS; SLOTERVAART HOSP,DEPT PHARM,1066 EC AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute; Slotervaart Hospital	SCHINKEL, AH (corresponding author), NETHERLANDS CANC INST,DIV MOLEC BIOL,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.		Van Tellingen, Olaf/A-1344-2014	Van Tellingen, Olaf/0000-0002-1037-6269				AMES BN, 1990, P NATL ACAD SCI USA, V87, P7782, DOI 10.1073/pnas.87.19.7782; ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; BRADBURY MWB, 1985, CIRC RES, V57, P213, DOI 10.1161/01.RES.57.2.213; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRADLEY G, 1990, J CELL PHYSIOL, V145, P398, DOI 10.1002/jcp.1041450303; CALLAGHAN R, 1993, J BIOL CHEM, V268, P16059; Campbell WW, 1989, IVERMECTIN ABAMECTIN; CEFALU WT, 1985, J NEUROCHEM, V45, P1954, DOI 10.1111/j.1471-4159.1985.tb10557.x; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FISHER MH, 1992, ANNU REV PHARMACOL, V32, P537, DOI 10.1146/annurev.pa.32.040192.002541; FORD JM, 1990, PHARMACOL REV, V42, P155; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GOLDSTEIN GW, 1986, SCI AM, V255, P70; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREIG NH, 1990, CANCER CHEMOTH PHARM, V26, P263, DOI 10.1007/BF02897227; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HORTON JK, 1989, BIOCHEM PHARMACOL, V38, P1727, DOI 10.1016/0006-2952(89)90405-X; HSU SIH, 1989, J BIOL CHEM, V264, P12053; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; KASTER KR, 1983, NUCLEIC ACIDS RES, V11, P6895, DOI 10.1093/nar/11.19.6895; LADURON PM, 1979, BIOCHEM PHARMACOL, V28, P2161, DOI 10.1016/0006-2952(79)90198-9; LEVIN VA, 1980, J MED CHEM, V23, P682, DOI 10.1021/jm00180a022; PULLIAM JD, 1985, VET MED-US, V80, P33; RAYMOND M, 1990, MOL CELL BIOL, V10, P1642, DOI 10.1128/MCB.10.4.1642; RAYMOND M, 1989, P NATL ACAD SCI USA, V86, P6488, DOI 10.1073/pnas.86.17.6488; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; SAEKI T, 1993, J BIOL CHEM, V268, P6077; Sambrook J, 1989, MOL CLONING LABORATO; SCHINKEL AH, 1991, CANCER RES, V51, P2628; SIKIC BI, 1993, J CLIN ONCOL, V11, P1629, DOI 10.1200/JCO.1993.11.9.1629; SLATER LM, 1986, J CLIN INVEST, V77, P1405, DOI 10.1172/JCI112450; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SUGAWARA I, 1988, CANCER RES, V48, P1926; TANIGAWARA Y, 1992, J PHARMACOL EXP THER, V263, P840; TATSUTA T, 1992, J BIOL CHEM, V267, P20383; TAYLOR HR, 1990, SCIENCE, V250, P116, DOI 10.1126/science.2218502; TEETER LD, 1990, MOL CELL BIOL, V10, P5728, DOI 10.1128/MCB.10.11.5728; THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; TREZISE AEO, 1992, EMBO J, V11, P4291, DOI 10.1002/j.1460-2075.1992.tb05528.x; TSURUO T, 1981, CANCER RES, V41, P1967; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; UEDA K, 1992, J BIOL CHEM, V267, P24248; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; VANDERLUGT N, 1991, GENE, V105, P263, DOI 10.1016/0378-1119(91)90161-4; VANDOMMELEN FS, 1986, BIOCHEM J, V236, P771, DOI 10.1042/bj2360771; VANTELLINGEN O, 1993, CANCER CHEMOTH PHARM, V32, P286, DOI 10.1007/BF00686174; VANTELLINGEN O, 1993, CANCER RES, V53, P2061	58	1917	1980	1	131	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 20	1994	77	4					491	502		10.1016/0092-8674(94)90212-7	http://dx.doi.org/10.1016/0092-8674(94)90212-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NM832	7910522				2022-12-28	WOS:A1994NM83200005
J	CHAPEL, HM; LEE, M; HARGREAVES, R; PAMPHILON, DH; PRENTICE, AG				CHAPEL, HM; LEE, M; HARGREAVES, R; PAMPHILON, DH; PRENTICE, AG			RANDOMIZED TRIAL OF INTRAVENOUS IMMUNOGLOBULIN AS PROPHYLAXIS AGAINST INFECTION IN PLATEAU-PHASE MULTIPLE-MYELOMA	LANCET			English	Article							BACTERIAL-INFECTION	Patients with plateau-phase multiple myeloma have an increased risk of life-threatening bacterial infections and polyclonal humoral immune suppression. We conducted a randomised, double-blind, placebo-controlled, multicentre trial of intravenous immunoglobulin (IVIg) as prophylaxis against infection. 82 patients with stable multiple myeloma received monthly infusions of IVIg at 0.4 g/kg body weight or an equivalent volume of placebo (0.4% albumin) intravenously for 1 year. Other interventions, including chemotherapy, were not affected; no patient received prophylactic antibiotics. There were no differences at entry or on study in clinical or laboratory variables between patients in the two groups. There were no episodes of septicaemia or pneumonia in patients receiving IVIg compared with 10 in placebo patients (p=0.002). There were 57 serious infections; 38 occurred in 470 patient-months on placebo, compared with 19 in 449 patient-months on IVIg (p=0.019). IVIg also protected against recurrent infections (p=0.021) in 60 patients who completed a year. Before treatment, 54 patients were immunised with Pneumovax and specific IgG responses were measured. A poor pneumococcal IgG antibody response (less than 2-fold increase) identified patients who had maximum benefit from IVIg. Mild adverse reactions were noted in 12% of IVIg infusions and 5% of placebo infusions. IVIg can be given safely to plateau-phase myeloma patients. It protects against life-threatening infections and significantly reduces the risk of recurrent infections. The individuals who benefit most can be identified prospectively by measuring IgG antibody responses to pneumococcal immunisation.	JOHN RADCLIFFE HOSP,DEPT MICROBIOL,OXFORD OX3 9DU,ENGLAND; BAXTER HEALTHCARE CORP,IRVINE,CA; SW BLOOD TRANSFUS SERV,BRISTOL,AVON,ENGLAND; DERRIFORD HOSP,DEPT HAEMATOL,PLYMOUTH,DEVON,ENGLAND	University of Oxford; Baxter International Inc; Derriford Hospital	CHAPEL, HM (corresponding author), JOHN RADCLIFFE HOSP,DEPT IMMUNOL,OXFORD OX3 9DU,ENGLAND.							DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; ESPERSEN F, 1984, SCAND J INFECT DIS, V16, P169, DOI 10.3109/00365548409087137; FAHEY JL, 1963, AM J MED, V35, P698, DOI 10.1016/0002-9343(63)90140-2; GRIFFITHS H, 1992, CLIN EXP IMMUNOL, V89, P374; HARGREAVES R, 1991, BLOOD S, V76, P352; HARGREAVES RM, 1990, PROGR IMMUNE DEFICIE; JACOBSEN D, 1986, SEMIN ONCOL, V13, P82; LEE ML, 1993, S DRUGS DRUG CO QUAL; PERRI RT, 1981, AM J MED, V71, P935, DOI 10.1016/0002-9343(81)90303-X; REINHART WH, 1992, LANCET, V339, P662, DOI 10.1016/0140-6736(92)90806-E; SAVAGE DG, 1982, ANN INTERN MED, V96, P47, DOI 10.7326/0003-4819-96-1-47; SCHEDEL I, 1986, CLIN USES INTRAVENOU, P123; SCHIFFERLI J, 1990, LANCET, V336, P457; TWOMEY JJ, 1973, ARCH INTERN MED, V132, P562, DOI 10.1001/archinte.132.4.562; 1988, NEW ENGL J MED, V317, P902; 1980, BRIT J CANCER, V42, P831; 1973, BRIT J HAEMATOL, V24, P123	17	173	179	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 30	1994	343	8905					1059	1063		10.1016/S0140-6736(94)90180-5	http://dx.doi.org/10.1016/S0140-6736(94)90180-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ694	7909099				2022-12-28	WOS:A1994NJ69400008
J	MULDER, DW; NUNN, AJ; KAMALI, A; NAKIYINGI, J; WAGNER, HU; KENGEYAKAYONDO, JF				MULDER, DW; NUNN, AJ; KAMALI, A; NAKIYINGI, J; WAGNER, HU; KENGEYAKAYONDO, JF			2-YEAR HIV-1-ASSOCIATED MORTALITY IN A UGANDAN RURAL-POPULATION	LANCET			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; HIV INFECTION; AFRICAN CITY; AIDS; ZAIRE; EMPLOYEES; KINSHASA	The mortality in 15 villages in South-West Uganda was studied in relation to HIV infection. After a population census, serum samples were tested for antibodies to HIV-1. Deaths were ascertained over 2 years. Unequivocal HIV-1 serology results were available for 9389 individuals. The prevalence of infection was 4.8% for all ages and 8.2% for adults (aged 13 or more). 198 deaths were recorded during 15725 person years of observation. Mortality among seronegative adults was 7.7 per 1000 and among seropositive adults 115.9 per 1000. The excess annual death rate associated with HIV-1 infection was 5.3 per 1000 and in adults 7.9 per 1000. Highest excess mortality was 16.9 per 1000 in the age group 25-34. Among adults, half of all deaths and among those aged 13-44 over 80% of deaths were attributable to HIV-1 infection. These results show the strong im pact that HIV-1 infection is having on mortality in a rural area of Uganda where the overall HIV-1 adult prevalence rate is below 10%-a rate lower than in many other parts of East Africa.	UGANDA VIRUS RES INST,ENTEBBE,UGANDA	Uganda Virus Research Institute	MULDER, DW (corresponding author), MRC UK,ODA,UVRI,PROGRAMME AIDS UGANDA,POB 49,ENTEBBE,UGANDA.			Nunn, Andrew/0000-0002-9158-4595				ANDERSON RM, 1991, AIDS, V5, pS37; ANZALA A, 1991, 7 INT C AIDS FLOR; BONGAARTS J, 1989, STAT MED, V8, P103, DOI 10.1002/sim.4780080111; COLEBUNDERS RL, 1991, AIDS, V5, pS103; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HIRA SK, 1990, J ACQ IMMUN DEF SYND, V3, P87; KNOWANE BM, 1991, AIDS, V5, pS7; LEE CA, 1989, BRIT J HAEMATOL, V73, P228, DOI 10.1111/j.1365-2141.1989.tb00257.x; LINDAN CP, 1992, ANN INTERN MED, V116, P320, DOI 10.7326/0003-4819-116-4-320; MANN JM, 1986, JAMA-J AM MED ASSOC, V255, P3255, DOI 10.1001/jama.255.23.3255; MULDER DW, 1994, AIDS, V8, P87, DOI 10.1097/00002030-199401000-00013; NELSON AM, 1991, AIDS, V5, P583, DOI 10.1097/00002030-199105000-00018; NGALY B, 1988, NEW ENGL J MED, V319, P1123, DOI 10.1056/NEJM198810273191704; NUNK AJ, 1994, IN PRESS METH INFORM, V33; NUNN AJ, 1993, AIDS, V7, P1057, DOI 10.1097/00002030-199308000-00005; PIOT P, 1991, AIDS, V5, pS1; RYDER RW, 1990, AIDS, V4, P725, DOI 10.1097/00002030-199008000-00002; SERWADDA D, 1992, AIDS, V6, P983, DOI 10.1097/00002030-199209000-00012; WAY PO, 1992, 8 INT C AIDS AMST; 1990, CURRENT FUTURE DIMEN; 1986, WKLY EPID REC, V61, P72	22	111	112	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 23	1994	343	8904					1021	1023		10.1016/S0140-6736(94)90133-3	http://dx.doi.org/10.1016/S0140-6736(94)90133-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909054				2022-12-28	WOS:A1994NG68200015
J	FANG, JWS; BIRD, GLA; NAKAMURA, T; DAVIS, GL; LAU, JYN				FANG, JWS; BIRD, GLA; NAKAMURA, T; DAVIS, GL; LAU, JYN			HEPATOCYTE PROLIFERATION AS AN INDICATOR OF OUTCOME IN ACUTE ALCOHOLIC HEPATITIS	LANCET			English	Article							LIVER-DISEASE; THERAPY; GROWTH; TRIAL; DNA	To determine whether clinical outcome in patients with acute alcoholic hepatitis is related to the regenerative capability of the liver, liver biopsy specimens from 25 prospectively recruited patients with acute alcoholic hepatitis were studied for hepatic expression of mRNA for two proliferation markers, proliferating cell nuclear antigen and human histone, and for transforming growth factor alpha (TGFalpha) and TGFbeta1 and hepatocyte growth factor (HGF), which regulate hepatocyte proliferation. Proliferation markers were detected to varying degrees in 0-80% of hepatocytes and occasionally in sinusoidal cells and bile-duct epithelium in 19 patients (76%). Patients who survived for 6 months had greater expression of proliferation markers than those who did not survive (p < 0.01). TGFalpha was detected in hepatocytes and bile-duct epithelium, whereas TGFbeta1 was detected mainly in sinusoidal cells and was associated with perivenular fibrosis. Patients who survived for 6 months had greater expression of TGFs than non-survivors (p < 0.02). HGF was detected in sinusoidal cells in 7 patients and correlated with survival (p < 0.01). These data indicate that hepatocyte proliferation, which is possibly related to the pattern of hepatotrophic factor expression, is a good indicator of outcome in acute alcoholic hepatitis.	UNIV FLORIDA,DEPT MED,HEPATOBILIARY DIS SECT,POB 100214 JHMHC,GAINESVILLE,FL 32610; OSAKA UNIV,SCH MED,SUITA,OSAKA 565,JAPAN; GARTNAVEL ROYAL HOSP,MED UNIT A,GLASGOW G12 0YN,SCOTLAND	State University System of Florida; University of Florida; Osaka University; Gartnavel Royal Hospital								BAKER AL, 1981, GASTROENTEROLOGY, V80, P1410; BAPTISTA A, 1981, Lancet, V1, P707; BIRD GLA, 1988, MOL ASPECTS MED, V10, P97, DOI 10.1016/0098-2997(88)90017-9; CASTILLA A, 1991, NEW ENGL J MED, V324, P933, DOI 10.1056/NEJM199104043241401; DALKE DD, 1990, HEPATOLOGY, V12, P1085, DOI 10.1002/hep.1840120502; FAIRMAN MP, 1990, J CELL SCI, V95, P1; FAUSTO N, 1989, LAB INVEST, V60, P4; LAU JYN, 1991, J CLIN PATHOL, V44, P905, DOI 10.1136/jcp.44.11.905; MADDREY WC, 1978, GASTROENTEROLOGY, V75, P193; SCHUMPERLI D, 1986, CELL, V45, P471, DOI 10.1016/0092-8674(86)90277-1; SIERRA F, 1982, P NATL ACAD SCI-BIOL, V79, P1795, DOI 10.1073/pnas.79.6.1795; THEODOSSI A, 1982, GUT, V23, P75, DOI 10.1136/gut.23.1.75	12	61	63	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					820	823		10.1016/S0140-6736(94)92025-7	http://dx.doi.org/10.1016/S0140-6736(94)92025-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908077				2022-12-28	WOS:A1994ND79200008
J	BAKER, D				BAKER, D			POVERTY AND ISCHEMIC-HEART-DISEASE - THE MISSING LINKS	LANCET			English	Editorial Material											BAKER, D (corresponding author), UNIV BATH,SCH SOCIAL SCI,BATH,AVON,ENGLAND.							BAKER D, 1993, J PUBLIC HEALTH MED, V15, P243; BAKER D, 1990, INT J HLTH SCI, V1, P89; BARKER D, 1992, BRIT MED J; Black D., 1980, INEQUALITIES HLTH; ILLSLEY R, 1991, SOC SCI MED, V32, P359, DOI 10.1016/0277-9536(91)90336-B; MARMOT MG, 1978, BMJ-BRIT MED J, V2, P1109, DOI 10.1136/bmj.2.6145.1109; MCKEOWN T, 1976, ROLE MED; ROSE G, 1991, OXFORD TXB PUBLIC HL, V3, P175; 1994, BRIT MED J, V308, P308	9	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					496	496		10.1016/S0140-6736(94)91455-9	http://dx.doi.org/10.1016/S0140-6736(94)91455-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MX888	7906754				2022-12-28	WOS:A1994MX88800003
J	WHEELER, T; SOLLERO, C; ALDERMAN, S; LANDEN, J; ANTHONY, F; OSMOND, C				WHEELER, T; SOLLERO, C; ALDERMAN, S; LANDEN, J; ANTHONY, F; OSMOND, C			RELATION BETWEEN MATERNAL HEMOGLOBIN AND PLACENTAL HORMONE CONCENTRATIONS IN EARLY-PREGNANCY	LANCET			English	Article							HIGH-ALTITUDES; HYPOXIA; FETAL	Environmental factors that influence placental development are of particular interest because of the reported association between adult hypertension, low birthweight, and large placental size. Maternal anaemia is one environmental factor that is associated with an increase in placental size at birth. We have examined the relation between haematological status and plasma concentrations of chorionic gonadotropin (hCG) and placental lactogen (hPL) in 175 women at about 10 weeks of pregnancy. There were significant negative correlations between maternal haemoglobin concentration and the levels of hCG (p=0.03) and hPL (p=0.02). Although 21% of women had low iron stores (ferritin < 13 mu g/L), no relation was found between serum ferritin and the two placental hormones. There was no association between plasma volume (calculated from maternal weight and height) and hCG or hPL concentrations.	SOUTHAMPTON GEN HOSP, MRC, ENVIRONM EPIDEMIOL UNIT, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND	University of Southampton	WHEELER, T (corresponding author), UNIV SOUTHAMPTON, PRINCESS ANNE HOSP, DEPT OBSTET & GYNAECOL, SOUTHAMPTON, HANTS, ENGLAND.			Osmond, Clive/0000-0002-9054-4655				BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BEISCHER N A, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P398; BERNSTEIN L, 1989, BRIT J OBSTET GYNAEC, V96, P92, DOI 10.1111/j.1471-0528.1989.tb01582.x; CLAPP JF, 1988, AM J OBSTET GYNECOL, V159, P1456, DOI 10.1016/0002-9378(88)90574-1; FLETCHER J, 1969, CLIN SCI, V36, P209; FOX H, 1970, AM J OBSTET GYNECOL, V107, P1058, DOI 10.1016/0002-9378(70)90629-0; GODFREY KM, 1991, BRIT J OBSTET GYNAEC, V98, P886, DOI 10.1111/j.1471-0528.1991.tb13510.x; Gregory F., 1990, DIETARY NUTR SURVEY; HAY DL, 1988, BRIT J OBSTET GYNAEC, V95, P1268, DOI 10.1111/j.1471-0528.1988.tb06817.x; HOWE D, IN PRESS J PHYSL; HUSTIN J, 1992, 1ST 12 WEEKS GESTATI, P97; JACKSON MR, 1987, J ANAT, V152, P173; KRUGER H, 1970, AM J OBSTET GYNECOL, V106, P586; LUND CJ, 1967, AM J OBSTET GYNECOL, V98, P393, DOI 10.1016/0002-9378(67)90160-3; MAYHEW TM, 1990, PLACENTA, V11, P493, DOI 10.1016/S0143-4004(05)80195-X; PARKER DJP, 1992, J EPIDEMIOL COMMUN H, V46, P8, DOI 10.1136/jech.46.1.8; RESHETNIKOVA OS, 1993, J PHYSIOL-LONDON, V459, pP308; RODESCH F, 1992, OBSTET GYNECOL, V80, P283; RYBO G, 1973, CLIN HAEMATOL, P269; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; WHITTAKER PG, 1993, BRIT J OBSTET GYNAEC, V100, P587, DOI 10.1111/j.1471-0528.1993.tb15315.x	21	35	35	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 26	1994	343	8896					511	513		10.1016/S0140-6736(94)91461-3	http://dx.doi.org/10.1016/S0140-6736(94)91461-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906760				2022-12-28	WOS:A1994MX88800009
J	MOAKE, JL				MOAKE, JL			HEMOLYTIC-UREMIC SYNDROME - BASIC SCIENCE	LANCET			English	Article							HEMOLYTIC-UREMIC SYNDROME; THROMBOTIC THROMBOCYTOPENIC PURPURA; PLASMA VONWILLEBRAND-FACTOR; HUMAN ENDOTHELIAL-CELLS; FACTOR-VIII; PLATELET-AGGREGATION; ESCHERICHIA-COLI; VWF MULTIMERS; EXPRESSION; RECEPTOR		RICE UNIV,HOUSTON,TX	Rice University	MOAKE, JL (corresponding author), BAYLOR COLL MED,METHODIST HOSP,6565 FANNIN,MS902,HOUSTON,TX 77030, USA.							ASADA Y, 1985, THROMB RES, V38, P469, DOI 10.1016/0049-3848(85)90180-X; ASHKENAZI S, 1993, ANNU REV MED, V44, P11, DOI 10.1146/annurev.med.44.1.11; ATKINSON K, 1983, BRIT J HAEMATOL, V54, P59, DOI 10.1111/j.1365-2141.1983.tb02067.x; BELL WR, 1991, NEW ENGL J MED, V325, P398, DOI 10.1056/NEJM199108083250605; BENIGNI A, 1992, LANCET, V339, P835, DOI 10.1016/0140-6736(92)90281-7; BERGSTEIN JM, 1982, AM J MED, V73, P322, DOI 10.1016/0002-9343(82)90717-3; BOYD B, 1989, NEPHRON, V51, P207, DOI 10.1159/000185286; CHARBA D, 1993, AM J HEMATOL, V42, P268, DOI 10.1002/ajh.2830420306; CHEN SH, 1989, THROMB HAEMOSTASIS, V62, P568; CLEARY TG, 1988, PEDIATR CLIN N AM, V35, P485; FITZPATRICK MM, 1992, KIDNEY INT, V42, P951, DOI 10.1038/ki.1992.372; FRANGOS JA, 1989, AM J PHYSIOL, V256, pH1635, DOI 10.1152/ajpheart.1989.256.6.H1635; GASSER C, 1955, Schweiz Med Wochenschr, V85, P905; GOTTSCHALL JL, 1991, BLOOD, V77, P306; HABIB R, 1992, HEMOLYTIC UREMIC SYN, P315; HARKNESS DR, 1981, JAMA-J AM MED ASSOC, V246, P1931, DOI 10.1001/jama.246.17.1931; KAPLAN BS, 1987, SEMIN HEMATOL, V24, P1408; KARMALI MA, 1992, HEMOLYTIC UREMIC SYN, P199; KOVACS MJ, 1990, AM J MED, V88, P177, DOI 10.1016/0002-9343(90)90470-X; LEUNG DYM, 1988, LANCET, V2, P183; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; MANNUCCI PM, 1989, BLOOD, V74, P978; MARCUS AJ, 1991, J CLIN INVEST, V88, P1690, DOI 10.1172/JCI115485; MILFORD D, 1989, LANCET, V2, P1153; MOAKE JL, 1984, BLOOD, V64, P592; MOAKE JL, 1982, NEW ENGL J MED, V307, P1432, DOI 10.1056/NEJM198212023072306; MOAKE JL, 1986, J CLIN INVEST, V78, P1456, DOI 10.1172/JCI112736; MOAKE JL, 1989, AM J MED, V87; MOORE JC, 1990, BRIT J HAEMATOL, V74, P457, DOI 10.1111/j.1365-2141.1990.tb06335.x; Moschcowitz E., 1924, P NY PATHOL SOC, V24, P21; NORIS M, 1992, AM J KIDNEY DIS, V20, P144, DOI 10.1016/S0272-6386(12)80542-7; Obrig TG, 1992, HEMOLYTIC UREMIC SYN, P405; PFUELLER SL, 1990, THROMB HAEMOSTASIS, V63, P279; RABADI SJ, 1982, CANCER TREAT REP, V66, P1244; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; ROSE PE, 1984, ARCH DIS CHILD, V59, P1135, DOI 10.1136/adc.59.12.1135; SIDDIQUI FA, 1985, J CLIN INVEST, V76, P1330, DOI 10.1172/JCI112107; SUGIHARA K, 1992, BLOOD, V80, P2634; TAYLOR CM, 1990, PEDIATR NEPHROL, V4, P59, DOI 10.1007/BF00858441; VANDEKAR NCAJ, 1992, BLOOD, V80, P2755; WALTERS MDS, 1989, PEDIATR NEPHROL, V3, P130, DOI 10.1007/BF00852893; WICK TM, 1993, AM J HEMATOL, V42, P284, DOI 10.1002/ajh.2830420308	42	170	175	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					393	397		10.1016/S0140-6736(94)91227-0	http://dx.doi.org/10.1016/S0140-6736(94)91227-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905556				2022-12-28	WOS:A1994MW28300013
J	NIEDOBITEK, G; YOUNG, LS				NIEDOBITEK, G; YOUNG, LS			EPSTEIN-BARR-VIRUS PERSISTENCE AND VIRUS-ASSOCIATED TUMORS	LANCET			English	Review							LYMPHOEPITHELIOMA-LIKE CARCINOMA; ORAL HAIRY LEUKOPLAKIA; T-CELL LYMPHOMAS; INSITU HYBRIDIZATION; EPITHELIAL-CELLS; LYMPHOCYTES-T; EXPRESSION; INFECTION; RECEPTOR; DNA	The Epstein-Barr virus (EBV) has been implicated in the aetiology of many human lymphoid and epithelial malignancies. Although EBV is B lymphotropic in vitro, it has been hypothesised that oropharyngeal epithelium is important in primary EBV infection, replication, and persistence in vivo, and that infection of B lymphocytes is secondary. This hypothesis has been challenged by several recent studies. On the basis of current evidence, we propose that primary EBV infection and virus persistence are mediated through B lymphocytes, and that latent infection of epithelial cells is accidental and irrelevant to virus persistence, although important in the development of certain carcinomas. To what extent T cells are involved in EBV persistence remains uncertain. Clarification of the possible part played by EBV in the development of virus-associated tumours requires a better understanding of the mode of EBV persistence and the identification of the stage in the carcinogenic process at which EBV infection occurs.	UNIV BIRMINGHAM,DEPT CANC STUDIES,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham	YOUNG, LS (corresponding author), UNIV BIRMINGHAM,DEPT PATHOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		Young, Lawrence S/B-7213-2009	Young, Lawrence S/0000-0003-3919-4298				ALLDAY MJ, 1988, LANCET, V1, P855; BAYLISS GJ, 1980, NATURE, V287, P164, DOI 10.1038/287164a0; BIRKENBACH M, 1992, J EXP MED, V176, P1405, DOI 10.1084/jem.176.5.1405; CARR KA, 1992, AM J SURG PATHOL, V16, P909, DOI 10.1097/00000478-199209000-00010; DIMERY IW, 1988, CANCER, V61, P2475, DOI 10.1002/1097-0142(19880615)61:12<2475::AID-CNCR2820611215>3.0.CO;2-5; FISCHER E, 1991, J IMMUNOL, V146, P865; GRATAMA JW, 1988, P NATL ACAD SCI USA, V85, P8693, DOI 10.1073/pnas.85.22.8693; HAMILTONDUTOIT SJ, 1991, HUM PATHOL, V22, P811, DOI 10.1016/0046-8177(91)90210-G; HAMILTONDUTOIT SJ, 1993, BLOOD, V82, P619; HARABUCHI Y, 1990, LANCET, V335, P128, DOI 10.1016/0140-6736(90)90002-M; KAWAGUCHI H, 1993, J CLIN INVEST, V92, P1444, DOI 10.1172/JCI116721; KIKUTA H, 1988, NATURE, V333, P455, DOI 10.1038/333455a0; KLEIN G, 1979, EPSTEINBARR VIRUS, P339; KORBJUHN P, 1993, BLOOD, V82, P217, DOI 10.1182/blood.V82.1.217.bloodjournal821217; NIEDOBITEK G, 1992, BLOOD, V79, P2520; NIEDOBITEK G, 1993, J PATHOL, V170, P457, DOI 10.1002/path.1711700409; NIEDOBITEK G, 1991, J GEN VIROL, V72, P3035, DOI 10.1099/0022-1317-72-12-3035; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PITTALUGA S, 1993, AM J SURG PATHOL, V17, P678, DOI 10.1097/00000478-199307000-00004; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; ROWLANDS DC, 1993, BRIT J CANCER, V68, P1014, DOI 10.1038/bjc.1993.472; SAM CK, 1993, INT J CANCER, V53, P957; SHIBATA D, 1991, AM J PATHOL, V139, P469; SIXBEY JW, 1984, NEW ENGL J MED, V310, P1225, DOI 10.1056/NEJM198405103101905; SIXBEY JW, 1992, SCIENCE, V255, P1579; SU IJ, 1991, BLOOD, V77, P799; WEISS LM, 1989, AM J SURG PATHOL, V13, P625, DOI 10.1097/00000478-198908000-00001; YAO QY, 1989, INT J CANCER, V43, P61, DOI 10.1002/ijc.2910430114; YEUNG WM, 1993, INT J CANCER, V53, P746, DOI 10.1002/ijc.2910530507; YOUNG LS, 1989, INT J CANCER, V43, P786, DOI 10.1002/ijc.2910430508; YOUNG LS, 1991, J VIROL, V65, P2868, DOI 10.1128/JVI.65.6.2868-2874.1991; ZURHAUSE.H, 1970, NATURE, V228, P1056, DOI 10.1038/2281056a0	32	144	149	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 5	1994	343	8893					333	335		10.1016/S0140-6736(94)91167-3	http://dx.doi.org/10.1016/S0140-6736(94)91167-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905149				2022-12-28	WOS:A1994MU98500013
J	ERDEM, G; TEKINALP, G; YURDAKOK, M; OZSOYLU, S; KANRA, T; DURUKAN, T				ERDEM, G; TEKINALP, G; YURDAKOK, M; OZSOYLU, S; KANRA, T; DURUKAN, T			PERINATAL TRANSMISSION OF HEPATITIS-B VIRUS-INFECTION	LANCET			English	Letter											ERDEM, G (corresponding author), HACETTEPE UNIV,CHILDRENS HOSP,06100 ANKARA,TURKEY.							ROSENDAHL C, 1983, LANCET, V1, P1127; WRIGHT, 1993, LANCET, V342, P1335	2	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					289	289		10.1016/S0140-6736(94)91133-9	http://dx.doi.org/10.1016/S0140-6736(94)91133-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905108				2022-12-28	WOS:A1994MT44000029
J	MURPHY, TH; BARABAN, JM; WIER, WG; BLATTER, LA				MURPHY, TH; BARABAN, JM; WIER, WG; BLATTER, LA			VISUALIZATION OF QUANTAL SYNAPTIC TRANSMISSION BY DENDRITIC CALCIUM IMAGING	SCIENCE			English	Article							LONG-TERM POTENTIATION; RAT HIPPOCAMPAL SLICES; PHORBOL ESTERS; CURRENTS; NEURONS; VARIABILITY; RESPONSES; SPINES; NMDA; CA2+	As changes in synaptic strength are thought to be critical for learning and memory, it would be useful to monitor the activity of individual identified synapses on mammalian central neurons. Calcium imaging of cortical neurons grown in primary culture was used to visualize the activation of individual postsynaptic elements by miniature excitatory synaptic currents elicited by spontaneous quantal release. This approach revealed that the probability of spontaneous activity differed among synapses on the same dendrite. Furthermore, synapses that undergo changes in activity induced by glutamate or phorbol ester treatment were identified.	UNIV MARYLAND, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	MURPHY, TH (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA.		Murphy, Timothy/AAW-1975-2021; Wier, Withrow/AAE-2451-2020; Murphy, Timothy H/I-4982-2014; Blatter, Lothar/AAC-8431-2020	Murphy, Timothy/0000-0002-0093-4490; Murphy, Timothy H/0000-0002-0093-4490; Baraban, Jay/0000-0002-8165-2638				AMARAL DG, 1990, PROG BRAIN RES, V83, P1; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLATTER LA, 1992, AM J PHYSIOL, V263, pH576, DOI 10.1152/ajpheart.1992.263.2.H576; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CORMIER RJ, 1993, NEURON, V10, P907, DOI 10.1016/0896-6273(93)90206-7; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FABER DS, 1992, SCIENCE, V258, P1494, DOI 10.1126/science.1279813; FINCH DM, 1990, BRAIN RES, V518, P269, DOI 10.1016/0006-8993(90)90979-L; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTHRIE PB, 1991, NATURE, V354, P76, DOI 10.1038/354076a0; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; KOCH C, 1993, J NEUROSCI, V13, P413; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; LISMAN JE, 1993, TRENDS NEUROSCI, V16, P141, DOI 10.1016/0166-2236(93)90122-3; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; MURPHY TF, UNPUB; MURPHY TH, 1992, J NEUROSCI, V12, P4834; MURPHY TH, 1994, J NEUROSCI, V14, P1320, DOI 10.1523/JNEUROSCI.14-03-01320.1994; OTMAKHOV N, 1993, NEURON, V10, P1101, DOI 10.1016/0896-6273(93)90058-Y; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; REGEHR WG, 1990, NATURE, V345, P807, DOI 10.1038/345807a0; ROBITAILLE R, 1991, NEUROSCIENCE, V40, P571, DOI 10.1016/0306-4522(91)90142-B; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; STEVENS CF, 1993, CELL, V72, P55, DOI 10.1016/S0092-8674(05)80028-5; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; YOSHIKAMI D, 1984, NATURE, V310, P53, DOI 10.1038/310053a0	30	72	73	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	1994	263	5146					529	532		10.1126/science.7904774	http://dx.doi.org/10.1126/science.7904774			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT966	7904774				2022-12-28	WOS:A1994MT96600036
J	SMYTH, RL; VANVELZEN, D; SMYTH, AR; LLOYD, DA; HEAF, DP				SMYTH, RL; VANVELZEN, D; SMYTH, AR; LLOYD, DA; HEAF, DP			STRICTURES OF ASCENDING COLON IN CYSTIC-FIBROSIS AND HIGH-STRENGTH PANCREATIC-ENZYMES	LANCET			English	Note							MECONIUM ILEUS EQUIVALENT	We have observed five children with cystic fibrosis, who presented over 2 months, with meconium ileus equivalent that failed to respond to medical management. At surgery, four had a stricture in the ascending colon, and all had histopathological changes of post-ischaemic ulceration repair, with mucosal and submucosal fibrosis. The only common change in the management of these children was a switch from conventional enteric-coated pancreatic enzymes to high-strength products 12-15 months before presentation.	ROYAL LIVERPOOL CHILDRENS HOSP,DEPT FETAL & INFANT PATHOL,LIVERPOOL L7 7DG,MERSEYSIDE,ENGLAND; ROYAL LIVERPOOL CHILDRENS HOSP,DEPT PEDIAT SURG,LIVERPOOL L12 2AP,ENGLAND	Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital	SMYTH, RL (corresponding author), ROYAL LIVERPOOL CHILDRENS HOSP,RESP UNIT,ALDER HEY,LIVERPOOL L12 2AP,ENGLAND.			Smyth, Alan/0000-0001-5494-5438				DALZELL AM, 1990, ARCH DIS CHILD, V65, P540, DOI 10.1136/adc.65.5.540; DISANTAGNESE PA, 1953, PEDIATRICS, V12, P549; MATESHE JW, 1977, GASTROENTEROLOGY, V72, P732; OHALLORAN SM, 1986, ARCH DIS CHILD, V61, P1128, DOI 10.1136/adc.61.11.1128; OJEDA VJ, 1986, DIS COLON RECTUM, V29, P567, DOI 10.1007/BF02554256	5	226	229	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					85	86		10.1016/S0140-6736(94)90817-6	http://dx.doi.org/10.1016/S0140-6736(94)90817-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903780				2022-12-28	WOS:A1994MQ09200012
J	SCHNEIDERMAUNOURY, S; TOPILKO, P; SEITANIDOU, T; LEVI, G; COHENTANNOUDJI, M; POURNIN, S; BABINET, C; CHARNAY, P				SCHNEIDERMAUNOURY, S; TOPILKO, P; SEITANIDOU, T; LEVI, G; COHENTANNOUDJI, M; POURNIN, S; BABINET, C; CHARNAY, P			DISRUPTION OF KROX-20 RESULTS IN ALTERATION OF RHOMBOMERE-3 AND RHOMBOMERE-5 IN THE DEVELOPING HINDBRAIN	CELL			English	Article							SEGMENT-SPECIFIC EXPRESSION; DEVELOPING MOUSE HINDBRAIN; DEVELOPING CHICK HINDBRAIN; CRANIAL NEURAL CREST; ZINC-FINGER GENE; TRANSCRIPTION FACTOR; TARGETED DISRUPTION; EMBRYO HINDBRAIN; VERTEBRATE HEAD; REGION	The zinc finger gene Krox-20 is transcribed in two alternate segments (rhombomeres) of the developing hindbrain. To investigate its function, we have used homologous recombination to generate mice carrying an in-frame insertion of the E. coli lacZ gene within Krox-20. Analysis of the beta-galactosidase pattern in heterozygous embryos confirmed the known profile with expression restricted to rhombomeres (r) 3 and 5. Mice homozygous for the mutation die during the first two weeks after birth. Anatomical analysis of the hindbrain and of the cranial nerves during embryogenesis, combined with the determination of the expression patterns of rhombomere-specific genes, demonstrated that Krox-20 inactivation results in a marked reduction or elimination of r3 and r5. We conclude that Krox-20, although not required for the initial delimitation of r3 and r5, plays an important role in the process of segmentation governing hindbrain development.	ECOLE NORMALE SUPER, CNRS, UNITE RECH ASSOCIEE 1337, F-75230 PARIS 05, FRANCE; INST SCI TUMORI, CTR BIOTECNOL AVANZATE, I-16132 GENOA, ITALY; INST PASTEUR, CNRS, UNITE RECH ASSOCIEE 361, UNITE GENET MAMMIFERES, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	SCHNEIDERMAUNOURY, S (corresponding author), ECOLE NORMALE SUPER, INSERM, UNITE 368, F-75230 PARIS 05, FRANCE.		Levi, Giovanni/B-4416-2013; Schneider-Maunoury, Sylvie/K-6795-2017	Schneider-Maunoury, Sylvie/0000-0002-0797-4735; Levi, Giovanni/0000-0002-7041-6787; Cohen-Tannoudji, Michel/0000-0002-6405-2657; Charnay, Patrick/0000-0002-3847-6042	NICHD NIH HHS [N01-HD-6-2915] Funding Source: Medline; Telethon [94] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD062915] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Telethon(Fondazione Telethon); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CHAVRIER P, 1988, MOL CELL BIOL, V8, P1319, DOI 10.1128/MCB.8.3.1319; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FROHMAN MA, 1993, DEVELOPMENT, V117, P925; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GAUNT SJ, 1989, DEVELOPMENT, V107, P131; GILARDI P, 1991, BIOCHIMIE, V73, P85, DOI 10.1016/0300-9084(91)90079-G; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; GUTHRIE S, 1991, J NEUROBIOL, V22, P742, DOI 10.1002/neu.480220709; GUTHRIE S, 1993, DEVELOPMENT, V118, P527; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; HUNT P, 1991, DEVELOPMENT, V112, P43; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; KALLEN B, 1956, KLUNG FYSIOGRAF SALL, V26, P1; KURATANI SC, 1993, DEVELOPMENT, V117, P105; LEDOUARIN N, 1982, DEV CELL BIOL, V12; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUMSDEN A, 1990, TRENDS NEUROSCI, V13, P329, DOI 10.1016/0166-2236(90)90144-Y; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; MADEN M, 1992, MECH DEVELOP, V37, P13, DOI 10.1016/0925-4773(92)90011-8; MARK M, 1993, DEVELOPMENT, V119, P319; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NIETO MA, 1992, DEVELOPMENT, V116, P1137; NODEN DM, 1983, DEV BIOL, V96, P144, DOI 10.1016/0012-1606(83)90318-4; NODEN DM, 1988, DEVELOPMENT, V103, P121; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; RUBERTE E, 1992, DEVELOPMENT, V115, P973; SERBEDZIJA GN, 1992, DEVELOPMENT, V116, P297; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SOFRONIEW MV, 1985, RAT NERVOUS SYSTEM, V1, P471; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; Vaage S., 1969, ERG ANAT ENTWICKLU, V41, P1; VESQUE C, 1992, NUCLEIC ACIDS RES, V20, P2485, DOI 10.1093/nar/20.10.2485; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WILKINSON DG, 1990, SEMINARS DEV BIOL, V1, P127	50	382	385	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 17	1993	75	6					1199	1214		10.1016/0092-8674(93)90329-O	http://dx.doi.org/10.1016/0092-8674(93)90329-O			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	7903221				2022-12-28	WOS:A1993MM89300018
J	HOKKENKOELEGA, ACS; STIJNEN, T; DERIDDER, MAJ; KEIZERSCHRAMA, SMPFD; WOLFF, ED; DEJONG, MCJW; DONCKERWOLCKE, RA; GROOTHOFF, JW; BLUM, WF; DROP, SLS				HOKKENKOELEGA, ACS; STIJNEN, T; DERIDDER, MAJ; KEIZERSCHRAMA, SMPFD; WOLFF, ED; DEJONG, MCJW; DONCKERWOLCKE, RA; GROOTHOFF, JW; BLUM, WF; DROP, SLS			GROWTH-HORMONE TREATMENT IN GROWTH-RETARDED ADOLESCENTS AFTER RENAL-TRANSPLANT	LANCET			English	Article							KIDNEY-TRANSPLANTATION; PREPUBERTAL CHILDREN; FACTOR BINDING; FACTOR-I; FAILURE; FORMULA; HEIGHT; UREMIA	Growth failure is a psychosocial problem for many patients who have undergone renal transplantation. 18 adolescents (mean age 15.6, range 11.3-19.5) with severe growth retardation after renal transplantation were treated with biosynthetic growth hormone (GH) for 2 years. All received prednisone, administered daily or on alternate days, with azathioprine and/or cyclosporin A. 16 were blindly assigned to one of two GH doses (4 vs 8 IU per m(2) per day). Growth, bone maturation, renal graft function, plasma insulinlike growth factors, serum binding proteins, and other biochemical parameters were checked regularly. Glomerular filtration rate and effective renal plasma flow were tested with I-125-Thalamate and I-131-Hippuran. Data on growth and glomerular filtration rate during GH treatment were also compared with those of matched non-GH-treated controls. Mean (standard deviation) increment in height after 2 yea rs of GH was 15.7 (5.1) cm, significantly greater (p < 0.0001) than in matched controls, 5.8 (3.4) cm. Results were similar for the two GH dosage groups. Bone maturation was not accelerated. Glomerular filtration rate and effective renal plasma flow did not change significantly. The incidence of a > 25% reduction in glomerular filtration rate over 2 years was not significantly higher in GH-treated patients than in non-GH-treated controls (39% vs 32%, p = 0.97). Although a few patients had deterioration of graft function, we could not find a relation with GH treatment. Our results show that sustained improvement of height can be achieved with GH in severely growth-retarded adolescents after renal transplantation.	SOPHIA CHILDRENS UNIV HOSP,DEPT PEDIAT,DIV NEPHROL,3000 LL ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS; UNIV NIJMEGEN ST RADBOUD HOSP,DEPT PEDIAT,DIV NEPHROL,6500 HB NIJMEGEN,NETHERLANDS; UNIV HOSP AMSTERDAM,WILHELMINA CHILDRENS HOSP,DEPT PEDIAT,DIV NEPHROL,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT PEDIAT,DIV NEPHROL,1105 AZ AMSTERDAM,NETHERLANDS; UNIV TUBINGEN,CHILDRENS HOSP,TUBINGEN,GERMANY	Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital; Erasmus University Rotterdam; Radboud University Nijmegen; University of Amsterdam; Academic Medical Center Amsterdam; Wilhelmina Kinderziekenhuis; University of Amsterdam; Academic Medical Center Amsterdam; Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL	HOKKENKOELEGA, ACS (corresponding author), SOPHIA CHILDRENS UNIV HOSP,DEPT PEDIAT,DIV ENDOCRINOL,POB 70029,3000 LL ROTTERDAM,NETHERLANDS.							ALLEN DB, 1992, PEDIATRICS, V89, P416; BLUM WF, 1991, PEDIATR NEPHROL, V5, P539, DOI 10.1007/BF01453697; BLUM WF, 1989, P WORKSHOP IGF BINDI; BOSQUE M, 1983, ARCH DIS CHILD, V58, P110, DOI 10.1136/adc.58.2.110; BROYER M, 1992, J PEDIATR-US, V120, P721, DOI 10.1016/S0022-3476(05)80234-3; DOI T, 1988, AM J PATHOL, V131, P398; FINE RN, 1991, PEDIATR NEPHROL, V5, P147, DOI 10.1007/BF00852873; HACKENG WHL, 1986, J CLIN ENDOCR METAB, V63, P447, DOI 10.1210/jcem-63-2-447; HOKKENKOELEGA ACS, 1993, J CLIN ENDOCR METAB, V77, P932, DOI 10.1210/jc.77.4.932; HOKKENKOELEGA ACS, 1990, J CLIN ENDOCR METAB, V71, P688, DOI 10.1210/jcem-71-3-688; HOKKENKOELEGA ACS, 1991, LANCET, V338, P585, DOI 10.1016/0140-6736(91)90604-N; HOKKENKOELEGA ACS, 1994, IN PRESS PEDIATR RES; INGULLI E, 1993, KID INT, V44, P65; ISAKSSON OGP, 1982, SCIENCE, V216, P1237, DOI 10.1126/science.7079756; KOVACS G, 1991, KIDNEY INT, V40, P1032, DOI 10.1038/ki.1991.311; Leb D E, 1979, Proc Clin Dial Transplant Forum, V9, P136; MORRIS MC, 1982, ARCH DIS CHILD, V57, P611, DOI 10.1136/adc.57.8.611; NAGAKAWA K, 1987, ACTA ENDOCRINOL-COP, V116, P165; POLITO C, 1986, ACTA PAEDIATR SCAND, V75, P245, DOI 10.1111/j.1651-2227.1986.tb10193.x; REES L, 1988, ARCH DIS CHILD, V63, P1326, DOI 10.1136/adc.63.11.1326; RIZZONI G, 1984, KIDNEY INT, V26, P52, DOI 10.1038/ki.1984.133; ROEDE MJ, 1985, TIJDSCHR SOC GEZON S, V63, P1, DOI DOI 10.1007/978-1-4471-1721-6_10; SCHULLER AGP, 1993, GROWTH REGULAT, V3, P32; TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170; Tanner JM., 1983, ASSESSMENT SKELETAL; TONSHOFF B, 1990, J PEDIATR-US, V116, P561, DOI 10.1016/S0022-3476(05)81603-8; VANDIEMENSTEENVOORDE R, 1987, J PEDIATR-US, V110, P351, DOI 10.1016/S0022-3476(87)80493-6; WATSON AR, 1991, LANCET, V337, P108, DOI 10.1016/0140-6736(91)90764-G; WEHRENBERG WB, 1990, ENDOCRINOLOGY, V126, P3200, DOI 10.1210/endo-126-6-3200; ZIETSE R, 1993, KIDNEY INT, V43, P969	30	87	87	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1313	1317		10.1016/S0140-6736(94)92465-1	http://dx.doi.org/10.1016/S0140-6736(94)92465-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910322	Green Submitted			2022-12-28	WOS:A1994NN21700008
J	VONREYN, CF; MASLOW, JN; BARBER, TW; FALKINHAM, JO; ARBEIT, RD				VONREYN, CF; MASLOW, JN; BARBER, TW; FALKINHAM, JO; ARBEIT, RD			PERSISTENT COLONIZATION OF NOTABLE WATER AS A SOURCE OF MYCOBACTERIUM-AVIUM INFECTION IN AIDS	LANCET			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; RESPIRATORY-TRACT; POTABLE WATER; COMPLEX; INTRACELLULARE; OUTBREAK; DISEASE; SYSTEMS	The source of Mycobacterium avium infection in AIDS has not been identified and it is not known whether most patients with AIDS acquire the organism from recent infection or by reactivation of previous infection. As part of a prospective epidemiological study, we isolated multiple colonies of M avium from patients with AIDS and from potable water to which they had been exposed. All isolates were analysed with pulsed field gel electrophoresis (PFGE). As judged by PFGE, 29 (81%) of 36 patients were infected with one or more unique clinical strains of M avium. 7 patients (19%) were infected with three groups of common strains. Group 1 included 3 patients who lived in separate rural areas and had no common exposures apart from treatment at hospital A. The same strain was isolated repeatedly during 41 months from a recirculating hot water system at hospital A; residential water cultures were negative. Group 2 included 2 patients with no common exposures apart from treatment at hospital B; the same strain was isolated repeatedly over a period of 24 months from a recirculating hot water system at hospital B. Patients in groups 1 and 2 had numerous possible exposures to hospital hot water. Group 3 included 2 patients treated at the same methadone treatment facility. In an institution the hot water system may be persistently colonised with a particular strain of M avium. HIV-infected patients exposed to these water sources can develop disseminated M avium infection.	BOSTON UNIV, SCH MED, DEPT MED, BOSTON, MA 02118 USA; VET AFFAIRS MED CTR, RES SERV, BOSTON, MA USA; BOSTON CITY HOSP, DIV INFECT DIS, BOSTON, MA USA; VIRGINIA POLYTECH INST & STATE UNIV, DEPT BIOL, BLACKSBURG, VA 24061 USA	Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Boston Medical Center; Virginia Polytechnic Institute & State University	VONREYN, CF (corresponding author), DARTMOUTH HITCHCOCK MED CTR, DEPT MED, INFECT DIS SECT, 1 MED CTR DR, LEBANON, NH 03756 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030373] Funding Source: NIH RePORTER; NIAID NIH HHS [1ROI AI30373] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARBEIT RD, 1993, J INFECT DIS, V167, P1384, DOI 10.1093/infdis/167.6.1384; BOLAN G, 1985, J INFECT DIS, V152, P1013, DOI 10.1093/infdis/152.5.1013; BURNS DN, 1991, AM REV RESPIR DIS, V144, P1153, DOI 10.1164/ajrccm/144.5.1153; CHIN DP, 1994, J INFECT DIS, V169, P289, DOI 10.1093/infdis/169.2.289; COSTRINI AM, 1981, AM REV RESPIR DIS, V123, P104; du Moulin G. C., 1986, ASM NEWS, V52, P525; DUMOULIN GC, 1988, JAMA-J AM MED ASSOC, V260, P1599, DOI 10.1001/jama.260.11.1599; DUMOULIN GC, 1978, APPL ENVIRON MICROB, V36, P771, DOI 10.1128/AEM.36.5.771-773.1978; DUMOULIN GC, 1985, J CLIN MICROBIOL, V22, P9, DOI 10.1128/JCM.22.1.9-12.1985; GEORGE KL, 1986, CAN J MICROBIOL, V32, P10, DOI 10.1139/m86-003; GRANGE JM, 1990, J APPL BACTERIOL, V68, P411, DOI 10.1111/j.1365-2672.1990.tb02892.x; HAAS CN, 1983, J AM WATER WORKS ASS, V75, P139; HORSBURGH CR, 1992, AIDS, V6, P512; HORSBURGH CR, 1989, AM REV RESPIR DIS, V139, P4, DOI 10.1164/ajrccm/139.1.4; HORSBURGH CR, 1991, NEW ENGL J MED, V324, P1332, DOI 10.1056/NEJM199105093241906; ISEMAN MD, 1989, NEW ENGL J MED, V321, P896, DOI 10.1056/NEJM198909283211310; LOCKWOOD WW, 1989, AM REV RESPIR DIS, V140, P1614, DOI 10.1164/ajrccm/140.6.1614; LOWRY PW, 1988, NEW ENGL J MED, V319, P978, DOI 10.1056/NEJM198810133191504; Maslow Joel N., 1993, P563; MASUR H, 1993, NEW ENGL J MED, V329, P898, DOI 10.1056/NEJM199309163291228; MERKAL RS, 1979, APPL ENVIRON MICROB, V38, P827, DOI 10.1128/AEM.38.5.827-830.1979; NEL EE, 1981, REV INFECT DIS, V3, P1013; NIGHTINGALE SD, 1993, NEW ENGL J MED, V329, P828, DOI 10.1056/NEJM199309163291202; NIGHTINGALE SD, 1992, J INFECT DIS, V165, P1082, DOI 10.1093/infdis/165.6.1082; PELLETIER PA, 1988, MICROBIOL SCI, V5, P147; PRINCE DS, 1989, NEW ENGL J MED, V321, P863, DOI 10.1056/NEJM198909283211304; SHAFRAN SD, 1994, NEW ENGL J MED, V330, P438, DOI 10.1056/NEJM199402103300616; SNIADACK DH, 1993, INFECT CONT HOSP EP, V14, P636; SPACH DH, 1993, ANN INTERN MED, V118, P117, DOI 10.7326/0003-4819-118-2-199301150-00008; STOTTMEIER KD, 1967, AM REV RESPIR DIS, V96, P1072; STOUT JE, 1992, NEW ENGL J MED, V326, P151, DOI 10.1056/NEJM199201163260302; TSANG AY, 1992, J CLIN MICROBIOL, V30, P479, DOI 10.1128/JCM.30.2.479-484.1992; VONREYN CF, 1993, J INFECT DIS, V168, P1553, DOI 10.1093/infdis/168.6.1553; VONREYN CF, 1993, J CLIN MICROBIOL, V31, P3227, DOI 10.1128/JCM.31.12.3227-3230.1993; VONREYN CF, 1994, NEW ENGL J MED, V330, P437; VONREYN CF, 1993, 9TH INT C AIDS BERL; YU VL, 1993, INFECT CONT HOSP EP, V14, P567, DOI 10.1086/646638	37	328	333	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 7	1994	343	8906					1137	1141		10.1016/S0140-6736(94)90239-9	http://dx.doi.org/10.1016/S0140-6736(94)90239-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK730	7910236	hybrid			2022-12-28	WOS:A1994NK73000013
J	PAWLIKOWSKA, T; CHALDER, T; HIRSCH, SR; WALLACE, P; WRIGHT, DJM; WESSELY, S				PAWLIKOWSKA, T; CHALDER, T; HIRSCH, SR; WALLACE, P; WRIGHT, DJM; WESSELY, S			POPULATION-BASED STUDY OF FATIGUE AND PSYCHOLOGICAL DISTRESS	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY CARE; PREVALENCE; BEHAVIOR	Objectives-To determine the prevalence of fatigue in the general population and the factors associated with fatigue. Design-Postal survey. Setting-Six general practices in southern England. Subjects-31 651 men and women aged 18-45 years registered with the practices. Main outcome measures-Responses to the 12 item general health questionnaire and a fatigue questionnaire which included self reported measures of duration, severity, and causes of fatigue. Results-15 283 valid questionnaires were returned, giving a response rate of 48.3%, (64% after adjustment for inaccuracies in the practice registers). 2798 (18.3%) of respondents reported substantial fatigue lasting six months or longer. Fatigue and psychological morbidity were moderately correlated (r = 0.62). Women were more likely to complain of fatigue than men, even after adjustment for psychological distress. The commonest cited reasons for fatigue were psychosocial (40% of patients). Of 2798 patients with excessive tiredness, only 38 (1.4%) attributed this to the chronic fatigue syndrome. Conclusion-Fatigue is distributed as a continuous variable in the community and is closely associated with psychological morbidity.	KINGS COLL, SCH MED & DENT, DEPT PSYCHOL MED, LONDON SE5 9RS, ENGLAND; ST MARYS HOSP, SCH MED, DEPT GEN PRACTICE, LONDON, ENGLAND; CHARING CROSS HOSP, SCH MED, DEPT MED MICROBIOL, LONDON, ENGLAND; CHARING CROSS HOSP, SCH MED, DEPT PSYCHIAT, LONDON, ENGLAND; ROYAL FREE HOSP, SCH MED, DEPT GEN PRACTICE, LONDON NW3, ENGLAND	University of London; King's College London; Imperial College London; Imperial College London; Imperial College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Wessely, Simon C/A-8713-2008; Chalder, Trudie/A-5717-2011	Chalder, Trudie/0000-0003-0775-1045; Wessely, Simon Charles/0000-0002-6743-9929				BEHAN P, 1988, CRIT REV NEURBIOL, V42, P157; BICKLER G, 1993, BRIT MED J, V306, P1167, DOI 10.1136/bmj.306.6886.1167; BUTLER S, 1991, J NEUROL NEUROSUR PS, V54, P153, DOI 10.1136/jnnp.54.2.153; CATHEBRAS PJ, 1992, J GEN INTERN MED, V7, P276, DOI 10.1007/BF02598083; CHALDER T, 1993, H PSYCHOSOMATIC RES, V37, P147; CROFT P, 1993, J RHEUMATOL, V20, P710; DAVID A, 1990, BMJ-BRIT MED J, V301, P1199, DOI 10.1136/bmj.301.6762.1199; DAVID AS, 1988, BRIT MED J, V296, P696, DOI 10.1136/bmj.296.6623.696; DAVID AS, 1991, BRIT MED BULL, V47, P966, DOI 10.1093/oxfordjournals.bmb.a072524; Goldberg DPW, 1988, USERS GUIDE GEN HLTH; JONES R, 1992, BRIT MED J, V304, P87, DOI 10.1136/bmj.304.6819.87; KATON W, 1992, ARCH INTERN MED, V152, P1604, DOI 10.1001/archinte.152.8.1604; KROENKE K, 1988, JAMA-J AM MED ASSOC, V260, P929, DOI 10.1001/jama.260.7.929; LEWIS G, 1992, J EPIDEMIOL COMMUN H, V46, P92, DOI 10.1136/jech.46.2.92; MANU P, 1988, ARCH INTERN MED, V148, P2213, DOI 10.1001/archinte.148.10.2213; MCDONALD E, 1993, PSYCHOL MED, V23, P987, DOI 10.1017/S0033291700026453; SHARPE M, 1992, BRIT MED J, V302, P347; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940	19	465	472	0	19	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 19	1994	308	6931					763	766		10.1136/bmj.308.6931.763	http://dx.doi.org/10.1136/bmj.308.6931.763			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC348	7908238	Green Published			2022-12-28	WOS:A1994NC34800024
J	SPRUANCE, SL; PAVIA, AT; PETERSON, D; BERRY, A; POLLARD, R; PATTERSON, TF; FRANK, I; REMICK, SC; THOMPSON, M; MACARTHUR, RD; MOREY, GE; RAMIREZRONDA, CH; BERNSTEIN, BM; SWEET, DE; CRANE, L; PETERSON, EA; PACHUCKI, CT; GREEN, SL; BRAND, J; RIOS, A; DUNKLE, LM; CROSS, A; BROWN, MJ; INGRAHAM, P; GUGLIOTTI, R; SCHINDZIELORZ, AH; SMALDONE, L; BECKER, T; BIA, FJ; BUJWIT, C; DONABEDIAN, H; EVANS, TG; FIELLIN, M; KAEMPFER, S; OKEEFE, JP; LIPTON, L; MARK, RJ; OTT, G; REIMER, LG; RIES, K; WATERMAN, K; WEST, MM				SPRUANCE, SL; PAVIA, AT; PETERSON, D; BERRY, A; POLLARD, R; PATTERSON, TF; FRANK, I; REMICK, SC; THOMPSON, M; MACARTHUR, RD; MOREY, GE; RAMIREZRONDA, CH; BERNSTEIN, BM; SWEET, DE; CRANE, L; PETERSON, EA; PACHUCKI, CT; GREEN, SL; BRAND, J; RIOS, A; DUNKLE, LM; CROSS, A; BROWN, MJ; INGRAHAM, P; GUGLIOTTI, R; SCHINDZIELORZ, AH; SMALDONE, L; BECKER, T; BIA, FJ; BUJWIT, C; DONABEDIAN, H; EVANS, TG; FIELLIN, M; KAEMPFER, S; OKEEFE, JP; LIPTON, L; MARK, RJ; OTT, G; REIMER, LG; RIES, K; WATERMAN, K; WEST, MM			DIDANOSINE COMPARED WITH CONTINUATION OF ZIDOVUDINE IN HIV-INFECTED PATIENTS WITH SIGNS OF CLINICAL DETERIORATION WHILE RECEIVING ZIDOVUDINE - A RANDOMIZED, DOUBLE-BLIND CLINICAL-TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS; DIDANOSINE; ZIDOVUDINE; AIDS-RELATED COMPLEX; ACQUIRED IMMUNODEFICIENCY SYNDROME	IMMUNODEFICIENCY-VIRUS INFECTION; 2',3'-DIDEOXYINOSINE; RESISTANCE; TYPE-1; AZT	Objective: To determine the benefits of switching to didanosine compared with continuing zidovudine among patients infected with human immunodeficiency virus (HIV) who have previously used zidovudine and have signs of clinical deterioration. Design:Randomized, double-blind, two-armed, parallel, comparative clinical trial with a blinded, compassionate crossover provision at 12 weeks. Setting: Outpatient clinics at 19 tertiary care medical centers. Patients: 312 patients infected with HIV who had received zidovudine for 6 months or more, had CD4 cell counts of 300/mm(3) or less, and had signs of clinical deterioration within 12 weeks before study entry. Intervention: Peroral didanosine tablets (600 mg/d adjusted for weight, ''high dose'') or zidovudine capsules (600 mg/d). Measurements: Primary study end points were death, a new acquired immunodeficiency syndrome (AIDS)-defining event, or the combination of two new or recurrent HIV-related diagnoses with a 50% decrease in CD4 cells. Results: Switching to didanosine was associated with fewer end points than continuing zidovudine (relative risk [RR] for zidovudine:didanosine = 1.5; 95% Cl, 1.1 to 2.0). This benefit was consistent across subgroups of patients with either AIDS-related complex or AIDS and was most apparent among those with a CD4 count at entry of 100/mm(3) or more (RR = 2.2; Cl, 1.1 to 4.4). Conclusions: This study shows a positive treatment effect for switching from zidovudine to didanosine among patients with either AIDS-related complex or AIDS and validates the common practice of using clinical signs or a decrease in the CD4 count as an indication for changing therapy.	HOLY CROSS HOSP, SALT LAKE CITY, UT 84102 USA; UNIV TEXAS, SW MED CTR DALLAS, DALLAS, TX 75235 USA; UNIV ARIZONA, HLTH SCI CTR, INFECT DIS SECT, TUCSON, AZ 85724 USA; AUDIE L MURPHY MEM VET ADM MED CTR, SAN ANTONIO, TX 78284 USA; YALE UNIV, SCH MED, NEW HAVEN, CT USA; UNIV PENN, IMMUNODEFICIENCY PROGRAM, PHILADELPHIA, PA 19104 USA; ALBANY MED CTR, ALBANY, NY USA; AIDS RES CONSORTIUM ATLANTA, ATLANTA, GA USA; MED COLL OHIO, DEPT MED, TOLEDO, OH 43614 USA; VET AFFAIRS MED CTR, SAN JUAN, PR 00927 USA; MED COLL WISCONSIN, MILWAUKEE, WI 53226 USA; UNIV KANSAS, SCH MED, WICHITA, KS 67214 USA; VET AFFAIRS EDWARD HINES JR HOSP, INFECT DIS SECT, HINES, IL 60141 USA; UNIV ARIZONA, HLTH SCI CTR, TUCSON, AZ 85724 USA; HOME HLTH CARE SERV, RES INST, ORLANDO, FL USA; BRISTOL MYERS SQUIBB, PHARMACEUT RES INST, WALLINGFORD, CT 06492 USA; UNIV TEXAS, MED BRANCH, GALVESTON, TX 77555 USA; HARPER GRACE HOSP, DETROIT, MI 48201 USA; UNIV PUERTO RICO, SCH MED & AFFILIATED HOSP, SAN JUAN, PR USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Arizona; University of Arizona Health Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Yale University; University of Pennsylvania; Albany Medical College; US Department of Veterans Affairs; Veterans Health Administration (VHA); Medical College of Wisconsin; University of Kansas; University of Kansas Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; University of Arizona; University of Arizona Health Sciences; Bristol-Myers Squibb; University of Texas System; University of Texas Medical Branch Galveston; University of Puerto Rico	SPRUANCE, SL (corresponding author), UNIV UTAH, HLTH SCI AIDS CTR, MC 4B322, 50 N MED DR, SALT LAKE CITY, UT 84132 USA.							COX DR, 1972, J R STAT SOC B, V34, P187; CROSS A, 1993, 9TH INT C AIDS BERL, V1, P486; DAQUILA R, 1993, 9TH INT C AIDS BERL, V1, P476; DARBYSHIRE JH, 1992, LANCET, V340, P1346, DOI 10.1016/0140-6736(92)92524-J; DOLIN R, 1993, 9TH INT C AIDS BERL, V1, P67; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FLEISS JL, 1973, STATISTICAL METHODS; GAO Q, 1992, J VIROL, V66, P12, DOI 10.1128/JVI.66.1.12-19.1992; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; GU ZX, 1992, J VIROL, V66, P7128, DOI 10.1128/JVI.66.12.7128-7135.1992; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HARTMAN NR, 1991, CLIN PHARMACOL THER, V50, P278, DOI 10.1038/clpt.1991.137; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOZAL MJ, 1993, J INFECT DIS, V167, P526, DOI 10.1093/infdis/167.3.526; MCLEOD GX, 1992, ANTIMICROB AGENTS CH, V36, P920, DOI 10.1128/AAC.36.5.920; MONTANER JSG, 1993, AIDS, V7, P189, DOI 10.1097/00002030-199302000-00006; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; REICHMAN RC, 1993, ANTIVIR RES, V20, P267, DOI 10.1016/0166-3542(93)90071-P; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WEI LJ, 1984, J AM STAT ASSOC, V79, P653, DOI 10.2307/2288413; YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840; 1987, MORB MORTAL WKLY S1, V36, pS1	24	73	73	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1994	120	5					360	368		10.7326/0003-4819-120-5-199403010-00002	http://dx.doi.org/10.7326/0003-4819-120-5-199403010-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY497	7905722				2022-12-28	WOS:A1994MY49700002
J	WITTEMAN, JCM; GROBBEE, DE; VALKENBURG, HA; VANHEMERT, AM; STIJNEN, T; BURGER, H; HOFMAN, A				WITTEMAN, JCM; GROBBEE, DE; VALKENBURG, HA; VANHEMERT, AM; STIJNEN, T; BURGER, H; HOFMAN, A			J-SHAPED RELATION BETWEEN CHANGE IN DIASTOLIC BLOOD-PRESSURE AND PROGRESSION OF AORTIC ATHEROSCLEROSIS	LANCET			English	Article							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; CALCIFICATION; MORTALITY; RISK	The J-shaped relation between diastolic blood pressure and mortality from coronary heart disease continues to provoke controversy. We examined the association between diastolic blood pressure and progression of aortic atherosclerosis in a population-based cohort of 855 women, aged 45-64 years at baseline. The women were examined radiographically for calcified deposits in the abdominal aorta, which have been shown to reflect intimal atherosclerosis. After 9 years of follow-up, slight progression of atherosclerosis was noted in 19% of women and substantial progression in 16%. The age-adjusted relative risk of substantial atherosclerotic progression in women with a decrease in diastolic pressure of 10 mm Hg or more was 2.5 (95% CI 1.3-5.6), compared with the reference group of women who had a smaller decrease or no change. The excess risk in this group was confined to women whose increase in pulse pressure was above the median (3.9 [1.5-9.9] vs 1.1 [0.3-4.2] in women with an increase in pulse pressure below the median). The relative risks for women with rises in diastolic pressure of 1-9 mm Hg and 10 mm Hg or more were 2.2 (1.1-4.3) and 3.5 (1.6-8.0), respectively. These findings suggest that a decline in diastolic blood pressure indicates vessel wall stiffening associated with atherosclerotic progression. They support the hypothesis that in low-risk subjects progression of atherosclerosis may be accompanied by a decrease in diastolic blood pressure rather than the opposing idea that low diastolic blood pressure precipitates the occurrence of atherosclerotic events.	UNIV HOSP LEIDEN,DEPT PSYCHIAT,LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	WITTEMAN, JCM (corresponding author), ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.		Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				BOTS ML, 1993, ATHEROSCLEROSIS, V102, P99, DOI 10.1016/0021-9150(93)90088-C; COOPE J, 1988, J HUM HYPERTENS, V2, P79; CRUICKSHANK JM, 1988, BMJ-BRIT MED J, V297, P1227, DOI 10.1136/bmj.297.6658.1227; CRUICKSHANK JM, 1987, LANCET, V1, P581; DAGOSTINO RB, 1991, BRIT MED J, V303, P385, DOI 10.1136/bmj.303.6799.385; Dixon W. J., 1990, BMDP STATISTICAL SOF; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; Fineberg MH, 1927, AM J MED SCI, V173, P835; FLETCHER AE, 1992, NEW ENGL J MED, V326, P251; HYMAN JB, 1954, AM HEART J, V47, P540; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MEGNIEN JL, 1992, CIRCULATION, V85, P1799, DOI 10.1161/01.CIR.85.5.1799; SLEIGHT P, 1988, LANCET, V1, P235; TAYLOR JO, 1991, AM J EPIDEMIOL, V134, P489, DOI 10.1093/oxfordjournals.aje.a116121; VANHEMERT AM, 1990, AM J EPIDEMIOL, V132, P123, DOI 10.1093/oxfordjournals.aje.a115624; VANMERODE T, 1988, ULTRASOUND MED BIOL, V14, P563, DOI 10.1016/0301-5629(88)90122-6; Wiggers CJ, 1932, ANN INTERN MED, V6, P12, DOI 10.7326/0003-4819-6-1-12; WITTEMAN JCM, 1986, LANCET, V2, P1120; WITTEMAN JCM, 1990, AM J CARDIOL, V66, P1060, DOI 10.1016/0002-9149(90)90505-U; WITTEMAN JCM, 1993, CIRCULATION, V88, P2156, DOI 10.1161/01.CIR.88.5.2156	20	218	223	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					504	507		10.1016/S0140-6736(94)91459-1	http://dx.doi.org/10.1016/S0140-6736(94)91459-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906758	Green Submitted			2022-12-28	WOS:A1994MX88800007
J	CAYGILL, CPJ; HILL, MJ; BRADDICK, M; SHARP, JCM				CAYGILL, CPJ; HILL, MJ; BRADDICK, M; SHARP, JCM			CANCER MORTALITY IN CHRONIC TYPHOID AND PARATYPHOID CARRIERS	LANCET			English	Article							CARCINOMA; PANCREAS	It has been shown in vitro that bacteria are able to form or release carcinogens, mutagens, or promoters from intestinal secretions such as bile, or from excretions such as urine. It is, therefore, of interest to find out whether chronic infection of the gallbladder is associated with carcinogens, as in chronic infection of the urinary bladder. A study of cancer risk in chronic typhoid and paratyphoid carriers showed a large excess (observed/expected cases) for cancer of the gallbladder (167.0; 95% confidence interval 54.1-389) and also excess risks of cancer of the pancreas (8.1), colorectum (3.0), lung (2.5), and all neoplasms (2.6). There was no similar excess risk in a group of 386 people with typhoid from the 1964 Aberdeen outbreak. This indicates that it is long-term typhoid carriage, not acute infection, which is the risk factor. This has important implications for cancer prevention. Eradication of chronic carriage, by use of antibiotics or elective cholecystectomy, should be re-emphasised, and the need for good documentation of carriers is, therefore, of great importance.	PUBL HLTH LAB SERV,CTR APPL MICROBIOL RES,DIV PATHOL,PORTON DOWN,WILTS,ENGLAND; WEXHAM PK HOSP,EUROPEAN CANC PREVENT ORG HEADQUARTERS,LADY SOBELL GASTROINTESTINAL UNIT,INVERNESS,SCOTLAND; HILTON HOSP,DEPT PUBL HLTH,INVERNESS,SCOTLAND; RUCHILL HOSP,DEPT COMMUNICABLE DIS,GLASGOW G20 9NB,SCOTLAND									CAYGILL CPJ, 1986, LANCET, V1, P929; ELZAYADI A, 1991, HEPATO-GASTROENTEROL, V38, P337; FRAUMENI JF, 1975, CANCER RES, V35, P3437; GARDNER MJ, 1989, BMJ; Hill M J, 1986, MICROBES HUMAN CARCI; KINOSHITA N, 1978, SCIENCE, V199, P307, DOI 10.1126/science.619459; Ledingham JCG, 1912, CARRIER PROBLEM INFE, P5; LINOS DA, 1981, LANCET, V2, P379; LOWENFELS AB, 1978, LANCET, V2, P239; MELLEMGAARD A, 1988, J NATL CANCER I, V80, P288, DOI 10.1093/jnci/80.4.288; WELTON JC, 1979, LANCET, V1, P791; WYNDER EL, 1975, CANCER RES, V35, P2228	12	136	142	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					83	84		10.1016/S0140-6736(94)90816-8	http://dx.doi.org/10.1016/S0140-6736(94)90816-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903779				2022-12-28	WOS:A1994MQ09200011
J	BURNS, DN; GELLERT, GA; CRONE, RK				BURNS, DN; GELLERT, GA; CRONE, RK			TUBERCULOSIS IN EASTERN-EUROPE AND THE FORMER SOVIET-UNION - HOW CONCERNED SHOULD WE BE	LANCET			English	Editorial Material									PROJECT HOPE,CTR HLTH SCI EDUC,MILLWOOD,VA		BURNS, DN (corresponding author), NIH,BETHESDA,MD 20892, USA.							BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; CHEN LC, 1992, LANCET, V339, P1465, DOI 10.1016/0140-6736(92)92044-G; ELLNER JJ, 1993, J INFECT DIS, V168, P537, DOI 10.1093/infdis/168.3.537; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; NEVILLE K, 1994, CHEST, V105, P45, DOI 10.1378/chest.105.1.45; RAVIGLIONE MC, 1993, B WORLD HEALTH ORGAN, V71, P297; RAVIGLIONE MC, 1994, WHOTB94176 DOC; 1993, MMWR-MORBID MORTAL W, V42, P696	8	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1445	1446		10.1016/S0140-6736(94)92576-3	http://dx.doi.org/10.1016/S0140-6736(94)92576-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911172				2022-12-28	WOS:A1994NQ41500003
J	MCKEIGUE, P				MCKEIGUE, P			DIETS FOR SECONDARY PREVENTION OF CORONARY HEART-DISEASE - CAN LINOLENIC ACID SUBSTITUTE FOR OILY FISH	LANCET			English	Editorial Material							FATTY-ACIDS; CANOLA OIL; PLASMA; PLATELET				MCKEIGUE, P (corresponding author), LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1,ENGLAND.							BURR ML, 1989, LANCET, V2, P757; CHAN JK, 1993, LIPIDS, V28, P811, DOI 10.1007/BF02536235; INDU M, 1992, NUTR RES, V12, P569, DOI 10.1016/S0271-5317(05)80027-2; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; MCDONALD BE, 1989, AM J CLIN NUTR, V50, P1382, DOI 10.1093/ajcn/50.6.1382; NETTLETON JA, 1991, J AM DIET ASSOC, V91, P331; SANDERS TAB, 1981, BRIT J NUTR, V45, P613, DOI 10.1079/BJN19810139; SEPPANENLAAKSO T, 1992, BRIT J NUTR, V68, P639, DOI 10.1079/BJN19920122; WEAVER BJ, 1990, AM J CLIN NUTR, V51, P594, DOI 10.1093/ajcn/51.4.594; 1992, ECONOMIST       1128, P65	10	17	17	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1445	1445		10.1016/S0140-6736(94)92575-5	http://dx.doi.org/10.1016/S0140-6736(94)92575-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911171				2022-12-28	WOS:A1994NQ41500002
J	PRICE, P; GRIFFITHS, J				PRICE, P; GRIFFITHS, J			TUMOR PHARMACOKINETICS - WE DO NEED TO KNOW	LANCET			English	Editorial Material									ST GEORGE HOSP,SCH MED,CRC,BIOMED MAGNET RESONANCE RES GRP,LONDON,ENGLAND	St Georges University London	PRICE, P (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CLIN ONCOL,LONDON W12 0HS,ENGLAND.		Griffiths, John R/F-2853-2010					BIGNALL J, 1994, LANCET, V343, P786, DOI 10.1016/S0140-6736(94)91854-6; FINDLAY MPN, 1993, ANN ONCOL, V4, P597, DOI 10.1093/oxfordjournals.annonc.a058595; GUTTIEREZ AA, 1992, LANCET, V339, P715; MOERTEL CG, 1994, NEW ENGL J MED, V330, P1136; ROWLANDS IJ, 1993, 12TH P ANN SMRM M, V1, P244; STEVENS AN, 1984, BRIT J CANCER, V50, P113, DOI 10.1038/bjc.1984.146; TILSLEY DWO, NEW TECHNIQUES PHARM, V4; 1994, FINANCIAL TIMES 0323	8	14	14	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1174	1175		10.1016/S0140-6736(94)92395-7	http://dx.doi.org/10.1016/S0140-6736(94)92395-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909863				2022-12-28	WOS:A1994NL17500004
J	BANATVALA, JE; CHRYSTIE, IL				BANATVALA, JE; CHRYSTIE, IL			HIV SCREENING IN PREGNANCY - UK TAGS	LANCET			English	Editorial Material											BANATVALA, JE (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,DEPT VIROL,LONDON,ENGLAND.							ADES AE, 1993, BRIT MED J, V306, P1296, DOI 10.1136/bmj.306.6888.1296; BARBACCI M, 1991, LANCET, V337, P709, DOI 10.1016/0140-6736(91)90286-X; Chrystie I, 1992, Health Trends, V24, P13; DAVISON CF, 1993, AIDS CARE, V5, P135, DOI 10.1080/09540129308258593; GOUDEAU A, 1989, PARS TOURS COOPERATI; HOWARD LC, 1989, BRIT J OBSTET GYNAEC, V96, P135, DOI 10.1111/j.1471-0528.1989.tb01651.x; LINDGREN S, 1993, BRIT MED J, V307, P1447, DOI 10.1136/bmj.307.6917.1447; MEADOWS J, 1990, AIDS Care, V2, P229, DOI 10.1080/09540129008257735; MEADOWS J, 1992, LANCET, V339, P622; SIMMONDS RJ, 1992, 41ST EP INT SERV ANN, P35; 1992, IMMUNISATION INFECTI, P114; 1994, CLIN ALERT IMPORTANT; 1992, DEP HLTH GUIDANCE PL; 1993, AIDS SURVEILLANCE EU, V37, P20	14	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1994	343	8906					1113	1114		10.1016/S0140-6736(94)90230-5	http://dx.doi.org/10.1016/S0140-6736(94)90230-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK730	7910227				2022-12-28	WOS:A1994NK73000004
J	GODFREY, R				GODFREY, R			THE NOSE AND THE LOWER AIRWAYS	LANCET			English	Editorial Material							EXERCISE; ASTHMA				GODFREY, R (corresponding author), SOUTHAMPTON GEN HOSP,DEPT MED,SOUTHAMPTON,ENGLAND.							ANDERSEN I, 1974, ARCH ENVIRON HEALTH, V28, P31, DOI 10.1080/00039896.1974.10666429; BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; GILBERT IA, 1988, J APPL PHYSIOL, V64, P2167, DOI 10.1152/jappl.1988.64.5.2167; Proctor DF, 1982, NOSE UPPER AIRWAY PH; RUBINSTEIN I, 1988, AM REV RESPIR DIS, V138, P1164, DOI 10.1164/ajrccm/138.5.1164; SCHUMACHER MJ, 1986, J ALLERGY CLIN IMMUN, V78, P30, DOI 10.1016/0091-6749(86)90111-9; SERRABATLLES J, 1994, THORAX, V49, P128, DOI 10.1136/thx.49.2.128; WIDDICOMBE JG, 1990, EUR RESPIR J S12, V3, P564	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 23	1994	343	8904					991	992		10.1016/S0140-6736(94)90122-8	http://dx.doi.org/10.1016/S0140-6736(94)90122-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909089				2022-12-28	WOS:A1994NG68200005
J	HAUSEN, HZ				HAUSEN, HZ			DISRUPTED DICHOTOMOUS INTRACELLULAR CONTROL OF HUMAN PAPILLOMAVIRUS INFECTION IN CANCER OF THE CERVIX	LANCET			English	Note							FINITE LIFE-SPAN; GENE-EXPRESSION; HUMAN KERATINOCYTES; EPITHELIAL-CELLS; T-ANTIGEN; E7 GENE; TYPE-16; PHENOTYPE; HPV16; PROGRESSION	The role of specific human papillomaviruses (HPVs) in the aetiology of cancer of the cervix is firmly established. Progression of an HPV-infected cell clone to invasive growth involves consecutive modifications of a set of host cell genes. Some of these modifications suppress viral oncogene functions post-transcriptionally, and others suppress transcription via a signalling pathway stimulated by activated macrophages and possibly by additional cells. I describe a scheme that tries to unify available data by postulating the existence of two intracellular signalling pathways.in the control of latent HPV infections.			HAUSEN, HZ (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM, NEUENHEIMER FELD 280, D-69120 HEIDELBERG, GERMANY.							BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLANTON RA, 1992, CELL GROWTH DIFFER, V3, P791; BOHM S, 1993, INT J CANCER, V55, P791, DOI 10.1002/ijc.2910550517; BOSCH FX, 1990, J VIROL, V64, P4743, DOI 10.1128/JVI.64.10.4743-4754.1990; CHANG SE, 1985, BIOCHIM BIOPHYS ACTA, V823, P161; CHEN TM, 1993, CANCER RES, V53, P1167; CROMME FV, 1993, ONCOGENE, V8, P2969; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DREWS RE, 1992, MOL CELL BIOL, V12, P198, DOI 10.1128/MCB.12.1.198; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; DURST M, 1991, J VIROL, V65, P796; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ESTERVIG DN, 1989, J VIROL, V63, P2718, DOI 10.1128/JVI.63.6.2718-2725.1989; FRAZER IH, 1986, LANCET, V2, P657; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARPER JW, 1993, CELL, V75, P805; HASHIDA T, 1991, J GEN VIROL, V72, P1569, DOI 10.1099/0022-1317-72-7-1569; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; KIVIAT NB, 1993, AIDS, V7, P43, DOI 10.1097/00002030-199301000-00007; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; NICOLSON GL, 1987, CANCER RES, V47, P1473; OSHIMA J, 1993, ONCOGENE, V8, P2987; PECORARO G, 1991, AM J PATHOL, V138, P1; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PEREIRASMITH OM, 1981, SOMAT CELL GENET, V7, P411, DOI 10.1007/BF01542986; ROSL F, 1988, EMBO J, V7, P1321, DOI 10.1002/j.1460-2075.1988.tb02947.x; ROSL F, 1991, EMBO J, V10, P1337, DOI 10.1002/j.1460-2075.1991.tb07653.x; ROSL F, 1994, J VIROL, V68, P2142; SMITS PHM, 1992, EMBO J, V11, P4601, DOI 10.1002/j.1460-2075.1992.tb05562.x; Snijders P J, 1994, Curr Top Microbiol Immunol, V186, P177; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; VONKNEBEL M, 1992, INT J CANCER, V51, P831, DOI 10.1002/ijc.2910510527; WHITAKER NJ, 1992, J VIROL, V66, P1202, DOI 10.1128/JVI.66.2.1202-1206.1992; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; zur Hausen H, 1994, Curr Top Microbiol Immunol, V186, P131; Zur Hausen H, 1982, LANCET, V2, P1370, DOI DOI 10.1016/S0140-6736(82)91273-9; ZURHAUSEN H, 1989, ADV VIRAL ONCOL, V8, P1; ZURHAUSEN H, 1977, BEHRING I MITT, V61, P23	40	85	92	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 16	1994	343	8903					955	957		10.1016/S0140-6736(94)90070-1	http://dx.doi.org/10.1016/S0140-6736(94)90070-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909014				2022-12-28	WOS:A1994NF70000014
J	ADAMS, DH; SHAW, S				ADAMS, DH; SHAW, S			LEUKOCYTE-ENDOTHELIAL INTERACTIONS AND REGULATION OF LEUKOCYTE MIGRATION	LANCET			English	Review							LEUKOCYTE ADHESION DEFICIENCY; MOLECULE-1; CELLS; INFLAMMATION; EXPRESSION; TISSUES; SELECTINS; INTEGRIN; BINDING; ELAM-1		NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	ADAMS, DH (corresponding author), QUEEN ELIZABETH HOSP,LIVER RES LABS,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.		Adams, David H/C-9092-2009	Adams, David H/0000-0001-6776-0336				ADAMS DH, 1994, HEPATOLOGY, V19, P588, DOI 10.1002/hep.1840190308; ADAMS DH, 1989, LANCET, V2, P1122; ADAMS DH, IN PRESS P NATL ACAD; Anderson A O, 1993, Semin Immunol, V5, P271, DOI 10.1006/smim.1993.1031; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; BERGASA NV, 1993, GASTROENTEROLOGY, V104, pA877; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CORKILL MM, 1991, J RHEUMATOL, V18, P1453; COSIMI AB, 1991, STRUCTURE FUNCTION R, P373; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; GUNDEL RH, 1991, J CLIN INVEST, V88, P1407, DOI 10.1172/JCI115447; HORGAN KJ, 1992, CHEM IMMUNOL, V54, P72; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; KOCH AE, 1991, LAB INVEST, V64, P313; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; MACKAY CR, 1993, CURR OPIN IMMUNOL, V5, P423, DOI 10.1016/0952-7915(93)90063-X; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; POBER JS, 1991, LAB INVEST, V64, P301; RICE GE, 1991, AM J PATHOL, V138, P385; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; SALMI M, 1992, SCIENCE, V257, P1407, DOI 10.1126/science.1529341; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHWEIGHOFFER T, 1993, J IMMUNOL, V151, P717; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SMITH CW, 1990, LEUKOCYTE ADHESION MOLECULES, P170; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SWERLICK RA, 1992, J IMMUNOL, V149, P698; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; VOLPES R, 1992, HEPATOLOGY, V15, P269, DOI 10.1002/hep.1840150216; WINN RK, 1993, AGENT ACTION SUPPL, V41, P113; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2	44	550	560	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					831	836		10.1016/S0140-6736(94)92029-X	http://dx.doi.org/10.1016/S0140-6736(94)92029-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908081				2022-12-28	WOS:A1994ND79200012
J	WILKINSON, D				WILKINSON, D			HIGH-COMPLIANCE TUBERCULOSIS TREATMENT PROGRAM IN A RURAL-COMMUNITY	LANCET			English	Note								The global tuberculosis epidemic is being fuelled by dual infection with human immunodeficiency virus type I, Short-course chemotherapy is effective but usually fails for operational reasons. A community-based treatment programme of twice-weekly fully-supervised treatment is described in which 89% of surviving patients completed treatment under programme conditions. Half the patients were successfully supervised by non-health workers. New approaches are needed to combat the global tuberculosis epidemic.	HLABLSA HOSP,HLABLSA 3937,SOUTH AFRICA				Wilkinson, David/A-6207-2008	Wilkinson, David/0000-0002-7265-9846	PHS HHS [1-D43-T200231-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Chaulet P, 1987, Tubercle, V68, P19, DOI 10.1016/0041-3879(87)90016-X; CHOWDHURY AMR, 1992, LANCET, V339, P1181, DOI 10.1016/0140-6736(92)90788-5; CUNEO WD, 1989, CLIN CHEST MED, V10, P375; ELLIOTT AM, 1992, TROP DOCT, V22, P147, DOI 10.1177/004947559202200402; FOX W, 1981, BRIT J DIS CHEST, V75, P331, DOI 10.1016/0007-0971(81)90022-X; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; LEOWSKI J, 1988, M WORKING GROUP SHOR; NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G; RODRIGUES LC, 1990, T ROY SOC TROP MED H, V84, P739, DOI 10.1016/0035-9203(90)90172-B; SUTHERLAND I, 1988, BRIT MED BULL, V44, P665, DOI 10.1093/oxfordjournals.bmb.a072275; 1992, TUBERCULOSIS TREATME	12	135	136	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 12	1994	343	8898					647	648		10.1016/S0140-6736(94)92640-9	http://dx.doi.org/10.1016/S0140-6736(94)92640-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906815				2022-12-28	WOS:A1994NA09300013
J	JACKSON, R				JACKSON, R			WHICH HYPERTENSIVE PATIENTS SHOULD BE TREATED	LANCET			English	Editorial Material							CORONARY				JACKSON, R (corresponding author), UNIV AUCKLAND,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND.			Jackson, Rod/0000-0001-5914-6934				ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; [Anonymous], 1993, BMJ, V307, P1541; BEARD K, 1992, BMJ-BRIT MED J, V304, P412, DOI 10.1136/bmj.304.6824.412; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; MACMAHON S, IN PRESS J VASC MED; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; 1993, ARCH INTERN MED, V153, P154; 1988, ARCH INTERN MED, V148, P1023	9	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					496	497		10.1016/S0140-6736(94)91456-7	http://dx.doi.org/10.1016/S0140-6736(94)91456-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906755				2022-12-28	WOS:A1994MX88800004
J	VANLEEUWEN, FE; BENRAADT, J; COEBERGH, JWW; KIEMENEY, LALM; GIMBRERE, CHF; OTTER, R; SCHOUTEN, LJ; DAMHUIS, RAM; BONTENBAL, M; DIEPENHORST, FW; VANDENBELTDUSEBOUT, AW; VANTINTEREN, H				VANLEEUWEN, FE; BENRAADT, J; COEBERGH, JWW; KIEMENEY, LALM; GIMBRERE, CHF; OTTER, R; SCHOUTEN, LJ; DAMHUIS, RAM; BONTENBAL, M; DIEPENHORST, FW; VANDENBELTDUSEBOUT, AW; VANTINTEREN, H			RISK OF ENDOMETRIAL CANCER AFTER TAMOXIFEN TREATMENT OF BREAST-CANCER	LANCET			English	Article							ADJUVANT TAMOXIFEN; VAGINAL EPITHELIUM; PREVENTION; THERAPY; RADIOTHERAPY; DISEASE	Since large trials have been set up to assess whether tamoxifen decreases the risk of breast cancer in healthy women, it has become important to investigate the drug's potential adverse effects, including occurrence of endometrial cancer. We undertook a case-control study in the Netherlands to assess the effect of tamoxifen on the risk of endometrial cancer after breast cancer. Through the population-based Netherlands Cancer Registry and two older, hospital-based, registries, we identified 98 patients who had endometrial cancer diagnosed at least 3 months after a diagnosis of primary breast cancer. Detailed information about treatment was obtained for all these patients, and for 285 controls, who were matched to the cases for age, year of breast cancer diagnosis, and survival time with intact uterus. Tamoxifen had been used by 24% of patients with subsequent endometrial cancer and 20% of controls (relative risk 1.3 [95% Cl 0.7-2.4]). Women who had used tamoxifen for more than 2 years had a 2.3 (0.9-5.9) times greater risk of endometrial cancer than never users. There was a significant trend of increasing risk of endometrial cancer with duration of tamoxifen use (p=0.049), and also with cumulative dose (p=0.046). The duration-response trends were similar with daily doses of 40 mg or 30 mg and less. These findings support the hypothesis that tamoxifen use increases the risk of endometrial cancer. This oestrogenic effect on the endometrium was not related to the dose intensity. Physicians should be aware of the higher risk of endometrial cancer in tamoxifen users.	COMPREHENS CANC CTR,AMSTERDAM,NETHERLANDS; COMPREHENS CANC CTR S NETHERLANDS,EINDHOVEN,NETHERLANDS; COMPREHENS CANC CTR MIDDLE NETHERLANDS,UTRECHT,NETHERLANDS; COMPREHENS CANC CTR,LIMBURG,NETHERLANDS; COMPREHENS CANC CTR,ROTTERDAM,NETHERLANDS; COMPREHENS CANC CTR STEDENDRIEHOEK,TWENTE,NETHERLANDS; DR DANIEL DEN HOED CANC CTR,ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	VANLEEUWEN, FE (corresponding author), NETHERLANDS CANC INST,DEPT EPIDEMIOL,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.		Schouten, Leo J/G-3713-2012; Schouten, Leo J/AAB-2275-2019; Kiemeney, Lambertus A./D-3357-2009	Schouten, Leo J/0000-0003-3361-7560; Kiemeney, Lambertus A./0000-0002-2368-1326; Coebergh, Jan Willem/0000-0002-2419-3930				ANDERSSON M, 1992, ACTA ONCOL, V31, P259, DOI 10.3109/02841869209088912; ANDERSSON M, 1991, J NATL CANCER I, V83, P1013, DOI 10.1093/jnci/83.14.1013; BOCCARDO F, 1981, ONCOLOGY, V38, P281, DOI 10.1159/000225571; BOCCARDO F, 1984, TUMORI, V70, P61, DOI 10.1177/030089168407000110; Breslow N, 1980, STATISTICAL METHODS, V32; BURING JE, 1986, AM J EPIDEMIOL, V124, P434, DOI 10.1093/oxfordjournals.aje.a114414; COLLETTE HJA, 1984, LANCET, V1, P1224; COLLINS J, 1980, LANCET, V2, P961; CREASMAN WT, 1990, OBSTET GYNECOL, V75, P287; DEMUYLDER X, 1991, INT J GYNECOL OBSTET, V36, P127, DOI 10.1016/0020-7292(91)90767-Y; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; ELWOOD JM, 1980, GYNECOL ONCOL, V10, P173, DOI 10.1016/0090-8258(80)90079-7; FERRAZZI E, 1977, BRIT MED J, V1, P1351, DOI 10.1136/bmj.1.6072.1351-e; FISHER B, 1991, J NATL CANCER I, V83, P1278, DOI 10.1093/jnci/83.18.1278; FISHER B, 1989, NEW ENGL J MED, V320, P489; FORNANDER T, 1989, LANCET, V1, P117; FUGHBERMAN A, 1992, LANCET, V340, P1143, DOI 10.1016/0140-6736(92)93161-F; GOTTARDIS MM, 1988, CANCER RES, V48, P812; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; MAGRIPLES U, 1993, J CLIN ONCOL, V11, P485, DOI 10.1200/JCO.1993.11.3.485; MUIR C, 1987, CANCER INCIDENCE 5 C, V5; NAYFIELD SG, 1991, J NATL CANCER I, V83, P1450, DOI 10.1093/jnci/83.20.1450; NEVEN P, 1993, LANCET, V342, P452, DOI 10.1016/0140-6736(93)91590-I; POWLES TJ, 1992, LANCET, V340, P1145, DOI 10.1016/0140-6736(92)93162-G; POWLES TJ, 1990, EUR J CANCER, V26, P680, DOI 10.1016/0277-5379(90)90116-B; STEWART HJ, 1989, LANCET, V1, P375; SUNDERLAND MC, 1991, J CLIN ONCOL, V9, P1283, DOI 10.1200/JCO.1991.9.7.1283; 1988, BRIT J CANCER, V57, P604; 1992, INCIDENCE CANCER NET; 1992, LANCET, V339, P71	30	492	498	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 19	1994	343	8895					448	452		10.1016/S0140-6736(94)92692-1	http://dx.doi.org/10.1016/S0140-6736(94)92692-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905955	Green Submitted			2022-12-28	WOS:A1994MW69000010
J	LANE, HC; LAUGHON, BE; FALLOON, J; KOVACS, JA; DAVEY, RT; POLIS, MA; MASUR, H				LANE, HC; LAUGHON, BE; FALLOON, J; KOVACS, JA; DAVEY, RT; POLIS, MA; MASUR, H			RECENT ADVANCES IN THE MANAGEMENT OF AIDS-RELATED OPPORTUNISTIC INFECTIONS	ANNALS OF INTERNAL MEDICINE			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; MULTIDRUG-RESISTANT TUBERCULOSIS; MYCOBACTERIUM-AVIUM COMPLEX; PLACEBO-CONTROLLED TRIAL; TOXOPLASMA-GONDII; CYTOMEGALOVIRUS RETINITIS; HIV-INFECTION; TRIMETHOPRIM-SULFAMETHOXAZOLE; RANDOMIZED TRIAL	Secondary infections remain the leading cause of death in patients with the acquired immunodeficiency syndrome (AIDS). Dealing with the rapidly evolving spectrum of infectious problems seen in patients with AIDS requires knowledge of current therapeutic and prophylactic strategies. Through an extensive preclinical trials network supported by both industry and government, an increasing number of new agents are being identified and rapidly moved into clinical trials. Several agents are now available to treat diseases caused by Pneumocystis carinii, and corticosteroids have become a useful adjunct to antimicrobial agents in the treatment of P. carinii pneumonia. Although the treatment of toxoplasmosis remains a challenge, alternatives to sulfadiazine and pyrimethamine are now available. Mycobacterial infections, particularly with Mycobacterium tuberculosis, have become an increasing problem for patients with AIDS, and both old and new combination drug regimens are being used. Cytomegalovirus disease, until recently an untreatable problem, can now at least be partially managed with antiviral agents. The use of more complete prophylactic regimens may decrease the morbidity and mortality from opportunistic infections.	NIH, DEPT CRIT CARE MED, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA	LANE, HC (corresponding author), NIAID, BLDG 10, ROOM 11B09, BETHESDA, MD 20892 USA.		Kovacs, Joseph/AAU-6105-2021	Kovacs, Joseph/0000-0002-5191-9880; Laughon, Barbara/0000-0002-8683-3681; Polis, Michael/0000-0002-9151-2268				ALLEGRA CJ, 1987, NEW ENGL J MED, V317, P978, DOI 10.1056/NEJM198710153171602; ARAUJO FG, 1988, ANTIMICROB AGENTS CH, V32, P755, DOI 10.1128/AAC.32.5.755; ARAUJO FG, 1991, ANTIMICROB AGENTS CH, V35, P293, DOI 10.1128/AAC.35.2.293; ARAUJO FG, 1974, ANTIMICROB AGENTS CH, V5, P647, DOI 10.1128/AAC.5.6.647; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BLACK JR, 1991, EUR J CLIN MICROBIOL, V10, P204, DOI 10.1007/BF01964465; BOZZETTE SA, 1990, NEW ENGL J MED, V323, P1451, DOI 10.1056/NEJM199011223232104; BUHLES WC, 1988, REV INFECT DIS, V10, pS495; CHANG HR, 1988, ANTIMICROB AGENTS CH, V32, P524, DOI 10.1128/AAC.32.4.524; COKER RJ, 1991, LANCET, V338, P574, DOI 10.1016/0140-6736(91)91141-G; CONTE JE, 1990, ANN INTERN MED, V113, P203, DOI 10.7326/0003-4819-113-3-203; COOPER DA, 1993, NEW ENGL J MED, V329, P297, DOI 10.1056/NEJM199307293290501; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DANNEMANN B, 1992, ANN INTERN MED, V116, P33, DOI 10.7326/0003-4819-116-1-33; DAUTZENBERG B, 1993, ARCH INTERN MED, V153, P368, DOI 10.1001/archinte.153.3.368; DAUTZENBERG B, 1991, AM REV RESPIR DIS, V144, P564, DOI 10.1164/ajrccm/144.3_Pt_1.564; DERAY G, 1989, AM J NEPHROL, V9, P316, DOI 10.1159/000167987; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DREW WL, 1992, CLIN INFECT DIS, V14, P608, DOI 10.1093/clinids/14.2.608-a; DREW WL, 1991, J INFECT DIS, V163, P716, DOI 10.1093/infdis/163.4.716; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FALLOON J, 1991, NEW ENGL J MED, V325, P1534, DOI 10.1056/NEJM199111283252202; FERNANDEZMARTIN J, 1991, ANTIMICROB AGENTS CH, V35, P2049, DOI 10.1128/AAC.35.10.2049; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; HOCHSTER H, 1990, ANN INTERN MED, V113, P111, DOI 10.7326/0003-4819-113-2-111; HOO GWS, 1990, ANN INTERN MED, V113, P195, DOI 10.7326/0003-4819-113-3-195; Hopewell P C, 1989, Semin Respir Infect, V4, P111; HOY J, 1990, J INFECT DIS, V161, P801, DOI 10.1093/infdis/161.4.801; HUGHES W, 1993, NEW ENGL J MED, V328, P1521, DOI 10.1056/NEJM199305273282103; HUSKINSONMARK J, 1991, J INFECT DIS, V164, P170, DOI 10.1093/infdis/164.1.170; ISEMAN MD, 1993, NEW ENGL J MED, V329, P784, DOI 10.1056/NEJM199309093291108; ISRAELSKI D, 1990, EUR J CLIN MICROBIOL, V9, P358, DOI 10.1007/BF01973746; JABS DA, 1992, NEW ENGL J MED, V326, P213, DOI 10.1056/NEJM199201233260401; JACOBSON MA, 1991, J INFECT DIS, V163, P1348, DOI 10.1093/infdis/163.6.1348; JACOBSON MA, 1991, J CLIN ENDOCR METAB, V72, P1130, DOI 10.1210/jcem-72-5-1130; KOVACS JA, 1992, LANCET, V340, P637, DOI 10.1016/0140-6736(92)92172-C; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; LEPORT C, 1988, AM J MED, V84, P94, DOI 10.1016/0002-9343(88)90014-9; LITTLER E, 1992, NATURE, V358, P160, DOI 10.1038/358160a0; LUFT BJ, 1988, J INFECT DIS, V157, P1, DOI 10.1093/infdis/157.1.1; MacDonell K B, 1989, Semin Respir Infect, V4, P123; MANISCHEWITZ JF, 1990, ANTIMICROB AGENTS CH, V34, P373, DOI 10.1128/AAC.34.2.373; MASUR H, 1990, NEW ENGL J MED, V323, P1500, DOI 10.1056/NEJM199011223232131; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MCCABE RE, 1984, J INFECT DIS, V150, P961, DOI 10.1093/infdis/150.6.961; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; NAIK S, 1989, ANTIMICROB AGENTS CH, V33, P1614, DOI 10.1128/AAC.33.9.1614; NELSON MR, 1991, LANCET, V338, P250, DOI 10.1016/0140-6736(91)90385-3; NOSKIN GA, 1992, CLIN INFECT DIS, V14, P183, DOI 10.1093/clinids/14.1.183; OBERG B, 1989, PHARMACOL THERAPEUT, V40, P213, DOI 10.1016/0163-7258(89)90097-1; PALESTINE AG, 1991, ANN INTERN MED, V115, P665, DOI 10.7326/0003-4819-115-9-665; POLIS MA, 1993, 31ST ANN M INF DIS S; POLIS MA, 1993, 33RD INT C ANT AG CH; RASTOGI N, 1991, ANTIMICROB AGENTS CH, V35, P2473, DOI 10.1128/AAC.35.12.2473; REMINGTON JS, 1991, LANCET, V338, P1142, DOI 10.1016/0140-6736(91)91997-9; SAFRIN S, 1991, J ACQ IMMUN DEF SYND, V4, P244; SATTLER FR, 1988, ANN INTERN MED, V109, P280, DOI 10.7326/0003-4819-109-4-280; SATTLER FR, 1994, IN PRESS J INFECT DI; SELIGMANN M, 1994, LANCET, V343, P871; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SHARMA SD, 1985, J IMMUNOL, V135, P4160; SHIRATSUCHI H, 1991, J IMMUNOL, V146, P3165; SMITH D, 1990, AIDS, V4, P1019, DOI 10.1097/00002030-199010000-00012; SNYDMAN DR, 1987, NEW ENGL J MED, V317, P1049, DOI 10.1056/NEJM198710223171703; SPECTOR SA, 1993, J INFECT DIS, V168, P557, DOI 10.1093/infdis/168.3.557; SQUIRES KE, 1989, J INFECT DIS, V159, P599, DOI 10.1093/infdis/159.3.599; SULLIVAN V, 1992, NATURE, V358, P162, DOI 10.1038/358162a0; SUZUKI Y, 1988, SCIENCE, V240, P516, DOI 10.1126/science.3128869; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WEBSTER A, 1989, LANCET, V2, P63; YOUNG LS, 1991, LANCET, V338, P1107, DOI 10.1016/0140-6736(91)91965-W; ZURLO JJ, 1993, ANN INTERN MED, V118, P12, DOI 10.7326/0003-4819-118-1-199301010-00003; 1991, HIV AIDS SURVEILLANC, P1; 1993, MMWR MORB MORTAL WKL, V42, P1	76	61	63	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1994	120	11					945	955		10.7326/0003-4819-120-11-199406010-00007	http://dx.doi.org/10.7326/0003-4819-120-11-199406010-00007			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN110	7909657				2022-12-28	WOS:A1994NN11000007
J	WILLIAMS, NS; HUGHES, SF; STUCHFIELD, B				WILLIAMS, NS; HUGHES, SF; STUCHFIELD, B			CONTINENT COLONIC CONDUIT FOR RECTAL EVACUATION IN SEVERE CONSTIPATION	LANCET			English	Article							IDIOPATHIC CONSTIPATION; OUTLET OBSTRUCTION; ANISMUS; PROCTOCOLECTOMY; APPENDIX; SURGERY; ENEMA	We describe a new operation for the treatment of rectal evacuatory disorders: a continent colonic conduit, incorporating an intussuscepted valve, was constructed from the sigmoid colon. Intubation of the conduit allowed irrigation and evacuation of the distal colon and rectum. Initially all 10 patients reported a reduction in time taken and the discomfort involved in completing evacuation. The number of stools passed per week increased in 9 out of 10 patients, from a median of 1.5 (range 0.25-7) to a median of 7 (range 3-7) postoperatively. Subsequently, 3 patients developed complications, 2 of whom required conversion to an ileostomy. Overall, the colonic conduit procedure was successful in treating the rectal evacuatory disorder in 7 patients, failed in 2, and 1 patient has a temporary defunctioning ileostomy. The procedure is a relatively simple surgical alternative for the treatment of a condition which is often resistant to conservative measures.			WILLIAMS, NS (corresponding author), ROYAL LONDON HOSP,SURG UNIT,LONDON E1 1BB,ENGLAND.							DUDLEY HAF, 1980, BRIT J SURG, V67, P80, DOI 10.1002/bjs.1800670203; HALLAN RI, 1988, LANCET, V2, P714; HOSIE KB, 1990, BRIT J SURG, V77, P801, DOI 10.1002/bjs.1800770726; HUGHES ESR, 1981, AUST NZ J SURG, V51, P144, DOI 10.1111/j.1445-2197.1981.tb05926.x; KAMM MA, 1988, BRIT J SURG, V75, P661, DOI 10.1002/bjs.1800750713; KOCK NG, 1969, ARCH SURG-CHICAGO, V99, P223; LESTAR B, 1991, INT J COLORECTAL DIS, V6, P202, DOI 10.1007/BF00341391; MALONE PS, 1990, LANCET, V336, P1217, DOI 10.1016/0140-6736(90)92834-5; MARTELLI H, 1978, GASTROENTEROLOGY, V75, P623; MITROFANOFF P, 1980, CHIR PEDIATR, V21, P297; NICHOLLS RJ, 1988, DIS COLON RECTUM, V31, P968, DOI 10.1007/BF02554897; PRESTON DM, 1985, DIGEST DIS SCI, V30, P413, DOI 10.1007/BF01318172; RYAN JA, 1985, AM J SURG, V149, P636, DOI 10.1016/S0002-9610(85)80145-8; SQUIRE R, 1993, J PEDIATR SURG, V28, P1012, DOI 10.1016/0022-3468(93)90505-F; TAYLOR T, 1989, BRIT MED J, V299, P300, DOI 10.1136/bmj.299.6694.300; WASSERMAN I F, 1964, Dis Colon Rectum, V7, P87, DOI 10.1007/BF02616902; WEXNER SD, 1991, DIS COLON RECTUM, V34, P851, DOI 10.1007/BF02049695; WHEELER RA, 1991, BRIT J SURG, V78, P1283, DOI 10.1002/bjs.1800781103; WILLIAMS NS, 1980, BRIT MED J, V281, P107, DOI 10.1136/bmj.281.6233.107; WILLIAMS NS, SURGICAL THERAPY CON, P757; YOSHIOKA K, 1987, BRIT J SURG, V74, P373, DOI 10.1002/bjs.1800740516	21	40	40	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1321	1324		10.1016/S0140-6736(94)92467-8	http://dx.doi.org/10.1016/S0140-6736(94)92467-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910324				2022-12-28	WOS:A1994NN21700010
J	IDJRADINATA, P; WATKINS, WE; POLLITT, E				IDJRADINATA, P; WATKINS, WE; POLLITT, E			ADVERSE EFFECT OF IRON SUPPLEMENTATION ON WEIGHT-GAIN OF IRON-REPLETE YOUNG-CHILDREN	LANCET			English	Article							INFANT	The efficacy of iron supplementation for iron-deficient subjects is in no doubt. However, the assumption that iron supplementation of iron-replete subjects is harmless may not be valid. We have studied the effect of iron supplementation on growth rate in 47 iron-sufficient young children (12-18 months) in Indonesia. The children were randomly assigned either ferrous sulphate (3 mg/kg daily) or placebo every day for 4 months. Before treatment the length, weight, and arm circumference of the two groups were similar. During the 4 months of supplementation the rate of weight gain was significantly greater in the placebo group than in the iron-supplemented group (0.106 [SE 0.010] vs 0.070 [0.011] kg every 2 weeks, p=0.02). The rates of gain in length and arm circumference did not differ significantly by treatment. There were no differences between the groups in rates of respiratory and gastrointestinal infections. These results suggest that iron supplementation of iron-replete children may retard their growth.	UNIV CALIF DAVIS, DEPT PEDIAT, DAVIS, CA 95616 USA; UNIV CALIF DAVIS, PROGRAM INT NUTR, DAVIS, CA USA; PADJADJARAN STATE UNIV, FAC MED, DEPT CHILD HLTH, BANDUNG, INDONESIA	University of California System; University of California Davis; University of California System; University of California Davis; Universitas Padjadjaran								AUKETT MA, 1986, ARCH DIS CHILD, V61, P849, DOI 10.1136/adc.61.9.849; DALLMAN PR, 1990, ACTA PAEDIATR SCAND, P28; DALLMAN PR, 1989, J NUTR, V119, P1852, DOI 10.1093/jn/119.12_Suppl.1852; FAIRWEATHERTAIT SJ, 1989, J NUTR, V119, P599, DOI 10.1093/jn/119.4.599; GORDEUK VR, 1992, BAILLIERE CLIN HAEM, V5, P169, DOI 10.1016/S0950-3536(11)80040-5; GUTTERIDGE JMC, 1990, ACTA PAEDIATR SC   S, V365, P78; HARVEY PWJ, 1989, AM J TROP MED HYG, V40, P12, DOI 10.4269/ajtmh.1989.40.12; IDJRADINATA P, 1993, LANCET, V341, P1, DOI 10.1016/0140-6736(93)92477-B; MURRAY MJ, 1978, BRIT MED J, V2, P1113, DOI 10.1136/bmj.2.6145.1113; OPPENHEIMER SJ, 1986, T ROY SOC TROP MED H, V80, P596, DOI 10.1016/0035-9203(86)90153-7; OPPENHEIMER SJ, 1990, ACTA PAEDIATR SC   S, V365, P53; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; SCRIMSHAW NS, 1991, SCI AM, V265, P46, DOI 10.1038/scientificamerican1091-46; 1977, NCHS GROWTH CURVES C	14	119	121	1	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 21	1994	343	8908					1252	1254		10.1016/S0140-6736(94)92151-2	http://dx.doi.org/10.1016/S0140-6736(94)92151-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910275				2022-12-28	WOS:A1994NM14400009
J	CHAGANTI, RSK; RODRIGUEZ, E; MATHEW, S				CHAGANTI, RSK; RODRIGUEZ, E; MATHEW, S			ORIGIN OF ADULT MALE MEDIASTINAL GERM-CELL TUMORS	LANCET			English	Article							CARCINOMA-INSITU; TUMORS; TESTIS	The origin of primary extragonadal germ-cell tumours, especially mediastinal and pineal germ-cell tumours in adult males remains uncertain, although the predominant view is that they originate in misplaced primordial germ cells retained in extra-gonadal sites, in contrast to gonadal germ-cell tumours which are considered to arise in premeiotic spermatocytes. We hypothesised that if mediastinal germ-cell tumours and gonadal germ-cell tumours were derived from precursor cells in different developmental states and in different cellular environments, non-random genetic changes in the two groups would be significantly different. To test this hypothesis, we compared non-random chromosomal abnormalities in mediastinal germ-cell tumours with those in gonadal germ-cell tumours. Our results show that although the two groups differed in the composition of histological subsets, their non-random chromosomal changes were essentially the same. These data suggest gonadal origin of all germ-cell tumours with occasional migration of precursors early in development to extragonadal sites to become established as primary extragonadal germ-cell tumours. Based on a review of cytogenetic data on carcinoma in situ, primary mediastinal and gonodal germ-cell tumours, embryonal migration of primordial germ-cells, and meiotic behaviour of spermatocytes, a model of origin of all germ-cell tumours in males is suggested.			CHAGANTI, RSK (corresponding author), MEM SLOAN KETTERING CANC CTR,1275 YORK AVE,NEW YORK,NY 10021, USA.			Rodriguez Yunta, Eduardo/0000-0002-7947-3868	NCI NIH HHS [CA-05826, CA-08748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748, P01CA005826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEARD J, 1890, ANAT ANZEIGER, V18, P465; BOHLE A, 1986, J UROLOGY, V135, P939, DOI 10.1016/S0022-5347(17)45930-1; CHAGANTI RSK, 1989, GENE CHROMOSOME CANC, V1, P83, DOI 10.1002/gcc.2870010113; CHAGANTI RSK, 1993, UROL CLIN N AM, V20, P55; CHAGANTI RSK, 1990, MOL GENETICS DIAGNOS; CHIQUOINE AD, 1954, ANAT REC, V118, P135, DOI 10.1002/ar.1091180202; COHNHEIM J, 1877, PATHOLOGIE; COLLINS D. H., 1964, BRIT J UROL, V36, P1; DAUGAARD G, 1987, LANCET, V2, P528; GLAZER HS, 1982, AM J ROENTGENOL, V138, P673, DOI 10.2214/ajr.138.4.673; GRECO FA, 1982, SEMIN ONCOL, V9, P448; LADANYI M, 1990, J NATL CANCER I, V82, P221, DOI 10.1093/jnci/82.3.221; MOTZER RJ, 1991, J NATL CANCER I, V83, P341, DOI 10.1093/jnci/83.5.341; Prym P, 1927, VIRCHOWS ARCH A, V265, P239, DOI 10.1007/BF01894164; RODRIGUEZ E, 1993, GENE CHROMOSOME CANC, V8, P230, DOI 10.1002/gcc.2870080405; RODRIGUEZ E, 1992, CANCER RES, V52, P2285; ROOSENRU.EC, 1973, J REPROD FERTIL, V35, P339; ROSAI J, 1975, ATLAS TUMOR PATHOLOG; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; TITTER MA, 1992, THYMUS, P9; VIRCHOW R, 1880, ARCH PATH ANAT PHYS, P185; VOS A, 1990, CANCER GENET CYTOGEN, V46, P75, DOI 10.1016/0165-4608(90)90011-X; WANG N, 1981, CANCER RES, V41, P2135; Witschi Emil, 1948, CONTRIBUTIONS TO EMBRYOLOGY [CARNEGIE INST OF WASHINGTON PUBL], V32, P67; 1991, GUIDELINES CANCER S	25	96	98	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1994	343	8906					1130	1132		10.1016/S0140-6736(94)90235-6	http://dx.doi.org/10.1016/S0140-6736(94)90235-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK730	7910232				2022-12-28	WOS:A1994NK73000009
J	ROUSSEAUXPREVOST, R; LESUR, P; COLLIER, F; RIGOT, JM; VENEZIA, ND; POL, PS; DELAUNAY, J; GAUTHIER, A; ROUSSEAUX, J				ROUSSEAUXPREVOST, R; LESUR, P; COLLIER, F; RIGOT, JM; VENEZIA, ND; POL, PS; DELAUNAY, J; GAUTHIER, A; ROUSSEAUX, J			ABNORMAL EXPRESSION OF PROTEIN-4.1 IN SPERMATOZOA OF INFERTILE MEN WITH TERATOSPERMIA	LANCET			English	Note							SPERM	Molecular defects responsible for morphologically abnormal spermatozoa (teratospermia) associated with male sterility are largely unknown. We report defective expression of protein 4.1, a cytoskeletal protein initially recognised in red cells. In some patients with severely amorphous sperm heads, protein 4.1 had an abnormal sub-cellular localisation (tail instead of head) and appeared as high-molecular-weight isoforms, especially a 135 kDa species instead of the 82 kDa isoform seen in fertile sperm. Because the 135 kDa isoform is characteristic of immature germ cells from testis, its presence in teratospermia suggests profoundly disturbed sperm differentiation.	LAB ANAL MED LIBERTE, LILLE, FRANCE; CTR HOSP REG & UNIV LILLE, SERV GYNECOL SOCLALE, LILLE, FRANCE; CTR HOSP REG & UNIV LILLE, SERV UROL, LILLE, FRANCE; CNRS, URA 1171, LYON, FRANCE; CTR HOSP REG & UNIV LILLE, CECOS NORD, LILLE, FRANCE	Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; CHU Lille	ROUSSEAUXPREVOST, R (corresponding author), INST RECH CANC LILLE, PL VERDUN, F-59045 LILLE, FRANCE.		VENEZIA, Nicole DALLA/C-6542-2017	VENEZIA, Nicole DALLA/0000-0002-4553-3535				ARBOLEDA CE, 1988, DEV BIOL, V125, P217, DOI 10.1016/0012-1606(88)90075-9; BACCETTI B, 1988, J SUBMICR CYTOL PATH, V20, P209; CHEVAILLIER P, 1987, LANCET, V2, P806; CONBOY JG, 1993, SEMIN HEMATOL, V30, P58; ESCALIER D, 1990, International Journal of Developmental Biology, V34, P287; MIRANDA PV, 1992, MOL REPROD DEV, V33, P443, DOI 10.1002/mrd.1080330411; VENEZIA ND, 1992, J CLIN INVEST, V90, P1713, DOI 10.1172/JCI116044; VIRTANEN I, 1984, J CELL BIOL, V99, P1083, DOI 10.1083/jcb.99.3.1083	8	13	13	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 26	1994	343	8900					764	765		10.1016/S0140-6736(94)91840-6	http://dx.doi.org/10.1016/S0140-6736(94)91840-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907733				2022-12-28	WOS:A1994NC35100012
J	STURGESS, R; DAY, P; ELLIS, HJ; LUNDIN, KEA; GJERTSEN, HA; KONTAKOU, M; CICLITIRA, PJ				STURGESS, R; DAY, P; ELLIS, HJ; LUNDIN, KEA; GJERTSEN, HA; KONTAKOU, M; CICLITIRA, PJ			WHEAT PEPTIDE CHALLENGE IN CELIAC-DISEASE	LANCET			English	Article							CELIAC-DISEASE; GLIADIN PEPTIDES; ORGAN-CULTURE; A-GLIADIN; TOXICITY; SEQUENCE; GLUTEN; SPRUE	The exact nature of the cereal moiety that exacerbates coeliac disease is unknown. In-vitro studies have implicated both the N-terminal and far C-terminal domains of one of the wheat prolamins, A-gliadin. Peptides within these regions may act as epitopes that trigger immune events leading to enteropathy. We synthesised three peptides corresponding to aminoacids 3-21, 31-49, and 202-220 of A-gliadin. Four patients with coeliac disease were challenged by intraduodenal infusion of 1 g of gliadin or 200 mg of the synthetic peptides. Jejunal biopsies were taken before and at hourly intervals for 6 h after the infusion. Morphometric variables were measured and intraepithelial lymphocytes counted. Significant histological changes occurred in the small intestinal mucosa after challenge with a synthetic peptide corresponding to amino acids 31-49 of A-gliadin. The N-terminal peptide, residues 3-21 of A-gliadin, did not cause histological changes in any of the patients. In one of the four patients, minor histological changes following challenge with the peptide corresponding to residues 202-220 of A-gliadin were seen. Our results suggest that the oligopeptide corresponding to aminoacids 31-49 of A-gliadin is toxic in vivo, but there is no evidence of toxicity of the far N-terminal peptide, residues 3-21. The C-terminal peptide 202-220 may contain an epitope to which patients with coeliac disease display variable sensitivity. Since the oligopeptide corresponding to aminoacids 31-49 of A-gliadin is recognised by HLA DQ2-restricted T cells, the observed effects may be due to immune activation within the intestinal mucosa.	ST THOMAS HOSP,RAYNE INST,DIV PHARMACOL,LONDON SE1 7EH,ENGLAND; NATL HOSP NORWAY,INST TRANSPLANTAT IMMUNOL,N-0027 OSLO,NORWAY	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Oslo; National Hospital Norway			Lundin, Knut E. A./AAW-9519-2021	Lundin, Knut E. A./0000-0003-1713-5545				AURICCHIO S, 1991, Gastroenterology, V100, pA194; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; CICLITIRA PJ, 1984, CLIN SCI, V66, P357, DOI 10.1042/cs0660357; DERITIS G, 1988, GASTROENTEROLOGY, V94, P41, DOI 10.1016/0016-5085(88)90607-5; DEVERY JM, 1991, INT ARCH ALLER A IMM, V95, P356, DOI 10.1159/000235473; ELLIS HJ, 1993, SCAND J GASTROENTERO, V28, P212, DOI 10.3109/00365529309096074; FALCHUK ZM, 1974, J CLIN INVEST, V53, P487, DOI 10.1172/JCI107582; FRAZER AC, 1959, LANCET, V2, P252; GJERTSEN HA, IN PRESS HUM IMMUNOL; KAGNOFF MF, 1984, J EXP MED, V160, P1544, DOI 10.1084/jem.160.5.1544; KARAGIANNIS JA, 1987, LANCET, V1, P884; KASARDA DD, 1984, P NATL ACAD SCI-BIOL, V81, P4712, DOI 10.1073/pnas.81.15.4712; LUNDIN KEA, 1993, J EXP MED, V178, P187, DOI 10.1084/jem.178.1.187; MANTZARIS G, 1991, SCAND J GASTROENTERO, V26, P392, DOI 10.3109/00365529108996500; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P; MEEUWISSE GW, 1970, ACTA PAEDIATR SCAND, V59, P461; PATEY AL, 1973, J SCI FOOD AGR, V24, P1229, DOI 10.1002/jsfa.2740241011; SOLLID LM, 1989, J EXP MED, V169, P345, DOI 10.1084/jem.169.1.345; TATHAM AS, 1990, BIOCHEM J, V270, P313, DOI 10.1042/bj2700313; TRIER JS, 1991, NEW ENGL J MED, V325, P1709, DOI 10.1056/NEJM199112123252406; VAN DE KAMER J H, 1953, Acta Paediatr, V42, P223, DOI 10.1111/j.1651-2227.1953.tb05586.x; WIESER H, 1986, Z LEBENSM UNTERS FOR, V182, P115, DOI 10.1007/BF01454241; WIESER H, 1984, Z LEBENSM UNTERS FOR, V179, P371, DOI 10.1007/BF01043432	24	225	236	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 26	1994	343	8900					758	761		10.1016/S0140-6736(94)91837-6	http://dx.doi.org/10.1016/S0140-6736(94)91837-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907731				2022-12-28	WOS:A1994NC35100009
J	ELIAS, D; COHEN, IR				ELIAS, D; COHEN, IR			PEPTIDE THERAPY FOR DIABETES IN NOD MICE	LANCET			English	Note							PROTEIN; MOUSE	NOD mice spontaneously develop autoimmune diabetes that mimics insulin-dependent diabetes mellitus (IDDM) in man. A peptide of the 60 kDa heat shock protein (hsp60), designated p277, can serve as a target for diabetogenic T-cell clones, and diabetes was prevented by using the p277 peptide to turn off anti-p277 immunity early in life. We report that the p277 peptide, administered once, can arrest the autoimmune process even after it is far advanced. Successful therapy was associated with down-regulation of the autoimmune process and regression of islet inflammation. Thus the immune system is responsive to manipulation by a specific signal even in the face of a virulent, full-blown autoimmune process.	WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science			Cohen, Irun R/B-3542-2009					BENDELAC A, 1987, J EXP MED, V166, P823, DOI 10.1084/jem.166.4.823; BRUDZYNSKI K, 1992, DIABETOLOGIA, V35, P316, DOI 10.1007/BF00401198; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; COHEN IR, 1992, IMMUNOL TODAY, V13, P490, DOI 10.1016/0167-5699(92)90024-2; COHEN IR, 1992, IMMUNOL TODAY, V13, P441, DOI 10.1016/0167-5699(92)90071-E; ELIAS D, 1991, P NATL ACAD SCI USA, V88, P3088, DOI 10.1073/pnas.88.8.3088; KARJALAINEN J, 1992, NEW ENGL J MED, V327, P302, DOI 10.1056/NEJM199207303270502; LIDER O, 1988, SCIENCE, V239, P181, DOI 10.1126/science.2447648; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; ZHANG JW, 1993, SCIENCE, V261, P1451, DOI 10.1126/science.7690157	10	176	191	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					704	706		10.1016/S0140-6736(94)91582-2	http://dx.doi.org/10.1016/S0140-6736(94)91582-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907681				2022-12-28	WOS:A1994NB80900011
J	TORRES, BA; STROMQUIST, CI; MOYA, FR; DECLUE, T				TORRES, BA; STROMQUIST, CI; MOYA, FR; DECLUE, T			PRENATAL ADMINISTRATION OF THYROTROPIN-RELEASING-HORMONE AND POSTNATAL THYROXINE VALUES	LANCET			English	Letter							INFANTS; FETAL		UNIV TEXAS, SW MED CTR, DEPT PEDIAT, DALLAS, TX USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	TORRES, BA (corresponding author), UNIV S FLORIDA, DEPT PEDIAT, TAMPA, FL 33606 USA.							BALLARD PL, 1992, PEDIATR RES, V32, P673, DOI 10.1203/00006450-199212000-00009; BALLARD RA, 1992, LANCET, V339, P510, DOI 10.1016/0140-6736(92)90337-3; MAYA F, 1991, J PEDIATR-US, V119, P966, DOI 10.1016/S0022-3476(05)83057-4; MORALES WJ, 1989, OBSTET GYNECOL, V73, P111; MOYA F, 1986, PEDIATR RES, V20, P982, DOI 10.1203/00006450-198610000-00018	5	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 19	1994	343	8899					730	730		10.1016/S0140-6736(94)91608-X	http://dx.doi.org/10.1016/S0140-6736(94)91608-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907695				2022-12-28	WOS:A1994NB80900035
J	WILSON, R; AINSCOUGH, R; ANDERSON, K; BAYNES, C; BERKS, M; BURTON, J; CONNELL, M; BONFIELD, J; COPSEY, T; COOPER, J; COULSON, A; CRAXTON, M; DEAR, S; DU, Z; DURBIN, R; FAVELLO, A; FRASER, A; FULTON, L; GARDNER, A; GREEN, P; HAWKINS, T; HILLIER, L; JIER, M; JOHNSTON, L; JONES, M; KERSHAW, J; KIRSTEN, J; LAISSTER, N; LATREILLE, P; LLOYD, C; MORTIMORE, B; OCALLAGHAN, M; PARSONS, J; PERCY, C; RIFKEN, L; ROOPRA, A; SAUNDERS, D; SHOWNKEEN, R; SIMS, M; SMALDON, N; SMITH, A; SMITH, M; SONNHAMMER, E; STADEN, R; SULSTON, J; THIERRYMIEG, J; THOMAS, K; VAUDIN, M; VAUGHAN, K; WATERSTON, R; WATSON, A; WEINSTOCK, L; WILKINSONSPROAT, J; WOHLDMAN, P				WILSON, R; AINSCOUGH, R; ANDERSON, K; BAYNES, C; BERKS, M; BURTON, J; CONNELL, M; BONFIELD, J; COPSEY, T; COOPER, J; COULSON, A; CRAXTON, M; DEAR, S; DU, Z; DURBIN, R; FAVELLO, A; FRASER, A; FULTON, L; GARDNER, A; GREEN, P; HAWKINS, T; HILLIER, L; JIER, M; JOHNSTON, L; JONES, M; KERSHAW, J; KIRSTEN, J; LAISSTER, N; LATREILLE, P; LLOYD, C; MORTIMORE, B; OCALLAGHAN, M; PARSONS, J; PERCY, C; RIFKEN, L; ROOPRA, A; SAUNDERS, D; SHOWNKEEN, R; SIMS, M; SMALDON, N; SMITH, A; SMITH, M; SONNHAMMER, E; STADEN, R; SULSTON, J; THIERRYMIEG, J; THOMAS, K; VAUDIN, M; VAUGHAN, K; WATERSTON, R; WATSON, A; WEINSTOCK, L; WILKINSONSPROAT, J; WOHLDMAN, P			2.2 MB OF CONTIGUOUS NUCLEOTIDE-SEQUENCE FROM CHROMOSOME-III OF C-ELEGANS	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; EDITING PROGRAM; DNA; GENOME; GENES; ENCODES; SIMILARITY; PROTEIN; LIN-12; RNA	As part of our effort to sequence the 100-megabase (Mb) genome of the nematode Caenorhabditis elegans, we have completed the nucleotide sequence of a contiguous 2,181,032 base pairs in the central gene cluster of chromosome III. Analysis of the finished sequence has indicated an average density of about one gene per five kilobases; comparison with the public sequence databases reveals similarities to previously known genes for about one gene in three. In addition, the genomic sequence contains several intriguing features, including putative gene duplications and a variety of other repeats with potential evolutionary implications.	WASHINGTON UNIV,SCH MED,CTR GENOME SEQUENCING,ST LOUIS,MO 63110; MRC,MOLEC BIOL LAB,CAMBRIDGE CB10 1RQ,CAMBS,ENGLAND; SANGER CTR,CAMBRIDGE CB10 1RQ,CAMBS,ENGLAND; CNRS,CTR RECH BIOCHIM MACROMOLEC & PHYS MATH,F-34033 MONTPELLIER,FRANCE	Washington University (WUSTL); MRC Laboratory Molecular Biology; Wellcome Trust Sanger Institute; Centre National de la Recherche Scientifique (CNRS)	WILSON, R (corresponding author), WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110, USA.		Durbin, Richard/AAE-7178-2019; Wilson, Richard K./AAF-4139-2019; THIERRY-MIEG, Jean/F-1975-2017; Smith, Andy/A-7512-2011; Cooper, John/D-4448-2014	Durbin, Richard/0000-0002-9130-1006; Wilson, Richard K./0000-0002-1992-1358; THIERRY-MIEG, Jean/0000-0002-0396-6789; Smith, Andy/0000-0001-8580-278X; Sonnhammer, Erik/0000-0002-9015-5588; Bonfield, James/0000-0002-6447-4112; Cooper, John/0000-0002-0933-4571				Alschul S F, 1990, J Mol Biol, V215, P403; BANKIER AT, 1983, TECHNIQUES NUCLEIC B, V5, P1; BRENNER S, 1974, GENETICS, V77, P71; BURGLIN TR, 1991, NATURE, V351, P703, DOI 10.1038/351703a0; CAMPBELL HD, 1993, P NATL ACAD SCI USA, V90, P11386, DOI 10.1073/pnas.90.23.11386; CHISHOLM A, 1991, DEVELOPMENT, V111, P921; CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; COLLINS J, 1989, GENETICS, V121, P47; CONNELL C, 1987, BIOTECHNIQUES, V5, P342; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; CRAXTON M, 1991, Methods (Orlando), V3, P20, DOI 10.1016/S1046-2023(05)80159-8; Dear S, 1992, DNA Seq, V3, P107, DOI 10.3109/10425179209034003; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; DEININGER PL, 1983, ANAL BIOCHEM, V129, P216, DOI 10.1016/0003-2697(83)90072-6; DU ZJ, 1993, METHOD ENZYMOL, V218, P104; FICHANT GA, 1991, J MOL BIOL, V220, P659, DOI 10.1016/0022-2836(91)90108-I; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; GLEESON T, 1991, NUCLEIC ACIDS RES, V19, P6481, DOI 10.1093/nar/19.23.6481; GLEESON TJ, 1991, COMPUT APPL BIOSCI, V7, P398; GREEN P, 1993, SCIENCE, V259, P1711, DOI 10.1126/science.8456298; GUO XD, 1991, NATURE, V349, P707, DOI 10.1038/349707a0; HALLORAN N, 1992, METHOD MOL BIOL, V10, P297; HAWKINS TL, 1992, ELECTROPHORESIS, V13, P552, DOI 10.1002/elps.11501301113; HILLENBRAND C, 1991, J ROY ASIATIC SOC, V1, P124, DOI 10.1017/S1356186300000201; KOOP BF, 1993, BIOTECHNIQUES, V14, P442; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LEE LG, 1992, NUCLEIC ACIDS RES, V20, P2471, DOI 10.1093/nar/20.10.2471; MCCOMBIE WR, 1992, NAT GENET, V1, P124, DOI 10.1038/ng0592-124; NAITO M, 1992, NUCLEIC ACIDS RES, V20, P2967, DOI 10.1093/nar/20.12.2967; PATEL N, 1993, P NATL ACAD SCI USA, V90, P9181, DOI 10.1073/pnas.90.19.9181; SCHRIEFER LA, 1990, NUCLEIC ACIDS RES, V18, P7455, DOI 10.1093/nar/18.24.7455; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; SULSTON J, 1992, NATURE, V357, P106; SULSTON JE, 1974, GENETICS, V77, P95; UBER DC, 1991, BIOTECHNIQUES, V11, P642; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WATERSTON RH, 1978, NATURE, V275, P715, DOI 10.1038/275715a0; WATERSTON RH, 1990, GENBANK LOCUS CESUP5; WATSON A, 1993, NATURE, V362, P569, DOI 10.1038/362569a0; WESTON K, 1989, NUCLEIC ACIDS RES, V17, P2138, DOI 10.1093/nar/17.5.2138; Wood WB, 1988, NEMATODE CAENORHABDI; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0; YUAN JY, 1991, P NATL ACAD SCI USA, V88, P3334, DOI 10.1073/pnas.88.8.3334	49	1297	1685	0	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 3	1994	368	6466					32	38		10.1038/368032a0	http://dx.doi.org/10.1038/368032a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY569	7906398				2022-12-28	WOS:A1994MY56900044
J	CAIRNS, JA				CAIRNS, JA			ORAL ANTICOAGULANTS OR ASPIRIN AFTER MYOCARDIAL-INFARCTION	LANCET			English	Editorial Material											CAIRNS, JA (corresponding author), MCMASTER UNIV, DEPT MED, HAMILTON, ON, CANADA.		Cairns, John/AAI-8744-2021					ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; BOISSEL JP, 1982, NEW ENGL J MED, V307, P701; BREDDIN K, 1980, CIRCULATION, V62, P63; CAIRNS JA, 1992, CHEST, V102, pS456, DOI 10.1378/chest.102.4_Supplement.456S; CAIRNS JA, IN PRESS CARDIOL CLI; HIRSH J, 1992, CHEST, V102, pS312, DOI 10.1378/chest.102.4.312S; ROOS J, 1980, LANCET, V2, P989; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302	8	16	16	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 26	1994	343	8896					497	498		10.1016/S0140-6736(94)91457-5	http://dx.doi.org/10.1016/S0140-6736(94)91457-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906756				2022-12-28	WOS:A1994MX88800005
J	LUYAO, GL; GREENBERG, ER				LUYAO, GL; GREENBERG, ER			CHANGES IN PROSTATE-CANCER INCIDENCE AND TREATMENT IN USA	LANCET			English	Article							UNITED-STATES; SURVIVAL	We examined time trends and geographical variations in the detection and treatment of prostate cancer in USA, based on information from white men aged 50 to 79 who resided in areas covered by the Surveillance, Epidemiology, and End Results (SEER) program of the United States National Cancer Institute. Prostate-cancer incidence and treatment rates were determined for the 9 population-based cancer registries which participate in the SEER program. Prostate-cancer mortality rates were assessed from data compiled by the National Center for Health Statistics. Prostate cancer incidence rates increased by 6.4% per year between 1983 and 1989. The increase appeared to be due to detection of early-stage disease; there was no increase in the incidence rate of metastatic cancer. Incidence rates varied widely among the SEER program areas: in 1989 from 267.9 per 100 000 in Connecticut to 606.8 in Seattle. Radical prostatectomy rates more than tripled between 1983 and 1989 in the SEER areas as a whole. Among men aged 70-79, the rate of prostatectomy increased by nearly 35% per year. There was a five-fold variation among SEER areas in radical prostatectomy rates in 1989, with a low of 43.4 per 100 000 in Connecticut and a high of 224.4 in Seattle. Prostate cancer mortality rates did not increase during the period of study; there was little variation among areas in prostate-cancer mortality rates, and no apparent correlation between the incidence and mortality rates for an area. Increases in rates of prostate cancer incidence and prostate surgery have occurred in the United States without clear evidence that screening and prostectomy are effective in reducing mortality. Moreover, much of the growth in incidence and radical prostatectomy rates has occurred among older men, who appear least likely to benefit from early detection and surgery of occult prostate cancer.	DARTMOUTH COLL, SCH MED, CTR EVALUAT CLIN SCI, 7251 STRASENBURGH HALL, HANOVER, NH 03755 USA; DARTMOUTH COLL, NORRIS COTTON CANC CTR, HANOVER, NH 03755 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center				Lu-Yao, Grace/0000-0002-6017-9175	AHRQ HHS [HS06336] Funding Source: Medline; NCI NIH HHS [CA 23108] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKNER M, 1985, J CHRON DIS, V38, P225, DOI 10.1016/0021-9681(85)90065-7; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; DEVESA SS, 1987, J NATL CANCER I, V79, P701; FEINSTEIN AR, 1985, NEW ENGL J MED, V312, P1604, DOI 10.1056/NEJM198506203122504; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; GARNICK MB, 1993, ANN INTERN MED, V118, P804, DOI 10.7326/0003-4819-118-10-199305150-00008; GIBBONS R P, 1988, NCI (National Cancer Institute) Monographs, P123; GITTES RF, 1991, NEW ENGL J MED, V324, P236, DOI 10.1056/NEJM199101243240406; GOLDBLOOM R, 1991, CAN MED ASSOC J, V145, P413; GREENBERG ER, 1982, J NATL CANCER I, V68, P743; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; LANGE PH, 1993, JAMA-J AM MED ASSOC, V269, P95, DOI 10.1001/jama.269.1.95; LEPOR H, 1988, NATL CANCER I MONOGR, V7, P117; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; MCPHERSON K, 1982, NEW ENGL J MED, V307, P1310, DOI 10.1056/NEJM198211183072104; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; MILLER BA, 1992, CANCER STATISTICS RE; POTOSKY AL, 1990, J NATL CANCER I, V82, P1624, DOI 10.1093/jnci/82.20.1624; STAMEY TA, 1993, CANCER, V71, P933, DOI 10.1002/1097-0142(19930201)71:3+<933::AID-CNCR2820711408>3.0.CO;2-L; WALSH PC, 1987, J UROLOGY, V138, P823, DOI 10.1016/S0022-5347(17)43385-4; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487; WHITMORE WF, 1993, JAMA-J AM MED ASSOC, V269, P2676, DOI 10.1001/jama.269.20.2676; WHITMORE WF, 1993, CANCER-AM CANCER SOC, V71, P970, DOI 10.1002/1097-0142(19930201)71:3+<970::AID-CNCR2820711412>3.0.CO;2-6; YOUNG JL, 1981, NATL CANCER I MONOGR, V57, P642; YOUNG JL, 1981, NATL CANCER I MONOGR, V57, P110; 1989, GUIDE CLIN PREVENTIV, P63; 1987, JAMA-J AM MED ASSOC, V258, P2727; 1993, J NATL CANCER I, V85, P947	28	208	208	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 29	1994	343	8892					251	254		10.1016/S0140-6736(94)91109-6	http://dx.doi.org/10.1016/S0140-6736(94)91109-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905093	hybrid			2022-12-28	WOS:A1994MT44000007
J	REES, M				REES, M			ON MENSTRUAL BLEEDING WITH HORMONE REPLACEMENT THERAPY	LANCET			English	Editorial Material							PROGESTOGEN; WOMEN				REES, M (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND.							ANDERSSON K, 1992, OBSTET GYNECOL, V79, P963; CHRISTIANSEN C, 1990, BRIT J OBSTET GYNAEC, V97, P1087, DOI 10.1111/j.1471-0528.1990.tb02495.x; COOPE J, 1992, MATURITAS, V15, P151, DOI 10.1016/0378-5122(92)90249-4; HALLBERG L, 1966, ACTA OBSTET GYN SCAN, V45, P320, DOI 10.3109/00016346609158455; HAWTHORN RJS, 1991, BRIT J OBSTET GYNAEC, V98, P939, DOI 10.1111/j.1471-0528.1991.tb13519.x; MACLENNAN AH, 1993, MED J AUSTRALIA, V159, P102, DOI 10.5694/j.1326-5377.1993.tb137744.x; REES MCP, 1991, BRIT J OBSTET GYNAEC, V98, P106, DOI 10.1111/j.1471-0528.1991.tb10322.x; REES MCP, 1993, WOMENS PROBLEMS GENE, P171; SPORRONG T, 1992, BRIT J OBSTET GYNAEC, V99, P399, DOI 10.1111/j.1471-0528.1992.tb13757.x; STALAND B, 1981, MATURITAS, V3, P14	10	10	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					250	250		10.1016/S0140-6736(94)91108-8	http://dx.doi.org/10.1016/S0140-6736(94)91108-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905092				2022-12-28	WOS:A1994MT44000006
J	PERSSON, MG; ZETTERSTROM, O; AGRENIUS, V; IHRE, E; GUSTAFSSON, LE				PERSSON, MG; ZETTERSTROM, O; AGRENIUS, V; IHRE, E; GUSTAFSSON, LE			SINGLE-BREATH NITRIC-OXIDE MEASUREMENTS IN ASTHMATIC-PATIENTS AND SMOKERS	LANCET			English	Note							GUINEA-PIGS; HUMANS	Exhaled nitric oxide (NO) concentrations were measured in asthmatic outpatients and in non-smoking and smoking healthy controls. In single exhalations, NO showed a peak suggestive of airway origin in both controls and asthmatic patients. The peak NO concentration was higher in asthmatic patients and lower in smokers than in non-smoking controls (p<0.05). The findings support a role for NO in the host defence response in asthma and suggest that NO measurements can discriminate between different types of lung disorders.	KAROLINSKA INST,DEPT PHYSIOL,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,INST ENVIRONM SCI,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA HOSP,DEPT THORAC MED,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital			Gustafsson, Lars E/E-6950-2013					BELVISI MG, 1992, EUR J PHARMACOL, V210, P221, DOI 10.1016/0014-2999(92)90676-U; BOUSQUET J, 1992, ALLERGY, V47, P129, DOI 10.1111/j.1398-9995.1992.tb00952.x; DUPUY PM, 1992, J CLIN INVEST, V90, P421, DOI 10.1172/JCI115877; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; JORENS PG, 1993, EUR RESPIR J, V6, P258; NORMAN V, 1965, NATURE, V205, P915, DOI 10.1038/205915b0; PERSSON MG, 1993, AM REV RESPIR DIS, V148, P1210, DOI 10.1164/ajrccm/148.5.1210; PERSSON MG, 1993, ACTA PHYSIOL SCAND, V149, P461, DOI 10.1111/j.1748-1716.1993.tb09643.x; PERSSON MG, 1993, EUR J PHARMACOL, V249, P7	9	413	425	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 15	1994	343	8890					146	147		10.1016/S0140-6736(94)90935-0	http://dx.doi.org/10.1016/S0140-6736(94)90935-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7904005				2022-12-28	WOS:A1994MQ86900011
J	SMALL, PM; HOPEWELL, PC; SINGH, SP; PAZ, A; PARSONNET, J; RUSTON, DC; SCHECTER, GF; DALEY, CL; SCHOOLNIK, GK				SMALL, PM; HOPEWELL, PC; SINGH, SP; PAZ, A; PARSONNET, J; RUSTON, DC; SCHECTER, GF; DALEY, CL; SCHOOLNIK, GK			THE EPIDEMIOLOGY OF TUBERCULOSIS IN SAN-FRANCISCO - A POPULATION-BASED STUDY USING CONVENTIONAL AND MOLECULAR METHODS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESISTANT MYCOBACTERIUM-TUBERCULOSIS; HUMAN-IMMUNODEFICIENCY-VIRUS; LENGTH-POLYMORPHISM ANALYSIS; COMPLEX STRAINS; TRANSMISSION; OUTBREAK; TOOL; INFECTION; SEQUENCE; IS6110	Background. The epidemiology of tuberculosis in urban populations is changing. Combining conventional epidemiologic techniques with DNA fingerprinting of Mycobacterium tuberculosis can improve the understanding of how tuberculosis is transmitted. Methods. We used restriction-fragment-length polymorphism (RFLP) analysis to study M. tuberculosis isolates from all patients reported to the tuberculosis registry in San Francisco during 1991 and 1992. These results were interpreted along with clinical, demographic, and epidemiologic data. Patients infected with the same strains were identified according to their RFLP patterns, and patients with identical patterns were grouped in clusters. Risk factors for being in a cluster were analyzed. Results. Of 473 patients studied, 191 appeared to have active tuberculosis as a result of recent infection. Tracing of patients' contacts with the use of conventional methods identified links among only 10 percent of these patients. DNA fingerprinting, however, identified 44 clusters, 20 of which consisted of only 2 persons and the largest of which consisted of 30 persons. In patients under 60 years of age, Hispanic ethnicity (odds ratio, 3.3; P = 0.02), black race (odds ratio, 2.3; P = 0.02), birth in the United States (odds ratio, 5.8; P < 0.001), and a diagnosis of the acquired immunodeficiency syndrome (odds ratio, 1.8; P = 0.04) were independently associated with being in a cluster. Further study of patients in clusters confirmed that poorly compliant patients with infectious tuberculosis have a substantial adverse effect on the control of this disease. Conclusions. Despite an efficient tuberculosis-control program, nearly a third of new cases of tuberculosis in San Francisco are the result of recent infection. Few of these instances of transmission are identified by conventional contact tracing.	STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; SAN FRANCISCO GEN HOSP,MED SERV,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; SAN FRANCISCO DEPT PUBL HLTH,DIV TB CONTROL,SAN FRANCISCO,CA	Howard Hughes Medical Institute; Stanford University; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco Department of Public Health	SMALL, PM (corresponding author), STANFORD UNIV,BECKMAN CTR,SCH MED,DEPT MED,DIV INFECT DIS & GEOG MED,RM 251,STANFORD,CA 94305, USA.		Daley, Charles L./AAC-3231-2021	Parsonnet, Julie/0000-0001-7342-5366	NIAID NIH HHS [R0I-AI34238-01, K08 AI01137-01] Funding Source: Medline; PHS HHS [U52-CCU 900454] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034238, K08AI001137] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; CHEVRELDELLAGI D, 1993, J CLIN MICROBIOL, V31, P2446, DOI 10.1128/JCM.31.9.2446-2450.1993; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; Davis W, 1980, IARC SCI PUBL, V32, P192; DWYER B, 1993, J INFECT DIS, V167, P490, DOI 10.1093/infdis/167.2.490; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; GENEWEIN A, 1993, LANCET, V342, P841, DOI 10.1016/0140-6736(93)92698-S; GODFREYFAUSSETT P, 1992, BRIT MED J, V305, P221, DOI 10.1136/bmj.305.6847.221; HERMANS PWM, 1991, INFECT IMMUN, V59, P2695, DOI 10.1128/IAI.59.8.2695-2705.1991; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; HORWITZ O, 1973, HEALTH SERV REP, V88, P493, DOI 10.2307/4594837; OTAL I, 1991, J CLIN MICROBIOL, V29, P1252, DOI 10.1128/JCM.29.6.1252-1254.1991; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; RASTOGI N, 1992, EUR J CLIN MICROBIOL, V11, P901, DOI 10.1007/BF01962370; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SMALL PM, 1993, J CLIN MICROBIOL, V31, P1677, DOI 10.1128/JCM.31.7.1677-1682.1993; TABET SR, 1994, J INFECT DIS, V169, P189, DOI 10.1093/infdis/169.1.189; TAKAHASHI M, 1993, MICROBIOL IMMUNOL, V37, P289, DOI 10.1111/j.1348-0421.1993.tb03212.x; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991; YUEN LKW, 1993, J CLIN MICROBIOL, V31, P1615, DOI 10.1128/JCM.31.6.1615-1618.1993; 1993, AM REV RESPIR DIS, V146, P1623; 1991, MMWR-MORBID MORTAL W, V40, P585; 1992, MMWR-MORBID MORTAL W, V41, P507; 1993, TUBERCULOSIS STATIST	28	1027	1057	1	32	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 16	1994	330	24					1703	1709		10.1056/NEJM199406163302402	http://dx.doi.org/10.1056/NEJM199406163302402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR109	7910661				2022-12-28	WOS:A1994NR10900002
J	HOPKINS, KD; LEHMANN, ED; GOSLING, RG				HOPKINS, KD; LEHMANN, ED; GOSLING, RG			AORTIC COMPLIANCE MEASUREMENTS - A NONINVASIVE INDICATOR OF ATHEROSCLEROSIS	LANCET			English	Editorial Material							WAVE VELOCITY; CORONARY		ST THOMAS HOSP,DIV MED,LONDON,ENGLAND; GUYS HOSP,DIV RADIOL SCI,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust	HOPKINS, KD (corresponding author), GUYS HOSP,DEPT OBSTET & GYNAECOL,LONDON SE1 9RT,ENGLAND.							CRAVEN TE, 1990, CIRCULATION, V82, P1230, DOI 10.1161/01.CIR.82.4.1230; CROUSE JR, 1993, CIRCULATION, V87, P17; FARRAR DJ, 1991, CIRCULATION, V83, P1754, DOI 10.1161/01.CIR.83.5.1754; FURBERG CD, 1993, CIRCULATION, V87, P82; HIRAI T, 1989, CIRCULATION, V80, P78, DOI 10.1161/01.CIR.80.1.78; Kelly R, 1989, J VASC MED BIOL, V3, P142; LEHMANN ED, 1993, ULTRASOUND MED BIOL, V19, P683, DOI 10.1016/0301-5629(93)90087-5; MOHIADDIN RH, 1993, J APPL PHYSIOL, V74, P492, DOI 10.1152/jappl.1993.74.1.492; PEARSON TA, 1993, CIRCULATION, V87, P2; PROBSTFIELD JL, 1993, CIRCULATION, V87, P74; ROBERTS JC, 1959, CIRCULATION, V20, P511, DOI 10.1161/01.CIR.20.4.511; TANGANELLI P, 1993, ARTERIOSCLER THROMB, V13, P1700, DOI 10.1161/01.ATV.13.11.1700	12	40	41	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1447	1447		10.1016/S0140-6736(94)92577-1	http://dx.doi.org/10.1016/S0140-6736(94)92577-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911173				2022-12-28	WOS:A1994NQ41500004
J	CONNELL, WR; KAMM, MA; DICKSON, M; BALKWILL, AM; RITCHIE, JK; LENNARDJONES, JE				CONNELL, WR; KAMM, MA; DICKSON, M; BALKWILL, AM; RITCHIE, JK; LENNARDJONES, JE			LONG-TERM NEOPLASIA RISK AFTER AZATHIOPRINE TREATMENT IN INFLAMMATORY BOWEL-DISEASE	LANCET			English	Article							CROHNS-DISEASE; HUMAN PAPILLOMAVIRUS; ULCERATIVE-COLITIS; CANCER	The incidence of various cancers, especially non-Hodgkin lymphoma (NHL), is higher among patients who receive azathioprine for immunosuppression after organ transplants than in the general population. We have studied the risk of neoplasia after azathioprine in 755 patients treated for inflammatory bowel disease. The patients received 2 mg/kg daily for a median of 12.5 months (range 2 days to 15 years) between 1962 and 1991; median follow-up was 9 years (range 2 weeks to 29 years). Overall there was no significant excess of cancer: 31 azathioprine-treated patients developed cancer before age 85 compared with 24.3 expected from rates in the general population (observed/expected ratio 1.27, p=0.186). There was a difference in the frequency of colorectal (13) and anal (2) carcinomas (expected 2.27; ratio 6.7, p=0.00001); these tumours are recognised complications of chronic inflammatory bowel disease. There were 2 cases of invasive cervical cancer (expected 0.5), but no case of NHL. Among patients with extensive chronic ulcerative colitis there was no difference in cancer frequency between 86 who had received azathioprine and 180 matched patients who had never received it. Thus, azathioprine treatment does not substantially increase the risk of cancer in inflammatory bowel disease.	ST MARKS HOSP,LONDON EC1V 2PS,ENGLAND; UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH,CANC RES CAMPAIGN,EPIDEMIOL GRP,OXFORD,ENGLAND	Imperial College London; Radcliffe Infirmary; University of Oxford								ALLOUB MI, 1989, BMJ-BRIT MED J, V298, P153, DOI 10.1136/bmj.298.6667.153; CHURCH JM, 1985, DIS COLON RECTUM, V26, P361; EKBOM A, 1990, LANCET, V336, P357, DOI 10.1016/0140-6736(90)91889-I; Gelb A, 1983, Am J Gastroenterol, V78, P316; GLICK SN, 1984, RADIOLOGY, V153, P337, DOI 10.1148/radiology.153.2.6484163; GREENSTEIN AJ, 1981, CANCER, V48, P2742, DOI 10.1002/1097-0142(19811215)48:12<2742::AID-CNCR2820481231>3.0.CO;2-P; GYDE SN, 1988, GUT, V29, P206, DOI 10.1136/gut.29.2.206; GYDE SN, 1980, GUT, V21, P1024, DOI 10.1136/gut.21.12.1024; HALPERT R, 1986, OBSTET GYNECOL, V68, P251; HOOVER R, 1973, LANCET, V2, P55; KINLEN LJ, 1979, BRIT MED J, V2, P1461, DOI 10.1136/bmj.2.6203.1461; KINLEN LJ, 1985, AM J MED, V78, P44, DOI 10.1016/0002-9343(85)90245-1; KINLEN LJ, 1992, AUTOIMMUNITY, V5, P363; KORELITZ BI, 1983, AM J GASTROENTEROL, V78, P44; PRESENT DH, 1989, ANN INTERN MED, V111, P641, DOI 10.7326/0003-4819-111-8-641; SLATER G, 1984, ANN SURG, V199, P348, DOI 10.1097/00000658-198403000-00016; SOMERVILLE KW, 1984, GUT, V25, P1124, DOI 10.1136/gut.25.10.1124; WEEDON DD, 1973, NEW ENGL J MED, V289, P1099, DOI 10.1056/NEJM197311222892101	18	412	416	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1249	1252		10.1016/S0140-6736(94)92150-4	http://dx.doi.org/10.1016/S0140-6736(94)92150-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910274				2022-12-28	WOS:A1994NM14400008
J	FARROW, S				FARROW, S			ALLELIC VARIATION AND THE VITAMIN-D RECEPTOR	LANCET			English	Editorial Material							MESSENGER-RNA; EXPRESSION				FARROW, S (corresponding author), UCL, SCH MED, DEPT MED, LONDON W1N 8AA, ENGLAND.							BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; MORRISON NA, 1992, P NATL ACAD SCI USA, V89, P6665, DOI 10.1073/pnas.89.15.6665; MURPHY D, 1992, MOL CELL BIOL, V12, P2624, DOI 10.1128/MCB.12.6.2624; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TEWARI M, 1991, MOL ENDOCRINOL, V5, P653, DOI 10.1210/mend-5-5-653	6	30	33	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1242	1242		10.1016/S0140-6736(94)92147-4	http://dx.doi.org/10.1016/S0140-6736(94)92147-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910271				2022-12-28	WOS:A1994NM14400005
J	MCSHANE, R; HOPE, T; WILKINSON, J				MCSHANE, R; HOPE, T; WILKINSON, J			TRACKING PATIENTS WHO WANDER - ETHICS AND TECHNOLOGY	LANCET			English	Editorial Material									JOHN RADCLIFFE HOSP,OXFORD PRACTICE SKILLS PROJECT,OXFORD,ENGLAND; RADCLIFFE INFIRM,OXFORD,ENGLAND; OXFORDSHIRE DEPT SOCIAL SERV,ABINGDON,OXON,ENGLAND	University of Oxford; Radcliffe Infirmary								BALLARD CG, 1987, INT J GERIATRIC PSYC, V2, P207; Beauchamp T, 1989, PRINCIPLES BIOMEDICA; HOPE RA, 1990, INT J GERIATR PSYCH, V5, P239, DOI 10.1002/gps.930050406; LANGLEY GE, 1981, BRIT MED J, V283, P1376, DOI 10.1136/bmj.283.6303.1376; PITT B, 1987, INT J GERIATR PSYCH, V2, P207, DOI 10.1002/gps.930020402; SANFORD J, 1975, BRIT MED J, V3, P473; 1993, PEOPLE NOT PARCELS D	7	37	38	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1274	1274		10.1016/S0140-6736(94)92159-8	http://dx.doi.org/10.1016/S0140-6736(94)92159-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NM144	7910283				2022-12-28	WOS:A1994NM14400017
J	NAKAZATO, H; KOIKE, A; SAJI, S; OGAWA, N; SAKAMOTO, J				NAKAZATO, H; KOIKE, A; SAJI, S; OGAWA, N; SAKAMOTO, J			EFFICACY OF IMMUNOCHEMOTHERAPY AS ADJUVANT TREATMENT AFTER CURATIVE RESECTION OF GASTRIC-CANCER	LANCET			English	Article							COLORECTAL-CANCER; PSK; CARCINOMA; FLUOROURACIL; COMBINATION; LEVAMISOLE; THERAPY	In Japan the standard adjuvant treatment after resection of gastric cancer is intravenous mitomycin plus oral fluorouracil. We have assessed the efficacy of protein-bound polysaccharide (PSK) in addition to standard chemotherapy in patients who had undergone curative gastrectomy at 46 institutions in central Japan. 262 patients were randomly assigned standard treatment alone or with PSK. The minimum follow-up time was 5 years (range 5-7 years). PSK improved both the 5-year disease-free rate (70.7 vs 59.4% in standard treatment group, p=0.047) and 5-year survival (73.0 vs 60.0%, p=0.044). The two regimens had only slight toxic effects, consisting of nausea, leucopenia, and liver function impairment, and there were no significant differences between the groups. The treatments were clinically well tolerated and compliance was good. Addition of PSK to adjuvant chemotherapy with mitomycin and fluorouracil is beneficial as treatment after curative gastrectomy.	AICHI CANC CTR, DEPT GASTROENTEROL SURG, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN; AICHI MED UNIV, YOKOYAMA GASTROINTESTINAL HOSP, AICHI, JAPAN; AICHI MED UNIV, DEPT SURG 1, AICHI, JAPAN; GIFU UNIV, SCH MED, DEPT SURG 2, GIFU, JAPAN; EHIME UNIV, SCH MED, DEPT PHARMACOL, MATSUYAMA, EHIME 790, JAPAN	Aichi Cancer Center; Aichi Medical University; Aichi Medical University; Gifu University; Ehime University								DAY DW, 1980, RECENT ADV GASTROINT, P285; EBINA T, 1990, JPN J CANCER RES, V81, P1307, DOI 10.1111/j.1349-7006.1990.tb02695.x; ENDOH H, 1988, INT J IMMUNOPHARMACO, V10, P103, DOI 10.1016/0192-0561(88)90085-9; GEHAN EA, 1973, CANCER MEDICINE, P499; HIROSE K, 1990, LYMPHOKINE RES, V9, P475; HOSOKAWA M, 1986, CANCER IMMUNOL IMMUN, V22, P181; ICHIHASHI H, 1987, JPN J CANC CHEMOTHER, V14, P2758; INOKUCHI K, 1984, CANCER, V53, P2393, DOI 10.1002/1097-0142(19840601)53:11<2393::AID-CNCR2820531104>3.0.CO;2-L; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; Katano M, 1987, JPN J CANC CHEMOTHER, V14, P2321; Kondo M, 1985, BASIC MECHANISMS CLI, P623; KONDO T, 1991, BIOTHERAPY, V3, P287, DOI 10.1007/BF02221321; Kondo T, 1989, BIOTHERAPY, V3, P655; LAURIE JA, 1989, J CLIN ONCOL, V7, P1447, DOI 10.1200/JCO.1989.7.10.1447; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MICKEY DD, 1989, J UROLOGY, V142, P1594, DOI 10.1016/S0022-5347(17)39175-9; MITOMI T, 1992, DIS COLON RECTUM, V35, P123, DOI 10.1007/BF02050666; MIWA K, 1979, GANN MONOGR, V22, P61; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; Nakajima T, 1989, JPN J CANC CHEMOTHER, V16, P799; NIIMOTO M, 1981, NIPPON SHOKAKI GEKA, V14, P704; SAJI S, 1991, BIOTHERAPY TOKYO, V5, P1996; SAKAMOTO J, 1979, NIPPON GEKA GAKKAI Z, V80, P861; TORISU M, 1990, CANCER IMMUNOL IMMUN, V31, P261, DOI 10.1007/BF01740932; 1985, TNM ATLAS, P90	25	215	228	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 7	1994	343	8906					1122	1126		10.1016/S0140-6736(94)90233-X	http://dx.doi.org/10.1016/S0140-6736(94)90233-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK730	7910230				2022-12-28	WOS:A1994NK73000007
J	FIRTH, HV; BOYD, P; CHAMBERLAIN, P; MACKENZIE, I; MORRISSKAY, GM; HUSON, SM				FIRTH, HV; BOYD, P; CHAMBERLAIN, P; MACKENZIE, I; MORRISSKAY, GM; HUSON, SM			ANALYSIS OF LIMB REDUCTION DEFECTS IN BABIES EXPOSED TO CHRONIC VILLUS SAMPLING	LANCET			English	Article							ABNORMALITIES; CVS	In 1991 we reported a cluster of babies with limb abnormalities and suggested that chorionic villus sampling (CVS) was aetiologically associated with these defects. To address the issue more objectively, we have assessed reported limb reduction defects in 75 babies exposed to CVS in utero. 13 babies had an absent limb or a defect through the humerus or femur; 9 had defects through the radius or tibia; 22 defects of the carpus, tarsus, metacarpus, or metatarsus; 25 defects of the digits; and 6 defects of the terminal phalanx or nail only. There was a strong correlation between the severity of the defects and the duration of gestation when CVS was done. The median gestational age at CVS ranged from 56 (range 49-65) postmenstrual days for the most severe category to 72 (51-98) days for the least severe. The relation was seen for both isolated limb defects and for cases with oromandibular-limb hypogenesis syndromes. This relation is further evidence that CVS has an aetiological role in some limb reduction anomalies.	JOHN RADCLIFFE HOSP,OXFORD REG PRENATAL DIAG SERV,OXFORD,ENGLAND; JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,DEPT HUMAN ANAT,OXFORD OX1 3QX,ENGLAND	University of Oxford; University of Oxford; University of Oxford	FIRTH, HV (corresponding author), CHURCHILL HOSP,OXFORD REG GENET SERV,OXFORD OX3 7LJ,ENGLAND.							BRAMBATI B, 1992, PRENATAL DIAG, V12, P789, DOI 10.1002/pd.1970121004; BURTON BK, 1992, OBSTET GYNECOL, V79, P726; BURTON BK, 1993, PEDIATRICS, V91, P989; CHRISTIAENS GCML, 1989, PRENATAL DIAG, V9, P67, DOI 10.1002/pd.1970090110; CORLISS CE, 1976, PATTENS HUMAN EMBRYO; DOLK H, 1992, LANCET, V339, P876, DOI 10.1016/0140-6736(92)90325-W; FIRTH HV, 1991, LANCET, V337, P762, DOI 10.1016/0140-6736(91)91374-4; FIRTH HV, 1991, LANCET, V338, P51, DOI 10.1016/0140-6736(91)90036-O; FROSTERISKENIUS UG, 1989, TERATOLOGY, V39, P127, DOI 10.1002/tera.1420390205; GHIRARDINI G, 1991, LANCET, V338, P695, DOI 10.1016/0140-6736(91)91271-U; HSIEH FJ, 1991, LANCET, V337, P1092; IBBA RM, 1992, PRENATAL DIAGN S, V12, pS98; JACKSON LG, 1991, LANCET, V337, P1423; Lin S. P., 1992, American Journal of Human Genetics, V51, pA261; LOS FJ, 1993, LANCET, V342, P1559, DOI 10.1016/S0140-6736(05)80137-0; MAHONEY MJ, 1991, LANCET, V337, P1422, DOI 10.1016/0140-6736(91)93117-R; MASTROIACOVO P, 1992, AM J MED GENET, V44, P856, DOI 10.1002/ajmg.1320440639; MONNI G, 1991, LANCET, V337, P1091; PLANTEYDT HT, 1986, LANCET, V2, P756; QUINTERO RA, 1992, LANCET, V339, P193, DOI 10.1016/0140-6736(92)90272-5; RICHMAN JM, 1992, DEV BIOL, V154, P299, DOI 10.1016/0012-1606(92)90069-S; RODECK CH, 1993, LANCET, V341, P500, DOI 10.1016/0140-6736(93)90259-J; SCHLOO R, 1992, AM J MED GENET, V42, P404, DOI 10.1002/ajmg.1320420338; SMIDTJENSEN S, 1992, LANCET, V340, P1237, DOI 10.1016/0140-6736(92)92946-D; WEBSTER WS, 1987, TERATOLOGY, V35, P253, DOI 10.1002/tera.1420350212; WILSON RD, 1992, AM J HUMAN GENET S, V51, pS176	26	115	124	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 30	1994	343	8905					1069	1071		10.1016/S0140-6736(94)90182-1	http://dx.doi.org/10.1016/S0140-6736(94)90182-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ694	7909100				2022-12-28	WOS:A1994NJ69400010
J	GOODDY, W				GOODDY, W			MUCH MORE DUE TO BROWN-SEQUARD	LANCET			English	Editorial Material											GOODDY, W (corresponding author), KING EDWARD VII HOSP,MIDHURST,W SUSSEX,ENGLAND.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					809	810		10.1016/S0140-6736(94)92021-4	http://dx.doi.org/10.1016/S0140-6736(94)92021-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908074				2022-12-28	WOS:A1994ND79200004
J	MARCHANT, A; DEVIERE, J; BYL, B; DEGROOTE, D; VINCENT, JL; GOLDMAN, M				MARCHANT, A; DEVIERE, J; BYL, B; DEGROOTE, D; VINCENT, JL; GOLDMAN, M			INTERLEUKIN-10 PRODUCTION DURING SEPTICEMIA	LANCET			English	Note								Interleukin-10 is produced during incubation of human whole blood with bacterial lipopolysaccharide (LPS) and down-regulates tumour necrosis factor-alpha production in this in-vitro model of endotoxaemia. 39 out of 69 (57%) patients with gram-negative (n = 25) or gram-positive septicaemia (n = 44) had increased plasma interleukin-10 (range 12-2740 pg/mL), whereas interleukin-10 was undetectable in 29 out of 33 control patients without infection and in 20 healthy volunteers. Patients with septic shock (n = 21) had higher interleukin-10 (median 58 pg/mL) than septicaemic patients without shock (11 pg/mL, p<0.001). We conclude that interleukin-10 is produced during sepsis and might be involved in the control of the inflammatory response induced by bacterial products.	UNIV LIBRE BRUXELLES,HOP ERASME,DEPT IMMUNOL,B-1070 BRUSSELS,BELGIUM; UNIV LIBRE BRUXELLES,HOP ERASME,DEPT GASTROENTEROL,B-1070 BRUSSELS,BELGIUM; UNIV LIBRE BRUXELLES,HOP ERASME,DEPT INFECT DIS,B-1070 BRUSSELS,BELGIUM; UNIV LIBRE BRUXELLES,HOP ERASME,INTENS CARE UNIT,B-1070 BRUSSELS,BELGIUM; MEDGENIX GRP,DEPT RES & DEV,FLEURUS,BELGIUM	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles								BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; DUREZ P, 1993, J EXP MED, V177, P551, DOI 10.1084/jem.177.2.551; GERARD C, 1993, J EXP MED, V177, P547, DOI 10.1084/jem.177.2.547; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; HOWARD M, 1993, J EXP MED, V177, P1205, DOI 10.1084/jem.177.4.1205; ISHIDA H, 1993, CELL IMMUNOL, V148, P371, DOI 10.1006/cimm.1993.1119; MALEFYT RD, 1991, J EXP MED, V174, P1209; PRADIER O, 1993, EUR J IMMUNOL, V23, P2700, DOI 10.1002/eji.1830231048	8	297	302	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					707	708		10.1016/S0140-6736(94)91584-9	http://dx.doi.org/10.1016/S0140-6736(94)91584-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907683				2022-12-28	WOS:A1994NB80900013
J	SHEHADEH, N; CALCINARO, F; BRADLEY, BJ; BRUCHLIM, I; VARDI, P; LAFFERTY, KJ				SHEHADEH, N; CALCINARO, F; BRADLEY, BJ; BRUCHLIM, I; VARDI, P; LAFFERTY, KJ			EFFECT OF ADJUVANT THERAPY ON DEVELOPMENT OF DIABETES IN MOUSE AND MAN	LANCET			English	Note							NOD MICE; PREVENTION	Freund's complete adjuvant (CFA) and BCG vaccine modulate the development of type 1 diabetes in animal models. In non-obese diabetic mice, CFA and BCG significantly reduced the proportion developing diabetes compared with controls. Histological examination showed that autoimmune disease still developed but had been diverted to become nondestructive. In a preliminary trial in 17 newly diagnosed, type 1 diabetic patients, intracutaneous administration of 0.1 mL of BCG 1 mg/mL led to clinical remission in 11 (65%)-by week 4 in 6. Remission has been sustained in 3 for 6-10 months. No side-effects were reported. A double-blind trial of BCG is warranted.	RAMBAM MED CTR,JUVENLLE DIABET CTR,HAIFA,ISRAEL; BARBARA DAVIS CTR CHILDHOOD DIABET,DENVER,CO	Rambam Health Care Campus; Technion Israel Institute of Technology					NIDDK NIH HHS [DK46621] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046621] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		GUYTINGCO R, 1991, DIABETES, V40, pA152; LAKEY JRT, 1992, TRANSPLANT P, V24, P2848; MCINERNEY MF, 1991, DIABETES, V40, P715, DOI 10.2337/diabetes.40.6.715; QIN HY, 1993, J IMMUNOL, V150, P2072; SHEHADEH NN, 1993, J AUTOIMMUN, V6, P291, DOI 10.1006/jaut.1993.1025; WANG T, 1992, DIABETES, V41, P114, DOI 10.2337/diabetes.41.1.114	6	140	149	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					706	707		10.1016/S0140-6736(94)91583-0	http://dx.doi.org/10.1016/S0140-6736(94)91583-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907682				2022-12-28	WOS:A1994NB80900012
J	KOMBIAN, SB; MALENKA, RC				KOMBIAN, SB; MALENKA, RC			SIMULTANEOUS LTP OF NON-NMDA-RECEPTER-MEDIATED AND LTD OF NMDA-RECEPTER-MEDIATED RESPONSES IN THE NUCLEUS-ACCUMBENS	NATURE			English	Article							LONG-TERM DEPRESSION; MOLECULAR MECHANISMS; MEMBRANE-PROPERTIES; NEURONS INVITRO; AREA CA1; RAT; HIPPOCAMPUS; POTENTIALS; ASPARTATE; DOPAMINE	THE nucleus accumbens (NA), a ventral extension of the striatum, plays a role in several complex behaviour patterns(1) and also is a major site of action of drugs of abuse such as cocaine(1-3). Intrinsic NA cells are predominantly quiescent(4,5) and their activity depends on excitatory input from cortical and subcortical limbic afferents(6,7). Here we examine the mechanisms of synaptic plasticity at the synapse between prelimbic cortical afferents and cells in the core region of the NA(8-10). Manipulations that induce a Ca2+- dependent long-term potentiation (LTP) of non-NMDA (N-methyl-D-aspartate)-receptor-mediated responses also produce a simultaneous long-term depression (LTD) of NMDA-receptor-mediated responses. These results indicate that in a single cell the same change in postsynaptic Ca2+ concentration can have opposite effects on non-NMDA- and NMDA-receptor-mediated synaptic responses. This may be particularly important in the NA, where NMDA receptors are critical for mediating the behavioural actions of drugs of abuse(11-13).	UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,LPPI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; Bear M F, 1993, Curr Opin Neurobiol, V3, P197, DOI 10.1016/0959-4388(93)90210-P; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHANG HT, 1986, BRAIN RES, V366, P392, DOI 10.1016/0006-8993(86)91326-0; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHRISTIE MJ, 1987, NEUROSCIENCE, V22, P425, DOI 10.1016/0306-4522(87)90345-9; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; KELLEY AE, 1992, BRAIN RES BULL, V29, P247, DOI 10.1016/0361-9230(92)90034-U; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCBAIN CJ, 1993, J PHYSIOL-LONDON, V462, P373, DOI 10.1113/jphysiol.1993.sp019560; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; NESTLER EJ, 1992, J NEUROSCI, V12, P2439; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; ODONNELL P, 1993, SYNAPSE, V13, P135, DOI 10.1002/syn.890130206; PENNARTZ CMA, 1991, EXP BRAIN RES, V86, P190, DOI 10.1007/BF00231053; PENNARTZ CMA, 1993, EUR J NEUROSCI, V5, P107, DOI 10.1111/j.1460-9568.1993.tb00475.x; PENNARTZ CMA, 1992, NEUROSCI LETT, V136, P109, DOI 10.1016/0304-3940(92)90660-Y; PERKEL DJ, 1993, J PHYSIOL-LONDON, V471, P481, DOI 10.1113/jphysiol.1993.sp019911; PHILLIPSON OT, 1985, NEUROSCIENCE, V16, P275, DOI 10.1016/0306-4522(85)90002-8; PULVIRENTI L, 1992, BRAIN RES, V594, P327, DOI 10.1016/0006-8993(92)91145-5; PULVIRENTI L, 1991, PHARMACOL BIOCHEM BE, V40, P841, DOI 10.1016/0091-3057(91)90095-J; SWERDLOW NR, 1987, BEHAV BRAIN SCI, V10, P197, DOI 10.1017/S0140525X00047488; UCHIMURA N, 1991, J PHARMACOL EXP THER, V258, P663; UCHIMURA N, 1989, J NEUROPHYSIOL, V61, P769, DOI 10.1152/jn.1989.61.4.769	30	172	175	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					242	246		10.1038/368242a0	http://dx.doi.org/10.1038/368242a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	7908412				2022-12-28	WOS:A1994NA87000055
J	CACCIATORE, B; STENMAN, UH; YLOSTALO, P				CACCIATORE, B; STENMAN, UH; YLOSTALO, P			EARLY SCREENING FOR ECTOPIC PREGNANCY IN HIGH-RISK SYMPTOM-FREE WOMEN	LANCET			English	Note								We screened 225 symptom-free pregnantwomen at increased risk for ectopic pregnancy with transvaginal sonography and human chorionic gonadotropin (hCG) assays. Among 55 (24.4%), who proved to have an ectopic pregnancy, 46 (84%) cases were diagnosed at the initial screening at a median of 37 days of gestation, and the rest at repeated scans. The false-positive rate was 1.2%. Early diagnosis prevented tubal rupture, substantial haemorrhage, and the need for emergency care, allowing elective treatment. Such early surveillance reduced the risk of complications and facilitated treatment, and should be offered to at-risk women.	HELSINKI UNIV,CENT HOSP,DEPT OBSTET & GYNAECOL 2,SF-00290 HELSINKI,FINLAND	University of Helsinki; Helsinki University Central Hospital	CACCIATORE, B (corresponding author), HELSINKI UNIV,CENT HOSP,DEPT OBSTET & GYNAECOL 1,HAARTMANINKATU 2,SF-00290 HELSINKI,FINLAND.							CACCIATORE B, 1990, BRIT J OBSTET GYNAEC, V97, P904, DOI 10.1111/j.1471-0528.1990.tb02445.x; CARSON SA, 1993, NEW ENGL J MED, V329, P1174; GRUDZINSKAS JG, 1993, BRIT J OBSTET GYNAEC, V100, P510, DOI 10.1111/j.1471-0528.1993.tb15298.x; LOWER AM, 1992, HUM REPROD, V7, P711, DOI 10.1093/oxfordjournals.humrep.a137723; SHEPHERD RW, 1990, OBSTET GYNECOL, V75, P417; Stabile I, 1990, Obstet Gynecol Surv, V45, P335, DOI 10.1097/00006254-199006000-00001; YLOSTALO P, 1992, OBSTET GYNECOL, V80, P345	7	62	64	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					517	518		10.1016/S0140-6736(94)91464-8	http://dx.doi.org/10.1016/S0140-6736(94)91464-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906763				2022-12-28	WOS:A1994MX88800012
J	SHORT, RV				SHORT, RV			DARWIN, HAVE I FAILED YOU	LANCET			English	Editorial Material											SHORT, RV (corresponding author), MONASH UNIV,DEPT PHYSIOL,CLAYTON,VIC 3168,AUSTRALIA.							DAWKIN R, 1986, BLIND WATCHMAKER; DIAMOND J, 1991, RISE FALL 3RD CHIMPA; 1992, CAMBRIDGE ENCYCLOPAE; 1991, MANS PLACE EVOLUTION	4	5	5	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					528	529		10.1016/S0140-6736(94)91469-9	http://dx.doi.org/10.1016/S0140-6736(94)91469-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906767				2022-12-28	WOS:A1994MX88800017
J	OCONNOR, JJ; ROWAN, MJ; ANWYL, R				OCONNOR, JJ; ROWAN, MJ; ANWYL, R			LONG-LASTING ENHANCEMENT OF NMDA RECEPTOR-MEDIATED SYNAPTIC TRANSMISSION BY METABOTROPIC GLUTAMATE-RECEPTOR ACTIVATION	NATURE			English	Article							TERM POTENTIATION; TRANS-ACPD; TRANS-1-AMINOCYCLOPENTANE-1,3-DICARBOXYLIC ACID; RAT HIPPOCAMPUS; CURRENTS; SLICES; CELLS; RESPONSES; AGONIST	SYNAPTIC transmission mediated by the N-methyl-D-aspartate (NMDA) glutamate receptor plays a key role in a range of plastic processes in the nervous system. These include long-term potentiation of synaptic transmission mediated by the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor, neuronal development, excitotoxicity and certain learning tasks1,2. Recently, long-term potentiation of NMDA receptor-mediated synaptic transmission was found to occur following high-frequency (tetanic) stimulation via an unknown mechanism3-7. We show here that activation of metabotropic glutamate (mGlu) receptors by neurally released transmitter underlies this type of long-term potentiation. The whole-cell patch-clamp technique in the 'thick' slice of the rat dentate gyrus was used to measure NMDA receptor-mediated excitatory postsynaptic currents. We have found that mGlu receptor activation by a selective agonist produced a long-lasting enhancement which was mutually exclusive with long-term potentiation of these NMDA currents. Moreover, both forms of potentiation were greatly reduced by the mGlu receptor antagonists L-2-amino-3-phosphonopropionate and (R,S)-alpha-methyl-4-carboxyphenylglycine.	UNIV DUBLIN TRINITY COLL, DEPT PHARMACOL & THERAPEUT, DUBLIN 2, IRELAND; UNIV DUBLIN TRINITY COLL, DEPT PHYSIOL, DUBLIN 2, IRELAND	Trinity College Dublin; Trinity College Dublin				O'Connor, John/0000-0001-8229-8602; Rowan, Michael Joseph/0000-0002-3867-9536	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANIKSZTEJN L, 1992, EUR J NEUROSCI, V4, P500, DOI 10.1111/j.1460-9568.1992.tb00900.x; ASZTELY F, 1992, EUR J NEUROSCI, V4, P681, DOI 10.1111/j.1460-9568.1992.tb00177.x; BASHIR ZI, 1991, NATURE, V349, P156, DOI 10.1038/349156a0; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; BEHNISCH T, 1991, NEUROREPORT, V2, P386, DOI 10.1097/00001756-199107000-00008; BERETTA N, 1991, EUR J NEUROSCI, V3, P850; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BORTOLOTTO ZA, 1993, NEUROPHARMACOLOGY, V32, P1, DOI 10.1016/0028-3908(93)90123-K; CERNE R, 1992, NEUROSCI LETT, V144, P180, DOI 10.1016/0304-3940(92)90745-S; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COLLINGRIDGE GL, 1992, INT ACAD B, V2, P41; COLLINS GGS, 1993, BRIT J PHARMACOL, V108, P422, DOI 10.1111/j.1476-5381.1993.tb12820.x; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; KELLER BU, 1991, J PHYSIOL-LONDON, V435, P275, DOI 10.1113/jphysiol.1991.sp018510; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; LOVINGER DM, 1991, NEUROSCI LETT, V129, P17, DOI 10.1016/0304-3940(91)90710-B; MCGUINNESS N, 1991, NEUROREPORT, V2, P688, DOI 10.1097/00001756-199111000-00014; MCGUINNESS N, 1991, EUR J PHARMACOL, V197, P231, DOI 10.1016/0014-2999(91)90529-Y; MULLER D, 1992, HIPPOCAMPUS, V2, P29, DOI 10.1002/hipo.450020105; MUSGRAVE MA, 1993, NEUROREPORT, V4, P171, DOI 10.1097/00001756-199302000-00014; NICOLETTI F, 1986, J NEUROCHEM, V46, P40, DOI 10.1111/j.1471-4159.1986.tb12922.x; PALMER E, 1989, EUR J PHARMACOL, V166, P585, DOI 10.1016/0014-2999(89)90383-X; XIE X, 1992, NEUROPHYSIOL, V67, P1009	24	160	162	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 10	1994	367	6463					557	559		10.1038/367557a0	http://dx.doi.org/10.1038/367557a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV863	7906392				2022-12-28	WOS:A1994MV86300058
J	SCHECHTER, M; HARRISON, LH; HALSEY, NA; TRADE, G; SANTINO, M; MOULTON, LH; QUINN, TC				SCHECHTER, M; HARRISON, LH; HALSEY, NA; TRADE, G; SANTINO, M; MOULTON, LH; QUINN, TC			COINFECTION WITH HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-I AND HIV IN BRAZIL - IMPACT ON MARKERS OF HIV DISEASE PROGRESSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTRAVENOUS-DRUG-USERS; HTLV-II; HOMOSEXUAL MEN; LEUKEMIA; INFECTION; RETROVIRUS; AIDS; LYMPHOCYTES; LYMPHOMA; CLINICS	Objectives.-To study the effect of human T-cell lymphtropic virus type I (HTLV-1) on markers of human immunodeficiency virus (HIV) disease progression. Design.-A retrospective, nested case-control study. Setting.-A university hospital outpatient HIV clinic in Rio de Janeiro, Brazil. Participants.-Human immunodeficiency virus-seropositive adults participating in a prospective HIV cohort study. Main Outcome Measures.-The HIV clinical stage, CD4+ lymphocyte counts, and other laboratory parameters in 27 individuals infected with HIV and HTLV-1 (coinfection) and 99 age-matched, HIV-seropositive, HTLV-seronegative controls (single infection). Results.-Variables independently associated with coinfection included higher CD4+ lymphocyte count (odds ratio [OR], 2.3; 95% confidence limits [CL], 1.3, 4.1), higher CD4+ percentage (OR, 2.0; 95% CL, 1.3, 3.2), beta2-Microglobulin level of 254 nmol/L or more (OR, 6.8; 95% CL, 1.3, 35.4), World Health Organization stages 3 and 4 (OR, 4.4; 95% CL, 1.1, 18.0), and reporting a parenteral risk factor (OR, 7.4; 95% CL, 1.4, 38.9). When stratified by p24 antigenemia, coinfection was associated with an estimated 82% higher CD4+ lymphocyte count (P<.05). Conclusion.-Coinfection was associated with higher CD4+ lymphocyte counts, more advanced clinical disease, and higher beta2-MiCroglobulin levels than HIV infection alone. The higher mean CD4+ lymphocyte count does not appear to offer immunologic benefit. Caution should be exercised when using CD4+ lymphocytes as a surrogate marker in studies of HIV infection in-populations where HTLV-I is prevalent. Further studies are needed to address whether current CD4+ lymphocyte values for the initiation of antiretroviral therapy and chemoprophylaxis against opportunistic infections in HIV infection are appropriate in coinfection.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH,ROOM 5515,615 N WOLFE ST,BALTIMORE,MD 21205; UNIV FED RIO DE JANEIRO,HOSP UNIV CLEMENTINO FRAGA FILHO,DEPT PREVENT MED,INFECT DIS SERV,RIO JANEIRO,BRAZIL; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOSTAT,BALTIMORE,MD 21205; NIAID,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205	Johns Hopkins University; Universidade Federal do Rio de Janeiro; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; Johns Hopkins University				Moulton, Lawrence/0000-0001-7041-7387				[Anonymous], 1990, Wkly Epidemiol Rec, V65, P221; BARTHOLOMEW C, 1987, LANCET, V2, P1469; BARTHOLOMEW C, 1990, 6TH INT C AIDS SAN F; BOLLINGER RC, 1992, J INFECT DIS, V165, P913, DOI 10.1093/infdis/165.5.913; BUNN PA, 1983, NEW ENGL J MED, V309, P257, DOI 10.1056/NEJM198308043090501; CLEGHORN FR, 1992, ARCH INTERN MED, V152, P1372, DOI 10.1001/archinte.152.7.1372; DESORMEAUX J, 1991, 7TH INT C AIDS FLOR; GALLO RC, 1991, J INFECT DIS, V164, P235, DOI 10.1093/infdis/164.2.235; HERSHOW RC, 1993, 9TH INT C AIDS BERL; HJELLE B, 1992, LANCET, V339, P645, DOI 10.1016/0140-6736(92)90797-7; HJELLE B, 1991, J INFECT DIS, V163, P435, DOI 10.1093/infdis/163.3.435; HOLLSBERG P, 1992, J IMMUNOL, V148, P3256; HORTA B L, 1992, Boletin de la Oficina Sanitaria Panamericana, V113, P131; IJICHI S, 1992, J EXP MED, V176, P293, DOI 10.1084/jem.176.1.293; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; KHABBAZ RF, 1992, NEW ENGL J MED, V326, P375, DOI 10.1056/NEJM199202063260604; KRIMER A, 1990, HUMAN RETROVIROLOGY, P79; LAL RB, 1991, J CLIN MICROBIOL, V29, P2253, DOI 10.1128/JCM.29.10.2253-2258.1991; LIMA LAA, 1993, AIDS, V7, P295, DOI 10.1097/00002030-199302000-00031; MONTANER JSG, 1992, AIDS, V6, P719, DOI 10.1097/00002030-199207000-00016; MOREIRA ED, 1993, J ACQ IMMUN DEF SYND, V6, P959; OSAME M, 1987, ANN NEUROL, V21, P117, DOI 10.1002/ana.410210203; PAGE JB, 1990, LANCET, V335, P1439, DOI 10.1016/0140-6736(90)91456-K; PAGLIUCA A, 1990, LANCET, V336, P383, DOI 10.1016/0140-6736(90)91931-Y; PARK LP, 1992, J ACQ IMMUN DEF SYND, V5, P1124; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; QUINN TC, 1989, NEW ENGL J MED, V320, P1005, DOI 10.1056/NEJM198904133201509; RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990; ROSENBLATT JD, 1987, LEUKEMIA, V1, P397; ROSENBLATT JD, 1986, NEW ENGL J MED, V315, P372, DOI 10.1056/NEJM198608073150606; SCHECHTER M, 1992, 8TH INT C AIDS AMST; VILLIGER PM, 1991, J IMMUNOL, V146, P550; WEISS SH, 1989, 5 INT C AIDS MONTR; WEISS SH, 1992, 1992 ANN M SPONS LAB; WELLES SL, 1992, 5TH P INT C HUM RETR; WIKTOR SZ, 1992, J INFECT DIS, V165, P920, DOI 10.1093/infdis/165.5.920; WIKTOR SZ, 1991, LANCET, V337, P327, DOI 10.1016/0140-6736(91)90947-N; WUCHERPFENNIG KW, 1992, P NATL ACAD SCI USA, V89, P2110, DOI 10.1073/pnas.89.6.2110; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; 1989, MMWR MORB MORTAL WKL, V38, P845	40	83	86	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	1994	271	5					353	357		10.1001/jama.271.5.353	http://dx.doi.org/10.1001/jama.271.5.353			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR983	7904317				2022-12-28	WOS:A1994MR98300029
J	CHALLACOMBE, D				CHALLACOMBE, D			WHEN IS A CELIAC	LANCET			English	Editorial Material							CELIAC-DISEASE; ANTIGLIADIN; ANTIBODIES				CHALLACOMBE, D (corresponding author), MUSGROVE PK HOSP, SOMERSET CHILDRENS RES UNIT, TAUNTON, ENGLAND.							AURICCHIO S, 1988, PEDIATR CLIN N AM, V35, P157; BARRY RE, 1974, CLIN GASTROENTEROL, V3, P55; BURGINWOLFF A, 1991, ARCH DIS CHILD, V66, P941, DOI 10.1136/adc.66.8.941; DIAS J, 1987, LANCET, V2, P157; FERREIRA M, 1992, GUT, V33, P1633, DOI 10.1136/gut.33.12.1633; HOLMES GKT, 1989, GUT, V30, P333, DOI 10.1136/gut.30.3.333; MEEUWISSE GW, 1970, ACTA PAEDIATR SCAND, V59, P461; ROSSI TM, 1988, J PEDIATR GASTR NUTR, V7, P858, DOI 10.1097/00005176-198811000-00011; UNSWORTH DJ, 1994, GUT, V35, P61, DOI 10.1136/gut.35.1.61	9	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	1994	343	8891					188	188		10.1016/S0140-6736(94)90984-9	http://dx.doi.org/10.1016/S0140-6736(94)90984-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT332	7904663				2022-12-28	WOS:A1994MT33200003
J	DEMARTINO, M; TOVO, PA; GALLI, L; GABIANO, C; VEGLIA, F; GIAQUINTO, C; TULISSO, S; LOY, A; FERRARIS, G; ZUCCOTTI, GV; SCHOELLER, MC; VIERUCCI, A; MARCHISIO, P; GATTINARA, GC; CASELLI, D; DALLACASA, P; FUNDARO, C; STEGAGNO, M; ANZIDEI, G; SORESINA, A; CHIAPPE, F; RUGGERI, M; COCCHI, P; CONSOLINI, R; MAZZONI, PL; BENAGLIA, G; RISSO, S; CICCIMARRA, F; FORNI, GL; PORTELLI, V; DEMATTIA, D; MAZZA, A; BEZZI, T; CORRIAS, A; RAGAZZINI, I; GAMBARETTO, G; BASSANETTI, F; CECCHI, MT; MICHELETTI, E; OSIMANI, P; STICCA, M; TARALLO, L; GUARINO, A; FALCONIERI, P				DEMARTINO, M; TOVO, PA; GALLI, L; GABIANO, C; VEGLIA, F; GIAQUINTO, C; TULISSO, S; LOY, A; FERRARIS, G; ZUCCOTTI, GV; SCHOELLER, MC; VIERUCCI, A; MARCHISIO, P; GATTINARA, GC; CASELLI, D; DALLACASA, P; FUNDARO, C; STEGAGNO, M; ANZIDEI, G; SORESINA, A; CHIAPPE, F; RUGGERI, M; COCCHI, P; CONSOLINI, R; MAZZONI, PL; BENAGLIA, G; RISSO, S; CICCIMARRA, F; FORNI, GL; PORTELLI, V; DEMATTIA, D; MAZZA, A; BEZZI, T; CORRIAS, A; RAGAZZINI, I; GAMBARETTO, G; BASSANETTI, F; CECCHI, MT; MICHELETTI, E; OSIMANI, P; STICCA, M; TARALLO, L; GUARINO, A; FALCONIERI, P			FEATURES OF CHILDREN PERINATALLY INFECTED WITH HIV-1 SURVIVING LONGER THAN 5 YEARS	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROGRESSION; AIDS; TRANSMISSION; ZIDOVUDINE; PHENOTYPE; TYPE-1; RISK	Children infected with HIV do not necessarily develop AIDS to a set pattern but can be divided into long-term and short-term survivors. We examined long-term survival in children perinatally infected with HIV-1. Out of a total of 624, we studied 182 children who survived longer than 5 years (long-term survivors [LTS]) and 120 children who died of HIV-1-related disease before 5 years (defined as short-term survivors [STS]). 28 (15%) LTS were symptomless (Centers for Disease Control [CDC) P-1 children). 154 (85%) had symptoms (CDC P-2). The proportion of LTS with less than 0.2 x 10(9)/CD4 cells per L was 24/116 (21%) at 61-72 months, rising to 11/26 (41%) at more than 96 months. On at least one occasion, p24 antigenaemia was observed in 112 (62%) LTS. Annual rate of CD4 cell loss was lower in LTS (25% [95% Cl: 21-29]) than in STS (53% [45-60]) and in LTS symptomless or with solitary P-2A signs (17%; [13-21]) than in LTS with severe manifestations (30% [25-35]). A new outlook emerges. A substantial number of children do survive after early childhood; severe diseases, low CD4 cell numbers, and p24 antigenaemia do not necessarily preclude long-term survival. The study shows that a CD4 cell decrease early in life can be predictive of outcome.			DEMARTINO, M (corresponding author), UNIV FLORENCE, DEPT PEDIAT, ITALIAN REGISTER HIV INFECT CHILDREN, VIA LUCA GIORDANO 13, I-50132 FLORENCE, ITALY.		Giaquinto, Carlo/AAB-5016-2020; castelli, guido/AAA-1507-2020	castelli, guido/0000-0002-3282-7462; Guarino, Alfredo/0000-0003-0199-0336				ALCABES P, 1993, AIDS, V7, P513, DOI 10.1097/00002030-199304000-00010; CROXSON TS, 1990, AIDS RES HUM RETROV, V6, P455, DOI 10.1089/aid.1990.6.455; DEMARTINO M, 1992, AIDS, V6, P991, DOI 10.1097/00002030-199209000-00013; DEMARTINO M, 1991, J PEDIATR-US, V119, P702, DOI 10.1016/S0022-3476(05)80283-5; DEMARTINO M, 1991, ARCH DIS CHILD, V66, P1235, DOI 10.1136/adc.66.10.1235; DEMARTINO M, 1992, 8 INT C AIDS AMST; ELLAURIE M, 1991, ARCH DIS CHILD, V66, P200, DOI 10.1136/adc.66.2.200; GABIANO C, 1992, PEDIATRICS, V90, P369; GRANT MD, 1992, AIDS, V6, P1085, DOI 10.1097/00002030-199210000-00004; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; ITESCU S, 1992, J ACQ IMMUN DEF SYND, V5, P37; JACOBSON MA, 1991, BRIT MED J, V302, P73, DOI 10.1136/bmj.302.6768.73; JOHNSON JP, 1989, AM J DIS CHILD, V143, P1147, DOI 10.1001/archpedi.1989.02150220037017; KATZENSTEIN DA, 1992, J ACQ IMMUN DEF SYND, V5, P107; KELLY DA, 1987, LANCET, V1, P806; KOOT M, 1992, AIDS, V6, P49, DOI 10.1097/00002030-199201000-00006; KRIVINE A, 1992, LANCET, V339, P1187, DOI 10.1016/0140-6736(92)91131-Q; LEPAGE P, 1991, AM J DIS CHILD, V145, P1248, DOI 10.1001/archpedi.1991.02160110040017; MANTEL N, 1966, CANCER CHEMOTH REP, V50, P1163; MOFENSON LM, 1991, NEW ENGL J MED, V325, P73, DOI 10.1056/NEJM199107113250201; MOFENSON LM, 1992, 8 INT C AIDS AMST; PECKHAM CS, 1991, LANCET, V337, P253; SCHELLEKENS PTA, 1992, AIDS, V6, P665, DOI 10.1097/00002030-199207000-00008; THOMAS P, 1992, PEDIATR INFECT DIS J, V11, P34, DOI 10.1097/00006454-199201000-00009; TOVO PA, 1992, LANCET, V339, P1249, DOI 10.1016/0140-6736(92)91592-V; TOZZI AE, 1990, AIDS, V4, P1293, DOI 10.1097/00002030-199012000-00021; 1987, MMWR, V36, pS1; 1988, LANCET, V2, P1042; [No title captured]; 1992, LANCET, V340, P422	30	111	113	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	1994	343	8891					191	195						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT332	7904665				2022-12-28	WOS:A1994MT33200006
J	PAGE, C				PAGE, C			SODIUM CROMOGLYCATE, A TACHYKININ ANTAGONIST	LANCET			English	Editorial Material											PAGE, C (corresponding author), UNIV LONDON KINGS COLL HOSP,SCH MED,SACKLER INST PULM PHARMACOL,LONDON SE5 8RX,ENGLAND.							BASRAN G S, 1983, European Journal of Pharmacology, V86, P143; COX J S G, 1971, British Journal of Diseases of the Chest, V65, P189, DOI 10.1016/0007-0971(71)90028-3; CROSSMAN DC, 1993, J APPL PHYSIOL, V75, P167, DOI 10.1152/jappl.1993.75.1.167; DIXON M, 1979, BRIT J PHARMACOL, V67, P567; MYERS DJ, 1986, AM REV RESPIR DIS, V133, P1150; SPINA D, 1991, BRIT J PHARMACOL, V103, P1268, DOI 10.1111/j.1476-5381.1991.tb12335.x; STOKES TC, 1981, BR J DIS CHEST, V75, P11	7	10	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					70	70		10.1016/S0140-6736(94)90812-5	http://dx.doi.org/10.1016/S0140-6736(94)90812-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903775				2022-12-28	WOS:A1994MQ09200007
J	WILLIAMS, G				WILLIAMS, G			MANAGEMENT OF NON-INSULIN-DEPENDENT DIABETES-MELLITUS	LANCET			English	Article							NIDDM PATIENTS; THERAPY; BIGUANIDES; ONSET				WILLIAMS, G (corresponding author), UNIV LIVERPOOL,DEPT MED,POB 147,LIVERPOOL L69 3BX,ENGLAND.							ALBERTI KGMM, 1988, DIABETIC MED, V5, P275, DOI 10.1111/j.1464-5491.1988.tb00984.x; ANDREWS WJ, 1984, DIABETES, V33, P634, DOI 10.2337/diabetes.33.7.634; BAILEY CJ, 1992, DIABETES CARE, V15, P755, DOI 10.2337/diacare.15.6.755; BAILEY CJ, 1992, NEW ANTIDIABETIC DRU; Clarke BF, 1979, RES CLIN FORUMS, V1, P53; COULSTON AM, 1989, DIABETES CARE, V94, P101; DODSON PM, 1989, BMJ-BRIT MED J, V298, P227, DOI 10.1136/bmj.298.6668.227; DRYDEN S, IN PRESS EUR J CLIN; ERIKSSON KF, 1991, DIABETOLOGIA, V34, P891, DOI 10.1007/BF00400196; GARG A, 1990, DIABETES CARE, V13, P153, DOI 10.2337/diacare.13.2.153; GENUTH S, 1990, DIABETES CARE, V13, P1240, DOI 10.2337/diacare.13.12.1240; GIUGLIANO D, 1993, EUR J CLIN PHARMACOL, V44, P107, DOI 10.1007/BF00315466; GROOP LC, 1986, DIABETES CARE, V9, P129, DOI 10.2337/diacare.9.2.129; HADDEN DR, 1986, Q J MED, V59, P574; HARRIS MI, 1992, DIABETES CARE, V15, P815, DOI 10.2337/diacare.15.7.815; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; HENRY RR, 1993, DIABETES CARE, V16, P21, DOI 10.2337/diacare.16.1.21; HERMANN LS, 1990, DIABETES CARE, V13, P37, DOI 10.2337/diacare.13.3.37; JARRETT RJ, 1992, LANCET, V340, P469, DOI 10.1016/0140-6736(92)91781-3; LEAN MEJ, 1991, TXB DIABETES, P453; LEBOVITZ HE, 1992, INT TXB DIABETES MEL, P745; NISKANEN LK, 1990, DIABETES CARE, V13, P41, DOI 10.2337/diacare.13.1.41; NUTTALL FQ, 1993, DIABETES, V42, P503, DOI 10.2337/diabetes.42.4.503; PEACOCK I, 1984, BRIT MED J, V288, P1956, DOI 10.1136/bmj.288.6435.1956; PUGH JA, 1992, DIABETES CARE, V15, P953, DOI 10.2337/diacare.15.8.953; SCHNEIDER S H, 1990, Diabetes Care, V13, P785; SELTZER HS, 1989, ENDOCRIN METAB CLIN, V18, P163, DOI 10.1016/S0889-8529(18)30395-5; SONERU IL, 1993, DIABETES CARE, V16, P896, DOI 10.2337/diacare.16.6.896; STENMAN S, 1993, ANN INTERN MED, V118, P169, DOI 10.7326/0003-4819-118-3-199302010-00002; STOUT RW, 1987, LANCET, V1, P1077; YKIJARVINEN H, 1992, NEW ENGL J MED, V327, P1426, DOI 10.1056/NEJM199211123272005; YKIJARVINEN H, 1994, LANCET, V343, P91, DOI 10.1016/S0140-6736(94)90821-4; YUDKIN JS, 1993, BMJ-BRIT MED J, V306, P1313, DOI 10.1136/bmj.306.6888.1313; 1983, DIABETOLOGIA, V24, P404; 1979, DIABETES CARE, V2, P1; 1987, DIABETES CARE, V10, P639; 1993, J R COLL PHYS, V27, P259; 1992, DIABETIC MED, V9, P189	38	82	86	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					95	100		10.1016/S0140-6736(94)90822-2	http://dx.doi.org/10.1016/S0140-6736(94)90822-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903785				2022-12-28	WOS:A1994MQ09200017
J	CLERICI, M; LUCEY, DR; BERZOFSKY, JA; PINTO, LA; WYNN, TA; BLATT, SP; DOLAN, MJ; HENDRIX, CW; WOLF, SF; SHEARER, GM				CLERICI, M; LUCEY, DR; BERZOFSKY, JA; PINTO, LA; WYNN, TA; BLATT, SP; DOLAN, MJ; HENDRIX, CW; WOLF, SF; SHEARER, GM			RESTORATION OF HIV-SPECIFIC CELL-MEDIATED IMMUNE-RESPONSES BY INTERLEUKIN-12 IN-VITRO	SCIENCE			English	Article							LYMPHOCYTE MATURATION FACTOR; STIMULATORY FACTOR; RECOMBINANT INTERLEUKIN-2; HETERODIMERIC CYTOKINE; IDENTIFICATION; PURIFICATION; INDUCTION; SYNERGY; PEPTIDE	Peripheral blood mononuclear cells (PBMCs) from many asymptomatic individuals infected with human immunodeficiency virus-type 1 (HIV) are unresponsive as measured by in vitro T cell proliferation and interleukin-2 (IL-2) production to influenza virus and synthetic peptides of HIV envelope (Env). Strong influenza virus- and Env-stimulated IL-2 responses and T cell proliferation were restored when cultures were stimulated in the presence of IL-12. Interferon-gamma production by PBMCs from HIV seropositive (HIV+) patients was also restored with IL-12. Furthermore, in vitro antigen-specific production of IL-2 and proliferation of PBMCs from HIV- donors were suppressed by antibody to IL-12, but were not enhanced by addition of exogenous IL-12. Thus, IL-12 may be limiting in PBMCs from HIV+ but not HIV- individuals. These findings demonstrate that IL-12 can restore HIV-specific cell-mediated immunity in vitro in HIV-infected individuals and suggest a potential use of IL-12 in augmenting the diminished immunologic functions associated with HIV infection.	NCI,EXPTL IMMUNOL BRANCH,BLDG 10,ROOM 4B-17,BETHESDA,MD 20892; GENET INST INC,CAMBRIDGE,MA 02140; NCI,METAB BRANCH,BETHESDA,MD 20892; NIAID,PARASIT DIS LAB,BETHESDA,MD 20892; WILFORD HALL USAF MED CTR,HIV UNIT,LACKLAND AFB,TX 78236	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); United States Department of Defense; United States Air Force			Wynn, Thomas A/C-2797-2011; Wynn, Thomas A/AAO-3523-2021; Hendrix, Craig W/G-4182-2014	Wynn, Thomas A/0000-0002-7244-8731; Hendrix, Craig W/0000-0002-5696-8665; Clerici, Mario/0000-0001-5920-6191				ACTOR JK, 1993, P NATL ACAD SCI USA, V90, P948, DOI 10.1073/pnas.90.3.948; CEASE KB, 1987, P NATL ACAD SCI USA, V84, P4249, DOI 10.1073/pnas.84.12.4249; CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869; CHEHIMI J, 1992, J EXP MED, V175, P789, DOI 10.1084/jem.175.3.789; CHEHIMI J, 1993, 9TH INT C AIDS BERL, P24; CLERICI M, 1989, NATURE, V339, P383, DOI 10.1038/339383a0; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; CLERICI M, IN PRESS J CLIN INVE; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; DOLAN MJ, 1993, 9TH INT C AIDS BERL, P45; GATELY MK, 1991, J IMMUNOL, V147, P874; GATELY MK, 1986, J IMMUNOL, V136, P1274; GATELY MK, 1992, CELL IMMUNOL, V143, P127, DOI 10.1016/0008-8749(92)90011-D; GAZZINELLI RT, 1993, P NATL ACAD SCI USA, V90, P6115, DOI 10.1073/pnas.90.13.6115; Hale P M, 1989, Int Immunol, V1, P409, DOI 10.1093/intimm/1.4.409; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; LUCEY DR, 1991, J INFECT DIS, V164, P631, DOI 10.1093/infdis/164.4.631; MACOTONIA SE, 1993, INT IMMUNOL, V5, P1119; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; NAUME B, 1993, CYTOKINE, V5, P38, DOI 10.1016/1043-4666(93)90022-W; PINTO LH, UNPUB; SALK J, 1993, SCIENCE, V260, P1270, DOI 10.1126/science.8098553; SCOTT P, 1993, SCIENCE, V260, P496, DOI 10.1126/science.8097337; STERN AS, 1990, P NATL ACAD SCI USA, V87, P6808, DOI 10.1073/pnas.87.17.6808; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; TRIPP CS, 1993, P NATL ACAD SCI USA, V90, P3725, DOI 10.1073/pnas.90.8.3725; WOLF SF, 1991, J IMMUNOL, V146, P3074; WONG HL, 1988, CELL IMMUNOL, V111, P39, DOI 10.1016/0008-8749(88)90049-4	33	409	426	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 10	1993	262	5140					1721	1724		10.1126/science.7903123	http://dx.doi.org/10.1126/science.7903123			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	7903123				2022-12-28	WOS:A1993ML22000038
J	QUEIROZ, DMM; MOURA, SB; MENDES, EN; ROCHA, GA; BARBOSA, AJA; DECARVALHO, AST				QUEIROZ, DMM; MOURA, SB; MENDES, EN; ROCHA, GA; BARBOSA, AJA; DECARVALHO, AST			EFFECT OF HELICOBACTER-PYLORI ERADICATION ON G-CELL AND D-CELL DENSITY IN CHILDREN	LANCET			English	Article							CAMPYLOBACTER-PYLORI; DUODENAL-ULCER; UREASE ACTIVITY; GASTRIN; SOMATOSTATIN; HYPERGASTRINEMIA; AMOXYCILLIN; ACID	Helicobacter pylori infection is associated with abnormalities in serum gastrin concentration, antral gastrin and somatostatin content, and D-cell density in adults. We have studied the effects of H pylori infection in children. We studied 13 children positive for H pylori and 7 negative children. The median antral somatostatin content was significantly lower in the positive than in the negative group (0.69 [range 0.35-0.91] vs 1.31 [0.73-1.67] ng/mg, p = 0.007). Both antral and serum gastrin concentrations were significantly higher in the positive group (30.1 [15.3-83.6] vs 14.8 [13.8-28.8] ng/mg, p = 0.008; and 89.9 [59.4-313.2] vs 29.5 [13.9-71.1] pg/mL, p = 0.006). Treatment to eradicate H pylori was successful in 11 of the 13 positive patients. With eradication antral somatostatin increased to within the normal range (by a median of 0.41 [0.21-0.86] ng/mg to 1.10 [0.81-1.55] ng/mg, p = 0.016). Serum and antral gastrin decreased (by 37.1 [5.5-265.2] pg/mL to 52.8 [21.4-267.5] ng/mg, p = 0.001; and by 8.0 [2.0-47.2] ng/mg to 22.1 [10.9-37.5] ng/mg, p = 0.001). Eradication of H pylori also significantly increased antral D-cell density (8 [5-22] to 15 [9-22] cells per mm, p = 0.031) and decreased G-cell density (138 [89-161] to 88 [33-121] cells per mm, p = 0.016). The hypergastrinaemia in children positive for H pylori may be due to a deficiency of antral somatostatin, which inhibits gastrin synthesis and release.	UNIV FED MINAS GERAIS, FAC MED, DEPT PATHOL, BELO HORIZONTE, MG, BRAZIL; UNIV FED MINAS GERAIS, FAC MED, DEPT PEDIAT, BELO HORIZONTE, MG, BRAZIL	Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais	QUEIROZ, DMM (corresponding author), UNIV FED MINAS GERAIS, FAC MED, RES BACTERIOL LAB, AVE ALFREDO BALENA 190-464, BR-30130100 BELO HORIZONTE, MG, BRAZIL.		Moura, Sílvia B/K-7344-2012; Queiroz, Dulciene/AAU-9386-2020; Rocha, Gifone A/N-6913-2018	Queiroz, Dulciene/0000-0003-1334-9423; Rocha, Gifone A/0000-0002-1858-3166				ARNOLD R, 1980, CLIN GASTROENTEROL, V9, P733; BRYANT MG, 1982, RADIOIMMUNOASSAY GUT, P336; CARVALHO AST, 1991, BRAZ J MED BIOL RES, V24, P163; CHITTAJALLU RS, 1991, GUT, V32, P1286, DOI 10.1136/gut.32.11.1286; ELNUJUMI AM, 1991, GUT, V32, P866, DOI 10.1136/gut.32.8.866; ELOMAR E, 1993, GUT, V34, P1060, DOI 10.1136/gut.34.8.1060; GRAHAM DY, 1993, GASTROENTEROLOGY, V104, P1655, DOI 10.1016/0016-5085(93)90642-P; GRAHAM DY, 1990, AM J GASTROENTEROL, V85, P394; KANEKO H, 1992, DIGEST DIS SCI, V37, P409, DOI 10.1007/BF01307736; Kramling H J, 1987, Adv Exp Med Biol, V216A, P427; LEVI S, 1989, LANCET, V1, P1167; MAHONY MJ, 1990, ARCH DIS CHILD, V65, P1212; MCCOLL KEL, 1989, LANCET, V2, P499; MOSS SF, 1992, LANCET, V340, P930, DOI 10.1016/0140-6736(92)92816-X; NAKANISHI T, 1993, AM J GASTROENTEROL, V88, P440; ODERDA G, 1989, ARCH DIS CHILD, V64, P326, DOI 10.1136/adc.64.3.326; ODERDA G, 1989, LANCET, V1, P690; QUEIROZ DMM, 1993, SCAND J GASTROENTERO, V28, P858, DOI 10.3109/00365529309103125; QUEIROZ DMM, 1987, J CLIN MICROBIOL, V25, P2378, DOI 10.1128/JCM.25.12.2378-2379.1987; SCHUSDZIARRA V, 1983, SCAND J GASTROENTERO, V18, P69; SMITH JTL, 1990, GUT, V31, P522, DOI 10.1136/gut.31.5.522; STERNBERG LA, 1986, IMMUNOCYTOCHEMISTRY; WILLIAMS G, 1988, HORM METAB RES, V20, P668, DOI 10.1055/s-2007-1010913; WOLFE MM, 1988, NEW ENGL J MED, V319, P1707; YEUNG CK, 1990, J PEDIATR GASTR NUTR, V10, P357, DOI 10.1097/00005176-199004000-00016	25	49	51	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 14	1994	343	8907					1191	1193		10.1016/S0140-6736(94)92401-5	http://dx.doi.org/10.1016/S0140-6736(94)92401-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909869				2022-12-28	WOS:A1994NL17500010
J	SALTUARI, L; MAROSI, M				SALTUARI, L; MAROSI, M			COMMA AFTER CARDIAC-ARREST - WILL HE RECOVER ALL RIGHT	LANCET			English	Editorial Material											SALTUARI, L (corresponding author), UNIV INNSBRUCK HOSP,NEUROREHABIL UNIT,INNSBRUCK,AUSTRIA.							BELL JA, 1974, BRAIN, V97, P361, DOI 10.1093/brain/97.1.361; GERSTENBRAND F, 1988, N TRENDS CLIN NEUROP, V1, P71; KARKELA J, 1992, CRIT CARE MED, V20, P378; LECHLEITNER P, 1993, CIRCULATION S, V88, P1; LONGSTRETH WT, 1983, NEW ENGL J MED, V308, P1378, DOI 10.1056/NEJM198306093082302; MADL C, 1993, LANCET, V341, P855, DOI 10.1016/0140-6736(93)93061-5; MAROSI MJ, 1991, LANCET, V337, P1043; MARTIN GB, 1991, STROKE, V22, P462, DOI 10.1161/01.STR.22.4.462; MULLIE A, 1988, LANCET, V1, P137; 1986, CURRENT OPINIONS, P12; 1991, NEW ENGL J MED, V324, P1225	11	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 30	1994	343	8905					1052	1053		10.1016/S0140-6736(94)90176-7	http://dx.doi.org/10.1016/S0140-6736(94)90176-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ694	7909095				2022-12-28	WOS:A1994NJ69400004
J	WEBER, K; PFISTER, HW				WEBER, K; PFISTER, HW			CLINICAL MANAGEMENT OF LYME BORRELIOSIS	LANCET			English	Article							ERYTHEMA MIGRANS; PENICILLIN-G; NEUROLOGIC MANIFESTATIONS; CONTROLLED TRIAL; TICK BITES; DISEASE; CEFTRIAXONE; DOXYCYCLINE; CEFOTAXIME; ARTHRITIS		UNIV MUNICH, NEUROL KLIN GROSSHADERN, D-81377 MUNICH, GERMANY	University of Munich								BURGDORFER W, 1991, SCAND J INFECT DIS, P35; DATTWYLER RJ, 1988, LANCET, V1, P1191; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; HASSLER D, 1991, LANCET, V338, P193, DOI 10.1016/0140-6736(91)90188-U; HASSLER D, 1990, INFECTION, V18, P16, DOI 10.1007/BF01644175; Herzer P., 1993, Aspects of Lyme borreliosis., P340; JAENSON TGT, 1991, SCAND J INFECT DIS, P151; KOHLHEPP W, 1989, J NEUROL, V236, P464, DOI 10.1007/BF00328508; KRISTOFERITSCH W, 1986, Zentralblatt fuer Bakteriologie Mikrobiologie und Hygiene Series A, V263, P357; LIU NY, 1989, ARTHRITIS RHEUM S, V32, P46; LOGIGIAN EL, 1990, NEW ENGL J MED, V323, P1438, DOI 10.1056/NEJM199011223232102; LUFT BJ, 1992, 5TH INT C LYM BORR A; MAGID D, 1992, NEW ENGL J MED, V327, P534, DOI 10.1056/NEJM199208203270806; MASSAROTTI EM, 1992, AM J MED, V92, P396, DOI 10.1016/0002-9343(92)90270-L; Mayer-Berger W., 1993, Aspects of Lyme borreliosis., P344; MULLEGGER RR, 1991, INFECTION, V19, P279, DOI 10.1007/BF01644967; NADELMAN RB, 1992, ANN INTERN MED, V117, P273, DOI 10.7326/0003-4819-117-4-273; PAUL H, 1986, Zentralblatt fuer Bakteriologie Mikrobiologie und Hygiene Series A, V263, P473; Pfister H. W., 1993, Aspects of Lyme borreliosis., P328; PFISTER HW, 1988, ANN NY ACAD SCI, V539, P485, DOI 10.1111/j.1749-6632.1988.tb31915.x; PFISTER HW, 1989, ARCH NEUROL-CHICAGO, V46, P1190, DOI 10.1001/archneur.1989.00520470044025; PFISTER HW, 1991, J INFECT DIS, V163, P311, DOI 10.1093/infdis/163.2.311; PREACMURSIC V, 1989, INFECTION, V17, P355, DOI 10.1007/BF01645543; PREACMURSIC V, 1993, ASPECTS LYME BORRELI, P301; SCHOEN RT, 1991, ARTHRITIS RHEUM, V34, P1056, DOI 10.1002/art.1780340817; Schonherr U., 1993, Aspects of Lyme borreliosis., P248; SHAPIRO ED, 1992, NEW ENGL J MED, V327, P1769, DOI 10.1056/NEJM199212173272501; STEER AC, 1983, ANN INTERN MED, V99, P767, DOI 10.7326/0003-4819-99-6-767; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; STEERE AC, 1985, NEW ENGL J MED, V312, P869, DOI 10.1056/NEJM198504043121401; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STRLE F, 1992, J ANTIMICROB CHEMOTH, V30, P543, DOI 10.1093/jac/30.4.543; WEBER K, 1989, ZBL BAKT P, V18, P263; WEBER K, 1988, ANN NY ACAD SCI, V539, P324, DOI 10.1111/j.1749-6632.1988.tb31867.x; WEBER K, 1986, Zentralblatt fuer Bakteriologie Mikrobiologie und Hygiene Series A, V263, P377; Weber K., 1993, Aspects of Lyme borreliosis., P312; WEBER K, 1993, INFECTION, V21, P367, DOI 10.1007/BF01728915; WEBER K, 1990, INFECTION, V18, P91, DOI 10.1007/BF01641422; WEBER K, 1984, HAUTARZT, V35, P588	40	42	43	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 23	1994	343	8904					1017	1020		10.1016/S0140-6736(94)90131-7	http://dx.doi.org/10.1016/S0140-6736(94)90131-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909053				2022-12-28	WOS:A1994NG68200014
J	MARKHAM, RB; COBERLY, J; RUFF, AJ; HOOVER, D; GOMEZ, J; HOLT, E; DESORMEAUX, J; BOULOS, R; QUINN, TC; HALSEY, NA				MARKHAM, RB; COBERLY, J; RUFF, AJ; HOOVER, D; GOMEZ, J; HOLT, E; DESORMEAUX, J; BOULOS, R; QUINN, TC; HALSEY, NA			MATERNAL IGG1 AND IGA ANTIBODY TO V3 LOOP CONSENSUS SEQUENCE AND MATERNAL-INFANT HIV-1 TRANSMISSION	LANCET			English	Note							HUMAN-IMMUNODEFICIENCY-VIRUS; GP120; MOTHERS	Maternal-infant transmission of HIV-1 occurs in 13-40% of pregnancies. Studies on transmission of maternal immunity to HIV antigens have used antigens from viruses not representative of clinical isolates and have been conflicting. Using a consensus peptide sequence based on HIV isolates found in Haiti, we found that Haitian mothers who transmitted infection to their offspring had significantly higher mean concentrations of IgG1 antibodies to the V3 loop of the primary neutralising domain of the viral envelope (gp 160) than non-transmitters (p = 0.02). Concentrations of IgA antibody to this domain were similar in transmitters and non-transmitters.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21205; CTR DEV & HLTH,PORT AU PRINCE,HAITI	Johns Hopkins University; Johns Hopkins University	MARKHAM, RB (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT IMMUNOL & INFECT DIS,615 N WOLFE ST,BALTIMORE,MD 21205, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028748, R01AI032468] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32468, P30 AI28748] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DEVASH Y, 1990, P NATL ACAD SCI USA, V87, P3445, DOI 10.1073/pnas.87.9.3445; HALSEY NA, 1992, J ACQ IMMUN DEF SYND, V5, P153; HALSEY NA, 1990, JAMA-J AM MED ASSOC, V264, P2088, DOI 10.1001/jama.264.16.2088; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; PAREKH BS, 1991, AIDS, V5, P1179, DOI 10.1097/00002030-199110000-00004; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; WESTERVELT P, 1992, J VIROL, V66, P2577, DOI 10.1128/JVI.66.4.2577-2582.1992; YERLY S, 1992, J INFECT DIS, V166, P269, DOI 10.1093/infdis/166.2.269; 1992, J ACQUIR IMMUN DEFIC, V5, P1019	9	31	33	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					390	391		10.1016/S0140-6736(94)91225-4	http://dx.doi.org/10.1016/S0140-6736(94)91225-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905554	hybrid			2022-12-28	WOS:A1994MW28300011
J	GOODEVE, AC; PRESTON, FE; PEAKE, IR				GOODEVE, AC; PRESTON, FE; PEAKE, IR			FACTOR-VIII GENE REARRANGEMENTS IN PATIENTS WITH SEVERE HEMOPHILIA-A	LANCET			English	Note							HEMOPHILIA-A	Sequences within intron 22 of the factor VIII (FVIII) gene have been implicated in the cause of haemophilia in almost 50% of severely affected patients. The changes result from intrachromosomal rearrangements of the tip of the long arm of the X chromosome, one break-point being within intron 22 of the FVIII gene. The rearrangements can be identified by Southern blot and we report use of this procedure to detect rearrangements in 11 of 23 unrelated families with severe haemophilia A. Of 22 patients studied, none of the 10 with the gene rearrangement had at any time developed inhibitors to FVIII, compared with 7 of 12 lacking the rearrangement.	ROYAL HALLAMSHIRE HOSP,DEPT MED & PHARMACOL,HAEMATOL SECT,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND; ROYAL HALLAMSHIRE HOSP,DEPT MED & PHARMACOL,MOLEC GENET SECT,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield; University of Sheffield				Goodeve, Anne/0000-0002-6177-7062				HIGUCHI M, 1991, P NATL ACAD SCI USA, V88, P7405, DOI 10.1073/pnas.88.16.7405; LAKICH D, 1993, NAT GENET, V5, P236, DOI 10.1038/ng1193-236; MILLAR DS, 1990, HUM GENET, V86, P219; NAYLOR J, 1993, HUM MOL GENET, V2, P1773, DOI 10.1093/hmg/2.11.1773; NAYLOR JA, 1993, HUM MOL GENET, V2, P11, DOI 10.1093/hmg/2.1.11; PEAKE IR, 1993, BLOOD COAGUL FIBRIN, V4, P313, DOI 10.1097/00001721-199304000-00013; WION KL, 1986, NUCLEIC ACIDS RES, V14, P4553	7	66	66	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 5	1994	343	8893					329	330		10.1016/S0140-6736(94)91165-7	http://dx.doi.org/10.1016/S0140-6736(94)91165-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905147				2022-12-28	WOS:A1994MU98500011
J	GORE, M; BRIDGEWATER, J; CHANG, J; SCHOFIELD, J; FISHER, C; JACOBS, I; PONDER, B; AHERN, R; MCKEAGE, M; KELLAND, L; HARRAP, K				GORE, M; BRIDGEWATER, J; CHANG, J; SCHOFIELD, J; FISHER, C; JACOBS, I; PONDER, B; AHERN, R; MCKEAGE, M; KELLAND, L; HARRAP, K			NONSURGICAL ASPECTS OF OVARIAN-CANCER	LANCET			English	Discussion							SEROUS BORDERLINE TUMORS; HISTOLOGIC FEATURES; PROGNOSIS; CISPLATIN		ROYAL MARSDEN HOSP,DEPT HISTOPATHOL,LONDON SW3 6JJ,ENGLAND; ROYAL MARSDEN HOSP,DEPT COMP & INFORMAT,LONDON SW3 6JJ,ENGLAND; CRC,HUMAN CANC GENET UNIT,CAMBRIDGE,ENGLAND; UNIV CAMBRIDGE,DEPT OBSTET & GYNAECOL,CAMBRIDGE,ENGLAND; INST CANC RES,DRUG DEV SECT,SUTTON SM2 5PX,SURREY,ENGLAND	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of Cambridge; University of London; Institute of Cancer Research - UK	GORE, M (corresponding author), ROYAL MARSDEN HOSP,DEPT MED ONCOL,LONDON SW3 6JJ,ENGLAND.		Jacobs, Ian J/F-1743-2013; Bridgewater, John/J-5957-2018	Jacobs, Ian J/0000-0002-8112-4624; 				[Anonymous], 1991, J CLIN ONCOL, V9, P1668; BELL DA, 1988, CANCER, V62, P2212, DOI 10.1002/1097-0142(19881115)62:10<2212::AID-CNCR2820621024>3.0.CO;2-W; BELL DA, 1990, HUM PATHOL, V21, P397, DOI 10.1016/0046-8177(90)90201-F; BOURNE TH, 1993, BRIT MED J, V306, P1025, DOI 10.1136/bmj.306.6884.1025; CALVERT AH, 1989, J CLIN ONCOL, V7, P1748, DOI 10.1200/JCO.1989.7.11.1748; CAMPBELL S, 1989, BMJ-BRIT MED J, V299, P1363, DOI 10.1136/bmj.299.6712.1363; EASTON DF, 1993, AM J HUM GENET, V52, P678; EINHORN N, 1992, OBSTET GYNECOL, V80, P14; FRIEDLANDER ML, 1984, PATHOLOGY, V16, P301, DOI 10.3109/00313028409068541; GORE ME, 1990, GYNECOL ONCOL, V36, P207, DOI 10.1016/0090-8258(90)90174-J; HARRAP KR, 1991, PLATINUM AND OTHER METAL COORDINATION COMPOUNDS IN CANCER CHEMOTHERAPY, P391; JACOBS I, 1988, LANCET, V1, P268; JACOBS I, 1993, BRIT MED J, V306, P1030, DOI 10.1136/bmj.306.6884.1030; JURMAN RJ, 1993, INT J GYNECOL PATHOL, V12, P120; KATZENSTEIN ALA, 1978, AM J SURG PATHOL, V2, P339, DOI 10.1097/00000478-197812000-00001; KAYE SB, 1992, LANCET, V340, P329, DOI 10.1016/0140-6736(92)91404-V; KELLAND LR, 1993, CANCER RES, V53, P2581; LEAKE JF, 1992, GYNECOL ONCOL, V47, P150, DOI 10.1016/0090-8258(92)90099-5; LYNCH HT, 1985, CANCER, V56, P934, DOI 10.1002/1097-0142(19850815)56:4<934::AID-CNCR2820560439>3.0.CO;2-I; MCKEAGE J, 1993, P AM SOC CLIN ONCOL, V12, pA320; MCKEAGE MJ, 1993, BRIT J CANCER, V67, P996, DOI 10.1038/bjc.1993.182; MCKEAGE MJ, 1992, P AM ASSOC CANC RES, V33, pA3197; PONDER BAJ, 1990, OVARIAN CANCER BIOL, P3; TOBACMAN JK, 1982, LANCET, V2, P795; Williams C J, 1992, Semin Oncol, V19, P120; 1991, ICON UK PROTOCOL; 1991, BRIT MED J, V303, P884	27	16	16	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 5	1994	343	8893					335	340						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905150				2022-12-28	WOS:A1994MU98500014
J	HENG, MCY; HENG, SY; ALLEN, SG				HENG, MCY; HENG, SY; ALLEN, SG			COINFECTION AND SYNERGY OF HUMAN IMMUNODEFICIENCY VIRUS-1 AND HERPES-SIMPLEX VIRUS-1	LANCET			English	Article							LYMPHOCYTES-T; HUMAN CYTOMEGALOVIRUS; LANGERHANS CELLS; HIV-1; TYPE-1; MACROPHAGES; REPLICATION; EXPRESSION; GENE; TRANSACTIVATION	The human immunodeficiency virus (HIV-1) uses the CD4 molecule, expressed by T helper cells and activated macrophages, as a receptor for entry into host cells. In tissues co-infected with herpes simplex type 1 (HSV-1), HIV-1 virions were observed to infect keratinocytes, which, because they lack the CD4 molecule, are normally incapable of being infected by HIV-1. Although a number of other viruses have been reported to enhance HIV-1 viral transcription in vitro, this is the first in-vivo report to our knowledge of reciprocal enhancement of viral replication associated with co-infection of keratinocytes and macrophages by HIV-1 and HSV-1 in patients with AIDS and non-genital herpes simplex lesions. The virions in the coinfected cells were larger, morphologically atypical, and appear to be hybrids; most contain the HIV-1 envelope necessary for infectivity. The increased viral load and the proximity of the virions to the cutaneous surface may lead to increased risk of transcutaneous transmission of both viruses. These findings point to the need for incorporation of suppressive treatment for herpes simplex in the treatment of AIDS.			HENG, MCY (corresponding author), VET AFFAIRS MED CTR,UCLA SAN FERNANDO VALLEY INTERNAL MED PROGRAM,DEPT MED,DIV DERMATOL,SEPULVEDA,CA 91343, USA.							COOPER DA, 1993, AIDS, V7, P197, DOI 10.1097/00002030-199302000-00007; CROWE S, 1987, AIDS RES HUM RETROV, V3, P135, DOI 10.1089/aid.1987.3.135; DAVIS MG, 1987, P NATL ACAD SCI USA, V84, P8642, DOI 10.1073/pnas.84.23.8642; EILBOTT DJ, 1989, P NATL ACAD SCI USA, V86, P3337, DOI 10.1073/pnas.86.9.3337; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; HO WZ, 1991, J ACQ IMMUN DEF SYND, V4, P1098; HO WZ, 1990, J GEN VIROL, V71, P97, DOI 10.1099/0022-1317-71-1-97; KEET IPM, 1990, GENITOURIN MED, V66, P330; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; LI XL, 1990, J VIROL, V64, P1383, DOI 10.1128/JVI.64.3.1383-1387.1990; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; MOSCA JD, 1987, NATURE, V325, P67, DOI 10.1038/325067a0; NELSON JA, 1988, VIROLOGY, V165, P280; POPOVIC M, 1987, LANCET, V2, P916; RANDO RF, 1987, ONCOGENE, V1, P13; RAPPERSBERGER K, 1988, INTERVIROLOGY, V29, P185; TSCHACHLER E, 1987, J INVEST DERMATOL, V88, P233, DOI 10.1111/1523-1747.ep12525402; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988	20	152	155	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					255	258		10.1016/S0140-6736(94)91110-X	http://dx.doi.org/10.1016/S0140-6736(94)91110-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905094				2022-12-28	WOS:A1994MT44000008
J	BRISCO, MJ; CONDON, J; HUGHES, E; NEOH, SH; SYKES, PJ; SESHADRI, R; TOOGOOD, I; WATERS, K; TAURO, G; EKERT, H; MORLEY, AA				BRISCO, MJ; CONDON, J; HUGHES, E; NEOH, SH; SYKES, PJ; SESHADRI, R; TOOGOOD, I; WATERS, K; TAURO, G; EKERT, H; MORLEY, AA			OUTCOME PREDICTION IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA BY MOLECULAR QUANTIFICATION OF RESIDUAL DISEASE AT THE END OF INDUCTION	LANCET			English	Article							POLYMERASE CHAIN-REACTION; LYMPHOPROLIFERATIVE DISORDERS; OLIGONUCLEOTIDE PROBES; INVITRO AMPLIFICATION; GENE REARRANGEMENTS; LEUKEMIA; LINEAGE; RELAPSE; CELLS; PCR	Methods to detect and quantify minimal residual disease (MRD) after chemotherapy for acute lymphoblastic leukaemic (ALL) could improve treatment by identifying patients who need more or less intensive therapy. We have used a clone-specific polymerase chain reaction to detect rearranged immunoglobulin heavy-chain gene from the leukaemic clone, and quantified the clone by limiting dilution analysis. MRD was successfully quantified, by extracting DNA from marrow slides, from 88 of 181 children with ALL, who had total leucocyte counts below 100 x 10(9)/L at presentation and were enrolled in two clinical trials, in 1980-84 and 1985-89, Leukaemia was detected in the first remission marrow of 38 patients, in amounts between 6.7 x 10(2) and 9.9 x 10(-7) cells; 26 of these patients relapsed. Of 50 patients with no MRD detected, despite study of 522-496 000 genomes, only 6 relapsed. The association between MRD detection and outcome was significant for patients in each trial. In the first trial, patients relapsed at all levels of detected MRD, whereas in the later trial, in which treatment was more intensive and results were better, the extent of MRD was closely related to the probability of relapse (5 of 5 patients with >10(-3) MRD, 4 of 10 with 10(-3)to 2 x 10(-5), 0 of 3 with levels below 2 x 10(-5), and 2 of 26 with no MRD detected). Early quantification of leukaemic cells after chemotherapy may be a successful strategy for predicting outcome and hence individualising treatment in childhood ALL, because the results indicate both in-vivo drug sensitivity of the leukaemia and the number of leukaemic cells that remain to be killed by post-induction therapy.	FLINDERS UNIV S AUSTRALIA,MED CTR,DEPT HAEMATOL,BEDFORD PK,SA 5042,AUSTRALIA; WOMENS & CHILDRENS HOSP,ADELAIDE,SA,AUSTRALIA	Flinders University South Australia; Womens & Childrens Hospital Australia				Sykes, Pam/0000-0001-9239-7639				BEISHUIZEN A, 1991, NEW ENGL J MED, V324, P772; BIONDI A, 1992, LEUKEMIA, V6, P282; BOURGUIN A, 1990, P NATL ACAD SCI USA, V87, P8536, DOI 10.1073/pnas.87.21.8536; BRISCO MJ, 1991, BRIT J HAEMATOL, V79, P211, DOI 10.1111/j.1365-2141.1991.tb04524.x; BRISCO MJ, 1993, LEUKEMIA, V7, P1514; BRISCO MJ, 1990, BRIT J HAEMATOL, V75, P163, DOI 10.1111/j.1365-2141.1990.tb02643.x; DAURIOL L, 1989, LEUKEMIA, V3, P155; DEANE M, 1991, BRIT J HAEMATOL, V77, P274, DOI 10.1111/j.1365-2141.1991.tb08570.x; EKERT H, 1990, CANCER THERAPY CONTR, V1, P87; HANSENHAGGE TE, 1989, BLOOD, V74, P1762; JONSSON OG, 1990, BLOOD, V76, P2072; KIYOI H, 1991, BONE MARROW TRANSPL, V8, P59; MACINTYRE EA, 1990, J CLIN INVEST, V86, P2125, DOI 10.1172/JCI114951; MCCARTHY KP, 1990, J CLIN PATHOL, V43, P429, DOI 10.1136/jcp.43.5.429; NEALE GAM, 1991, BLOOD, V78, P739, DOI 10.1182/blood.V78.3.739.bloodjournal783739; NIZET Y, 1991, BRIT J HAEMATOL, V79, P205, DOI 10.1111/j.1365-2141.1991.tb04523.x; POTTER MN, 1993, BRIT J HAEMATOL, V83, P412, DOI 10.1111/j.1365-2141.1993.tb04665.x; RALPH QM, 1993, BLOOD, V82, P202, DOI 10.1182/blood.V82.1.202.bloodjournal821202; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SYKES PJ, 1992, BIOTECHNIQUES, V13, P444; TRAINOR KJ, 1991, BLOOD, V78, P192; TRAINOR KJ, 1990, BLOOD, V75, P2220; VANDENVELDE C, 1991, NOUV REV FR HEMATOL, V33, P25; VEELKEN H, 1991, BLOOD, V78, P1318; WASSERMAN R, 1992, BLOOD, V79, P223; WASSERMAN R, 1992, J CLIN ONCOL, V10, P1879, DOI 10.1200/JCO.1992.10.12.1879; YAMADA M, 1989, P NATL ACAD SCI USA, V86, P5123, DOI 10.1073/pnas.86.13.5123; YAMADA M, 1990, NEW ENGL J MED, V323, P448, DOI 10.1056/NEJM199008163230705; YOKOTA S, 1991, BLOOD, V77, P331	29	257	297	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 22	1994	343	8891					196	200		10.1016/S0140-6736(94)90988-1	http://dx.doi.org/10.1016/S0140-6736(94)90988-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT332	7904666				2022-12-28	WOS:A1994MT33200007
J	MULLER, MJ; HERNDON, DN				MULLER, MJ; HERNDON, DN			THE CHALLENGE OF BURNS	LANCET			English	Article							HUMAN GROWTH-HORMONE; INHALATION INJURY; THERMAL-INJURY; EARLY EXCISION; MAJOR BURNS; MORTALITY		SHRINERS BURNS INST,815 MARKET ST,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DEPT SURG,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston			Herndon, David/AAC-3354-2020; Muller, Michael J/B-5133-2014	Muller, Michael J/0000-0003-2682-6962				Artz C P, 1976, J Trauma, V16, P2; Brown M, 1988, J Burn Care Rehabil, V9, P22, DOI 10.1097/00004630-198801000-00007; BULL JP, 1954, ANN SURG, V139, P269, DOI 10.1097/00000658-195403000-00002; BURKE JF, 1974, J TRAUMA, V14, P389, DOI 10.1097/00005373-197405000-00005; Carvajal H F, 1977, Compr Ther, V3, P17; CIOFFI WG, 1993, ANN SURG, V218, P328, DOI 10.1097/00000658-199309000-00012; CIOFFI WG, 1991, ANN SURG, V213, P575, DOI 10.1097/00000658-199106000-00007; COX CS, 1993, SURG GYNECOL OBSTET, V176, P339; CURRERI PW, 1974, J AM DIET ASSOC, V65, P415; DEITCH EA, 1983, J TRAUMA, V23, P895, DOI 10.1097/00005373-198310000-00009; DEMLING R, 1990, SURGERY, V104, P846; DEMLING RH, 1990, J TRAUMA, V30, P557; DESAI M H, 1991, Journal of Burn Care and Rehabilitation, V12, P482, DOI 10.1097/00004630-199109000-00016; DESAI MH, 1990, ANN SURG, V211, P753, DOI 10.1097/00000658-199006000-00015; FLEMING RYD, 1992, J TRAUMA, V32, P698, DOI 10.1097/00005373-199206000-00005; GILPIN DA, 1993, IN PRESS ANN SURG; GORE DC, 1991, ARCH SURG-CHICAGO, V126, P38; HEIMBACH D, 1988, ANN SURG, V208, P313, DOI 10.1097/00000658-198809000-00008; HERNDON D N, 1992, Journal of Burn Care and Rehabilitation, V13, P154, DOI 10.1097/00004630-199201000-00034; Herndon D N, 1989, J Burn Care Rehabil, V10, P309, DOI 10.1097/00004630-198907000-00004; HERNDON DN, 1990, ANN SURG, V212, P424, DOI 10.1097/00000658-199010000-00005; HERNDON DN, 1989, ANN SURG, V209, P547, DOI 10.1097/00000658-198905000-00006; HERNDON DN, 1987, SURGERY, V102, P341; HERNDON DN, 1988, BURNS, V14, P349, DOI 10.1016/0305-4179(88)90002-2; HERNDON DN, 1987, J TRAUMA, V27, P195, DOI 10.1097/00005373-198702000-00018; HERNDON DN, 1993, CRIT CARE MED, V21, pS50, DOI 10.1097/00003246-199302001-00010; HERNDON DN, 1988, ANN SURG, V208, P484, DOI 10.1097/00000658-198810000-00010; Hildreth M A, 1988, J Burn Care Rehabil, V9, P616, DOI 10.1097/00004630-198811000-00009; HONEYCUTT D, 1992, Journal of Burn Care and Rehabilitation, V13, P181, DOI 10.1097/00004630-199203000-00001; JAMES MI, 1992, THESIS U EDINBURGH; JANZEKOVIC Z, 1975, J TRAUMA, V15, P42; KIMURA R, 1988, CIRC SHOCK, V24, P183; LALONDE C, 1989, SURGERY, V102, P862; LARSON DL, 1971, J TRAUM, V11, P807, DOI 10.1097/00005373-197110000-00001; MAGGI SP, 1993, SURG FORUM, P1081; MUNSTER AM, 1993, ANN SURG, V218, P321, DOI 10.1097/00000658-199309000-00011; RUTAN TC, 1986, J TRAUMA, V26, P140, DOI 10.1097/00005373-198602000-00007; SHIRANI KZ, 1987, ANN SURG, V205, P82, DOI 10.1097/00000658-198701000-00015; WILMORE DW, 1974, ANN SURG, V180, P653, DOI 10.1097/00000658-197410000-00031	39	69	74	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 22	1994	343	8891					216	220		10.1016/S0140-6736(94)90995-4	http://dx.doi.org/10.1016/S0140-6736(94)90995-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT332	7904672				2022-12-28	WOS:A1994MT33200014
J	KHARITONOV, SA; YATES, D; ROBBINS, RA; LOGANSINCLAIR, R; SHINEBOURNE, EA; BARNES, PJ				KHARITONOV, SA; YATES, D; ROBBINS, RA; LOGANSINCLAIR, R; SHINEBOURNE, EA; BARNES, PJ			INCREASED NITRIC-OXIDE IN EXHALED AIR OF ASTHMATIC-PATIENTS	LANCET			English	Article							HUMANS	Nitric oxide (NO) gas is produced by various cells within the lower respiratory tract, including inflammatory and epithelial cells, and is detectable in the exhaled air of normal human subjects. We have measured exhaled NO in patients with asthma, since several cell types that are activated in asthma can produce NO after induction. NO was measured reproducibly by a slow vital capacity manoeuvre and an adapted chemiluminescence analyser. NO was detectable in exhaled air of 67 control subjects (mean peak concentration 80.2 [SE 4.1] ppb) and was significantly reduced by inhalation of the specific NO synthase inhibitor N(G)-monomethyl-L-arginine. 61 non-steroid-treated asthmatic subjects had significantly higher peak expired NO concentrations than controls (283 [16] ppb, p < 0.001) but 52 asthmatic patients receiving inhaled corticosteroids had levels similar to controls (101 [71 ppb). High exhaled NO concentrations in asthmatic patients may reflect induction of NO synthase, which is known to be inhibited by steroids. Measurement of exhaled NO concentrations may be clinically useful in detection and management of cytokine-mediated inflammatory lung disorders.	NATL HEART & LUNG INST, DEPT THORAC MED, LONDON SW3 6HP, ENGLAND; ROYAL BROMPTON HOSP, DEPT BIOMED ENGN, LONDON SW3 6HP, ENGLAND; ROYAL BROMPTON HOSP, DEPT PAEDIAT, LONDON SW3 6HP, ENGLAND	Imperial College London; Royal Brompton Hospital; Royal Brompton Hospital				Barnes, Peter/0000-0002-5122-4018				ARCHER S, 1993, FASEB J, V7, P349, DOI 10.1096/fasebj.7.2.8440411; BARNES PJ, 1993, ANNU REV MED, V44, P229, DOI 10.1146/annurev.me.44.020193.001305; BARNES PJ, 1993, EUR RESPIR J, V6, P163; BELVISI MG, 1992, EUR J PHARMACOL, V210, P221, DOI 10.1016/0014-2999(92)90676-U; DINHXUAN AT, 1992, EUR RESPIR J, V5, P757; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; JORENS PG, 1991, EUR J PHARMACOL, V200, P205, DOI 10.1016/0014-2999(91)90573-9; KOBZIK L, 1993, AM REV RESPIR DIS, V147, pA515; KUO HP, 1992, EUR J PHARMACOL, V221, P385; LIU SF, 1993, BIOCHEM BIOPH RES CO, V196, P1208, DOI 10.1006/bbrc.1993.2380; NAKAYAMA DK, 1992, AM J RESP CELL MOL, V7, P471, DOI 10.1165/ajrcmb/7.5.471; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; ROBBINS RA, 1993, LIFE SCI, V52, P709, DOI 10.1016/0024-3205(93)90232-R; SPRINGALL DR, 1993, AM REV RESPIR DIS, V147, pA515; WARD JK, 1993, J CLIN INVEST, V92, P736, DOI 10.1172/JCI116644; WRIGHT CD, 1989, BIOCHEM BIOPH RES CO, V160, P813, DOI 10.1016/0006-291X(89)92506-0	16	1217	1245	1	68	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	1994	343	8890					133	135		10.1016/S0140-6736(94)90931-8	http://dx.doi.org/10.1016/S0140-6736(94)90931-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7904001				2022-12-28	WOS:A1994MQ86900007
J	NOORDERMEER, J; KLINGENSMITH, J; PERRIMON, N; NUSSE, R				NOORDERMEER, J; KLINGENSMITH, J; PERRIMON, N; NUSSE, R			DISHEVELLED AND ARMADILLO ACT IN THE WINGLESS SIGNALING PATHWAY IN DROSOPHILA	NATURE			English	Article							POLARITY GENE ARMADILLO; PROTEIN; EXPRESSION; PRODUCT; ENCODES; EMBRYOGENESIS; REQUIREMENTS; SECRETION; EPIDERMIS; HEDGEHOG	THE Wnt genes encode conserved secreted proteins that play a role in normal development and tumorigenesis1,2. Little is known about the signal transduction pathways of Wnt gene products. One of the best characterized Wnt family members is the Drosophila segment polarity gene wingless3-6. We have investigated whether segment polarity genes with a wingless-like phenotype mediate the wingless signal. We used a wingless transgene controlled by a heat-shock promoter for genetic epistasis experiments. We show that wingless acts through dishevelled and armadillo to affect the expression of the homeobox gene engrailed and cuticle differentiation.	STANFORD UNIV, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT DEV BIOL, STANFORD, CA 94305 USA; HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA	Howard Hughes Medical Institute; Stanford University; Stanford University; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School				Perrimon, Norbert/0000-0001-7542-472X				ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; CHOU TB, 1992, GENETICS, V131, P643; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; EBERL DF, 1992, GENETICS, V130, P569; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KLINGENSMITH J, 1989, DEV BIOL, V134, P130, DOI 10.1016/0012-1606(89)90084-5; KLINGENSMITH J, IN PRESS GENES DEV; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MOHLER J, 1988, GENETICS, V120, P1061; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PERRIMON N, 1987, DEV BIOL, V119, P587, DOI 10.1016/0012-1606(87)90061-3; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SAMPEDRO J, 1993, DEVELOPMENT, V117, P677; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANDENHEUVEL M, IN PRESS EMBO J; WIESCHAUS E, 1987, CELL, V49, P177, DOI 10.1016/0092-8674(87)90558-7; Wieschaus E., 1986, DROSOPHILA PRACTICAL	33	332	335	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	1994	367	6458					80	83		10.1038/367080a0	http://dx.doi.org/10.1038/367080a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP865	7906389				2022-12-28	WOS:A1994MP86500064
J	OZONOFF, D				OZONOFF, D			LEAD ON THE RANGE	LANCET			English	Editorial Material							INDOOR FIRING RANGE; EXPOSURE; INSTRUCTORS; ABSORPTION				OZONOFF, D (corresponding author), BOSTON UNIV, SCH PUBL HLTH, DEPT ENVIRONM HLTH, BOSTON, MA 02215 USA.			Ozonoff, David/0000-0002-4281-4171				BICKIS U, 1988, AM J PUBLIC HEALTH, V78, P95, DOI 10.2105/AJPH.78.1.95; BREWER F, 1989, J OCCUP ENVIRON MED, V31, P409; FISCHBEIN A, 1992, ISRAEL J MED SCI, V28, P560; FISCHBEIN A, 1993, CLIN IMMUNOL IMMUNOP, V66, P163, DOI 10.1006/clin.1993.1020; FISHERFISCHBEIN J, 1987, JAMA-J AM MED ASSOC, V257, P803, DOI 10.1001/jama.257.6.803; GEORGE PM, 1993, NEW ZEAL MED J, V106, P422; GOLDBERG RL, 1991, J OCCUP ENVIRON MED, V33, P718, DOI 10.1097/00043764-199106000-00013; LANDRIGAN PJ, 1975, JAMA-J AM MED ASSOC, V234, P394, DOI 10.1001/jama.234.4.394; MAIZLISH N, 1990, AM J PUBLIC HEALTH, V80, P931, DOI 10.2105/AJPH.80.8.931; MILLER CH, 1984, OCCUP HLTH, V36, P8; MUSKETT CJ, 1980, ANN OCCUP HYG, V23, P283, DOI 10.1093/annhyg/23.3.283; NOVOTNY T, 1987, AM J PUBLIC HEALTH, V77, P1225, DOI 10.2105/AJPH.77.9.1225; Smith D L, 1976, J Soc Occup Med, V26, P139, DOI 10.1093/occmed/26.4.139; SVENSSON BG, 1992, INT ARCH OCC ENV HEA, V64, P219, DOI 10.1007/BF00378278; TRIPATHI RK, 1991, AM J PUBLIC HEALTH, V81, P753, DOI 10.2105/AJPH.81.6.753; TRIPATHI RK, 1990, AM IND HYG ASSOC J, V51, P28, DOI 10.1080/15298669091369286; VALWAY SE, 1989, AM J PUBLIC HEALTH, V79, P1029, DOI 10.2105/AJPH.79.8.1029	17	12	12	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	1994	343	8888					6	7		10.1016/S0140-6736(94)90871-0	http://dx.doi.org/10.1016/S0140-6736(94)90871-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905076				2022-12-28	WOS:A1994MN93700007
J	REMUZZI, G; RUGGENENTI, P; MAUER, SM				REMUZZI, G; RUGGENENTI, P; MAUER, SM			PANCREAS AND KIDNEY-PANCREAS TRANSPLANTS - EXPERIMENTAL MEDICINE OR REAL IMPROVEMENT	LANCET			English	Review							CADAVERIC RENAL-TRANSPLANTATION; DEPENDENT DIABETES-MELLITUS; LONG-TERM; PANCREATECTOMIZED DOGS; EXPERIENCE; SURVIVAL; NEUROPATHY; MORBIDITY; ISLETS	Although 4000 pancreas transplants have now been done, alone or in combination with a kidney transplant, the risk/benefit profile of the procedure has not been established by controlled studies. A solo pancreas transplant abolishes the need for daily insulin but requires chronic immunosuppression, has high failure rates, and is not proved to lessen the chronic complications of diabetes. Thus, it is probably justified only in those diabetic patients with incapacitating disease. For uraemic diabetic patients, combined pancreas and kidney transplantation often removes dependence on both insulin and dialysis, and has lower rejection rates than pancreas transplant alone. However, it needs more immunosuppression than kidney transplant alone, has no proven benefit on chronic complications of diabetes, and carries an increased risk of rejection, infection, and cancer. Living-related-donor kidney transplantation followed by cadaver pancreas transplantation is a possible alternative. Transplantation of pancreatic islets could offer the advantages of strict metabolic control without the drawbacks of immunosuppressive therapy. Thus, research efforts should concentrate on immune-protected islet transplantation. An alternative approach to avoiding long-term immunosuppression is the promotion of allograft tolerance.	OSPED RIUNITI BERGAMO, DIV NEPHROL & DIALYSIS, I-24100 BERGAMO, ITALY; UNIV MINNESOTA, SCH MED, DEPT PEDIAT, DIV NEPHROL, MINNEAPOLIS, MN 55455 USA	Ospedali Riuniti di Bergamo; University of Minnesota System; University of Minnesota Twin Cities	REMUZZI, G (corresponding author), MARIO NEGRI INST PHARMACOL RES, VIA GAVAZZENI 11, I-24125 BERGAMO, ITALY.		Remuzzi, Giuseppe/V-9766-2017	Remuzzi, Giuseppe/0000-0002-6194-3446				BARKER C F, 1980, Diabetes, V29, P86; BATTINGER WF, 1972, SURGERY, V72, P175; BERTANI T, 1991, KIDNEY INT, V40, P243, DOI 10.1038/ki.1991.206; BILOUS RW, 1989, NEW ENGL J MED, V321, P80, DOI 10.1056/NEJM198907133210204; CHEUNG AHS, 1992, KIDNEY INT, V41, P924, DOI 10.1038/ki.1992.141; CHEUNG AHS, 1993, TRANSPLANT P, V25, P1184; FIORETTO P, 1993, LANCET, V342, P1193, DOI 10.1016/0140-6736(93)92183-T; KELLY WD, 1967, SURGERY, V61, P827; KENNEDY WR, 1990, NEW ENGL J MED, V322, P1031, DOI 10.1056/NEJM199004123221503; LANDGRAF R, 1989, DIABETES, V38, P33, DOI 10.2337/diab.38.1.S33; LANZA RP, 1992, DIABETES, V41, P886, DOI 10.2337/diabetes.41.7.886; MAUER SM, 1989, DIABETES, V38, P516, DOI 10.2337/diabetes.38.4.516; MOREL P, 1991, TRANSPLANTATION, V51, P1184, DOI 10.1097/00007890-199106000-00008; NAJARIAN JS, 1989, TRANSPLANTATION, V47, P106, DOI 10.1097/00007890-198901000-00024; NAVARRO X, 1990, DIABETES, V39, P802, DOI 10.2337/diabetes.39.7.802; PARVING HH, 1983, LANCET, V1, P1175; POSSELT AM, 1990, SCIENCE, V249, P1293, DOI 10.1126/science.2119056; RAMSAY RC, 1988, NEW ENGL J MED, V318, P208, DOI 10.1056/NEJM198801283180403; REMUZZI G, 1991, LANCET, V337, P750, DOI 10.1016/0140-6736(91)91368-5; RITZ E, 1992, OXFORD TXB CLIN NEPH, P1635; ROSEN CB, 1991, TRANSPLANTATION, V51, P123, DOI 10.1097/00007890-199101000-00019; ROSEN CB, 1991, TRANSPLANT P, V23, P1613; SELAWRY HP, 1984, DIABETES, V33, P405, DOI 10.2337/diabetes.33.4.405; SHAFFER D, 1992, ARCH SURG-CHICAGO, V127, P574; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SOLDERS G, 1987, LANCET, V2, P1232; SOLLINGER HW, 1988, ANN SURG, V208, P475, DOI 10.1097/00000658-198810000-00009; SOLLINGER HW, 1991, ANN SURG, V214, P703, DOI 10.1097/00000658-199112000-00010; SOONSHIONG P, 1993, P NATL ACAD SCI USA, V90, P5843, DOI 10.1073/pnas.90.12.5843; SULLIVAN FP, 1987, TRANSPLANTATION, V44, P465, DOI 10.1097/00007890-198710000-00001; SULLIVAN SJ, 1991, SCIENCE, V252, P718, DOI 10.1126/science.2024124; SUTHERLAND DER, 1993, DIABETES REV, V1, P1; SWINNEN LJ, 1990, NEW ENGL J MED, V323, P1723, DOI 10.1056/NEJM199012203232502; WARNOCK GL, 1991, DIABETOLOGIA, V34, P55, DOI 10.1007/BF00404026; WARNOCK GL, 1992, TRANSPLANT REV, V6, P195; YAO Z, 1992, TRANSPLANT P, V24, P2948	36	65	66	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	1994	343	8888					27	31		10.1016/S0140-6736(94)90880-X	http://dx.doi.org/10.1016/S0140-6736(94)90880-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905046				2022-12-28	WOS:A1994MN93700016
J	PRZYBILLA, B; EBERLEINKONIG, B; RUEFF, F				PRZYBILLA, B; EBERLEINKONIG, B; RUEFF, F			PRACTICAL MANAGEMENT OF ATONIC ECZEMA	LANCET			English	Article							ATOPIC-DERMATITIS; DOUBLE-BLIND; THERAPY; HYPERSENSITIVITY; AVOIDANCE; EFFICACY; TRIAL; DIET				PRZYBILLA, B (corresponding author), UNIV MUNICH,DERMATOL KLIN & POLIKLIN,D-80337 MUNICH,GERMANY.							ATHERTON DJ, 1978, LANCET, V1, P401; BJORNEBOE A, 1987, BRIT J DERMATOL, V117, P462; BOS JD, 1994, LANCET, V343, P1338, DOI 10.1016/S0140-6736(94)92473-2; BRAUNFALCO O, 1984, HAUTARZT, V35, P447; BROBERG A, 1990, ACTA DERM-VENEREOL, V70, P495; BUSINCO L, 1991, HDB ATOPIC ECZEMA, P407; COTTERILL JA, 1991, HDB ATOPIC ECZEMA, P459; CRONIN E, 1993, CONTACT DERMATITIS, V28, P225, DOI 10.1111/j.1600-0536.1993.tb03407.x; DEVLIN J, 1991, ARCH DIS CHILD, V66, P93, DOI 10.1136/adc.66.1.93; DOOMSGOOSSENS A, 1992, CONTACT DERMATITIS, V26, P182, DOI 10.1111/j.1600-0536.1992.tb00290.x; GOERZ G, 1991, HDB ATOPIC ECZEMA, P375; GRAHAMBROWN R, 1992, LANCET, V340, P673, DOI 10.1016/0140-6736(92)92208-W; HANIFIN JM, 1993, J AM ACAD DERMATOL, V28, P189, DOI 10.1016/0190-9622(93)70026-P; HANNUKSELA A, 1992, ACTA DERM-VENEREOL, V72, P42; HEALSMITH M, 1991, J DERMATOL TREAT, V1, P325; Heijer A., 1993, ALLERGO J, V2, P3; JEKLER J, 1991, PHOTODERMATOL PHOTO, V8, P151; JONES RR, 1991, LANCET, V338, P55, DOI 10.1016/0140-6736(91)90044-P; KEMMETT D, 1991, BRIT J DERMATOL, V125, P59, DOI 10.1111/j.1365-2133.1991.tb06041.x; KJELLMAN NIM, 1993, ALLERGY CLIN IMMUNOL, V5, P37; KRUTMANN J, 1992, J AM ACAD DERMATOL, V26, P225, DOI 10.1016/0190-9622(92)70031-A; LARSEN FS, 1993, MONOGR ALLERGY, V31, P9; LEROY BP, 1993, J AM ACAD DERMATOL, V28, P232, DOI 10.1016/0190-9622(93)70033-P; LEUNG DYM, 1990, J ALLERGY CLIN IMMUN, V85, P927, DOI 10.1016/0091-6749(90)90079-J; LODEN M, 1992, ACTA DERM-VENEREOL, V72, P327; MORSE PF, 1989, BRIT J DERMATOL, V121, P75, DOI 10.1111/j.1365-2133.1989.tb01403.x; PRZYBILLA B, 1990, SEMIN DERMATOL, V9, P220; RAJKA G, 1989, ESSENTIAL ASPECTS AT; RING J, 1992, ALLERGY, V47, P265, DOI 10.1111/j.1398-9995.1992.tb02051.x; RYSTEDT I, 1989, ALLERGY, V44, P79, DOI 10.1111/j.1398-9995.1989.tb04321.x; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SANDA T, 1992, J ALLERGY CLIN IMMUN, V89, P653, DOI 10.1016/0091-6749(92)90370-H; SAVOLAINEN J, 1990, CLIN EXP ALLERGY, V20, P549, DOI 10.1111/j.1365-2222.1990.tb03148.x; SCHAICH B, 1992, HAUTARZT, V43, P403; SEPP N, 1993, BRIT J DERMATOL, V128, P213, DOI 10.1111/j.1365-2133.1993.tb15154.x; SHARPE GR, 1990, LANCET, V335, P667, DOI 10.1016/0140-6736(90)90459-I; SHEEHAN MP, 1992, BRIT J DERMATOL, V126, P179, DOI 10.1111/j.1365-2133.1992.tb07817.x; SHEEHAN MP, 1992, LANCET, V340, P13, DOI 10.1016/0140-6736(92)92424-E; TAGAMI H, 1991, NEW TRENDS ALLERGY, V3, P200; VICKERS CFH, 1991, HDB ATOPIC ECZEMA, P80; VIELUF D, 1990, Journal of Allergy and Clinical Immunology, V85, P206; WAHLGREN CF, 1992, ALLERGY, V47, P65, DOI 10.1111/j.1398-9995.1992.tb05091.x; WILSON BB, 1993, CUTIS, V51, P191; YOSHIDA H, 1989, ANN ALLERGY, V62, P507; [No title captured]	46	41	41	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1342	1346		10.1016/S0140-6736(94)92474-0	http://dx.doi.org/10.1016/S0140-6736(94)92474-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910331				2022-12-28	WOS:A1994NN21700017
J	ANGGARD, E				ANGGARD, E			NITRIC-OXIDE - MEDIATOR, MURDERER, AND MEDICINE	LANCET			English	Review							HYPOXIC PULMONARY VASOCONSTRICTION; L-ARGININE; RELAXING FACTOR; ENDOTHELIAL DYSFUNCTION; VASCULAR ENDOTHELIUM; CELLS; RELAXATION; BIOSYNTHESIS; METABOLISM; MECHANISMS	In the past ten years several research fields have converged to show that the tiny molecule nitric oxide (NO), a reactive gas, functions both as a signalling molecule in endothelial and nerve cells and as a killer molecule by activated immune cells-and it can be used as a new medicine by inhalation. This article reviews the biology of this remarkable molecule and discusses the implications for clinical medicine.			ANGGARD, E (corresponding author), ST BARTHOLOMEWS HOSP,COLL MED,WILLIAM HARVEY RES INST,CHARTERHOUSE SQ,LONDON EC1M 6BQ,ENGLAND.							BARNES PJ, 1993, EUR RESPIR J, V6, P163; BENJAMIN N, 1994, NATURE, V368, P502, DOI 10.1038/368502a0; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; CALVER A, 1992, J CLIN INVEST, V90, P2548, DOI 10.1172/JCI116149; CALVER A, 1993, EXP PHYSIOL, V78, P303, DOI 10.1113/expphysiol.1993.sp003687; CORBETT JA, 1993, P NATL ACAD SCI USA, V90, P8992, DOI 10.1073/pnas.90.19.8992; DESAI KM, 1991, NATURE, V351, P477, DOI 10.1038/351477a0; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; FLAVAHAN NA, 1992, CIRCULATION, V85, P1927, DOI 10.1161/01.CIR.85.5.1927; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; FROSTELL CG, 1993, ANESTHESIOLOGY, V78, P427, DOI 10.1097/00000542-199303000-00005; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GREEN LC, 1981, P NATL ACAD SCI-BIOL, V78, P7764, DOI 10.1073/pnas.78.12.7764; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; HENDERSON AH, 1991, BRIT HEART J, V65, P116; HENRY Y, 1993, FASEB J, V7, P1124, DOI 10.1096/fasebj.7.12.8397130; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HIGENBOTTAM T, 1993, Q J MED, V86, P555; IGNARRO LJ, 1989, FASEB J, V3, P31, DOI 10.1096/fasebj.3.1.2642868; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P33; IVENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; JORENS PG, 1993, EUR RESPIR J, V6, P258; KERWIN JF, 1994, MED RES REV, V14, P23, DOI 10.1002/med.2610140103; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; LOWENSTEIN CJ, 1994, ANN INTERN MED, V120, P227, DOI 10.7326/0003-4819-120-3-199402010-00009; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MISKO TP, 1993, EUR J PHARMACOL, V233, P119, DOI 10.1016/0014-2999(93)90357-N; Mitchell HH, 1916, J BIOL CHEM, V24, P461; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NEEDLEMAN P, 1976, ANNU REV PHARMACOL, V16, P81, DOI 10.1146/annurev.pa.16.040176.000501; NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171, DOI 10.1002/jlb.54.2.171; PALMER RMJ, 1988, BIOCHEM BIOPH RES CO, V153, P1251, DOI 10.1016/S0006-291X(88)81362-7; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; PERSSON MG, 1994, LANCET, V343, P146, DOI 10.1016/S0140-6736(94)90935-0; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P639, DOI 10.1111/j.1476-5381.1987.tb11367.x; RAIFER J, 1992, NEW ENGL J MED, V326, P90; RAND MJ, 1992, CLIN EXP PHARMACOL P, V19, P147, DOI 10.1111/j.1440-1681.1992.tb00433.x; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; SANDERS KM, 1992, AM J PHYSIOL, V262, pG379, DOI 10.1152/ajpgi.1992.262.3.G379; SCHMIDT HHHW, 1992, SCIENCE, V255, P721, DOI 10.1126/science.1371193; SESSA WC, 1994, CIRC RES, V74, P349, DOI 10.1161/01.RES.74.2.349; SNYDER SH, 1992, SCIENCE, V54, P171; SPRAGUE RS, 1992, P NATL ACAD SCI USA, V89, P8711, DOI 10.1073/pnas.89.18.8711; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; THIEMERMANN C, 1993, P NATL ACAD SCI USA, V90, P267, DOI 10.1073/pnas.90.1.267; VALLANCE P, 1992, LANCET, V339, P572; VALLANCE P, 1989, LANCET, V2, P987; VANDERWINDEN JM, 1992, N ENGL J MED; VANE JR, 1990, NEW ENGL J MED, V323, P27; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WRIGHT CE, 1992, CARDIOVASC RES, V26, P48, DOI 10.1093/cvr/26.1.48; ZORUMSKI CF, 1993, BIOCHEM PHARMACOL, V46, P777, DOI 10.1016/0006-2952(93)90484-E	60	680	724	1	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1199	1206		10.1016/S0140-6736(94)92405-8	http://dx.doi.org/10.1016/S0140-6736(94)92405-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909873				2022-12-28	WOS:A1994NL17500014
J	TAS, S; ABDELLA, NA				TAS, S; ABDELLA, NA			BLOOD-PRESSURE, CORONARY-ARTERY DISEASE, AND GLYCEMIC CONTROL IN TYPE-2 DIABETES-MELLITUS - RELATION TO APOLIPOPROTEIN-CIII GENE POLYMORPHISM	LANCET			English	Note							APO-CIII; HYPERTRIGLYCERIDEMIA; MECHANISM	The apolipoprotein CIII allele S2 is associated with hypertriglyceridaemia and myocardial infarction. 15 subjects with type 2 diabetes mellitus and the S2 allele had significantly greater systolic blood pressure than 48 without this allele (mean 142 [SD 10]) vs 129 [14] mm Hg), despite being on antihypertensives more frequently. S2 patients showed better glycaemic control (glycated haemoglobin [HbA(1C)] 8.4 [2.0] vs 9.9 [2.0]%). Stepwise multiple regression indicated S2 as an independent predictor of both blood pressure and HbA(1C). These findings suggest mechanisms for relations between glucose and triglyceride metabolism and blood pressure.	KUWAIT UNIV,FAC MED,DEPT PATHOL,KUWAIT,KUWAIT; KUWAIT UNIV,FAC MED,DEPT MED,KUWAIT,KUWAIT; MUBARAK AL KABEER HOSP,DEPT CLIN LABS,KUWAIT,KUWAIT; MUBARAK AL KABEER HOSP,DEPT MED,KUWAIT,KUWAIT	Kuwait University; Kuwait University; Mubarak Al-Kabeer Hospital; Mubarak Al-Kabeer Hospital								AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; DAMMERMAN M, 1993, P NATL ACAD SCI USA, V90, P4562, DOI 10.1073/pnas.90.10.4562; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; FELBER JP, 1990, HORM METAB RES, V22, P11; GINSBERG HN, 1986, J CLIN INVEST, V78, P1287, DOI 10.1172/JCI112713; OBRIEN T, 1993, MAYO CLIN PROC, V68, P141, DOI 10.1016/S0025-6196(12)60161-X; SHOULDERS CC, 1991, ATHEROSCLEROSIS, V87, P239, DOI 10.1016/0021-9150(91)90026-Y; TAS S, 1989, CLIN CHEM, V35, P256; TAS S, 1991, LANCET, V337, P113, DOI 10.1016/0140-6736(91)90770-P; TAS S, 1990, CLIN CHEM, V36, P1825	10	22	22	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1194	1195		10.1016/S0140-6736(94)92402-3	http://dx.doi.org/10.1016/S0140-6736(94)92402-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909870				2022-12-28	WOS:A1994NL17500011
J	HOLLAND, SM; EISENSTEIN, EM; KUHNS, DB; TURNER, ML; FLEISHER, TA; STROBER, W; GALLIN, JI				HOLLAND, SM; EISENSTEIN, EM; KUHNS, DB; TURNER, ML; FLEISHER, TA; STROBER, W; GALLIN, JI			TREATMENT OF REFRACTORY DISSEMINATED NONTUBERCULOUS MYCOBACTERIAL INFECTION WITH INTERFERON-GAMMA - A PRELIMINARY-REPORT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC GRANULOMATOUS-DISEASE; AVIUM-INTRACELLULARE; LEPROMATOUS LEPROSY; TUBERCULOSIS; IMMUNODEFICIENCY; COMPLEX; SUSCEPTIBILITY; EXPRESSION	Background. Studies conducted in vitro and in animals suggest that cytokine signals to monocytes or macrophages by interferon gamma are important in the containment and clearance of disseminated nontuberculous mycobacterial infections. Methods. We studied seven patients with refractory disseminated nontuberculous mycobacterial infections who were not infected with the human immunodeficiency virus. Three patients were from a family predisposed to the development of Mycobacterium avium complex infections; four patients had idiopathic CD4+ T-lymphocytopenia. Their infections were culture- or biopsy-proved, involved at least two organ systems, and had been treated with the maximal tolerated medical therapy. Cellular proliferation, cytokine production, and phagocyte function were assessed in peripheral-blood cells. Interferon gamma was administered subcutaneously two or three times weekly in a dose of 25 to 50 mu g per square meter of body-surface area in addition to antimycobacterial medications. Clinical effects were monitored by cultures, biopsies, radiographs, and in one patient a change in the need for paracentesis. Results. In response to phytohemagglutinin, the production of interferon gamma by mononuclear cells from the patients was lower than in normal subjects (P<0.001), whereas stimulation with ionomycin and phorbol myristate acetate led to normal production of interferon gamma in the patients. Within eight weeks of the start of interferon gamma therapy, all seven patients had marked clinical improvement, with abatement of fever, clearing of many lesions and quiescence of others, radiographic improvement, and a reduction in the need for paracentesis. Conclusions. Interferon gamma in combination with conventional therapy may be effective for some cases of refractory disseminated nontuberculous mycobacterial infection.	NIAID,CLIN INVEST LAB,BETHESDA,MD 20892; NCI,DERMATOL BRANCH,BETHESDA,MD 20892; NIH,WARREN GRANT MAGNUSON CLIN CTR,BETHESDA,MD 20892; PRI DYNCORP INC,FREDERICK,MD	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA	HOLLAND, SM (corresponding author), NIAID,HOST DEF LAB,BLDG 10, RM 11N103,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							ABEL L, 1988, AM J HUM GENET, V42, P256; BADARO R, 1993, J INFECT DIS, V167, pS13, DOI 10.1093/infdis/167.Supplement_1.S13; BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104; COHEN JI, 1991, MEDICINE, V70, P137, DOI 10.1097/00005792-199103000-00005; COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621; CREGAN P, 1992, J INFECT DIS, V166, P191, DOI 10.1093/infdis/166.1.191; DIBELLA NJ, 1977, CANCER, V40, P1276, DOI 10.1002/1097-0142(197709)40:3<1276::AID-CNCR2820400342>3.0.CO;2-X; DOLECKOVA V, 1977, TUBERCLE, V58, P13, DOI 10.1016/S0041-3879(77)80004-4; DUNCAN RA, 1993, NEW ENGL J MED, V328, P393, DOI 10.1056/NEJM199302113280604; EISENSTEIN EM, 1993, J CLIN IMMUNOL, V13, P247, DOI 10.1007/BF00919383; ENGBAEK HC, 1964, ACTA TUBERC PNEUM SC, V45, P105; EWEL C, 1992, MANUAL CLIN LAB IMMU, P923; EZEKOWITZ RAB, 1987, J CLIN INVEST, V80, P1009, DOI 10.1172/JCI113153; FISCHER A, 1980, CLIN IMMUNOL IMMUNOP, V17, P296, DOI 10.1016/0090-1229(80)90099-9; GALLO JH, 1983, PATHOLOGY, V15, P241, DOI 10.3109/00313028309083500; HO DD, 1993, NEW ENGL J MED, V328, P380, DOI 10.1056/NEJM199302113280602; HORSBURGH CR, 1985, MEDICINE, V64, P36, DOI 10.1097/00005792-198501000-00003; KAPLAN G, 1989, P NATL ACAD SCI USA, V86, P8073, DOI 10.1073/pnas.86.20.8073; LINCOLN EM, 1972, AM REV RESPIR DIS, V105, P683; NATHAN CF, 1986, NEW ENGL J MED, V315, P6, DOI 10.1056/NEJM198607033150102; NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670; NEDOROST ST, 1991, INT J DERMATOL, V30, P491, DOI 10.1111/j.1365-4362.1991.tb04869.x; NIGHTINGALE SD, 1992, J INFECT DIS, V165, P1082, DOI 10.1093/infdis/165.6.1082; SAMPAIO EP, 1992, J EXP MED, V175, P1729, DOI 10.1084/jem.175.6.1729; Schonell M E, 1968, Tubercle, V49, P12, DOI 10.1016/S0041-3879(68)80003-0; SCHWINZER R, 1990, J EXP MED, V171, P1803, DOI 10.1084/jem.171.5.1803; SECHLER JMG, 1988, P NATL ACAD SCI USA, V85, P4874, DOI 10.1073/pnas.85.13.4874; SHIELDS ED, 1987, J CLIN INVEST, V79, P1139, DOI 10.1172/JCI112930; SMITH DK, 1993, NEW ENGL J MED, V328, P373, DOI 10.1056/NEJM199302113280601; SPIRA TJ, 1993, NEW ENGL J MED, V328, P386, DOI 10.1056/NEJM199302113280603; STEAD WW, 1992, ANN INTERN MED, V116, P937, DOI 10.7326/0003-4819-116-11-937; STONE AB, 1992, PEDIATR INFECT DIS J, V11, P960, DOI 10.1097/00006454-199211110-00011; UCHIYAMA N, 1981, J PEDIATR-US, V98, P785, DOI 10.1016/S0022-3476(81)80848-7; VILJANEN MK, 1993, J CLIN MICROBIOL, V31, P1376, DOI 10.1128/JCM.31.5.1376-1378.1993; 1991, NEW ENGL J MED, V324, P509	35	280	286	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 12	1994	330	19					1348	1355		10.1056/NEJM199405123301904	http://dx.doi.org/10.1056/NEJM199405123301904			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK753	7908719	Bronze			2022-12-28	WOS:A1994NK75300004
J	BUCHER, HU; KEEL, M; WOLF, M; VONSIEBENTHAL, K; DUC, G				BUCHER, HU; KEEL, M; WOLF, M; VONSIEBENTHAL, K; DUC, G			ARTIFACTUAL PULSE OXIMETRY ESTIMATION IN NEONATES	LANCET			English	Note								Two sources of artifactual pulse-oximetry estimation were investigated in 20 neonates. Increased pressure on tissue due to inappropriate sensor fixation was mimicked with a blood pressure cuff. The error in arterial oxygen saturation (pSO(2)) exceeded 2 SD ( > 3%) in 25% subjects at 50 mm Hg which in an ancillary experiment was produced by 11 of 26 nurses fixing the sensor. Venous congestion at 30 and 40 mm Hg permitted normal detection of pulse rate but induced errors in pSO(2) over 2 SD in 15% and 30% of subjects, respectively. Pulse-oximeter values need to be scrutinised for these common errors.			BUCHER, HU (corresponding author), UNIV SPITAL ZURICH,DEPT OBSTET & GYNAECOL,NEONATAL CLIN,CH-8091 ZURICH,SWITZERLAND.		Bucher, Hans/AAL-1100-2020; Bucher, Hans Ulrich/AAF-2995-2020; Bucher, Hans/AAL-1739-2020	Bucher, Hans/0000-0003-4458-1161; Bucher, Hans Ulrich/0000-0003-4458-1161; Bucher, Hans/0000-0003-4458-1161				KELLEHER JF, 1989, J CLIN MONITOR, V5, P37, DOI 10.1007/BF01618369; KIM JM, 1986, ANESTH ANALG, V65, P1333; MORRIS RW, 1989, ANAESTH INTENS CARE, V17, P62, DOI 10.1177/0310057X8901700113; SOUTHALL DP, 1992, LANCET, V40, P481; 1990, LANCET, V335, P130	5	14	15	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1994	343	8906					1135	1136		10.1016/S0140-6736(94)90238-0	http://dx.doi.org/10.1016/S0140-6736(94)90238-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK730	7910235				2022-12-28	WOS:A1994NK73000012
J	DAHL, JB				DAHL, JB			ANTIHISTAMINE PROPHYLAXIS AND GENERAL-ANESTHESIA	LANCET			English	Editorial Material							ADVERSE REACTIONS; ANESTHESIA				DAHL, JB (corresponding author), UNIV COPENHAGEN,BISPEBJERG HOSP,DEPT ANAESTHESIOL,DK-1168 COPENHAGEN,DENMARK.							Fisher, 1988, THEORETICAL SURG, V3, P145; FISHER MM, 1981, ANAESTH INTENS CARE, V9, P226, DOI 10.1177/0310057X8100900304; FISHER MM, 1990, DRUG SAFETY, V5, P86, DOI 10.2165/00002018-199005020-00002; LORENZ W, 1984, CLIN ANAESTHESIOL, V2, P403; OSTERGAARD D, 1989, MED TOXICOL ADV DRUG, V4, P351, DOI 10.1007/BF03259917	5	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					929	930		10.1016/S0140-6736(94)90059-0	http://dx.doi.org/10.1016/S0140-6736(94)90059-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909004				2022-12-28	WOS:A1994NF70000003
J	KANKI, PJ; TRAVERS, KU; MBOUP, S; HSIEH, CC; MARLINK, RG; GUEYENDIAYE, A; SIBY, T; THIOR, I; HERNANDEZAVILA, M; SANKALE, JL; NDOYE, I; ESSEX, ME				KANKI, PJ; TRAVERS, KU; MBOUP, S; HSIEH, CC; MARLINK, RG; GUEYENDIAYE, A; SIBY, T; THIOR, I; HERNANDEZAVILA, M; SANKALE, JL; NDOYE, I; ESSEX, ME			SLOWER HETEROSEXUAL SPREAD OF HIV-2 THAN HIV-1	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-2; VERTICAL TRANSMISSION; WEST-AFRICA; AIDS; INFECTION	Because of the similar virological properties of HIV types 1 and 2, HIV-2 was assumed to be as infectious and capable of inducing AIDS as HIV-1. Seroepidemiological studies have shown significant rates of HIV-2 infection in West Africa, and surveys from other regions of the world indicate that the spread of HIV-2 infection continues. However the pathogenic potential of HIV-2 is considered to be lower than that of HIV-1. It is therefore important to understand the transmission properties of HIV-2 and its contribution to the AIDS pandemic. Since 1985, we have prospectively studied 1452 registered female prostitutes in Dakar, Senegal, with sequential evaluation of their antibody status to HIV-1 and HIV-2. During the study the overall incidence of HIV-1 and HIV-2 was the same (1-11 per 100 person-years of observation [pyo]). However, the annual incidence of HIV-1 increased substantially: there was a 1.4-fold increased risk per year and thus a 12-fold increase in risk over the entire study period. The incidence of HIV-2 remained stable, despite higher HIV-2 prevalence. In our population the heterosexual spread of HIV-2 is significantly slower than that of HIV-1, which strongly suggests differences in the viruses' infectivity potential.	NATL INST PUBL HLTH,CUERNAVACA,MEXICO; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; UNIV CHEIKH ANTA DIOP,VIROL & BACTERIOL LAB,DAKAR,SENEGAL; INST SOCIAL HYG,DAKAR,SENEGAL	Instituto Nacional de Salud Publica; Harvard University; Harvard T.H. Chan School of Public Health; University Cheikh Anta Diop Dakar	KANKI, PJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115, USA.			Travers, Karin/0000-0002-9097-1710; Essex, M./0000-0002-4576-7841	NATIONAL CANCER INSTITUTE [R35CA039805] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39805] Funding Source: Medline; PHS HHS [P01 A1 30795] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON RM, 1989, AIDS, V3, P333, DOI 10.1097/00002030-198906000-00001; ANDERSON RM, 1988, NATURE, V333, P514, DOI 10.1038/333514a0; Breslow NE, 1987, STATISTICAL METHODS, P1; CLAVEL F, 1987, NEW ENGL J MED, V316, P1180, DOI 10.1056/NEJM198705073161903; GAYLE HD, 1992, J ACQ IMMUN DEF SYND, V5, P513; KANKI P, 1992, AM J EPIDEMIOL, V136, P895, DOI 10.1093/aje/136.7.895; KINGSLEY LA, 1991, AM J EPIDEMIOL, V134, P331, DOI 10.1093/oxfordjournals.aje.a116094; MARLINK RG, 1988, AIDS RES HUM RETROV, V4, P137, DOI 10.1089/aid.1988.4.137; Marlink Richard, 1994, P47; MATHERON S, 1990, LANCET, V335, P1103, DOI 10.1016/0140-6736(90)92682-8; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; POULSEN AG, 1992, J ACQ IMMUN DEF SYND, V5, P25; ROMIEU I, 1990, J ACQ IMMUN DEF SYND, V3, P220; WINKELSTEIN W, 1987, AM J PUBLIC HEALTH, V76, P685; 1990, WKLY EPIDEMIOL REC, V65, P281	15	282	290	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					943	946		10.1016/S0140-6736(94)90065-5	http://dx.doi.org/10.1016/S0140-6736(94)90065-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909009				2022-12-28	WOS:A1994NF70000009
J	STEEL, C; GUINEA, A; MCCARTHY, JS; OTTESEN, EA				STEEL, C; GUINEA, A; MCCARTHY, JS; OTTESEN, EA			LONG-TERM EFFECT OF PRENATAL EXPOSURE TO MATERNAL MICROFILAREMIA ON IMMUNE RESPONSIVENESS TO FILARIAL PARASITE ANTIGENS	LANCET			English	Article							LYMPHATIC FILARIASIS; ONCHOCERCA-VOLVULUS; ENDEMIC FILARIASIS; BRUGIA-PAHANGI; PACIFIC ISLAND; INFECTION; UNRESPONSIVENESS; SENSITIZATION; RESPONSES; TOLERANCE	To identify long-term effects of prenatal exposure to maternal filarial-parasite infection, we assessed lymphocyte responses in 21 Polynesian children born 17-19 years previously to mothers diagnosed as being microfilaraemic or infection-free. All children lived on an island endemic for bancroftian filariasis but were free from infection at the ti me of study. While children (n = 10) of infection-free mothers responded vigorously to microfilarial antigen with lymphocyte proliferation, production of interleukin 2 (IL-2), IL-5, IL-10, granulocyte macrophage colony-stimulating factor (GM-CSF), and interferon gamma (IFN-gamma), cellular hyporesponsiveness was seen in children (n = 11) born to microfilaraemic mothers. The hyporesponsiveness appeared restricted to microfilarial antigens and did not extend to non-parasite antigens. These findings suggest that hyporesponsiveness resulted from in-utero acquisition of tolerance to microfilarial antigens in chronically-infected mothers.	HLTH DEPT,MAUKE,COOK ISLANDS		STEEL, C (corresponding author), NIH,PARASIT DIS LAB,BLDG 4 ROOM 126,BETHESDA,MD 20892, USA.		McCarthy, James S/C-1681-2009	McCarthy, James/0000-0001-6596-9718				BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; ELOISANTOS SM, 1989, J CLIN INVEST, V84, P1028, DOI 10.1172/JCI114225; GIMMI CD, 1993, P NATL ACAD SCI USA, V90, P6586, DOI 10.1073/pnas.90.14.6586; GUSMAO RD, 1981, EXP PARASITOL, V52, P147, DOI 10.1016/0014-4894(81)90070-9; HAQUE A, 1988, EUR J IMMUNOL, V18, P1167, DOI 10.1002/eji.1830180804; HAQUE A, 1982, NATURE, V299, P361, DOI 10.1038/299361a0; KAUSHAL NA, 1984, CLIN EXP IMMUNOL, V56, P567; KING CL, 1992, J CLIN INVEST, V89, P1403, DOI 10.1172/JCI115729; KING CL, 1993, J CLIN INVEST, V92, P1667, DOI 10.1172/JCI116752; KLEI TR, 1986, T ROY SOC TROP MED H, V80, P214, DOI 10.1016/0035-9203(86)90014-3; KLION AD, 1991, J INFECT DIS, V163, P1318, DOI 10.1093/infdis/163.6.1318; LAMMIE PJ, 1991, LANCET, V337, P1005, DOI 10.1016/0140-6736(91)92661-K; NUTMAN TB, 1987, J CLIN INVEST, V79, P1516, DOI 10.1172/JCI112982; NUTMAN TB, 1987, J IMMUNOL, V138, P3954; OTTESEN E A, 1989, American Journal of Tropical Medicine and Hygiene, V41, P9; OTTESEN EA, 1977, IMMUNOLOGY, V33, P413; OTTESEN EA, 1981, ACTA TROP, V38, P205; OTTESEN EA, 1985, J IMMUNOL, V134, P2707; OTTESEN EA, 1982, AM J TROP MED HYG, V31, P953, DOI 10.4269/ajtmh.1982.31.953; PARTONO F, 1978, AM J TROP MED HYG, V27, P910, DOI 10.4269/ajtmh.1978.27.910; PETRALANDA I, 1988, AM J TROP MED HYG, V38, P372, DOI 10.4269/ajtmh.1988.38.372; PIESSENS WF, 1980, J CLIN INVEST, V65, P172, DOI 10.1172/JCI109648; PROST A, 1979, TROPENMED PARASITOL, V30, P477; RAGHAVAN N. G. S., 1958, Bulletin of the National Society of India for Malaria and Other Mosquito-Borne Diseases, V6, P147; STEEL C, 1991, J INFECT DIS, V164, P581, DOI 10.1093/infdis/164.3.581; WARTMAN WB, 1947, MEDICINE, V12, P181; WEIL GJ, 1983, J CLIN INVEST, V71, P1124, DOI 10.1172/JCI110862; WEIL GJ, 1987, J INFECT DIS, V156, P350, DOI 10.1093/infdis/156.2.350; WELLER PF, 1982, AM J TROP MED HYG, V31, P942, DOI 10.4269/ajtmh.1982.31.942; ZIMMERMAN PA, 1993, NUCLEIC ACIDS RES, V21, P4541, DOI 10.1093/nar/21.19.4541	30	134	134	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 9	1994	343	8902					890	893		10.1016/S0140-6736(94)90009-4	http://dx.doi.org/10.1016/S0140-6736(94)90009-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF213	7908359				2022-12-28	WOS:A1994NF21300009
J	OSBORNE, M; EVANS, TW				OSBORNE, M; EVANS, TW			ALLOCATION OF RESOURCES IN INTENSIVE-CARE - A TRANSATLANTIC PERSPECTIVE	LANCET			English	Article							CRITICALLY ILL; LIFE-SUPPORT; HEALTH-CARE; NHS; WITHDRAWAL	The USA and the UK have differed substantially in approaches to health care and especially in intensive care provision. We have compared the health care systems, clinical justification for intensive care, selection of patients likely to benefit from such care, and the performance of the systems. The differences are lessening. Both countries are moving away from clinical autonomy as the driving force of medical decision-making. There is increasing recognition that not all patients will benefit from intensive care and that the doctor's obligation to the patient can be limited by constraints set by society.	ROYAL BROMPTON NATL HEART & LUNG HOSP,NATL HEART & LUNG INST,LONDON SW3 6NP,ENGLAND; OREGON HLTH SCI UNIV,PORTLAND,OR	Imperial College London; Oregon Health & Science University								AARON H, 1990, SCIENCE, V247, P418, DOI 10.1126/science.2300804; ANNAS GJ, 1990, NEW ENGL J MED, V323, P686, DOI 10.1056/NEJM199009063231020; BONE RC, 1990, CHEST, V97, P949, DOI 10.1378/chest.97.4.949; CRAWFORD SW, 1992, AM REV RESPIR DIS, V145, P510, DOI 10.1164/ajrccm/145.3.510; DOUGLASS PS, 1987, CHEST, V91, P413, DOI 10.1378/chest.91.3.413; DRUMMOND MF, 1992, LANCET, V339, P230, DOI 10.1016/0140-6736(92)90019-Y; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HILLMAN AL, 1987, NEW ENGL J MED, V317, P1743, DOI 10.1056/NEJM198712313172725; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LANKEN P, 1992, ANN INTERN MED, V115, P478; LIGHT DW, 1991, BRIT MED J, V303, P568, DOI 10.1136/bmj.303.6802.568; LUCE JM, 1993, CRIT CARE MED, V21, P1233, DOI 10.1097/00003246-199308000-00026; MCGLADREY J, 1990, 6TH INT C AIDS SAN F; OSBORNE ML, 1992, CHEST, V101, P217, DOI 10.1378/chest.101.1.217; PEAR R, 1992, NY TIMES        0225, pA1; RAFFIN T A, 1989, American Review of Respiratory Disease, V140, pS28; ROBERTS J, 1991, BRIT MED J, V302, P34, DOI 10.1136/bmj.302.6767.34; ROWAN KM, 1993, BRIT MED J, V307, P977, DOI 10.1136/bmj.307.6910.977; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SCHROEDER SA, 1984, JAMA-J AM MED ASSOC, V252, P240, DOI 10.1001/jama.252.2.240; SIEGLER M, 1993, MAYO CLIN PROC, V68, P461, DOI 10.1016/S0025-6196(12)60195-5; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; SPIBY J, 1989, ANAESTHESIA, V44, P428; VINCENT JL, 1990, INTENS CARE MED, V322, P309; WACHTER RM, 1989, 5TH INT C AIDS MONTR; Wagner D P, 1983, Health Care Financ Rev, V5, P81; WILLIAMS BT, 1989, BRIT MED J, V289, P978; 1993, NATIONAL ITU AUDIT 1; 1983, CRIT CARE MED, V11, P463	30	34	34	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 26	1994	343	8900					778	780		10.1016/S0140-6736(94)91845-7	http://dx.doi.org/10.1016/S0140-6736(94)91845-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907737				2022-12-28	WOS:A1994NC35100017
J	VANEIJCK, CHJ; KRENNING, EP; BOOTSMA, A; OEI, HY; VANPEL, R; LINDEMANS, J; JEEKEL, J; REUBI, JC; LAMBERTS, SWJ				VANEIJCK, CHJ; KRENNING, EP; BOOTSMA, A; OEI, HY; VANPEL, R; LINDEMANS, J; JEEKEL, J; REUBI, JC; LAMBERTS, SWJ			SOMATOSTATIN RECEPTOR SCINTIGRAPHY IN PRIMARY BREAST-CANCER	LANCET			English	Article							EPIDERMAL GROWTH-FACTOR; ENDOCRINE TUMORS; LOCALIZATION; CARCINOMAS; INHIBITION; HORMONE; INVIVO; ANALOG; SANDOSTATIN; TISSUE	Somatostatin-receptor (SS-R) scintigraphy successfully shows primary cancers and distant metastases in most patients with carcinoids, islet cells tumours, and paragangliomas. Previous in-vitro studies indicated that somatostatin receptors are present in human breast cancers. We report positive scintigraphy with [In-111-DTPA-D-Phe(1)]-octreotide in 39 of 52 primary breast cancers (75%). Parallel in-vitro autoradiography with [I-125-Tyr(3)]-octreotide of 30 of these showed a corresponding somatostatin-receptor status in 28. Significantly more invasive ductal cancers could be shown than invasive lobular carcinomas (85% vs 56%; p < 0.05). Also the number of T-1 cancers which were shown was higher than T-1 (86% vs 61%; p < 0.05). Imaging of the axillae showed non-palpable cancer-containing lymphnodes in 4 of 13 patients with subsequently histologically-proven metastases. In the follow-up after a mean of 2.5 yr, SS-R scintigraphy in 28 of the 37 patients with an originally SS-R-positive cancer, was positive in the 2 patients with clinically-recognised metastases, as well as in 6 of the remaining 26 patients who were symptom-free. Raised carcinoembryonic antigent (CEA) and CA 15-3 values were observed in only 2 and 1, respectively, of these patients. Most primary breast cancers can be shown by SS-R scintigraphy, especially invasive ductal cancers. This technique may be of value in selecting patients for clinical trials with somatostatin analogues or other medical treatments. Furthermore, SS-R scintigraphy is more sensitive than measurements of the usual serum cancer markers for detecting recurrences of SS-R-positive breast cancer.	ERASMUS UNIV ROTTERDAM,DEPT MED,ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,DEPT NUCL MED,ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,DEPT CLIN CHEM,ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,DEPT PATHOL,ROTTERDAM,NETHERLANDS; UNIV BERN,INST PATHOL,BERN,SWITZERLAND	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus University Rotterdam; University of Bern	VANEIJCK, CHJ (corresponding author), UNIV HOSP DIJKZIGT,DEPT SURG,40 DR MOLEWATERPLEIN,3015 GD ROTTERDAM,NETHERLANDS.		van Eijck, casper/K-5983-2019; Krenning, Eric P/L-1064-2013; Van Eijck, Casper/ABD-1655-2020					BAKKER WH, 1991, LIFE SCI, V49, P1583, DOI 10.1016/0024-3205(91)90052-D; BUSSOLATI G, 1985, AM J PATHOL, V120, P186; COLOMER R, 1989, CANCER, V64, P1674, DOI 10.1002/1097-0142(19891015)64:8<1674::AID-CNCR2820640820>3.0.CO;2-V; FEKETE M, 1989, J CLIN LAB ANAL, V3, P137, DOI 10.1002/jcla.1860030302; FOEKENS JA, 1989, CANCER RES, V49, P7002; HAYNES DF, 1986, J CLIN ONCOL, V4, P1542; KRENNING EP, 1993, EUR J NUCL MED, V20, P716, DOI 10.1007/BF00181765; KRENNING EP, 1989, LANCET, V1, P242; LAMBERTS SWJ, 1990, J CLIN ENDOCR METAB, V71, P566, DOI 10.1210/jcem-71-3-566; LAMBERTS SWJ, 1990, NEW ENGL J MED, V323, P1246, DOI 10.1056/NEJM199011013231805; LAMBERTS SWJ, 1990, METABOLISM, V39, P152, DOI 10.1016/0026-0495(90)90235-5; NELSON J, 1989, BRIT J CANCER, V59, P739, DOI 10.1038/bjc.1989.154; PAPOTTI M, 1989, INT J CANCER, V43, P365, DOI 10.1002/ijc.2910430302; REUBI JC, 1987, CANCER RES, V47, P5758; REUBI JC, 1987, J CLIN ENDOCR METAB, V65, P1127, DOI 10.1210/jcem-65-6-1127; REUBI JC, 1989, CANCER, V64, P1254, DOI 10.1002/1097-0142(19890915)64:6<1254::AID-CNCR2820640615>3.0.CO;2-D; REUBI JC, 1987, CANCER RES, V47, P551; REUBI JC, 1986, NEUROSCIENCE, V18, P329, DOI 10.1016/0306-4522(86)90158-2; REUBI JC, 1990, METABOLISM, V39, P78, DOI 10.1016/0026-0495(90)90217-Z; REUBI JC, 1992, INT J CANCER, V47, P416; SCAMBIA G, 1988, J CANCER RES CLIN, V114, P306, DOI 10.1007/BF00405839; SETYONOHAN B, 1987, CANCER RES, V47, P1566; SZENDE B, 1989, BREAST CANCER RES TR, V14, P307, DOI 10.1007/BF01806302; VANBONMARTENS MJH, 1992, NED TIJDSCHR GENEES, V134, P287; WEBER C, 1989, SURGERY, V106, P416	25	126	128	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 12	1994	343	8898					640	643		10.1016/S0140-6736(94)92637-9	http://dx.doi.org/10.1016/S0140-6736(94)92637-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906813	Green Submitted			2022-12-28	WOS:A1994NA09300010
J	SAVEN, A; PIRO, L				SAVEN, A; PIRO, L			NEWER PURINE ANALOGS FOR THE TREATMENT OF HAIRY-CELL LEUKEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LOW-DOSE DEOXYCOFORMYCIN; PHASE-II TRIAL; HUMAN-LYMPHOCYTES; PENTOSTATIN 2'-DEOXYCOFORMYCIN; 2-CHLORODEOXYADENOSINE 2-CDA; LYMPHOBLASTIC-LEUKEMIA; LYMPHOID MALIGNANCIES; DEAMINASE DEFICIENCY; COMPLETE REMISSION; INTERFERON-ALPHA				SAVEN, A (corresponding author), SCRIPPS CLIN & RES FDN,IDA M & CECIL H GREEN CANC CTR,DIV HEMATOL ONCOL,10666 N TORREY PINES RD,LA JOLLA,CA 92037, USA.							AVERY TL, 1989, CANCER RES, V49, P4972; BEUTLER E, 1991, LEUKEMIA LYMPHOMA, V5, P1, DOI 10.3109/10428199109068099; BOURONCLE BA, 1958, BLOOD, V13, P609, DOI 10.1182/blood.V13.7.609.609; CARRERA CJ, 1990, J CLIN INVEST, V86, P1480, DOI 10.1172/JCI114865; CARRERA CJ, 1987, CLIN RES, V35, pA597; CARRERA CJ, 1987, MOL BASIS BLOOD DISE, P407; CARRERA CJ, 1990, BLOOD S, V76, pA260; CARSON DA, 1978, J IMMUNOL, V121, P1726; CARSON DA, 1980, P NATL ACAD SCI-BIOL, V77, P6865, DOI 10.1073/pnas.77.11.6865; CARSON DA, 1983, BLOOD, V62, P737; CASSILETH PA, 1991, J CLIN ONCOL, V9, P243, DOI 10.1200/JCO.1991.9.2.243; COHEN A, 1978, P NATL ACAD SCI USA, V75, P472, DOI 10.1073/pnas.75.1.472; CUMMINGS FJ, 1991, J CLIN ONCOL, V9, P565, DOI 10.1200/JCO.1991.9.4.565; DILLMAN RO, 1989, J CLIN ONCOL, V7, P433, DOI 10.1200/JCO.1989.7.4.433; ESTEY EH, 1992, BLOOD, V79, P882; FOON KA, 1986, BLOOD, V68, P297; GIBLETT ER, 1972, LANCET, V2, P1067; GLASPY JA, 1988, ANN INTERN MED, V109, P789, DOI 10.7326/0003-4819-109-10-789; GLASPY JA, 1990, P AN M AM SOC CLIN, V9, P213; GOLOMB HM, 1987, BLOOD, V69, P979; GOLOMB HM, 1978, ANN INTERN MED, V89, P677, DOI 10.7326/0003-4819-89-5-677; GOLOMB HM, 1988, SEMIN ONCOL, V15, P7; GREVER M, 1992, P AN M AM SOC CLIN, V11, P868; GREVER MR, 1983, BLOOD, V61, P279; GREVER MR, 1985, J CLIN ONCOL, V3, P1196, DOI 10.1200/JCO.1985.3.9.1196; HAKIMIAN D, 1993, BLOOD, V82, P1798; HO AD, 1989, J CLIN ONCOL, V7, P1533, DOI 10.1200/JCO.1989.7.10.1533; HOFFMAN M, 1991, BLOOD S, V78, pA454; JANSEN J, 1981, CANCER, V47, P2066, DOI 10.1002/1097-0142(19810415)47:8<2066::AID-CNCR2820470827>3.0.CO;2-V; JOHNSTON JB, 1986, BRIT J HAEMATOL, V63, P525, DOI 10.1111/j.1365-2141.1986.tb07530.x; JULIUSSON G, 1992, BLOOD, V79, P888; KANTARJIAN HM, 1990, SEMIN ONCOL, V17, P66; KANTARJIAN HM, 1991, CANCER, V67, P1291, DOI 10.1002/1097-0142(19910301)67:5<1291::AID-CNCR2820670503>3.0.CO;2-Y; KAWASAKI H, 1993, BLOOD, V81, P597; KAY AC, 1992, J CLIN ONCOL, V10, P371, DOI 10.1200/JCO.1992.10.3.371; KRAUT EH, 1986, BLOOD, V68, P1119; KRAUT EH, 1989, J CLIN ONCOL, V7, P168, DOI 10.1200/JCO.1989.7.2.168; LAURIA F, 1991, BLOOD S, V78, pA34; MINTZ U, 1979, CANCER RES, V39, P2366; O'Dwyer P J, 1988, Oncology (Williston Park), V2, P17; ODWYER PJ, 1988, ANN INTERN MED, V108, P733, DOI 10.7326/0003-4819-108-5-733; ODWYER PJ, 1988, ONCOLOGY, V2, P26; PIRO LD, 1990, NEW ENGL J MED, V322, P1117, DOI 10.1056/NEJM199004193221605; PIRO LD, 1987, NEW ENGL J MED, V317, P901; PIRO LD, 1992, P AN M AM SOC CLIN, V11, P846; POPLACK DG, 1981, CANCER RES, V41, P3343; PRENTICE HG, 1980, LANCET, V2, P170; ROBBINS BA, 1993, BLOOD, V82, P1277; ROBERTSON LE, 1993, BLOOD, V81, P143; SAVEN A, 1992, BLOOD, V80, P587; SAVEN A, 1992, BLOOD, V79, P1111; SAVEN A, 1993, CANCER INVEST, V11, P559, DOI 10.3109/07357909309011674; SAVEN A, 1993, ANN INTERN MED, V119, P278, DOI 10.7326/0003-4819-119-4-199308150-00005; SAVEN A, 1991, LEUKEMIA LYMPHOMA, V5, P133, DOI 10.3109/10428199109103394; SETO S, 1985, J CLIN INVEST, V75, P377, DOI 10.1172/JCI111710; SETO S, 1986, J IMMUNOL, V136, P2839; SEYMOUR JF, 1993, BLOOD, V82, pA142; SORENSEN JM, 1991, P AN M AM SOC CLIN, V10, P232; SPIERS A S D, 1986, Proceedings American Society of Clinical Oncology Annual Meeting, V5, P151; SPIERS ASD, 1984, J CLIN ONCOL, V2, P1336, DOI 10.1200/JCO.1984.2.12.1336; SPIERS ASD, 1987, NEW ENGL J MED, V316, P825, DOI 10.1056/NEJM198704023161401; TALLMAN MS, 1992, BLOOD, V80, P2203; URBA WJ, 1989, BLOOD, V73, P38; VAICKUS L, 1991, CRIT REV ONCOL HEMAT, V11, P267, DOI 10.1016/1040-8428(91)90029-C; YAM LT, 1971, NEW ENGL J MED, V284, P357, DOI 10.1056/NEJM197102182840704; [No title captured]	66	99	100	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 10	1994	330	10					691	697						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY575	7906385				2022-12-28	WOS:A1994MY57500007
J	GULBA, DC; SCHMID, C; BORST, HG; LICHTLEN, P; DIETZ, R; LUFT, FC				GULBA, DC; SCHMID, C; BORST, HG; LICHTLEN, P; DIETZ, R; LUFT, FC			MEDICAL COMPARED WITH SURGICAL-TREATMENT FOR MASSIVE PULMONARY-EMBOLISM	LANCET			English	Note							MORTALITY	We compared embolectomy (when available) with thrombolysis in patients with shock and massive pulmonary embolism. 13 patients were operated on, 10 (77%) of whom survived. The inferior vena cava was routinely clipped. The 24 medically treated patients were given alteplase until systemic and pulmonary artery pressures stabilised and heparin thereafter; 16 (67%) survived. Major haemorrhage occurred in 28% of medically treated patients, but was not fatal. 1 patient had a small cerebral haemorrhage that resolved without drainage. One-fifth of the medical group had a re-embolism, which suggests that temporary caval umbrellas are indicated in medically treated patients. Thrombolysis may provide a life-saving option and a randomised trial is warranted.	UNIV HANNOVER,DEPT MED,DIV CARDIOL,W-3000 HANNOVER,GERMANY; UNIV HANNOVER,DEPT THORAC & VASC SURG,W-3000 HANNOVER,GERMANY; FREE UNIV BERLIN,W-1000 BERLIN,GERMANY	Leibniz University Hannover; Leibniz University Hannover; Free University of Berlin				Luft, Friedrich/0000-0002-8635-1199				ALPERT JS, 1976, JAMA-J AM MED ASSOC, V236, P1477, DOI 10.1001/jama.236.13.1477; CHAVAN A, 1993, Z KARDIOL, V82, P191; COME PC, 1987, J AM COLL CARDIOL, V10, P971, DOI 10.1016/S0735-1097(87)80333-9; GOLDHABER SZ, 1993, LANCET, V341, P507, DOI 10.1016/0140-6736(93)90274-K; JARDIN F, 1987, J AM COLL CARDIOL, V10, P1201, DOI 10.1016/S0735-1097(87)80119-5; LILIENFELD DE, 1990, CHEST, V98, P1067, DOI 10.1378/chest.98.5.1067; SCHMID C, 1991, ANN THORAC SURG, V52, P1102, DOI 10.1016/0003-4975(91)91288-7; THERY C, 1990, EUR HEART J, V11, P334, DOI 10.1093/oxfordjournals.eurheartj.a059707; Wittlich N, 1992, J Am Soc Echocardiogr, V5, P515	9	143	151	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 5	1994	343	8897					576	577		10.1016/S0140-6736(94)91523-7	http://dx.doi.org/10.1016/S0140-6736(94)91523-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906331				2022-12-28	WOS:A1994MY84300011
J	BROYER, M; GUEST, G; CROSNIER, H; BERARD, E				BROYER, M; GUEST, G; CROSNIER, H; BERARD, E			RECOMBINANT GROWTH-HORMONE IN CHILDREN AFTER RENAL-TRANSPLANTATION	LANCET			English	Letter											BROYER, M (corresponding author), HOP NECKER ENFANTS MALAD,DEPT PAEDIAT,F-75743 PARIS,FRANCE.							KELLEY KW, 1989, BIOCHEM PHARMACOL, V38, P705, DOI 10.1016/0006-2952(89)90222-0; TONSHOFF B, 1993, KIDNEY INT, V44, P199, DOI 10.1038/ki.1993.231; TYDEN G, 1990, LANCET, V336, P1455, DOI 10.1016/0140-6736(90)93170-T; Van Es A, 1991, Acta Paediatr Scand Suppl, V379, P42; VANDOP C, 1992, J PEDIATR-US, V120, P244	5	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					539	540		10.1016/S0140-6736(94)91491-5	http://dx.doi.org/10.1016/S0140-6736(94)91491-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906778				2022-12-28	WOS:A1994MX88800042
J	LI, G; REGUNATHAN, S; BARROW, CJ; ESHRAGHI, J; COOPER, R; REIS, DJ				LI, G; REGUNATHAN, S; BARROW, CJ; ESHRAGHI, J; COOPER, R; REIS, DJ			AGMATINE - AN ENDOGENOUS CLONIDINE-DISPLACING SUBSTANCE IN THE BRAIN	SCIENCE			English	Article							BIOSYNTHETIC ARGININE DECARBOXYLASE; IMIDAZOLINE-PREFERRING RECEPTORS; VENTROLATERAL MEDULLA; ESCHERICHIA-COLI; BINDING-SITES; ALPHA-2-ADRENERGIC RECEPTOR; BOVINE BRAIN; PURIFICATION; RILMENIDINE; CDS	Clonidine, an antihypertensive drug, binds to alpha(2)-adrenergic and imidazoline receptors. The endogenous ligand for imidazoline receptors may be a clonidine-displacing substance, a small molecule isolated from bovine brain. This clonidine-displacing substance was purified and determined by mass spectroscopy to be agmatine (decarboxylated arginine), here-tofore not detected in brain. Agmatine binds to alpha(2)-adrenergic and imidazoline receptors and stimulates release of catecholamines from adrenal chromaffin cells. Its biosynthetic enzyme, arginine decarboxylase, is present in brain. Agmatine, locally synthesized, is an endogenous agonist at imidazoline receptors, a noncatecholamine ligand at alpha(2)-adrenergic receptors and may act as a neurotransmitter.	CORNELL UNIV,COLL MED,DEPT NEUROL & NEUROSCI,DIV NEUROBIOL,NEW YORK,NY 10021; STERLING WINTHROP PHARMACEUT RES DIV,MALVERN,PA 19355	Cornell University					NHLBI NIH HHS [HL18974] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018974] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATLAS D, 1991, BIOCHEM PHARMACOL, V41, P1541, DOI 10.1016/0006-2952(91)90152-U; ATLAS D, 1984, EUR J BIOCHEM, V144, P287, DOI 10.1111/j.1432-1033.1984.tb08462.x; BUCH JK, 1985, J BACTERIOL, V163, P522, DOI 10.1128/JB.163.2.522-527.1985; COUPRY I, 1990, J PHARMACOL EXP THER, V252, P293; DIAMANT S, 1987, EUR J PHARMACOL, V144, P247, DOI 10.1016/0014-2999(87)90377-3; DIAMANT S, 1986, BIOCHEM BIOPH RES CO, V134, P184, DOI 10.1016/0006-291X(86)90545-0; EINARSSON S, 1983, J CHROMATOGR, V282, P609, DOI 10.1016/S0021-9673(00)91638-8; ERNSBERGER P, 1990, J PHARMACOL EXP THER, V253, P408; ERNSBERGER P, 1993, J PHARMACOL EXP THER, V264, P172; ERNSBERGER P, 1987, EUR J PHARMACOL, V134, P1, DOI 10.1016/0014-2999(87)90125-7; ERNSBERGER P, 1990, AM J HYPERTENS, V3, P90, DOI 10.1093/ajh/3.2.90; ERNSBERGER P, 1988, BRAIN RES, V441, P309, DOI 10.1016/0006-8993(88)91409-6; FELSEN D, 1987, EUR J PHARMACOL, V142, P453, DOI 10.1016/0014-2999(87)90087-2; GOMEZ RE, 1991, EUR J PHARMACOL, V195, P181, DOI 10.1016/0014-2999(91)90534-W; HIMSWICH WA, 1969, HDB NEUROCHEMISTRY, V1, P33; IVERSEN L, 1969, HDB NEUROCHEMISTRY, V4, P197; KAMISAKI Y, 1990, BRAIN RES, V514, P15, DOI 10.1016/0006-8993(90)90430-J; KAWABATA T, 1978, J AGR FOOD CHEM, V26, P334, DOI 10.1021/jf60216a038; LORING RH, 1990, BRIT J PHARMACOL, V99, P207, DOI 10.1111/j.1476-5381.1990.tb14680.x; MAJUMDER S, 1992, J PARASITOL, V78, P371, DOI 10.2307/3283493; MEELEY MP, 1986, LIFE SCI, V38, P1119, DOI 10.1016/0024-3205(86)90248-1; MEELEY MP, 1989, SOC NEUR ABSTR, V15, P1159; MICHEL MC, 1989, TRENDS PHARMACOL SCI, V10, P342, DOI 10.1016/0165-6147(89)90002-3; MICHEL MC, 1992, TRENDS PHARMACOL SCI, V13, P369; MOORE RC, 1990, J BACTERIOL, V172, P4631, DOI 10.1128/jb.172.8.4631-4640.1990; NICHOLS AJ, 1991, MOL BIOL BIOCH PHARM, P75; PARINI A, 1989, J BIOL CHEM, V264, P11874; QUIK M, 1985, BRAIN RES, V325, P79, DOI 10.1016/0006-8993(85)90304-X; REGUNATHAN S, 1993, BIOCHEM PHARMACOL, V45, P1667, DOI 10.1016/0006-2952(93)90308-J; REGUNATHAN S, 1993, J NEUROSCI RES, V34, P681, DOI 10.1002/jnr.490340611; REGUNATHAN S, 1991, MOL PHARMACOL, V40, P884; SCHAEFFER JM, 1990, BIOCHEM J, V270, P599, DOI 10.1042/bj2700599; SENER A, 1989, BIOCHEM PHARMACOL, V38, P327, DOI 10.1016/0006-2952(89)90044-0; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TESSON F, 1991, J BIOL CHEM, V266, P155; TIBIRICA E, 1991, EUR J PHARMACOL, V209, P213, DOI 10.1016/0014-2999(91)90172-M; WANG H, 1992, MOL PHARMACOL, V42, P762; WEITZEL G, 1980, HOPPESEYLERS Z PHYSL, V36, P51; WIKBERG JES, 1992, PHARMACOL TOXICOL, V70, P208; WU WH, 1973, J BIOL CHEM, V248, P1687	40	653	698	4	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 18	1994	263	5149					966	969		10.1126/science.7906055	http://dx.doi.org/10.1126/science.7906055			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX165	7906055				2022-12-28	WOS:A1994MX16500035
J	TUDDENHAM, EGD				TUDDENHAM, EGD			FLIP TIP INVERSION AND HEMOPHILIA-A	LANCET			English	Editorial Material							FACTOR-VIII GENE; HEMOPHILIA-A; DELETIONS				TUDDENHAM, EGD (corresponding author), CLIN RES CTR,HAEMOSTASIS RES GRP,HARROW HA1 3UJ,MIDDX,ENGLAND.		Tuddenham, Edward/AAS-6196-2020	Tuddenham, Edward/0000-0001-8955-2909				ALY AM, 1990, BRIT J HAEMATOL, V76, P238, DOI 10.1111/j.1365-2141.1990.tb07878.x; HIGUCHI M, 1991, P NATL ACAD SCI USA, V88, P8307, DOI 10.1073/pnas.88.19.8307; LAKICH D, 1993, NAT GENET, V5, P236, DOI 10.1038/ng1193-236; LIN SW, 1993, GENOMICS, V18, P496, DOI 10.1016/S0888-7543(11)80005-4; LUSHER JM, 1993, NEW ENGL J MED, V328, P453, DOI 10.1056/NEJM199302183280701; MILLAR DS, 1990, HUM GENET, V86, P219; NAYLOR J, 1993, HUM MOL GENET, V2, P1773, DOI 10.1093/hmg/2.11.1773; NAYLOR JA, 1993, HUM MOL GENET, V2, P11, DOI 10.1093/hmg/2.1.11; TUDDENHAM EGD, 1991, NUCLEIC ACIDS RES, V19, P4821, DOI 10.1093/nar/19.18.4821; TUDDENHAM EGD, 1993, BLOOD, V82, pA466	10	3	3	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 5	1994	343	8893					307	308		10.1016/S0140-6736(94)91157-6	http://dx.doi.org/10.1016/S0140-6736(94)91157-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905139				2022-12-28	WOS:A1994MU98500003
J	SWALES, J				SWALES, J			QUIS-CUSTODIET	LANCET			English	Editorial Material											SWALES, J (corresponding author), UNIV LEICESTER,DEPT MED,LEICESTER LE1 7RH,ENGLAND.							BROWN R, 1993, PSYCHIATR B, V418, P22; MARMOT MG, 1986, LANCET, V2, P274; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; 1993, RES HLTH	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					247	247		10.1016/S0140-6736(94)91104-5	http://dx.doi.org/10.1016/S0140-6736(94)91104-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905088				2022-12-28	WOS:A1994MT44000002
J	BIGRIGG, A; HAFFENDEN, DK; SHEEHAN, AL; CODLING, BW; READ, MD				BIGRIGG, A; HAFFENDEN, DK; SHEEHAN, AL; CODLING, BW; READ, MD			EFFICACY AND SAFETY OF LARGE-LOOP EXCISION OF THE TRANSFORMATION ZONE	LANCET			English	Article							DIATHERMY EXCISION	Large-loop excision of the transformation zone (LLETZ) has become a popular treatment for women with cervical intraepithelial neoplasia (CIN) before long-term effectiveness and safety have been fully evaluated. Women who took part in a 1990 study of the procedure have been followed-up by cervical cytology for longer than 2 years. The rate of recurrences and residual lesions was 5.0% in the first year and 0.6% in the second year. LLETZ was also effective when used as a repeat procedure, although the negative histology rate was much higher (4.7% for initial procedures and 20% for repeat procedures). 250 women from the original study group of 1000 answered a questionnaire on fertility and menstrual symptoms 3 years after LLETZ. We found no differences between these women and controls of the same age, living in the same geographical area, with a history of negative cervical smears. LLETZ is a safe and effective procedure with no effect on menstruation or fertility.	GLOUCESTERSHIRE ROYAL HOSP,DEPT OBSTET & GYNAECOL,GLOUCESTER,ENGLAND; ST MICHAELS HOSP,DEPT HISTOPATHOL,BRISTOL,ENGLAND; GLOUCESTERSHIRE ROYAL HOSP,DEPT HISTOPATHOL,GLOUCESTER,ENGLAND	Gloucestershire Royal Hospital; Gloucestershire Royal Hospital	BIGRIGG, A (corresponding author), UNIV BRISTOL,SOUTHMEAD HOSP,DEPT OBSTET & GYNAECOL,BRISTOL BS10 5NB,AVON,ENGLAND.							Altman D.G., 1991, PRACTICAL STAT MED R, DOI [DOI 10.1002/SIM.4780101015, 10.1002/sim.4780101015]; BIGRIGG MA, 1990, LANCET, V336, P229, DOI 10.1016/0140-6736(90)91746-W; BIGRIGG MA, 1991, BRIT MED J, V302, P577, DOI 10.1136/bmj.302.6776.577; COPPLESON M, 1981, GYNAECOLOGIC ONCOLOG, P428; HAMMOND RH, 1990, BRIT MED J, V301, P1344, DOI 10.1136/bmj.301.6765.1344; KITCHENER HC, 1991, BRIT J OBSTET GYNAEC, V98, P1112, DOI 10.1111/j.1471-0528.1991.tb15363.x; LUESLEY DM, 1990, BRIT MED J, V300, P1690, DOI 10.1136/bmj.300.6741.1690; MACINDOE WA, 1984, OBSTET GYNECOL, V64, P451; MURDOCH JB, 1991, INT J GYNECOL CANCER, V1, P105, DOI 10.1111/j.1525-1438.1991.tb00024.x	9	112	116	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					32	34		10.1016/S0140-6736(94)90881-8	http://dx.doi.org/10.1016/S0140-6736(94)90881-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905048				2022-12-28	WOS:A1994MN93700017
J	RIFAT, SL				RIFAT, SL			ALUMINUM HYPOTHESIS LIVES	LANCET			English	Editorial Material							ALZHEIMERS-DISEASE				RIFAT, SL (corresponding author), NIAGARA HLTH SERV DEPT, DIV EPIDEMIOL, ST CATHARINES, ON, CANADA.							BIRCHALL JD, 1989, NATURE, V338, P146, DOI 10.1038/338146a0; BIRCHALL JD, 1988, LANCET, V2, P1008, DOI 10.1016/S0140-6736(88)90754-4; BIRCHALL JD, 1991, ALZHEIMERS DISEASE E, P70; COMMENGES D, 1992, NEUROBIOL AGING S1, V13, pS116; DOLL R, 1993, AGE AGEING, V22, P138, DOI 10.1093/ageing/22.2.138; DRISCOLL CT, 1988, J ENVIRON ENG-ASCE, V114, P21, DOI 10.1061/(ASCE)0733-9372(1988)114:1(21); EDWARDSON JA, 1993, LANCET, V342, P211, DOI 10.1016/0140-6736(93)92301-9; JACQMIN H, IN PRESS AM J EPIDEM; KRAUS AS, 1992, CAN J PUBLIC HEALTH, V83, P97; LANDSBERG JP, 1992, NATURE, V360, P65, DOI 10.1038/360065a0; MCLACHLAN DRC, 1991, CAN MED ASSOC J, V145, P793; MICHEL P, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P387	12	12	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	1994	343	8888					3	4		10.1016/S0140-6736(94)90868-0	http://dx.doi.org/10.1016/S0140-6736(94)90868-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905047				2022-12-28	WOS:A1994MN93700004
J	SANDLE, GI; MCNICHOLAS, CM; LOMAX, RB				SANDLE, GI; MCNICHOLAS, CM; LOMAX, RB			POTASSIUM CHANNELS IN COLONIC CRYPTS	LANCET			English	Note							EPITHELIAL-CELL LINE; MEMBRANE; TRANSPORT; CA-2+; CAMP	A characteristic feature of intestinal epithelia is their ability to secrete chloride (Cl-), a process that occurs mainly in intestinal crypts and is the critical transport event in secretory diarrhoea. Increased potassium (K+) channel activity in the basolateral membrane has an important role in the Cl-secretory process by hyperpolarising the cell and maintaining a favourable electrochemical driving force for Cl- exit at the apical membrane. We have shown, using patch-clamp techniques, that the basolateral membrane of human colonic crypt cells contains low conductance K+ channels that are voltage and calcium (Ca2+) sensitive and blocked by barium (Ba2+). These K+ channels are regulated by cytosolic cyclic adenosine monophosphate (cAMP) and Ca2+, intracellular second messengers that also stimulate Cl- secretion. This population of human intestinal K+ channels may be a target for the pharmacological control of Cl- secretory diarrhoea.			SANDLE, GI (corresponding author), UNIV MANCHESTER,HOPE HOSP,SCH MED,DEPT MED,SALFORD M6 8HD,LANCS,ENGLAND.		Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285; McNicholas-Bevensee, Carmel/0000-0002-7013-8764	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARRETT KE, 1993, ADV COMP ENV PHYSL, V16, P215; Binder HJ, 1987, PHYSL GASTROINTESTIN, P1389; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DHARMSATHAPHORN K, 1986, J CLIN INVEST, V77, P348, DOI 10.1172/JCI112311; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAWKER PC, 1978, GASTROENTEROLOGY, V74, P1241; LOO DDF, 1989, J MEMBRANE BIOL, V110, P19, DOI 10.1007/BF01870989; MANDEL KG, 1986, J BIOL CHEM, V261, P704; RAMBAUD JC, 1986, CLIN GASTROENTEROL, V15, P603; WEYER A, 1985, J CLIN INVEST, V76, P1828	10	60	61	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					23	25		10.1016/S0140-6736(94)90878-8	http://dx.doi.org/10.1016/S0140-6736(94)90878-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905044				2022-12-28	WOS:A1994MN93700014
J	CULOTTA, E; KOSHLAND, DE				CULOTTA, E; KOSHLAND, DE			P53 SWEEPS THROUGH CANCER-RESEARCH	SCIENCE			English	Editorial Material																			0	89	98	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					1958	1961		10.1126/science.7903477	http://dx.doi.org/10.1126/science.7903477			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	7903477				2022-12-28	WOS:A1993MN10800012
J	DAVIES, MH; MUTIMER, D; LOWES, J; ELIAS, E; NEUBERGER, J				DAVIES, MH; MUTIMER, D; LOWES, J; ELIAS, E; NEUBERGER, J			RECOVERY DESPITE IMPAIRED CEREBRAL PERFUSION IN FULMINANT HEPATIC-FAILURE	LANCET			English	Note							LIVER-TRANSPLANTATION	We report 4 patients with fulminant hepatic failure who developed prolonged intracranial hypertension (> 35 mm Hg for 24-38 h) that was refractpty to standard therapy and associated with impaired cerebral perfusion pressure (< 50 mm Hg for 2-72 h). All survived with complete neurological recovery. Refractory elevation of intracranial pressure and reduced cerebral perfusion pressure are generally thought to contra-indicate liver transplantation in hepatic failure and are indications to withdraw support. Our observations challenge this concept.	QUEEN ELIZABETH HOSP,LIVER UNIT,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham			Neuberger, James/ABG-3010-2020					ALMDAL T, 1989, SCAND J GASTROENTERO, V24, P299, DOI 10.3109/00365528909093050; DONOVAN JP, 1992, HEPATOLOGY, V16, P267, DOI 10.1002/hep.1840160138; EMOND JC, 1989, GASTROENTEROLOGY, V96, P1583, DOI 10.1016/0016-5085(89)90530-1; Kanter M J, 1991, Neurosurg Clin N Am, V2, P257; LLIDOFSKY SD, 1992, HEPATOLOGY, V16, P1; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MUNOZ SJ, 1993, TRANSPLANTATION, V55, P1071, DOI 10.1097/00007890-199305000-00025; MUNOZ SJ, 1993, SEMIN LIVER DIS, V13, P395; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4	9	44	45	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1329	1330		10.1016/S0140-6736(94)92471-6	http://dx.doi.org/10.1016/S0140-6736(94)92471-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910328				2022-12-28	WOS:A1994NN21700014
J	PRESANT, CA; WOLF, W; WALUCH, V; WISEMAN, C; KENNEDY, P; BLAYNEY, D; BRECHNER, RR				PRESANT, CA; WOLF, W; WALUCH, V; WISEMAN, C; KENNEDY, P; BLAYNEY, D; BRECHNER, RR			ASSOCIATION OF INTRATUMORAL PHARMACOKINETICS OF FLUOROURACIL WITH CLINICAL-RESPONSE	LANCET			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; 5-FLUOROURACIL; INVIVO; METABOLISM; TOXICITY	In-vivo fluorine-19 nuclear magnetic resonance spectroscopy (NMRS) allows non-invasive, real-time, chemical identification of specific fluorinated compounds inside human tumours after administration of fluorouracil (5-fluorouracil). Kinetic measures of the administered drug and metabolites allow estimation of the tumoral half-life of fluorouracil. We studied 57 patients by F-19 NMRS immediately after they had received 600 mg/m(2) fluorouracil intravenously. Serial spectra were acquired with the surface coil positioned on the shin above the tumour. We defined an intratumoral half-life of fluorouracil of 20 min or more as indicating trapping of the drug, based on the blood half-life of 8-12 min. 19 patients had intratumoral half-lives indicating trapping of fluorouracil, 27 had half-lives less than 20 min, and 11 had no detectable fluorouracil in their rumours. 8 of 9 evaluable patients whose tumours showed trapping had partial responses to chemotherapy that included fluorouracil compared with only 2 of 25 patients whose tumours did not trap the drug (p = 0.000021). F-19 NMRS can identify patients likely to respond to chemotherapy with fluorouracil and could be used clinically to tailor optimum treatment.	ST VINCENTS MED CTR,MRI SECT,LOS ANGELES,CA; UNIV SO CALIF,RADIOPHARM PROGRAM,LOS ANGELES,CA; UNIV SO CALIF,DEPT MED,LOS ANGELES,CA; UNIV SO CALIF,DEPT RADIOL,LOS ANGELES,CA; CENT LOS ANGELES COMMUNITY CLIN ONCOL PROGRAM,LOS ANGELES,CA	University of Southern California; University of Southern California; University of Southern California	PRESANT, CA (corresponding author), ST VINCENTS MED CTR,LOS ANGELES ONCOL INST,CTR NONINVAS PHARMACOL,BOX 57992,2131 W 3RD ST,LOS ANGELES,CA 90057, USA.		Blayney, Douglas/AAK-2920-2020; Wiseman MD, Charles/AHC-6808-2022	Blayney, Douglas/0000-0002-7931-4533; 	NATIONAL CANCER INSTITUTE [U10CA035200, R01CA056138, R55CA048255] Funding Source: NIH RePORTER; NCI NIH HHS [CA-35200, 1-R55-CA-48255, CA-56138] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLGER M, 1987, OPERATIONAL INSTRUCT; COHEN JL, 1974, CANCER CHEMOTH REP 1, V58, P723; COUSTERE C, 1991, CANCER CHEMOTH PHARM, V28, P123, DOI 10.1007/BF00689701; ELTAHTAWY A, 1991, CANCER RES, V51, P5806; FINDLAY MPN, 1993, ANN ONCOL, V4, P597, DOI 10.1093/oxfordjournals.annonc.a058595; GUERQUIN-KERN JL, 1991, CANCER RES, V51, P5770; MCSHEEHY PMJ, 1989, BRIT J CANCER, V60, P303, DOI 10.1038/bjc.1989.275; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; PRESANT CA, 1990, J CLIN ONCOL, V8, P1868, DOI 10.1200/JCO.1990.8.11.1868; PRESANT CA, 1993, P AM CLIN ONCOL, V11, P501; SCHLEMMER HP, 1991, RADIOLOGY, V181, P210; VALLABHAJOSULA SR, 1982, EUR J NUCL MED, V7, P462; WALUCH V, 1992, P ANN M SOC MAGNETIC, V11, P3616; WOHLHUETER RM, 1980, J CELL PHYSIOL, V104, P309, DOI 10.1002/jcp.1041040305; WOLF W, 1987, MAGN RESON IMAGING, V5, P165, DOI 10.1016/0730-725X(87)90016-6; WOLF W, 1990, P NATL ACAD SCI USA, V87, P492, DOI 10.1073/pnas.87.1.492; WOLF W, 1993, P AACR, V34, P2365	17	162	164	1	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1184	1187		10.1016/S0140-6736(94)92399-X	http://dx.doi.org/10.1016/S0140-6736(94)92399-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909867				2022-12-28	WOS:A1994NL17500008
J	BENTON, EC				BENTON, EC			WARTS IN BUTCHERS - A CAUSE FOR CONCERN	LANCET			English	Editorial Material											BENTON, EC (corresponding author), ROYAL INFIRM,DEPT DERMATOL,EDINBURGH,SCOTLAND.							COGGON D, 1989, BRIT J IND MED, V46, P188; DEVILLIERS EM, 1989, ARCH DERMATOL, V125, P1590, DOI 10.1001/archderm.125.11.1590; KEEFE M, 1994, BRIT J DERMATOL, V130, P15, DOI 10.1111/j.1365-2133.1994.tb06875.x; KEEFE M, 1994, BRIT J DERMATOL, V130, P9, DOI 10.1111/j.1365-2133.1994.tb06874.x; MELCHERS W, 1993, J CLIN MICROBIOL, V31, P2547, DOI 10.1128/JCM.31.9.2547-2549.1993; RUDLINGER R, 1989, BRIT J DERMATOL, V120, P375, DOI 10.1111/j.1365-2133.1989.tb04163.x; STEHRGREEN PA, 1993, INT J EPIDEMIOL, V22, P294, DOI 10.1093/ije/22.2.294; YOUSEM SA, 1992, CANCER-AM CANCER SOC, V69, P693, DOI 10.1002/1097-0142(19920201)69:3<693::AID-CNCR2820690316>3.0.CO;2-Y	8	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1994	343	8906					1114	1114		10.1016/S0140-6736(94)90231-3	http://dx.doi.org/10.1016/S0140-6736(94)90231-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK730	7910228				2022-12-28	WOS:A1994NK73000005
J	DEVITA, C; FAZZINI, PF; GERACI, E; TAVAZZI, L; TOGNONI, G; VECCHIO, C; BOERI, R; DAMICO, G; LOI, U; MARUBINI, E; PAGLIARO, L; ROVELLI, F; FRANZOSI, MG; LATINI, R; MAGGIONI, AP; MAURI, F; VOLPI, A; BARLERA, S; NEGRI, E; NICOLIS, E; SANTORO, E; SANTORO, L; BONFANTI, E; CAPELLO, T; CASATI, A; CORATO, A; GARDINALE, E; NEGRINI, M; NOBILI, A; STASZEWSKY, L; TAVANELLI, M; TORTA, D; GAMBELLI, G; MORONI, L; PELLANDA, JJ; PIETROPAOLO, F; BALLI, E; BARBIERI, A; BECHI, S; CARRONE, M; CATANZARO, M; FASCIOLO, L; FRESCO, C; GHIANI, A; IACUITTI, G; LEDDA, A; LEVANTESI, G; PASINI, P; PECI, P; PIZZETTI, F; SAGONE, A; TURAZZA, F; VILLELLA, A; VILLELLA, M; BRAGGIO, N; DISERTORI, M; FREZZATI, S; GARATTINI, S; MARINO, P; MASERI, A; MAZZOTTA, G; NICOLOSI, G; PIRELLI, S; SANNA, GP; VALAGUSSA, F; DARGIE, HJ; PETO, R; POCOCK, S; SLEIGHT, P; YUSUF, S; GIORDANO, F; VARLESE, A; LOPARCO, G; IBERTI, V; GIAMUNDO, L; ANASTASI, R; PACIARONI, E; RAFFAELI, S; PURCARO, A; CIAMPANI, N; RITA, E; CUCCARONI, G; BALDINELLI, A; ALTIERI, A; GIORNETTI, R; AZZARO, G; FERRAGUTO, P; SALICI, G; LACONI, E; TIBURZI, FM; BERNARDI, D; LUNARDI, M; COLONNA, L; BOVENZI, F; AMODIO, F; SARCINA, G; CARPAGNANO, A; MATERA, A; MALACRIDA, R; RIGOTTI, R; DALLEMULE, J; DEBIASI, A; BRIDDA, A; INVERNIZZI, G; PITI, A; COLOMBO, L; TOMASSINI, B; BIASIA, R; SOLDA, P; SCARAMUZZINO, G; MIRRI, A; BRACCHETTI, D; DECASTRO, U; LINTNER, W; ERLICHER, A; GRONDA, M; DEVECCHI, P; GAGLIARDI, RS; BATTISTONI, N; STORELLI, A; GUADALUPI, M; NADOVEZZA, S; ZUFFIANO, D; DEPETRA, V; SCERVINO, R; TABACCHI, G; DESSALVI, F; SCORCU, G; GIARDINA, G; RAFFO, M; BOI, W; CAMMALLERI, G; GRUTTADAURIA, G; BALDINI, F; PAOLONE, P; PANTALEONI, A; CONTESSOTTO, F; DECONTI, F; PIGNATTI, F; FRIGNANI, A; IVALDI, M; ALETTO, C; PETTINATI, G; CIRICUGNO, A; MUSCELLA, A; CORREALE, E; ROMANO, S; DANDREA, D; MURENA, E; LONGOBARDI, R; DIMARTINO, N; PAOLINI, E; GADDI, P; CALVELLI, C; DULCETTI, F; GALASSI, A; COCO, R; COPPOLA, A; CENTAMORE, G; CALABRESE, G; SGALAMBRO, G; CIRCO, A; RACITI, S; DELLAMONICA, R; MALINCONICO, M; DEPONTI, C; PARMIGIANI, ML; BELLET, C; BORTOLINI, F; BUFFOLI, L; TIBERI, A; FERRARI, A; ROSSI, A; CIGLIA, C; DICENSO, M; MANGIAROTTI, E; ORNAGHI, M; DO, V; SPAPPERI, D; MAIOLINO, P; DELIO, U; CARROZZA, A; MARINONI, C; GUASCONI, C; SONNINO, S; PAGLIEI, M; FERRARI, G; POLITI, A; DELAZZARO, M; RINALDIS, G; CALCAGNILE, A; LUSETTI, L; BENDINELLI, S; MOLLAIOLI, M; COSMI, F; PLASTINA, F; MISURACA, G; SERAFINI, O; VENNERI, N; CATELLI, P; POLUZZI, C; BERGAMASCHI, G; FADIN, MB; DECHIARA, F; ZAMPAGLIONE, G; ELIA, M; RACCA, E; MEINARDI, F; CASASSO, F; BERTOCCHI, P; DONZELLI, W; PESSINA, S; TIRELLA, G; SAURO, G; TESSITORI, M; BINI, A; BARTOLETTI, A; AGNELLI, D; ZAGAMI, A; ANDREOLI, L; BASTONI, L; PUCCI, P; SANTINI, A; BUONAMICI, PG; FILICE, M; BADOLATI, S; ZERAUCHEK, M; DEMATTEIS, D; MAULUCCI, G; DANTUONO, C; LIBERTI, R; MENICONO, L; MATTOLI, A; TALLONE, M; DIVITA, G; MANCA, G; LICCI, E; CANZIANI, R; GUIDALI, P; RANCAN, E; MARIELLO, F; PENNETTA, A; MINELLI, C; BALDINI, MR; CAZZANI, E; ROMANO, M; BELLOTTI, P; CAMERINI, A; DAVI, R; PIAZZA, R; MUSSO, G; ROSSI, P; GIACCHERO, C; SEU, V; TOSELLI, A; DIGIACINTO, N; DICIO, G; SPANGHERO, M; CRESTI, A; SVETONI, N; BRUNO, G; DISTEFANO, S; GIOVANELLI, N; FINI, M; DETHOMATIS, M; PANDINI, R; CARRINO, C; GIAMMARIA, M; PISTELLI, P; RONZANI, G; OTTELLO, B; MELAPPIONI, A; ZAPPELLI, L; MARSILI, P; SCIMIA, A; RAGAZZINI, G; GRAMENZI, S; MOTTO, A; TULLIO, D; TUCCI, D; ROSSELLI, P; GAGGIOLI, G; BOLLINI, R; FAZIO, AM; RUSSO, R; BOSSI, M; SAVOIA, M; VALSECCHI, MA; BARBARESI, F; BARBIERO, M; BONOFIGLIO, C; GEMELLI, M; BONAGLIA, M; BOSSONI, E; LANZINI, A; DELBENE, P; CASCONE, M; ORLANDI, M; ODDONE, A; SALLAZZO, V; PANUCCIO, D; CANE, G; MOCCETTI, T; PASOTTI, E; TOGNOLI, T; CARAVITA, L; MAGGI, A; BARDELLI, GC; TUSA, M; MAGGI, G; GUERRA, GP; REGGIANI, A; IZZO, A; COLOMBO, G; FOTI, F; CONSOLO, F; ARRIGO, F; SACCA, AM; MAFRICI, A; ALBERTI, A; BELLI, C; DOSSENA, MG; SPINOLA, A; CASIRAGHI, MG; AZZOLLINI, M; POZZONI, L; SALMOIRAGO, E; MASSIRONI, L; SALA, R; BRESSI, R; RIGO, R; CAPPELLI, S; MALAVASI, V; PASCOTTO, P; PASQUAL, AS; SARTO, P; SANI, F; TOSONI, D; SPINNLER, MT; PERSICO, D; ORSI, R; LUGLIENGO, V; PAROLINI, V; ZILIO, G; SANDRI, R; NERI, G; ALITTO, F; PETRI, D; CUSA, EN; MAZZITELLI, L; PIANTADOSI, FR; DANIELLO, L; POLIMENO, S; MININNI, N; GRECO, R; BISCONTI, C; CUCCHIARI, C; DALLAVILLA, W; RANDON, L; ALLEGRI, M; MARCHI, SM; SANNA, E; DELUCA, C; MANETTA, M; DALLAVOLTA, S; MADDALENA, F; DONZELLI, M; PULISANO, U; DIMARIA, B; CELONA, G; MARCHI, S; VIVIRITO, A; CARRUBBA, A; LAMALFA, RG; SCHICCHI, R; BELLANCA, G; BATTAGLIA, A; CIRRINCIONE, V; RIBAUDO, E; STRIZZOLO, L; CARONE, M; DIGREGORIO, D; MANTINI, L; COREA, L; COCCHIERI, M; NOTARISTEFANO, A; CATANESE, C; FALEBURLE, M; SGARBI, E; CESARONI, P; BALDINI, PM; PAPI, L; LAVARINI, L; LORENZINI, M; TARDITI, V; MENARA, N; CONTI, M; FERRO, M; GIANOTTI, A; CRIVELLO, R; MICHELI, G; CONTI, U; CABANI, E; DAVINI, P; DELCITERNA, F; GIOMI, A; ALFIERI, A; CHITI, M; CODELUPPI, P; SMERIERI, O; DINAPOLI, T; CAPOZZOLI, MR; TOPI, PL; PAPERINI, L; TOPI, A; ZANUTTINI, D; NICOLOSI, GL; VISENTIN, P; CHARMET, PA; PETRELLA, A; BARDAZZI, L; NASSI, F; BIANCO, GA; CELLAMMARE, G; LICITRA, R; CINTOLO, C; SPADOLA, V; GUARRELLA, L; CASALI, G; MONDUCCI, I; ZOBBI, G; GUIDUCCI, U; CERRI, P; VIOLI, E; ROVELLI, G; TRIULZI, E; RUSCONI, L; SABATTINI, R; DESANCTIS, A; BOCK, R; ORAZI, S; PALMIERI, M; ROSSI, F; PESARESI, A; CIOPPI, F; PALAMARA, A; MANCINI, P; FERRAIUOLO, G; AZZOLINI, P; NEJA, CP; RISA, MP; BORGIA, MC; BORGIA, C; ZANCHI, E; RISA, AL; COLACE, F; TOZZI, Q; JESI, AP; TASSONI, G; VITUCCI, NC; LIRONCURTI, C; ALTIERI, T; VISCOMI, A; STRIANO, U; SALITURI, S; TARANTINO, F; GIRARDINI, D; ZONZIN, P; RONCON, L; FERRARESE, E; RAVERA, B; BUGATTI, U; PADULA, G; GIGANTINO, A; ALLEMANO, P; REYNAUD, S; FANELLI, R; DERITO, V; CROCE, A; GALLI, M; BERTOLI, D; VIVALDI, F; PEDRAZZINI, F; BARANI, R; DILEO, M; DORONZO, B; GAMBARATI, GP; ZOBBI, M; CARAMANNO, G; CRAPARO, FG; GIANI, P; ANTONGIOVANNI, GB; GRASSO, V; MOSSUTI, E; ROSELLA, MG; SKOUSE, D; GIUSTINIANI, S; CUCCHI, G; CONTI, E; FAGAGNINI, L; PARDI, L; CORE, A; STANISCIA, D; SERAFINI, N; CERRUTI, P; BAZZUCCHI, M; PETRUCCI, G; TRINCHERO, R; CECCHI, E; DEMARIE, D; BRUSASCO, G; GANDOLFO, N; SAVIOLO, R; BERGERONE, S; BERGANDI, G; BARBIERI, D; MINA, E; BIONDO, GB; LEDDA, G; TRAPANI, G; FRIGO, G; BENETTIN, A; GALATI, A; ACCOGLI, M; FERUGLIO, GA; GIANFAGNA, P; PRELLI, L; GIAMPERI, M; GHELLER, G; CUDALI, A; LIGUORI, G; DIMARCO, G; BOTTARI, E; VALENTE, S; GIGLIOLI, C; RAMOSCELLO, G; RIZZI, GM; PELLINGHELLI, G; PERRINI, A; DELUCA, F; SAVELLI, S; CAPEZZUTO, A; GANDOLFI, P; BERGOGNONI, G; BALLESTRA, AM; VIOLO, C				DEVITA, C; FAZZINI, PF; GERACI, E; TAVAZZI, L; TOGNONI, G; VECCHIO, C; BOERI, R; DAMICO, G; LOI, U; MARUBINI, E; PAGLIARO, L; ROVELLI, F; FRANZOSI, MG; LATINI, R; MAGGIONI, AP; MAURI, F; VOLPI, A; BARLERA, S; NEGRI, E; NICOLIS, E; SANTORO, E; SANTORO, L; BONFANTI, E; CAPELLO, T; CASATI, A; CORATO, A; GARDINALE, E; NEGRINI, M; NOBILI, A; STASZEWSKY, L; TAVANELLI, M; TORTA, D; GAMBELLI, G; MORONI, L; PELLANDA, JJ; PIETROPAOLO, F; BALLI, E; BARBIERI, A; BECHI, S; CARRONE, M; CATANZARO, M; FASCIOLO, L; FRESCO, C; GHIANI, A; IACUITTI, G; LEDDA, A; LEVANTESI, G; PASINI, P; PECI, P; PIZZETTI, F; SAGONE, A; TURAZZA, F; VILLELLA, A; VILLELLA, M; BRAGGIO, N; DISERTORI, M; FREZZATI, S; GARATTINI, S; MARINO, P; MASERI, A; MAZZOTTA, G; NICOLOSI, G; PIRELLI, S; SANNA, GP; VALAGUSSA, F; DARGIE, HJ; PETO, R; POCOCK, S; SLEIGHT, P; YUSUF, S; GIORDANO, F; VARLESE, A; LOPARCO, G; IBERTI, V; GIAMUNDO, L; ANASTASI, R; PACIARONI, E; RAFFAELI, S; PURCARO, A; CIAMPANI, N; RITA, E; CUCCARONI, G; BALDINELLI, A; ALTIERI, A; GIORNETTI, R; AZZARO, G; FERRAGUTO, P; SALICI, G; LACONI, E; TIBURZI, FM; BERNARDI, D; LUNARDI, M; COLONNA, L; BOVENZI, F; AMODIO, F; SARCINA, G; CARPAGNANO, A; MATERA, A; MALACRIDA, R; RIGOTTI, R; DALLEMULE, J; DEBIASI, A; BRIDDA, A; INVERNIZZI, G; PITI, A; COLOMBO, L; TOMASSINI, B; BIASIA, R; SOLDA, P; SCARAMUZZINO, G; MIRRI, A; BRACCHETTI, D; DECASTRO, U; LINTNER, W; ERLICHER, A; GRONDA, M; DEVECCHI, P; GAGLIARDI, RS; BATTISTONI, N; STORELLI, A; GUADALUPI, M; NADOVEZZA, S; ZUFFIANO, D; DEPETRA, V; SCERVINO, R; TABACCHI, G; DESSALVI, F; SCORCU, G; GIARDINA, G; RAFFO, M; BOI, W; CAMMALLERI, G; GRUTTADAURIA, G; BALDINI, F; PAOLONE, P; PANTALEONI, A; CONTESSOTTO, F; DECONTI, F; PIGNATTI, F; FRIGNANI, A; IVALDI, M; ALETTO, C; PETTINATI, G; CIRICUGNO, A; MUSCELLA, A; CORREALE, E; ROMANO, S; DANDREA, D; MURENA, E; LONGOBARDI, R; DIMARTINO, N; PAOLINI, E; GADDI, P; CALVELLI, C; DULCETTI, F; GALASSI, A; COCO, R; COPPOLA, A; CENTAMORE, G; CALABRESE, G; SGALAMBRO, G; CIRCO, A; RACITI, S; DELLAMONICA, R; MALINCONICO, M; DEPONTI, C; PARMIGIANI, ML; BELLET, C; BORTOLINI, F; BUFFOLI, L; TIBERI, A; FERRARI, A; ROSSI, A; CIGLIA, C; DICENSO, M; MANGIAROTTI, E; ORNAGHI, M; DO, V; SPAPPERI, D; MAIOLINO, P; DELIO, U; CARROZZA, A; MARINONI, C; GUASCONI, C; SONNINO, S; PAGLIEI, M; FERRARI, G; POLITI, A; DELAZZARO, M; RINALDIS, G; CALCAGNILE, A; LUSETTI, L; BENDINELLI, S; MOLLAIOLI, M; COSMI, F; PLASTINA, F; MISURACA, G; SERAFINI, O; VENNERI, N; CATELLI, P; POLUZZI, C; BERGAMASCHI, G; FADIN, MB; DECHIARA, F; ZAMPAGLIONE, G; ELIA, M; RACCA, E; MEINARDI, F; CASASSO, F; BERTOCCHI, P; DONZELLI, W; PESSINA, S; TIRELLA, G; SAURO, G; TESSITORI, M; BINI, A; BARTOLETTI, A; AGNELLI, D; ZAGAMI, A; ANDREOLI, L; BASTONI, L; PUCCI, P; SANTINI, A; BUONAMICI, PG; FILICE, M; BADOLATI, S; ZERAUCHEK, M; DEMATTEIS, D; MAULUCCI, G; DANTUONO, C; LIBERTI, R; MENICONO, L; MATTOLI, A; TALLONE, M; DIVITA, G; MANCA, G; LICCI, E; CANZIANI, R; GUIDALI, P; RANCAN, E; MARIELLO, F; PENNETTA, A; MINELLI, C; BALDINI, MR; CAZZANI, E; ROMANO, M; BELLOTTI, P; CAMERINI, A; DAVI, R; PIAZZA, R; MUSSO, G; ROSSI, P; GIACCHERO, C; SEU, V; TOSELLI, A; DIGIACINTO, N; DICIO, G; SPANGHERO, M; CRESTI, A; SVETONI, N; BRUNO, G; DISTEFANO, S; GIOVANELLI, N; FINI, M; DETHOMATIS, M; PANDINI, R; CARRINO, C; GIAMMARIA, M; PISTELLI, P; RONZANI, G; OTTELLO, B; MELAPPIONI, A; ZAPPELLI, L; MARSILI, P; SCIMIA, A; RAGAZZINI, G; GRAMENZI, S; MOTTO, A; TULLIO, D; TUCCI, D; ROSSELLI, P; GAGGIOLI, G; BOLLINI, R; FAZIO, AM; RUSSO, R; BOSSI, M; SAVOIA, M; VALSECCHI, MA; BARBARESI, F; BARBIERO, M; BONOFIGLIO, C; GEMELLI, M; BONAGLIA, M; BOSSONI, E; LANZINI, A; DELBENE, P; CASCONE, M; ORLANDI, M; ODDONE, A; SALLAZZO, V; PANUCCIO, D; CANE, G; MOCCETTI, T; PASOTTI, E; TOGNOLI, T; CARAVITA, L; MAGGI, A; BARDELLI, GC; TUSA, M; MAGGI, G; GUERRA, GP; REGGIANI, A; IZZO, A; COLOMBO, G; FOTI, F; CONSOLO, F; ARRIGO, F; SACCA, AM; MAFRICI, A; ALBERTI, A; BELLI, C; DOSSENA, MG; SPINOLA, A; CASIRAGHI, MG; AZZOLLINI, M; POZZONI, L; SALMOIRAGO, E; MASSIRONI, L; SALA, R; BRESSI, R; RIGO, R; CAPPELLI, S; MALAVASI, V; PASCOTTO, P; PASQUAL, AS; SARTO, P; SANI, F; TOSONI, D; SPINNLER, MT; PERSICO, D; ORSI, R; LUGLIENGO, V; PAROLINI, V; ZILIO, G; SANDRI, R; NERI, G; ALITTO, F; PETRI, D; CUSA, EN; MAZZITELLI, L; PIANTADOSI, FR; DANIELLO, L; POLIMENO, S; MININNI, N; GRECO, R; BISCONTI, C; CUCCHIARI, C; DALLAVILLA, W; RANDON, L; ALLEGRI, M; MARCHI, SM; SANNA, E; DELUCA, C; MANETTA, M; DALLAVOLTA, S; MADDALENA, F; DONZELLI, M; PULISANO, U; DIMARIA, B; CELONA, G; MARCHI, S; VIVIRITO, A; CARRUBBA, A; LAMALFA, RG; SCHICCHI, R; BELLANCA, G; BATTAGLIA, A; CIRRINCIONE, V; RIBAUDO, E; STRIZZOLO, L; CARONE, M; DIGREGORIO, D; MANTINI, L; COREA, L; COCCHIERI, M; NOTARISTEFANO, A; CATANESE, C; FALEBURLE, M; SGARBI, E; CESARONI, P; BALDINI, PM; PAPI, L; LAVARINI, L; LORENZINI, M; TARDITI, V; MENARA, N; CONTI, M; FERRO, M; GIANOTTI, A; CRIVELLO, R; MICHELI, G; CONTI, U; CABANI, E; DAVINI, P; DELCITERNA, F; GIOMI, A; ALFIERI, A; CHITI, M; CODELUPPI, P; SMERIERI, O; DINAPOLI, T; CAPOZZOLI, MR; TOPI, PL; PAPERINI, L; TOPI, A; ZANUTTINI, D; NICOLOSI, GL; VISENTIN, P; CHARMET, PA; PETRELLA, A; BARDAZZI, L; NASSI, F; BIANCO, GA; CELLAMMARE, G; LICITRA, R; CINTOLO, C; SPADOLA, V; GUARRELLA, L; CASALI, G; MONDUCCI, I; ZOBBI, G; GUIDUCCI, U; CERRI, P; VIOLI, E; ROVELLI, G; TRIULZI, E; RUSCONI, L; SABATTINI, R; DESANCTIS, A; BOCK, R; ORAZI, S; PALMIERI, M; ROSSI, F; PESARESI, A; CIOPPI, F; PALAMARA, A; MANCINI, P; FERRAIUOLO, G; AZZOLINI, P; NEJA, CP; RISA, MP; BORGIA, MC; BORGIA, C; ZANCHI, E; RISA, AL; COLACE, F; TOZZI, Q; JESI, AP; TASSONI, G; VITUCCI, NC; LIRONCURTI, C; ALTIERI, T; VISCOMI, A; STRIANO, U; SALITURI, S; TARANTINO, F; GIRARDINI, D; ZONZIN, P; RONCON, L; FERRARESE, E; RAVERA, B; BUGATTI, U; PADULA, G; GIGANTINO, A; ALLEMANO, P; REYNAUD, S; FANELLI, R; DERITO, V; CROCE, A; GALLI, M; BERTOLI, D; VIVALDI, F; PEDRAZZINI, F; BARANI, R; DILEO, M; DORONZO, B; GAMBARATI, GP; ZOBBI, M; CARAMANNO, G; CRAPARO, FG; GIANI, P; ANTONGIOVANNI, GB; GRASSO, V; MOSSUTI, E; ROSELLA, MG; SKOUSE, D; GIUSTINIANI, S; CUCCHI, G; CONTI, E; FAGAGNINI, L; PARDI, L; CORE, A; STANISCIA, D; SERAFINI, N; CERRUTI, P; BAZZUCCHI, M; PETRUCCI, G; TRINCHERO, R; CECCHI, E; DEMARIE, D; BRUSASCO, G; GANDOLFO, N; SAVIOLO, R; BERGERONE, S; BERGANDI, G; BARBIERI, D; MINA, E; BIONDO, GB; LEDDA, G; TRAPANI, G; FRIGO, G; BENETTIN, A; GALATI, A; ACCOGLI, M; FERUGLIO, GA; GIANFAGNA, P; PRELLI, L; GIAMPERI, M; GHELLER, G; CUDALI, A; LIGUORI, G; DIMARCO, G; BOTTARI, E; VALENTE, S; GIGLIOLI, C; RAMOSCELLO, G; RIZZI, GM; PELLINGHELLI, G; PERRINI, A; DELUCA, F; SAVELLI, S; CAPEZZUTO, A; GANDOLFI, P; BERGOGNONI, G; BALLESTRA, AM; VIOLO, C			GISSI-3 - EFFECTS OF LISINOPRIL AND TRANSDERMAL GLYCERYL TRINITRATE SINGLY AND TOGETHER ON 6-WEEK MORTALITY AND VENTRICULAR-FUNCTION AFTER ACUTE MYOCARDIAL-INFARCTION	LANCET			English	Article							CAPTOPRIL; DYSFUNCTION; SURVIVAL; ECHOCARDIOGRAPHY; DILATATION; EXPANSION; VOLUME; HEART	GISSI-3 is a multicentre randomised clinical trial to assess the efficacy of lisinopril, transdermal glyceryl trinitrate (GTN), and their combination in improving survival and ventricular function after acute myocardial infarction (AMI). Between June, 1991, and July, 1993, 19 394 patients were randomised from 200 coronary care units in Italy. Eligible patients presented within 24 h of symptom onset and had no clear indications for or against the study treatments. In a factorial design patients were randomly assigned 6 weeks of oral lisinopril (5 mg initial dose and then 10 mg daily) or open control as well as nitrates (intravenous for the first 24 h followed by transdermal GTN 10 mg daily) or open control. Complete clinical data and 6-week follow-up were available for 18 895 (97.4%) patients randomised. Two-dimensional echocardiographic data were available for 14 209 patients. Overall 6-week mortality was 6.7%. Lisinopril, started within 24 h from AMI symptoms, produced significant reductions in overall mortality (odds ratio 0.88 [95% CI 0.79-0.99]) and in the combined outcome measure of mortality and severe ventricular dysfunction (0.90 [0.84-0.98]). In the same trial the systematic administration of transdermal GTN did not show any independent effect on the same outcome measures (0.94 [0.84-1.05] and 0.94 [0.87-1.02]). Systematic combined administration of lisinopril and GTN also produced significant reductions in overall mortality (0.83 [0.70-0.97]) and in the combined endpoint (0.85 [0.76-0.94]). The favourable effect of lisinopril alone or with GTN was clear also in the predefined high-risk populations (elderly patients and women) for the combined endpoint. These findings were obtained in a population intensively exposed to recommended treatments (thrombolysis 72%, beta-blockade 31%, and aspirin 84%); non-protocol treatment with angiotensin-converting-enzyme inhibitors and nitrates was allowed for specific clinical indications. No excess of unfavourable clinically relevant events in the treated groups was reported.			DEVITA, C (corresponding author), GRP ITALIANO STUDIO SOPRAWIVENZA INFARTO MIOCARD,COORDINATING CTR,VIA ERITREA 62,I-20157 MILAN,ITALY.		Negri, Eva Vanna Lorenza/AAC-5698-2019; malavasi, vincenzo/GQQ-9078-2022; Nicolosi, Gian Luigi/AAT-9893-2020; Agnelli, Davide/AAJ-6891-2021; Musso, Giovanni/AAB-7884-2022; Tavazzi, Luigi/ABD-5119-2020; Garattini, Silvio/AAA-6390-2020; Sonnino, Sandro/R-4154-2017; Negri, Eva/B-7244-2013; Fresco, Claudio/M-5203-2015; Fini, Massimo/AAA-9948-2021; Nobili, Alessandro/ABG-4516-2020; Guerra, Gustavo Petri/AAU-2862-2021; Alessandro, Nobili/AAA-7512-2020; Negrini, Massimo/J-2377-2016; Turazza, Fabio/AAB-8736-2020; Latini, Roberto/AAB-1410-2020	Negri, Eva Vanna Lorenza/0000-0001-9712-8526; Nicolosi, Gian Luigi/0000-0002-2218-2808; Agnelli, Davide/0000-0001-8332-5019; Tavazzi, Luigi/0000-0003-0336-8356; Garattini, Silvio/0000-0003-0647-9297; Sonnino, Sandro/0000-0001-8180-5908; Negri, Eva/0000-0001-9712-8526; Fresco, Claudio/0000-0001-7123-8153; Nobili, Alessandro/0000-0002-7813-0572; Guerra, Gustavo Petri/0000-0001-6995-5348; Negrini, Massimo/0000-0002-0007-1920; Turazza, Fabio/0000-0002-2348-5309; Latini, Roberto/0000-0002-3729-4650				[Anonymous], 1990, Lancet, V336, P65; [Anonymous], 1986, Lancet, V1, P397; [Anonymous], 1993, LANCET, V342, P821; DAKAK N, 1990, AM J CARDIOL, V66, P608, DOI 10.1016/0002-9149(90)90489-N; DEVITA C, 1990, LANCET, V335, P289, DOI 10.1016/0140-6736(90)90104-D; EATON LW, 1979, NEW ENGL J MED, V300, P57, DOI 10.1056/NEJM197901113000202; EDWARDS WD, 1981, MAYO CLIN PROC, V56, P479; Fleiss JL, 1981, STAT METHODS RATES P; JUGDUTT BI, 1988, CIRCULATION, V78, P906, DOI 10.1161/01.CIR.78.4.906; MAGGIONI AP, 1993, NEW ENGL J MED, V329, P1442, DOI 10.1056/NEJM199311113292002; METELITSA VI, 1992, AM J CARDIOL, V69, P291, DOI 10.1016/0002-9149(92)90222-K; MOSS AJ, 1987, PROG CARDIOVASC DIS, V29, P389, DOI 10.1016/0033-0620(87)90014-4; OLDROYD KG, 1991, AM J CARDIOL, V68, P713, DOI 10.1016/0002-9149(91)90641-W; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161; PFEFFER MA, 1988, NEW ENGL J MED, V319, P80, DOI 10.1056/NEJM198807143190204; SANTORO E, 1993, CONTROLLED CLIN TRIA, V14, P430; SHARPE N, 1988, LANCET, V1, P255; SHARPE N, 1991, LANCET, V337, P872, DOI 10.1016/0140-6736(91)90202-Z; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; VOLPI A, 1993, CIRCULATION, V88, P416, DOI 10.1161/01.CIR.88.2.416; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; WYATT HL, 1980, CIRCULATION, V61, P1119, DOI 10.1161/01.CIR.61.6.1119; YUSUF S, 1988, LANCET, V1, P1088; 1991, NEW ENGL J MED, V325, P293; [No title captured]; 1993, CIRCULATION, V38, P394; 1992, NEW ENGL J MED, V327, P685; 1983, NEW ENGL J MED, V309, P331	29	1155	1192	0	26	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1994	343	8906					1115	1122						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK730	7910229				2022-12-28	WOS:A1994NK73000006
J	MALLIDIS, C; LIM, TC; HILL, ST; SKINNER, DJ; BROWN, DJ; JOHNSTON, WIH; BAKER, HWG				MALLIDIS, C; LIM, TC; HILL, ST; SKINNER, DJ; BROWN, DJ; JOHNSTON, WIH; BAKER, HWG			COLLECTION OF SEMEN FROM MEN IN ACUTE-PHASE OF SPINAL-CORD INJURY	LANCET			English	Note							ELECTROEJACULATION; STATE; ART	In chronic spinal cord injury, semen obtained by assisted ejaculation is usually abnormal. We have assessed electroejaculation early after injury in seven patients. There were no adverse effects. Initial samples contained few or no spermatozoa but as patients emerged from spinal shock, semen improved and five had specimens cryopreserved. Thereafter sperm motility and viability decreased towards the pattern of chronic spinal cord injury by day 16. Cryopreservation was not possible in one patient with many medical complications and another who started electroejaculation 15 days after injury. Semen storage within the first 2 weeks after spinal cord injury is recommended for future fertility treatment.	AUSTIN HOSP,SPINAL INJURIES UNIT,MELBOURNE,VIC 3084,AUSTRALIA; UNIV MELBOURNE,DEPT OBSTET & GYNECOL,MELBOURNE,VIC,AUSTRALIA; ROYAL WOMENS HOSP,REPROD BIOL UNIT,CARLTON,AUSTRALIA; MELBOURNE IVF,MELBOURNE,AUSTRALIA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne				Mallidis, Con/0000-0001-9531-3808				BRINDLEY GS, 1981, J NEUROL NEUROSUR PS, V44, P9, DOI 10.1136/jnnp.44.1.9; HALSTEAD LS, 1987, PARAPLEGIA, V25, P120, DOI 10.1038/sc.1987.21; LIM TC, 1994, PARAPLEGIA, V32, P142, DOI 10.1038/sc.1994.27; Linsenmeyer T A, 1991, J Am Paraplegia Soc, V14, P116; SARKARATI M, 1987, J UROLOGY, V138, P59, DOI 10.1016/S0022-5347(17)42988-0; SHERMAN JK, 1973, FERTIL STERIL, V24, P397; SIOSTEEN A, 1990, PARAPLEGIA, V20, P96; TALBOT HS, 1955, J UROLOGY, V73, P91, DOI 10.1016/S0022-5347(17)67370-1; WOLF DP, 1989, J IN VITRO FERTIL EM, V6, P325, DOI 10.1007/BF01138770; 1992, WHO LABORATORY MANUA	10	41	42	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 30	1994	343	8905					1072	1073		10.1016/S0140-6736(94)90183-X	http://dx.doi.org/10.1016/S0140-6736(94)90183-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ694	7909101				2022-12-28	WOS:A1994NJ69400011
J	SOONSHIONG, P; HEINTZ, RE; MERIDETH, N; YAO, QX; YAO, ZW; ZHENG, TL; MURPHY, M; MOLONEY, MK; SCHMEHL, M; HARRIS, M; MENDEZ, R; MENDEZ, R; SANDFORD, PA				SOONSHIONG, P; HEINTZ, RE; MERIDETH, N; YAO, QX; YAO, ZW; ZHENG, TL; MURPHY, M; MOLONEY, MK; SCHMEHL, M; HARRIS, M; MENDEZ, R; MENDEZ, R; SANDFORD, PA			INSULIN INDEPENDENCE IN A TYPE-1 DIABETIC PATIENT AFTER ENCAPSULATED ISLET TRANSPLANTATION	LANCET			English	Note							MICROENCAPSULATED ISLETS; BIOARTIFICIAL PANCREAS; MICROCAPSULES	Identification of a biocompatible immunoprotective membrane to prevent graft rejection remained elusive until the development of microcapsules formulated in alginate high in guluronic acid. We report insulin independence in a type 1 diabetic patient after encapsulated islet transplantation. Encapsulated human islets were injected intrapperitoneally in a diabetic patient with a functioning kidney graft. Insulin independence with tight glycaemic control was demonstrated 9 months after the procedure. These results warrant a trial of a high dose of encapsulated islets in early-onset diabetic patients.			SOONSHIONG, P (corresponding author), ST VINCENTS MED CTR,2131 W 3RD ST,LOS ANGELES,CA 90057, USA.							CALAFIORE R, 1990, HORM METAB RES, V25, P213; GOOSEN MFA, 1985, BIOTECHNOL BIOENG, V27, P146, DOI 10.1002/bit.260270207; LIM F, 1980, SCIENCE, V210, P908, DOI 10.1126/science.6776628; OTTERLEI M, 1991, J IMMUNOTHER, V10, P286, DOI 10.1097/00002371-199108000-00007; RICORDI C, 1992, TRANSPLANTATION, V53, P407, DOI 10.1097/00007890-199202010-00027; Soon-Shiong P, 1992, ASAIO J, V38, P851; SOONSHIONG P, 1992, TRANSPLANTATION, V54, P769, DOI 10.1097/00007890-199211000-00001; SOONSHIONG P, 1993, P NATL ACAD SCI USA, V90, P5843, DOI 10.1073/pnas.90.12.5843; SOONSHIONG P, 1991, TRANSPLANT P, V23, P758; YAO Z, 1992, TRANSPLANT P, V24, P2948	10	504	522	3	37	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					950	951		10.1016/S0140-6736(94)90067-1	http://dx.doi.org/10.1016/S0140-6736(94)90067-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909011				2022-12-28	WOS:A1994NF70000011
J	DARLING, M; HIGGINS, J				DARLING, M; HIGGINS, J			CLASP - MILLSTONE OR MILESTONE	LANCET			English	Editorial Material							PREGNANCY-INDUCED HYPERTENSION; ASPIRIN; PREECLAMPSIA				DARLING, M (corresponding author), ROTUNDA HOSP,DUBLIN,DUBLIN,IRELAND.							MCPARLAND P, 1990, LANCET, V335, P1552, DOI 10.1016/0140-6736(90)91377-M; OBRIEN WF, 1990, OBSTET GYNECOL, V75, P445; ROBERTS JM, 1991, SEMIN PERINATOL, V15, P86; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; ROBERTSON WB, 1986, AM J OBSTET GYNECOL, V155, P401, DOI 10.1016/0002-9378(86)90843-4; SCHIFF E, 1989, NEW ENGL J MED, V321, P351, DOI 10.1056/NEJM198908103210603; SIBAI BM, 1993, NEW ENGL J MED, V329, P1213, DOI 10.1056/NEJM199310213291701; WALLENBURG HCS, 1986, LANCET, V1, P1; ZHOU Y, 1993, J CLIN INVEST, V91, P950, DOI 10.1172/JCI116316; 1993, LANCET, V341, P396; 1994, 1988 1990 DEP HLTH W, P22	11	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 12	1994	343	8898					616	617		10.1016/S0140-6736(94)92630-1	http://dx.doi.org/10.1016/S0140-6736(94)92630-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906806				2022-12-28	WOS:A1994NA09300003
J	NIEHRS, C; STEINBEISSER, H; DEROBERTIS, EM				NIEHRS, C; STEINBEISSER, H; DEROBERTIS, EM			MESODERMAL PATTERNING BY A GRADIENT OF THE VERTEBRATE HOMEOBOX GENE GOOSECOID	SCIENCE			English	Article							XENOPUS-LAEVIS; EMBRYOS; EXPRESSION; TRANSCRIPTION; ORGANIZER; ACTIVIN; HOMOLOG; ACTIVATION; INDUCTION; DOMAIN	Amphibian mesoderm arises from the marginal zone of the early gastrula and generates various tissues such as notochord, muscle, kidney, and blood. Small changes (twofold) in the amount of microinjected messenger RNA encoding the goosecoid (gsc) homeodomain protein resulted in marked changes in the differentiation of mesoderm in Xenopus laevis. At least three thresholds were observed, which were sufficient to specify four mesodermal cell states. Endogenous gsc messenger RNA was expressed in the marginal zone in a graded fashion that is congruent with a role for this gene in dorso-ventral patterning of mesoderm at the early gastrula stage.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT CHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles				De Robertis, Edward/0000-0002-7843-1869	NICHD NIH HHS [HD21502-08] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021502, R37HD021502] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; CUNLIFFE V, 1992, NATURE, V358, P427, DOI 10.1038/358427a0; DALE L, 1987, DEVELOPMENT, V100, P279; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; NIEHRS C, 1993, CELL, V72, P491, DOI 10.1016/0092-8674(93)90069-3; NIEHRS C, UNPUB; NUSSLEINVOLHARD C, 1901, DEVELOPMENT S, V1, P1; PATIENT RK, 1982, NUCLEIC ACIDS RES, V10, P7935, DOI 10.1093/nar/10.24.7935; PERRY M, 1985, J MOL BIOL, V185, P479, DOI 10.1016/0022-2836(85)90065-8; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SATO SM, 1990, DEV BIOL, V137, P135, DOI 10.1016/0012-1606(90)90014-A; SCHULTEMERKER S, IN PRESS DEVELOPMENT; SLACK JMW, 1993, MECH DEVELOP, V41, P91, DOI 10.1016/0925-4773(93)90040-5; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; STEINBEISSER H, 1993, CR ACAD SCI III-VIE, V316, P966; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120	27	149	149	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 11	1994	263	5148					817	820		10.1126/science.7905664	http://dx.doi.org/10.1126/science.7905664			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV866	7905664				2022-12-28	WOS:A1994MV86600038
J	MITTRA, I				MITTRA, I			BREAST SCREENING - THE CASE FOR PHYSICAL-EXAMINATION WITHOUT MAMMOGRAPHY	LANCET			English	Article							CANCER DETECTION; MORTALITY	Many studies have shown that screening for breast cancer can reduce mortality from the disease. Mammography has come to be regarded as the screening method of choice, but evidence Suggests that physical examination (PE) is at least as effective in reducing mortality. Mammography detects many noninfiltrating and small, non-palpable tumours, but we do not know whether these would ever cause symptoms or threaten the woman's life. It is doubtful whether the time gained by early mammographic detection confers any survival benefit over PE detection. PE has substantial advantages over mammography in terms of human and economic costs. The question we should be asking is not how to refine mammographic screening but whether we need it at a all.			MITTRA, I (corresponding author), TATA MEM HOSP,DEPT SURG,BOMBAY 400012,INDIA.			Mittra, Indraneel/0000-0002-5768-3821				BAILAR JC, 1976, ANN INTERN MED, V84, P77, DOI 10.7326/0003-4819-84-1-77; BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; BRESLOW L, 1977, J NATL CANCER I, V59, P467, DOI 10.1093/jnci/59.2.479; FENTIMAN IS, 1988, LANCET, V1, P1041; HENDRICK RE, 1992, RADIOL CLIN N AM, V30, P243; KALLIONIEMI OP, 1988, INT J CANCER, V42, P697, DOI 10.1002/ijc.2910420511; KLEMI PJ, 1992, BRIT MED J, V304, P467, DOI 10.1136/bmj.304.6825.467; KOPANS DB, 1990, AM J ROENTGENOL, V155, P748, DOI 10.2214/ajr.155.4.ajronline_155_4_001; LANDERCASPER J, 1987, SURG GYNECOL OBSTET, V164, P399; MILLER AB, 1987, AM J ROENTGENOL, V148, P1093; MILLER AB, 1992, CAN MED ASSOC J, V147, P1477; MILLER AB, 1991, CAN J PUBLIC HEALTH, V82, P162; Miller Anthony B., 1992, World Health Forum, V13, P277; MORRISON AS, 1991, J NATL CANCER I, V83, P226, DOI 10.1093/jnci/83.4.226; SEIDMAN H, 1987, CA-CANCER J CLIN, V37, P258, DOI 10.3322/canjclin.37.5.258; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; 1993, FEB INT WORKSH SCREE; 1993, NHS BREAST SCREENING; 1982, CA, V32, P226; 1987, BREAST CANCER SCREEN; 1983, CA, V33, P255; 1979, J NATL CANCER I, V62, P639; 1987, WORKING GUIDELINES E; 1988, LANCET, V2, P953	25	39	39	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 5	1994	343	8893					342	344		10.1016/S0140-6736(94)91170-3	http://dx.doi.org/10.1016/S0140-6736(94)91170-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905152				2022-12-28	WOS:A1994MU98500016
J	WALD, NJ; BOWER, C				WALD, NJ; BOWER, C			FOLIC-ACID, PERNICIOUS-ANEMIA, AND PREVENTION OF NEURAL-TUBE DEFECTS	LANCET			English	Editorial Material											WALD, NJ (corresponding author), MED COLL ST BARTHOLOMEWS HOSP,WOLFSON INST PREVENT MED,LONDON,ENGLAND.		Wald, Nicholas/AAY-8924-2021; Wald, Nicholas/AAY-2814-2021					LINDENBAUM J, 1988, NEW ENGL J MED, V318, P1720, DOI 10.1056/NEJM198806303182604; WALD NJ, 1994, CIBA F SYMP, V181, P192; 1992, MMWR, V41, P1; 1994, BRIT MED J, V208, P223; 1991, LANCET, V338, P132; 1992, FOLIC ACID PREVENTIO	6	34	34	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 5	1994	343	8893					307	307		10.1016/S0140-6736(94)91156-8	http://dx.doi.org/10.1016/S0140-6736(94)91156-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905138				2022-12-28	WOS:A1994MU98500002
J	FFRENCHCONSTANT, C				FFRENCHCONSTANT, C			PATHOGENESIS OF MULTIPLE-SCLEROSIS	LANCET			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; T-CELL; AUTOIMMUNE ENCEPHALOMYELITIS; LESION DEVELOPMENT; PROGENITOR CELLS; OLIGODENDROCYTES; ANTIBODIES; DIFFERENTIATION; DEMYELINATION; PROTEIN		UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE,ENGLAND	University of Cambridge	FFRENCHCONSTANT, C (corresponding author), WELLCOME CRC INST DEV BIOL & CANC,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEGRETTA M, 1990, SCIENCE, V247, P718, DOI 10.1126/science.1689076; ALLEN I, 1993, J NEUROPATH EXP NEUR, V52, P95, DOI 10.1097/00005072-199303000-00001; ARCHELOS JJ, 1993, ANN NEUROL, V34, P145, DOI 10.1002/ana.410340209; BARRES BA, 1993, CURR BIOL, V3, P489, DOI 10.1016/0960-9822(93)90039-Q; BARRES BA, 1993, DEVELOPMENT, V118, P283; BERNARD CCA, 1992, CURR OPIN IMMUNOL, V4, P760, DOI 10.1016/0952-7915(92)90058-M; BIRNBAUM G, 1993, ANN NEUROL, V34, P18, DOI 10.1002/ana.410340106; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; BROSNAN CF, 1980, NATURE, V285, P235, DOI 10.1038/285235a0; CANNELLA B, 1991, J NEUROIMMUNOL, V35, P295, DOI 10.1016/0165-5728(91)90183-8; DYER CA, 1990, J CELL BIOL, V111, P625, DOI 10.1083/jcb.111.2.625; FFRENCHCONSTANT C, 1986, NATURE, V319, P499, DOI 10.1038/319499a0; FREEDMAN MS, 1991, ANN NEUROL, V30, P794, DOI 10.1002/ana.410300608; GODFRAIND C, 1989, J CELL BIOL, V109, P2405, DOI 10.1083/jcb.109.5.2405; GOVERMAN J, 1993, CELL, V72, P551, DOI 10.1016/0092-8674(93)90074-Z; GROVES AK, 1993, NATURE, V362, P453, DOI 10.1038/362453a0; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; KERMODE AG, 1990, BRAIN, V113, P1477, DOI 10.1093/brain/113.5.1477; LEE SC, 1990, J NEUROPATH EXP NEUR, V49, P122, DOI 10.1097/00005072-199003000-00005; LEVINE SM, 1992, MED HYPOTHESES, V39, P271, DOI 10.1016/0306-9877(92)90121-R; LIGHTMAN S, 1987, BRAIN, V110, P405, DOI 10.1093/brain/110.2.405; LININGTON C, 1993, EUR J IMMUNOL, V23, P1364, DOI 10.1002/eji.1830230627; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MUMFORD CJ, IN PRESS ANN NEUROL; OKSENBERG JR, 1993, NATURE, V362, P68, DOI 10.1038/362068a0; Olerup O., 1990, TISSUE ANTIGENS, V38, P1; PRINEAS JW, 1993, ANN NEUROL, V33, P137, DOI 10.1002/ana.410330203; PRINEAS JW, 1989, LAB INVEST, V61, P489; RAINE CS, 1991, NEUROPATH APPL NEURO, V17, P265, DOI 10.1111/j.1365-2990.1991.tb00724.x; RAINE CS, 1993, J NEUROPATH EXP NEUR, V52, P199, DOI 10.1097/00005072-199305000-00003; REINGOLD SC, 1993, J NEUROIMMUNOL, V44, P221, DOI 10.1016/0165-5728(93)90047-3; REYNOLDS R, 1993, J NEUROSCI RES, V36, P417; SADOVNICK AD, 1963, CURR OPIN NEUROL NEU, V6, P189; SCOLDING NJ, 1989, NATURE, V339, P620, DOI 10.1038/339620a0; SCOLDING NJ, 1990, IMMUNOLOGY, V70, P6; SELMAJ K, 1991, P NATL ACAD SCI USA, V88, P6452, DOI 10.1073/pnas.88.15.6452; SELMAJ K, 1991, J IMMUNOL, V147, P1522; TEMPLE S, 1986, CELL, V44, P773, DOI 10.1016/0092-8674(86)90843-3; The IFNB Multiple Sclerosis Study Group, 1993, NEUROLOGY, V43, P655; TRAUGOTT U, 1987, J NEUROIMMUNOL, V16, P283, DOI 10.1016/0165-5728(87)90082-8; WARREN KG, 1993, J NEUROL SCI, V115, P169, DOI 10.1016/0022-510X(93)90221-J; WOLSWIJK G, 1989, DEVELOPMENT, V105, P387; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0; XIAO BG, 1991, J NEUROIMMUNOL, V31, P91, DOI 10.1016/0165-5728(91)90014-X; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	47	152	156	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					271	275		10.1016/S0140-6736(94)91118-5	http://dx.doi.org/10.1016/S0140-6736(94)91118-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905102				2022-12-28	WOS:A1994MT44000016
J	YAMAGUCHI, K				YAMAGUCHI, K			HUMAN T-LYMPHOTROPIC VIRUS TYPE-I IN JAPAN	LANCET			English	Review							CELL LEUKEMIA-VIRUS; HTLV-I; CLINICAL ENTITY; PROVIRAL DNA; BLOOD-DONORS; NATION-WIDE; LYMPHOMA; RETROVIRUS; ANTIBODIES; CARRIERS	Adult T-cell leukaemia (ATL) was first reported in Japan, where it has a high incidence in the southwest region. The retrovirus human T-lymphotropic virus type I (HTLV-1) is the cause of ATL; and in ATL-endemic areas, the rate of carriage of antibodies to HTLV-1 is high. A definite diagnosis of ATL is based on the presence of HTLV-1 proviral DNA in the tumour-cell DNA. ATL cells originate from the CD4 subset of peripheral T cells. ATL shows diverse clinical features but can be divided into four subtypes-acute, chronic, smouldering, and lymphoma type. lt is resistant to chemotherapy. and the acute and lymphoma types have a poor prognosis. Familial occurrence of ATL is common. HTLV-1 infection is caused by transmission of live infected lymphocytes from mother to child, from man to woman, or by transfusion. Infection with HTLV-1 can lead to other diseases, including HTLV-1-associated myelopathy/tropical spastic paraparesis and HTLV-1 uveitis, possibly via induction of immunodeficiency or hyperreactivity against HTLV-1-infected cells.			YAMAGUCHI, K (corresponding author), KUMAMOTO UNIV,SCH MED,BLOOD TRANSFUS SERV,1-1-1 HONJO,KUMAMOTO 860,JAPAN.							GESSAIN A, 1985, LANCET, V2, P407; HATTORI T, 1981, BLOOD, V58, P645; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; KAMADA N, 1992, CANCER RES, V52, P1481; KAMIHIRA S, 1992, LEUKEMIA RES, V16, P435, DOI 10.1016/0145-2126(92)90168-7; KONDO T, 1989, INT J CANCER, V43, P1061, DOI 10.1002/ijc.2910430618; MAEDA Y, 1984, INT J CANCER, V33, P717, DOI 10.1002/ijc.2910330602; MIYAMOTO Y, 1985, CANCER, V55, P181, DOI 10.1002/1097-0142(19850101)55:1<181::AID-CNCR2820550128>3.0.CO;2-E; MIYOSHI I, 1980, GANN, V71, P155; MOCHIZUKI M, 1992, JPN J CANCER RES, V83, P236, DOI 10.1111/j.1349-7006.1992.tb00092.x; MOCHIZUKI M, 1992, AM J OPHTHALMOL, V114, P123, DOI 10.1016/S0002-9394(14)73974-1; NAKADA K, 1987, INT J CANCER, V40, P145, DOI 10.1002/ijc.2910400203; OHSHIMA K, 1992, CANCER, V69, P239, DOI 10.1002/1097-0142(19920101)69:1&lt;239::AID-CNCR2820690139&gt;3.0.CO;2-#; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SANADA I, 1989, JPN J CANCER RES, V80, P401, DOI 10.1111/j.1349-7006.1989.tb02326.x; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; SHIMOYAMA M, 1988, J CLIN ONCOL, V6, P1088, DOI 10.1200/JCO.1988.6.7.1088; SONODA S, 1992, GANN MONOGR CANCER R, V39, P81; TAJIMA K, 1990, INT J CANCER, V45, P237, DOI 10.1002/ijc.2910450206; Takatsuki K., 1977, TOPICS HEMATOLOGY, P73; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WATANABE T, 1984, VIROLOGY, V133, P238, DOI 10.1016/0042-6822(84)90446-X; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; YAMAGUCHI K, 1992, J ACQ IMMUN DEF SYND, V5, P533, DOI 10.1097/00126334-199205000-00020; YAMAGUCHI K, 1990, HUMAN RETROVIROLOGY : HTLV, P163; YAMAGUCHI K, 1984, BLOOD, V63, P1235; YAMAGUCHI K, 1983, BLOOD, V62, P758; YAMAGUCHI K, IN PRESS BR J OPHTHA; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yoshida M., 1992, GANN MONOGRAPH CANCE, P217	33	149	153	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 22	1994	343	8891					213	216		10.1016/S0140-6736(94)90994-6	http://dx.doi.org/10.1016/S0140-6736(94)90994-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT332	7904671				2022-12-28	WOS:A1994MT33200013
J	RIJLI, FM; MARK, M; LAKKARAJU, S; DIERICH, A; DOLLE, P; CHAMBON, P				RIJLI, FM; MARK, M; LAKKARAJU, S; DIERICH, A; DOLLE, P; CHAMBON, P			A HOMEOTIC TRANSFORMATION IS GENERATED IN THE ROSTRAL BRANCHIAL REGION OF THE HEAD BY DISRUPTION OF HOXA-2, WHICH ACTS AS A SELECTOR GENE	CELL			English	Article							HOMEOBOX GENE; NEURAL CREST; DEVELOPMENTAL DEFECTS; TARGETED DISRUPTION; CHICK-EMBRYO; EXPRESSION; HINDBRAIN; SEGMENTATION; ORIGIN; MORPHOGENESIS	The Hoxa-2 gene was disrupted by homologous recombination. Homozygous mutant mice died at birth. Defects were found in the branchial region of the head, which corresponds to the Hoxa-2 rostral expression domain. While rhombomeric and neural crest cell (NCC) segmentation was not affected, mesenchymal NCC derivatives of the second arch were lacking, and second arch mesenchymal NCC identity was changed to first arch identity, resulting in homeotic transformation of second to first arch skeletal elements. These results reveal the existence of a skeletogenic ground pattern program common to at least the mesenchymal NCC that originated from rhombomeres 2 and 4. The appearance of an atavistic reptilian pterygoquadrate element in Hoxa-2 mutants suggests that this ground pattern is intermediate between reptiles and mammals. The ground pattern program appears to be modified in the mouse first arch by a Hox-independent process, whereas Hoxa-2 acts as a selector gene in the second arch.			RIJLI, FM (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL, GENET MOLEC EUCARYOTES LAB, CNRS, F-67085 STRASBOURG, FRANCE.		Dolle, Pascal/A-8037-2010; RIJLI, Filippo/AAP-2516-2020	Dolle, Pascal/0000-0002-9294-9090; RIJLI, Filippo/0000-0003-0515-0182				ALLIN EF, 1975, J MORPHOL, V147, P403, DOI 10.1002/jmor.1051470404; BRYANT SV, 1981, SCIENCE, V212, P993, DOI 10.1126/science.212.4498.993; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CLARKE JDW, 1993, DEVELOPMENT, V118, P151; de Beer G.R, 1971, DEV VERTEBRATE SKULL; DEDOUARIN N, 1993, DEV BIOL, V159, P24; DOLLE P, 1993, P NATL ACAD SCI USA, V90, P7666, DOI 10.1073/pnas.90.16.7666; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; GANS C, 1983, SCIENCE, V220, P268, DOI 10.1126/science.220.4594.268; GAUNT SJ, 1993, DEVELOPMENT, V117, P769; GAUNT SJ, 1988, DEVELOPMENT S, V104, P71; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; Hall B. K., 1999, EVOLUTIONARY DEV BIO; HALL BK, 1982, J CRAN GENET DEV BIO, V2, P309; HOLLAND PWH, 1992, DEVELOPMENT, V116, P653; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KEYNES R, 1990, NEURON, V4, P1, DOI 10.1016/0896-6273(90)90438-L; KRUMLAUF R, 1993, TRENDS GENET, V9, P106, DOI 10.1016/0168-9525(93)90203-T; LANGILLE RM, 1989, BIOL REV, V64, P73, DOI 10.1111/j.1469-185X.1989.tb00672.x; Lawrence Peter A, 1993, MAKING FLY GENETICS, V6; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; MARK M, 1993, DEVELOPMENT, V119, P319; MORRISSKAY G, 1991, J CRAN GENET DEV BIO, V11, P181; NODEN DM, 1983, DEV BIOL, V96, P144, DOI 10.1016/0012-1606(83)90318-4; NODEN DM, 1988, DEVELOPMENT, V103, P121; OLSON EC, 1959, EVOLUTION, V13, P344, DOI 10.2307/2406111; PENDLETON JW, 1993, P NATL ACAD SCI USA, V90, P6300, DOI 10.1073/pnas.90.13.6300; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; SECHRIST J, 1993, DEVELOPMENT, V118, P691; SERBEDZIJA GN, 1992, DEVELOPMENT, V116, P297; Stadtmuller F., 1936, HDB VERGLEICHENDEN A, V4, P839; TAN DP, 1992, P NATL ACAD SCI USA, V89, P6280, DOI 10.1073/pnas.89.14.6280; VERSLUYS VJ, 1936, HDB VERGLEICHENDEN A, V4, P699; WILKINSON DG, 1993, BIOESSAYS, V15, P499, DOI 10.1002/bies.950150802	44	516	522	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 31	1993	75	7					1333	1349		10.1016/0092-8674(93)90620-6	http://dx.doi.org/10.1016/0092-8674(93)90620-6			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	7903601				2022-12-28	WOS:A1993MP86900012
J	BOYD, O; GROUNDS, RM; BENNETT, ED				BOYD, O; GROUNDS, RM; BENNETT, ED			A RANDOMIZED CLINICAL-TRIAL OF THE EFFECT OF DELIBERATE PERIOPERATIVE INCREASE OF OXYGEN DELIVERY ON MORTALITY IN HIGH-RISK SURGICAL PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-DISTRESS SYNDROME; ILL POSTOPERATIVE-PATIENTS; THERAPEUTIC GOALS; SUPRANORMAL VALUES; SUPPLY DEPENDENCY; RECEPTOR AGONIST; CARDIAC-OUTPUT; HEART-FAILURE; ORGAN FAILURE; DOPEXAMINE	Objective.-To assess the effect of deliberate perioperative increase in oxygen delivery on mortality and morbidity in patients who are at high risk of both following surgery. Design.-Prospective, randomized clinical trial. Setting.-A teaching hospital general intensive care unit, London, England. Patients.-A total of 107 surgical patients, who were assessed as high risk from previously identified criteria, were studied during an 18-month period. Interventions.-Patients were randomly assigned to a control group (n=54) that received best standard perioperative care, or to a protocol group (n=53) that, in addition, had deliberate increase of oxygen delivery index to greater than 600 mL/min per square meter by use of dopexamine hydrochloride infusion. Outcome Measures.-Mortality and complications were assessed to 28 days postoperatively. Results.-Groups were similar with respect to demographics, admission criteria, operation type, and admission hemodynamic variables. Groups were treated similarly to maintain blood pressure, arterial saturation, hemoglobin concentration, and pulmonary artery occlusion pressure; however, once additional treatment with dopexamine hydrochloride had been given, the protocol group had significantly higher oxygen delivery preoperatively (median, 597 vs 399 mL/min per square meter; P<.001) and postoperatively (P<.001). Results indicate a 75% reduction in mortality (5.7% vs 22.2%; P=.01 5) and a halving of the mean (+/-SEM) number of complications per patient (0.68 [+/-0.16] vs 1.35 [+/-0.20]; P=.008) in patients randomized to the protocol group. Conclusion.-Perioperative increase of oxygen delivery with dopexamine hydrochloride significantly reduces mortality and morbidity in high-risk surgical patients.	ST GEORGE HOSP,DEPT MED,LONDON SW17 0QT,ENGLAND; ST GEORGE HOSP,DEPT ANESTHET,LONDON SW17 0QT,ENGLAND	St Georges University London; St Georges University London	BOYD, O (corresponding author), ST GEORGE HOSP,GEN INTENS CARE UNIT,BLACKSHAW RD,LONDON SW17 0QT,ENGLAND.							BERLAUK JF, 1991, ANN SURG, V214, P289, DOI 10.1097/00000658-199109000-00011; BHATT SB, 1992, BRIT J ANAESTH, V69, P298, DOI 10.1093/bja/69.3.298; BIHARI D, 1987, NEW ENGL J MED, V317, P397, DOI 10.1056/NEJM198708133170701; BLAND R, 1978, SURG GYNECOL OBSTET, V147, P833; BOYD O, 1993, ANESTH ANALG, V76, P372; BOYD O, 1992, CHEST, V101, P1619, DOI 10.1378/chest.101.6.1619; BOYD O, 1993, LANCET, V341, P1573, DOI 10.1016/0140-6736(93)90706-M; Boyd O, 1992, YB INTENSIVE CARE EM, P310; BROWN RA, 1985, BRIT J PHARMACOL, V85, P599, DOI 10.1111/j.1476-5381.1985.tb10554.x; BUSH HL, 1977, ARCH SURG-CHICAGO, V112, P1301; CAIN SM, 1984, AM J MED SCI, V288, P119, DOI 10.1097/00000441-198410000-00005; CLARKE C, 1991, CRIT CARE MED, V19, P497, DOI 10.1097/00003246-199104000-00007; CLOWES GHA, 1960, METABOLISM, V9, P67; CZER LSC, 1978, SURG GYNECOL OBSTET, V147, P363; DAWSON JR, 1985, BRIT HEART J, V54, P313; DELGUERCIO LRM, 1985, ANN SURG, V202, P519, DOI 10.1097/00000658-198510000-00012; DEMARCO T, 1988, AM J CARDIOL, V62, pC57; FELLOWS IW, 1985, CLIN SCI, V69, P215, DOI 10.1042/cs0690215; FLEMING A, 1992, ARCH SURG-CHICAGO, V127, P1175; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; GREEN CJ, 1992, CLIN SCI, V82, P77, DOI 10.1042/cs0820077; GREENBURG AG, 1993, CRIT CARE MED, V21, P954, DOI 10.1097/00003246-199307000-00003; GUTIERREZ G, 1986, Journal of Critical Care, V1, P45, DOI 10.1016/S0883-9441(86)80116-2; HANKELN KB, 1991, CRIT CARE MED, V19, P642, DOI 10.1097/00003246-199105000-00010; HEISTAD DD, 1972, J CLIN INVEST, V51, P1469, DOI 10.1172/JCI106943; HSOEMAKER WC, 1993, CHEST, V103, P663; JEWITT D, 1974, LANCET, V2, P363; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KVIETYS PR, 1985, AM J PHYSIOL, V249, pG246, DOI 10.1152/ajpgi.1985.249.2.G246; LEIER CV, 1988, AM J CARDIOL, V62, P94, DOI 10.1016/0002-9149(88)91371-9; Lowe HJ, 1981, QUANTITATIVE PRACTIC, V146; MAGRINI F, 1988, AM J CARDIOL, V62, pC53, DOI 10.1016/S0002-9149(88)80068-7; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MCCONACHIE I, 1990, INTENS CARE MED, V15, pS57; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; POWERS SR, 1973, ANN SURG, V178, P265, DOI 10.1097/00000658-197309000-00005; ROBIN ED, 1987, CHEST, V92, P727, DOI 10.1378/chest.92.4.727; RODRIGUEZ JL, 1983, CIRCULATION, V68, P1238, DOI 10.1161/01.CIR.68.6.1238; ROUBY JJ, 1981, CIRCULATION, V64, P530; SAVINO JA, 1985, SURG CLIN N AM, V65, P763; SHAH KB, 1984, ANESTHESIOLOGY, V61, P271, DOI 10.1097/00000542-198409000-00007; SHOEMAKER WC, 1983, AM J SURG, V146, P43, DOI 10.1016/0002-9610(83)90257-X; SHOEMAKER WC, 1988, CRIT CARE MED, V16, P1117, DOI 10.1097/00003246-198811000-00007; SHOEMAKER WC, 1992, CHEST, V102, P208, DOI 10.1378/chest.102.1.208; SHOEMAKER WC, 1973, ARCH SURG-CHICAGO, V106, P630; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; SHOEMAKER WC, 1982, CRIT CARE MED, V10, P398, DOI 10.1097/00003246-198206000-00015; SHOEMAKER WC, 1972, SURG GYNECOL OBSTETR, V134, P810; SJOSTROM L, 1983, AM J PHYSIOL, V245, pE431, DOI 10.1152/ajpendo.1983.245.5.E431; SMITH GW, 1989, CARDIOVASC DRUG REV, V7, P141, DOI 10.1111/j.1527-3466.1989.tb00522.x; SVEDMYR N, 1966, ACTA PHYSIOL SCAND, V68, P84, DOI 10.1111/j.1748-1716.1966.tb03405.x; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; WHITTEMORE AD, 1980, ANN SURG, V192, P414, DOI 10.1097/00000658-198009000-00017; YANG SC, 1986, AM SURGEON, V52, P536; 1992, CRIT CARE MED, V20, P928	56	683	701	0	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2699	2707		10.1001/jama.270.22.2699	http://dx.doi.org/10.1001/jama.270.22.2699			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ821	7907668				2022-12-28	WOS:A1993MJ82100029
J	KUSCHNER, RA; HEPPNER, DG; ANDERSEN, SL; WELLDE, BT; HALL, T; SCHNEIDER, I; BALLOU, WR; FOULDS, G; SADOFF, JC; SCHUSTER, B; TAYLOR, DN				KUSCHNER, RA; HEPPNER, DG; ANDERSEN, SL; WELLDE, BT; HALL, T; SCHNEIDER, I; BALLOU, WR; FOULDS, G; SADOFF, JC; SCHUSTER, B; TAYLOR, DN			AZITHROMYCIN PROPHYLAXIS AGAINST A CHLOROQUINE-RESISTANT STRAIN OF PLASMODIUM-FALCIPARUM	LANCET			English	Note							PHARMACOKINETICS; MEFLOQUINE; SAFETY	Azithromycin has antimalarial activity and favourable pharmacokinetic properties for a prophylactic antimalarial agent. We investigated the ability of azithromycin to prevent malaria in volunteers infected with a chloroquine-resistant strain of Plasmodium falciparum. 4 volunteers received oral azithromycin 500 mg followed by 250 mg daily for 7 further days. Subjects were infected on the third day of azithromycin. 3 subjects were protected compared with none of 15 controls. The volunteer not protected by azithromycin had unquantifiable plasma levels of azithromycin, probably because of poor absorption. Azithromycin could be a promising prophylactic agent for P falciparum malaria.	WALTER REED ARMY INST RES,DIV EXPTL THERAPEUT,WASHINGTON,DC 20307; PFIZER INC,CENT RES,GROTON,CT	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Pfizer	KUSCHNER, RA (corresponding author), WALTER REED ARMY INST RES,DIV COMMUNICABLE DIS & IMMUNOL,WASHINGTON,DC 20307, USA.							BURKOT TR, 1984, T ROY SOC TROP MED H, V78, P339, DOI 10.1016/0035-9203(84)90114-7; CHULAY WR, 1985, J TROP MED HYG, V35, P66; COATES P, 1991, EUR J CLIN MICROBIOL, V10, P850, DOI 10.1007/BF01975839; FOULDS G, 1990, J ANTIMICROB CHEMOTH, V25, P73, DOI 10.1093/jac/25.suppl_A.73; FOULDS G, 1993, 33RD INT C ANT AG CH; GLADUE RP, 1989, ANTIMICROB AGENTS CH, V33, P277, DOI 10.1128/AAC.33.3.277; HOPKINS S, 1991, AM J MED, V91, pS40, DOI 10.1016/0002-9343(91)90401-I; KIATFUENGFOO R, 1989, MOL BIOCHEM PARASIT, V34, P109, DOI 10.1016/0166-6851(89)90002-9; PALMER KJ, 1993, DRUGS, V45, P430, DOI 10.2165/00003495-199345030-00009; SANCHEZ JL, 1993, LANCET, V341, P1021, DOI 10.1016/0140-6736(93)91107-W; SHMUKLARSKY MJ, 1994, ANN INTERN MED, V120, P294, DOI 10.7326/0003-4819-120-4-199402150-00006	11	47	50	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1396	1397		10.1016/S0140-6736(94)92526-7	http://dx.doi.org/10.1016/S0140-6736(94)92526-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910886				2022-12-28	WOS:A1994NP95500012
J	NIGRO, G; ZERBINI, M; KRZYSZTOFIAK, A; GENTILOMI, G; PORCARO, MA; MANGO, T; MUSIANI, M				NIGRO, G; ZERBINI, M; KRZYSZTOFIAK, A; GENTILOMI, G; PORCARO, MA; MANGO, T; MUSIANI, M			ACTIVE OR RECENT PARVOVIRUS B19 INFECTION IN CHILDREN WITH KAWASAKI-DISEASE	LANCET			English	Note								Because parvovirus B19 occasionally causes some of the features typical of Kawasaki disease, we investigated B19 involvement in 15 children with Kawasaki disease. Active or recent B19 infection, as shown by B19-DNAaemia, positive B19-specific IgM antibodies, or both, was diagnosed in 10 patients (67%). A high frequency of all major criteria for diagnosis of Kawasaki disease (60%), anaemia (60%), coronary aneurysms (30%), and arthropathy (30%) was found in children with B19-associated Kawasaki disease. Thus B19 may have a pathogenic role in the development of Kawasaki disease, with other predisposing factors.	UNIV ROMA LA SAPIENZA,INST PAEDIAT,ROME,ITALY; CNR,INST EXPTL MED,ROME,ITALY; UNIV BOLOGNA,INST MICROBIOL,BOLOGNA,ITALY	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); University of Bologna								KATO H, 1992, LANCET, V340, P1127, DOI 10.1016/0140-6736(92)93152-D; KURTZMAN GJ, 1989, J CLIN INVEST, V84, P1114, DOI 10.1172/JCI114274; LEVIN M, 1991, ARCH DIS CHILD, V66, P1369, DOI 10.1136/adc.66.12.1369; MORTIMER PP, 1985, LANCET, V2, P730; MUSIANI M, 1993, J MED VIROL, V40, P157, DOI 10.1002/jmv.1890400214; NIGRO G, 1993, AIDS, V7, P288, DOI 10.1097/00002030-199302000-00026; PLUMMER FA, 1985, NEW ENGL J MED, V313, P74, DOI 10.1056/NEJM198507113130203; ROWLEY AH, 1991, ADV PEDIATR, P51; ZERBINI M, 1993, J VIROL METHODS, V40, P157	9	112	115	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1260	1261		10.1016/S0140-6736(94)92154-7	http://dx.doi.org/10.1016/S0140-6736(94)92154-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910278				2022-12-28	WOS:A1994NM14400012
J	SHIMELL, MJ; SIMON, J; BENDER, W; OCONNOR, MB				SHIMELL, MJ; SIMON, J; BENDER, W; OCONNOR, MB			ENHANCER POINT MUTATION RESULTS IN A HOMEOTIC TRANSFORMATION IN DROSOPHILA	SCIENCE			English	Article							BITHORAX COMPLEX; ANTENNAPEDIA GENE; EXPRESSION; HUNCHBACK; ULTRABITHORAX; SEGMENTATION; PRODUCTS; PROTEINS; EMBRYOS; KRUPPEL	In Drosophila, the misexpression or altered activity of genes from the bithorax complex results in homeotic transformations. One of these genes, abd-A, normally specifies the identity of the second through fourth abdominal segments (A2 to A4). In the dominant Hyperabdominal mutations (Hab), portions of the third thoracic segment (T3) are transformed toward A2 as the result of ectopic abd-A expression. Sequence analysis and deoxyribonuclease I footprinting demonstrate that the misexpression of abd-A in two independent Hab mutations results from the same single base change in a binding site for the gap gene Kruppel protein. These results establish that the spatial limits of the homeotic genes are directly regulated by gap gene products.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717; UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92717; UNIV MINNESOTA,DEPT BIOCHEM,ST PAUL,MN 55108; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	University of California System; University of California Irvine; University of California System; University of California Irvine; University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Harvard Medical School			O'Connor, Michael B/C-9977-2014	O'Connor, Michael B/0000-0002-3067-5506				Bencini DA, 1984, BIOTECHNIQUES, V2, P4; BERRY M, 1992, NATURE, V358, P499, DOI 10.1038/358499a0; CELNIKER SE, 1989, GENE DEV, V3, P1424, DOI 10.1101/gad.3.9.1424; CELNIKER SE, 1993, P NATL ACAD SCI USA, V90, P1566, DOI 10.1073/pnas.90.4.1566; CRIBBS DL, 1992, GENETICS, V132, P699; CURTIS D, 1989, GENETICS, V122, P653; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DUNCAN I, 1987, ANNU REV GENET, V21, P285, DOI 10.1146/annurev.ge.21.120187.001441; DUNCAN I, COMMUNICATION; FRISCHER LE, 1986, CELL, V47, P1017, DOI 10.1016/0092-8674(86)90816-0; GYURKOVICS H, 1990, EMBO J, V9, P2579, DOI 10.1002/j.1460-2075.1990.tb07439.x; HARDING K, 1988, EMBO J, V7, P205, DOI 10.1002/j.1460-2075.1988.tb02801.x; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; IRISH VF, 1989, EMBO J, V8, P1527, DOI 10.1002/j.1460-2075.1989.tb03537.x; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; JORGENSEN EM, 1987, GENE DEV, V1, P544, DOI 10.1101/gad.1.6.544; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KARCH F, UNPUB; Kaufman T C, 1990, Adv Genet, V27, P309; KAZAZIAN HH, 1986, COLD SPRING HARB SYM, V51, P371, DOI 10.1101/SQB.1986.051.01.045; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Lewis Edith, COMMUNICATION; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; Pankratz Michael J., 1993, P467; PEIFER M, 1987, GENE DEV, V1, P891, DOI 10.1101/gad.1.9.891; QIAN S, 1991, EMBO J, V10, P1415, DOI 10.1002/j.1460-2075.1991.tb07662.x; QIAN S, 1993, EMBO J, V12, P3865, DOI 10.1002/j.1460-2075.1993.tb06065.x; REINITZ J, 1990, DEV BIOL, V140, P57, DOI 10.1016/0012-1606(90)90053-L; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SHIMELL M, UNPUB; SIMON J, 1990, EMBO J, V9, P3945, DOI 10.1002/j.1460-2075.1990.tb07615.x; SIMON J, UNPUB; SIMON J, 1993, DEV BIOL, V158, P134; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; WHITE RAH, 1986, CELL, V47, P311, DOI 10.1016/0092-8674(86)90453-8; WHITE RAH, 1985, NATURE, V318, P567, DOI 10.1038/318567a0; ZHANG CC, 1991, DEVELOPMENT, V113, P1171	43	77	77	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 13	1994	264	5161					968	971		10.1126/science.7909957	http://dx.doi.org/10.1126/science.7909957			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK974	7909957				2022-12-28	WOS:A1994NK97400036
J	BORNMAN, PC; KRIGE, JE; TERBLANCHE, J				BORNMAN, PC; KRIGE, JE; TERBLANCHE, J			MANAGEMENT OF ESOPHAGEAL-VARICES	LANCET			English	Article							BLEEDING ESOPHAGEAL-VARICES; ENDOSCOPIC INJECTION SCLEROTHERAPY; PROSPECTIVE RANDOMIZED TRIAL; CONTROLLED CLINICAL-TRIAL; DISTAL SPLENORENAL SHUNT; LONG-TERM MANAGEMENT; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; PLUS NITROGLYCERIN; BALLOON TAMPONADE		UNIV CAPE TOWN,MRC,LIVER RES CTR,CAPE TOWN,SOUTH AFRICA; UNIV CAPE TOWN,DEPT SURG,CAPE TOWN,SOUTH AFRICA	University of Cape Town; University of Cape Town	BORNMAN, PC (corresponding author), GROOTE SCHUUR HOSP,E23GIT CLIN,OBSERV,CAPE TOWN 7925,SOUTH AFRICA.		Krige, Jake E/G-3496-2015	Krige, Jake E/0000-0002-7057-9156				ARKIVIADIS E, 1989, DIGEST DIS SCI, V34, P1068; BEPPU K, 1981, GASTROINTEST ENDOSC, V27, P213, DOI 10.1016/S0016-5107(81)73224-3; BORNMAN PC, 1988, ANN SURG, V208, P175, DOI 10.1097/00000658-198808000-00007; BORNMAN PC, 1986, S AFR MED J, V70, P34; BOSCH J, 1989, HEPATOLOGY, V10, P962, DOI 10.1002/hep.1840100612; BURROUGHS AK, 1990, GASTROENTEROLOGY, V99, P1388, DOI 10.1016/0016-5085(90)91166-4; BURROUGHS AK, 1989, GUT, V30; CONN HO, 1993, HEPATOLOGY, V17, P148, DOI 10.1016/0270-9139(93)90205-2; CORREIA JP, 1984, HEPATOLOGY, V4, P885, DOI 10.1002/hep.1840040515; FORT E, 1990, HEPATOLOGY, V11, P678, DOI 10.1002/hep.1840110423; GIMSON AES, 1993, LANCET, V342, P391, DOI 10.1016/0140-6736(93)92812-8; GIMSON AES, 1986, HEPATOLOGY, V6, P410, DOI 10.1002/hep.1840060314; HASHIZUME M, 1993, GASTROINTEST ENDOSC, V39, P123, DOI 10.1016/S0016-5107(93)70050-4; HAYES PC, 1990, LANCET, V336, P153, DOI 10.1016/0140-6736(90)91668-Z; HENDERSON JM, 1989, ANN SURG, V210, P332, DOI 10.1097/00000658-198909000-00009; HIGASHI H, 1989, HEPATO-GASTROENTEROL, V36, P337; HWANG SJ, 1992, J HEPATOL, V16, P320, DOI 10.1016/S0168-8278(05)80663-4; INFANTERIVARD C, 1989, GASTROENTEROLOGY, V96, P1087, DOI 10.1016/0016-5085(89)91627-2; INK O, 1992, HEPATOLOGY, V16, P912, DOI 10.1002/hep.1840160410; JENKINS SA, 1991, J HEPATOL, V12, P296, DOI 10.1016/0168-8278(91)90830-5; JENKINS SA, 1985, BRIT MED J, V290, P275, DOI 10.1136/bmj.290.6464.275; JENKINS SA, 1991, GUT, V32, pA838; JENSEN LS, 1990, SCAND J GASTROENTERO, V25, P352, DOI 10.3109/00365529009095498; JOHLIN FC, 1992, DIGEST DIS SCI, V37, P1373, DOI 10.1007/BF01296006; KITANO S, 1987, HEPATOLOGY, V7, P810, DOI 10.1002/hep.1840070503; KRAVETZ D, 1984, HEPATOLOGY, V4, P442, DOI 10.1002/hep.1840040315; LAINE L, 1993, ANN INTERN MED, V119, P1, DOI 10.7326/0003-4819-119-1-199307010-00001; LANGER B, 1985, GASTROENTEROLOGY, V88, P424, DOI 10.1016/0016-5085(85)90502-5; LARSON AW, 1986, JAMA-J AM MED ASSOC, V255, P497, DOI 10.1001/jama.255.4.497; MILLIKAN WJ, 1985, ANN SURG, V201, P712; PAGLIARO L, 1990, LANCET, V336, P1001, DOI 10.1016/0140-6736(90)92458-T; PAGLIARO L, 1992, ANN INTERN MED, V117, P59, DOI 10.7326/0003-4819-117-1-59; RESNICK RH, 1990, GASTROENTEROLOGY, V99, P1524, DOI 10.1016/0016-5085(90)91189-D; RIKKERS LF, 1993, AM J SURG, V165, P27, DOI 10.1016/S0002-9610(05)80400-3; SAARI A, 1990, AM J GASTROENTEROL, V85, P804; SARIN SK, 1986, GUT, V27, P710, DOI 10.1136/gut.27.6.710; SARIN SK, 1987, GUT, V28, P657, DOI 10.1136/gut.28.6.657; SHIELDS R, 1992, J HEPATOL, V16, P128, DOI 10.1016/S0168-8278(05)80105-9; SODERLUND C, 1985, ACTA CHIR SCAND, V151, P449; SODERLUND C, 1990, SCAND J GASTROENTERO, V25, P622, DOI 10.3109/00365529009095539; SPINA GP, 1992, J HEPATOL, V16, P338, DOI 10.1016/S0168-8278(05)80666-X; SUNG JJY, 1993, LANCET, V342, P637, DOI 10.1016/0140-6736(93)91758-E; TAMURA S, 1991, AM J GASTROENTEROL, V86, P477; TERBLANCHE J, 1983, LANCET, V2, P1328; VALENZUELA JE, 1989, HEPATOLOGY, V10, P958, DOI 10.1002/hep.1840100611; VANSTIEGMANN G, 1988, GASTROINTEST ENDOSC, V34, P113, DOI 10.1016/S0016-5107(88)71274-2; VANSTIEGMANN GV, 1992, NEW ENGL J MED, V326, P1527; VINEL JP, 1992, GASTROENTEROLOGY, V102, P1760, DOI 10.1016/0016-5085(92)91740-U; WARREN WD, 1986, ANN SURG, V203, P454, DOI 10.1097/00000658-198605000-00002; WESTABY D, 1984, GUT, V25, P129, DOI 10.1136/gut.25.2.129; WESTABY D, 1986, HEPATOLOGY, V6, P673, DOI 10.1002/hep.1840060422; 1991, NEW ENGL J MED, V324, P1779; 1988, NEW ENGL J MED, V319, P983	53	46	50	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 30	1994	343	8905					1079	1084		10.1016/S0140-6736(94)90186-4	http://dx.doi.org/10.1016/S0140-6736(94)90186-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ694	7909104				2022-12-28	WOS:A1994NJ69400014
J	LEVINE, M; HIRSH, J; GENT, M; ARNOLD, A; WARR, D; FALANGA, A; SAMOSH, M; BRAMWELL, V; PRITCHARD, KI; STEWART, D; GOODWIN, P				LEVINE, M; HIRSH, J; GENT, M; ARNOLD, A; WARR, D; FALANGA, A; SAMOSH, M; BRAMWELL, V; PRITCHARD, KI; STEWART, D; GOODWIN, P			DOUBLE-BLIND RANDOMIZED TRIAL OF VERY-LOW-DOSE WARFARIN FOR PREVENTION OF THROMBOEMBOLISM IN STAGE-IV BREAST-CANCER	LANCET			English	Article							ORAL ANTICOAGULANT-THERAPY; FIXED MINIDOSE WARFARIN; DEEP-VEIN THROMBOSIS; VENOUS THROMBOSIS; REPLACEMENT; DIAGNOSIS; INTENSITIES; PROPHYLAXIS; ACTIVATION; CARCINOMA	Patients receiving chemotherapy for metastatic breast cancer are at high risk of thromboembolic disease. Long-term oral anticoagulant therapy is needed but increases the risk of haemorrhagic complications. We have assessed the safety and efficacy of warfarin in very low doses as prophylaxis. Women receiving chemotherapy for metastatic breast cancer were randomly assigned either very-low-dose warfarin (152 patients) or placebo (159). The warfarin dose was 1 mg daily for 6 weeks and was then adjusted to maintain the prothrombin time at an international normalised ratio (INR) of 1.3 to 1.9. Study treatment continued until 1 week after the end of chemotherapy. The average daily dose from initiation of titration was 2.6 (SD 1.2) mg for the warfarin group and the mean INR was 1.52. The mean time at risk of thrombosis was 199 (126) days for warfarin-treated patients and 188 (137) days for placebo recipients (p = 0.45). There were 7 thromboembolic events(6 deep-vein thrombosis, 1 pulmonary embolism) in the placebo group and 1 (pulmonary embolism) in the warfarin group, a relative risk reduction of about 85% (p = 0.031). Major bleeding occurred in 2 placebo recipients and 1 warfarin-treated patient. There was no detectable difference in survival between the treatment groups. Very-low-dose warfarin is a safe and effective method for prevention of thromboembolism in patients with metastatic breast cancer who are receiving chemotherapy.	MCMASTER UNIV, DEPT MED, HAMILTON, ON, CANADA; MCMASTER UNIV, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON, ON, CANADA; LONDON REG CANC CTR, LONDON, ON, CANADA; TORONTO BAYVIEW REG CANC CTR, TORONTO, ON, CANADA; OTTAWA REG CANC CTR, OTTAWA, ON, CANADA; PRINCESS MARGARET HOSP, TORONTO M4X 1K9, ON, CANADA; MT SINAI HOSP, TORONTO M5G 1X5, ON, CANADA; HOP HOTEL DIEU, ST CATHARINES, ON, CANADA; OSPED RIUNITI BERGAMO, I-24100 BERGAMO, ITALY	McMaster University; McMaster University; Western University (University of Western Ontario); University of Toronto; University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Ospedali Riuniti di Bergamo	LEVINE, M (corresponding author), OCTRF, HAMILTON REG CANC CTR, 699 CONCESS ST, HAMILTON L8V 5C2, ON, CANADA.		Goodwin, Pamela/K-1477-2013; Pritchard, Kathleen I/I-2184-2014	Goodwin, Pamela/0000-0003-2637-6906; Pritchard, Kathleen I/0000-0003-0758-9666; Falanga, Anna/0000-0001-6906-9020; Falanga, Anna/0000-0002-5007-3457				ALTMAN R, 1991, J THORAC CARDIOV SUR, V101, P427; BAUER KA, 1987, BLOOD, V70, P343; BERN MM, 1990, ANN INTERN MED, V112, P423, DOI 10.7326/0003-4819-76-3-112-6-423; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; DALE C, 1991, BRIT MED J, V303, P224, DOI 10.1136/bmj.303.6796.224; FORDYCE MJF, 1991, BRIT MED J, V303, P219, DOI 10.1136/bmj.303.6796.219; GOODNOUGH LT, 1984, CANCER-AM CANCER SOC, V54, P1264, DOI 10.1002/1097-0142(19841001)54:7<1264::AID-CNCR2820540706>3.0.CO;2-R; HIRSH J, 1992, CHEST, V102, pS312, DOI 10.1378/chest.102.4.312S; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; HULL R, 1976, CIRCULATION, V53, P696, DOI 10.1161/01.CIR.53.4.696; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LEVINE M, 1990, SEMIN ONCOL, V17, P160; LEVINE MN, 1991, ANN INTERN MED, V114, P545, DOI 10.7326/0003-4819-114-7-545; LEVINE MN, 1988, NEW ENGL J MED, V318, P404, DOI 10.1056/NEJM198802183180703; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MEADE TW, 1992, THROMB HAEMOSTASIS, V68, P1; POLLER L, 1987, BRIT MED J, V295, P1309, DOI 10.1136/bmj.295.6609.1309; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; RICKLES FR, 1983, BLOOD, V62, P14; SALZMAN EM, 1987, HEMOSTASIS THROMBOSI, P1252; SAPHNER T, 1991, J CLIN ONCOL, V9, P286, DOI 10.1200/JCO.1991.9.2.286; TURPIE AGG, 1988, LANCET, V1, P1242; WEISS RB, 1981, CANCER TREAT REP, V65, P677; ZACHARSKI LR, 1981, JAMA-J AM MED ASSOC, V245, P831, DOI 10.1001/jama.245.8.831; ZACHARSKI LR, 1986, HAEMOSTASIS, V16, P300	27	453	467	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 9	1994	343	8902					886	889		10.1016/S0140-6736(94)90008-6	http://dx.doi.org/10.1016/S0140-6736(94)90008-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF213	7908358				2022-12-28	WOS:A1994NF21300008
J	JOBST, KA; SMITH, AD; SZATMARI, M; ESIRI, MM; JASKOWSKI, A; HINDLEY, N; MCDONALD, B; MOLYNEUX, AJ				JOBST, KA; SMITH, AD; SZATMARI, M; ESIRI, MM; JASKOWSKI, A; HINDLEY, N; MCDONALD, B; MOLYNEUX, AJ			RAPIDLY PROGRESSING ATROPHY OF MEDIAL TEMPORAL-LOBE IN ALZHEIMERS-DISEASE	LANCET			English	Note							DEMENTIA; TOMOGRAPHY	The symptoms of Alzheimer's disease are associated with pathological change and loss of neurons in the medial temporal lobe. By yearly temporal-lobe-oriented computed tomograms the average rate of atrophy of the medial temporal lobe was 15.1% per year (95% CI 10.0, 20.2) in 20 patients with histopathologically, confirmed Alzheimer's disease and 1.5% (0.2, 2.8) in 47 healthy ageing controls. Such excessive atrophy presumably reflects the vulnerability of the medial temporal lobe to a catastrophic event, probably a pathological cascade process. Thus, Alzheimer's disease may not be due simply to an acceleration of normal ageing but, rather, is the consequence of a true disease process.	UNIV OXFORD,DEPT PHARMACOL,OXFORD PROJECT INVESTIGATE MEMORY & AGEING,OXFORD OX1 3QT,ENGLAND; UNIV OXFORD,DEPT CLIN NEUROL,OXFORD OX1 3QT,ENGLAND; RADCLIFFE INFIRM,DEPT NEUROPATHOL,OXFORD OX2 6HE,ENGLAND; RADCLIFFE INFIRM,DEPT NEURORADIOL,OXFORD OX2 6HE,ENGLAND	University of Oxford; University of Oxford; Radcliffe Infirmary; Radcliffe Infirmary			Smith, Anthony D./A-4233-2010	Smith, Anthony D./0000-0002-1095-6722				BOWEN DM, 1979, LANCET, V1, P11; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRAYNE C, 1988, LANCET, V1, P1265; DECARLI C, 1990, NEUROLOGY, V40, P872, DOI 10.1212/WNL.40.6.872; DECARLI C, 1992, NEUROLOGY, V42, P2029; DELEON MJ, 1989, LANCET, V2, P672; JOBST KA, 1992, LANCET, V340, P1179; JORM AF, 1990, EPIDEMIOLOGY ALZHEIM; LUXENBERG JS, 1987, NEUROLOGY, V37, P1135, DOI 10.1212/WNL.37.7.1135; MANN DMA, 1988, NEW ENGL J MED, V318, P789	10	189	190	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					829	830		10.1016/S0140-6736(94)92028-1	http://dx.doi.org/10.1016/S0140-6736(94)92028-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908080				2022-12-28	WOS:A1994ND79200011
J	MCBRIDE, R; CHESEBRO, JH; WIEBERS, DO; HOLLAND, AE; LINKER, S; BARDSLEY, WT; KOPECKY, S; LITIN, SC; MEISSNER, I; ZERBE, DM; FLAKER, GC; WEBEL, R; NOLTE, B; STEVENSON, P; BYER, J; JENKINS, JS; WRIGHT, W; ANDERSON, DC; ASINGER, RW; NEWBURG, SM; BUNDLIE, SR; FARMER, CC; KOLLER, RL; HAUGLAND, JM; NANCE, MA; TARREL, RM; DUNBAR, DN; JORGENSEN, CR; SHARKEY, SW; LEONARD, ADS; KANTER, MC; SOLOMON, DH; ZABALGOITIA, M; MCANULTY, JH; MARCHANT, C; COULL, BM; KELLEY, RE; CHAHINE, R; PALERMO, M; TEIXEIRO, P; FELDMAN, G; HAYWARD, A; MACMILLAN, K; GANDARA, E; ANDERSON, W; BLANK, N; STRAUSS, R; FEINBERG, WM; VOLD, BK; KERN, KB; APPLETON, C; BRUCK, D; DORR, S; DITTRICH, HC; ROTHROCK, JF; KERRIDGE, C; LOGAN, WR; HAMILTON, WP; GREEN, BJ; BACON, RS; HELGASON, CM; KONDOS, GT; HOFF, J; MCRAE, RP; HALPERIN, JL; ROTHLAUF, EB; WEINBERGER, JM; GOLDMAN, ME; MILLER, VT; HOCKERSMITH, CJ; COHEN, BA; JANOSIK, DL; CADELL, DJ; KELLERMAN, L; GOMEZ, CR; LABOVITZ, AJ; ROTHBART, RM; BAILEY, GH; BURKHARDT, C; HORWITZ, L; BLACKSHEAR, JL; WEAVER, L; BAKER, V; LEE, G; LANE, G; RUBINO, F; SAFFORD, R; KRONMAL, RA; PEARCE, LA; FLETCHER, KA; NASCO, E; HART, RG; SHERMAN, DG; TALBERT, RL; DACY, TL; HERBERLING, PA				MCBRIDE, R; CHESEBRO, JH; WIEBERS, DO; HOLLAND, AE; LINKER, S; BARDSLEY, WT; KOPECKY, S; LITIN, SC; MEISSNER, I; ZERBE, DM; FLAKER, GC; WEBEL, R; NOLTE, B; STEVENSON, P; BYER, J; JENKINS, JS; WRIGHT, W; ANDERSON, DC; ASINGER, RW; NEWBURG, SM; BUNDLIE, SR; FARMER, CC; KOLLER, RL; HAUGLAND, JM; NANCE, MA; TARREL, RM; DUNBAR, DN; JORGENSEN, CR; SHARKEY, SW; LEONARD, ADS; KANTER, MC; SOLOMON, DH; ZABALGOITIA, M; MCANULTY, JH; MARCHANT, C; COULL, BM; KELLEY, RE; CHAHINE, R; PALERMO, M; TEIXEIRO, P; FELDMAN, G; HAYWARD, A; MACMILLAN, K; GANDARA, E; ANDERSON, W; BLANK, N; STRAUSS, R; FEINBERG, WM; VOLD, BK; KERN, KB; APPLETON, C; BRUCK, D; DORR, S; DITTRICH, HC; ROTHROCK, JF; KERRIDGE, C; LOGAN, WR; HAMILTON, WP; GREEN, BJ; BACON, RS; HELGASON, CM; KONDOS, GT; HOFF, J; MCRAE, RP; HALPERIN, JL; ROTHLAUF, EB; WEINBERGER, JM; GOLDMAN, ME; MILLER, VT; HOCKERSMITH, CJ; COHEN, BA; JANOSIK, DL; CADELL, DJ; KELLERMAN, L; GOMEZ, CR; LABOVITZ, AJ; ROTHBART, RM; BAILEY, GH; BURKHARDT, C; HORWITZ, L; BLACKSHEAR, JL; WEAVER, L; BAKER, V; LEE, G; LANE, G; RUBINO, F; SAFFORD, R; KRONMAL, RA; PEARCE, LA; FLETCHER, KA; NASCO, E; HART, RG; SHERMAN, DG; TALBERT, RL; DACY, TL; HERBERLING, PA			WARFARIN VERSUS ASPIRIN FOR PREVENTION OF THROMBOEMBOLISM IN ATRIAL-FIBRILLATION - STROKE PREVENTION IN ATRIAL-FIBRILLATION-II STUDY	LANCET			English	Article							COMPLICATIONS; THERAPY	Warfarin is an established treatment for prevention of ischaemic stroke in patients with atrial fibrillation, but the value of this agent relative to aspirin is unclear. In the first Stroke Prevention in Atrial Fibrillation (SPAF-I) study, direct comparison of warfarin with aspirin was limited by the small number of thromboembolic events. SPAF-II aims to address this issue and also to assess the differential effects of the two treatments according to age. We compared warfarin (prothrombin time ratio 1.3-1.8, international normalised ratio 2.0-4.5) with aspirin 325 mg daily for prevention of ischaemic stroke and systemic embolism (primary events) in two parallel randomised trials involving 715 patients aged 75 years or less and 385 patients older than 75; we sought reductions in the absolute rate of primary events by warfarin compared with aspirin of 2% per year and 4% per year, respectively. In the younger patients, warfarin decreased the absolute rate of primary events by 0.7% per year (95% Cl - 0.4 to 1.7). The primary event rate per year was 1.3% with warfarin and 1.9% with aspirin (relative risk [RR] 0.67, p = 0.24). The absolute rate of primary events in low-risk younger patients (without hypertension, recent heart failure, or previous thromboembolism) on aspirin was 0.5% per year (95% Cl 0.1 to 1.9). Among older patients, warfarin decreased the absolute rate of primary events by 1.2% per year (95% Cl - 1.7 to 4.1). The primary event rate per year was 3.6% with warfarin and 4.8% with aspirin (RR 0.73, p = 0.39). In this older group, the rate of all stroke with residual deficit (ischaemic or haemorrhagic) was 4.3% per year with aspirin and 4.6% per year with warfarin (RR 1.1). Warfarin may be more effective than aspirin for prevention of ischaemic stroke in patients with atrial fibrillation, but the absolute reduction in stroke rate by warfarin is small. Younger patients without risk factors had a low rate of stroke when treated with aspirin. In older patients the rate of stroke (ischaemic and haemorrhagic) was substantial, irrespective of which agent was given. Patient age and the inherent risk of thromboembolism should be considered in the choice of antithrombotic prophylaxis for patients with atrial fibrillation.	MAYO CLIN & MAYO FDN, ROCHESTER, MN USA; UNIV MISSOURI, COLUMBIA, MO USA; HENNEPIN CTY MED CTR, MINNEAPOLIS, MN USA; ABBOTT NW HOSP, MINNEAPOLIS, MN USA; PARK NICOLLET MED CTR, MINNEAPOLIS, MN USA; UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX USA; AUDIE L MURPHY MEM VET ADM MED CTR, SAN ANTONIO, TX 78284 USA; OREGON HLTH SCI UNIV, PORTLAND, OR 97201 USA; UNIV MIAMI, SCH MED, MIAMI, FL USA; KAISER PERMANENTE CTR HLTH RES, PORTLAND, OR USA; UNIV ARIZONA, COLL MED, TUCSON, AZ USA; UNIV CALIF SAN DIEGO, MED CTR, SAN DIEGO, CA 92103 USA; ST JOHNS MERCY MED CTR, ST LOUIS, MO USA; UNIV CHICAGO, COLL MED, CHICAGO, IL 60637 USA; UNIV ILLINOIS, COLL MED, PEORIA, IL 61656 USA; MT SINAI MED CTR, NEW YORK, NY 10029 USA; NORTHWESTERN UNIV, SCH MED, CHICAGO, IL USA; ST LOUIS UNIV, MED CTR, ST LOUIS, MO USA; UNIV COLORADO, SCH MED, DENVER, CO USA; MAYO CLIN, JACKSONVILLE, FL USA; UNIV WASHINGTON, SEATTLE, WA USA	Mayo Clinic; University of Missouri System; University of Missouri Columbia; Hennepin County Medical Center; Park Nicollet Clinic; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Oregon Health & Science University; University of Miami; Kaiser Permanente; University of Arizona; University of California System; University of California San Diego; Saint Johns Mercy Medical Center; University of Chicago; University of Illinois System; University of Illinois Peoria; Icahn School of Medicine at Mount Sinai; Northwestern University; Saint Louis University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Mayo Clinic; University of Washington; University of Washington Seattle	MCBRIDE, R (corresponding author), STAT & EPIDEMIOL RES CORP, 1107 NE 45TH ST, SUITE 520, SEATTLE, WA 98105 USA.		Halperin, Jonathan/AAJ-4721-2020	Halperin, Jonathan/0000-0002-8318-5471	NINDS NIH HHS [R01-NS-24224] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024224] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Breslow N. E., 1987, STATISTICAL METHODS, VII; BUSSEY HI, 1992, ARCH INTERN MED, V152, P278, DOI 10.1001/archinte.152.2.278; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FLEMING TR, 1989, J NATL CANCER I, V81, P188, DOI 10.1093/jnci/81.3.188; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; LAKE FR, 1989, AUST NZ J MED, V19, P321, DOI 10.1111/j.1445-5994.1989.tb00271.x; LANDEFELD CS, 1989, J CLIN EPIDEMIOL, V42, P711, DOI 10.1016/0895-4356(89)90066-8; PETERSEN P, 1989, LANCET, V1, P175; PETERSEN P, 1990, NEW ENGL J MED, V323, P482; PHILLIPS SJ, 1990, MAYO CLIN PROC, V65, P344, DOI 10.1016/S0025-6196(12)62535-X; SINGER DE, 1992, AM HEART J, V124, P1567, DOI 10.1016/0002-8703(92)90074-6; 1993, J STROKE CEREBROVASC, V3, P181; 1990, STROKE, V21, P538; 1991, CIRCULATION, V84, P527; 1992, CEREBROVASC DIS, V2, P332; 1993, LANCET, V342, P1255; 1992, ANN INTERN MED, V1, P1; 1990, NEW ENGL J MED, V322, P863	20	866	875	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 19	1994	343	8899					687	691						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907677				2022-12-28	WOS:A1994NB80900006
J	VELDE, ERT; VANLEUSDEN, HAIM				VELDE, ERT; VANLEUSDEN, HAIM			HORMONAL TREATMENT FOR THE CLIMACTERIC - ALLEVIATION OF SYMPTOMS AND PREVENTION OF POSTMENOPAUSAL DISEASE	LANCET			English	Article							ESTROGEN REPLACEMENT THERAPY; BREAST-CANCER; PROGESTOGEN REPLACEMENT; TRANSDERMAL ESTRADIOL; RISK-FACTORS; WOMEN		RIJNSTATE EG HOSP, DEPT OBSTET & GYNAECOL, 6800 EK ARNHEM, NETHERLANDS	Rijnstate Hospital	VELDE, ERT (corresponding author), UNIV HOSP UTRECHT, DEPT OBSTET & GYNAECOL, POB 85500, 3508 GA UTRECHT, NETHERLANDS.							BARLOW DH, 1991, BR MED B, V48, P356; BARRETTCONNOR E, 1992, BRIT MED BULL, V48, P345, DOI 10.1093/oxfordjournals.bmb.a072550; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BERGKVIST L, 1988, INT J EPIDEMIOL, V17, P732, DOI 10.1093/ije/17.4.732; CAMPBELL S, 1977, CLIN OBSTET GYNAECOL, V4, P31; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; FURUHJELM M, 1984, ACTA OBSTET GYN SCAN, V63, P655, DOI 10.3109/00016348409155556; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRADY D, 1992, ANN INTERN MED, V117, P1038; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HILLARD TC, 1992, FERTIL STERIL, V58, P959; JUDD HL, 1987, MENOPAUSE PHYSL PHAR, P327; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; KUHL H, 1990, MATURITAS, V12, P171, DOI 10.1016/0378-5122(90)90003-O; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; LEATHER AT, 1991, OBSTET GYNECOL, V78, P1008; LEE SJ, 1988, HUM REPROD, V3, P851, DOI 10.1093/oxfordjournals.humrep.a136796; OLDENHAVE A, 1977, AM J OBSTET GYNECOL, V4, P31; PADWICK ML, 1986, NEW ENGL J MED, V315, P930, DOI 10.1056/NEJM198610093151504; PERSSON I, 1992, LANCET, V340, P1044, DOI 10.1016/0140-6736(92)93064-T; RAZ R, 1993, NEW ENGL J MED, V329, P753, DOI 10.1056/NEJM199309093291102; RIJPKEMA AHM, 1990, MATURITAS, V12, P259, DOI 10.1016/0378-5122(90)90007-S; SPEROFF L, 1992, BR MED B, V48, P426; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; STEINGOLD KA, 1991, J CLIN ENDOCR METAB, V73, P275, DOI 10.1210/jcem-73-2-275; TEVELDE ER, 1993, LANCET, V341, P1125, DOI 10.1016/0140-6736(93)93133-L; TRELOAR AE, 1967, INT J FERTIL, V12, P77; TZIGOUNIS VA, 1980, ACTA ENDOCR-COP    S, V233, P45; VANERPECUM KJ, 1991, GASTROENTEROLOGY, V100, P482, DOI 10.1016/0016-5085(91)90220-F; Wren BG, 1988, MENOPAUSE, P181	32	28	30	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 12	1994	343	8898					654	658		10.1016/S0140-6736(94)92642-5	http://dx.doi.org/10.1016/S0140-6736(94)92642-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906817				2022-12-28	WOS:A1994NA09300015
J	PAOLISSO, G; GAMBARDELLA, G; GALZERANO, D; VARRICCHIO, M; DONOFRIO, F				PAOLISSO, G; GAMBARDELLA, G; GALZERANO, D; VARRICCHIO, M; DONOFRIO, F			ANTIOXIDANTS IN ADIPOSE-TISSUE AND RISK OF MYOCARDIAL-INFARCTION	LANCET			English	Letter							CORONARY HEART-DISEASE; INSULIN RESISTANCE; HYPERINSULINEMIA; HYPERTENSION; DYSLIPIDEMIA		UNIV NAPLES 2,DEPT GERIATR MED & METAB DIS,NAPLES,ITALY	Universita della Campania Vanvitelli	PAOLISSO, G (corresponding author), CLIN DIABET & NUTR SECT,4212 N 16TH ST,PHOENIX,AZ 85016, USA.		paolisso, giuseppe/AAP-8516-2020	paolisso, giuseppe/0000-0002-2137-455X; GAMBARDELLA, Antonio/0000-0002-4125-0618				DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; FONTBONNE A, 1991, DIABETOLOGIA, V34, P356, DOI 10.1007/BF00405009; PAOLISSO G, 1993, AM J CLIN NUTR, V57, P650, DOI 10.1093/ajcn/57.5.650; REAVEN GM, 1991, AM HEART J, V121, P1283, DOI 10.1016/0002-8703(91)90434-J; WHITESELL RR, 1989, BIOCHEMISTRY-US, V28, P5618, DOI 10.1021/bi00439a042	5	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 5	1994	343	8897					596	596						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906339				2022-12-28	WOS:A1994MY84300033
J	VAGERO, D; LEON, D				VAGERO, D; LEON, D			ISCHEMIC-HEART-DISEASE AND LOW-BIRTH-WEIGHT - A TEST OF THE FETAL-ORIGINS HYPOTHESIS FROM THE SWEDISH-TWIN-REGISTRY	LANCET			English	Article							ADULT LIFE; HEIGHT; MORTALITY; GROWTH; INFANCY; COHORT; DEATH	Twins constitute a population with lower than average birth weight for reasons that are not a consequence of social disadvantage. The hypothesis that ischaemic heart disease (IHD) is linked to low birth weight was tested by analysing whether or not 8174 female and 6612 male Swedish twins had a higher mortality compared to the general Swedish population. The association between adult body height and IHD mortality was also analysed in a nested case-control study among monozygotic and dizygotic twins. Ischaemic heart disease mortality was not higher among twins (women: relative risk [RR] 0.99; 95% confidence limits [CL] 0.89-1.10; men: RR 0.85; CL 0.79-0.92). However, the shorter twin in a twin pair was more likely to die of heart disease than the taller (odds ratio [OR] 1.15, CL 1.03-1.25). We suggest that postnatal influences may well be as important as prenatal influences in producing any effect on ischaemic heart disease mortality and that the type of growth retardation in utero experienced by twins may not constitute a risk for ischaemic heart disease in adulthood.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND	University of London; London School of Hygiene & Tropical Medicine	VAGERO, D (corresponding author), UNIV STOCKHOLM, SWEDISH INST SOCIAL RES, S-10691 STOCKHOLM, SWEDEN.		Leon, David A/G-2195-2010	Leon, David A/0000-0001-9747-1762; Vagero, Denny/0000-0002-1854-2292				BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1991, J ROY COLL PHYS LOND, V25, P129; BARKER DJP, 1990, ANN HUM BIOL, V17, P1, DOI 10.1080/03014469000000732; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; CAMPELL D, 1988, TWINNING TWINS; CEDERLOF R, 1966, TWIN METHOD EPIDEMIO; CEDERLOF R, 1977, ACTA MED SCAND, V202, pS49; FISCHBEIN S, 1990, 29 U STOCKH DEP SOC; FLEIGNER JR, 1984, AUSTR NZ J OBS GYNEC, V24, P192; ILLSLEY R, 1955, BRIT MED J, V2, P1520, DOI 10.1136/bmj.2.4955.1520; KUH D, 1989, INT J EPIDEMIOL, V18, P663, DOI 10.1093/ije/18.3.663; MACINTYRE S, 1988, SOC SCI MED, V27, P327, DOI 10.1016/0277-9536(88)90266-3; MARMOT MG, 1984, LANCET, V1, P1003; MOILANEN I, 1989, GROWTH DEVELOP AGING, V53, P145; NAEYE RL, 1964, PEDIATRICS, V33, P546; NOTKOLA V, 1985, LIVING CONDITIONS CH; PECK AMN, 1989, J EPIDEMIOL COMMUN H, V43, P380, DOI 10.1136/jech.43.4.380; PHILLIPS DIW, 1993, LANCET, V341, P1008, DOI 10.1016/0140-6736(93)91086-2; VAGERO D, 1994, IN PRESS PREMATURE A; WILSON R, 1986, HUMAN GROWTH COMPREH, V3; WILSON RS, 1974, ANN HUM BIOL, V1, P57, DOI 10.1080/03014467400000061; WILSON RS, 1979, ANN HUM BIOL, V6, P205, DOI 10.1080/03014467900007212; WILSON RS, 1974, ANN HUM BIOL, V1, P175, DOI 10.1080/03014467400000191; [No title captured]	26	122	122	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 29	1994	343	8892					260	263		10.1016/S0140-6736(94)91112-6	http://dx.doi.org/10.1016/S0140-6736(94)91112-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905096				2022-12-28	WOS:A1994MT44000010
J	MASTRO, TD; SATTEN, GA; NOPKESORN, T; SANGKHAROMYA, S; LOGINI, IM				MASTRO, TD; SATTEN, GA; NOPKESORN, T; SANGKHAROMYA, S; LOGINI, IM			PROBABILITY OF FEMALE-TO-MALE TRANSMISSION OF HIV-1 IN THAILAND	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RISK-FACTORS; INFECTION; PARTNERS; CHILDREN; VIREMIA; TYPE-1; ADULTS; AIDS	The epidemic of human immunodeficiency virus type 1 (HIV-1) infection in Thailand has allowed an estimate to be made of the probability of female-to-male HIV-1 transmission per sexual contact. In a study of 1115 21 year-old male military conscripts, of whom 77 (6.9%) were HIV-1 seropositive, sex with female prostitutes was identified as the principal mode of HIV-1. transmission. With a mathematical model including data on conscript's age at first sexual contact, frequency of sex with female prostitutes, and province of origin; as well as province-specific HIV-1 seroprevalence of prostitutes, we estimated the probability of HIV-1 transmission per sexual contact to be 0.031 (95% confidence limits [CL] 0.025-0.040). Allowing for random error in the self-reported frequency of contacts, the estimate was 0.056 (95% CL 0.041-0.075). The transmission probability was significantly greater among men with a history of sexually-transmitted diseases. These estimates are substantially higher than analogous estimates made in North America. This high per-act probability of heterosexual transmission helps to explain the rapid spread of HIV-1 in the emerging epidermic in Thailand and perhaps in other countries where HIV-1 transmission is predominately heterosexual.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA; SOMDEJ PRANARESUAN MAHARAJ HOSP,PHITSANULOKE,THAILAND; EMORY UNIV,SCH PUBL HLTH,DIV BIOSTAT,ATLANTA,GA 30322	Centers for Disease Control & Prevention - USA; Emory University	MASTRO, TD (corresponding author), HIV AIDS COLLABORAT,88-7 SOI BAMRASNARADURA,TIVANON RD,NONTHABURI 11000,THAILAND.			Satten, Glen/0000-0001-7275-5371				CAMERON DW, 1989, LANCET, V2, P403; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DEGRUTTOLA V, 1989, J CLIN EPIDEMIOL, V42, P849, DOI 10.1016/0895-4356(89)90098-X; EISENBERG B, 1989, STAT MED, V8, P83, DOI 10.1002/sim.4780080109; FISCHL MA, 1987, JAMA-J AM MED ASSOC, V257, P640, DOI 10.1001/jama.257.5.640; HAVERKOS HW, 1992, JAMA-J AM MED ASSOC, V268, P1855, DOI 10.1001/jama.1992.03490140063023; HORSBURGH CR, 1989, LANCET, V2, P637; JEWELL NP, 1990, BIOMETRICS, V46, P1133, DOI 10.2307/2532454; KOOPMAN JS, 1991, AM J EPIDEMIOL, V133, P1199, DOI 10.1093/oxfordjournals.aje.a115832; LIMPAKARNJANARA.K, 1993, 9 INT C AIDS BERL; MYERS G, 1992, HUMAN RETROVIRUSES A; NELSON KE, 1993, JAMA-J AM MED ASSOC, V270, P955, DOI 10.1001/jama.270.8.955; NOPKESORN T, 1993, AIDS, V7, P1233, DOI 10.1097/00002030-199309000-00013; OU CY, 1993, LANCET, V341, P1171, DOI 10.1016/0140-6736(93)91001-3; PAU CP, 1993, AIDS, V7, P337, DOI 10.1097/00002030-199303000-00005; SAAG MS, 1991, J INFECT DIS, V164, P72, DOI 10.1093/infdis/164.1.72; SATTEN GA, IN PRESS STAT MED; SIRAYSIRISOPANA N, 1992, 8 INT C AIDS AMST; SIRISOPANA N, 1993, 9 INT C AIDS BERL; TAYLOR DN, 1984, SEX TRANSM DIS, V11, P148, DOI 10.1097/00007435-198407000-00005; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011; WILEY JA, 1989, STAT MED, V8, P93, DOI 10.1002/sim.4780080110; [No title captured]; 1993, WHOGPACNPEVA931 PUBL	25	177	179	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 22	1994	343	8891					204	207		10.1016/S0140-6736(94)90990-3	http://dx.doi.org/10.1016/S0140-6736(94)90990-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT332	7904668				2022-12-28	WOS:A1994MT33200009
J	WALD, NJ; LAW, M; WATT, HC; WU, TS; BAILEY, A; JOHNSON, AM; CRAIG, WY; LEDUE, TB; HADDOW, JE				WALD, NJ; LAW, M; WATT, HC; WU, TS; BAILEY, A; JOHNSON, AM; CRAIG, WY; LEDUE, TB; HADDOW, JE			APOLIPOPROTEINS AND ISCHEMIC-HEART-DISEASE - IMPLICATIONS FOR SCREENING	LANCET			English	Article							CORONARY-ARTERY DISEASE; MYOCARDIAL-INFARCTION; SERUM; RISK; CHOLESTEROL; MEN	Apolipoproteins and lipids are established risk factors of ischaemic heart disease (IHD) but their efficacy as screening tests is not known. We therefore examined the mortality from IHD and serum concentrations of lipids and apolipoproteins in a prospective study of 21 520 men aged 35-64 years. Serum apo B was the apolipoprotein most strongly associated with IHD risk; a decrease in apo B of 10% was associated with 22% lower risk of IHD. However, measurement of apo B alone detected only 17% of all IHD deaths at the cost of a 5% false-positive rate. Combining apo B with apo Al and apo (a) increased the detection rate to 19%. With systolic blood pressure, smoking, and family history of IHD the detection rate increased to 28%. We conclude that screening for IHD by measuring apo B alone or with apo Al and apo (a) is too poor to discriminate between recommending drug therapy or lifestyle change for some and not others. It is not advisable to screen for IHD by measuring any combination of cholesterol, apo B, apo Al, apo (a) and the other risk factors. The primary aim in prevention of ischaemic heart disease should be to lower the risk factors in the population.	BUPA MED RES, LONDON WC2, ENGLAND; FDN BLOOD RES, SCARBOROUGH, ME USA	Foundation for Blood Research (FBR)	WALD, NJ (corresponding author), ST BARTHOLOMEWS HOSP, MED COLL, DEPT ENVIRONM & PREVENT MED, WOLFSON INST PREVENT MED, LONDON EC1M 6BQ, ENGLAND.		Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021; H, V/M-5550-2014					BUCOLO G, 1973, CLIN CHEM, V19, P476; CREMER P, 1988, KLIN WOCHENSCHR, V66, P42; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; IRISH GR, 1987, CLIN CHEM, V33, P1267; IRISH GR, 1987, CLIN CHEM, V33, P1266; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; LAW MR, IN PRESS BMJ; MACIEJKO JJ, 1987, CLIN CHEM, V33, P2065; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; SALONEN JT, 1985, AM J CARDIOL, V56, P226, DOI 10.1016/0002-9149(85)90839-2; SIGURDSSON G, 1992, AM J CARDIOL, V69, P1251, DOI 10.1016/0002-9149(92)91215-P; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, 1992, CORONARY HEART DIS E, P358; WARNICK GR, 1982, CLIN CHEM, V28, P1379; ZHAO SP, 1991, CLIN CHEM, V37, P1139	18	235	239	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 8	1994	343	8889					75	79		10.1016/S0140-6736(94)90814-1	http://dx.doi.org/10.1016/S0140-6736(94)90814-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903777				2022-12-28	WOS:A1994MQ09200009
J	MCGLAVE, PB; DEFABRITIIS, P; DEISSEROTH, A; GOLDMAN, J; BARNETT, M; REIFFERS, J; SIMONSSON, B; CARELLA, A; AEPPLI, D				MCGLAVE, PB; DEFABRITIIS, P; DEISSEROTH, A; GOLDMAN, J; BARNETT, M; REIFFERS, J; SIMONSSON, B; CARELLA, A; AEPPLI, D			AUTOLOGOUS TRANSPLANTS FOR CHRONIC MYELOGENOUS LEUKEMIA - RESULTS FROM 8 TRANSPLANT GROUPS	LANCET			English	Article							MARROW TRANSPLANTATION; LEUKEMIA; INTERFERON; CELLS; CML; PROGENITORS; GAMMA	Chronic myelogenous leukaemia (CML) can be cured by donor marrow transplant. Unfortunately, suitably HLA-matched related or unrelated donors are not available for the majority of patients. Transplant of stem cells derived from a patient's own marrow or peripheral blood (autologous transplant) avoids the need for an HLA-matched donor, is associated with a less complicated and shorter hospital course than donor transplantation, and has been successful in the treatment of other haematological malignancies. We report results of autologous transplants in 200 patients with CML at eight marrow transplant centres over seven yeats. This is the first multicentre analysis of autologous transplants for CML and reports on the largest number of patients studied to date. We show that autologous transplants provide a plateau in the survival curve not observed in conventional treatments. Autologous transplants are associated with a high engraftment rate, low mortality, and prompt return of both younger and older patients to normal activity levels. Our results suggest that autologous transplants provide an alternative to conventional treatment in the care of patients not eligible for donor transplant.	INST HEMATOL,ROME,ITALY; MD ANDERSON CANC CTR,DEPT HEMATOL,HOUSTON,TX 77030; HAMMERSMITH HOSP,DEPT HAEMATOL,LONDON,ENGLAND; VANCOUVER GEN HOSP,LEUKEMIA & BONE MARROW TRANSPLANTAT PROGRAM,VANCOUVER,BC,CANADA; HOSP HAUT LEVEQUE,UNITE GREFFE,BORDEAUX,FRANCE; UNIV UPPSALA HOSP,DEPT MED,UPPSALA,SWEDEN; OSPED SAN MARTINO GENOVA,GENOA,ITALY; UNIV MINNESOTA,SCH PUBL HLTH,MINNEAPOLIS,MN 55455	University of Texas System; UTMD Anderson Cancer Center; Imperial College London; University of British Columbia; CHU Bordeaux; Uppsala University; Uppsala University Hospital; University of Genoa; IRCCS AOU San Martino IST; University of Minnesota System; University of Minnesota Twin Cities	MCGLAVE, PB (corresponding author), UNIV MINNESOTA,SCH MED,DEPT MED,MARROW TRANSPLANT PROGRAM,MINNEAPOLIS,MN 55455, USA.			de Fabritiis, Paolo/0000-0002-1835-0581				BARNETT MJ, 1989, BONE MARROW TRANSPL, V4, P345; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; CARELLA AM, 1993, BONE MARROW TRANSPL, V12, P267; CARLOSTELLA C, 1991, BONE MARROW TRANSPL, V8, P265; DEFABRITIIS P, 1990, BONE MARROW TRANSPL, V6, P247; DEISSEROTH AB, IN PRESS BLOOD; ELAUDTJOHNSON RC, 1980, SURVIVAL MODELS DATA; GOLDMAN JM, 1993, IN PRESS BLOOD; HIGANO CS, 1992, BLOOD, V80, P1437; HOYLE C, 1994, BRIT J HAEMATOL, V86, P76, DOI 10.1111/j.1365-2141.1994.tb03255.x; Karnofsky D., 1949, CLIN EVALUATION CHEM, P191; LEEMHUIS T, 1992, EXP HEMATOL, V20, P782; MCGLAVE P, 1987, EXP HEMATOL, V15, P331; MCGLAVE P, 1993, BLOOD, V81, P543; MCGLAVE PB, 1990, BONE MARROW TRANSPL, V6, P115; MCGLAVE PB, 1990, BONE MARROW TRANSPL, P235; REIFFERS J, 1991, BRIT J HAEMATOL, V77, P339, DOI 10.1111/j.1365-2141.1991.tb08581.x; SHPALL EJ, 1994, J CLIN ONCOL, V12, P28, DOI 10.1200/JCO.1994.12.1.28; SIMONSSON B, 1992, LEUKEMIA LYMPHOMA, V7, P55, DOI 10.3109/10428199209061566; SOKAL JE, 1985, BLOOD, V66, P1342; TURHAN AG, 1990, BLOOD, V76, P2402; VERFAILLIE CM, 1992, BLOOD, V79, P1003	22	195	197	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1486	1488		10.1016/S0140-6736(94)92589-5	http://dx.doi.org/10.1016/S0140-6736(94)92589-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911185				2022-12-28	WOS:A1994NQ41500016
J	CHAPMAN, KR; KESTEN, S; SZALAI, JP				CHAPMAN, KR; KESTEN, S; SZALAI, JP			REGULAR VS AS-NEEDED INHALED SALBUTAMOL IN ASTHMA CONTROL	LANCET			English	Article							BETA-AGONISTS; BRONCHIAL RESPONSIVENESS; TERBUTALINE; FENOTEROL; FORMOTEROL	Recent studies have suggested that regular use of inhaled beta, agonists cause loss of asthma control as measured by worsening peak-flow rates, increased asthma symptoms, and more frequent need for supplementary bronchodilators. However, the magnitude of this effect and the reliability of investigator-originated definitions of control is unknown. We studied 341 people with asthma in a four-week, randomised, crossover trial of regular salbutamol (2 puffs-200 mu g-four times daily) for two weeks and as needed for two weeks. There were no significant differences in morning and evening peak-flow rates between treatments but asthma symptoms and supplementary bronchodilator use were significantly less frequent when salbutamol was given regularly. Asthma episodes occurred 1.39 (1.52) times per day during regular treatment and 2.44 (1.75) times per day during as-needed treatment (p<0.0001) and 0.50 (0.56) vs 0.65 (0.66) times per night (p < 0.0001). Daytime use of supplementary salbutamol was 1.14 (1.40) vs 2.35 (1.71) puffs per day, (p <0.0001); night-time use was 0.45 (0.55) vs 0.64 (0.66) puffs per night (p < 0.0001). When control endpoints were compared between treatment periods for each individual by two blinded investigators and control judged by six different sets of criteria, in 70 asthmatics there was no difference in symptom control between periods but in the remainder, control was achieved more often by regular than by as-needed salbutamol (166 vs 69, p < 0.0001). In asthma of moderate severity, regularly administered salbutamol does not produce lower peak flow rates than as-needed salbutamol and is associated with less frequent asthma symptoms.	UNIV TORONTO,DIV RESP MED,TORONTO,ON,CANADA; UNIV TORONTO,DEPT PREVENT MED & BIOSTAT,TORONTO,ON,CANADA	University of Toronto; University of Toronto	CHAPMAN, KR (corresponding author), TORONTO HOSP,CTR ASTHMA,SUITE 4-011,ECW,399 BATHURST ST,TORONTO M5T 2S8,ON,CANADA.			Kesten, Steven/0000-0002-5522-7910				COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; CRANE J, 1989, LANCET, V1, P917; JENNE JW, 1993, BRONCHIAL ASTHMA MEC, P700; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KESTEN S, 1991, AM REV RESPIR DIS, V144, P622, DOI 10.1164/ajrccm/144.3_Pt_1.622; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; KUITERT LM, 1992, THORAX, V47, P568, DOI 10.1136/thx.47.7.568; LOFDAHL CG, 1991, EUR RESPIR J, V4, P218; OCONNOR BJ, 1992, NEW ENGL J MED, V327, P1204, DOI 10.1056/NEJM199210223271704; RAMSDALE EH, 1991, AM REV RESPIR DIS, V143, P998, DOI 10.1164/ajrccm/143.5_Pt_1.998; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; SEARS MR, 1991, LANCET, V338, P1331, DOI 10.1016/0140-6736(91)92627-E; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPECTOR SL, 1986, J ALLERGY CLIN IMMUN, V77, P65, DOI 10.1016/0091-6749(86)90325-8; SPITZER W, 1993, NEW ENGL J MED, V326, P501; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134; TREMBATH PW, 1979, J ALLERGY CLIN IMMUN, V63, P395, DOI 10.1016/0091-6749(79)90212-4; VATHENEN AS, 1988, LANCET, V1, P554; WONG CS, 1990, LANCET, V336, P1396, DOI 10.1016/0140-6736(90)93099-B; 1987, AM REV RESPIR DIS, V136, P225	20	77	77	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1379	1382		10.1016/S0140-6736(94)92520-8	http://dx.doi.org/10.1016/S0140-6736(94)92520-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910880				2022-12-28	WOS:A1994NP95500006
J	TREASURE, T				TREASURE, T			THE PULMONARY AUTOGRAFT AS AN AORTIC-VALVE REPLACEMENT	LANCET			English	Editorial Material											TREASURE, T (corresponding author), ST GEORGE HOSP,LONDON,ENGLAND.							ELKINS RC, 1994, NEW ENGL J MED, V330, P59, DOI 10.1056/NEJM199401063300111; KOUCHOUKOS NT, 1994, NEW ENGL J MED, V330, P1, DOI 10.1056/NEJM199401063300101; ROSS D, 1992, EUR J CARDIO-THORAC, V6, P113, DOI 10.1016/1010-7940(92)90115-E; ROSS D, 1991, ANN THORAC SURG, V52, P1346, DOI 10.1016/0003-4975(91)90032-L; ROSS DN, 1967, LANCET, V2, P956	5	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1308	1308		10.1016/S0140-6736(94)92463-5	http://dx.doi.org/10.1016/S0140-6736(94)92463-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910320				2022-12-28	WOS:A1994NN21700006
J	VINEIS, P; BARTSCH, H; CAPORASO, N; HARRINGTON, AM; KADLUBAR, FF; LANDI, MT; MALAVEILLE, C; SHIELDS, PG; SKIPPER, P; TALASKA, G; TANNENBAUM, SR				VINEIS, P; BARTSCH, H; CAPORASO, N; HARRINGTON, AM; KADLUBAR, FF; LANDI, MT; MALAVEILLE, C; SHIELDS, PG; SKIPPER, P; TALASKA, G; TANNENBAUM, SR			GENETICALLY BASED N-ACETYLTRANSFERASE METABOLIC POLYMORPHISM AND LOW-LEVEL ENVIRONMENTAL EXPOSURE TO CARCINOGENS	NATURE			English	Article							EXFOLIATED UROTHELIAL CELLS; HEMOGLOBIN ADDUCTS; DNA ADDUCTS; URINARY MUTAGENICITY; CIGARETTE SMOKERS; SMOKING; ACETYLATION; PHENOTYPE; CANCER	THE metabolic activation or inactivation of carcinogens varies considerably in human populations, and is partly genetically determined(1,2). Inter-individual variability in the susceptibility to carcinogens may be particularly important at low degrees of environmental exposure. Examples of probable human carcinogens that present widespread low-dose exposures are environmental tobacco smoke and diesel exhaust(3,4). We have determined levels of DNA adducts in bladder cells and of 4-aminobiphenyl-haemoglobin adducts in 97 volunteers, together with the N-acetylation non-inducible phenotype, the corresponding genotype, and the levels of nicotine-cotinine in the urine. We find that among the slow acetylators, 4-aminobiphenyl adducts were higher than in rapid acetylators at low or null nicotine-cotinine levels, whereas the difference between slow and rapid acetylators was less evident at increasing nicotine-cotinine levels. The N-acetyltransferase genotype is highly predictive of the acetylation phenotype. Our results indicate that the clearance of low-dose carcinogens is decreased in the genetically based slow-acetylator phenotype. Such genetic modulation of low-dose environmental risks is relevant to 'risk assessment' procedures.	MAIN HOSP,I-10126 TURIN,ITALY; GERMAN CANC RES CTR,D-69120 HEIDELBERG,GERMANY; NCI,GENET EPIDEMIOL BRANCH,ROCKVILLE,MD 20892; NCI,HUMAN CARCINOGENESIS LAB,BETHESDA,MD 20892; NATL CTR TOXICOL RES,JEFFERSON,AR 72079; UNIV MILAN,IST MED LAVORO,I-20122 MILAN,ITALY; INT AGCY RES CANC,F-69372 LYON,FRANCE; MIT,DEPT CHEM,CAMBRIDGE,MA 02139; UNIV CINCINNATI,DEPT ENVIRONM HLTH,CINCINNATI,OH	Helmholtz Association; German Cancer Research Center (DKFZ); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); University of Milan; World Health Organization; International Agency for Research on Cancer (IARC); Massachusetts Institute of Technology (MIT); University System of Ohio; University of Cincinnati	VINEIS, P (corresponding author), UNIV TURIN,DIPARTIMENTO SCI BIOMED & ONCOL UMANA,CANC EPIDEMIOL UNIT,I-10126 TURIN,ITALY.		Shields, Peter G/I-1644-2012					[Anonymous], 1974, IARC MONOGRAPHS EVAL, V4; BARTSCH H, 1990, JNCI-J NATL CANCER I, V82, P1826, DOI 10.1093/jnci/82.23.1826; BELL DA, 1993, CARCINOGENESIS, V14, P1689, DOI 10.1093/carcin/14.8.1689; BLUM M, 1991, P NATL ACAD SCI USA, V88, P5237, DOI 10.1073/pnas.88.12.5237; BRYANT MS, 1988, P NATL ACAD SCI USA, V85, P9788, DOI 10.1073/pnas.85.24.9788; BUTLER MA, 1992, PHARMACOGENETICS, V2, P116, DOI 10.1097/00008571-199206000-00003; CAPORASO N, 1991, PHARMACOGENETICS, V1, P4, DOI 10.1097/00008571-199110000-00003; Case R A, 1966, Ann R Coll Surg Engl, V39, P213; SHIELDS PG, 1991, JAMA-J AM MED ASSOC, V266, P681, DOI 10.1001/jama.266.5.681; TALASKA G, 1990, CARCINOGENESIS, V11, P639, DOI 10.1093/carcin/11.4.639; TALASKA G, 1991, P NATL ACAD SCI USA, V88, P5350, DOI 10.1073/pnas.88.12.5350; TALASKA G, 1991, CANCER EPIDEM BIOMAR, V1, P61; VINEIS P, 1990, CANCER RES, V50, P3002; WOODWARD A, 1991, EUR J CANCER, V27, P1472, DOI 10.1016/0277-5379(91)90034-B; 1989, IARC MONOGRAPHS EVAL, V46	15	270	274	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 12	1994	369	6476					154	156		10.1038/369154a0	http://dx.doi.org/10.1038/369154a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK971	7909916				2022-12-28	WOS:A1994NK97100051
J	DECOSAS, J				DECOSAS, J			FIGHTING AIDS OR RESPONDING TO THE EPIDEMIC - CAN PUBLIC-HEALTH FIND ITS WAY	LANCET			English	Editorial Material											DECOSAS, J (corresponding author), GTZ REG AIDS PROGRAMME W & CENT AFRICA,POB 9698,KOTOKA INT AIRPORT,ACCRA,GHANA.							SCHEPERHUGHES N, 1993, LANCET, V342, P965, DOI 10.1016/0140-6736(93)92006-F	1	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1994	343	8906					1145	1146		10.1016/S0140-6736(94)90241-0	http://dx.doi.org/10.1016/S0140-6736(94)90241-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NK730	7910238				2022-12-28	WOS:A1994NK73000015
J	VANDERVIES, SM; GATENBY, AA; GEORGOPOULOS, C				VANDERVIES, SM; GATENBY, AA; GEORGOPOULOS, C			BACTERIOPHAGE-T4 ENCODES A CO-CHAPERONIN THAT CAN SUBSTITUTE FOR ESCHERICHIA-COLI GROES IN PROTEIN-FOLDING	NATURE			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; MORPHOGENESIS; INTERACTS; MUTATION; GENE-31; ATP	SEVERAL bacteriophages use the Escherichia coli GroES and GroEL chaperonins for folding and assembly of their morphogenetic structures1. Bacteriophage T4 is unusual in that it encodes a specialized protein (Gp31) that is thought to interact with the host GroEL and to be absolutely required for the correct assembly of the major capsid protein (Gp23) in vivo2-4. Here we show that despite the absence of amino-acid sequence similarity between Gp31 and GroES5,6 Gp31 can functionally substitute for the GroES co-chaperonin in the morphogenesis of bacteriophages lambda and T5, the in vivo and in vitro chaperonin-dependent assembly of ribulose bisphosphate carboxylase (Rubisco), as well as overall bacterial growth at the non-permissive temperature. Like GroES, the bacteriophage Gp31 protein forms a stable complex with the E. coli GroEL protein in the presence of Mg-ATP and inhibits the ATPase activity of GroEL in vitro.	DUPONT CO INC,CENT RES & DEV,DIV MOLEC BIOL,EXPTL STN,WILMINGTON,DE 19880	DuPont	VANDERVIES, SM (corresponding author), UNIV GENEVA,DEPT BIOCHIM MED,CH-1211 GENEVA 4,SWITZERLAND.							CASTILLO CJ, 1978, J BIOL CHEM, V253, P2132; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; GATENBY AA, 1985, NATURE, V314, P617, DOI 10.1038/314617a0; GEORGOPOULOS CP, 1972, NATURE-NEW BIOL, V239, P38, DOI 10.1038/newbio239038a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KEPPEL F, 1990, GENE, V86, P19, DOI 10.1016/0378-1119(90)90109-5; LAEMMLI UK, 1970, J MOL BIOL, V47, P69, DOI 10.1016/0022-2836(70)90402-X; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LORIMER GH, 1977, ANAL BIOCHEM, V78, P65; NIVINSKAS R, 1988, GENE, V73, P251, DOI 10.1016/0378-1119(88)90332-0; STERNBERG N, 1973, J MOL BIOL, V76, P1, DOI 10.1016/0022-2836(73)90078-8; TAKANO T, 1972, NATURE-NEW BIOL, V239, P34, DOI 10.1038/newbio239034a0; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505	19	90	92	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					654	656		10.1038/368654a0	http://dx.doi.org/10.1038/368654a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	7908418				2022-12-28	WOS:A1994NF39200066
J	ADZICK, NS; HARRISON, MR				ADZICK, NS; HARRISON, MR			FETAL SURGICAL THERAPY	LANCET			English	Review							HEMATOPOIETIC STEM-CELLS; DIAPHRAGMATIC-HERNIA; INUTERO TRANSPLANTATION; SURGERY; TWIN; HYDROTHORAX; HYSTEROTOMY; OCCLUSION; DELIVERY; CREATION				ADZICK, NS (corresponding author), UNIV CALIF SAN FRANCISCO, MED CTR, CTR FETAL TREATMENT, ROOM 1601 HSW, SAN FRANCISCO, CA 94143 USA.		Harrison, Michael/GYD-8608-2022					Adzick N S, 1993, Semin Pediatr Surg, V2, P103; ADZICK NS, 1989, J PEDIATR SURG, V24, P654, DOI 10.1016/S0022-3468(89)80713-4; ADZICK NS, 1993, J PEDIATR SURG, V28, P806; ADZICK NS, 1985, SEMIN PERINATOL, V9, P79; Adzick NS, 1992, FETAL WOUND HEALING, Vxv; BOND SJ, 1989, OBSTET GYNECOL, V74, P25; CROMBLEHOLME TM, 1990, J PEDIATR SURG, V25, P587, DOI 10.1016/0022-3468(90)90339-B; DELIA JE, 1990, OBSTET GYNECOL, V75, P1046; ESTES JM, 1992, J PEDIATR SURG, V27, P950, DOI 10.1016/0022-3468(92)90538-I; ESTES JM, 1992, PLAST RECONSTR SURG, V90, P743, DOI 10.1097/00006534-199211000-00001; ESTES JM, 1993, SEMIN PEDIATR SURG, V2, P932; Flake A W, 1993, Semin Pediatr Surg, V2, P113; FLAKE AW, 1986, SCIENCE, V233, P776, DOI 10.1126/science.2874611; FRIES MH, 1992, OBSTET GYNECOL, V79, P601; Harrison M R, 1993, Semin Pediatr Surg, V2, P136; Harrison M.R., 1990, UNBORN PATIENT PRENA; HARRISON MR, 1990, NEW ENGL J MED, V322, P1582, DOI 10.1056/NEJM199005313222207; HARRISON MR, 1980, SURGERY, V88, P260; HARRISON MR, 1993, J PEDIATR SURG, V28, P1411, DOI 10.1016/S0022-3468(05)80338-0; HARRISON MR, 1989, LANCET, V2, P1425; HARRISON MR, 1994, JAMA-J AM MED ASSOC, V271, P382, DOI 10.1001/jama.271.5.382; HARRISON MR, 1991, ANN SURG, V213, P279, DOI 10.1097/00000658-199104000-00002; HARRISON MR, 1990, LANCET, V336, P965, DOI 10.1016/0140-6736(90)92420-M; Hedrick Marc H., 1993, Surgical Forum, V44, P644; HEDRICK MH, 1993, LANCET, V342, P1086, DOI 10.1016/0140-6736(93)92065-2; HOLZGREVE W, 1993, WESTERN J MED, V159, P333; JENNINGS RW, 1993, SURG GYNECOL OBSTET, V176, P59; JENNINGS RW, 1993, J MATERNAL FETAL MED, V2, P170; LONGAKER MT, 1991, JAMA-J AM MED ASSOC, V265, P737, DOI 10.1001/jama.265.6.737; LONGAKER MT, 1989, J PEDIATR SURG, V24, P573, DOI 10.1016/S0022-3468(89)80509-3; MANNING FA, 1986, NEW ENGL J MED, V315, P336, DOI 10.1056/NEJM198607313150532; MARTINEZFERRO M, 1994, J PEDIATR SURG, V29, P271; MAXWELL D, 1991, BRIT HEART J, V65, P256; NATUZZI ES, 1993, BIOCHEM BIOPH RES CO, V194, P1, DOI 10.1006/bbrc.1993.1776; NICOLAIDES K H, 1990, Fetal Diagnosis and Therapy, V5, P153; PORRECO RP, 1991, LANCET, V337, P326, DOI 10.1016/0140-6736(91)90946-M; QUINTERO RA, 1994, NEW ENGL J MED, V330, P469, DOI 10.1056/NEJM199402173300705; RODECK CH, 1988, NEW ENGL J MED, V319, P1135, DOI 10.1056/NEJM198810273191706; SCHMIDT KG, 1991, J AM COLL CARDIOL, V17, P1360, DOI 10.1016/S0735-1097(10)80148-2; SHAH M, 1992, LANCET, V339, P213, DOI 10.1016/0140-6736(92)90009-R; SHARLAND GK, 1992, AM J OBSTET GYNECOL, V166, P9, DOI 10.1016/0002-9378(92)91817-T; TOURAINE JL, 1992, HUM REPROD, V7, P44, DOI 10.1093/oxfordjournals.humrep.a137554; WEST LJ, 1994, LANCET, V343, P148, DOI 10.1016/S0140-6736(94)90936-9; WILSON JM, 1993, J PEDIATR SURG, V28, P1433, DOI 10.1016/0022-3468(93)90426-L; YALLAMPALLI C, 1994, AM J OBSTET GYNECOL, V170, P175	45	113	118	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 9	1994	343	8902					897	902		10.1016/S0140-6736(94)90012-4	http://dx.doi.org/10.1016/S0140-6736(94)90012-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF213	7908362				2022-12-28	WOS:A1994NF21300012
J	ANKUM, WM; VONK, J				ANKUM, WM; VONK, J			THE SPRING BALANCE - A SIMPLE MONITORING-SYSTEM FOR FLUID OVERLOAD DURING HYSTEROSCOPIC SURGERY	LANCET			English	Article							ABSORPTION; ETHANOL	Fluid overload may arise during hysteroscopic surgery, caused by absorption of fluid used to distend the uterus. continuous monitoring of the fluid balance is required to prevent this serious complication. Commercial equipment does not serve this purpose adequately. We describe a simple solution. We weigh the inflow and outflow volumes together on a spring balance; this method provides information about fluid balance, since any fluid lost as spillage or by absorption is reflected by a loss of weight on the balance. The method is simple, accurate, and inexpensive, and the components can be purchased readily.			ANKUM, WM (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT OBSTET & GYNAECOL,MELBERGDREEF 9,1105 AZ AMSTERDAM,NETHERLANDS.		Vonk, Judith M/ABA-3009-2020; Vonk, Judith/K-8477-2019	Vonk, Judith M/0000-0001-7531-4547; Vonk, Judith/0000-0001-7531-4547				DUFFY S, 1992, OBSTET GYNECOL, V79, P300; GARRY R, 1990, LANCET, V336, P1013, DOI 10.1016/0140-6736(90)92480-6; HARRISON RH, 1956, J UROLOGY, V75, P95, DOI 10.1016/S0022-5347(17)66783-1; HULTEN JO, 1986, SCAND J UROL NEPHROL, V20, P245, DOI 10.3109/00365598609024506; MACDONALD R, 1989, LANCET, V335, P1387; MAGOS AL, 1990, LANCET, V336, P44; MOLNAR BG, 1992, GYNAECOL ENDOSC, V1, P133; VULGAROPULOS SP, 1992, AM J OBSTET GYNECOL, V167, P386, DOI 10.1016/S0002-9378(11)91417-3; 1991, LANCET, V338, P606	9	7	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					836	837		10.1016/S0140-6736(94)92030-3	http://dx.doi.org/10.1016/S0140-6736(94)92030-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908082				2022-12-28	WOS:A1994ND79200013
J	MOTT, MG; BOYSE, J; HEWITT, M; RADFORD, M				MOTT, MG; BOYSE, J; HEWITT, M; RADFORD, M			DO MUTATIONS AT THE GLYCOPHORIN-A LOCUS IN PATIENTS TREATED FOR CHILDHOOD HODGKINS-DISEASE PREDICT SECONDARY LEUKEMIA	LANCET			English	Note							SOMATIC MUTATIONS; SURVIVORS	Childhood Hodgkin's disease has a high cure rate but second cancers are common, related to treatment and perhaps genetic predisposition. The glycophorin-A (GPA) mutation assay measures the frequency of NO and NN mutant erythrocytes of MN blood-group heterozygous individuals. Mutant frequencies in Hodgkin's disease patients were compared with controls. No significant difference from controls was found pretreatment or in patients treated with radiotherapy only. Patients who received chemotherapy had a significantly increased frequency (total mutation frequency per 10(6) cells: 31 vs 11, p < 0.001), which may be relevant to their known increased risk of secondary leukaemia.	UNIV NOTTINGHAM HOSP,QUEENS MED CTR,NOTTINGHAM NG7 2UH,ENGLAND; SOUTHAMPTON GEN HOSP,DEPT CHILD HLTH,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	University of Nottingham; University of Southampton	MOTT, MG (corresponding author), ROYAL HOSP SICK CHILDREN,INST CHILD HLTH,ST MICHAELS HILL,BRISTOL BS2 8BJ,ENGLAND.							BOICE JD, 1993, J NATL CANCER I, V85, P4, DOI 10.1093/jnci/85.1.4; CAGGANA M, 1991, ENVIRON MOL MUTAGEN, V18, P6, DOI 10.1002/em.2850180103; GLICKSMAN AS, 1982, CANCER TREAT REP, V66, P1035; HEWITT M, 1992, BRIT J CANCER, V66, P143, DOI 10.1038/bjc.1992.232; LANGLOIS RG, 1990, CYTOMETRY, V11, P513, DOI 10.1002/cyto.990110410; LANGLOIS RG, 1987, SCIENCE, V236, P445, DOI 10.1126/science.3563520; RADFORD M, 1991, MED PEDIATR ONCOL, V19, P400; SALATREPAT M, 1993, MUTAT RES, V289, P115, DOI 10.1016/0027-5107(93)90137-5; SWERDLOW AJ, 1992, BRIT MED J, V304, P1137, DOI 10.1136/bmj.304.6835.1137; TARBELL NJ, 1993, LANCET, V341, P1428, DOI 10.1016/0140-6736(93)90880-P	10	27	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					828	829		10.1016/S0140-6736(94)92027-3	http://dx.doi.org/10.1016/S0140-6736(94)92027-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908079				2022-12-28	WOS:A1994ND79200010
J	LIPTON, SA; ROSENBERG, PA				LIPTON, SA; ROSENBERG, PA			EXCITATORY AMINO-ACIDS AS A FINAL COMMON PATHWAY FOR NEUROLOGIC DISORDERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							METHYL-D-ASPARTATE; RECEPTOR-MEDIATED NEUROTOXICITY; CALCIUM-CHANNEL ANTAGONISTS; CORTICAL CELL-CULTURE; SPINAL-CORD NEURONS; GLUTAMATE NEUROTOXICITY; NMDA-RECEPTOR; HIPPOCAMPAL-NEURONS; RAT-BRAIN; CEREBRAL-ISCHEMIA		CHILDRENS HOSP,CELLULAR & MOLEC NEUROSCI LAB,BOSTON,MA; BETH ISRAEL HOSP,DEPT NEUROL,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT NEUROL,BOSTON,MA; MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA; HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	LIPTON, SA (corresponding author), CHILDRENS HOSP,HARVARD LONGWOOD NEUROL PROGRAM,300 LONGWOOD AVE,ENDERS BLDG,SUITE 361,BOSTON,MA 02115, USA.			Lipton, Stuart/0000-0002-3490-1259; Rosenberg, Paul/0000-0002-5185-1118				BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BEAL MF, 1993, TRENDS NEUROSCI, V16, P125, DOI 10.1016/0166-2236(93)90117-5; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BITO H, 1992, NEURON, V9, P285, DOI 10.1016/0896-6273(92)90167-C; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BUCHAN AM, 1991, NEUROSCI LETT, V132, P255, DOI 10.1016/0304-3940(91)90314-J; BURNASHEV N, 1992, SCIENCE, V257, P1415, DOI 10.1126/science.1382314; CARPENTER CL, 1988, BRAIN RES, V439, P372, DOI 10.1016/0006-8993(88)91497-7; Chan P. H., 1985, CEREBROVASC DIS, P161; CHEN HSV, 1992, J NEUROSCI, V12, P4427; CHOI DW, 1985, NEUROSCI LETT, V58, P293, DOI 10.1016/0304-3940(85)90069-2; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1987, BRAIN RES, V403, P333, DOI 10.1016/0006-8993(87)90070-9; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1987, J NEUROSCI, V7, P357; CLARK GD, 1992, NEURON, V9, P1211, DOI 10.1016/0896-6273(92)90078-R; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DONEVAN SD, 1993, NEURON, V10, P51, DOI 10.1016/0896-6273(93)90241-I; DUBINSKY JM, 1991, J NEUROSCI, V11, P2545; ELNASR MS, 1990, EUR J PHARMACOL, V185, P19, DOI 10.1016/0014-2999(90)90206-L; ERDO SL, 1991, EUR J PHARMACOL, V198, P215, DOI 10.1016/0014-2999(91)90625-Z; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FIGUERAS A, 1992, BRIT MED J, V305, P1330, DOI 10.1136/bmj.305.6865.1330; FRANDSEN A, 1992, P NATL ACAD SCI USA, V89, P2590, DOI 10.1073/pnas.89.7.2590; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; GOLDMAN RS, 1988, NEW ENGL J MED, V319, P1224; HAHN JS, 1988, P NATL ACAD SCI USA, V85, P6556, DOI 10.1073/pnas.85.17.6556; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; KVAMME E, 1985, NEUROCHEM RES, V10, P993, DOI 10.1007/BF00964635; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; LEI SHZ, 1992, BRAIN RES, V598, P196, DOI 10.1016/0006-8993(92)90183-A; Lipton S A, 1991, Adv Pharmacol, V22, P271, DOI 10.1016/S1054-3589(08)60038-1; LIPTON SA, 1993, CURR OPIN NEUROL NEU, V6, P588; LIPTON SA, 1989, TRENDS NEUROSCI, V12, P265, DOI 10.1016/0166-2236(89)90026-X; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LIPTON SA, 1992, TRENDS NEUROSCI, V15, P75, DOI 10.1016/0166-2236(92)90013-X; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MACDONALD JF, 1987, J NEUROPHYSIOL, V58, P251, DOI 10.1152/jn.1987.58.2.251; MANCHESTER KS, 1993, NEUROLOGY, V43, pA365; MATTSON MP, 1989, FASEB J, V3, P2519, DOI 10.1096/fasebj.3.13.2572500; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCCABE RT, 1993, J PHARMACOL EXP THER, V264, P1248; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MILLER B, 1992, NATURE, V355, P722, DOI 10.1038/355722a0; MINEMATSU K, 1993, NEUROLOGY, V43, P397, DOI 10.1212/WNL.43.2.397; MONYER H, 1992, NEURON, V8, P967, DOI 10.1016/0896-6273(92)90211-U; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; Olney J.W., 1978, KAINIC ACID TOOL NEU, P95; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; RANDALL RD, 1992, J NEUROSCI, V12, P1882; REGAN RF, 1991, NEUROSCIENCE, V43, P585, DOI 10.1016/0306-4522(91)90317-H; ROCCA WA, 1992, STROKE, V23, P519, DOI 10.1161/01.STR.23.4.519; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROSENBERG PA, 1992, J NEUROSCI, V12, P56; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; ROTHMAN SM, 1987, NEUROSCIENCE, V22, P471, DOI 10.1016/0306-4522(87)90347-2; ROTHSTEIN JD, 1984, J NEUROCHEM, V43, P1438, DOI 10.1111/j.1471-4159.1984.tb05406.x; Schousboe A, 1981, Int Rev Neurobiol, V22, P1, DOI 10.1016/S0074-7742(08)60289-5; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SMITH SE, 1992, STROKE, V23, P861, DOI 10.1161/01.STR.23.6.861; SONSALLA PK, 1992, J NEUROCHEM, V58, P1979, DOI 10.1111/j.1471-4159.1992.tb10081.x; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; SUCHER NJ, 1991, BRAIN RES, V551, P297, DOI 10.1016/0006-8993(91)90944-Q; SUCHER NJ, 1991, BRAIN RES, V559, P179; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; TOMEI LD, 1991, APOPTOSIS MOL BASIS; TROUT JJ, 1993, J NEUROCHEM, V60, P352, DOI 10.1111/j.1471-4159.1993.tb05858.x; TURSKI L, 1991, NATURE, V349, P414, DOI 10.1038/349414a0; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; VOLTERRA A, 1992, J NEUROCHEM, V59, P600, DOI 10.1111/j.1471-4159.1992.tb09411.x; WAHLESTEDT C, 1993, NATURE, V363, P260, DOI 10.1038/363260a0; WASTERLAIN CG, 1992, EUR J PHARMACOL, V212, P275, DOI 10.1016/0014-2999(92)90343-3; Wesemann W, 1980, J Neural Transm Suppl, P143; WHITE HS, 1992, EPILEPSIA, V33, P564, DOI 10.1111/j.1528-1157.1992.tb01711.x; WRATHALL JR, 1992, BRAIN RES, V586, P140, DOI 10.1016/0006-8993(92)91384-Q; ZEEVALK GD, 1992, J NEUROCHEM, V59, P1211, DOI 10.1111/j.1471-4159.1992.tb08430.x; ZORUMSKI CF, 1993, NEURON, V10, P61, DOI 10.1016/0896-6273(93)90242-J; 1992, STROKE, V23, P3; 1992, STROKE, V23, P615	90	2390	2541	1	76	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 3	1994	330	9					613	622						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY573	7905600				2022-12-28	WOS:A1994MY57300007
J	MENNERICK, S; ZORUMSKI, CF				MENNERICK, S; ZORUMSKI, CF			GLIAL CONTRIBUTIONS TO EXCITATORY NEUROTRANSMISSION IN CULTURED HIPPOCAMPAL CELLS	NATURE			English	Article							ELECTROGENIC GLUTAMATE UPTAKE; METHYL-D-ASPARTATE; TIME COURSE; RECEPTORS; NEURONS; ACTIVATION; MEMBRANE; CURRENTS; CHANNEL; PATCHES	ALTHOUGH many glial cells possess neurotransmitter receptors and transporters(1-5), little is known about glial participation in neurotransmission. To explore this issue, we recorded neuronal autaptic(6,7) and glial responses from cultured hippocampal single-neuron micro-islands(6,7). Excitatory synaptic events activate rapid electrogenic glial glutamate transporter currents similar to those elicited by exogenous glutamate in other preparations. We show here that glial transporter responses may be used to sense changes in presynaptic efficacy and that glial uptake helps to remove synaptically released glutamate, thereby contributing to the termination of excitatory synaptic currents under certain conditions. These observations provide a framework for understanding the role of glia in both normal and pathological processes.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,PROGRAM NEUROSCI,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	MENNERICK, S (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110, USA.		Mennerick, Steven/O-2806-2017	Mennerick, Steven/0000-0003-0868-0664				BARBOUR B, 1991, J PHYSIOL-LONDON, V436, P169, DOI 10.1113/jphysiol.1991.sp018545; BARRES BA, 1991, J NEUROSCI, V11, P3685; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; BRIDGES RJ, 1991, J MED CHEM, V34, P717, DOI 10.1021/jm00106a037; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; ECCLES JC, 1958, PROC R SOC SER B-BIO, V148, P38, DOI 10.1098/rspb.1958.0003; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; HARRISON NL, 1990, J PHYSIOL-LONDON, V422, P433, DOI 10.1113/jphysiol.1990.sp017993; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HILLE B, 1972, J GEN PHYSIOL, V59, P637, DOI 10.1085/jgp.59.6.637; KARWOSKI CJ, 1989, SCIENCE, V244, P578, DOI 10.1126/science.2785716; KATZ B, 1965, PROC R SOC SER B-BIO, V161, P496, DOI 10.1098/rspb.1965.0017; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; LESTER RAJ, 1992, J NEUROSCI, V12, P635; LUCERO MT, 1990, J GEN PHYSIOL, V95, P523, DOI 10.1085/jgp.95.3.523; MURPHY TH, 1993, J NEUROSCI, V13, P2672, DOI 10.1523/JNEUROSCI.13-06-02672.1993; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; PATNEAU DK, 1993, J NEUROSCI, V13, P3496; SARANTIS M, 1993, NEURON, V11, P541, DOI 10.1016/0896-6273(93)90158-N; SATHER W, 1992, J PHYSIOL-LONDON, V450, P643, DOI 10.1113/jphysiol.1992.sp019148; SEGAL MM, 1991, J NEUROPHYSIOL, V65, P761, DOI 10.1152/jn.1991.65.4.761; STEPHENS GJ, 1993, RECEPTOR CHANNEL, V1, P39; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; WYLLIE DJA, 1991, J PHYSIOL-LONDON, V432, P235, DOI 10.1113/jphysiol.1991.sp018383; YAMADA KA, 1993, J NEUROSCI, V13, P3904; ZORUMSKI CF, 1993, NEURON, V10, P61, DOI 10.1016/0896-6273(93)90242-J	30	295	296	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 3	1994	368	6466					59	62		10.1038/368059a0	http://dx.doi.org/10.1038/368059a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY569	7906399				2022-12-28	WOS:A1994MY56900052
J	STEWART, THM; RETSKY, MW; TSAI, SCJ; VERMA, S				STEWART, THM; RETSKY, MW; TSAI, SCJ; VERMA, S			DOSE-RESPONSE IN THE TREATMENT OF BREAST-CANCER	LANCET			English	Editorial Material							GROWTH-FACTOR; CARCINOMA; CELLS; GLUCOCORTICOIDS; THERAPY; CULTURE; INVITRO; INVIVO	We present evidence that drugs that are effective in causing regression of metastatic breast cancer in a dose-dependent fashion also cause a dose-dependent reduction of cytokines produced by the immune system. This may be an important factor in the occasional induction of a complete remission.	UNIV COLORADO, COLORADO SPRINGS, CO USA; ROCHE DIAGNOST SYST, BRANCHBURG, NJ USA; OTTAWA REG CANC CTR, OTTAWA, ON, CANADA	University of Colorado System; University of Colorado at Colorado Springs; Roche Holding; University of Ottawa; Ottawa Hospital Research Institute	STEWART, THM (corresponding author), OTTAWA GEN HOSP, ROOM LM-18, 501 SMYTH RD, OTTAWA K1H 8L6, ON, CANADA.							BASOLO F, 1992, INT J CANCER, V51, P634, DOI 10.1002/ijc.2910510421; BESCH GJ, 1986, CANCER RES, V46, P2306; COOPER KD, 1990, J AM ACAD DERMATOL, V23, P1318, DOI 10.1016/0190-9622(90)70360-T; DEMICHELI R, 1991, TUMORI J, V77, P189, DOI 10.1177/030089169107700302; DEMICHELI R, 1992, P AN M AM SOC CLIN, V11, P100; DODWELL DJ, 1993, LANCET, V341, P614, DOI 10.1016/0140-6736(93)90366-O; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; HIRAOKA D, 1987, CANCER RES, V47, P6560; JORDAN VC, 1992, SEMIN ONCOL, V19, P299; KURTZ JM, 1990, J CLIN ONCOL, V8, P591, DOI 10.1200/JCO.1990.8.4.591; LARSSON EL, 1980, J IMMUNOL, V124, P2828; LIPPMAN M, 1976, CANCER RES, V36, P4602; MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167-5699(92)90008-U; MCCULLOUGH JL, 1983, PSORIASIS CELL PROLI, P347; MEAKIN JW, 1979, CAN MED ASSOC J, V120, P1221; Meropol N J, 1992, Oncology (Williston Park), V6, P53; MICHIEL DF, 1992, CANCER BIOL, V3, P3; OLSEN GA, 1988, TRANSPLANTATION, V46, P57, DOI 10.1097/00007890-198807000-00009; PREHN RT, 1980, INSERM, V97, P297; RAMACHANDRA S, 1990, J PATHOL, V161, P7, DOI 10.1002/path.1711610104; RETSKY MW, 1993, ADJUVANT THERAPY BRE, P13; RUBENS RD, 1988, BRIT J CANCER, V58, P626, DOI 10.1038/bjc.1988.273; RUBENS RD, 1991, MED MANAGEMENT BREAS, P117; SHEARER WT, 1978, FED PROC, V37, P2385; SMITH KA, 1980, IMMUNOL REV, V51, P337, DOI 10.1111/j.1600-065X.1980.tb00327.x; STEWART THM, 1993, CLIN EXP METASTAS, V11, P295, DOI 10.1007/BF00058049; STEWART THM, 1992, CELLULAR IMMUNE MECHANISMS AND TUMOR DORMANCY, P213; STOLL BA, 1963, BMJ-BRIT MED J, P210, DOI 10.1136/bmj.2.5351.210; WAAGE A, 1990, EUR J IMMUNOL, V20, P2439, DOI 10.1002/eji.1830201112; WEETMAN AP, 1984, CLIN ENDOCRINOL, V21, P163, DOI 10.1111/j.1365-2265.1984.tb03456.x; WELTE K, 1984, BLOOD, V64, P380	31	15	15	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	1994	343	8894					402	404						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905558				2022-12-28	WOS:A1994MW28300015
J	LOUTAN, L; BOVIER, P; ALTHAUS, B; GLUCK, R				LOUTAN, L; BOVIER, P; ALTHAUS, B; GLUCK, R			INACTIVATED VIROSOME HEPATITIS-A VACCINE	LANCET			English	Article							SUPPRESSION	Immunopotentiating reconstituted influenza virosomes (IRIV) are efficient carrier systems for small virion particles such as hepatitis A virus (HAV). We evaluated immunogenicity and tolerability of an IRIV-HAV vaccine and the effectiveness of a booster by immunising 104 healthy HAV seronegative volunteers. A single dose was highly immunogenic, since 98% of volunteers had seroconverted after 2 weeks. Anti-HAV titres remained high, with 100% seroconversion rate 1 year later, when the booster was given. The vaccine was effective, with a 22-fold increase in geometric mean titres 1 month later. No serious adverse reactions were observed.	SWISS SERUM & VACCINE INST, DEPT MED & VIROL, BERN, SWITZERLAND		LOUTAN, L (corresponding author), UNIV GENEVA, HOP CANTONAL, DEPT MED, MED POLICLIN, COMMUNITY MED UNIT, CH-1211 GENEVA 14, SWITZERLAND.							AMBROSCH F, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P98; ANDRE FE, 1990, PROG MED VIROL, V37, P72; ANDRE FE, 1992, VACCINE, V10, pS160, DOI 10.1016/0264-410X(92)90576-6; ETLINGER HM, 1990, SCIENCE, V249, P423, DOI 10.1126/science.1696030; GLUCK R, 1992, J CLIN INVEST, V90, P2491, DOI 10.1172/JCI116141; GLUCK R, 1993, 3RD C INT TRAV MED P; GUPTA RK, 1993, VACCINE, V11, P293, DOI 10.1016/0264-410X(93)90190-9; HERZENBERG LA, 1982, J EXP MED, V155, P1730, DOI 10.1084/jem.155.6.1730; MILLINER DS, 1985, NEW ENGL J MED, V312, P165, DOI 10.1056/NEJM198501173120307; POOVORAWAN Y, IN PRESS J INFECT DI; SCHUTZE MP, 1989, J IMMUNOL, V142, P2635; 1992, LANCET, V339, P1198	12	75	77	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 5	1994	343	8893					322	324		10.1016/S0140-6736(94)91162-2	http://dx.doi.org/10.1016/S0140-6736(94)91162-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905144				2022-12-28	WOS:A1994MU98500008
J	CALNE, R; DAVIES, H				CALNE, R; DAVIES, H			ORGAN GRAFT TOLERANCE - THE LIVER EFFECT	LANCET			English	Editorial Material							TRANSPLANTATION; RECIPIENTS; CHIMERISM; ANTIGENS				CALNE, R (corresponding author), ADDENBROOKES HOSP,DEPT SURG,CAMBRIDGE CB2 2QQ,ENGLAND.							DAVIES HFS, 1989, TRANSPLANTATION, V47, P524; GONWA TA, 1988, TRANSPLANTATION, V46, P690, DOI 10.1097/00007890-198811000-00013; JAMIESON NV, 1991, TRANSPLANT INT, V4, P67, DOI 10.1111/j.1432-2277.1991.tb01950.x; KAMADA N, 1980, TRANSPLANTATION, V29, P429, DOI 10.1097/00007890-198005000-00021; MARGREITER R, 1988, TRANSPLANT P, V20, P522; RASMUSSEN A, 1993, 6TH C EUR SOC ORG TR; SRIWATANAWONGA V, 1993, THESIS U CAMBRIDGE; SRIWATANAWONGSA V, 1993, TRANSPLANT P, V25, P371; STARZL TE, 1993, TRANSPLANTATION, V55, P1272, DOI 10.1097/00007890-199306000-00012; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, 1992, LANCET, V340, P876, DOI 10.1016/0140-6736(92)93286-V; 1969, LANCET, V2, P940	12	75	75	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					67	68		10.1016/S0140-6736(94)90809-5	http://dx.doi.org/10.1016/S0140-6736(94)90809-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903772				2022-12-28	WOS:A1994MQ09200004
J	DEMOL, BA; KALLEWAARD, M; MCLELLAN, RB; VANHERWERDEN, LA; DEFAUW, JJ; VANDERGRAAF, Y				DEMOL, BA; KALLEWAARD, M; MCLELLAN, RB; VANHERWERDEN, LA; DEFAUW, JJ; VANDERGRAAF, Y			SINGLE-LEG STRUT FRACTURES IN EXPLANTED BJORK-SHILEY VALVES	LANCET			English	Article							PROSTHETIC VALVES; MANAGEMENT	A retrospective follow-up study in the Netherlands on the risk of fracture of Bjork-Shiley convexoconcave valves concluded that prophylactic replacement is advisable for certain groups of patients. We have examined valves explanted from twenty-two patients because they met epidemiological criteria for reoperation, with or without the presence of moderate cardiac impairment, or because there were other cardiac complaints not related to the valve. No information was available before explantation to suggest a valve defect. All patients survived their operations. Of the twenty-four valves, seven (29% [95% CI 13-52]) had fracture of one of the legs of the outlet strut (single-leg strut fracture [SLF]). Two other valves had features that suggested fatigue defects. As in the previous study, 70-degrees valves had the highest risk of SLF (five of sixteen, two aortic and three mitral). However, two of eight 60-degrees valves (both aortic) also had SLF. Current hazard calculations and explantation recommendations may need to be revised. Since several of the defective valves were welded by the same person, knowledge of manufacturing details may help in estimation of fracture risk for an individual patient.	DELFT UNIV TECHNOL,SAFETY SCI GRP,DELFT,NETHERLANDS; UNIV UTRECHT,DEPT EPIDEMIOL,UTRECHT,NETHERLANDS; CARDIOPULM SURG CTR,AMSTERDAM,NETHERLANDS; ST ANTONIUS HOSP,DEPT CARDIOPULM SURG,NIEUWEGEIN,NETHERLANDS; RICE UNIV,DEPT MECH ENGN & MAT SCI,HOUSTON,TX 77251; ERASMUS UNIV ROTTERDAM,HOSP DIJKZIGT,DEPT CARDIOPULM SURG,ROTTERDAM,NETHERLANDS	Delft University of Technology; Utrecht University; St. Antonius Hospital Utrecht; Rice University; Erasmus University Rotterdam; Erasmus MC				de Mol, Bastian/0000-0001-6888-9430; van Herwerden, Lex A./0000-0003-1087-1275				BIRKMEYER JD, 1992, LANCET, V340, P520, DOI 10.1016/0140-6736(92)91717-M; BJORK VO, 1985, SCAND J THORAC CARD, V19, P1, DOI 10.3109/14017438509102814; Blackstone E H, 1992, J Heart Valve Dis, V1, P3; ERICSSON A, 1992, EUR J CARDIO-THORAC, V6, P339, DOI 10.1016/1010-7940(92)90169-X; HEDGER P, 1993, IMPORTANT UPDATED IN; HEDGER P, 1992, IMPORTANT UPDATED IN; LINDBLOM D, 1992, BRIT HEART J, V68, P249; RITCHIE RO, 1986, J BIOMECH ENG-T ASME, V108, P153, DOI 10.1115/1.3138595; SACKS SH, 1986, THORAX, V41, P142, DOI 10.1136/thx.41.2.142; TREASURE T, 1991, BRIT HEART J, V66, P333; VANDERGRAAF Y, 1992, LANCET, V339, P257, DOI 10.1016/0140-6736(92)91328-6; VANDERMEULEN JHP, 1993, CIRCULATION, V88, P156, DOI 10.1161/01.CIR.88.1.156; VANSWIETEN HA, 1990, SURG HEART VALVE DIS, P616; WOODYARD CH, 1991, LOS ANGELES TIM 0428	14	34	34	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					9	12		10.1016/S0140-6736(94)90874-5	http://dx.doi.org/10.1016/S0140-6736(94)90874-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905086				2022-12-28	WOS:A1994MN93700010
J	BOYER, PJ; DILLON, M; NAVAIE, M; DEVEIKIS, A; KELLER, M; OROURKE, S; BRYSON, YJ				BOYER, PJ; DILLON, M; NAVAIE, M; DEVEIKIS, A; KELLER, M; OROURKE, S; BRYSON, YJ			FACTORS PREDICTIVE OF MATERNAL-FETAL TRANSMISSION OF HIV-1 - PRELIMINARY-ANALYSIS OF ZIDOVUDINE GIVEN DURING PREGNANCY AND/OR DELIVERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; INFECTION; TYPE-1; WOMEN; INFANTS; CHILDREN; ANTIGEN; RISK; MORTALITY	Objective.-To assess maternal risk factors potentially influencing vertical transmission of human immunodeficiency virus, type 1 (HIV-1), including maternal CD4 cell count; presence of immune complex dissociated (ICD) p24 antigen; maternal zidovudine therapy during pregnancy and/or delivery, complications of pregnancy, such as preterm labor and birth; and obstetric events during labor and delivery, such as duration of labor, mode of delivery, chorioamnionitis, and maternal blood exposure. Design and Setting.-A nonrandomized prospective cohort study at a university medical center and two general hospital affiliates. Patients.-Sixty-three HIV-1-seropositive pregnant women and their 68 infants. Intervention.-Twenty-six mothers received zidovudine therapy during pregnancy and/or during labor and delivery. Main Outcome Measure.-HIV-1 infection status of the infant. Results.-Thirteen of the 68 infants were vertically infected with HIV-1. Mothers with events involving fetal exposure to maternal blood were more likely to transmit infection (four [31%] of 13 vs three [5%] of 55, P=.02), as were women with plasma ICD p24 antigenemia at delivery (six [67%] of nine vs 11 [25%] of 44, P=.02). Zidovudine treatment was associated with a significant reduction in vertical transmission (one [4%] of 26 mothers treated with zidovudine vs 12 [29%] of 42 mothers not treated with zidovudine, P=.01), There was a significant protective effect of zidovudine treatment despite lower mean absolute CD4 cell counts (0.37x10(9)/L) in the 24 zidovudine-treated nontransmitters and in the nine non-zidovudine-treated transmitters (0.37x10(9)/L) than in the 24 non-zidovudine-treated nontransmitters (0.62x10(9)/L) (P=.008). Conclusion.-Maternal-fetal HIV-1 transmission is multifactorial, with increased risk associated both with ICD p24 antigenemia at term and with intrapartum events that increase fetal exposure to maternal blood. Zidovudine therapy given during pregnancy and/or labor and delivery was associated with a significant reduction in vertical transmission. These data suggest that the beneficial effects of zidovudine therapy in reducing maternal-fetal HIV-1 transmission recently found in protocol 076 of the placebo-controlled Acquired Immunodeficiency Syndrome Clinical Trials Group Study may extend to women with lower CD4 cell counts and suggest that prolonged treatment of infants may not be necessary.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT OBSTET & GYNECOL,LOS ANGELES,CA 90024; LONG BEACH MEM HOSP MED CTR,DEPT PEDIAT,LOS ANGELES,CA; UNIV CALIF LOS ANGELES,HARBOR MED CTR,DEPT PEDIAT,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032440, U01AI027550, R55AI032440] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 32440, AI 27550] Funding Source: Medline; NICHD NIH HHS [HD 26621] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BLANCHE S, 1994, NEW ENGL J MED, V330, P308, DOI 10.1056/NEJM199402033300502; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BORKOWSKY W, 1992, J INFECT DIS, V166, P616, DOI 10.1093/infdis/166.3.616; BRYSON Y, 1991, 7 INT C AIDS FLOR; BRYSON Y, 1993, 9TH INT C AIDS BERL; BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718; BURGARD M, 1992, NEW ENGL J MED, V327, P1192, DOI 10.1056/NEJM199210223271702; CHIN J, 1990, LANCET, V336, P221, DOI 10.1016/0140-6736(90)91743-T; DEVASH Y, 1990, P NATL ACAD SCI USA, V87, P3445, DOI 10.1073/pnas.87.9.3445; DEVASH Y, 1991, P NATL ACAD SCI USA, V88, P1084, DOI 10.1073/pnas.88.3.1084a; DICKOVER R, 1993, J CELL BIOCHEM, V1, P44; DULIEGE A, 1993, 9 INT C AIDS BERL; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; EHRNST A, 1991, LANCET, V338, P203, DOI 10.1016/0140-6736(91)90347-R; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; GOEDERT JJ, 1989, LANCET, V2, P1351; HALSEY NA, 1992, J ACQ IMMUN DEF SYND, V5, P153; HALSEY NA, 1990, JAMA-J AM MED ASSOC, V264, P2088, DOI 10.1001/jama.264.16.2088; HENLIN Y, 1993, J ACQ IMMUN DEF SYND, V6, P72; HUTTO C, 1991, J PEDIATR-US, V118, P347, DOI 10.1016/S0022-3476(05)82145-6; KRIVINE A, 1990, J PEDIATR-US, V116, P372, DOI 10.1016/S0022-3476(05)82823-9; KRIVINE A, 1992, LANCET, V339, P1187, DOI 10.1016/0140-6736(92)91131-Q; LEDERMAN SA, 1992, PEDIATRICS, V89, P290; LUZURIAGA K, 1993, J INFECT DIS, V167, P1008, DOI 10.1093/infdis/167.5.1008; MASQUELIER B, 1993, NEW ENGL J MED, V329, P1123; MAYERS MM, 1991, PEDIATRICS, V88, P1248; MAYERS MM, 1992, PEDIATRICS, V89, P228; MILES SA, 1993, NEW ENGL J MED, V328, P297, DOI 10.1056/NEJM199302043280501; MUNDY DC, 1987, LANCET, V2, P459; OSULLIVAN MJ, 1993, AM J OBSTET GYNECOL, V168, P1510, DOI 10.1016/S0002-9378(11)90791-1; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SPERLING RS, 1992, NEW ENGL J MED, V326, P857, DOI 10.1056/NEJM199203263261303; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; STRATTON P, 1992, 32ND INT C ANT AG CH; THOMAS P, 1992, 8 INT C AIDS AMST; 1993, MMWR-MORBID MORTAL W, V42, P481; 1993, MMWR HIV AIDS SURVEI, V5, P3; 1992, LANCET, V339, P1007; 1994, MMWR-MORBID MORTAL W, V43, P285	40	153	156	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 22	1994	271	24					1925	1930		10.1001/jama.271.24.1925	http://dx.doi.org/10.1001/jama.271.24.1925			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR598	7911164				2022-12-28	WOS:A1994NR59800029
J	FRANKLYN, JA				FRANKLYN, JA			DRUG-THERAPY - THE MANAGEMENT OF HYPERTHYROIDISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LONG-TERM FOLLOW; DOSE I-131 THERAPY; RADIOACTIVE IODINE THERAPY; ANTI-THYROID DRUG; GRAVES-DISEASE; ANTITHYROID DRUGS; RADIOIODINE THERAPY; HYPER-THYROIDISM; INDUCED AGRANULOCYTOSIS; THYROXINE REPLACEMENT				FRANKLYN, JA (corresponding author), UNIV BIRMINGHAM, QUEEN ELIZABETH HOSP, DEPT MED, BIRMINGHAM B15 2TT, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLANNIC H, 1990, J CLIN ENDOCR METAB, V70, P675, DOI 10.1210/jcem-70-3-675; AMINO N, 1978, CLIN EXP IMMUNOL, V31, P30; BARNES HV, 1972, J CLIN ENDOCR METAB, V35, P250, DOI 10.1210/jcem-35-2-250; BLICHERTTOFT M, 1977, ACTA CHIR SCAND, V143, P221; COOPER DS, 1983, ANN INTERN MED, V98, P26, DOI 10.7326/0003-4819-98-1-26; DAHLBERG PA, 1981, CLIN ENDOCRINOL, V14, P555, DOI 10.1111/j.1365-2265.1981.tb02965.x; DAVIES PH, 1992, J CLIN ENDOCR METAB, V74, P1189, DOI 10.1210/jc.74.5.1189; DAVIES PH, 1991, EUR J CLIN PHARMACOL, V40, P439, DOI 10.1007/BF00315221; DOBYNS BM, 1974, J CLIN ENDOCR METAB, V38, P976, DOI 10.1210/jcem-38-6-976; EVERED D, 1975, BRIT MED J, V1, P25, DOI 10.1136/bmj.1.5948.25; FEEK CM, 1980, NEW ENGL J MED, V302, P883, DOI 10.1056/NEJM198004173021602; FRANKLYN JA, 1988, CLIN CHEM, V34, P991; FRANKLYN JA, 1991, CLIN ENDOCRINOL, V34, P71, DOI 10.1111/j.1365-2265.1991.tb01738.x; FRANKLYN JA, 1990, BRIT MED J, V300, P693, DOI 10.1136/bmj.300.6726.693; FUI SCNT, 1979, CLIN ENDOCRINOL, V10, P69; GOLDMAN MB, 1988, AM J EPIDEMIOL, V127, P969, DOI 10.1093/oxfordjournals.aje.a114900; GOLDSTEIN R, 1983, NEW ENGL J MED, V309, P1473, DOI 10.1056/NEJM198312153092401; GOOLDEN AWG, 1986, CLIN ENDOCRINOL, V24, P217, DOI 10.1111/j.1365-2265.1986.tb00765.x; GREER MA, 1977, NEW ENGL J MED, V297, P174, DOI 10.1056/NEJM197707282970401; HALLP, 1992, LANCET, V340, P1; HAMBURGER JI, 1975, AM J MED, V58, P740, DOI 10.1016/0002-9343(75)90630-0; HARDISTY CA, 1990, J ROY COLL PHYS LOND, V24, P36; HASHIZUME K, 1991, NEW ENGL J MED, V324, P947, DOI 10.1056/NEJM199104043241403; HEDLEY AJ, 1989, CLIN ENDOCRINOL, V31, P209, DOI 10.1111/j.1365-2265.1989.tb01244.x; HENNEMANN G, 1986, LANCET, V1, P1369; HOLM LE, 1991, JNCI-J NATL CANCER I, V83, P1072, DOI 10.1093/jnci/83.15.1072; HOLM LE, 1982, J NUCL MED, V23, P103; KAMPMANN JP, 1980, LANCET, V1, P736, DOI 10.1016/S0140-6736(80)91233-7; KAMPMANN JP, 1981, CLIN PHARMACOKINET, V6, P401, DOI 10.2165/00003088-198106060-00001; KENDALLTAYLOR P, 1984, BRIT MED J, V289, P361, DOI 10.1136/bmj.289.6441.361; LEAROYD DL, 1992, THYROID, V2, P73, DOI 10.1089/thy.1992.2.73; LEESE GP, 1992, CLIN ENDOCRINOL, V37, P500, DOI 10.1111/j.1365-2265.1992.tb01480.x; LIAW YF, 1993, ANN INTERN MED, V118, P424, DOI 10.7326/0003-4819-118-6-199303150-00005; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; LIPPE BM, 1987, J CLIN ENDOCR METAB, V64, P1241, DOI 10.1210/jcem-64-6-1241; LOWDELL CP, 1985, J ROY SOC MED, V78, P197, DOI 10.1177/014107688507800305; MACFARLANE IA, 1979, BRIT MED J, V2, P421, DOI 10.1136/bmj.2.6187.421; MASHIO Y, 1988, ACTA ENDOCRINOL-COP, V119, P139, DOI 10.1530/acta.0.1190139; MCDEVITT DG, 1978, BRIT J CLIN PHARMACO, V6, P233, DOI 10.1111/j.1365-2125.1978.tb04590.x; MOLNAR GD, 1965, MAYO CLIN PROC, V40, P665; MOMOTANI N, 1989, CLIN ENDOCRINOL, V31, P591, DOI 10.1111/j.1365-2265.1989.tb01283.x; MOMOTANI N, 1986, NEW ENGL J MED, V315, P24, DOI 10.1056/NEJM198607033150104; MURCHISON LE, 1979, BRIT J CLIN PHARMACO, V8, P581, DOI 10.1111/j.1365-2125.1979.tb01048.x; NICOLOFF JT, 1990, J CLIN ENDOCR METAB, V71, P553, DOI 10.1210/jcem-71-3-553; NORDYKE RA, 1991, J NUCL MED, V32, P411; OKAMURA K, 1987, J CLIN ENDOCR METAB, V65, P719, DOI 10.1210/jcem-65-4-719; OTHMAN S, 1990, CLIN ENDOCRINOL, V32, P559, DOI 10.1111/j.1365-2265.1990.tb00898.x; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; PEDEN NR, 1982, BRIT J CLIN PHARMACO, V13, P835, DOI 10.1111/j.1365-2125.1982.tb01875.x; PETERSEN P, 1988, STROKE, V19, P15, DOI 10.1161/01.STR.19.1.15; PHILIPPOU G, 1992, CLIN ENDOCRINOL, V36, P573, DOI 10.1111/j.1365-2265.1992.tb02267.x; REINWEIN D, 1988, J ENDOCRINOL INVEST, V11, P193, DOI 10.1007/BF03350134; REINWEIN D, 1993, J CLIN ENDOCR METAB, V76, P1516; ROBERTSON JS, 1976, J NUCL MED, V17, P826; ROSS DS, 1990, J CLIN ENDOCR METAB, V71, P764, DOI 10.1210/jcem-71-3-764; ROSS DS, 1984, ANN INTERN MED, V101, P488, DOI 10.7326/0003-4819-101-4-488; ROSS DS, 1987, AM J MED, V82, P1167, DOI 10.1016/0002-9343(87)90219-1; ROTI E, 1988, CLIN ENDOCRINOL, V28, P305, DOI 10.1111/j.1365-2265.1988.tb01217.x; ROUDEBUSH CP, 1977, ANN INTERN MED, V87, P441, DOI 10.7326/0003-4819-87-4-441; RUIZ M, 1982, NEW ENGL J MED, V306, P635, DOI 10.1056/NEJM198203183061103; SAKATA S, 1985, ANN INTERN MED, V103, P579, DOI 10.7326/0003-4819-103-4-579; SARKAR SD, 1976, J NUCL MED, V17, P460; SAWIN CT, 1989, JAMA-J AM MED ASSOC, V261, P2653, DOI 10.1001/jama.261.18.2653; SAWYERS JL, 1972, ANN SURG, V175, P939, DOI 10.1097/00000658-197206010-00014; SCHLEUSENER H, 1989, ACTA ENDOCRINOL-COP, V121, P304, DOI 10.1530/acta.0.1210304; SCHLEUSENER H, 1989, ACTA ENDOCRINOL-COP, V120, P689, DOI 10.1530/acta.0.1200689; SCOTT GR, 1984, BRIT MED J, V289, P399, DOI 10.1136/bmj.289.6442.399; SPENCER RP, 1983, CLIN NUCL MED, V8, P216, DOI 10.1097/00003072-198305000-00007; SRIDAMA V, 1984, NEW ENGL J MED, V311, P426, DOI 10.1056/NEJM198408163110702; SRIDAMA V, 1989, AM J MED, V87, P70, DOI 10.1016/S0002-9343(89)80485-1; STOFFER SS, 1976, J NUCL MED, V17, P146; SUGRUE D, 1980, Q J MED, V49, P51; SURKS MI, 1990, JAMA-J AM MED ASSOC, V263, P1529, DOI 10.1001/jama.263.11.1529; TAJIRI J, 1990, ARCH INTERN MED, V150, P621, DOI 10.1001/archinte.150.3.621; TALLSTEDT L, 1992, NEW ENGL J MED, V326, P1733, DOI 10.1056/NEJM199206253262603; TAMAI H, 1980, ANN INTERN MED, V92, P488, DOI 10.7326/0003-4819-92-4-488; TAMAI H, 1989, CLIN ENDOCRINOL, V30, P525, DOI 10.1111/j.1365-2265.1989.tb01424.x; TENG CS, 1980, J CLIN ENDOCR METAB, V50, P144, DOI 10.1210/jcem-50-1-144; TOFT AD, 1982, SCOT MED J, V27, P216, DOI 10.1177/003693308202700304; TOFT AD, 1978, NEW ENGL J MED, V298, P643, DOI 10.1056/NEJM197803232981202; TOTTERMAN TH, 1987, NEW ENGL J MED, V316, P15, DOI 10.1056/NEJM198701013160104; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; TURNER J, 1985, EUR J NUCL MED, V11, P191, DOI 10.1007/BF00279066; VELKENIERS B, 1988, LANCET, V1, P1127; Wartofsky L, 1991, Thyroid, V1, P129, DOI 10.1089/thy.1991.1.129; WATSON AB, 1988, CLIN ENDOCRINOL, V28, P487, DOI 10.1111/j.1365-2265.1988.tb03683.x; WEETMAN AP, 1986, Q J MED, V59, P409; WILSON R, 1986, CLIN ENDOCRINOL, V25, P151, DOI 10.1111/j.1365-2265.1986.tb01676.x; WISE PH, 1973, BRIT MED J, V4, P143, DOI 10.1136/bmj.4.5885.143; YOUNG ET, 1988, Q J MED, V66, P175	90	213	231	1	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 16	1994	330	24					1731	1738						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR109	7910662				2022-12-28	WOS:A1994NR10900007
J	NIGHTINGALE, SL				NIGHTINGALE, SL			TREATMENT IND FOR ADVANCED NON-SMALL-CELL LUNG-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	1994	271	23					1818	1818						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP959	7910857				2022-12-28	WOS:A1994NP95900007
J	BERKOVITCH, M; LAXER, RM; INMAN, R; KOREN, G; PRITZKER, KPH; FRITZLER, MJ; OLIVIERI, NF				BERKOVITCH, M; LAXER, RM; INMAN, R; KOREN, G; PRITZKER, KPH; FRITZLER, MJ; OLIVIERI, NF			ARTHROPATHY IN THALASSEMIA PATIENTS RECEIVING DEFERIPRONE	LANCET			English	Note							IRON; L1	The iron chelator deferiprone (L1) reduces tissue iron stores in iron-loaded patients. Three of sixteen patients treated with deferiprone developed joint pain and swelling without evidence of systemic lupus erythematosus (SLE). Articular cartilage, synovial hypertrophy and iron deposition, and synovial lining cell proliferation, with no inflammatory or allergic reaction, were observed on synovial exploration and biopsy. Symptoms resolved partly or completely during continued drug administration. We hypothesise that deferiprone-induced shifts of iron to synovium resulted in tissue damage, accelerated by free-radical formation during incomplete complexation of iron and this bidentate chelator. This deferiprone-associated symptom complex is not associated with drug-induced SLE, and does not progress in severity during continued therapy.	HOSP SICK CHILDREN,DEPT PEDIAT,HAEMOGLOBINOPATHY PROGRAM,TORONTO M5G 1X8,ON,CANADA; UNIV TORONTO,TORONTO HOSP,DEPT MED,TORONTO,ON,CANADA; UNIV TORONTO,MT SINAI HOSP,DEPT PATHOL,TORONTO M5G 1X5,ON,CANADA; UNIV ALBERTA,MCCALG CTR JOINT INJURY & ARTHRITIS RES,CALGARY,AB,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Alberta			Olivieri, Nancy/AAI-2250-2020	Inman, Robert/0000-0002-4750-1422				AGARWAL MB, 1992, BRIT J HAEMATOL, V82, P460, DOI 10.1111/j.1365-2141.1992.tb06445.x; ALREFAIE FN, 1992, BLOOD, V80, P592; BERDOUKAS V, 1991, LANCET, V337, P672, DOI 10.1016/0140-6736(91)92483-I; BERKOVITCH M, 1992, BLOOD S1, V80, pA7; BLAKE DR, 1981, LANCET, V2, P1142; BRITTENHAM GM, 1992, BLOOD, V80, P569; GRATWICK GM, 1978, ANN INTERN MED, V88, P494, DOI 10.7326/0003-4819-88-4-494; HERSHKO C, 1991, BLOOD, V77, P2049; MAGARO M, 1990, ANN RHEUM DIS, V49, P268, DOI 10.1136/ard.49.4.268-b; MEHTA J, 1991, LANCET, V337, P298, DOI 10.1016/0140-6736(91)90906-6	10	59	61	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1471	1472		10.1016/S0140-6736(94)92585-2	http://dx.doi.org/10.1016/S0140-6736(94)92585-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911181				2022-12-28	WOS:A1994NQ41500012
J	NITTI, VW				NITTI, VW			INTRAVESICAL CAPSAICIN FOR TREATMENT OF NEUROGENIC BLADDER	LANCET			English	Editorial Material							SPINAL-CORD INJURY; MICTURITION; REFLEX				NITTI, VW (corresponding author), SUNY HLTH SCI CTR,BROOKLYN,NY 11203, USA.			Nitti, Victor/0000-0002-1390-7053				FOWLER CJ, 1994, J NEUROL NEUROSUR PS, V57, P169, DOI 10.1136/jnnp.57.2.169; KOLDEWIJN EL, 1994, J UROLOGY, V151, P955, DOI 10.1016/S0022-5347(17)35133-9; MAGGI CA, 1989, J UROLOGY, V142, P150, DOI 10.1016/S0022-5347(17)38701-3; MAGGI CA, 1989, NEUROSCIENCE, V31, P745, DOI 10.1016/0306-4522(89)90438-7; MCGUIRE EJ, 1991, NEUROUROL URODYNAM, V10, P223, DOI 10.1002/nau.1930100302; MCGUIRE EJ, 1994, J UROLOGY, V151, P965, DOI 10.1016/S0022-5347(17)35135-2; MCGUIRE EJ, 1983, J UROLOGY, V129, P775, DOI 10.1016/S0022-5347(17)52357-5; SIRLS LT, 1994, J UROLOGY, V151, P946, DOI 10.1016/S0022-5347(17)35131-5	8	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1448	1448		10.1016/S0140-6736(94)92578-X	http://dx.doi.org/10.1016/S0140-6736(94)92578-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911174				2022-12-28	WOS:A1994NQ41500005
J	HOWAT, WJ; MOORE, IE; JUDD, M; ROCHE, WR				HOWAT, WJ; MOORE, IE; JUDD, M; ROCHE, WR			PULMONARY IMMUNOPATHOLOGY OF SUDDEN-INFANT-DEATH-SYNDROME	LANCET			English	Article							MONOCLONAL-ANTIBODY; T-CELLS; ASSOCIATION; TEMPERATURE; RECOGNIZES; TISSUES; ANTIGEN	Sudden infant death syndrome (SIDS) is the most common cause of postneonatal mortality in the UK. Pathological investigations have shown evidence suggestive of respiratory obstruction with subsequent hypoxia leading to death. We examined 48 infants who died of SIDS and 30 who died of other, non-pulmonary, causes and identified pulmonary eosinophil and neutrophil leucocytes, mast cells, and T and B lymphocytes by immunocytochemistry. Positively stained cells were counted in the parenchyma and around the bronchi without knowledge of the tissue source. The results showed three times more eosinophils in the lungs of infants who died of SIDS (27.61 vs 7.91 [99% CI 1.76-5.87] cells/mm(2) for parenchyma) accompanied by increased T lymphocytes and B lymphocytes. There were more peribronchial mast cells in the SIDS group (22.1 vs 14.7 [1.03-2.10] cells/mm(2)) and insignificant differences in neutrophils and parenchymal mast cells. There were significant associations between eosinophil, B lymphocyte, and T lymphocyte numbers. These findings provide evidence for an abnormal T lymphocyte-mediated pulmonary inflammatory response In SIDS. Products of eosinophil degranulation can cause epithelial damage and pulmonary oedema, which could cause the respiratory obstruction and hypoxia associated with SIDS.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,DEPT PATHOL,SOUTHAMPTON S09 4XY,ENGLAND	University of Southampton								BECKWITH JB, 1970, SUDDEN INFANT DEATH, P83; BERRY PJ, 1992, J CLIN PATHOL S, V45, pS11; BONSER RSA, 1978, INT J EPIDEMIOL, V7, P335, DOI 10.1093/ije/7.4.335; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CAMPBELL MJ, 1989, MED J AUSTRALIA, V151, P365, DOI 10.5694/j.1326-5377.1989.tb101216.x; CLARK JW, 1979, J PEDIATR-US, V95, P85, DOI 10.1016/S0022-3476(79)80094-3; COOMBS RRA, 1990, CLIN EXP ALLERGY, V20, P359, DOI 10.1111/j.1365-2222.1990.tb02794.x; COSTA JJ, 1993, J CLIN INVEST, V91, P2673, DOI 10.1172/JCI116506; CUNNINGHAM AS, 1975, J PEDIATR-US, V87, P426, DOI 10.1016/S0022-3476(75)80650-0; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; HILTON JMN, 1989, PAEDIAT FORENSIC MED, P156; KAPSENBERG ML, 1992, CURR OPIN IMMUNOL, V4, P788, DOI 10.1016/0952-7915(92)90063-K; MASON DY, 1990, AM J PATHOL, V136, P1215; MASON DY, 1989, J CLIN PATHOL, V42, P1194, DOI 10.1136/jcp.42.11.1194; MIRCHANDANI HG, 1984, J FORENSIC SCI, V29, P425; NAEYE RL, 1976, AM J CLIN PATHOL, V66, P526, DOI 10.1093/ajcp/66.3.526; NELSON EAS, 1988, NEW ZEAL MED J, V101, P443; NORTON AJ, 1986, J CLIN PATHOL, V39, P399, DOI 10.1136/jcp.39.4.399; OPENSHAW PJM, 1992, INT IMMUNOL, V4, P493, DOI 10.1093/intimm/4.4.493; PULFORD KAF, 1988, J CLIN PATHOL, V41, P853, DOI 10.1136/jcp.41.8.853; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; ROWEN JL, 1991, AM REV RESPIR DIS, V142, P215; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; STEWART S, 1985, J PATHOL, V145, P53, DOI 10.1002/path.1711450105; STRIMER R, 1969, J AMER MED ASSOC, V209, P1493, DOI 10.1001/jama.209.10.1493; TAI PC, 1984, NATURE, V309, P182, DOI 10.1038/309182a0; UREN EC, 1980, MED J AUSTRALIA, V1, P417, DOI 10.5694/j.1326-5377.1980.tb134996.x; WALLS AF, 1990, J PATHOL, V162, P119, DOI 10.1002/path.1711620204; WILLIAMS AL, 1984, BRIT MED J, V288, P1491, DOI 10.1136/bmj.288.6429.1491; WOOD GS, 1981, J HISTOCHEM CYTOCHEM, V29, P1196, DOI 10.1177/29.10.7028859; 1992, OFFICE POPULATIO DH6	31	50	52	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1390	1392		10.1016/S0140-6736(94)92523-2	http://dx.doi.org/10.1016/S0140-6736(94)92523-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910883				2022-12-28	WOS:A1994NP95500009
J	LOUSSERTAJAKA, I; BRUNVEZINET, F; SIMON, F; LY, TD; CHAIX, ML; SARAGOSTI, S; COUROUCE, AM; INGRAND, D				LOUSSERTAJAKA, I; BRUNVEZINET, F; SIMON, F; LY, TD; CHAIX, ML; SARAGOSTI, S; COUROUCE, AM; INGRAND, D			HIV-1/HIV-2 SERONEGATIVITY IN HIV-1 SUBTYPE-O INFECTED PATIENTS	LANCET			English	Note								Nine patients with atypical HIV-1 western blot profiles were diagnosed as having HIV-1 subtype O infection. All the patients were living in France; eight originated from Cameroon and one from France. Lymphocyte DNA amplification by the polymerase chain reaction was only positive when HIV-1 subtype O specific primers were used. Preliminary sequence analysis of amplified products and serological reactivity against a specific subtype O synthetic env peptide confirmed HIV-1 subtype O infection. HIV-1/HIV-2 enzyme-linked immunosorbent assays, especially those based on env peptides or on the sandwich format, can be negative in HIV-1 subtype O infection.	BICHAT CLAUDE BERNARD HOSP,DEPT VIROL,VIROL LAB,F-75877 PARIS 18,FRANCE; ALFRED FOURNIER INST,PARIS,FRANCE; COCHIN HOSP,INSERM,U363,ICGM,PARIS,FRANCE; NATL BLOOD TRANSFUS INST,PARIS,FRANCE; ROBERT DEBRE HOSP,DEPT MICROBIOL,REIMS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; CHU de Reims								AGUT H, 1992, LANCET, V340, P681, DOI 10.1016/0140-6736(92)92226-6; GURTLER LG, 1994, J VIROL, V68, P1581; MYERS G, 1993, HUMAN RETROVIRUSES A; NKENGASONG JN, 1993, AIDS, V7, P1536, DOI 10.1097/00002030-199311000-00026; VANDENHAESEVELDE M, 1994, J VIROL, V68, P1586, DOI 10.1128/JVI.68.3.1586-1596.1994	5	210	214	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1393	1394		10.1016/S0140-6736(94)92524-0	http://dx.doi.org/10.1016/S0140-6736(94)92524-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910884				2022-12-28	WOS:A1994NP95500010
J	TUOMILEHTO, J; ZIMMET, P; MACKAY, IR; KOSKELA, P; VIDGREN, G; TOIVANEN, L; TUOMILEHTOWOLF, E; KOHTAMAKI, K; STENGARD, J; ROWLEY, MJ				TUOMILEHTO, J; ZIMMET, P; MACKAY, IR; KOSKELA, P; VIDGREN, G; TOIVANEN, L; TUOMILEHTOWOLF, E; KOHTAMAKI, K; STENGARD, J; ROWLEY, MJ			ANTIBODIES TO GLUTAMIC-ACID DECARBOXYLASE AS PREDICTORS OF INSULIN-DEPENDENT DIABETES-MELLITUS BEFORE CLINICAL ONSET OF DISEASE	LANCET			English	Article							ISLET CELL ANTIBODIES; AUTOANTIBODIES; CHILDREN; MARKERS; GABA; MICE; GAD	We have done a study designed to ascertain the effectiveness of measuring antibodies to glutamic acid decarboxylase (anti-GAD) in predicting insulin-dependent diabetes mellitus (IDDM). Anti-GAD was measured-in prediabetic sera from 151 women aged 20-39 years with newly diagnosed diabetes mellitus who had been identified through a nationwide diabetes register. Multiple serum samples had been collected from these women up to 10 years before the clinical onset of diabetes during their earlier pregnancies. Anti-GAD was measured with a radioimmunoprecipitation assay. Anti-GAD was detected in 82% of 28 women with IDDM, in 36% of 11 women with non-insulin-dependent diabetes mellitus, and in 5% of 112 women with gestational diabetes mellitus. In a random sample of 100 non-diabetic young Finnish women, none had anti-GAD. The sensitivity of the anti-GAD assay for predicting IDDM was 82.1% and the specificity was 100%. The longest time of anti-GAD positivity before clinical onset of IDDM was 10 years. Once positive, anti-GAD levers remained stable and no patients became negative after a positive test during the prediabetic period. Anti-GAD is a valuable early predictive marker and is associated with a very high risk for development of IDDM.	INT DIABET INST,CAULFIELD,VIC,AUSTRALIA; MONASH UNIV,CTR MOLEC BIOL & MED,CLAYTON,VIC 3168,AUSTRALIA; NATL PUBL HLTH INST,OULU,FINLAND	Monash University; Finland National Institute for Health & Welfare	TUOMILEHTO, J (corresponding author), NATL PUBL HLTH INST,DEPT EPIDEMIOL & HLTH PROMOT,MANNERHELMINTIE 166,SF-00300 HELSINKI,FINLAND.		Mackay, Ian R/A-7228-2010; Zimmet, Paul/O-8486-2019	Zimmet, Paul/0000-0003-0627-0776				ATKINSON MA, 1990, LANCET, V335, P1357, DOI 10.1016/0140-6736(90)91241-2; BAEKKESKOV S, 1982, NATURE, V298, P167, DOI 10.1038/298167a0; BAEKKESKOV S, 1987, J CLIN INVEST, V79, P926, DOI 10.1172/JCI112903; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BINGLEY PJ, 1993, DIABETES CARE, V16, P45, DOI 10.2337/diacare.16.1.45; BLOHME G, 1993, DIABETOLOGIA, V35, P56; BONNEVIENIELSEN V, 1981, DIABETES, V30, P424, DOI 10.2337/diabetes.30.5.424; CATALANO PM, 1990, DIABETES CARE, V13, P478, DOI 10.2337/diacare.13.5.478; CHEN QY, 1993, PEDIATR RES, V34, P785, DOI 10.1203/00006450-199312000-00018; CHRISTIE M, 1988, DIABETOLOGIA, V31, P597, DOI 10.1007/BF00264766; HAGOPIAN WA, 1993, J CLIN INVEST, V91, P368, DOI 10.1172/JCI116195; Harris M.I, 1992, INT TEXTB DIABETES M, P3; KAUFMAN DL, 1992, J CLIN INVEST, V89, P283, DOI 10.1172/JCI115573; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; LANDINOLSSON M, 1993, DIABETOLOGIA, V36, pA99; LERNMARK A, 1978, NEW ENGL J MED, V299, P375, DOI 10.1056/NEJM197808242990802; PALMER JP, 1983, SCIENCE, V222, P1337, DOI 10.1126/science.6362005; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; ROWLEY MJ, 1992, DIABETES, V41, P548, DOI 10.2337/diabetes.41.4.548; SCOTT RS, 1991, DIABETIC MED, V8, P1; SERJEANTSON SW, 1993, HUM IMMUNOL, V38, P97, DOI 10.1016/0198-8859(93)90525-6; SERJEANTSON SW, 1992, DIABETOLOGIA, V35, P996, DOI 10.1007/BF00401432; THIVOLET C, 1992, DIABETOLOGIA, V35, P570, DOI 10.1007/BF00400486; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; TUOMI T, 1993, DIABETES, V42, P359, DOI 10.2337/diabetes.42.2.359; TUOMILEHTOWOLF E, 1993, BRIT MED J, V307, P155, DOI 10.1136/bmj.307.6897.155; TUOMILEHTOWOLF E, 1991, ANN MED, V23, P481, DOI 10.3109/07853899109150507; WILKIN T, 1985, LANCET, V1, P480; ZIMMET PZ, 1994, DIABETIC MED, V11, P299, DOI 10.1111/j.1464-5491.1994.tb00275.x	29	161	164	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1383	1385		10.1016/S0140-6736(94)92521-6	http://dx.doi.org/10.1016/S0140-6736(94)92521-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910881				2022-12-28	WOS:A1994NP95500007
J	BOBBIO, M; DEMICHELIS, B; GIUSTETTO, G				BOBBIO, M; DEMICHELIS, B; GIUSTETTO, G			COMPLETENESS OF REPORTING TRIAL RESULTS - EFFECT ON PHYSICIANS WILLINGNESS TO PRESCRIBE	LANCET			English	Article							THERAPY; DECISIONS; REDUCTION; MORTALITY; DISEASE; CHOICES	Clinical trials may lead to conflicting results. We studied how different ways of reporting results affected physicians' recommendations. A questionnaire distributed to 148 general practitioners presented results of a clinical trial where a reduction of cardiac events and an increase of mortality was reported. Results were shown in four different ways-relative risk reduction, absolute risk reduction, percentages of event-free patients, number needing to be treated to prevent an event-as if they derived from different trials. A fifth presentation was the reduced rate of cardiac events along with the increased rate of mortality. Physicians were asked to estimate how much they would be willing to prescribe each drug. The mean agreement of physicians' decisions was 77 (28)% for relative risk reduction, 24 (28)% for absolute risk reduction, 37 (37)% for different percentages event-free patients, 34 (34)% for number need to treat, and 23 (28)% for events reduction and mortality for increase (p < 0.001 relative risk vs others). The method of reporting trial results and the completeness of information in the case of controversial results affects physicians willingness to prescribe.	SOC ITALIANA MED GEN,TURIN,ITALY		BOBBIO, M (corresponding author), UNIV TURIN,OSPED MOLINETTE,DIV CARDIOL,CORSO AM DOGLIOTTI 14,I-10126 TURIN,ITALY.							Bobbio M, 1992, Int J Cardiol, V37, P125, DOI 10.1016/0167-5273(92)90145-S; BRETT AS, 1989, NEW ENGL J MED, V321, P676, DOI 10.1056/NEJM198909073211009; BROCK DW, 1990, NEW ENGL J MED, V322, P1595, DOI 10.1056/NEJM199005313222209; CHINBURAPA V, 1992, J CLIN PHARM THER, V17, P333, DOI 10.1111/j.1365-2710.1992.tb01314.x; COMROE JH, 1978, SCIENCE, V200, P931, DOI 10.1126/science.644335; DERSIMONIAN R, 1982, NEW ENGL J MED, V306, P1332, DOI 10.1056/NEJM198206033062204; DORR AE, 1978, J CHRON DIS, V31, P5, DOI 10.1016/0021-9681(78)90076-0; Eraker S A, 1981, Med Decis Making, V1, P29, DOI 10.1177/0272989X8100100105; FEINSTEIN AR, 1992, AM J MED, V92, P117, DOI 10.1016/0002-9343(92)90099-W; FEINSTEIN AR, 1988, AM J MED, V84, P475, DOI 10.1016/0002-9343(88)90268-9; FIGON G, 1992, EUR J CLIN PHARMACOL, V43, P113, DOI 10.1007/BF01740654; FORROW L, 1992, AM J MED, V92, P121, DOI 10.1016/0002-9343(92)90100-P; FORROW L, 1988, JAMA-J AM MED ASSOC, V259, P3161, DOI 10.1001/jama.259.21.3161; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; HSIA J, 1990, NEW ENGL J MED, V323, P1433, DOI 10.1056/NEJM199011223232101; LICHTLEN PR, 1990, LANCET, V335, P1109, DOI 10.1016/0140-6736(90)91121-P; LUPACIS A, 1988, NEW ENGL J MED, V318, P1728; MCNEIL BJ, 1982, NEW ENGL J MED, V306, P1259, DOI 10.1056/NEJM198205273062103; NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916; NIGHTINGALE SD, 1988, CHEST, V93, P684, DOI 10.1378/chest.93.4.684; PICKERING TG, 1983, JAMA-J AM MED ASSOC, V249, P399, DOI 10.1001/jama.249.3.399; REDELMAIER DA, 1990, NEW ENGL J MED, V322, P1262; Sackett DL, 1985, CLIN EPIDEMIOLOGY BA; SAFAVI KT, 1992, J GEN INTERN MED, V7, P32, DOI 10.1007/BF02599099; SPILKER B, 1986, GUIDE CLIN INTERPRET; VERGANI C, 1991, JAMA-J AM MED ASSOC, V6, P3; WEISSLER AM, 1989, J AM COLL CARDIOL, V13, P764, DOI 10.1016/0735-1097(89)90623-2; 1990, AM J CARDIOL, V66, P779; 1982, EUR HEAR J, V3, P583; 1992, NEW ENGL J MED, V327, P685	30	156	157	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1209	1211		10.1016/S0140-6736(94)92407-4	http://dx.doi.org/10.1016/S0140-6736(94)92407-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909875				2022-12-28	WOS:A1994NL17500016
J	BATEMAN, DN				BATEMAN, DN			NSAIDS - TIME TO REEVALUATE GUT TOXICITY	LANCET			English	Editorial Material							DRUGS				BATEMAN, DN (corresponding author), UNIV NEWCASTLE UPON TYNE,DEPT CLIN PHARMACOL,NEWCASTLE TYNE,ENGLAND.							HAWKEY CJ, 1990, BMJ-BRIT MED J, V300, P278, DOI 10.1136/bmj.300.6720.278; KAUFMAN DW, 1993, CLIN PHARMACOL THER, V53, P485, DOI 10.1038/clpt.1993.55; LANGMAN M J S, 1988, American Journal of Medicine, V84, P15, DOI 10.1016/0002-9343(88)90249-5; LAPORTE JR, 1991, LANCET, V337, P85, DOI 10.1016/0140-6736(91)90744-A; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; ROSSI AC, 1987, BRIT MED J, V294, P147, DOI 10.1136/bmj.294.6565.147; WILLETT LR, 1994, DRUG SAFETY, V10, P170, DOI 10.2165/00002018-199410020-00006; [No title captured]	8	65	66	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 30	1994	343	8905					1051	1052		10.1016/S0140-6736(94)90175-9	http://dx.doi.org/10.1016/S0140-6736(94)90175-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ694	7909094				2022-12-28	WOS:A1994NJ69400003
J	WATSON, BA; STARR, SE				WATSON, BA; STARR, SE			VARICELLA VACCINE FOR HEALTHY-CHILDREN	LANCET			English	Editorial Material											WATSON, BA (corresponding author), CHILDRENS HOSP PHILADELPHIA,DIV ALLERGY IMMUNOL & INFECT DIS,PHILADELPHIA,PA 19104, USA.							ASANO Y, 1985, PEDIATRICS, V75, P667; BERNSTEIN HH, 1993, PEDIATRICS, V92, P833; DUNKLE LM, 1991, NEW ENGL J MED, V325, P1539, DOI 10.1056/NEJM199111283252203; KUTER BJ, 1991, VACCINE, V9, P643, DOI 10.1016/0264-410X(91)90189-D; LIEU TA, 1994, JAMA-J AM MED ASSOC, V271, P375, DOI 10.1001/jama.271.5.375; PREBLUD SR, 1985, POSTGRAD MED J, V61, P17; WATSON B, 1974, J INFECT DIS, V164, P197; WATSON BM, 1993, PEDIATRICS, V91, P17; WHITE CJ, 1992, PEDIATR INFECT DIS J, V11, P19, DOI 10.1097/00006454-199201000-00006	9	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					928	929		10.1016/S0140-6736(94)90058-2	http://dx.doi.org/10.1016/S0140-6736(94)90058-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909003				2022-12-28	WOS:A1994NF70000002
J	THOMSON, AD				THOMSON, AD			ALCOHOLIC HEPATITIS	LANCET			English	Editorial Material											THOMSON, AD (corresponding author), GREENWICH DIST HOSP,DEPT MED,LONDON,ENGLAND.							ACHORD JL, 1993, AM J GASTROENTEROL, V88, P1822; BIRD GLA, 1990, ALCOHOL ALCOHOLISM, V25, P197, DOI 10.1093/oxfordjournals.alcalc.a044993; FANG JWS, 1994, LANCET, V343, P820, DOI 10.1016/S0140-6736(94)92025-7; LEEVY CM, 1973, LIVER REGENERATION M; SHERON N, 1993, HEPATOLOGY, V18, P41, DOI 10.1002/hep.1840180108; THOMSON AD, 1974, NATURE, V252, P721, DOI 10.1038/252721a0; THOMSON AD, 1991, GUT, P97	7	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					810	810		10.1016/S0140-6736(94)92022-2	http://dx.doi.org/10.1016/S0140-6736(94)92022-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908075				2022-12-28	WOS:A1994ND79200005
J	GLEICHER, N				GLEICHER, N			AUTOANTIBODIES AND PREGNANCY LOSS	LANCET			English	Editorial Material							ANTIBODIES		FDN REPROD MED,CHICAGO,IL		GLEICHER, N (corresponding author), CTR HUMAN REPROD,CHICAGO,IL, USA.							AOKI K, 1993, AM J REPROD IMMUNOL, V29, P82, DOI 10.1111/j.1600-0897.1993.tb00570.x; BAKIMER R, 1992, J CLIN INVEST, V89, P1158; BLANK M, 1991, P NATL ACAD SCI USA, V88, P3069, DOI 10.1073/pnas.88.8.3069; CHRISTIANSEN OB, 1989, HUM REPROD, V4, P913, DOI 10.1093/oxfordjournals.humrep.a137011; CLARK DA, 1991, AM J REPROD IMMUNOL, V25, P18, DOI 10.1111/j.1600-0897.1991.tb01058.x; EROGLU GE, 1994, AM J REPROD IMMUNOL, V31, P1; GLEICHER N, 1992, AM J OBSTET GYNECOL, V167, P637, DOI 10.1016/S0002-9378(11)91563-4; GLINOER D, 1991, J CLIN ENDOCR METAB, V73, P421, DOI 10.1210/jcem-73-2-421; PRATT DE, 1993, FERTIL STERIL, V60, P1001; STAGNAROGREEN A, 1990, JAMA-J AM MED ASSOC, V264, P1422, DOI 10.1001/jama.264.11.1422; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; XU L, 1990, AM J OBSTET GYNECOL, V163, P1493, DOI 10.1016/0002-9378(90)90612-B	12	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 26	1994	343	8900					747	748		10.1016/S0140-6736(94)91833-3	http://dx.doi.org/10.1016/S0140-6736(94)91833-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907727				2022-12-28	WOS:A1994NC35100005
J	BEADLE, C; LONG, GW; WEISS, WR; MCELROY, PD; MARET, SM; OLOO, AJ; HOFFMAN, SL				BEADLE, C; LONG, GW; WEISS, WR; MCELROY, PD; MARET, SM; OLOO, AJ; HOFFMAN, SL			DIAGNOSIS OF MALARIA BY DETECTION OF PLASMODIUM-FALCIPARUM HRP-2 ANTIGEN WITH A RAPID DIPSTICK ANTIGEN-CAPTURE ASSAY	LANCET			English	Article							HISTIDINE-RICH PROTEINS; RADIOIMMUNOASSAY	Two field studies in Kenya and an experimental challenge study in the USA were done to assess the accuracy of a dipstick antigen-capture assay based on qualitative detection of Plasmodium falciparum histidine-rich protein 2 (PfHRP-2) in peripheral blood for diagnosis of P fafciparum infection. In these studies, the assay was 96.5-100% sensitive for detection of greater than 60 P falciparum asexual parasites/ mu L blood, 70-81% sensitive for 11-60 parasites/mu L blood, and 11-67% sensitive for 10 parasites or less/mu L blood. Specificity was 95% (95% CI 85-105%; n = 20) among naive American volunteers, 98% (96-101%; n=112) among volunteers exposed to the bite of P falciparium-infected mosquitoes, and 88% (84-92%; n=285) among Kenyans living in an area with holoendemic malaria. Our results also indicated that PfHRP-2 antigen was not detectable in blood 6 days after initiation of curative chemotherapy, and suggest that such circulating antigens rarely lead to false-positive tests. The dipstick assay's sensitivity, specificity, simplicity, and speed may make it an important tool in the battle against malaria.	USN,MED RES INST,MALARIA PROGRAM,ROCKVILLE,MD 20852; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD; USN,NAVAL MED RES INSST DETACHMENT,KISUMU,KENYA; USA,ARMY MED RES UNIT,KISUMU,KENYA; BECTON DICKINSON CO,DIV ADV DIAGNOST,BALTIMORE,MD; KENYA GOVT MED RES CTR,VECTOR BIOL & CONTROL CLIN RES CTR,KISUMU,KENYA	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; Johns Hopkins University; Becton Dickinson; Kenya Medical Research Institute			Oloo, James Aggrey/CAF-3948-2022	Oloo, James Aggrey/0000-0001-7495-1827				[Anonymous], 1991, MALARIA OBSTACLES OP; AVIDOR B, 1985, J IMMUNOL METHODS, V82, P121, DOI 10.1016/0022-1759(85)90231-5; AVRAHAM H, 1983, AM J TROP MED HYG, V32, P11, DOI 10.4269/ajtmh.1983.32.11; BEIER JC, IN PRESS AM J TROP M; Fleiss JL, 1981, STAT METHODS RATES P, P218; HULLEY SB, 1988, DESIGNING CLIN RES E, P145; NAMSIRIPONGPUN V, 1993, T ROY SOC TROP MED H, V87, P32, DOI 10.1016/0035-9203(93)90410-R; PARRA ME, 1991, J CLIN MICROBIOL, V29, P1629, DOI 10.1128/JCM.29.8.1629-1634.1991; ROCK EP, 1987, PARASITOLOGY, V95, P209, DOI 10.1017/S0031182000057681; SPENCER H C, 1987, Annals of Tropical Medicine and Parasitology, V81, P13; TAYLOR DW, 1993, T ROY SOC TROP MED H, V87, P29, DOI 10.1016/0035-9203(93)90409-J; WELLEMS TE, 1986, P NATL ACAD SCI USA, V83, P6065, DOI 10.1073/pnas.83.16.6065	12	237	250	4	38	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 5	1994	343	8897					564	568		10.1016/S0140-6736(94)91520-2	http://dx.doi.org/10.1016/S0140-6736(94)91520-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906328	hybrid, Green Submitted			2022-12-28	WOS:A1994MY84300008
J	TOON, PD				TOON, PD			JUSTICE FOR GATEKEEPERS	LANCET			English	Editorial Material									ST BARTHOLOMEWS HOSP,MED ETH MED COLL,DEPT GEN PRACTICE & PRIMARY CARE,LONDON,ENGLAND; ROYAL LONDON HOSP,MED ETH MED COLL,DEPT HUMAN SCI,LONDON E1 1BB,ENGLAND	University of London; Queen Mary University London; Barts Health NHS Trust; Royal London Hospital								AQUINAS T, 1990, SUMMA THEOLOGICA AE, V2, P64; Doyal L, 1992, Qual Health Care, V1, P178, DOI 10.1136/qshc.1.3.178; Honigsbaum F., 1979, DIVISION BRIT MED HI; Lucas JohnRandolph., 1980, ON JUSTICE; MacIntyre A., 2007, AFTER VIRTUE, V3rd; MATHERS N, 1989, BRIT MED J, V298, P172, DOI 10.1136/bmj.298.6667.172; Pellegrino E., 1981, PHILOS BASIS MED PRA; Rawls J., 1972, SOCIAL JUSTICE LIBER; TOON PD, 1992, BRIT J GEN PRACT, V42, P486; 1989, WHITE PAPER REORGANI; 1989, PRACTICE BUDGETS GEN; 1989, REPORT SPECIAL C REP	12	13	13	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 5	1994	343	8897					585	587		10.1016/S0140-6736(94)91527-X	http://dx.doi.org/10.1016/S0140-6736(94)91527-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906335				2022-12-28	WOS:A1994MY84300015
J	BLUNT, SB; SILVA, M; KENNARD, C; WISE, R				BLUNT, SB; SILVA, M; KENNARD, C; WISE, R			VITAMIN-B12 DEFICIENCY PRESENTING WITH SEVERE PSEUDOATHETOSIS OF UPPER LIMBS	LANCET			English	Letter											BLUNT, SB (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,ACAD UNIT NEUROSCI,LONDON W6 8RF,ENGLAND.							ASBURY AK, 1987, SEMIN NEUROL, V7, P58, DOI 10.1055/s-2008-1041406; Asbury AK, 1968, ACTA NEUROL SCAN S34, V44, P1; BARR M, 1992, HUMAN NERVOUS SYSTEM; HEALTON EB, 1991, MEDICINE, V70, P229, DOI 10.1097/00005792-199107000-00001; Pallis C.A., 1974, NEUROLOGY GASTROINTE	5	15	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					550	550		10.1016/S0140-6736(94)91507-5	http://dx.doi.org/10.1016/S0140-6736(94)91507-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906800				2022-12-28	WOS:A1994MX88800066
J	BRAATEN, BA; NOU, XW; KALTENBACH, LS; LOW, DA				BRAATEN, BA; NOU, XW; KALTENBACH, LS; LOW, DA			METHYLATION PATTERNS IN PAP REGULATORY DNA CONTROL PYELONEPHRITIS-ASSOCIATED PILI PHASE VARIATION IN ESCHERICHIA-COLI	CELL			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; X-CHROMOSOME INACTIVATION; URINARY-TRACT; EXPRESSION; PROTEIN; MODEL; METHYLTRANSFERASE; TRANSPOSITION; REPLICATION; MECHANISM	We have examined the roles of pap DNA methylation patterns in the regulation of the switch between phase ON and OFF pyelonephritis-associated pill (Pap) expression states in E. coli. Two Dam methyltransferase sites, GATC(1028) and GATC(1130), were shown previously to be differentially methylated in phase ON versus phase OFF cells. In work presented here, these sites were mutated so that they could not be methylated, and the effects of these mutations on Pap phase variation were examined. Our results show that methylation of GATC(1028) blocks formation of the ON state by inhibiting the binding of Lrp and Papl regulatory proteins to this site. Conversely, methylation of GATC(1130) is required for the ON state. Evidence indicates that this occurs by the inhibition of binding of Lrp to sites overlapping the pilin promoter. A model describing how the transition between the phase ON and OFF methylation states might occur is presented.			BRAATEN, BA (corresponding author), UNIV UTAH, HLTH SCI CTR, DEPT PATHOL, DIV CELL BIOL & IMMUNOL, SALT LAKE CITY, UT 84132 USA.		Low, David A/M-7536-2014		NCI NIH HHS [5P30 CA42014-07] Funding Source: Medline; NIAID NIH HHS [2R01 AI23348, 5K04 AI881] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023348] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Antequera F., 1993, Experientia Supplementum (Basel), V64, P169; Ausubel FM, 1988, MOL REPROD DEV; BAGA M, 1985, EMBO J, V4, P3887, DOI 10.1002/j.1460-2075.1985.tb04162.x; BAKKER A, 1989, J BACTERIOL, V171, P5738, DOI 10.1128/jb.171.10.5738-5742.1989; BLYN LB, 1989, EMBO J, V8, P613, DOI 10.1002/j.1460-2075.1989.tb03416.x; BLYN LB, 1990, EMBO J, V9, P4045, DOI 10.1002/j.1460-2075.1990.tb07626.x; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; BRAATEN BA, 1992, P NATL ACAD SCI USA, V89, P4250, DOI 10.1073/pnas.89.10.4250; BRAATEN BA, 1991, J BACTERIOL, V173, P1789, DOI 10.1128/jb.173.5.1789-1800.1991; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; FEDOROFF N, 1989, BIOESSAYS, V10, P139, DOI 10.1002/bies.950100502; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GORANSSON M, 1989, MOL MICROBIOL, V3, P1557, DOI 10.1111/j.1365-2958.1989.tb00141.x; GORANSSON M, 1990, NATURE, V344, P682, DOI 10.1038/344682a0; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Holliday R, 1993, EXS, V64, P452; Hultgren SJ, 1991, CURR OPIN GENET DEV, V1, P313, DOI 10.1016/S0959-437X(05)80293-X; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LOW D, 1987, MOL MICROBIOL, V1, P335, DOI 10.1111/j.1365-2958.1987.tb01940.x; MARINUS MG, 1984, GENE, V28, P123, DOI 10.1016/0378-1119(84)90095-7; MODRICH P, 1989, J BIOL CHEM, V264, P6597; NOU XW, 1993, MOL MICROBIOL, V7, P545, DOI 10.1111/j.1365-2958.1993.tb01145.x; OHANLEY P, 1985, J CLIN INVEST, V75, P347, DOI 10.1172/JCI111707; OHANLEY P, 1985, NEW ENGL J MED, V313, P414, DOI 10.1056/NEJM198508153130704; PETERSON KR, 1985, MOL GEN GENET, V201, P14, DOI 10.1007/BF00397979; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; ROBERTS D, 1985, CELL, V43, P117, DOI 10.1016/0092-8674(85)90017-0; ROBERTS JA, 1989, INFECTION, V17, P401, DOI 10.1007/BF01645559; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; VANDERWOUDE MW, 1992, MOL MICROBIOL, V6, P2429; WANG MX, 1992, NATURE, V360, P606, DOI 10.1038/360606a0; WANG Q, 1993, J MOL BIOL, V229, P306, DOI 10.1006/jmbi.1993.1036; WANG Q, 1993, EMBO J, V12, P2495, DOI 10.1002/j.1460-2075.1993.tb05904.x; WILLINS DA, 1991, J BIOL CHEM, V266, P10768; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806	41	156	161	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 11	1994	76	3					577	588		10.1016/0092-8674(94)90120-1	http://dx.doi.org/10.1016/0092-8674(94)90120-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	7906204				2022-12-28	WOS:A1994MX20700017
J	ARBOGAST, BW; LEEPER, SC; MERRICK, RD; OLIVE, KE; TAYLOR, RN				ARBOGAST, BW; LEEPER, SC; MERRICK, RD; OLIVE, KE; TAYLOR, RN			WHICH PLASMA FACTORS BRING ABOUT DISTURBANCE OF ENDOTHELIAL FUNCTION IN PREECLAMPSIA	LANCET			English	Article							LOW-DENSITY LIPOPROTEINS; CELLS; PREECLAMPSIA; TRIGLYCERIDE; WOMEN; ACCUMULATION; ALBUMIN; INJURY; SERUM	The characteristic pathophysiological changes in preeclampsia are thought to be related to abnormalities of the maternal vascular endothelium. We suggest that the blood components that affect the risk of such damage are very-low-density lipoproteins (VLDL), which injure the endothelium, and toxicity-preventing activity (the pl 5.6 form of plasma albumin), which protects against VLDL-induced injury.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT OBSTET GYNECOL & REPROD SCI, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	ARBOGAST, BW (corresponding author), E TENNESSEE STATE UNIV, JAMES H QUILLEN COLL MED, DEPT INTERNAL MED, JOHNSON CITY, TN 37614 USA.		Olive, Kenneth/AAR-3428-2021					ARBOGAST BW, 1984, ATHEROSCLEROSIS, V51, P31, DOI 10.1016/0021-9150(84)90142-4; ARBOGAST BW, 1985, ATHEROSCLEROSIS, V57, P75, DOI 10.1016/0021-9150(85)90139-X; ARBOGAST BW, 1982, DIABETES, V31, P593, DOI 10.2337/diabetes.31.7.593; ARBOGAST BW, 1984, FED PROC, V43, P714; ARBOGAST BW, 1993, FASEB J, V7, pA796; ARBOGAST BW, 1988, ATHEROSCLEROSIS, V73, P259, DOI 10.1016/0021-9150(88)90049-4; ARBOGAST LY, 1990, SAAS B BIOCH BIOTECH, V3, P80; BASU SP, 1978, BIOCHIM BIOPHYS ACTA, V533, P66, DOI 10.1016/0005-2795(78)90548-2; DIECKMANN WJ, 1941, TOXEMIAS PREGNANCY, P370; ENDRESEN MJ, 1992, AM J OBSTET GYNECOL, V167, P440, DOI 10.1016/S0002-9378(11)91426-4; FRIEDMAN SA, 1988, OBSTET GYNECOL, V71, P122; GIANTURCO SH, 1982, J CLIN INVEST, V70, P168, DOI 10.1172/JCI110590; HOWARD BV, 1977, J LIPID RES, V18, P561; LORENTZEN B, 1991, THROMB RES, V63, P363, DOI 10.1016/0049-3848(91)90139-N; POTTER JM, 1979, AM J OBSTET GYNECOL, V133, P165, DOI 10.1016/0002-9378(79)90469-1; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; RODGERS GM, 1988, AM J OBSTET GYNECOL, V159, P908, DOI 10.1016/S0002-9378(88)80169-8; TAYLOR RN, 1990, J CLIN ENDOCR METAB, V71, P1675, DOI 10.1210/jcem-71-6-1675	18	43	45	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 5	1994	343	8893					340	341		10.1016/S0140-6736(94)91169-X	http://dx.doi.org/10.1016/S0140-6736(94)91169-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905151				2022-12-28	WOS:A1994MU98500015
J	LAWRENCE, K				LAWRENCE, K			MINIMAL ACCESS SURGERY - HARNESSING THE REVOLUTION	LANCET			English	Editorial Material											LAWRENCE, K (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,OXFORD,ENGLAND.							ANDERSON GM, 1988, AM J PUBLIC HEALTH, V78, P251, DOI 10.2105/AJPH.78.3.251; MCMAHON AJ, 1994, LANCET, V343, P135, DOI 10.1016/S0140-6736(94)90932-6; MCNEIL BJ, 1981, NEW ENGL J MED, V305, P982, DOI 10.1056/NEJM198110223051704; MILROY SJ, 1994, BRIT MED J, V308, P199, DOI 10.1136/bmj.308.6922.199c; ORLANDO R, 1993, ARCH SURG-CHICAGO, V128, P494; VITALE GC, 1991, AM J SURG, V161, P396, DOI 10.1016/0002-9610(91)90606-E; 1994, LANCET, V343, P286; 1994, MINIMAL ACCESS SURGE	8	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 5	1994	343	8893					308	309		10.1016/S0140-6736(94)91158-4	http://dx.doi.org/10.1016/S0140-6736(94)91158-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905140				2022-12-28	WOS:A1994MU98500004
J	CROSS, AS				CROSS, AS			INDUCING AN ABSCESS	LANCET			English	Editorial Material							POLYSACCHARIDE; BACTEROIDES				CROSS, AS (corresponding author), WALTER REED ARMY INST RES,DEPT SOCIOL,WASHINGTON,DC 20307, USA.							BYCROFT BW, 1989, ANTIMICROB AGENTS CH, V33, P1516, DOI 10.1128/AAC.33.9.1516; DOMENICO P, 1993, J INFECT DIS, V168, P766, DOI 10.1093/infdis/168.3.766; ONDERDONK AB, 1977, J INFECT DIS, V136, P82, DOI 10.1093/infdis/136.1.82; RANNEY DF, 1985, SCIENCE, V227, P182, DOI 10.1126/science.3966151; SCHIFFMANN E, 1975, P NATL ACAD SCI USA, V72, P1059, DOI 10.1073/pnas.72.3.1059; SHAPIRO ME, 1982, J EXP MED, V154, P1188; TAKAHASHI T, 1991, INFECT IMMUN, V59, P18, DOI 10.1128/IAI.59.1.18-23.1991; TZIANABOS AO, 1993, SCIENCE, V262, P416, DOI 10.1126/science.8211161; VERINGA EM, 1989, J ANTIMICROB CHEMOTH, V23, P577, DOI 10.1093/jac/23.4.577; WEINSTEIN WM, 1975, J INFECT DIS, V132, P282, DOI 10.1093/infdis/132.3.282	10	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					248	249		10.1016/S0140-6736(94)91106-1	http://dx.doi.org/10.1016/S0140-6736(94)91106-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905090				2022-12-28	WOS:A1994MT44000004
J	JANEWAY, CA; BOTTOMLY, K				JANEWAY, CA; BOTTOMLY, K			SIGNALS AND SIGNS FOR LYMPHOCYTE-RESPONSES	CELL			English	Review							T-CELL ACTIVATION; ANTIGEN-PRESENTING CELLS; HEAT-STABLE ANTIGEN; B-CELLS; COSTIMULATORY MOLECULE; MONOCLONAL-ANTIBODY; CD4 RECEPTOR; EXPRESSION; PROTEIN; INDUCTION		HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Howard Hughes Medical Institute	JANEWAY, CA (corresponding author), YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510, USA.				NCI NIH HHS [CA-38350] Funding Source: Medline; NIAID NIH HHS [AI-14579, AI-26810] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014579, R01AI026810, R37AI014579] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BASKAR S, 1993, P NATL ACAD SCI USA, V90, P5687, DOI 10.1073/pnas.90.12.5687; BOTTOMLY K, 1988, IMMUNOL TODAY, V9, P268, DOI 10.1016/0167-5699(88)91308-4; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; CUMBERBATCH M, 1992, IMMUNOLOGY, V75, P257; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; DIANZANI U, 1990, EUR J IMMUNOL, V20, P2249, DOI 10.1002/eji.1830201014; DIANZANI U, 1992, J IMMUNOL, V148, P678; EVAVOLD BD, 1993, J IMMUNOL, V150, P3131; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; EYNON EE, 1992, J EXP MED, V175, P131, DOI 10.1084/jem.175.1.131; FEARON DT, 1993, CURR OPIN IMMUNOL, V5, P341, DOI 10.1016/0952-7915(93)90051-S; FREEMAN GJ, 1993, SCIENCE, V262, P907, DOI 10.1126/science.7694362; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; GALVIN F, 1992, J IMMUNOL, V149, P3802; HALLENBAUGH D, 1992, EMBO J, V11, P4313; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HATHCOCK KS, 1993, SCIENCE, V262, P905, DOI 10.1126/science.7694361; HOGG N, 1993, CURR OPIN IMMUNOL, V5, P383, DOI 10.1016/0952-7915(93)90057-Y; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; JANEWAY CA, 1989, COLD SH Q B, V54, P657; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JANEWAY CA, 1988, NATURE, V335, P208, DOI 10.1038/335208a0; JENKINS MK, 1988, J IMMUNOL, V140, P3324; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KAYE J, 1984, J IMMUNOL, V133, P1339; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KNIGHT SC, 1993, CURR OPIN IMMUNOL, V5, P374, DOI 10.1016/0952-7915(93)90056-X; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; LARSEN CP, 1992, J EXP MED, V176, P1215, DOI 10.1084/jem.176.4.1215; LEDBETTER JA, 1992, SCIENCE, V257, P792; LENSCHOW DJ, 1993, P NATL ACAD SCI USA, V90, P11054, DOI 10.1073/pnas.90.23.11054; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LEVIN D, 1993, J IMMUNOL, V151, P6742; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, J EXP MED, V176, P1595, DOI 10.1084/jem.176.6.1595; LIU H, 1991, P NATL ACAD SCI USA, V88, P8705, DOI 10.1073/pnas.88.19.8705; LIU Y, 1992, J EXP MED, V175, P437, DOI 10.1084/jem.175.2.437; LIU Y, 1992, P NATL ACAD SCI USA, V89, P3845, DOI 10.1073/pnas.89.9.3845; LIU Y, 1991, INT IMMUNOL, V3, P323, DOI 10.1093/intimm/3.4.323; LIU Y, 1992, EUR J IMMUNOL, V22, P2855, DOI 10.1002/eji.1830221115; LIU Y, 1993, J EXP MED, V18, P1789; LIU YJ, 1992, IMMUNOL TODAY, V13, P17, DOI 10.1016/0167-5699(92)90199-H; LUQMAN M, 1992, J IMMUNOL, V149, P2300; MACATONIA SE, 1989, J EXP MED, V169, P1255, DOI 10.1084/jem.169.4.1255; MARRACK P, 1991, ANNU REV IMMUNOL, V9, P745; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MURRAY JS, 1989, J EXP MED, V170, P2135, DOI 10.1084/jem.170.6.2135; NABAVI N, 1992, NATURE, V360, P266, DOI 10.1038/360266a0; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; OROURKE AM, 1990, SCIENCE, V249, P171, DOI 10.1126/science.2164711; RACIOPPI L, 1993, J EXP MED, V177, P1047, DOI 10.1084/jem.177.4.1047; RANHEIM EA, 1993, J EXP MED, V177, P925, DOI 10.1084/jem.177.4.925; ROJO JM, 1988, J IMMUNOL, V140, P1081; RON Y, 1981, EUR J IMMUNOL, V11, P964, DOI 10.1002/eji.1830111203; RONCHESE F, 1993, J EXP MED, V177, P679, DOI 10.1084/jem.177.3.679; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RUPPERT J, 1993, P NATL ACAD SCI USA, V90, P2671, DOI 10.1073/pnas.90.7.2671; SANSOM DM, 1993, EUR J IMMUNOL, V23, P295, DOI 10.1002/eji.1830230148; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SCOTT P, 1993, SCIENCE, V260, P496, DOI 10.1126/science.8097337; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TITE JP, 1984, EUR J IMMUNOL, V14, P553, DOI 10.1002/eji.1830140613; TITE JP, 1986, J MOL CELL IMMUNOL, V2, P179; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; VANSEVENTER GA, 1991, CURR OPIN IMMUNOL, V3, P294, DOI 10.1016/0952-7915(91)90027-X; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VREMEC D, 1992, J EXP MED, V176, P47, DOI 10.1084/jem.176.1.47; WATTS TH, 1993, J IMMUNOL, V150, P2192; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J	87	773	800	1	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 28	1994	76	2					275	285		10.1016/0092-8674(94)90335-2	http://dx.doi.org/10.1016/0092-8674(94)90335-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	7904901				2022-12-28	WOS:A1994MU67800011
J	MOROCUTTI, C; COCCHERI, S				MOROCUTTI, C; COCCHERI, S			ASPIRIN AND PREVENTION OF STROKE	LANCET			English	Letter									UNIV BOLOGNA,DEPT ANGIOL,I-40126 BOLOGNA,ITALY	University of Bologna	MOROCUTTI, C (corresponding author), UNIV ROMA LA SAPIENZA,DEPT NEUROL,SIFA STEERING COMM,I-00185 ROME,ITALY.							CATTANEO M, 1987, HAEMOSTASIS, V17, P293; DAVI G, 1993, ARTERIOSCLER THROMB, V13, P1346, DOI 10.1161/01.ATV.13.9.1346; FORNARO G, 1992, CIRCULATION, V87, P162; LAUPACIS, 1993, LANCET, V342, P1251; 1991, COR ART DIS, V2, P897; 1991, CIRCULATION, V84, P527	6	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 22	1994	343	8891					234	234						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT332	7904685				2022-12-28	WOS:A1994MT33200038
J	NEAL, KR; BRIJ, SO; SLACK, RCB; HAWKEY, CJ; LOGAN, RFA				NEAL, KR; BRIJ, SO; SLACK, RCB; HAWKEY, CJ; LOGAN, RFA			RECENT TREATMENT WITH H(2) ANTAGONISTS AND ANTIBIOTICS AND GASTRIC-SURGERY AS RISK-FACTORS FOR SALMONELLA INFECTION	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM,DIV GASTROENTEROL,NOTTINGHAM NG7 2UH,ENGLAND; NOTTINGHAM HLTH AUTHOR,DIV GASTROENTEROL,NOTTINGHAM NG3 5AF,ENGLAND	University of Nottingham	NEAL, KR (corresponding author), UNIV NOTTINGHAM,DEPT HLTH MED & EPIDEMIOL,NOTTINGHAM NG7 2UH,ENGLAND.							GIANNELLA RA, 1972, GUT, V13, P251, DOI 10.1136/gut.13.4.251; HOLT P, 1985, PRACTITIONER, V229, P1027; HOWDEN CW, 1987, GUT, V28, P96, DOI 10.1136/gut.28.1.96; NORDBRING F, 1962, ACTA MED SCAND, V171, P783; PAVIA AT, 1990, J INFECT DIS, V161, P255, DOI 10.1093/infdis/161.2.255	5	74	75	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	1994	308	6922					176	176						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR974	7906170				2022-12-28	WOS:A1994MR97400020
J	LADWIG, KH; ROLL, G; BREITHARDT, G; BUDDE, T; BORGGREFE, M				LADWIG, KH; ROLL, G; BREITHARDT, G; BUDDE, T; BORGGREFE, M			POSTINFARCTION DEPRESSION AND INCOMPLETE RECOVERY 6 MONTHS AFTER ACUTE MYOCARDIAL-INFARCTION	LANCET			English	Article							CORONARY-ARTERY DISEASE; MORTALITY; LIFE	Patients who suffer from post-infarction depression are a high risk group with an increased mortality risk. The reasons for this are not known although it may be because such patients cannot cope with the chronic condition of cardiac disease. We designed a profile of clinical and behavioural outcome measurements representing recovery after myocardial infarction. 552 male survivors of acute myocardial infarction (29-65 years; mean=53) were grouped at study entry according to their depression status. 377 patients were reassessed after 6 months and were divided into the following subgroups: 50 (13.3%) patients had severe depression; 85 (22.5%) moderate depression and 242 (64.2%) low degrees of depression in the initial study. There were no substantial differences in baseline characteristics between the index group and the drop-out group. The unadjusted relative risk for follow-up angina pectoris among patients with depression (severe versus low) was 3.12 (95% CI 1.58 to 6.16) and was 5.55 (CI 2.87 to 10.71) for emotional instability. The relative risk for maintenance of smoking habits was 2.63 (CI 1.23 to 5.60) and was for work resumption 0.39 (CI 0.18 to 0.88). There was no association between depression and the occurrence of late potentials. After adjustment for univariate variables (age, social class, recurrent infarction, helplessness) only small and nonsignificant changes in the relative risks were found. However the inverse association of depression and work resumption was lost after adjustment. The investigation revealed that persistent postinfarction depression is an independent and important source of subsequent morbidity and long-acting reduced quality of life. Depression has adverse effects on illness behaviour and pain perception.	TECH UNIV MUNICH,PSYCHOSOMAT MED PSYCHOTHERAPIE & MED PSYCHOL POLIKLIN,MUNICH,GERMANY; GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST MED INFORMAT & SYST FORSCH,MUNICH,GERMANY; UNIV MUNSTER,MED KLIN & POLIKLIN,W-4400 MUNSTER,GERMANY	Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munster	LADWIG, KH (corresponding author), TECH UNIV MUNICH,INST PSYCHOSOMAT MED PSYCHOTHERAPIE & MED PSYCHOL,LANGER STR 3,D-81675 MUNICH,GERMANY.		Ladwig, Karl-Heinz/B-5351-2014	Ladwig, Karl-Heinz/0000-0003-0710-1720				AHERN DK, 1990, AM J CARDIOL, V66, P59, DOI 10.1016/0002-9149(90)90736-K; AHNVE J, 1988, AM HEART J, V117, P925; BORGGREFE M, 1990, European Heart Journal, V11, P403; BREITHARDT G, 1987, CIRCULATION, V75, P1091, DOI 10.1161/01.CIR.75.6.1091; Breslow N, 1980, STATISTICAL METHODS, V32; CARNEY RM, 1987, AM J CARDIOL, V60, P1273, DOI 10.1016/0002-9149(87)90607-2; CARNEY RM, 1988, J PSYCHOSOM RES, V32, P159, DOI 10.1016/0022-3999(88)90050-5; DALY LE, 1983, BMJ-BRIT MED J, V287, P324, DOI 10.1136/bmj.287.6388.324; DEMUYNCK RU, 1980, DIAGNOSE THERAPIE SO; FLETCHER AE, 1987, J CHRON DIS, V40, P557, DOI 10.1016/0021-9681(87)90014-2; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; GILPIN E, 1989, CIRCULATION, V80, P457; HAWIK OE, 1990, J PSYCHOSOM RES, V34, P271; KENNEDY GJ, 1987, PSYCHOSOM MED, V49, P410, DOI 10.1097/00006842-198707000-00010; LADWIG KH, 1992, J PSYCHOSOM RES, V36, P723, DOI 10.1016/0022-3999(92)90130-T; LADWIG KH, 1986, KARDIOVASKULARE HYPE; MOSS AJ, 1990, NEW ENGL J MED, V322, P743, DOI 10.1056/NEJM199003153221107; PYSZCZYNSKI T, 1987, PSYCHOL BULL, V102, P122, DOI 10.1037/0033-2909.102.1.122; SCHLEIFER SJ, 1989, ARCH INTERN MED, V149, P1785, DOI 10.1001/archinte.149.8.1785; SILVERSTONE PH, 1990, J PSYCHOSOM RES, V34, P659, DOI 10.1016/0022-3999(90)90110-P; SIMSON MB, 1981, CIRCULATION, V64, P235, DOI 10.1161/01.CIR.64.2.235; YOUNG LD, 1988, CARDIOLOGY, V75, P10, DOI 10.1159/000174344; ZUNG WWK, 1984, J CLIN PSYCHIAT, V45, P26; ZUNG WWK, 1983, J CLIN PSYCHIAT, V44, P3	24	185	187	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					20	23		10.1016/S0140-6736(94)90877-X	http://dx.doi.org/10.1016/S0140-6736(94)90877-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MN937	7905043				2022-12-28	WOS:A1994MN93700013
J	STRAUS, SE; COREY, L; BURKE, RL; SAVARESE, B; BARNUM, G; KRAUSE, PR; KOST, RG; MEIER, JL; SEKULOVICH, R; ADAIR, SF; DEKKER, CL				STRAUS, SE; COREY, L; BURKE, RL; SAVARESE, B; BARNUM, G; KRAUSE, PR; KOST, RG; MEIER, JL; SEKULOVICH, R; ADAIR, SF; DEKKER, CL			PLACEBO-CONTROLLED TRIAL OF VACCINATION WITH RECOMBINANT GLYCOPROTEIN-D OF HERPES-SIMPLEX VIRUS TYPE-2 FOR IMMUNOTHERAPY OF GENITAL HERPES	LANCET			English	Article							T-CELL CLONES; MONOCLONAL-ANTIBODIES; ORAL ACYCLOVIR; DOUBLE-BLIND; INFECTION; PROTECTION; EFFICACY; ANTIGEN; RISK; MICE	Immunotherapy of chronic viral diseases with vaccines is an important but unproven concept. We investigated the effect of a vaccine containing recombinant glycoprotein D (gD2) of herpes simplex virus type 2 (HSV-2) on the frequency of symptomatic outbreaks in patients with genital herpes. 98 patients with documented genital herpes who reported 4-14 recurrences per year were enrolled in a double-blind, placebo-controlled trial. Subjects received injections of either 100 mu g gD2 in alum or alum alone (placebo) at 0 and 2 months, and recurrences were documented for 1 year. The vaccine was well tolerated, gD2 recipients reported fewer recurrences per month than placebo recipients (mean 0.42 [SE 0.05] vs 0.55 [0.05]; p = 0.055), had fewer virologically confirmed recurrences per month (0.18 [0.03] vs 0.28 [0.03]; p = 0.019), and had a lower median number of recurrences for the study year (4 [range 0-17] vs 6 [0-15]; p = 0.039). Neither genital recurrence nor the placebo vaccine had any discernible effect on HSV-2-specific antibody responses, but gD2 vaccine boosted neutralising antibodies to HSV-2 fourfold and gD2-specific titres sevenfold over baseline levels. These results inspire optimism about the potential use of vaccine for the treatment of chronic,recurring viral diseases.	UNIV WASHINGTON,DEPT LAB MED,DIV VIROL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA; BIOCINE CO,EMERYVILLE,CA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	STRAUS, SE (corresponding author), NIAID,CLIN INVEST LAB,MED VIROL SECT,BLDG 10,ROOM 11N-228,BETHESDA,MD 20892, USA.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436; Krause, Philip/0000-0002-1045-7536; Meier, Jeffery/0000-0001-9491-1697				ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BALACHANDRAN N, 1982, INFECT IMMUN, V37, P1132, DOI 10.1128/IAI.37.3.1132-1137.1982; BERMAN PW, 1985, SCIENCE, V227, P1490, DOI 10.1126/science.2983428; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; BURKE RL, 1991, REV INFECT DIS, V13, pS906; BURKE RL, 1992, HERPES SIMPLEX VIRUS, P137; DOUGLAS JM, 1984, NEW ENGL J MED, V310, P1545; HEBERKATZ E, 1988, J EXP MED, V167, P275, DOI 10.1084/jem.167.2.275; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; JOHNSON RM, 1990, J IMMUNOL, V145, P702; KAVAKLOVA L, 1986, ACTA VIROL, V30, P402; KERN AB, 1964, ARCH DERMATOL, V89, P844, DOI 10.1001/archderm.1964.01590300072021; KUTINOVA L, 1988, VACCINE, V6, P223, DOI 10.1016/0264-410X(88)90215-0; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MERTZ GJ, 1990, J INFECT DIS, V161, P653, DOI 10.1093/infdis/161.4.653; MERTZ GJ, 1986, J INFECT DIS, V150, P249; MINSON AC, 1986, J GEN VIROL, V67, P1001, DOI 10.1099/0022-1317-67-6-1001; REDFIELD RR, 1991, NEW ENGL J MED, V324, P1678; REICHMAN RC, 1984, JAMA-J AM MED ASSOC, V251, P2103, DOI 10.1001/jama.251.16.2103; SALK J, 1987, NATURE, V327, P473, DOI 10.1038/327473a0; SKINNER GRB, 1987, MED MICROBIOL IMMUN, V176, P161, DOI 10.1007/BF00193897; STANBERRY LR, 1987, J INFECT DIS, V155, P914, DOI 10.1093/infdis/155.5.914; STANBERRY LR, 1988, J INFECT DIS, V157, P156, DOI 10.1093/infdis/157.1.156; STANBERRY LR, 1989, J GEN VIROL, V70, P3177, DOI 10.1099/0022-1317-70-12-3177; STRAUS SE, 1993, J INFECT DIS, V167, P1045, DOI 10.1093/infdis/167.5.1045; STRAUS SE, 1984, NEW ENGL J MED, V310, P1545, DOI 10.1056/NEJM198406143102401; TIGGES MA, 1992, OCT P INT C ANT AG C; ZARLING JM, 1986, J IMMUNOL, V136, P4669	28	172	183	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1460	1463		10.1016/S0140-6736(94)92581-X	http://dx.doi.org/10.1016/S0140-6736(94)92581-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911177				2022-12-28	WOS:A1994NQ41500008
J	CHRISTOFORI, G; NAIK, P; HANAHAN, D				CHRISTOFORI, G; NAIK, P; HANAHAN, D			A 2ND SIGNAL SUPPLIED BY INSULIN-LIKE GROWTH-FACTOR-II IN ONCOGENE-INDUCED TUMORIGENESIS	NATURE			English	Article							BETA-CELL TUMORS; TRANSGENIC MICE; INDUCTION; TISSUES; PROTEIN; LINEAGE; GENE	TRANSGENIC mice expressing the simian virus-40 large T-antigen (Tag) under the control of the insulin gene regulatory region offer a useful model for tumorigenesis(1,2). All the islets of Langerhans express Tag, although there is at first no aberrant proliferation. Over half of the islets become hyperplastic, however, and neovascularization of a further subset (about 10%)(3) leads eventually to formation of highly vascularized solid tumours in 1-2% of islets by about 14 weeks of age. Here we show that the initial proliferative switch is correlated with focal activation of insulin-like growth factor II (IGF-II). Transfection with an antisense oligonucleotide to the IGF-II messenger RNA interferes with tumour cell proliferation in vitro, and transgenic mice homozygous for a disruption of the IGF-II gene develop tumours with reduced malignancy and a higher incidence of apoptosis. Several signals, in this case including an oncoprotein and a growth/survival factor, thus appear to be needed to elicit hyperproliferation.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HORMONE RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DECHIARA TM, 1990, NATURE, V345, P75; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FERGUSONSMITH AC, 1991, NATURE, V351, P155; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; GARCIA RL, 1989, AM J PATHOL, V134, P733; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HARRINGTON EA, IN PRESS EMBO J; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LEROITH D, 1991, INSULIN LIKE GROWTH; RAPPOLEE DA, 1992, GENE DEV, V6, P939, DOI 10.1101/gad.6.6.939; RECHLER MM, 1990, HDB EXPT PHARM, V95, P263; SCHOFIELD PN, 1992, INSULIN LIKE GROWTH; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SMITH KM, 1990, J LIPID RES, V31, P995; TEITELMAN G, 1988, CELL, V52, P97, DOI 10.1016/0092-8674(88)90534-X	24	383	396	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 2	1994	369	6479					414	418		10.1038/369414a0	http://dx.doi.org/10.1038/369414a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP174	7910953				2022-12-28	WOS:A1994NP17400061
J	WRIGHT, EC				WRIGHT, EC			A LESSON IN NONCOMPLIANCE	LANCET			English	Editorial Material																		BABIKER IE, 1986, PSYCHIAT DEV, V4, P329; GREENBERG RN, 1984, CLIN THER, V65, P590; HAYNES RB, 1987, PATIENT EDUC COUNS, V10, P155, DOI 10.1016/0738-3991(87)90095-4; WALKER R, 1992, PHARM J, V249, P695; 1994, J PEDIATR, V124, P383	5	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1305	1305		10.1016/S0140-6736(94)92460-0	http://dx.doi.org/10.1016/S0140-6736(94)92460-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NN217	7910317				2022-12-28	WOS:A1994NN21700003
J	KANDA, Y; SHIGENO, K; KINOSHITA, N; NAKAO, K; YANO, M; MATSUO, H				KANDA, Y; SHIGENO, K; KINOSHITA, N; NAKAO, K; YANO, M; MATSUO, H			SUDDEN HEARING-LOSS ASSOCIATED WITH INTERFERON	LANCET			English	Note							ALPHA-INTERFERON; DISEASE; CANCER	With the increasing long-term use of interferon, several new adverse effects have been recognised. We have prospectively assessed auditory function in 49 patients receiving interferon, after we saw a case of sudden sensorineural hearing loss during interferon therapy. Auditory disability (tinnitus, hearing loss, or both) occurred in 22 patients (45%) during treatment with audiometry-documented sensorineural hearing loss in 18 (37%). The auditory disability often developed in the late stage of treatment and resolved in all patients within 7-14 days after discontinuation of interferon.	NAGASAKI CHUO NATL HOSP,DEPT OTOLARYNGOL,NAGASAKI,JAPAN; NAGASAKI CHUO NATL HOSP,INST CLIN RES,NAGASAKI,JAPAN; JAPANESE RED CROSS,NAGASAKI ATOM BOMB HOSP,DEPT OTOLARYNGOL,NAGASAKI,JAPAN; JAPANESE RED CROSS,NAGASAKI ATOM BOMB HOSP,DEPT INTERNAL MED,NAGASAKI,JAPAN; JAPANESE RED CROSS,NAGASAKI ATOM BOMB HOSP,DEPT NEUROL,NAGASAKI,JAPAN	Japanese Red Cross Medical Center; Japanese Red Cross Medical Center; Japanese Red Cross Medical Center	KANDA, Y (corresponding author), NAGASAKI UNIV,SCH MED,DEPT OTOLARYNGOL,1-7-1 SAKAMOTO,NAGASAKI 852,JAPAN.							BURMAN P, 1985, LANCET, V2, P100; CALVET MC, 1979, NATURE, V278, P558, DOI 10.1038/278558a0; COLE RR, 1988, AM J OTOL, V9, P211; CONLON KC, 1990, CANCER, V65, P2237, DOI 10.1002/1097-0142(19900515)65:10<2237::AID-CNCR2820651013>3.0.CO;2-5; GUYER DR, 1993, ARCH OPHTHALMOL-CHIC, V111, P350, DOI 10.1001/archopht.1993.01090030068041; KIRKWOOD JM, 1984, J CLIN ONCOL, V2, P336, DOI 10.1200/JCO.1984.2.4.336; QUESADA JR, 1986, J CLIN ONCOL, V4, P234, DOI 10.1200/JCO.1986.4.2.234; RENAULT PF, 1989, SEMIN LIVER DIS, V9, P273, DOI 10.1055/s-2008-1040523; SCHATTNER A, 1988, AM J MED SCI, V295, P532, DOI 10.1097/00000441-198806000-00007	9	52	54	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1994	343	8906					1134	1135		10.1016/S0140-6736(94)90237-2	http://dx.doi.org/10.1016/S0140-6736(94)90237-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK730	7910234				2022-12-28	WOS:A1994NK73000011
J	POJDA, Z; STRUZYNA, J				POJDA, Z; STRUZYNA, J			TREATMENT OF NONHEALING ULCERS WITH RHGM-CSF AND SKIN-GRAFTS	LANCET			English	Letter							COLONY-STIMULATING FACTORS		CSK WAM,DEPT BURN SURG,WARSAW,POLAND		POJDA, Z (corresponding author), WIHIE,DEPT RADIAT HEMATOL,PL-01163 WARSAW,POLAND.			Pojda, Zygmunt/0000-0001-5562-4433				BOENTE P, 1993, LANCET, V341, P1154, DOI 10.1016/0140-6736(93)93174-Y; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; DEDHAR S, 1989, P NATL ACAD SCI USA, V85, P9235; Kaplan Gilla, 1993, P205	5	31	33	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 30	1994	343	8905					1100	1100		10.1016/S0140-6736(94)90211-9	http://dx.doi.org/10.1016/S0140-6736(94)90211-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ694	7909116				2022-12-28	WOS:A1994NJ69400039
J	KERWIN, R; DUMON, V				KERWIN, R; DUMON, V			DOPAMINE-RECEPTOR GENES AND SCHIZOPHRENIA - THE TAIL WAGS THE DOG	LANCET			English	Editorial Material																		BRUTON CJ, 1990, PSYCHOL MED, V20, P285, DOI 10.1017/S0033291700017608; CROW TJ, 1980, BRIT MED J, V280, P66, DOI 10.1136/bmj.280.6207.66; FALKAI P, 1988, BIOL PSYCHIAT, V24, P515, DOI 10.1016/0006-3223(88)90162-X; GILL M, 1993, NEUROBIOLOGY PSYCHIA, V2, P1; GREEN MF, 1989, SCHIZOPHRENIA BULL, V15, P91, DOI 10.1093/schbul/15.1.91; KERWIN R, 1992, J PSYCHOPHARMACOL, V6, P230, DOI 10.1177/026988119200600217; KESHAVAN NS, 1994, SCHIZOPHR RES, V11, P136; PILOWSKY LS, 1994, BRIT J PSYCHIAT, V164, P16, DOI 10.1192/bjp.164.1.16; ROBERTS GW, 1987, BIOL PSYCHIAT, V22, P1450; SEEMAN P, 1993, NATURE, V365, P441, DOI 10.1038/365441a0; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0	11	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					686	686		10.1016/S0140-6736(94)91576-8	http://dx.doi.org/10.1016/S0140-6736(94)91576-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907676				2022-12-28	WOS:A1994NB80900005
J	TAKAHASHI, K; JUJI, T; MIYAMOTO, M; UCHIDA, S; AKAZA, T; TADOKORO, K; SHIBATA, Y; INO, T; HIDANO, A				TAKAHASHI, K; JUJI, T; MIYAMOTO, M; UCHIDA, S; AKAZA, T; TADOKORO, K; SHIBATA, Y; INO, T; HIDANO, A			ANALYSIS OF RISK-FACTORS FOR POSTTRANSFUSION GRAFT-VERSUS-HOST DISEASE IN JAPAN	LANCET			English	Article							ERYTHRODERMA; SURGERY	We distributed a questionnaire to highlight the effects of post transfusion graft-versus-host disease (PT-GVHD) and to elucidate the risk factors that would predispose people to the disease. The questionnaire described the pathogenesis and the clinical profiles of PT-GVHD and was distributed to doctors in Japan whose hospital conducted more than 1000 units of blood transfusions a year. Doctors were asked about their awareness and experience of PT-GVHD cases. Those who had seen cases of PT-GVHD were then asked to detail clinical course and laboratory data. Of the 14 083 doctors who replied to the first question, 47.4% did not realise that PT-GVHD could occur in immunocompetent hosts. From 304 cases where detailed information was supplied, 171 were considered clinically compatible with PT-GVHD. From these it seems that the risk factors linked to PT-GVHD are cardiovascular surgery, cancer, fresh and consanguineous blood transfusion, and being male. Patients with any of these factors should have some prophylactic therapy such as irradiation of blood before transfusion.	JAPANESE RED CROSS CENT BLOOD CTR,HIROO,TOKYO,JAPAN; UNIV TOKYO,FAC MED,DEPT TRANSFUS MED & IMMUNOHEMATOL,TOKYO,TOKYO,JAPAN; JICHI MED SCH,OOMLYA MED CTR,OMIYA,SAITAMA,JAPAN; TOKYO WOMENS COLL,FAC MED,DEPT DERMATOL,TOKYO,TOKYO,JAPAN	Japanese Red Cross Medical Center; University of Tokyo; Jichi Medical University; Tokyo Women's Medical University	TAKAHASHI, K (corresponding author), TORANOMON GEN HOSP,DEPT TRANSFUS MED & IMMUNOHEMATOL,MINATO KU,TORANOMON 2-2-2,TOKYO,TOKYO 105,JAPAN.							BUTTON LN, 1981, TRANSFUSION, V21, P419, DOI 10.1046/j.1537-2995.1981.21481275998.x; ITO K, 1988, LANCET, V1, P413; JUJI T, 1989, NEW ENGL J MED, V321, P56; LEITMANN SF, 1989, TRANSFUSION, V25, P293; MATSUSHITA H, 1988, VIRCHOWS ARCH B, V55, P237; OTSUKA S, 1989, TRANSFUSION, V29, P544, DOI 10.1046/j.1537-2995.1989.29689318456.x; SAKAKIBARA T, 1986, LANCET, V2, P1099; TAKAHASHI K, 1991, TRANSFUS SCI, V12, P281, DOI 10.1016/0955-3886(91)90108-F	8	37	38	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					700	702		10.1016/S0140-6736(94)91580-6	http://dx.doi.org/10.1016/S0140-6736(94)91580-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907679				2022-12-28	WOS:A1994NB80900009
J	JAVITT, NB; BUDAI, K; MILLER, DG; CAHAN, AC; RAJU, U; LEVITZ, M				JAVITT, NB; BUDAI, K; MILLER, DG; CAHAN, AC; RAJU, U; LEVITZ, M			BREAST GUT CONNECTION - ORIGIN OF CHENODEOXYCHOLIC ACID IN BREAST CYST FLUID	LANCET			English	Article							BILE-ACIDS; CANCER; IDENTIFICATION; ETIOLOGY; SERUM	The notion that a breast-gut connection might modulate the microenvironment of breast tissue was supported by the finding that breast cyst fluid contains bile acids that are characteristically found in the intestines. To establish that the gut, rather than circulating steroid precursors, is the source of bile acids in breast cyst fluid, we gave two patients deuterium-labelled chenodeoxycholic acid (three 200 mg doses by mouth), starting 9 days before aspiration of breast cysts. The chenodeoxycholic acid concentration of seven samples of aspirated cyst fluid ranged from 42 to 94 mu mol/L. The corresponding plasma concentrations of chenodeoxycholic acid on the same day were 0.80 and 2.90 mu mol/L, of which the labelled compound comprised 13.0% (0.38 mu mol/L) and 28.2% (0.23 mu mol/L). The deuterated chenodeoxycholic acid concentrations in cyst fluid were 1.8 and 1.4 mu mol/L in two samples from patient 1 and 4.7 mu mol/L in patient 2; these values are equivalent to 11-17% of the plasma concentrations. This study shows that intestinal bile acids rapidly gain access to cyst fluid. Further studies should investigate the mechanisms that govern the exchange processes and the maintenance of the high cyst fluid to plasma concentration gradients, and the biological half-lives of individual constituents.	NYU MED CTR, DEPT OBSTET & GYNECOL, NEW YORK, NY 10016 USA; STRANG CANC PREVENT CTR, NEW YORK, NY USA	New York University	JAVITT, NB (corresponding author), NYU MED CTR, DIV HEPAT DIS, NEW YORK, NY 10016 USA.			Javitt, Norman B/0000-0001-9265-3508	NATIONAL CANCER INSTITUTE [R01CA002071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032995] Funding Source: NIH RePORTER; NCI NIH HHS [CA02071] Funding Source: Medline; NIDDK NIH HHS [DK32995] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALI SS, 1970, CAN J BIOCHEM CELL B, V48, P1054, DOI 10.1139/o70-166; AXELSON M, 1988, J LIPID RES, V29, P629; BAKER PR, 1992, BRIT J CANCER, V65, P566, DOI 10.1038/bjc.1992.115; BAKER PR, 1988, BIOCHEM SOC T, V16, P741, DOI 10.1042/bst0160741; CHEAH PY, 1990, CANCER LETT, V49, P207, DOI 10.1016/0304-3835(90)90160-Y; DANIELSSON H, 1963, J BIOL CHEM, V238, P2299; GORBACH SL, 1984, REV INFECT DIS, V6, pS85; JAVITT NB, 1981, J BIOL CHEM, V256, P2644; JAVITT NB, 1989, BIOMED ENVIRON MASS, V18, P624, DOI 10.1002/bms.1200180820; MAHMOODA SK, 1982, CANCER RES, V42, P2792; MODAN B, 1977, CANCER-AM CANCER SOC, V40, P1887, DOI 10.1002/1097-0142(197710)40:4+<1887::AID-CNCR2820400819>3.0.CO;2-E; PETRAKIS NL, 1981, LANCET, V2, P1203; RAJU U, 1990, J CLIN ENDOCR METAB, V70, P1030, DOI 10.1210/jcem-70-4-1030; RANG EH, 1983, LANCET, V1, P1014	14	37	38	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 12	1994	343	8898					633	635		10.1016/S0140-6736(94)92635-2	http://dx.doi.org/10.1016/S0140-6736(94)92635-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906811	hybrid			2022-12-28	WOS:A1994NA09300008
J	MCCREADY, VR; HICKISH, TF				MCCREADY, VR; HICKISH, TF			SOMATOSTATIN IMAGING FUNCTION	LANCET			English	Editorial Material							CANCER		ROYAL MARSDEN HOSP,MED BREAST UNIT,SUTTON,SURREY,ENGLAND	Royal Marsden NHS Foundation Trust	MCCREADY, VR (corresponding author), ROYAL MARSDEN HOSP,DEPT NUCL MED,SUTTON,SURREY,ENGLAND.			Hickish, Tamas/0000-0001-6770-7279				BIHL H, 1992, HORMONE METABOLIC S, V27; FISHER B, 1991, MED MANAGEMENT BREAS, P281; LAMBERTS SWJ, 1987, EUR J CLIN INVEST, V17, P281, DOI 10.1111/j.1365-2362.1987.tb02188.x; PAGLIACCI MC, 1991, ENDOCRINOLOGY, V129, P2555, DOI 10.1210/endo-129-5-2555; REUBI JC, 1990, J STEROID BIOCHEM, V37, P1073, DOI 10.1016/0960-0760(90)90468-Z; SMITH IE, 1993, EUR J CANCER, V29A, P1796, DOI 10.1016/0959-8049(93)90133-Z; VOLKOW ND, 1992, SEMIN NUCL MED, V22, P254, DOI 10.1016/S0001-2998(05)80120-5	7	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 12	1994	343	8898					617	617		10.1016/S0140-6736(94)92631-X	http://dx.doi.org/10.1016/S0140-6736(94)92631-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906807				2022-12-28	WOS:A1994NA09300004
J	MELBYE, M; COTE, TR; KESSLER, L; GAIL, M; BIGGAR, RJ; LEMP, G; WEST, D; SINGLETON, J; YOUNG, J; KERNDT, P; DEAPEN, D; GINZBERG, M; ANTONCULVER, H; LIEB, S; HOPKINS, R; WILLIAMS, B; LIFF, J; MORGAN, D; PARKIN, W				MELBYE, M; COTE, TR; KESSLER, L; GAIL, M; BIGGAR, RJ; LEMP, G; WEST, D; SINGLETON, J; YOUNG, J; KERNDT, P; DEAPEN, D; GINZBERG, M; ANTONCULVER, H; LIEB, S; HOPKINS, R; WILLIAMS, B; LIFF, J; MORGAN, D; PARKIN, W			HIGH-INCIDENCE OF ANAL CANCER AMONG AIDS PATIENTS	LANCET			English	Article							IV HIV DISEASE; INTRAEPITHELIAL NEOPLASIA; PAPILLOMAVIRUS INFECTION; HUMAN IMMUNODEFICIENCY; HOMOSEXUAL MEN; MARITAL-STATUS; CARCINOMA; ASSOCIATION; PARALLEL	Until now, the only cancers that have been strongly associated with AIDS are Kaposi's sarcoma and non-Hodgkin lymphoma. We used a linkage between AIDS (50 050 reports) and cancer (859 398 reports) registries in seven health departments in the USA to investigate the association between HIV infection and epidermoid anal cancer. We compared the numbers of observed cases and expected cases, calculated from general population rates with adjustment for age, sex, and race. The relative risk of anal cancer at and after AIDS diagnosis was 84.1 (95% CI 46.4-152) among homosexual patients (11 cases) and 37.7 (9.4-151) among non-homosexual patients (2 cases). The relative risk of anal cancer up to 5 years before the AIDS diagnosis (23 cases) was also increased; it was 13.9 (6.6-29.2) in the period 2-5 years before AIDS and 27.4 (15.9-47.2) during the 2 years before AIDS diagnosis (p for trend = 0.004). Among homosexual men, the relative risk of anal cancer was inversely related to age at AIDS onset (p for trend < 0.001). Excess risks were found in all geographical areas. This study establishes a strikingly increased risk of anal cancer among people with AIDS, These data are consistent with a previously hypothesised association between HIV-induced immunodeficiency and anal cancer development, but because homosexual men were at increased risk of anal cancer even before the AIDS epidemic, we cannot say how much of the increased risk is attributable to HIV infection. Nevertheless, clinicians should be aware that AIDS patients have an increased risk of anal cancer.	NCI,DIV CANC ETIOL,VIRAL EPIDEMIOL BRANCH,ROCKVILLE,MD 20852; STATE SERUM INST,DANISH EPIDEMIOL SCI CTR,COPENHAGEN,DENMARK; NCI,DIV CANC PREVENT & CONTROL,APPL RES BRANCH,ROCKVILLE,MD 20852; NCI,DIV CANC ETIOL,BIOSTAT BRANCH,ROCKVILLE,MD 20852	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Aarhus University; Statens Serum Institut; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				melbye, mads/0000-0001-8264-6785				ADAM YG, 1987, SURGERY, V101, P253; BIGGAR RJ, 1994, AM J EPIDEMIOL, V139, P362, DOI 10.1093/oxfordjournals.aje.a117008; BLOHME I, 1985, TRANSPLANTATION, V39, P23; Breslow NE., 1987, STATISTICAL METHODS, P48; CAUSSY D, 1990, INT J CANCER, V46, P214, DOI 10.1002/ijc.2910460212; COTE T, 1993, 9TH INT C AIDS BERL; COTE TR, 1993, J NATL CANCER I, V85, P1113; DALING JR, 1987, NEW ENGL J MED, V317, P973, DOI 10.1056/NEJM198710153171601; FELDMAN AR, 1986, NEW ENGL J MED, V315, P1394, DOI 10.1056/NEJM198611273152206; FRAZER IH, 1986, LANCET, V2, P657; FRISCH M, 1993, BMJ-BRIT MED J, V306, P419, DOI 10.1136/bmj.306.6875.419; GOLDMAN S, 1989, ACTA CHIR SCAND, V155, P191; HOLLY EA, 1989, JNCI-J NATL CANCER I, V81, P1726, DOI 10.1093/jnci/81.22.1726; KIVIAT N, 1990, J INFECT DIS, V162, P358, DOI 10.1093/infdis/162.2.358; MELBYE M, 1991, LANCET, V338, P657, DOI 10.1016/0140-6736(91)91233-K; MELBYE M, 1990, INT J CANCER, V46, P203, DOI 10.1002/ijc.2910460210; MELBYE M, 1940, IN PRESS AM J EPIDEM; PALEFSKY JM, 1990, JAMA-J AM MED ASSOC, V263, P2911, DOI 10.1001/jama.263.21.2911; PALEFSKY JM, 1992, J ACQ IMMUN DEF SYND, V5, P1258; PENN I, 1986, CANCER-AM CANCER SOC, V58, P611, DOI 10.1002/1097-0142(19860801)58:3<611::AID-CNCR2820580303>3.0.CO;2-M; PETERS RK, 1983, BRIT J CANCER, V48, P629, DOI 10.1038/bjc.1983.244; RABKIN CS, 1991, CANCER SURV, V10, P151; RABKIN CS, 1992, AM J EPIDEMIOL, V136, P54, DOI 10.1093/oxfordjournals.aje.a116420; RIES LG, 1983, JNCI-J NATL CANCER I, V70, P693; SCHOLEFIELD JH, 1989, LANCET, V2, P765; SCHOLEFIELD JH, 1992, LANCET, V340, P1271, DOI 10.1016/0140-6736(92)92961-E; SCHOLEFIELD JH, 1990, BRIT J CANCER, V62, P286, DOI 10.1038/bjc.1990.279; 1992, MMWR, V41, P1; 1980, INT CLASSIFICATION D	29	208	210	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 12	1994	343	8898					636	639		10.1016/S0140-6736(94)92636-0	http://dx.doi.org/10.1016/S0140-6736(94)92636-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906812				2022-12-28	WOS:A1994NA09300009
J	CHAPPELL, PB				CHAPPELL, PB			SEQUENTIAL USE OF OPIOID ANTAGONISTS AND AGONISTS IN TOURETTES-SYNDROME	LANCET			English	Editorial Material											CHAPPELL, PB (corresponding author), YALE UNIV,CTR CHILD STUDY,NEW HAVEN,CT 06520, USA.							BRUUN R, 1991, MOVEMENT DISORD, V6, P184, DOI 10.1002/mds.870060221; CHAPPELL PB, 1992, TOURETTES SYNDROME N, P253; CHAPPELL PB, 1992, PSYCHIAT RES, V47, P267; HOFFMAN DC, 1991, BRAIN RES, V550, P205, DOI 10.1016/0006-8993(91)91319-V; KURLAN R, 1991, ANN NEUROL, V30, P19, DOI 10.1002/ana.410300105; MEULDIJK R, 1992, AM J PSYCHIAT, V149, P139; REISINE T, 1993, TRENDS NEUROSCI, V16, P506, DOI 10.1016/0166-2236(93)90194-Q	7	8	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 5	1994	343	8897					556	556		10.1016/S0140-6736(94)91516-4	http://dx.doi.org/10.1016/S0140-6736(94)91516-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906324				2022-12-28	WOS:A1994MY84300004
J	HOFMAN, A; GEELKERKEN, RH; WILLE, J; HAMMING, J; HERMANS, J; BRESLAU, P				HOFMAN, A; GEELKERKEN, RH; WILLE, J; HAMMING, J; HERMANS, J; BRESLAU, P			PRESSURE SORES AND PRESSURE-DECREASING MATTRESSES - CONTROLLED CLINICAL-TRIAL	LANCET			English	Article							ELDERLY PATIENTS	Pressure sores are a problem, especially in elderly patients. Our study was designed to determine the effectiveness in pressure-sore prevention of a new interface-pressure decreasing mattress. In a prospective randomised controlled clinical trial we tested the Comforter DeCube mattress (Comforter, Winona, USA) against our standard hospital mattress in 44 patients with femoral-neck fracture and concomitant high pressure-sore risk score. In addition both groups were treated according to the Dutch consensus protocol for the prevention of pressure sores. On admission and 1 and 2 weeks after admission, pressure sores were graded. The two groups were similar in patient characteristics and pressure-sore risk factors. At 1 week, 25% of the patients nursed on the DeCube mattress and 64% of the patients nursed on the standard mattress had clinically relevant pressure sores (grade 2 or more). At 2 weeks the figures were 24% and 68%, respectively. The maximum score over the several body regions of the pressure-sore grading, measured on a 5-point scale, was significantly different in favour of the DeCube mattress at 1 week (p=0.0043) and 2 weeks (p=0.0067) postoperatively. We show that the occurrence of pressure sores and their severity can be significantly reduced when patients at risk are nursed on an interface-pressure decreasing mattress.	UNIV HOSP LEIDEN, DEPT SURG, 2300 RC LEIDEN, NETHERLANDS; LEIDEN UNIV, DEPT MED STAT, 2300 RA LEIDEN, NETHERLANDS; RED CROSS HOSP, DEPT SURG, THE HAGUE, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University - Excl LUMC			Geelkerken, R. H./AAF-7404-2019					BAKKER, 1985, CONSENSUS BIJEENKOMS; BARBENEL JC, 1977, LANCET, V2, P548; BASTOW MD, 1983, BRIT MED J, V287, P1589, DOI 10.1136/bmj.287.6405.1589; Bliss M R, 1993, Prof Nurse, V8, P437; Bliss M R, 1993, Prof Nurse, V8, P292; Bliss M R, 1993, Prof Nurse, V8, ppassim; BLISS MR, 1967, BRIT MED J, V1, P394, DOI 10.1136/bmj.1.5537.394; COUGHLIN L, 1980, CLIN ORTHOP RELAT R, P192; DANIEL RK, 1981, ARCH PHYS MED REHAB, V62, P492; EXTONSMITH AN, 1982, LANCET, V1, P1288; Fernie GR, 1976, BEDSORE BIOMECHANICS, P315; FERRELL BA, 1993, JAMA-J AM MED ASSOC, V269, P494, DOI 10.1001/jama.269.4.494; FLECK A, 1991, LANCET, V337, P793, DOI 10.1016/0140-6736(91)91412-N; Fleiss JL, 1981, STAT METHODS RATES P; HAALBOOM JRE, 1990, S P EXERPTA MED, P39; KEMP MG, 1993, RES NURS HEALTH, V16, P89, DOI 10.1002/nur.4770160203; McCORMICK W. J., 1941, Medical Record, New York, V154, P389; Petrie L A, 1990, J Enterostomal Ther, V17, P212; VERSLUYSEN M, 1986, BRIT MED J, V292, P1311, DOI 10.1136/bmj.292.6531.1311; Warner D J, 1992, Decubitus, V5, P52; YOUNG JB, 1990, BMJ-BRIT MED J, V300, P1002, DOI 10.1136/bmj.300.6730.1002	21	73	75	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 5	1994	343	8897					568	571		10.1016/S0140-6736(94)91521-0	http://dx.doi.org/10.1016/S0140-6736(94)91521-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906329				2022-12-28	WOS:A1994MY84300009
J	LUSSO, P; GALLO, RC				LUSSO, P; GALLO, RC			HUMAN HERPESVIRUS-6 IN AIDS	LANCET			English	Editorial Material							VIRUS				LUSSO, P (corresponding author), NCI,TUMOR CELL BIOL LAB,BLDG 37,BETHESDA,MD 20892, USA.							CARRIGAN DR, 1991, LANCET, V338, P147, DOI 10.1016/0140-6736(91)90137-E; CORBELLINO M, 1993, LANCET, V342, P1242, DOI 10.1016/0140-6736(93)92226-J; LUSSO P, 1988, J EXP MED, V167, P1659, DOI 10.1084/jem.167.5.1659; LUSSO P, IN PRESS INTERACTION; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; YAMANISHI K, 1988, LANCET, V1, P1065	6	29	30	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 5	1994	343	8897					555	556		10.1016/S0140-6736(94)91515-6	http://dx.doi.org/10.1016/S0140-6736(94)91515-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906323				2022-12-28	WOS:A1994MY84300003
J	ASTROW, AB				ASTROW, AB			RETHINKING CANCER	LANCET			English	Editorial Material											ASTROW, AB (corresponding author), ST VINCENTS HOSP & MED CTR,DEPT MED,NEW YORK,NY 10011, USA.							BAILAR JC, 1986, NEW ENGL J MED, V314, P1226, DOI 10.1056/NEJM198605083141905; CHABNER BA, 1986, J CLIN ONCOL, V4, P625; DEVITA VT, 1993, PRINCIPLES CHEMOTHER, P289; LEDER P, 1993, 35TH ANN M; SCHIPPER H, 1993, CAN J ONCOL, V3, P207; SCHIPPER H, 1993, CAN J ONCOL, V3, P220; SCHNIPPER LE, 1986, NEW ENGL J MED, V314, P1423; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; 1993, NIH OBSERVER, V4, P1	9	20	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					494	495		10.1016/S0140-6736(94)91454-0	http://dx.doi.org/10.1016/S0140-6736(94)91454-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906753				2022-12-28	WOS:A1994MX88800002
J	CHARLTON, BG				CHARLTON, BG			IS INEQUALITY BAD FOR THE NATIONAL-HEALTH	LANCET			English	Editorial Material							SOCIOECONOMIC DIFFERENTIALS; MORTALITY; WHITEHALL				CHARLTON, BG (corresponding author), UNIV NEWCASTLE UPON TYNE,DEPT EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,ENGLAND.							ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; Antonovsky Aaron, 1985, HLTH STRESS COPING; BLANE D, 1993, SOCIOLOGY HLTH ILLNE, V15, P1, DOI DOI 10.1111/J.1467-9566.1993.TB00328.X; EAMES M, 1993, BRIT MED J, V307, P1097, DOI 10.1136/bmj.307.6912.1097; FEINSTEIN JS, 1993, MILBANK Q, V71, P279, DOI 10.2307/3350401; GURALNIK JM, 1993, NEW ENGL J MED, V329, P110, DOI 10.1056/NEJM199307083290208; KEIL JE, 1993, NEW ENGL J MED, V329, P73, DOI 10.1056/NEJM199307083290201; KELLY MP, 1992, BRIT J GEN PRACT, V42, P223; KELLY MP, 1993, HLTH CITIES RES PRAC; LEFANU J, 1993, PHANTOM CARNAGE; M'Gonigle G., 1936, POVERTY PUBLIC HLTH; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; SMITH GD, 1992, AM J PUBLIC HEALTH, V82, P1079, DOI 10.2105/AJPH.82.8.1079; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; SMITH GD, 1990, BMJ-BRIT MED J, V301, P373, DOI 10.1136/bmj.301.6748.373; SMITH GD, 1992, BRIT MED J, V305, P1554, DOI 10.1136/bmj.305.6868.1554; TOWNSEND P, 1982, BLACK REPORT HLTH DI; Townsend P., 1986, INEQUALITIES HLTH NO	19	19	20	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 22	1994	343	8891					221	222		10.1016/S0140-6736(94)90996-2	http://dx.doi.org/10.1016/S0140-6736(94)90996-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MT332	7904673				2022-12-28	WOS:A1994MT33200015
J	DOBYNS, WB; REINER, O; CARROZZO, R; LEDBETTER, DH				DOBYNS, WB; REINER, O; CARROZZO, R; LEDBETTER, DH			LISSENCEPHALY - A HUMAN BRAIN MALFORMATION ASSOCIATED WITH DELETION OF THE LIS1 GENE LOCATED AT CHROMOSOME-17P13	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							MILLER-DIEKER SYNDROME; SUBMICROSCOPIC DELETIONS; INSITU HYBRIDIZATION; MUSCULAR-DYSTROPHY; DUCHENNE; REGION	Objective.-We review the clinical phenotype, pathological changes, and results of cytogenetic and molecular genetic studies in 90 probands with lissencephaly (smooth brain) with emphasis on patients with the classical form (type I). We also describe the recent discovery of the lissencephaly gene (LIS1), deletions of which have been implicated as the cause of this disorder in many patients. Data Sources.-We have performed clinical, cytogenetic, and molecular genetic studies of 25 probands with Miller-Dieker syndrome and 65 probands with isolated lissencephaly sequence (ILS). We have further subdivided patients with ILS into those with classical lissencephaly and those with lissencephaly variants. Study Selection.-We consider primarily our own published and unpublished data, but include references to studies of other series of patients with lissencephaly. Data Synthesis.-Visible cytogenetic deletions of 17p13.3 were detected in 14 of 25 Miller-Dieker syndrome probands, and either visible cytogenetic or submicroscopic deletions in 23 (92%) of 25. Submicroscopic deletions were detected in eight of 45 patients with all types of ILS. If only ILS patients with the classical form are considered, we detected deletions in eight (38%) of 21. Conclusions.-Deletions of the lissencephaly critical region in chromosome 17p13.3, including LIS1, appear to be the most frequent cause of classical lissencephaly. Molecular cytogenetic studies, particularly fluorescence in situ hybridization, should be performed in all such patients. LIS1 shows homology to genes involved in signal transduction, which may be its function in development of the telencephalon. Other genetic causes of classical lissencephaly and genetic and nongenetic causes of other types of lissencephaly exist and are under study.	NATL CTR HUMAN GENOME RES,BLDG 49,ROOM 4A38,BETHESDA,MD 20892; UNIV MINNESOTA,SCH MED,DEPT NEUROL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT PEDIAT,MINNEAPOLIS,MN 55455; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Baylor College of Medicine			Dobyns, William Brian/ABC-6525-2021; Dobyns, William/AAI-2768-2020; Reiner, Orly/E-9455-2010	Dobyns, William/0000-0002-7681-2844; Reiner, Orly/0000-0001-7560-9599	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020619] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20619] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARTH PG, 1987, CAN J NEUROL SCI, V14, P1; BAUMBACH LL, 1989, NEUROLOGY, V39, P465, DOI 10.1212/WNL.39.4.465; BERRYKRAVIS E, 1992, ANN NEUROL, V32, P482; CARROZZO R, 1992, HUM MOL GENET, V2, P615; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; DERIJKVANANDEL JF, 1991, NEUROEPIDEMIOLOGY, V10, P200, DOI 10.1159/000110270; DERIJKVANANDEL JF, 1990, DEV MED CHILD NEUROL, V32, P707; Dobyns W B, 1987, Birth Defects Orig Artic Ser, V23, P225; DOBYNS WB, 1991, AM J HUM GENET, V48, P584; DOBYNS WB, 1992, NEUROLOGY, V42, P1375, DOI 10.1212/WNL.42.7.1375; DOBYNS WB, 1993, BRAIN DEV-JPN, V15, P242, DOI 10.1016/0387-7604(93)90074-I; DOBYNS WB, 1989, NEUROL CLIN, V7, P89, DOI 10.1016/S0733-8619(18)30830-2; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; GILLARD EF, 1989, AM J HUM GENET, V45, P507; JESSELL TM, 1993, CELL, V72, P1, DOI 10.1016/S0092-8674(05)80025-X; KOENIG M, 1989, AM J HUM GENET, V45, P498; KUWANO A, 1991, AM J HUM GENET, V49, P707; LEDBETTER DH, 1989, P NATL ACAD SCI USA, V86, P5136, DOI 10.1073/pnas.86.13.5136; LEDBETTER SA, 1992, AM J HUM GENET, V50, P182; OOSTRA BA, 1991, AM J MED GENET, V40, P383, DOI 10.1002/ajmg.1320400328; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; SCHMICKEL RD, 1986, J PEDIATR-US, V109, P231, DOI 10.1016/S0022-3476(86)80377-8; SCHWARTZ CE, 1988, AM J HUM GENET, V43, P597; TRASK BJ, 1991, TRENDS GENET, V7, P149, DOI 10.1016/0168-9525(91)90378-4; VANTUINEN P, 1988, AM J HUM GENET, V43, P587; WALSH C, 1993, NATURE, V362, P632, DOI 10.1038/362632a0	26	330	337	0	29	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1993	270	23					2838	2842		10.1001/jama.270.23.2838	http://dx.doi.org/10.1001/jama.270.23.2838			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK941	7907669				2022-12-28	WOS:A1993MK94100034
J	HASLAM, PL; HUGHES, DA; MACNAUGHTON, PD; BAKER, CS; EVANS, TW				HASLAM, PL; HUGHES, DA; MACNAUGHTON, PD; BAKER, CS; EVANS, TW			SURFACTANT REPLACEMENT THERAPY IN LATE-STAGE ADULT-RESPIRATORY-DISTRESS-SYNDROME	LANCET			English	Note								In four adult patients with late-stage acute respiratory distress syndrome (ARDS), a single dose of the artificial surfactant ALEC was given by intrabronchial instillation. There was no sustained clinical improvement, but bronchoalveolar lavage measurements indicated that phosphatidylcholine (PC) at 24 h after treatment had increased up to 4.4 fold and phosphatidylglycerol up to 34.7 fold. However, PC relative to total phospholipid remained below normal, and protein contamination relative to PC remained above normal. Thus, therapeutic formulations and regimens to achieve greater and more sustained supplementation of PC may be required in patients with late-stage ARDS.	ROYAL BROMPTON NATL HEART & LUNG HOSP,ADULT INTENS CARE UNIT,LONDON SW3 6NP,ENGLAND	Imperial College London	HASLAM, PL (corresponding author), NATL HEART & LUNG INST,CELL BIOL UNIT,LONDON SW3 6LY,ENGLAND.							HUGHES DA, 1990, EUR RESPIR J, V3, P1128; IKEGAMI M, 1993, AM REV RESPIR DIS, V148, P837, DOI 10.1164/ajrccm/148.4_Pt_1.837; JOBE A, 1987, AM REV RESPIR DIS, V136, P1256, DOI 10.1164/ajrccm/136.5.1256; LACHMANN B, 1989, EUR RESPIR J S3, V2, pS98; LEWIS JF, 1993, AM REV RESPIR DIS, V147, P218, DOI 10.1164/ajrccm/147.1.218; Morley C J, 1989, Eur Respir J Suppl, V3, p81s; NOSAKA S, 1990, LANCET, V336, P947, DOI 10.1016/0140-6736(90)92325-C; RICHMAN PS, 1989, EUR RESPIR J S3, V2, pS109; SEEGER W, 1993, EUR RESPIR J, V6, P971; WIEDEMANN H, 1992, American Review of Respiratory Disease, V145, pA184	10	34	34	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 23	1994	343	8904					1009	1011		10.1016/S0140-6736(94)90128-7	http://dx.doi.org/10.1016/S0140-6736(94)90128-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909050				2022-12-28	WOS:A1994NG68200011
J	ZHUO, M; HU, YH; SCHULTZ, C; KANDEL, ER; HAWKINS, RD				ZHUO, M; HU, YH; SCHULTZ, C; KANDEL, ER; HAWKINS, RD			ROLE OF GUANYLYL CYCLASE AND CGMP-DEPENDENT PROTEIN-KINASE IN LONG-TERM POTENTIATION	NATURE			English	Article							CYCLIC-GMP FORMATION; NITRIC-OXIDE; CORTICAL-NEURONS; INVOLVEMENT; CEREBELLUM; DEPRESSION; RELEASE	SEVERAL lines of evidence suggest that cyclic GMP might be involved in long-term potentiation (LTP) in the hippocampus1-6. Arachidonic acid, nitric oxide and carbon monoxide, three molecules that have been proposed to act as retrograde messengers in LTP7-9, all activate soluble guanylyl cyclase1,10,11. We report here that an inhibitor of guanylyl cyclase blocks the induction of LTP in the CA1 region of hippocampal slices. Conversely, cGMP analogues produce long-lasting enhancement of the excitatory postsynaptic potential if they are applied at the same time as weak tetanic stimulation of the presynaptic fibres. The enhancement is spatially restricted, is not blocked by valeric acid (APV), nifedipine, or picrotoxin, and partially occludes LTP. This synaptic enhancement may be mediated by the cGMP-dependent protein kinase (PKG). Inhibitors of PKG block the induction of LTP, and activators of PKG produce activity-dependent long-lasting enhancement. These results suggest that guanylyl cyclase and PKG contribute to LTP, possibly as activity-dependent presynaptic effectors of retrograde messengers.	NEW YORK STATE PSYCHIAT INST & HOSP,NEW YORK,NY 10032; HOWARD HUGHES MED INST,NEW YORK,NY 10032; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093	New York State Psychiatry Institute; Howard Hughes Medical Institute; University of California System; University of California San Diego	ZHUO, M (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032, USA.		Zhuo, Min/A-2072-2008	Zhuo, Min/0000-0001-9062-3241; Schultz, Carsten/0000-0002-5824-2171				Arancio O., 1993, Society for Neuroscience Abstracts, V19, P241; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRONS JF, 1980, J NEUROPHYSIOL, V44, P605, DOI 10.1152/jn.1980.44.3.605; CHETKOVICH DM, 1993, NEUROREPORT, V4, P919, DOI 10.1097/00001756-199307000-00020; DEVENTE J, 1992, ACTA HISTOCHEM, V92, P13, DOI 10.1016/S0065-1281(11)80138-8; EAST SJ, 1991, NEUROSCI LETT, V123, P17, DOI 10.1016/0304-3940(91)90147-L; FLEISCH JH, 1984, J PHARMACOL EXP THER, V229, P681; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GEIGER J, 1992, P NATL ACAD SCI USA, V89, P1031, DOI 10.1073/pnas.89.3.1031; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HAWKINS RD, IN PRESS J NEUROBIOL; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; Ito M, 1990, Neuroreport, V1, P129; SCHLICHTER DJ, 1978, NATURE, V273, P61, DOI 10.1038/273061a0; SCHULTZ C, 1993, J BIOL CHEM, V268, P6316; SCHULZ S, 1991, TRENDS PHARMACOL SCI, V12, P116, DOI 10.1016/0165-6147(91)90519-X; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SNIDER RM, 1984, P NATL ACAD SCI-BIOL, V81, P3905, DOI 10.1073/pnas.81.12.3905; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; TSOU K, 1993, P NATL ACAD SCI USA, V90, P3462, DOI 10.1073/pnas.90.8.3462; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x; WOODY CD, 1978, BRAIN RES, V158, P373, DOI 10.1016/0006-8993(78)90682-0; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368; ZHUO M, IN PRESS NEURO REPOR	28	331	347	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					635	639		10.1038/368635a0	http://dx.doi.org/10.1038/368635a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	7908417				2022-12-28	WOS:A1994NF39200061
J	MAHAN, MJ				MAHAN, MJ			REVEALING BACTERIAL-INFECTION STRATEGIES	LANCET			English	Editorial Material							INTEGRATION HOST FACTOR; SALMONELLA-TYPHIMURIUM; VIRULENCE; AVIRULENT; STRAINS				MAHAN, MJ (corresponding author), UNIV CALIF SANTA BARBARA,SANTA BARBARA,CA 93106, USA.							CAMILLI A, IN PRESS P NATL ACAD; DORMAN CJ, 1987, J BACTERIOL, V169, P3840, DOI 10.1128/jb.169.8.3840-3843.1987; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; LEUNK RD, 1982, INFECT IMMUN, V36, P1168, DOI 10.1128/IAI.36.3.1168-1174.1982; LOCKMAN HA, 1992, INFECT IMMUN, V60, P491, DOI 10.1128/IAI.60.2.491-496.1992; MAHAN MJ, 1993, SCIENCE, V259, P666; MAHAN MJ, 1994, INFECTIOUS AGENTS DI, V2, P263; Makela P. H., 1984, HDB ENDOTOXIN, P59; MCFARLAND WC, 1987, MICROB PATHOGENESIS, V3, P129, DOI 10.1016/0882-4010(87)90071-4; MEKALANOS JJ, 1992, J BACTERIOL, V174, P1; MILLER JF, 1989, SCIENCE, V243, P916, DOI 10.1126/science.2537530; Neuhard J, 1987, ESCHERICHIA COLI SAL, P445; NNALUE NA, 1990, INFECT IMMUN, V58, P2493, DOI 10.1128/IAI.58.8.2493-2501.1990; PLUM G, 1994, INFECT IMMUN, V62, P476, DOI 10.1128/IAI.62.2.476-483.1994	15	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 9	1994	343	8902					869	870		10.1016/S0140-6736(94)90005-1	http://dx.doi.org/10.1016/S0140-6736(94)90005-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF213	7908355				2022-12-28	WOS:A1994NF21300005
J	MITCHELL, I; WEBB, M; HUGHES, R; MAISEY, M; CAMERON, JS				MITCHELL, I; WEBB, M; HUGHES, R; MAISEY, M; CAMERON, JS			CEREBRAL LUPUS	LANCET			English	Discussion							CENTRAL-NERVOUS-SYSTEM; POSITRON EMISSION TOMOGRAPHY; ANTI-DNA; ERYTHEMATOSUS; INVOLVEMENT; ANTICARDIOLIPIN; VASCULITIS		GUYS HOSP, DEPT MED, LONDON SE1 9RT, ENGLAND; GUYS & ST THOMAS HOSP, UNITED MED & DENT SCH, LONDON, ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London				Mitchell, Imogen/0000-0001-6013-4922				BOUMPAS DT, 1991, Q J MED, V81, P975, DOI 10.1093/qjmed/81.3.975; BOUMPAS TD, 1992, NEW ENGL J MED, V340, P741; ELLISON D, 1993, J CLIN PATHOL, V46, P37, DOI 10.1136/jcp.46.1.37; EUSTACE S, 1991, Q J MED, V80, P739; Gladman Dafna D., 1992, Current Opinion in Rheumatology, V4, P681; HANSON VG, 1992, J EXP MED, V176, P565, DOI 10.1084/jem.176.2.565; HIRAIWA M, 1983, AM J NEURORADIOL, V4, P541; HUGHES GRV, 1993, LANCET, V342, P341, DOI 10.1016/0140-6736(93)91477-4; JOHNSON RT, 1968, MEDICINE, V47, P337, DOI 10.1097/00005792-196807000-00002; JONGEN PJH, 1990, NEUROLOGY, V40, P1593, DOI 10.1212/WNL.40.10.1593; LOVE PE, 1990, ANN INTERN MED, V112, P682, DOI 10.7326/0003-4819-112-9-682; PINCHING AJ, 1978, LANCET, V1, P898; SCHWARTZ MM, 1983, CLIN IMMUNOL IMMUNOP, V29, P369, DOI 10.1016/0090-1229(83)90040-5; SIBLEY JT, 1992, J RHEUMATOL, V19, P47; SMEENK RJT, 1987, ARTHRITIS RHEUM-US, V30, P607, DOI 10.1002/art.1780300602; SMEENK RJT, 1988, J IMMUNOL METHODS, V109, P27, DOI 10.1016/0022-1759(88)90438-3; STOPPE G, 1990, NEUROLOGY, V40, P304, DOI 10.1212/WNL.40.2.304; TAN EM, 1966, J CLIN INVEST, V45, P1732, DOI 10.1172/JCI105479; TANTER Y, 1987, PLASMA THER TRANSFUS, V8, P161, DOI 10.1016/S0278-6222(87)80025-6; VIDAILHET M, 1990, STROKE, V21, P1226, DOI 10.1161/01.STR.21.8.1226; WALLACE DJ, 1984, DM-DIS MON, V30, P1; WEINER DK, 1991, J RHEUMATOL, V18, P748; WONG KL, 1991, Q J MED, V81, P857	23	28	31	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 5	1994	343	8897					579	582		10.1016/S0140-6736(94)91525-3	http://dx.doi.org/10.1016/S0140-6736(94)91525-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906333				2022-12-28	WOS:A1994MY84300013
J	RAMSAY, MM; RIMOY, GH; RUBIN, PC				RAMSAY, MM; RIMOY, GH; RUBIN, PC			ARE ANTICONVULSANTS NECESSARY TO PREVENT ECLAMPSIA	LANCET			English	Letter									MUHIMBILI MED CTR,DEPT CLIN PHARMACOL,DAR ES SALAAM,TANZANIA		RAMSAY, MM (corresponding author), QUEENS MED CTR,DEPT MED,DIV THERAPEUT,NOTTINGHAM NG7 2UH,NOTTS,ENGLAND.							DOMMISSE J, 1990, BRIT J OBSTET GYNAEC, V97, P104, DOI 10.1111/j.1471-0528.1990.tb01734.x; HORN EH, 1990, BRIT MED J, V301, P794, DOI 10.1136/bmj.301.6755.794; LEWIS LK, 1988, NEURORADIOLOGY, V30, P59, DOI 10.1007/BF00341945; TEMPLETON A, 1979, HLTH B           MAR, P55	4	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					540	541		10.1016/S0140-6736(94)91492-3	http://dx.doi.org/10.1016/S0140-6736(94)91492-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906779				2022-12-28	WOS:A1994MX88800043
J	HOPPLER, S; BIENZ, M				HOPPLER, S; BIENZ, M			SPECIFICATION OF A SINGLE-CELL TYPE BY A DROSOPHILA HOMEOTIC GENE	CELL			English	Article							HOMEOBOX-CONTAINING GENES; ECTOPIC EXPRESSION; VISCERAL MESODERM; C-ELEGANS; DEVELOPMENTAL ANALYSIS; ANTENNAPEDIA-COMPLEX; SPATIAL EXPRESSION; BITHORAX COMPLEX; AUTO-REGULATION; NERVOUS-SYSTEM	Homeotic genes function in blocks of cells along the body axis to specify diverse developmental pathways. Among the Drosophila homeotic genes, only one is known to be expressed in the endoderm. We show here that expression of this gene, labial (lab), coincides with copper cells, highly specialized cells of the larval midgut. lab is strictly required for copper cell formation, a requirement that starts in the embryo and extends through larval stages. This implies a function of lab not only in the determination and differentiation of copper cells, but also in the maintenance of their differentiated state. Ectopic expression of lab during embryogenesis reprograms other midgut cells within and outside the lab domain to become copper cell-like. Thus, lab functions in the larval midgut to specify a single cell type.			HOPPLER, S (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, CAMBS, ENGLAND.			Hoppler, Stefan/0000-0003-0730-4798				AKAM M, 1987, DEVELOPMENT, V101, P1; AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; BIENZ M, 1988, NATURE, V333, P576, DOI 10.1038/333576a0; BIENZ M, 1988, CELL, V53, P567, DOI 10.1016/0092-8674(88)90573-9; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BURGLIN TR, 1991, NATURE, V351, P703, DOI 10.1038/351703a0; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHISHOLM A, 1991, DEVELOPMENT, V111, P921; CHOUINARD S, 1991, DEVELOPMENT, V113, P1267; CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; DIEDERICH RJ, 1991, DEVELOPMENT, V113, P273; DIEDERICH RJ, 1989, GENE DEV, V3, P399, DOI 10.1101/gad.3.3.399; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; FILSHIE BK, 1971, TISSUE CELL, V3, P77, DOI 10.1016/S0040-8166(71)80033-2; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GIBSON G, 1988, DEVELOPMENT, V102, P657; GONZALEZREYES A, 1990, NATURE, V344, P78, DOI 10.1038/344078a0; HARTENSTEIN V, 1985, Wilhelm Roux's Archives of Developmental Biology, V194, P213, DOI 10.1007/BF00848248; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HEUER JG, 1992, DEVELOPMENT, V115, P35; HOOPER JE, 1986, EMBO J, V5, P2321, DOI 10.1002/j.1460-2075.1986.tb04500.x; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; KAUFMAN TC, 1980, GENETICS, V94, P115; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; Lawrence Peter A, 1993, MAKING FLY GENETICS, V6; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LEWIS EB, 1963, AM ZOOL, V3, P33; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MERRILL VKL, 1989, DEV BIOL, V135, P376, DOI 10.1016/0012-1606(89)90187-5; MLODZIK M, 1988, EMBO J, V7, P2569, DOI 10.1002/j.1460-2075.1988.tb03106.x; MORATA G, 1976, ROUX ARCH DEV BIOL, V179, P125, DOI 10.1007/BF00848298; MULLER J, 1992, EMBO J, V11, P3653, DOI 10.1002/j.1460-2075.1992.tb05450.x; MURPHY P, 1991, DEVELOPMENT, V111, P61; MURTHA MT, 1991, P NATL ACAD SCI USA, V88, P10711, DOI 10.1073/pnas.88.23.10711; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PENVY L, 1991, NATURE, V349, P257; Poulsen D. F., 1952, Experimental Cell Research New York Supplement, VNo. 2, P161; Poulson D. F., 1950, BIOL DROSOPHILA, P168; POULSON DF, 1950, GENETICS, V35, P684; POULSON DF, 1960, AUST J BIOL SCI, V13, P540; QIAN S, 1991, EMBO J, V10, P1415, DOI 10.1002/j.1460-2075.1991.tb07662.x; REUTER R, 1990, DEVELOPMENT, V109, P289; REUTER R, 1990, DEVELOPMENT, V110, P1031; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SANCHEZHERRERO E, 1985, NATURE, V313, P108, DOI 10.1038/313108a0; SCHALLER D, 1990, NUCLEIC ACIDS RES, V18, P2033, DOI 10.1093/nar/18.8.2033; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SCHUMMER M, 1992, EMBO J, V11, P1815, DOI 10.1002/j.1460-2075.1992.tb05233.x; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SKAER H, 1993, IN PRESS DEV DROSOPH; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; TEUGELS E, 1985, NATURE, V314, P558, DOI 10.1038/314558a0; TREMML G, 1992, DEVELOPMENT, V116, P447; TREMML G, 1989, EMBO J, V8, P2677, DOI 10.1002/j.1460-2075.1989.tb08408.x; TREMML G, 1991, THESIS U ZURICH ZURI; WAKIMOTO BT, 1981, DEV BIOL, V81, P51, DOI 10.1016/0012-1606(81)90347-X; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEINZIERL R, 1987, GENE DEV, V1, P386, DOI 10.1101/gad.1.4.386; WHITE RAH, 1984, CELL, V39, P163, DOI 10.1016/0092-8674(84)90202-2	71	89	93	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 25	1994	76	4					689	702		10.1016/0092-8674(94)90508-8	http://dx.doi.org/10.1016/0092-8674(94)90508-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	7907275				2022-12-28	WOS:A1994MZ28500011
J	GOLDHIRSCH, A; GELBER, RD; PRICE, KN; CASTIGLIONE, M; COATES, AS; RUDENSTAM, CM; COLLINS, J; LINDTNER, J; HACKING, A; MARINI, G; BYRNE, M; CORTESFUNES, H; SCHNURCH, G; BRUNNER, KW; TATTERSALL, MHN; FORBES, J; SENN, HJ				GOLDHIRSCH, A; GELBER, RD; PRICE, KN; CASTIGLIONE, M; COATES, AS; RUDENSTAM, CM; COLLINS, J; LINDTNER, J; HACKING, A; MARINI, G; BYRNE, M; CORTESFUNES, H; SCHNURCH, G; BRUNNER, KW; TATTERSALL, MHN; FORBES, J; SENN, HJ			EFFECT OF SYSTEMIC ADJUVANT TREATMENT ON FIRST SITES OF BREAST-CANCER RELAPSE	LANCET			English	Article							PAST DECADE	Adjuvant systemic treatment for resectable breast cancer changes the natural history of the disease but provides only a small and delayed effect on survival. Evaluation of the types of first relapse avoided by available treatments may explain why effects on mortality are small and appear late during follow-up. In randomised clinical trials done by the International Breast Cancer Study Group (IBCSG) between 1978 and 1985, 2108 patients with node-positive disease received more-effective treatments (6 or more cycles of cyclophosphamide, methotrexate, fluorouracil and prednisone; with or without tamoxifen, or tamoxifen and prednisone alone), and 722 patients received less-effective treatments (no treatment or a single cycle of chemotherapy). 3 main categories of first site of relapse were defined and evaluated by cumulative incidence analysis: local or regional, and distant soft tissue,bone, and viscera. The more-effective treatments reduced the cumulative incidence of first relapse in local or regional and distant soft tissue sites at 10 years from 36% to 18% (p=00001); first relapse in bone and viscera was not altered by the more-effective treatments. These results were similar for premenopausal and postmenopausal women, and for patients with oestrogen-receptor-positive or oestrogen-receptor-negative tumours. Adjuvant systemic treatments in current use improve patient outcome mainly by reducing the incidence of first local or regional and distant soft-tissue relapses, while first recurrences in bone or viscera are influenced much less. More intensive treatments at present being tested in clinical trials might affect bone and visceral relapses and have a greater and earlier influence on survival.	DANA FARBER CANC INST,INT BREAST CANC STUDY GRP STAT CTR,DIV BIOSTAT,BOSTON,MA 02115; OSPED CIVICO,LUGANO,SWITZERLAND; IBCSG COORDINATING CTR,BERN,SWITZERLAND; ROYAL PRINCE ALFRED HOSP,CAMPERDOWN,NSW,AUSTRALIA; SAHLGRENS UNIV HOSP,GOTHENBURG,SWEDEN; ANTICANC COUNCIL VICTORIA,CARLTON,VIC,AUSTRALIA; INST ONCOL,LJUBLJANA,SLOVENIA; GROOTE SCHUUR HOSP,CAPE TOWN,SOUTH AFRICA; SPEDALI CIVIL BRESCIA,BRESCIA,ITALY; SIR CHARLES GALRDNER HOSP,NEDLANDS,WA,AUSTRALIA; MADRID BREAST CANC GRP,MADRID,SPAIN; UNIV DUSSELDORF,DUSSELDORF,GERMANY; INSELSPITAL BERN,CH-3010 BERN,SWITZERLAND; ROYAL PRINCE ALFRED HOSP,CAMPERDOWN,NSW,AUSTRALIA; MATER MISERICORDLAE HOSP,WARATAH,NSW,AUSTRALIA; KANTONSSPITAL,ST GALLEN,SWITZERLAND	Harvard University; Dana-Farber Cancer Institute; University of Sydney; Sahlgrenska University Hospital; Institute of Oncology - Slovenia; University of Cape Town; Hospital Spedali Civili Brescia; Heinrich Heine University Dusseldorf; University of Sydney; Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen								BUDMAN DR, 1992, P AN M AM SOC CLIN, V11, P51; COX DR, 1972, J R STAT SOC B, V34, P187; DONEGAN W L, 1970, Missouri Medicine, V67, P853; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; GELBER RD, 1991, ANN INTERN MED, V114, P621, DOI 10.7326/0003-4819-114-8-621; GOLDHIRSCH A, 1988, J CLIN ONCOL, V6, P89, DOI 10.1200/JCO.1988.6.1.89; GOLDHIRSCH A, 1987, LANCET, V2, P151; GOLDHIRSCH A, 1986, NCI MONOGRAPHS, V1, P55; GOLDHIRSCH A, 1984, LANCET, V2, P922; Goldhirsch A, 1992, J NCI MONOGR, V11, P89; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Greenwood M., 1926, REPORTS PUBLIC HLTH, V33, P1; HAYES DF, 1991, BREAST DISEASES, P505; HENDERSON IC, 1980, NEW ENGL J MED, V302, P17, DOI 10.1056/NEJM198001033020104; HENDERSON IC, 1980, NEW ENGL J MED, V302, P78, DOI 10.1056/NEJM198001103020203; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P169; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; PEDRAZZINI A, 1986, J CLIN ONCOL, V3, P389; VALAGUSSA P, 1982, BREAST CANCER RES TR, V1, P349; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421; 1978, CANCER, V42, P2809; 1983, LANCET, V2, P542; 1984, LANCET, V1, P1256; 1989, NEW ENGL J MED, V320, P491; 1988, NEW ENGL J MED, V319, P677; 1992, LANCET, V339, P71	27	72	74	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					377	381		10.1016/S0140-6736(94)91221-1	http://dx.doi.org/10.1016/S0140-6736(94)91221-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905550				2022-12-28	WOS:A1994MW28300007
J	OGRADY, J; STEWART, S; ELTON, RA; KRAJEWSKI, AS				OGRADY, J; STEWART, S; ELTON, RA; KRAJEWSKI, AS			EPSTEIN-BARR-VIRUS IN HODGKINS-DISEASE AND SITE OF ORIGIN OF TUMOR	LANCET			English	Note							PERSISTENCE; CELLS	Epstein-Barr virus (EBV) may be involved in the pathogenesis of Hodgkin's disease. We investigated whether EBV in Hodgkin's disease is related to the site of origin of the tumour. In 40 patients with stage I disease, there was a significant association between EBV latent membrane protein (LMP-1) expression and presentation in neck lymph nodes. There was no association in stage II-IV disease (57 cases). Nodular sclerosing subtype was rarely associated with LMP-1 expression. In some cases of Hodgkin's disease of mixed cellularity or lymphocyte predominant subtype originating in the neck, EBV may be an important aetiological co-factor.	UNIV EDINBURGH,MED STAT UNIT,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	University of Edinburgh	OGRADY, J (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PATHOL,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							ALLDAY MJ, 1988, LANCET, V1, P855; ARMSTRONG AA, 1992, LEUKEMIA, V6, P869; BURKITT D, 1958, BRIT J SURG, V46, P218, DOI 10.1002/bjs.18004619704; CHAN MKM, 1989, ACTA CYTOL, V33, P351; COATES PJ, 1991, J PATHOL, V164, P291, DOI 10.1002/path.1711640404; HO SC, 1990, HAEMATOL ONCOL, V8, P271; ISAACSON PG, 1992, J PATHOL, V2, P267; JARRETT RF, 1991, J CLIN PATHOL, V44, P844, DOI 10.1136/jcp.44.10.844; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; YAO QY, 1985, INT J CANCER, V35, P35, DOI 10.1002/ijc.2910350107	10	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					265	266		10.1016/S0140-6736(94)91114-2	http://dx.doi.org/10.1016/S0140-6736(94)91114-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905098				2022-12-28	WOS:A1994MT44000012
J	SOLOMON, T; FELIX, JM; SAMUEL, M; DENGO, GA; SALDANHA, RA; SCHAPIRA, A; PHILLIPS, RE				SOLOMON, T; FELIX, JM; SAMUEL, M; DENGO, GA; SALDANHA, RA; SCHAPIRA, A; PHILLIPS, RE			HYPOGLYCEMIA IN PEDIATRIC ADMISSIONS IN MOZAMBIQUE	LANCET			English	Note							SEVERE FALCIPARUM-MALARIA; HYPOGLYCEMIA; CHILDREN; CHILDHOOD	We studied the incidence and clinical associations of hypoglycaemia in an acute medical paediatric service in Maputo, Mozambique. Of 603 children, 43 (7.1%) were hypoglycaemic. 16 of these with Plasmodium falciparum malaria had a shorter illness, and a higher incidence of convulsions and focal neurological signs than those with other diagnoses, but were less likely to die. Hypoglycaemia also complicated protein energy malnutrition, pneumonia, encephalitis, intestinal parasite infection, and nephrotic syndrome. 25 of the 603 children died: 7 (16.3%) of 43 with hypoglycaemia and 18 (3.2%) of 560 who were normoglycaemic, (relative risk of death 5.8 [95% confidence interval 2.25 to 14.93]). Hypoglycaemia is common in children in hospital in Mozambique, and should be suspected in any acutely-ill child regardless of the primary disease.	JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND; UNIV EDUARDO MONDLANE,FAC MED,MAPUTO,MOZAMBIQUE; HOSP CENT MAPUTO,MAPUTO,MOZAMBIQUE; UNIV OXFORD,DEPT STAT,OXFORD,ENGLAND	University of Oxford; Eduardo Mondlane University; University of Oxford			Schapira, Allan/AAZ-8116-2020	Solomon, Tom/0000-0001-7266-6547; Saldanha, Richard/0000-0002-4137-3917	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENNISH ML, 1990, NEW ENGL J MED, V322, P1357, DOI 10.1056/NEJM199005103221905; FILKINS JP, 1974, AM J PHYSIOL, V227, P778, DOI 10.1152/ajplegacy.1974.227.4.778; GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404; MOLYNEUX ME, 1989, AM J TROP MED HYG, V40, P470, DOI 10.4269/ajtmh.1989.40.470; PAGLIARA AS, 1973, J PEDIATR-US, V82, P558, DOI 10.1016/S0022-3476(73)80581-5; PAGLIARA AS, 1973, J PEDIATR-US, V82, P365, DOI 10.1016/S0022-3476(73)80109-X; TAYLOR TE, 1988, NEW ENGL J MED, V319, P1040, DOI 10.1056/NEJM198810203191602; WHARTON B, 1970, LANCET, V1, P171; WHITE NJ, 1987, LANCET, V1, P708; 1990, T R SOC TROP MED H S, P1; 1972, LANCET, V2, P143	11	33	33	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 15	1994	343	8890					149	150		10.1016/S0140-6736(94)90937-7	http://dx.doi.org/10.1016/S0140-6736(94)90937-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7904007				2022-12-28	WOS:A1994MQ86900013
J	GOY, JJ; EECKHOUT, E; BURNAND, B; VOGT, P; STAUFFER, JC; HURNI, M; STUMPE, F; RUCHAT, P; SADEGHI, H; KAPPENBERGER, L				GOY, JJ; EECKHOUT, E; BURNAND, B; VOGT, P; STAUFFER, JC; HURNI, M; STUMPE, F; RUCHAT, P; SADEGHI, H; KAPPENBERGER, L			CORONARY ANGIOPLASTY VERSUS LEFT INTERNAL MAMMARY ARTERY GRAFTING FOR ISOLATED PROXIMAL LEFT ANTERIOR DESCENDING ARTERY-STENOSIS	LANCET			English	Article							FOLLOW-UP; SURVIVAL; SURGERY; DISEASE; TERM	Coronary artery bypass grafting (CABG) and percutaneous transluminal coronary angioplasty (PTCA) are more effective than medical treatment for the management of ischaemic heart disease. However, patients with single-vessel involvement have been excluded from prospective comparisons of the two methods. We have carried out such a comparison in patients with isolated proximal left anterior descending artery stenosis, conserved left ventricular function, and documented ischaemia. Eligible patients presenting to a single centre were randomly assigned PTCA (68 patients) or left internal mammary grafting (66). The procedures were technically feasible in all cases. The incidence of in-hospital complications was 2% (perioperative myocardial infarction) for CABG and 3% (emergency CABG for acute closure) for PTCA. Clinical and functional status improved similarly in both groups. However, patients in the PTCA group took more antianginal drugs. At median follow-up of 2.5 years, 86% of CABG-treated and 43% of PTCA-treated patients were free from adverse events (p<0.01; relative risk 2.0 [95% CI 1.7-2.3]). The adverse events that explain this difference were restenosis (32%) requiring subsequent surgical (16%) or percutaneous (15%) revascularisation (1% had medical therapy). Rates of cardiac death and myocardial infarction did not differ between the groups. Both CABG and PTCA improve the clinical status of symptomatic patients with single-vessel coronary artery disease. If patient and physician accept the risk of restenosis and reintervention associated with PTCA, this procedure remains a suitable option and a simpler initial alternative to CABG.	CHU VAUDOIS, INST SOCIAL & PREVENT MED, CH-1011 LAUSANNE, SWITZERLAND; CHU VAUDOIS, DEPT CARDIOVASC SURG, CH-1011 LAUSANNE, SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	GOY, JJ (corresponding author), CHU VAUDOIS, DIV CARDIOL, RUE BUGNON 17, CH-1011 LAUSANNE, SWITZERLAND.							CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; CHAITMAN BR, 1983, CIRCULATION, V67, P302, DOI 10.1161/01.CIR.67.2.302; DETRE KM, 1990, CIRCULATION, V82, P739, DOI 10.1161/01.CIR.82.3.739; FAVALORO RG, 1969, J THORAC CARDIOV SUR, V58, P178, DOI 10.1016/S0022-5223(19)42599-3; FRIERSON JH, 1992, J AM COLL CARDIOL, V19, P745, DOI 10.1016/0735-1097(92)90512-L; GRUENTZIG AR, 1987, NEW ENGL J MED, V316, P1127, DOI 10.1056/NEJM198704303161805; GRUNTZIG AR, 1979, NEW ENGL J MED, V301, P61, DOI 10.1056/NEJM197907123010201; HAMPTON JR, 1993, LANCET, V341, P573; KRAMER JR, 1989, AM HEART J, V118, P1144, DOI 10.1016/0002-8703(89)90002-1; LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; PEDUZZI P, 1992, CIRCULATION, V86, P121; POPE DL, 1984, COMP CARDIOL, V4, P71; REIBER JHC, 1985, CIRCULATION, V71, P280, DOI 10.1161/01.CIR.71.2.280; TOPOL EJ, 1993, NEW ENGL J MED, V329, P221, DOI 10.1056/NEJM199307223290401; VARNAUSKAS E, 1988, NEW ENGL J MED, V319, P332, DOI 10.1056/NEJM198808113190603; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203; 1990, LANCET, V335, P1315	18	133	142	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 11	1994	343	8911					1449	1453		10.1016/S0140-6736(94)92579-8	http://dx.doi.org/10.1016/S0140-6736(94)92579-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911175				2022-12-28	WOS:A1994NQ41500006
J	NEWELL, ML; DUNN, DT; PECKHAM, CS; ADES, AE; PARDI, G; SEMPRINI, AE; GIAQUINTO, C; TRUSCIA, D; DEROSSI, A; CHIECOBIANCHI, L; ZACHELLO, F; GROSCHWORNER, I; LANGHOF, M; MOK, J; JOHNSTONE, F; TERES, FO; BATES, I; GARCIARODRIQUEZ, MC; CANOSA, C; ASENSI, F; OTERO, MC; TAMARIT, AP; SCHERPBIER, H; MULDER, G; BOER, K; BOHLIN, AB; LINDGREN, S; FORSGREN, M; EHRNST, A; ANZEN, B; DEMARIA, A; FERRAZIN, A; GOTTA, C; LEVY, J; HOTTARD, A; PONCIN, M; SPRECHER, S; LEJEUNE, B; MUR, A; YAZBECK, H; LLORENZ, J; RAVIZZA, M; VUCETICH, A; ZUCOTTI, V; GUERRA, B; BIANCHI, S; DALLACASA, P; PRATI, E; TARANTINI, M; SCARAVELLI, G; STEGAGNO, M; QUINTI, I; DESANTIS, M; NOIA, G; MUGGIASCA, ML; MARCHISIO, P; IASCI, A; SPINILLO, A; MACCABRUNI, A; BIRAGHI, P; BUCCERI, A; GROSSI, E; FERRARIS, G; PLEBANI, A				NEWELL, ML; DUNN, DT; PECKHAM, CS; ADES, AE; PARDI, G; SEMPRINI, AE; GIAQUINTO, C; TRUSCIA, D; DEROSSI, A; CHIECOBIANCHI, L; ZACHELLO, F; GROSCHWORNER, I; LANGHOF, M; MOK, J; JOHNSTONE, F; TERES, FO; BATES, I; GARCIARODRIQUEZ, MC; CANOSA, C; ASENSI, F; OTERO, MC; TAMARIT, AP; SCHERPBIER, H; MULDER, G; BOER, K; BOHLIN, AB; LINDGREN, S; FORSGREN, M; EHRNST, A; ANZEN, B; DEMARIA, A; FERRAZIN, A; GOTTA, C; LEVY, J; HOTTARD, A; PONCIN, M; SPRECHER, S; LEJEUNE, B; MUR, A; YAZBECK, H; LLORENZ, J; RAVIZZA, M; VUCETICH, A; ZUCOTTI, V; GUERRA, B; BIANCHI, S; DALLACASA, P; PRATI, E; TARANTINI, M; SCARAVELLI, G; STEGAGNO, M; QUINTI, I; DESANTIS, M; NOIA, G; MUGGIASCA, ML; MARCHISIO, P; IASCI, A; SPINILLO, A; MACCABRUNI, A; BIRAGHI, P; BUCCERI, A; GROSSI, E; FERRARIS, G; PLEBANI, A			CESAREAN-SECTION AND RISK OF VERTICAL TRANSMISSION OF HIV-1 INFECTION	LANCET			English	Article							CESAREAN-SECTION; WOMEN; SECRETIONS	Indirect evidence suggests that a significant proportion of vertical transmission of HIV infection occurs late in pregnancy or during delivery. Caesarean section, therefore, may protect the fetus from infection. We looked at 1254 HIV-infected mothers and their children and the effects of different modes of delivery on transmission risk. We also included a detailed assessment of confounding factors associated with transmission risk. Women who had caesarean sections were more advanced in their disease progression which may cause the protective effect of caesarean section to be underestimated. When this and other potential confounding factors were taken into account, caesarean section was estimated to halve the rate of transmission. This finding is important in the design of studies to evaluate treatments aimed at reducing mother-to-child transmission.	UNIV PADUA,PADUA,ITALY; FREE UNIV BERLIN,KLINIKUM RUDOLF VIRCHOW,W-1000 BERLIN,GERMANY; CITY HOSP EDINBURGH,EDINBURGH,SCOTLAND; CTR REPROD BIOL,EDINBURGH,SCOTLAND; HOSP LA PAZ,MADRID,SPAIN; HOSP LA FE,E-46009 VALENCIA,SPAIN; ACAD MED CENTRUM,AMSTERDAM,NETHERLANDS; KAROLINSKA INST,HUDDINGE HOSP,S-10401 STOCKHOLM,SWEDEN; DANDERYD HOSP,STOCKHOLM,SWEDEN; CENT MICROBIOL LAB,STOCKHOLM,SWEDEN; IST GIANNINA GASLINI,I-16148 GENOA,ITALY; HOP ST PIERRE & ERASME,BRUSSELS,BELGIUM; HOSP DEL MAR,BARCELONA,SPAIN; OSPED SAN PAOLO,MILAN,ITALY; POLICLIN S ORSOLA,BOLOGNA,ITALY; UNIV BRESCIA,BRESCIA,ITALY; UNIV ROMA LA SAPIENZA,ROME,ITALY; UNIV CATTOLICA SACRO CUORE,ROME,ITALY; OSPED L SACCO,MILAN,ITALY; POLICLIN SAN MATTEO,I-27100 PAVIA,ITALY; CLIN MANGIAGALLI,MILAN,ITALY; CLIN DE MARCHI,MILAN,ITALY	University of Padua; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hospital Universitario La Paz; Hospital Universitari i Politecnic La Fe; University of Amsterdam; Academic Medical Center Amsterdam; Karolinska Institutet; Danderyds Hospital; University of Genoa; IRCCS Istituto Giannina Gaslini; Universite Libre de Bruxelles; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; San Paolo-Polo Universitaria Hospital; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Brescia; Sapienza University Rome; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Milan; Luigi Sacco Hospital; IRCCS Fondazione San Matteo	NEWELL, ML (corresponding author), INST CHILD HLTH,DEPT EPIDEMIOL & BIOSTAT,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND.		Spinillo, Arsenio/AAB-9315-2022; Newell, Marie-Louise/AAE-8222-2019; De Rossi, A./L-3128-2015; Plebani, Alessandro/C-8593-2011; Grossi, Enzo/AAF-7765-2020; Giaquinto, Carlo/AAB-5016-2020; De Rossi, Anita/Q-4845-2019	Spinillo, Arsenio/0000-0002-7755-1084; Newell, Marie-Louise/0000-0002-1074-7699; De Rossi, A./0000-0001-6435-7509; De Rossi, Anita/0000-0001-6435-7509; GIAQUINTO, CARLO/0000-0001-9365-0413; Dunn, David/0000-0003-1836-4446; Alimenti, Ariane/0000-0003-4999-8230				[Anonymous], MMWR; BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718; Chiodo F, 1986, Lancet, V1, P739; CHOO V, 1994, LANCET, V343, P533, DOI 10.1016/S0140-6736(94)91477-X; CLEMETSON DBA, 1993, JAMA-J AM MED ASSOC, V269, P2860, DOI 10.1001/jama.269.22.2860; DANFORTH DN, 1985, JAMA-J AM MED ASSOC, V253, P811, DOI 10.1001/jama.253.6.811; DEMUYLDER X, 1993, HEALTH POLICY PLANN, V8, P101, DOI 10.1093/heapol/8.2.101; FUITH LC, 1992, LANCET, V339, P1603, DOI 10.1016/0140-6736(92)91863-4; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; HENIN Y, 1993, J ACQ IMMUN DEF SYND, V6, P72; KEIRSE MJN, 1989, EFFECTIVE CARE PREGN, V2, P1270; PECKHAM C, 1993, MEASURES DECREASE RI, P1; RUBIN DB, 1991, STATS MED, V110, P585; SACHS BP, 1983, JAMA-J AM MED ASSOC, V250, P2157, DOI 10.1001/jama.250.16.2157; SLADE MS, 1975, SURGERY, V78, P363; SMITH JR, 1991, BRIT J OBSTET GYNAEC, V98, P124, DOI 10.1111/j.1471-0528.1991.tb13356.x; TOVO PA, 1993, LANCET, V342, P630, DOI 10.1016/0140-6736(93)91753-9; VILLARI P, 1993, ONLINE J CURR CLIN T; 1991, LANCET, V337, P253; 1992, LANCET, V339, P1007; 1987, MMWR-MORBID MORTAL W, V36, P225	21	135	139	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1464	1467						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911178				2022-12-28	WOS:A1994NQ41500009
J	JAAKKOLA, M; SILLANAUKEE, P; LOF, K; KOIVULA, T; NORDBACK, I				JAAKKOLA, M; SILLANAUKEE, P; LOF, K; KOIVULA, T; NORDBACK, I			BLOOD-TESTS FOR DETECTION OF ALCOHOLIC CAUSE OF ACUTE-PANCREATITIS	LANCET			English	Note							LIPASE AMYLASE RATIO; DRINKING; MARKER; SERUM; MEN	We investigated the ability of various blood markers to detect an alcoholic cause of acute pancreatitis. Serum carbohydrate-deficient transferrin (CDT) was significantly correlated with reported 2 month and 7 day ethanol consumptions and was significantly higher in 42 patients with alcoholic acute pancreatitis and in 24 patients with possibly alcoholic acute pancreatitis than in 20 patients with non-alcoholic disease. At a cutoff over 17 U/L, the specificity of CDT was 100% and the sensitivity was 75% to detect an alcoholic cause of acute pancreatitis. The lipase/amylase ratio index, erythrocyte mean corpuscular volume, and gamma glutamyl transferase could not distinguish alcoholic from non-alcoholic acute pancreatitis.	TAMPERE UNIV HOSP, DEPT SURG, SF-33250 TAMPERE, FINLAND; UNIV TAMPERE, DEPT CLIN MED, SF-33101 TAMPERE, FINLAND; TAMPERE UNIV HOSP, DEPT CLIN CHEM, TAMPERE, FINLAND; ALKO LTD, BIOMED RES CTR, TAMPERE, FINLAND	Tampere University; Tampere University Hospital; Tampere University; Tampere University; Tampere University Hospital								CHICK J, 1981, LANCET, V1, P1249; GUMASTE VV, 1991, GASTROENTEROLOGY, V101, P1361, DOI 10.1016/0016-5085(91)90089-4; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; NORONHA M, 1981, AM J GASTROENTEROL, V76, P114; PEZZILLI R, 1993, DIGEST DIS SCI, V38, P1265, DOI 10.1007/BF01296077; SILLANAUKEE P, 1993, ALCOHOL CLIN EXP RES, V17, P230, DOI 10.1111/j.1530-0277.1993.tb00754.x; Sillanaukee P, 1992, SUOM LAAKARILEHTI, V31, P2919; STIBLER H, 1991, CLIN CHEM, V37, P2029; STIBLER H, 1991, ALCOHOL ALCOHOLISM, P451; Stibler H, 1980, Subst Alcohol Actions Misuse, V1, P247	10	42	43	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 28	1994	343	8909					1328	1329		10.1016/S0140-6736(94)92470-8	http://dx.doi.org/10.1016/S0140-6736(94)92470-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910327				2022-12-28	WOS:A1994NN21700013
J	KEDAR, RP; BOURNE, TH; POWLES, TJ; COLLINS, WP; ASHLEY, SE; COSGROVE, DO; CAMPBELL, S				KEDAR, RP; BOURNE, TH; POWLES, TJ; COLLINS, WP; ASHLEY, SE; COSGROVE, DO; CAMPBELL, S			EFFECTS OF TAMOXIFEN ON UTERUS AND OVARIES OF POSTMENOPAUSAL WOMEN IN A RANDOMIZED BREAST-CANCER PREVENTION TRIAL	LANCET			English	Article							TRANSVAGINAL ULTRASONOGRAPHY; ENDOMETRIAL CHANGES; ADJUVANT; THERAPY; CHEMOTHERAPY	Randomised, double-blind controlled trials have been started to determine whether tamoxifen can prevent or delay development of breast cancer in healthy women with a family history of the disease. We recruited a randomised cohort of 111 postmenopausal women (aged 46-71 years) from the Pilot Breast Cancer Prevention Trial at the Royal Marsden Hospital to study the effect of tamoxifen on the uterus and ovaries. The main outcome measures were obtained by transvaginal ultrasonography with colour doppler imaging and microscopic examination of endometrial biopsies removed at the time of the scan. There was no significant difference between tamoxifen (20 mg/day) and placebo groups in the age of the women, or the time of the scan (and sampling) after randomisation. Women taking tamoxifen had a significantly larger uterus and a lower impedance to blood flow in the uterine arteries. 39% of women taking tamoxifen had histological evidence of an abnormal endometrium compared with 10% in the control group. 10 patients in the tamoxifen group (16%) had atypical hyperplasia and another 5 (8%) had a polyp. Women with a histological abnormality had a significantly thicker endometrium and a decreased impedance to blood flow in the uterine arteries. There was no correlation between the presence of uterine abnormalities and the age of the women, or the concentrations of tamoxifen or desmethyl tamoxifen in the peripheral blood. These findings confirm that tamoxifen can cause potentially malignant changes in the endometrium of postmenopausal women. Transvaginal ultrasonography can be used to identify those women who should have endometrial samples removed for microscopic analysis.	UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT OBSTET & GYNAECOL,LONDON SE5 8RX,ENGLAND; ROYAL MARSDEN HOSP,MED BREAST UNIT,LONDON SW3 6JJ,ENGLAND; ROYAL MARSDEN HOSP,DEPT COMP,LONDON SW3 6JJ,ENGLAND; ROYAL MARSDEN HOSP,DEPT ULTRASOUND,LONDON SW3 6JJ,ENGLAND; ROYAL MARSDEN HOSP,SUTTON,SURREY,ENGLAND	University of London; King's College London; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust			Bourne, Tom/I-6478-2012	Bourne, Tom/0000-0003-1421-6059				BONADONNA G, 1991, SEMIN ONCOL, V18, P515; BOURNE TH, 1991, GYNECOL ONCOL, V40, P253; BOURNE TH, 1993, BRIT MED J, V306, P1025, DOI 10.1136/bmj.306.6884.1025; BOURNE TH, 1994, ULTRASOUND OBST GYN, V4, P73, DOI 10.1046/j.1469-0705.1994.04010073.x; CATHERINO WH, 1993, DRUG SAFETY, V8, P381, DOI 10.2165/00002018-199308050-00005; COHEN I, 1993, BRIT J OBSTET GYNAEC, V100, P567, DOI 10.1111/j.1471-0528.1993.tb15310.x; COHEN I, 1993, J ULTRAS MED, V5, P275; CORLEY D, 1992, OBSTET GYNECOL, V79, P111; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; FORNANDER T, 1989, LANCET, V1, P117; FUGHBERMAN A, 1992, LANCET, V340, P1143, DOI 10.1016/0140-6736(92)93161-F; JORDAN VC, 1987, CANCER RES, V47, P4517; JORDAN VC, 1987, CANCER RES, V47, P624; JORDAN VC, 1993, BRIT MED J, V307, P1371, DOI 10.1136/bmj.307.6916.1371; LAHTI E, 1993, OBSTET GYNECOL, V81, P660; NAYFIELD SG, 1991, J NATL CANCER I, V83, P1450, DOI 10.1093/jnci/83.20.1450; NEVEN P, 1993, BRIT J OBSTET GYNAEC, V100, P893, DOI 10.1111/j.1471-0528.1993.tb15101.x; NEVEN P, 1993, LANCET, V342, P452, DOI 10.1016/0140-6736(93)91590-I; NEVEN P, 1990, EUR J OBSTET GYN R B, V35, P235, DOI 10.1016/0028-2243(90)90167-Y; NEVEN P, 1989, LANCET, V1, P375; NG ABP, 1991, COMPREHENSIVE CYTOPA, P257; POWLES TJ, 1992, LANCET, V340, P1145, DOI 10.1016/0140-6736(92)93162-G; POWLES TJ, 1990, EUR J CANCER, V26, P680, DOI 10.1016/0277-5379(90)90116-B; POWLES TJ, 1989, BRIT J CANCER, V60, P126, DOI 10.1038/bjc.1989.235; 1992, LANCET, V399, P1	25	438	443	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1318	1321		10.1016/S0140-6736(94)92466-X	http://dx.doi.org/10.1016/S0140-6736(94)92466-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910323				2022-12-28	WOS:A1994NN21700009
J	LUNDGREN, JD; PEDERSEN, C; CLUMECK, N; GATELL, JM; JOHNSON, AM; LEDERGERBER, B; VELLA, S; PHILLIPS, A; NIELSEN, JO; DEWIT, S; SOMMEREIJNS, B; NIELSEN, T; JENSEN, G; SKINHOJ, P; BENTSEN, K; GERSTOFT, J; MELBYE, M; RANKI, A; VALLE, SL; KATLAMA, C; BERLUREAU, P; DIETRICH, M; SCHWANDER, S; GOEBEL, FD; KOSMIDIS, J; STERGIOU, G; GOUZIA, T; PAPADOPOULOS, A; BANHEGYI, D; MULCAHY, F; YUST, I; BENISHAI, Z; BENTWICH, Z; SACKS, T; MAAYAN, S; CHIESI, A; ANCARANI, F; SCALISE, G; BERTAGGIA, A; FRANCAVILLA, E; CALONGHI, G; CARGNEL, A; ARLOTTI, M; CIAMMARUGHI, R; COLOMBA, A; DELALLA, F; FASSIO, P; FERLINI, A; FIACCADORI, F; PASETTI, G; GIANNELLI, F; GRILLONE, W; LAZZARIN, A; MONFORTE, AD; MIGNANI, E; NUNNARI, A; ORTONA, L; PANICHI, G; PAULUZZI, S; PIERSANTELLI, N; RANIERI, S; RICCIARDIELLO, P; ROSCIOLI, B; SORANZO, M; HEMMER, R; DANNER, S; ANTUNES, F; PROENCA, R; GONZALEZLAHOZ, J; MARTINEZBLANCO, L; CLOTET, B; BUIRA, E; MIRO, J; PEHRSON, P; LUTHY, R; OLSSON, C; GLAUSER, M; HIRSCHEL, B; HAWKES, S; BARTON, S; MORCINEK, J; PINCHING, A; COLEMAN, D				LUNDGREN, JD; PEDERSEN, C; CLUMECK, N; GATELL, JM; JOHNSON, AM; LEDERGERBER, B; VELLA, S; PHILLIPS, A; NIELSEN, JO; DEWIT, S; SOMMEREIJNS, B; NIELSEN, T; JENSEN, G; SKINHOJ, P; BENTSEN, K; GERSTOFT, J; MELBYE, M; RANKI, A; VALLE, SL; KATLAMA, C; BERLUREAU, P; DIETRICH, M; SCHWANDER, S; GOEBEL, FD; KOSMIDIS, J; STERGIOU, G; GOUZIA, T; PAPADOPOULOS, A; BANHEGYI, D; MULCAHY, F; YUST, I; BENISHAI, Z; BENTWICH, Z; SACKS, T; MAAYAN, S; CHIESI, A; ANCARANI, F; SCALISE, G; BERTAGGIA, A; FRANCAVILLA, E; CALONGHI, G; CARGNEL, A; ARLOTTI, M; CIAMMARUGHI, R; COLOMBA, A; DELALLA, F; FASSIO, P; FERLINI, A; FIACCADORI, F; PASETTI, G; GIANNELLI, F; GRILLONE, W; LAZZARIN, A; MONFORTE, AD; MIGNANI, E; NUNNARI, A; ORTONA, L; PANICHI, G; PAULUZZI, S; PIERSANTELLI, N; RANIERI, S; RICCIARDIELLO, P; ROSCIOLI, B; SORANZO, M; HEMMER, R; DANNER, S; ANTUNES, F; PROENCA, R; GONZALEZLAHOZ, J; MARTINEZBLANCO, L; CLOTET, B; BUIRA, E; MIRO, J; PEHRSON, P; LUTHY, R; OLSSON, C; GLAUSER, M; HIRSCHEL, B; HAWKES, S; BARTON, S; MORCINEK, J; PINCHING, A; COLEMAN, D			SURVIVAL DIFFERENCES IN EUROPEAN PATIENTS WITH AIDS, 1979-89	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PNEUMOCYSTIS-CARINII PNEUMONIA; PLACEBO-CONTROLLED TRIAL; VIRUS INFECTION; TERM SURVIVAL; DOUBLE-BLIND; ZIDOVUDINE; EFFICACY; TRENDS; AZT	Objectives-To examine the pattern of survival and factors associated with the outcome of disease in patients with AIDS. Design-Inception cohort. Data collected retrospectively from patients' charts. Setting-52 clinical centres in 17 European countries. Subjects-6578 adults diagnosed with AIDS from 1 January 1979 to 31 December 1989. Main outcome measures-Survival after the time of diagnosis. Results-The median survival after diagnosis was 17 months, with an estimated survival at three years of 16% (95% confidence interval 15% to 17%). Patients diagnosed in southern Europe had a shorter survival, particularly immediately after the time of diagnosis, compared with patients diagnosed in central and northern Europe (survival at one year (95% confidence interval) 54% (52% to 56%) 66% (64% to 68%), 65% (63% to 66%), respectively. The three year survival, however, was similar for all regions. The regional differences in survival were less pronounced for patients diagnosed in 1989 compared with earlier years. Improved survival in recent years was observed for patients with a variety of manifestations used to define AIDS but was significant only for patients diagnosed with Pneumocystis carinii pneumonia. The three S ear survival, however, remains unchanged over time. Conclusions-Survival of AIDS patients seems to vary within Europe, being shorter in southern than central and northern Europe. The magnitude of these differences, however, has declined gradually over time. Short term survival has improved in recent years, but the long term prognosis has remained equally poor, reflecting the fact that the underlying infection with HIV and many of the complicating diseases remains essentially uncontrolled.	UNIV COPENHAGEN, HVIDOVRE HOSP, DK-2650 HVIDOVRE, DENMARK; FREE UNIV BRUSSELS, HOP ST PIERRE, BRUSSELS, BELGIUM; UCL, UNIV COLL & MIDDLESEX SCH MED, LONDON, ENGLAND; SWISS HIV COHORT STUDY, ZURICH, SWITZERLAND; IST SUPER SANITA, VIROL LAB, I-00161 ROME, ITALY; FREDERIKSBERG UNIV HOSP, COPENHAGEN, DENMARK; RIGSHOSP, DK-2100 COPENHAGEN, DENMARK; UNIV HELSINKI, CENT HOSP, HELSINKI, FINLAND; HOP LA PITIE SALPETRIERE, PARIS, FRANCE; BERNHARD NOCHT INST TROP MED, HAMBURG, GERMANY; MED POLIKLIN, MUNICH, GERMANY; LAIKO ATHENS GEN HOSP, ATHENS, GREECE; IKA HOSP 1, ATHENS, GREECE; POSTGRAD MED UNIV, H-1389 BUDAPEST, HUNGARY; ST JAMES HOSP, DUBLIN 8, IRELAND; ICHILOV HOSP, IL-64239 TEL AVIV, ISRAEL; RAMBAM MED CTR, HAIFA, ISRAEL; KAPLAN HOSP, IL-76100 REHOVOT, ISRAEL; HADASSAH UNIV HOSP, IL-91120 JERUSALEM, ISRAEL; UNIV ANCONA, ANCONA, ITALY; OSPED CIVILE, PADUA, ITALY; ARCISPEDALE SANTA MARIA NUOVA, REGIO EMILIA, ITALY; OSPED L SACCO, MILAN, ITALY; OSPED INFERMI RIMINI, RIMINI, ITALY; OSPED CASA DEL SOLE, PALERMO, ITALY; OSPED CIVILE, VICENZA, ITALY; OO RR BERGAMI, BERGAMO, ITALY; OSPED INFERMI FAENZA, FAENZA, ITALY; OSPED RIUNITI PARMA, PARMA, ITALY; OSPED NIGUARDA CA GRANDA, MILAN, ITALY; OSPED AMEDEO SAVOIA, TURIN, ITALY; OSPED L SACCO, MILAN, ITALY; OSPED SANTA ANDREA, LA SPEZIA, ITALY; UNIV CATANIA, CATANIA, ITALY; UNIV CATTOLICA SACRO CUORE, ROME, ITALY; UNIV SASSARI, I-07100 SASSARI, ITALY; POLICLIN MONTELUCE, PERUGIA, ITALY; OSPED GALLIERA, GENOA, ITALY; OSPED SANTA MARIA CROCI, RAVENNA, ITALY; OSPED MAGGIORE NOVARA, NOVARA, ITALY; OSPED SANTA MARIA MADDALENA, TRIESTE, ITALY; CTR HOSP, LUXEMBOURG, LUXEMBOURG; UNIV AMSTERDAM, ACAD ZIEKENHUIS, AMSTERDAM, NETHERLANDS; HOSP SANTA MARIA, LISBON, PORTUGAL; HOSP CURRY CABRAL, LISBON, PORTUGAL; INST SALUD CARLOS 3, MADRID, SPAIN; HOSP CLIN BARCELONA, BARCELONA, SPAIN; HOSP GERMANS TRIAS & PUJOL, BARCELONA, SPAIN; KAROLINSKA INST, STOCKHOLM, SWEDEN; CHU VAUDOIS, CH-1011 LAUSANNE, SWITZERLAND; UNIV GENEVA, HOP CANTONAL, CH-1211 GENEVA, SWITZERLAND; CHELSEA & WESTMINSTER HOSP, ST STEPHENS CLIN, LONDON, ENGLAND; ST MARYS HOSP, LONDON, ENGLAND	University of Copenhagen; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of London; University College London; Istituto Superiore di Sanita (ISS); Rigshospitalet; University of Copenhagen; University of Helsinki; Helsinki University Central Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Bernhard Nocht Institut fur Tropenmedizin; Laiko General Hospital; Trinity College Dublin; Tel Aviv University; Rambam Health Care Campus; Technion Israel Institute of Technology; Hebrew University of Jerusalem; Kaplan Medical Center; Hebrew University of Jerusalem; Marche Polytechnic University; IRCCS Arcispedale S. Maria Nuova; University of Milan; Luigi Sacco Hospital; Hospital of Rimini; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; University of Milan; Luigi Sacco Hospital; University of Catania; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Sassari; Ente Ospedaliero Ospedali Galliera; Luxembourg Hospital Center; University of Amsterdam; Universidade de Lisboa; Hospital Santa Maria; Instituto de Salud Carlos III; University of Barcelona; Hospital Clinic de Barcelona; Hospital Germans Trias i Pujol; Karolinska Institutet; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva; Imperial College London; Imperial College London			Stergiou, George/J-3083-2019; Phillips, Andrew N/B-4427-2008; VELLA, STEFANO/ABI-3368-2020; Vella, Stefano/GZM-0519-2022; Hawkes, Sarah/AAK-7375-2020; Lundgren, Jens/AAE-6876-2019; Ledergerber, Bruno/B-5656-2009; VELLA, STEFANO/D-4912-2015	Stergiou, George/0000-0002-6132-0038; Phillips, Andrew N/0000-0003-2384-4807; Ledergerber, Bruno/0000-0002-6881-4401; Lundgren, Jens/0000-0001-8901-7850; VELLA, STEFANO/0000-0003-2347-5984; Johnson, Anne/0000-0003-1330-7100				ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; BUIRA E, 1992, J ACQ IMMUN DEF SYND, V5, P737; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FRIEDLAND GH, 1991, J ACQ IMMUN DEF SYND, V4, P144; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HARRIS J E, 1990, Journal of the American Medical Association, V263, P397, DOI 10.1001/jama.263.3.397; LEMP GF, 1992, J INFECT DIS, V166, P74, DOI 10.1093/infdis/166.1.74; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; PEDERSEN C, 1990, AIDS, V4, P1111, DOI 10.1097/00002030-199011000-00009; PETERS BS, 1991, BRIT MED J, V302, P203, DOI 10.1136/bmj.302.6770.203; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; VELLA S, 1992, JAMA-J AM MED ASSOC, V267, P1232, DOI 10.1001/jama.267.9.1232; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1989, MMWR S5, V38, P1; 1987, MMWR S, V36, P3; 1990, NEW ENGL J MED, V323, P1500	19	94	95	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 23	1994	308	6936					1068	1073		10.1136/bmj.308.6936.1068	http://dx.doi.org/10.1136/bmj.308.6936.1068			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH489	7909698	Green Published			2022-12-28	WOS:A1994NH48900021
J	WEISSMANN, C				WEISSMANN, C			THE PRION CONNECTION - NOW IN YEAST	SCIENCE			English	Editorial Material							SCRAPIE; GENE; PROTEIN				WEISSMANN, C (corresponding author), UNIV ZURICH, INST MOLEC BIOL 1, CH-8093 ZURICH, SWITZERLAND.							AIGLE M, 1975, MOL GEN GENET, V136, P327, DOI 10.1007/BF00341717; ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; KELLINGS K, 1992, J GEN VIROL, V73, P1025, DOI 10.1099/0022-1317-73-4-1025; LACROUTE F, 1971, J BACTERIOL, V106, P519, DOI 10.1128/JB.106.2.519-522.1971; MCKINLEY MP, 1991, J VIROL, V65, P1340, DOI 10.1128/JVI.65.3.1340-1351.1991; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1989, ANNU REV MICROBIOL, V43, P345, DOI 10.1146/annurev.mi.43.100189.002021; PRUSINER SB, 1993, PHILOS T R SOC B, V339, P239, DOI 10.1098/rstb.1993.0022; RAEBER AJ, 1992, J VIROL, V66, P6155, DOI 10.1128/JVI.66.10.6155-6163.1992	14	16	16	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 22	1994	264	5158					528	530		10.1126/science.7909168	http://dx.doi.org/10.1126/science.7909168			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH010	7909168				2022-12-28	WOS:A1994NH01000024
J	ROSENDAAL, FR				ROSENDAAL, FR			ANTICOAGULATION - HOW LOW CAN ONE GO	LANCET			English	Editorial Material							FIXED MINIDOSE WARFARIN; PROPHYLAXIS		LEIDEN UNIV HOSP,DEPT HAEMATOL,LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	ROSENDAAL, FR (corresponding author), LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,LEIDEN,NETHERLANDS.		Rosendaal, Frits/Q-3842-2017	Rosendaal, Frits/0000-0003-2558-7496				AZAR AJ, 1993, THESIS U ROTTERDAM; BRAUN PJ, 1992, THROMB HAEMOSTASIS, V68, P160; BUSSEY HI, 1994, LANCET, V343, P234; CANNEGIETER SC, 1993, THROMB HAEMOSTASIS, V69, P2363; FORDYCE MJF, 1991, BRIT MED J, V303, P219, DOI 10.1136/bmj.303.6796.219; Hirsh J, 1992, CHEST S, V102, P312; LOELIGER EA, 1992, ANN HEMATOL, V64, P60, DOI 10.1007/BF01715346; POLLER L, 1987, BRIT MED J, V295, P1309, DOI 10.1136/bmj.295.6609.1309; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557	11	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 9	1994	343	8902					867	868		10.1016/S0140-6736(94)90003-5	http://dx.doi.org/10.1016/S0140-6736(94)90003-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF213	7908353	Green Submitted			2022-12-28	WOS:A1994NF21300003
J	GENT, AE; HELLIER, MD; GRACE, RH; SWARBRICK, ET; COGGON, D				GENT, AE; HELLIER, MD; GRACE, RH; SWARBRICK, ET; COGGON, D			INFLAMMATORY BOWEL-DISEASE AND DOMESTIC HYGIENE IN INFANCY	LANCET			English	Note							ULCERATIVE-COLITIS; CROHNS-DISEASE; CHILDREN	To test the hypothesis that Crohn's disease is caused by delayed exposure to enteric infections, we did a case-control study. We compared 133 patients who have Crohn's disease and 231 with ulcerative colitis who have controls selected from the general population and matched for age and sex. Crohn's disease was more common in subjects whose first houses had a hot-water tap (odds ratio 5.0, 95% CI 1.4-17.3) and separate bathroom (3.3, 1.3-8.3). Ulcerative colitis showed no clear relation to household amenities in infancy. These findings may explain why the incidence of Crohn's disease has increased in developed countries over the past 50 years.	PRINCES MARGARET HOSP,SWINDON,WILTS,ENGLAND; NEW CROSS HOSP,WOLVERHAMPTON,ENGLAND; UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,ENGLAND	New Cross Hospital; University of Southampton	GENT, AE (corresponding author), SALISBURY DIST HOSP,SALISBURY SP2 8BJ,WILTS,ENGLAND.							BARKER DJP, 1988, BMJ-BRIT MED J, V296, P956, DOI 10.1136/bmj.296.6627.956; BARTON JR, 1989, GUT, V30, P618, DOI 10.1136/gut.30.5.618; Breslow N, 1980, STAT METHODS CANC RE, P248; CALKINS BM, 1984, DIGEST DIS SCI, V29, P913, DOI 10.1007/BF01312480; GILAT T, 1987, SCAND J GASTROENTERO, V22, P1009, DOI 10.3109/00365528708991950; LANGMAN MJS, 1983, INFLAMM BOWEL DIS, P17; RUTGEERTS P, 1993, GASTROENTEROLOGY, V104, pA772; 1966, CLASSIFICATION OCCUP	8	293	299	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 26	1994	343	8900					766	767		10.1016/S0140-6736(94)91841-4	http://dx.doi.org/10.1016/S0140-6736(94)91841-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907734				2022-12-28	WOS:A1994NC35100013
J	ZAHN, R; SPITZFADEN, C; OTTIGER, M; WUTHRICH, K; PLUCKTHUN, A				ZAHN, R; SPITZFADEN, C; OTTIGER, M; WUTHRICH, K; PLUCKTHUN, A			DESTABILIZATION OF THE COMPLETE PROTEIN SECONDARY STRUCTURE ON BINDING TO THE CHAPERONE GROEL	NATURE			English	Article							MOLECULAR CHAPERONE; BETA-LACTAMASE; CYCLOPHILIN; RECONSTITUTION; COOPERATIVITY; AGGREGATION; POLYPEPTIDE; INVITRO; ATP; NMR	PROTEIN folding in vivo is mediated by helper proteins, the molecular chaperones(1-3), of which Hsp60 and its Escherichia coli variant GroEL are some of the best characterized. GroEL is an oligomeric protein with 14 subunits each of M(r) 60K(4-6), which possesses weak, co-operative ATPase activity(7-9) and high plasticity(10). GroEL seems to interact with non-native proteins, binding one or two molecules per 14-mer(11-19) in a 'central cavity'(20), but little is known about the conformational state of the bound polypeptides. Here we use nuclear magnetic resonance techniques to show that the interaction of the small protein cyclophilin(21,22) with GroEL is reversible by temperature changes, and all amide protons in GroEL-bound cyclophilin are exchanged with the solvent, although this exchange does not occur in free cyclophilin. The complete secondary structure of cyclophilin must be disrupted when bound to GroEL.	MAX PLANCK INST BIOCHEM,PROT ENGN GRP,D-82152 MARTINSRIED,GERMANY; ETH HONGGERBERG,INST MOLEK BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND	Max Planck Society; Swiss Federal Institutes of Technology Domain; ETH Zurich			Plückthun, Andreas/C-2746-2009	Plückthun, Andreas/0000-0003-4191-5306				BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHYAN CL, 1993, BIOCHEMISTRY-US, V32, P5681, DOI 10.1021/bi00072a025; ELLIS RJ, 1991, A REV BIOCH, V60, P621; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JAENICKE R, 1993, CURR OPIN STRUC BIOL, V3, P104, DOI 10.1016/0959-440X(93)90209-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SPITZFADEN C, 1992, 15 INT C MAGN RES BI, P192; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WUTHRICH K, 1991, FEBS LETT, V285, P237, DOI 10.1016/0014-5793(91)80808-G; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZAHN R, 1993, J MOL BIOL, V229, P579, DOI 10.1006/jmbi.1993.1062; ZAHN R, 1992, BIOCHEMISTRY-US, V31, P3249, DOI 10.1021/bi00127a029	32	146	148	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					261	265		10.1038/368261a0	http://dx.doi.org/10.1038/368261a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	7908413				2022-12-28	WOS:A1994NA87000061
J	HOSKING, SW; LIN, TKW; CHUNG, SCS; YUNG, MY; CHENG, AFB; SUNG, JJY; LI, AKC				HOSKING, SW; LIN, TKW; CHUNG, SCS; YUNG, MY; CHENG, AFB; SUNG, JJY; LI, AKC			DUODENAL-ULCER HEALING BY ERADICATION OF HELICOBACTER-PYLORI WITHOUT ANTI-ACID TREATMENT - RANDOMIZED CONTROLLED TRIAL	LANCET			English	Article							CAMPYLOBACTER PYLORI; OMEPRAZOLE; BISMUTH; AMOXICILLIN; CIMETIDINE; RELAPSE; THERAPY; TABLETS	Randomised trials have shown that duodenal ulcers treated by H-2 blockers heal faster if Helicobacter pylori is eradicated concurrently. It remains unknown whether eradication of H pylori without suppression of acid-secretion, is sufficient to allow healing. 153 patients with H pylori infection and duodenal ulcer were randomised to receive either a 1-week course of bismuth subcitrate, tetracycline, and metronidazole (76), or omeprazole for 4 weeks with the same three-drug regimen for the first week (77). Endoscopy and antral biopsies were done at entry and 4 weeks after treatment. 132 patients were suitable for analysis. Duodenal ulcers healed in 60 (92%; 95% CI 86-100%) patients taking bismuth, tetracycline, and metronidazole compared with 63 (95%; 88-100%) taking omeprazole in addition to the three other drugs. H pylori was eradicated in 61 (94%; 88-100%) who received only three drugs compared with 66 (98%; 96-100%) who received omeprazole as well. Symptoms were reduced more effectively during the first week in patients who received omeprazole (p=0.003). We conclude that a 1-week regimen of bismuth, tetracycline, and metronidazole for patients with H pylori and duodenal ulcer eradicates the organism and heals the ulcer in most patients. Concurrent administration of omeprazole reduces ulcer pain more rapidly but has no effect on ulcer healing.	CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT SURG,SHA TIN,HONG KONG; CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT MED,SHA TIN,HONG KONG; CHINESE UNIM HONG KONG,PRINCE WALES HOSP,DEPT MICROBIOL,SHA TIN,HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital			Sung, Joseph J. Y./R-3203-2018	Sung, Joseph J. Y./0000-0003-3125-5199				ARCHAMBAULT AP, 1988, GASTROENTEROLOGY, V94, P1130, DOI 10.1016/0016-5085(88)90003-0; BAYERDORFFER E, 1992, EUR J GASTROEN HEPAT, V4, P697; BELL GD, 1991, EUR J GASTROEN HEPAT, V3, P923; BRAND DL, 1985, DIGESTIVE DISEASES S, V30, P147; BROWN C, 1992, BRIT MED J, V304, P135, DOI 10.1136/bmj.304.6820.135; COGHLAN JG, 1987, LANCET, V2, P1109; GOODWIN CS, 1992, HELICOBACTER PYLORI, P224; GRAHAM DY, 1991, ANN INTERN MED, V115, P266, DOI 10.7326/0003-4819-115-4-266; HOSKING SW, 1992, BRIT MED J, V305, P502, DOI 10.1136/bmj.305.6852.502; LEE FI, 1985, LANCET, V1, P1299; LOGAN RPH, 1991, LANCET, V338, P1249, DOI 10.1016/0140-6736(91)92111-E; MARSHALL BJ, 1988, LANCET, V2, P1437; PORRO GB, 1984, SCAND J GASTROENTERO, V19, P905, DOI 10.1080/00365521.1984.12005830; RAUTELIN H, 1992, ANTIMICROB AGENTS CH, V36, P163, DOI 10.1128/AAC.36.1.163; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; TURKKAN MT, 1985, B GUTHANE MIL MED AC, V27, P553; UNGE P, 1992, GASTROENTEROLOGY, V102, P183; WAGNER S, 1992, GUT, V33, P179, DOI 10.1136/gut.33.2.179; ZHENG ZT, 1985, LANCET, V1, P1048	19	300	305	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					508	510		10.1016/S0140-6736(94)91460-5	http://dx.doi.org/10.1016/S0140-6736(94)91460-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906759				2022-12-28	WOS:A1994MX88800008
J	COIMBRA, TLM; NASSAR, ES; BURATTINI, MN; DESOUZA, LTM; FERREIRA, IB; ROCCO, IM; DAROSA, APAT; VASCONCELOS, PFC; PINHEIRO, FP; LEDUC, J; RICOHESSE, R; GONZALEZ, JP; JAHRLING, PB; TESH, RB				COIMBRA, TLM; NASSAR, ES; BURATTINI, MN; DESOUZA, LTM; FERREIRA, IB; ROCCO, IM; DAROSA, APAT; VASCONCELOS, PFC; PINHEIRO, FP; LEDUC, J; RICOHESSE, R; GONZALEZ, JP; JAHRLING, PB; TESH, RB			NEW ARENAVIRUS ISOLATED IN BRAZIL	LANCET			English	Note								A new arenavirus, called Sabia, was isolated in Brazil from a fatal case of haemorrhagic fever initially thought to be yellow fever. Antigenic and molecular characterisation indicated that Sabia virus is a new member of the Tacaribe complex. A laboratory technician working with the agent was also infected and developed a prolonged, non-fatal influenza-like illness. Sabia virus is yet another arenavirus causing human disease in South America.	YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,YALE ARBOVIRUS RES UNIT,NEW HAVEN,CT 06520; ADOLFO LUTZ INST,VIRUS SERV,SAO PAULO,SP,BRAZIL; PAULISTA MED SCH,INFECT DIS CLIN,SAO PAULO,SP,BRAZIL; EVANDRO CHAGAS INST,DEPT ARBOVIRUS,BELEM,PARA,BRAZIL; PAN AMER HLTH ORG,COMMUNICABLE DIS PROGRAM,WASHINGTON,DC; WHO,MICROBIOL & IMMUNOL SUPPORT SECT,GENEVA,SWITZERLAND; USA,MED RES INST INFECT DIS,FREDERICK,MD	Yale University; Instituto Adolfo Lutz; Instituto Evandro Chagas; Pan American Health Organization; World Health Organization			Rico-Hesse, Rebeca/C-5294-2011; Gonzalez, J-P/C-3077-2013; Burattini, Marcelo N/J-9272-2014; Rico-Hesse, Rebecca/AAW-9501-2021; Vasconcelos, Pedro/AAH-3142-2019	Rico-Hesse, Rebeca/0000-0001-6216-1000; Gonzalez, J-P/0000-0003-3063-1770; Burattini, Marcelo N/0000-0002-5407-6890; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042795, R22AI010984, R37AI010984, R01AI010984] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-01124, R01 AI042795-01, AI-10984, AI-33983] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUCHMEIER MJ, 1991, CLASSIFICATION NOMEN, P284; Childs J.E., 1993, ARENAVIRIDAE, P331, DOI DOI 10.1007/978-1-4615-3028-2_19; CLEGG JCS, 1993, ARENAVIRIDAE, P175; Fisher-Hoch S.P., 1993, ARENAVIRIDAE, P299; JOHNSONKM, 1989, VIRAL INFECTIONS HUM, P133; RICOHESSE R, 1987, VIROLOGY, V160, P311, DOI 10.1016/0042-6822(87)90001-8; SALAS R, 1991, LANCET, V338, P1033, DOI 10.1016/0140-6736(91)91899-6; VASCONCELOS PFC, IN PRESS REV I MED T; WALKER DH, 1987, CURR TOP MICROBIOL, V133, P89	9	112	119	2	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					391	392		10.1016/S0140-6736(94)91226-2	http://dx.doi.org/10.1016/S0140-6736(94)91226-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905555	hybrid, Green Accepted, Green Published			2022-12-28	WOS:A1994MW28300012
J	LAMONT, JT				LAMONT, JT			WHY FIBER IS GOOD FOR YOU	LANCET			English	Editorial Material							CHAIN FATTY-ACIDS; COLON				LAMONT, JT (corresponding author), BOSTON UNIV,SCH MED,GASTROENTEROL SECT,BOSTON,MA 02118, USA.							BOWLING TE, 1993, LANCET, V342, P1266, DOI 10.1016/0140-6736(93)92360-6; CUMMINGS JH, 1987, GUT, V28, P1221, DOI 10.1136/gut.28.10.1221; HARIG JM, 1989, NEW ENGL J MED, V320, P23, DOI 10.1056/NEJM198901053200105; Kritchevsky D., 1986, DIETARY FIBER, P131, DOI DOI 10.1007/978-1-4613-2111-8_10; LEVITT MD, 1983, GASTROENTEROLOGY, V85, P769; MACFARLANE GT, 1993, LARGE INTESTINE PHYS, P51; ROEDIGER WEW, 1980, GUT, V21, P793, DOI 10.1136/gut.21.9.793; RUPPIN H, 1980, GASTROENTEROLOGY, V78, P1500; STEPHEN AM, 1983, GASTROENTEROLOGY, V85, P589	9	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					372	372		10.1016/S0140-6736(94)91219-X	http://dx.doi.org/10.1016/S0140-6736(94)91219-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905548				2022-12-28	WOS:A1994MW28300005
J	PRITCHARD, KI				PRITCHARD, KI			ADJUVANT SYSTEMIC THERAPY FOR BREAST-CANCER - A TALE OF RELAPSE AND SURVIVAL	LANCET			English	Editorial Material							TRIAL				PRITCHARD, KI (corresponding author), UNIV TORONTO,DEPT MED,TORONTO,ON,CANADA.		Pritchard, Kathleen I/I-2184-2014	Pritchard, Kathleen I/0000-0003-0758-9666				BONADONNA G, 1980, DIAGNOSIS THERAPY BR, P727; Cuzick J, 1988, Recent Results Cancer Res, V111, P108; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; FISHER B, 1986, J CLIN ONCOL, V4, P929, DOI 10.1200/JCO.1986.4.6.929; MCDONALD CC, 1991, BRIT MED J, V303, P435, DOI 10.1136/bmj.303.6800.435; MORRISON JM, 1989, BRIT J CANCER, V60, P911, DOI 10.1038/bjc.1989.389; PRITCHARD KI, 1987, ADJUVANT THERAPY CAN, P391; ROSE C, 1985, LANCET, V1, P16; 1992, LANCET, V339, P71	9	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					370	371		10.1016/S0140-6736(94)91217-3	http://dx.doi.org/10.1016/S0140-6736(94)91217-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905546				2022-12-28	WOS:A1994MW28300003
J	TSAKAYANNIS, D; LI, WW; RAZVI, S; SPIRITO, N				TSAKAYANNIS, D; LI, WW; RAZVI, S; SPIRITO, N			SUCRALFATE AND CHRONIC VENOUS STASIS ULCERS	LANCET			English	Letter									MASSACHUSETTS GEN HOSP, DIV MED SERV, BOSTON, MA USA	Harvard University; Massachusetts General Hospital	TSAKAYANNIS, D (corresponding author), ST ELIZABETHS MED CTR, DEPT SURG, BOSTON, MA 02135 USA.							FOLKMAN J, 1990, KAR INS NCS, P201; FOLKMAN J, 1991, ANN SURG, V214, P414, DOI 10.1097/00000658-199110000-00006; FOLKMAN J, 1989, HEPARIN, P317; KNIGHTON DR, 1990, SURG GYNECOL OBSTET, V170, P56; ROBSON MC, 1992, ANN SURG, V216, P401, DOI 10.1097/00000658-199210000-00002	5	9	10	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					424	425		10.1016/S0140-6736(94)91263-7	http://dx.doi.org/10.1016/S0140-6736(94)91263-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905584				2022-12-28	WOS:A1994MW28300056
J	BRAIR, ME; BRABIN, BJ; MILLIGAN, P; MAXWELL, S; HART, CA				BRAIR, ME; BRABIN, BJ; MILLIGAN, P; MAXWELL, S; HART, CA			REDUCED TRANSFER OF TETANUS ANTIBODIES WITH PLACENTAL MALARIA	LANCET			English	Note								Placental malaria may limit antibody transfer to the fetus. We compared concentrations of tetanus antibody in paired maternal-cord sera from 224 women living in a malarious area of Papua New Guinea. With heavy placental infection ( > 35 parasites per 200 white cells) the average cold tetanus antibody corresponding to a maternal level of 1 IU/mL was 0.18 (95% Cl 0.12-0.26); corresponding figures after light (<35 parasites per 200 white cells) or no infection were 0.23 (0.14-0.34) and 0 82 (0.57-1.21), respectively. About 10% of babies born to mothers with a placenta heavily infected with Plasmodium falciparum may fail to acquire protective levels of tetanus antibody despite adequate maternal antibody.	UNIV LIVERPOOL,LIVERPOOL SCH TROP MED,PEMBROKE PL,LIVERPOOL L3 5QA,ENGLAND; UNIV LIVERPOOL,FAC MED,DEPT MED MICROBIOL,LIVERPOOL L69 3BX,ENGLAND	Liverpool School of Tropical Medicine; University of Liverpool; University of Liverpool			Brabin, Bernard/AAJ-7389-2020; Milligan, Paul/D-8985-2017	Milligan, Paul/0000-0003-3430-3395; Brabin, Bernard/0000-0001-6860-2508				BRABIN BJ, 1984, B WORLD HEALTH ORGAN, V62, P919; BRABIN BJ, 1990, ANN TROP MED PARASIT, V84, P1; CHANDRA RK, 1975, MATERNOFOETAL TRANSM, P77; GALBRAITH RM, 1980, T ROY SOC TROP MED H, V74, P61, DOI 10.1016/0035-9203(80)90012-7; GENDREL D, 1990, J TROP PEDIATRICS, V36, P279, DOI 10.1093/tropej/36.6.279; LOGIE DE, 1973, B WORLD HEALTH ORGAN, V49, P547; NEWELL KW, 1966, B WORLD HEALTH ORGAN, V35, P863; SATISH S, 1990, INDIAN J PEDIATR, V57, P763; SCHOFIELD F, 1961, BMJ-BRIT MED J, V2, P785, DOI 10.1136/bmj.2.5255.785	9	89	90	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 22	1994	343	8891					208	209		10.1016/S0140-6736(94)90991-1	http://dx.doi.org/10.1016/S0140-6736(94)90991-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT332	7904669				2022-12-28	WOS:A1994MT33200010
J	STEINHARDT, RA; BI, GQ; ALDERTON, JM				STEINHARDT, RA; BI, GQ; ALDERTON, JM			CELL-MEMBRANE RESEALING BY A VESICULAR MECHANISM SIMILAR TO NEUROTRANSMITTER RELEASE	SCIENCE			English	Article							PROTEIN-KINASE-II; PLASMA-MEMBRANES; AXONAL-TRANSPORT; SYNAPSIN-I; KINESIN; INVIVO; DISRUPTIONS; ELECTROPORATION; INTEGRITY	After injury to the cell membrane, rapid resealing of the membrane occurs with little loss of intracellular contents. This process has been studied by measurement of the rate of dye loss after membrane puncture in both the sea urchin embryo and 3T3 fibroblasts. Resealing of disrupted cell membranes requires external calcium that can be antagonized by magnesium. Block of multifunctional calcium/calmodulin kinase, which regulates exocytotic vesicle availability at synapses, and of kinesin, which is required for outward-directed transport of vesicles, inhibited membrane resealing. Resealing was also inhibited by botulinum neurotoxins B and A, suggesting that the two synaptosomal-associated proteins synaptobrevin and SNAP-25 also participate in resealing. This pattern of inhibition indicates that the calcium-dependent mechanisms for cell membrane resealing may involve vesicle delivery, docking, and fusion, similar to the exocytosis of neurotransmitters.			STEINHARDT, RA (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.		Bi, Guo-Qiang/E-5075-2013	Bi, Guo-Qiang/0000-0001-8735-3818	NIAMS NIH HHS [R01 AR41129] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041129] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; BAUAAT M, 1989, EMBO J, V8, P379; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; CHANG DC, 1990, BIOPHYS J, V58, P1, DOI 10.1016/S0006-3495(90)82348-1; CRAWFORD AC, 1974, J PHYSIOL-LONDON, V240, P255, DOI 10.1113/jphysiol.1974.sp010609; DEMELLO WC, 1969, CIRC RES, V24, P475, DOI 10.1161/01.RES.24.3.475; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; FERREIRA A, 1992, J CELL BIOL, V117, P595, DOI 10.1083/jcb.117.3.595; GHO M, 1992, SCIENCE, V258, P313, DOI 10.1126/science.1384131; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; Hoffman J F, 1992, Adv Exp Med Biol, V326, P1; HUBBARD JI, 1968, J PHYSIOL-LONDON, V196, P75, DOI 10.1113/jphysiol.1968.sp008495; HUGHES K, 1989, BIOCHIM BIOPHYS ACTA, V981, P277, DOI 10.1016/0005-2736(89)90038-2; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; LECKBAND DE, 1993, BIOCHEMISTRY-US, V32, P1127, DOI 10.1021/bi00055a019; LEE B, 1985, BIOCHIM BIOPHYS ACTA, V815, P128, DOI 10.1016/0005-2736(85)90482-1; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MCNEIL PL, 1990, J CELL SCI, V96, P549; MCNEIL PL, 1989, GASTROENTEROLOGY, V96, P1238, DOI 10.1016/S0016-5085(89)80010-1; MCNEIL PL, 1992, AM J PATHOL, V140, P1097; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; POULAIN B, 1988, P NATL ACAD SCI USA, V85, P4090, DOI 10.1073/pnas.85.11.4090; REHDER V, 1992, NEUROSCIENCE, V51, P565, DOI 10.1016/0306-4522(92)90296-E; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SEVERS NJ, 1990, J MUSCLE RES CELL M, V11, P154, DOI 10.1007/BF01766494; SHAPIRO BM, 1991, SCIENCE, V252, P533, DOI 10.1126/science.1850548; SHEETZ MP, 1989, TRENDS NEUROSCI, V12, P474, DOI 10.1016/0166-2236(89)90099-4; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; SWEZEY RR, 1989, CELL REGUL, V1, P65, DOI 10.1091/mbc.1.1.65; TATHAM PER, 1991, J CELL SCI, V98, P217; VACQUIER VD, 1981, DEV BIOL, V84, P1, DOI 10.1016/0012-1606(81)90366-3; VALE RD, 1992, J CELL BIOL, V119, P1589, DOI 10.1083/jcb.119.6.1589; XIE XY, 1991, J NEUROSCI, V10, P3257; YU QC, 1992, AM J PATHOL, V141, P1349	39	405	415	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 21	1994	263	5145					390	393		10.1126/science.7904084	http://dx.doi.org/10.1126/science.7904084			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT034	7904084				2022-12-28	WOS:A1994MT03400038
J	MCMAHON, AJ; RUSSELL, IT; BAXTER, JN; ROSS, S; ANDERSON, JR; MORRAN, CG; SUNDERLAND, G; GALLOWAY, D; RAMSAY, G; ODWYER, PJ				MCMAHON, AJ; RUSSELL, IT; BAXTER, JN; ROSS, S; ANDERSON, JR; MORRAN, CG; SUNDERLAND, G; GALLOWAY, D; RAMSAY, G; ODWYER, PJ			LAPAROSCOPIC VERSUS MINILAPAROTOMY CHOLECYSTECTOMY - A RANDOMIZED TRIAL	LANCET			English	Article							SUBCOSTAL INCISION	Although laparoscopic cholecystectomy has rapidly become routine practice in the UK, there has been no rigorous comparison of it with open cholecystectomy. In our trial, 302 patients were randomised to laparoscopic or minilaparotomy cholecystectomy. Recovery after surgery was assessed by length of hospital stay, outpatient review at 10 days and 4 weeks, and patient questionnaires 1, 4, and 12 weeks after surgery. The mean operation time was 14 min shorter for minilaparotomy, while median post-operative hospital stay was 2 days shorter after laparoscopic cholecystectomy. The hospital costs were about 400 Pounds greater for the laparoscopic procedure. Laparoscopic patients returned to work in the home sooner; at 1 week, they had better physical and social functioning, were less limited by physical problems, and had less pain and depression. At 4 weeks, only physical functioning and depression scores were better in the laparoscopic group, and by 3 months there were no differences. Laparoscopic patients were more satisfied with the appearance of their scars. The incidence of complications after both procedures was 20%. Compared to minilaparotomy cholecystectomy, laparoscopic cholecystectomy results in shorter hospital stay, less postoperative dysfunction, and quicker return to normal activities, but is more costly.	UNIV GLASGOW,WESTERN INFIRM,DEPT SURG,GLASGOW G11 6NT,SCOTLAND; UNIV GLASGOW,GLASGOW ROYAL INFIRM,DEPT SURG,GLASGOW,SCOTLAND; UNIV ABERDEEN,HLTH SERV RES UNIT,ABERDEEN AB9 1FX,SCOTLAND; SO GEN HOSP,DEPT SURG,GLASGOW G51 4TF,SCOTLAND; GARTNAVEL ROYAL HOSP,DEPT SURG,GLASGOW G12 0YN,SCOTLAND; CROSSHOUSE HOSP,DEPT SURG,KILMARNOCK,SCOTLAND	University of Glasgow; University of Glasgow; University of Aberdeen; University of Glasgow; Gartnavel Royal Hospital			Russell, Ian T/H-1181-2012					BARKUN JS, 1992, LANCET, V340, P1116, DOI 10.1016/0140-6736(92)93148-G; BRANUM G, 1993, ANN SURG, V217, P532, DOI 10.1097/00000658-199305010-00014; CUSHIERI A, 1991, AM J SURG, V161, P385; DEZIEL DJ, 1993, AM J SURG, V165, P9, DOI 10.1016/S0002-9610(05)80397-6; FULLARTON GM, 1993, IN PRESS BR J SURG; GARRATT AM, 1993, BMJ-BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; GO PMNYH, 1993, BRIT J SURG, V80, P1180, DOI 10.1002/bjs.1800800938; Goco I R, 1988, South Med J, V81, P161; LEDET WP, 1990, ARCH SURG-CHICAGO, V125, P1434; MCMAHON AJ, 1993, BRIT J SURG, V80, P1593, DOI 10.1002/bjs.1800801233; MCMAHON AJ, 1993, IN PRESS SURGERY; MCMAHON AJ, 1993, J IR COLL PHYS SURG, V22, P186; ODWYER PJ, 1992, POSTGRAD MED J, V68, P817, DOI 10.1136/pgmj.68.804.817; OKELLY TJ, 1991, BRIT J SURG, V78, P762, DOI 10.1002/bjs.1800780638; ROSLYN JJ, 1993, ANN SURG, V218, P129, DOI 10.1097/00000658-199308000-00003; STOKER ME, 1992, ARCH SURG-CHICAGO, V127, P589; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 1991, NEW ENGL J MED, V324, P1073	18	327	340	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 15	1994	343	8890					135	138		10.1016/S0140-6736(94)90932-6	http://dx.doi.org/10.1016/S0140-6736(94)90932-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7904002				2022-12-28	WOS:A1994MQ86900008
J	BLADIN, CF; ALEXANDROV, AV; SMURAWSKA, LT				BLADIN, CF; ALEXANDROV, AV; SMURAWSKA, LT			SHOULD PATIENTS WITH STROKE SEE A NEUROLOGIST	LANCET			English	Editorial Material											BLADIN, CF (corresponding author), UNIV TORONTO,STROKE RES UNIT,TORONTO M5S 1A1,ONTARIO,CANADA.		bladin, chris/B-9136-2013	Alexandrov, Andrei V/0000-0001-8871-1023				ASPLUND K, 1993, CEREBROVASC DIS, V3, P34, DOI 10.1159/000108747; HEWER RL, 1992, J NEUROL NEUROSUR PS, V55, P8; ISARD PA, 1992, CEREBROVASC DIS, V2, P47, DOI 10.1159/000108988; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; NORRIS JW, 1982, LANCET, V1, P328; WARDLAW JM, 1992, STROKE, V23, P1826, DOI 10.1161/01.STR.23.12.1826; 1991, LANCET, V337, P1235; 1993, GUIDELINES CARE PATI; 1993, LANCET, V342, P1255; 1991, NEW ENGL J MED, V325, P445	10	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					69	70		10.1016/S0140-6736(94)90811-7	http://dx.doi.org/10.1016/S0140-6736(94)90811-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903774				2022-12-28	WOS:A1994MQ09200006
J	MCPHERSON, MA; DORMER, RL				MCPHERSON, MA; DORMER, RL			CYSTIC-FIBROSIS GENE AND MUCIN SECRETION	LANCET			English	Editorial Material							CELLS; CFTR				MCPHERSON, MA (corresponding author), UNIV WALES COLL MED,DEPT MED BIOCHEM,CARDIFF CF4 4XN,S GLAM,WALES.							BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; DRUMM ML, 1993, PEDIATR PULMONOL, V250; KUVER R, 1993, PEDIATR PULMONOL S9, V254; MCPHERSON MA, 1986, LANCET, V2, P1007; MILLS CL, 1992, BIOCHEM BIOPH RES CO, V188, P1146, DOI 10.1016/0006-291X(92)91351-P; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; TSENG HC, 1993, 7TH ANN N AM CF C DA	7	12	12	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					7	7		10.1016/S0140-6736(94)90872-9	http://dx.doi.org/10.1016/S0140-6736(94)90872-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905085				2022-12-28	WOS:A1994MN93700008
J	BRAHAMS, D				BRAHAMS, D			DEATHS IN US FIALURIDINE TRIAL	LANCET			English	Editorial Material																			0	25	25	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1494	1495		10.1016/S0140-6736(94)92599-2	http://dx.doi.org/10.1016/S0140-6736(94)92599-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911188				2022-12-28	WOS:A1994NQ41500025
J	KOIZUMI, A; AOKI, T; TSUKADA, M; NARUSE, M; SAITOH, N				KOIZUMI, A; AOKI, T; TSUKADA, M; NARUSE, M; SAITOH, N			MERCURY, NOT SULFUR-DIOXIDE, POISONING AS CAUSE OF SMELTER DISEASE IN INDUSTRIAL-PLANTS PRODUCING SULFURIC-ACID	LANCET			English	Article								Several episodes of ''smelter disease'', previously assumed to be caused by sulphur dioxide (SO2) poisoning, have been reported in workers replacing pipes in sulphuric acid manufacturing plants. One such incident, affecting 20 men, was recorded in Akita, Japan, in July, 1993, but the protection these workers used suggested that some cause other than SO2 needed to be looked for. 10 workers were affected despite wearing respirators with SO2 cartridges, the symptoms including dyspnoea, diarrhoea, colicky pain, muscle pain and eczema with erythema. Subsequently 10 other workers using face masks with supplied air were affected, though without respiratory symptoms. Sludge in the piping contained mercuric sulphate, and mercury fumes resulted when pipes were cut with gas burners. Blood and urine measurements confirmed heavy exposure to the metal, and simulation experiments in rats showed that skin absorption was likely too. The masks with supplied air ought to have excluded both SO2 and mercury fumes. The only way to avoid smelter disease reliably is to wear an encapsulated suit that prevents inhalation and skin absorption of industrial toxins.	SAKATA CITY HOSP,DEPT DERMATOL,MORIOKA,IWATE,JAPAN; IWATE PREFECTURAL LAB ENVIRONM SCI,MORIOKA,IWATE,JAPAN		KOIZUMI, A (corresponding author), AKITA UNIV,SCH MED,DEPT HYG,AKITA 010,JAPAN.							ELBERGER SY, 1993, HDB MED TOXICOLOGY, P285; HARA I, 1975, OSAKA FU KOEIKENKENK, V13, P31; SEATON A, 1978, BRIT J IND MED, V35, P258; WINDHOLZ M, 1983, MERCK INDEX, P841	4	10	10	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1411	1412		10.1016/S0140-6736(94)92530-5	http://dx.doi.org/10.1016/S0140-6736(94)92530-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910889				2022-12-28	WOS:A1994NP95500016
J	NAKAI, A; GOTO, Y; FUJISAWA, K; SHIGEMATSU, Y; KIKAWA, Y; KONISHI, Y; NONAKA, I; SUDO, M				NAKAI, A; GOTO, Y; FUJISAWA, K; SHIGEMATSU, Y; KIKAWA, Y; KONISHI, Y; NONAKA, I; SUDO, M			DIFFUSE LEUKODYSTROPHY WITH A LARGE-SCALE MITOCHONDRIAL-DNA DELETION	LANCET			English	Note								An 8-year-old girl with progressive ataxia and bulbar palsy showed diffuse white-matter lesions in the occipital to parietal lobes on magnetic resonance imaging. Since she had slightly elevated lactate in the cerebrospinal fluid, a muscle biopsy was done which revealed scattered ragged-red fibres and focal cytochrome c oxidase deficiency. Southern blot and polymerase-chain-reaction analyses revealed a large-scale mitochondrial DNA deletion, which was 6990 base-pairs in length with 6 base-pair (-TCATCG-) direct repeats at the junctions. Mitochondrial DNA mutation should be considered as one of the candidate causes for diffuse leukodystrophy in children.	NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV ULTRASTRUCT RES,KODAIRA 187,TOKYO,JAPAN	National Center for Neurology & Psychiatry - Japan	NAKAI, A (corresponding author), FUKUI MED SCH,DEPT PAEDIAT,MATSUOKA CHO,FUKUI 91011,JAPAN.							AICARDI J, 1993, J INHERIT METAB DIS, V16, P733, DOI 10.1007/BF00711905; DEMANGE P, 1989, AM J NEURORADIOL, V10, P91; ELSAS T, 1988, ACTA OPHTHALMOL, V66, P469; LESTIENNE P, 1988, LANCET, V1, P885; NAKAGAWA M, 1991, CLIN NEUROL, V31, P981; OHNO K, 1991, ANN NEUROL, V29, P364, DOI 10.1002/ana.410290406; ROTIG A, 1988, LANCET, V2, P567; SANDHU FS, 1991, AM J NEURORADIOL, V12, P375; SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184; SHINDO K, 1991, CLIN NEUROL TOKYO, V31, P539	10	31	31	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1397	1398		10.1016/S0140-6736(94)92527-5	http://dx.doi.org/10.1016/S0140-6736(94)92527-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910887				2022-12-28	WOS:A1994NP95500013
J	SACK, DA; HOQUE, ATMS; HUQ, A; ETHERIDGE, M				SACK, DA; HOQUE, ATMS; HUQ, A; ETHERIDGE, M			IS PROTECTION AGAINST SHIGELLOSIS INDUCED BY NATURAL INFECTION WITH PLESIOMONAS-SHIGELLOIDES	LANCET			English	Article							PEACE-CORPS VOLUNTEERS; DIARRHEAL DISEASE; ESCHERICHIA-COLI; UNITED-STATES; IMMUNIZATION; TEMPERATURE; ANTIBODIES; TRAVELERS; AEROMONAS; CHILDREN	Shigellosis due to Shigella sonnei is rare among people growing up and living in developing countries; however, infections due to S sonnei becomes more common than those due to S flexneri as societies develop economically. The relation between risk of S sonnei infection and economic development may be explained by the exposure of developing-country populations to Plesiomonas shigelloides. P shigelloides is often found in surface water, and one serotype (serotype 17) possesses a cell-wall lipopolysaccharide identical to that of S sonnei. Thus, exposure to P shigelloides by drinking contaminated water may immunise populations to S sonnei. As economic development occurs, water quality improves and populations become susceptible to S sonnei. Although drinking pure water has many advantages, immunisation against S sonnei may be one benefit of traditional water sources.	JOHNS HOPKINS UNIV,DEPT COMPARAT MED,BALTIMORE,MD 21205; UNIV MARYLAND,DEPT MICROBIOL,COLL PK,MD 20742	Johns Hopkins University; University System of Maryland; University of Maryland College Park	SACK, DA (corresponding author), JOHNS HOPKINS UNIV,DEPT INT HLTH,615 N WOLFE ST,BALTIMORE,MD 21205, USA.				NCRR NIH HHS [RR00130] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR000130] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AHMED F, 1992, PEDIATRICS, V90, P406; AHMED ZU, 1990, VACCINE, V8, P153, DOI 10.1016/0264-410X(90)90139-D; AKMAN M, 1965, TURKISH J PEDIATR, V7, P155; ALDOVA E, 1987, ZBL BAKT-INT J MED M, V265, P253; ALDOVA E, 1987, J HYG EPIDEMIOL IMMU, V31, P76; ARAI T, 1980, J HYG-CAMBRIDGE, V84, P203, DOI 10.1017/S002217240002670X; BRENDEN RA, 1988, REV INFECT DIS, V10, P303; CHOWDHURY K A, 1988, Journal of Diarrhoeal Diseases Research, V6, P221; CLEMENS JD, 1988, J INFECT DIS, V158, P372, DOI 10.1093/infdis/158.2.372; COHEN D, 1991, INT J EPIDEMIOL, V20, P546, DOI 10.1093/ije/20.2.546; Ekwall E, 1988, SERODIAGN IMMUNOTHER, V2, P47; FERGUSON WW, 1947, J BACTERIOL, V54, P179, DOI 10.1128/JB.54.2.179-181.1947; FERRECCIO C, 1991, AM J EPIDEMIOL, V134, P614, DOI 10.1093/oxfordjournals.aje.a116134; GAINES S, 1968, MIL MED, V133, P114, DOI 10.1093/milmed/133.2.114; GOMES TAT, 1991, J INFECT DIS, V164, P331, DOI 10.1093/infdis/164.2.331; GORDON JE, 1964, B WORLD HEALTH ORGAN, V31, P1; HERRINGTON DA, 1990, VACCINE, V8, P353, DOI 10.1016/0264-410X(90)90094-3; HERRINGTON DA, 1987, INFECT IMMUN, V55, P979, DOI 10.1128/IAI.55.4.979-985.1987; HOLMBERG SD, 1986, ANN INTERN MED, V105, P690, DOI [10.7326/0003-4819-105-5-690, 10.7326/0003-4819-105-5-683]; HOLMBERG SD, 1984, REV INFECT DIS, V6, P633; HOUNG HSH, 1992, J BACTERIOL, V174, P5910, DOI 10.1128/jb.174.18.5910-5915.1992; HUQ A, 1991, CAN J MICROBIOL, V37, P800, DOI 10.1139/m91-138; JOSEPH S W, 1988, Journal of Diarrhoeal Diseases Research, V6, P80; KAGALWALLA AF, 1992, PEDIATR INFECT DIS J, V11, P215, DOI 10.1097/00006454-199203000-00009; KAIN KC, 1989, J CLIN MICROBIOL, V27, P998, DOI 10.1128/JCM.27.5.998-1001.1989; KHAN MU, 1985, INT J EPIDEMIOL, V14, P607, DOI 10.1093/ije/14.4.607; KHARDORI N, 1988, ANNU REV MICROBIOL, V42, P395, DOI 10.1146/annurev.mi.42.100188.002143; KWAGA JKP, 1988, MICROBIOLOGICA, V11, P165; LEE LA, 1991, J INFECT DIS, V164, P894, DOI 10.1093/infdis/164.5.894; LOPEZBREA M, 1983, T ROY SOC TROP MED H, V77, P140, DOI 10.1016/0035-9203(83)90047-0; Matsushita S, 1991, Kansenshogaku Zasshi, V65, P857; RUTALA WA, 1982, LANCET, V1, P739; SACK D A, 1988, Journal of Diarrhoeal Diseases Research, V6, P107; SACK DA, 1977, JOHNS HOPKINS MED J, V141, P63; SACK DA, 1978, NEW ENGL J MED, V298, P758, DOI 10.1056/NEJM197804062981402; SAYEED S, 1989, Bangladesh Journal of Microbiology, V6, P7; SAYEED S, 1992, J MED MICROBIOL, V37, P382, DOI 10.1099/00222615-37-6-382; TSUKAMOTO T, 1978, J HYG-CAMBRIDGE, V80, P275, DOI 10.1017/S0022172400053638; VANDEVERG LL, 1992, J INFECT DIS, V166, P158, DOI 10.1093/infdis/166.1.158	39	24	24	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1413	1415		10.1016/S0140-6736(94)92531-3	http://dx.doi.org/10.1016/S0140-6736(94)92531-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910890	hybrid			2022-12-28	WOS:A1994NP95500017
J	LILLEYMAN, JS; LENNARD, L				LILLEYMAN, JS; LENNARD, L			MERCAPTOPURINE METABOLISM AND RISK OF RELAPSE IN CHILDHOOD LYMPHOBLASTIC-LEUKEMIA	LANCET			English	Article							ACUTE LYMPHOCYTIC-LEUKEMIA; MAINTENANCE CHEMOTHERAPY; 6-MERCAPTOPURINE; CHILDREN	Many months' treatment with daily oral mercaptopurine is an important part of therapy for nearly all children with lymphoblastic leukaemia (ALL). Even when prescribed the same dose based on body surface area, patients have widely different intracellular concentrations of drug metabolites. Whether this variation matters in terms of disease control is not yet clear. To find out, we followed up a large group of children with ALL in whom mercaptopurine-derived thioguanine nucleotides in the red cells were measured during treatment with an identical dose of mercaptopurine early in first remission. 172 unselected children (100 boys, 72 girls) were recruited between 1980 and 1992. At median follow-up of 5 years from diagnosis 42 (24%) had relapsed; 30 had erythrocyte thioguanine nucleotide concentrations below the group median (284 pmol per 8 x 10(8) erythrocytes) and 12 had values above the median. The actuarial relapse-free survival at 5 years was 63% in the below-median group and 84% in the above-median group (difference 21% [95% Cl 3-39%], p = 0.0018). Multivariate analysis showed that erythrocyte thioguanine nucleotide concentration was independent of other prognostic variables including age, leukaemia immunophenotype, white-blood-cell count at diagnosis, trial protocol, and sex. Whatever the cause, in childhood ALL variable formation of intracellular mercaptopurine metabolites seems to be clinically important. Therapeutic schedules that include long-term daily oral mercaptopurine might be more effective if such metabolites are monitored.	UNIV SHEFFIELD,CHILDRENS HOSP,DEPT PAEDIAT,PAEDIAT HAEMATOL SECT,SHEFFIELD,S YORKSHIRE,ENGLAND; UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,DEPT MED & PHARMACOL,PHARMACOL & THERAPEUT SECT,SHEFFIELD,S YORKSHIRE,ENGLAND	Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Sheffield; University of Sheffield			Lennard, Lynne/E-1131-2011					ADAMSON PC, 1990, NEW ENGL J MED, V323, P1565; BOSTROM B, 1993, AM J PEDIAT HEMATOL, V15, P80; BURCHENAL JH, 1953, BLOOD, V8, P965, DOI 10.1182/blood.V8.11.965.965; CHESSELLS JM, 1992, LEUKEMIA, V6, P157; DAVIES HA, 1993, BRIT MED J, V306, P1239, DOI 10.1136/bmj.306.6887.1239; EDEN OB, 1991, BRIT J HAEMATOL, V78, P187, DOI 10.1111/j.1365-2141.1991.tb04415.x; GALE RP, 1991, LANCET, V338, P1315, DOI 10.1016/0140-6736(91)92604-Z; GUERCIOLINI R, 1991, CLIN PHARMACOL THER, V50, P663, DOI 10.1038/clpt.1991.205; HALE JP, 1991, ARCH DIS CHILD, V66, P462, DOI 10.1136/adc.66.4.462; HAYDER S, 1989, THER DRUG MONIT, V11, P617, DOI 10.1097/00007691-198911000-00001; KOREN G, 1990, NEW ENGL J MED, V323, P17, DOI 10.1056/NEJM199007053230104; LENNARD L, 1992, J CHROMATOGR-BIOMED, V583, P83, DOI 10.1016/0378-4347(92)80347-S; LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V; LENNARD L, 1993, BRIT J CLIN PHARMACO, V36, P277, DOI 10.1111/j.1365-2125.1993.tb00365.x; LENNARD L, 1987, LANCET, V2, P785; LENNARD L, 1989, J CLIN ONCOL, V7, P1816, DOI 10.1200/JCO.1989.7.12.1816; LILLEYMAN JS, 1984, BRIT J CANCER, V49, P703, DOI 10.1038/bjc.1984.111; PINKEL D, 1993, J CLIN ONCOL, V11, P1826, DOI 10.1200/JCO.1993.11.9.1826; WEINSHILBOUM RM, 1980, AM J HUM GENET, V32, P651; ZIMM S, 1983, NEW ENGL J MED, V308, P1005, DOI 10.1056/NEJM198304283081705; [No title captured]	21	190	195	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1188	1190		10.1016/S0140-6736(94)92400-7	http://dx.doi.org/10.1016/S0140-6736(94)92400-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909868				2022-12-28	WOS:A1994NL17500009
J	YOUNG, E; STONEHAM, MD; PETRUCKEVITCH, A; BARTON, J; RONA, R				YOUNG, E; STONEHAM, MD; PETRUCKEVITCH, A; BARTON, J; RONA, R			A POPULATION STUDY OF FOOD INTOLERANCE	LANCET			English	Article							1ST 3 YEARS; ADVERSE REACTIONS; HYPERSENSITIVITY; CHILDREN; ALLERGY; INFANTS; LIFE	We did a population study to identify the prevalence of reactions to eight foods commonly perceived to cause sensitivity in the UK. A cross-sectional survey of 7500 households in the Wycombe Health Authority area and the same number of randomly-selected households nationwide was followed up by interviews of positive respondents from the Wycombe Health Authority area. Those who agreed entered a double-blind, placebo-controlled food challenge study to confirm food intolerance. 20.4% of the nationwide sample and 19.9% of the High Wycombe sample complained of food intolerance. Of the 93 subjects who entered the double-blind, placebo-controlled food challenge, 19.4% (95% confidence interval 11.4% -27.4%) had a positive reaction. The estimated prevalence of reactions to the eight foods tested in the population varied from 1.4% to 1.8% according to the definition used. Women perceived food intolerance more frequently and showed a higher rate of positive results to food challenge. There is a discrepancy between perception of food intolerance and the results of the double-blind placebo-controlled food challenges. The consequences of mistaken perception of food intolerance may be considerable in financial, nutritional, and health terms.	GUYS & ST THOMAS HOSP,DIV COMMUNITY HLTH,LONDON,ENGLAND	Guy's & St Thomas' NHS Foundation Trust	YOUNG, E (corresponding author), AMERSHAM HOSP,DEPT DERMATOL,AMERSHAM MP7 0JD,BUCKS,ENGLAND.		Rona, Roberto J/C-2348-2011	Rona, Roberto/0000-0003-3739-5571				ADNERSON JA, 1991, CLIN EXP ALLERGY, V21, P304; BOCK SA, 1987, PEDIATRICS, V79, P683; BOCK SA, 1986, J ALLERGY CLIN IMMUN, V78, P165, DOI 10.1016/0091-6749(86)90009-6; BUCKLEY RH, 1982, JAMA-J AM MED ASSOC, V1248, P2627; HIDE DW, 1983, BRIT J CLIN PRACT, V37, P285; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; MAY CD, 1986, J ALLERGY CLIN IMMUN, V78, P144, DOI 10.1016/0091-6749(86)90005-9; METCALFE DD, 1984, J ALLERGY CLIN IMMUN, V73, P749, DOI 10.1016/0091-6749(84)90442-1; NANDA R, 1989, GUT, V30, P1099, DOI 10.1136/gut.30.8.1099; POCOCK SJ, 1991, CLIN TRIALS DIAGNOST, P110; PRICE CE, 1988, BMJ-BRIT MED J, V296, P1696, DOI 10.1136/bmj.296.6638.1696; SAMPSON HA, 1988, ANN ALLERGY, V60, P262; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V81, P635, DOI 10.1016/0091-6749(88)91033-0; SCHRANDER JJP, 1993, EUR J PEDIATR, V152, P640, DOI 10.1007/BF01955238; WEBBER RW, 1991, IMMUNOL ALLERGY CLIN, V11, P831; YOUNG E, 1987, J ROY COLL PHYS LOND, V21, P241; 1984, P R COLL PHYS, V18, P83	17	478	494	0	40	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1994	343	8906					1127	1130		10.1016/S0140-6736(94)90234-8	http://dx.doi.org/10.1016/S0140-6736(94)90234-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK730	7910231				2022-12-28	WOS:A1994NK73000008
J	MARKUS, HS; DROSTE, DW; BROWN, MM				MARKUS, HS; DROSTE, DW; BROWN, MM			DETECTION OF ASYMPTOMATIC CEREBRAL EMBOLIC SIGNALS WITH DOPPLER ULTRASOUND	LANCET			English	Note								Can asymptomatic cerebral emboli be detected? With transcranial doppler ultrasonography of the middle cerebral artery, short-duration high-intensity asymptomatic embolic signals were detected in 6 of 25 patients with carotid stenosis and in 9 of 24 with prosthetic cardiac valves, but not in 20 normal controls. In carotid stenosis the signals were usually unilateral and ipsilateral to the stenosis. Embolic signals were significantly more common in patients with mechanical valves than with pig xenografts (8/13 vs 1/11). With mechanical valves embolic signals were usually bilateral. Detection of asymptomatic emboli may allow identification of and preventive treatment in at-risk patients.			MARKUS, HS (corresponding author), UNIV LONDON ST GEORGES HOSP,SCH MED,DIV CLIN NEUROSCI,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.			Brown, Martin M/0000-0002-3273-1356				AUSTEN WG, 1965, J SURG RES, V5, P283; Bland M., 1987, INTRO MED STAT, P276; HALL RJC, 1989, DISEASES CARDIAC VAL; MARKUS H, 1993, STROKE, V24, P1667, DOI 10.1161/01.STR.24.11.1667; MARKUS H, 1994, J NEUROL SCI, V122, P117, DOI 10.1016/0022-510X(94)90061-2; RUSSELL D, 1991, STROKE, V22, P253, DOI 10.1161/01.STR.22.2.253; RUSSELL D, 1992, RECENT ADV NEUROSONO, P57; RUSSELL RW, 1963, LANCET, V2, P1354; SIEBLER M, 1992, STROKE, V23, P1652, DOI 10.1161/01.STR.23.11.1652; SPENCER MP, 1990, STROKE, V21, P415, DOI 10.1161/01.STR.21.3.415; TEGLER CH, 1991, J NEUROIMAGING, V1, P61	11	63	64	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 23	1994	343	8904					1011	1012		10.1016/S0140-6736(94)90129-5	http://dx.doi.org/10.1016/S0140-6736(94)90129-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909051				2022-12-28	WOS:A1994NG68200012
J	RODRIGUEZ, LAG; JICK, H				RODRIGUEZ, LAG; JICK, H			RISK OF UPPER GASTROINTESTINAL-BLEEDING AND PERFORATION ASSOCIATED WITH INDIVIDUAL NONSTEROIDAL ANTIINFLAMMATORY DRUGS	LANCET			English	Article							DISEASE	Exposure to non-steroidal anti-inflammatory drugs (NSAIDs) is known to increase substantially the risk of upper gastrointestinal bleeding and perforation (UGIB). We have carried out a population-based retrospective case-control study to assess the variation in risk associated with various individual NSAIDs, with adjustment for features of use and other independent risk factors. The study sample comprised 1457 cases of UGIB and 10 000 control subjects identified from general practitioners' computerised records in the UK. The adjusted estimate of relative risk of UGIB associated with current NSAID use was 4.7 (95% CI 3.8-5.7). Previous UGIB was the single most important predictor of UGIB (relative risk 13.5 [10.3-17.7]). For all NSAIDs together, the risk was greater for high doses than for tow doses (7.0 [5.2-9.6] vs 2.6 [1.8-3.8]). The estimates of risk associated with the individual NSAIDs varied widely. Users of azapropazone (23.4 [6.9-79.5]) and piroxicam (18.0 [8.2-39.6]) had the highest risk of UGIB among the NSAIDs studied. All the other NSAIDs with sufficient data for individual analysis (ibuprofen, naproxen, diclofenac, ketoprofen, and indomethacin) had relative risks similar to that for overall NSAID use. NSAIDS should be used cautiously in patients who have other risk factors for UGIB; these include advanced age, smoking, history of peptic ulcer, and use of oral corticosteroids or anticoagulants.			RODRIGUEZ, LAG (corresponding author), BOSTON UNIV,BOSTON COLLABORAT DRUG SURVELLANCE PROGRAM,11 MUZZEY ST,LEXINGTON,MA 02173, USA.		rodriguez, luis a garcia/B-1980-2010	Jick, Hershel/0000-0003-4270-5992				BOLLINI P, 1992, ARCH INTERN MED, V152, P1289, DOI 10.1001/archinte.152.6.1289; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; HAWKEY CJ, 1990, BMJ-BRIT MED J, V300, P278, DOI 10.1136/bmj.300.6720.278; HOSMER DW, 1992, EPIDEMIOLOGY, V3, P452, DOI 10.1097/00001648-199209000-00012; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; Perry J, 1978, OXMIS PROBLEM CODES	7	818	841	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 26	1994	343	8900					769	772		10.1016/S0140-6736(94)91843-0	http://dx.doi.org/10.1016/S0140-6736(94)91843-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907735				2022-12-28	WOS:A1994NC35100015
J	ENG, C; STRATTON, M; PONDER, B; MURDAY, V; EASTON, D; SACKS, N; WATSON, M; EELES, R				ENG, C; STRATTON, M; PONDER, B; MURDAY, V; EASTON, D; SACKS, N; WATSON, M; EELES, R			FAMILIAL CANCER SYNDROMES	LANCET			English	Article							SUBCUTANEOUS MASTECTOMY; BREAST-CANCER		UNIV CAMBRIDGE,DEPT PATHOL,CRC HUMAN CANC GENET,CAMBRIDGE,CAMBS,ENGLAND; ST GEORGE HOSP,LONDON,ENGLAND; INST CANC RES,CRC,EPIDEMIOL SECT,SUTTON,SURREY,ENGLAND; INST CANC RES,CRC,MOLEC CARCINOGENESIS SECT,SUTTON,SURREY,ENGLAND; ROYAL MARSDEN HOSP,DEPT SURG,SUTTON,SURREY,ENGLAND; ROYAL MARSDEN HOSP,DEPT PSYCHOL MED,SUTTON,SURREY,ENGLAND	University of Cambridge; St Georges University London; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust				Eng, Charis/0000-0002-3693-5145; Eeles, Rosalind/0000-0002-3698-6241				ALEXANDER HR, 1991, ANN INTERN MED, V115, P133; CLAUS EB, 1991, AM J HUM GENET, V48, P232; CONDIE A, 1993, HUM MUTAT, V2, P58, DOI 10.1002/humu.1380020111; CORNELIS RS, 1993, ONCOGENE, V8, P781; EASTON D, 1990, CANCER SURV, V9, P395; EASTON DF, 1989, AM J HUM GENET, V44, P208; EASTON DF, 1993, AM J HUM GENET, V52, P678; EASTON DF, IN PRESS CANCER SURV; EELES RA, 1993, EUR J CANCER, V29A, P1361, DOI 10.1016/0959-8049(93)90001-V; FISHER J, 1988, CLIN PLAST SURG, V15, P667; FUER JE, 1993, J NATL CANCER I, V85, P892; GARDNER E, 1993, HUM MOL GENET, V2, P241, DOI 10.1093/hmg/2.3.241; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HERRERAORNELAS L, 1987, SEMIN SURG ONCOL, V3, P66, DOI 10.1002/ssu.2980030203; JACOBS IJ, 1993, CANCER RES, V53, P1218; JOSTEN D M, 1985, Journal of Psychosocial Oncology, V3, P5; KASH KM, 1992, J NATL CANCER I, V84, P24, DOI 10.1093/jnci/84.1.24; KELSELL DP, IN PRESS HUM MOLE GE; LERMAN C, IN PRESS J NATL CANC; LYONNET S, 1993, NAT GENET, V4, P346, DOI 10.1038/ng0893-346; MEYER L, 1986, SCAND J PLAST RECONS, V20, P101, DOI 10.3109/02844318609006302; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NAROD SA, 1991, LANCET, V338, P82; PENNISI VR, 1989, AESTHET PLAST SURG, V13, P15, DOI 10.1007/BF01570320; PONDER BAJ, 1992, CLIN ENDOCRINOL, P608; SHEARMAN CP, 1986, ANN ROY COLL SURG, V68, P17; SIMARD J, 1993, HUM MOL GENET, V2, P1193, DOI 10.1093/hmg/2.8.1193; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; WOLFE HJ, 1981, CLIN ENDOCRINOL META, V10, P351, DOI 10.1016/S0300-595X(81)80027-8; WONG JH, 1986, SURGERY, V99, P67; [No title captured]	31	31	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					709	713		10.1016/S0140-6736(94)91585-7	http://dx.doi.org/10.1016/S0140-6736(94)91585-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907684				2022-12-28	WOS:A1994NB80900014
J	BANNER, AS				BANNER, AS			THEOPHYLLINE - SHOULD WE DISCARD AN OLD FRIEND	LANCET			English	Editorial Material							AMINOPHYLLINE				BANNER, AS (corresponding author), HARVARD UNIV,SCH MED,CAMBRIDGE,MA 02138, USA.							[Anonymous], 1990, BMJ, V301, P797; HUANG D, 1993, ANN INTERN MED, V119, P1155, DOI 10.7326/0003-4819-119-12-199312150-00001; LITTENBERG B, 1988, JAMA-J AM MED ASSOC, V259, P1678, DOI 10.1001/jama.259.11.1678; MILGROM H, 1993, AM REV RESPIR DIS, V147, pS33, DOI 10.1164/ajrccm/147.6_Pt_2.S33; NEWHOUSE MT, 1990, CHEST, V98, P1, DOI 10.1378/chest.98.1.1; SHANNON M, 1993, ANN INTERN MED, V119, P1161, DOI 10.7326/0003-4819-119-12-199312150-00002; WRENN K, 1991, ANN INTERN MED, V115, P241, DOI 10.7326/0003-4819-115-4-241; 1991, 913042 US DEP HLTH H	8	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 12	1994	343	8898					618	618		10.1016/S0140-6736(94)92632-8	http://dx.doi.org/10.1016/S0140-6736(94)92632-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906808				2022-12-28	WOS:A1994NA09300005
J	ABBOUDI, ZH; MARSH, JCW; SMITHLAIN, G; GORDONSMITH, EC				ABBOUDI, ZH; MARSH, JCW; SMITHLAIN, G; GORDONSMITH, EC			FATAL APLASTIC-ANEMIA AFTER MESALAZINE	LANCET			English	Letter									MEDWAY HOSP,DEPT MED,GILLINGHAM,KENT,ENGLAND	Medway Maritime Hospital	ABBOUDI, ZH (corresponding author), ST GEORGE HOSP,SCH MED,DEPT HAEMATOL,LONDON SW17 0RE,ENGLAND.							DANESHMEND TK, 1991, LANCET, V337, P1297, DOI 10.1016/0140-6736(91)92973-6; RILEY SA, 1988, GASTROENTEROLOGY, V94, P1383, DOI 10.1016/0016-5085(88)90677-4; WYATT S, 1993, LANCET, V341, P1476, DOI 10.1016/0140-6736(93)90918-7	3	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					542	542		10.1016/S0140-6736(94)91495-8	http://dx.doi.org/10.1016/S0140-6736(94)91495-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906782				2022-12-28	WOS:A1994MX88800047
J	BROUSSOLLE, C; JEANDIDIER, N; HANAIREBROUTIN, H				BROUSSOLLE, C; JEANDIDIER, N; HANAIREBROUTIN, H			FRENCH MULTICENTER EXPERIENCE OF IMPLANTABLE INSULIN PUMPS	LANCET			English	Note							DEPENDENT DIABETIC-PATIENTS; METABOLIC CONTROL; ABSORPTION; INFUSION; TRIAL	Limitations of intensive diabetes treatment with subcutaneous insulin include achievement of only near-normoglycaemia and increased risk of hypoglycaemia. Programmable implantable pumps permit variable rates of intraperitoneal insulin infusion. The French experience represents 224 type I adult diabetic patients followed up for 353 patient-years in seven centres, Compared with pre-implantation values with intensive subcutaneous insulin, glycaemic control was significantly improved with implantable pumps: glycosylated haemoglobin fell from 7.4 (1.8)% to 6.8 (1.0)% at 6 months (mean, SD, p < 0.001). The incidence of severe episodes of hypoglycaemia decreased from 15.2 to 2.5 per 100 patient-years (p < 0.001). Intraperitoneal insulin delivery with implantable pumps improved the risk-benefit ratio of intensive insulin.	HOP LYON SUD, LYON, FRANCE; HOP CENT STRASBOURG, STRASBOURG, FRANCE; HOP RANGUELL, TOULOUSE, FRANCE	CHU Lyon; CHU Strasbourg								DCCT Res Grp, 1987, DIABETES CARE, V10, P1; FELDTRASMUSSEN B, 1991, DIABETOLOGIA, V34, P164, DOI 10.1007/BF00418270; MCCALL AL, 1992, DIABETES, V41, P557, DOI 10.2337/diabetes.41.5.557; MUHLHAUSER I, 1985, DIABETES CARE, V8, P268, DOI 10.2337/diacare.8.3.268; SAUDEK CD, 1989, NEW ENGL J MED, V321, P574, DOI 10.1056/NEJM198908313210904; SELAM JL, 1992, DIABETES CARE, V15, P877, DOI 10.2337/diacare.15.7.877; SELAM JL, 1992, DIABETES CARE, V15, P53, DOI 10.2337/diacare.15.1.53; SELAM JL, 1990, DIABETES, V39, P1361, DOI 10.2337/diabetes.39.11.1361; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; WREDLING R, 1991, DIABETES METAB, V17, P456	10	86	86	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 26	1994	343	8896					514	515		10.1016/S0140-6736(94)91462-1	http://dx.doi.org/10.1016/S0140-6736(94)91462-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906761				2022-12-28	WOS:A1994MX88800010
J	JACK, T; FOX, GL; MEYEROWITZ, EM				JACK, T; FOX, GL; MEYEROWITZ, EM			ARABIDOPSIS HOMEOTIC GENE APETALA3 ECTOPIC EXPRESSION - TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL REGULATION DETERMINE FLORAL ORGAN IDENTITY	CELL			English	Article							FLOWER DEVELOPMENT; PLANT TRANSFORMATION; MADS-BOX; THALIANA; DEFICIENS; LEAFY; INTERACTS; PRODUCT	APETALA3 (AP3) specifies the development of petals and stamens in the Arabidopsis flower. We constructed a transgenic line, 35S-AP3, that ectopically expresses AP3 under the control of a constitutive promoter. The resulting flowers exhibit a replacement of carpels by stamens and resemble flowers homozygous for the previously described Arabidopsis mutation superman. Although AP3 RNA is detected at high levels throughout the flower and stem in 35S-AP3, AP3 protein is detected at high levels only in the second, third, and fourth floral whorls, demonstrating that AP3 is posttranscriptionally regulated. Ectopic expression of AP3 causes a second floral homeotic gene, PISTILLATA (PI), to function in the fourth whorl of 35S-AP3 flowers. AP3 and PI also activate an AP3 promoter-reporter gene fusion, demonstrating that AP3 positively autoregulates.	CALTECH, DIV BIOL 15629, PASADENA, CA 91125 USA	California Institute of Technology			Meyerowitz, Elliot M/A-7118-2009		NIGMS NIH HHS [GM13667-5] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1992, DEVELOPMENT, V114, P599; BOWMAN JL, 1991, PLANT CELL, V3, P749, DOI 10.1105/tpc.3.8.749; BOWMAN JL, 1993, DEVELOPMENT, V119, P721; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; CHAUDHURY AM, 1989, PLANT CELL REP, V8, P368, DOI 10.1007/BF00716676; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COX KH, 1988, PLANT MOL BIOL PRACT, P1; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; FRALEY RT, 1985, BIO-TECHNOL, V3, P629, DOI 10.1038/nbt0785-629; HARLOW E, 1988, ANTIBODIES LABORATOR; HILL JP, 1989, CAN J BOT, V67, P2922, DOI 10.1139/b89-375; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; JACK T, 1988, GENE DEV, V2, P635, DOI 10.1101/gad.2.6.635; JEFFERSON RA, 1987, EMBO J, V6, P3901; KUNST L, 1989, PLANT CELL, V1, P1195, DOI 10.1105/tpc.1.12.1195; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; MANDEL MA, 1992, CELL, V71, P133, DOI 10.1016/0092-8674(92)90272-E; MARTON L, 1991, PLANT CELL REP, V10, P235, DOI 10.1007/BF00232565; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MEYEROWITZ EM, 1991, DEVELOPMENT, P157; MIZUKAMI Y, 1992, CELL, V71, P119, DOI 10.1016/0092-8674(92)90271-D; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; SCHULTZ EA, 1991, PLANT CELL, V3, P1221, DOI 10.1105/tpc.3.11.1221; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; SCHWARZSOMMER Z, 1992, EMBO J, V11, P251, DOI 10.1002/j.1460-2075.1992.tb05048.x; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; Stomp A., 1992, GUS protocols: using the GUS gene as a reporter of gene expression., P103; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TROBNER W, 1992, EMBO J, V11, P4693, DOI 10.1002/j.1460-2075.1992.tb05574.x; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WEIGEL D, 1993, SCIENCE, V261, P1723, DOI 10.1126/science.261.5129.1723; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	40	314	328	6	40	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 25	1994	76	4					703	716		10.1016/0092-8674(94)90509-6	http://dx.doi.org/10.1016/0092-8674(94)90509-6			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	7907276				2022-12-28	WOS:A1994MZ28500012
J	JOHNSON, A				JOHNSON, A			VOICE RESTORATION AFTER LARYNGECTOMY	LANCET			English	Editorial Material											JOHNSON, A (corresponding author), QUEEN ELIZABETH HOSP,DEPT OTOLARYNGOL,BIRMINGHAM,W MIDLANDS,ENGLAND.							DUGUAY MJ, 1989, J VOICE, V3, P265; GRASL MC, 1993, LARYNGOSCOPE, V103, P96; PARKER AJ, 1992, J LARYNGOL OTOL, V106, P154, DOI 10.1017/S0022215100118936; SCOTT PMJ, 1993, J LARYNGOL OTOL, V107, P430, DOI 10.1017/S0022215100123345; SINGER MI, 1980, ANN OTO RHINOL LARYN, V89, P529, DOI 10.1177/000348948008900608; SINGER MI, 1986, OTOLARYNGOLOGY HEAD, P2073; STGUILY JL, 1992, ARCH OTOLARYNGOL, V118, P252	7	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 19	1994	343	8895					431	432		10.1016/S0140-6736(94)92685-9	http://dx.doi.org/10.1016/S0140-6736(94)92685-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905949				2022-12-28	WOS:A1994MW69000003
J	BAKER, LRI; TUCKER, B; MACDOUGALL, IC; RAINE, AEG				BAKER, LRI; TUCKER, B; MACDOUGALL, IC; RAINE, AEG			TREATMENT OF IDIOPATHIC MEMBRANOUS NEPHROPATHY	LANCET			English	Letter											BAKER, LRI (corresponding author), ST BARTHOLOMEWS HOSP,LONDON EC1A 7BE,ENGLAND.							Baker L. R. I., 1993, Journal of the American Society of Nephrology, V4, P269; BROWN JH, IN PRESS NEPHROL DIA; WILLIAMS PS, 1989, NEPHROL DIAL TRANSPL, V4, P181, DOI 10.1093/oxfordjournals.ndt.a091853	3	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					290	291						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905111				2022-12-28	WOS:A1994MT44000032
J	DOCKE, WD; PROSCH, S; FIETZE, E; KIMEL, V; ZUCKERMANN, H; KLUG, C; SYRBE, U; KRUGER, DH; VONBAEHR, R; VOLK, HD				DOCKE, WD; PROSCH, S; FIETZE, E; KIMEL, V; ZUCKERMANN, H; KLUG, C; SYRBE, U; KRUGER, DH; VONBAEHR, R; VOLK, HD			CYTOMEGALOVIRUS REACTIVATION AND TUMOR-NECROSIS-FACTOR	LANCET			English	Note							FACTOR-ALPHA; IMMUNODEFICIENCY; CELLS	Tumour necrosis factor-alpha (TNF) stimulates cytomegalovirus (CMV) activity in a transfected human monocytic cell line. We assessed whether this finding is relevant in vivo by evaluating the frequency of active CMV infection in patients with diseases that enhance plasma TNF. In septic disease, peripheral blood mononuclear cells of almost all patients studied were positive for CMV. Furthermore, CMV antigenaemia and enhanced plasma TNF occurred in many patients with liver cirrhosis, common variable immunodeficiency, and B-cell chronic lymphocytic leukaemia. Thus, TNF may have a central role in CMV reactivation.	HUMBOLDT UNIV BERLIN,MED SCH CHARITE,INST VIROL,D-10098 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,MED SCH CHARITE,DEPT SURG,D-10098 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,MED SCH CHARITE,DEPT ANAESTHESIOL & INTENS CARE,D-10098 BERLIN,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	DOCKE, WD (corresponding author), HUMBOLDT UNIV BERLIN,MED SCH CHARITE,INST MED IMMUNOL,D-10098 BERLIN,GERMANY.		volk, hans-dieter/AAV-8053-2021; Syrbe, Uta/T-7557-2017	volk, hans-dieter/0000-0002-7743-6668; Syrbe, Uta/0000-0001-8463-7890				CORDONNIER C, 1990, Revue de Pneumologie Clinique, V46, P244; DOCKE WD, 1991, LANCET, V338, P1597, DOI 10.1016/0140-6736(91)92422-X; FOA R, 1990, BLOOD, V76, P393; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; PROSCH S, 1992, J MED VIROL, V38, P246, DOI 10.1002/jmv.1890380404; RUBIN RH, 1990, REV INFECT DIS    S7, V12, P5754; STEIN J, 1993, J GEN VIROL, V74, P2333, DOI 10.1099/0022-1317-74-11-2333; TANAKA S, 1992, HEPATOLOGY, V16, P1409, DOI 10.1002/hep.1840160617; TAYLORWIEDEMAN J, 1991, J GEN VIROL, V72, P2059, DOI 10.1099/0022-1317-72-9-2059; TLG H, 1992, GASTROENTEROLOGY, V103, P264	10	217	219	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					268	269		10.1016/S0140-6736(94)91116-9	http://dx.doi.org/10.1016/S0140-6736(94)91116-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905100				2022-12-28	WOS:A1994MT44000014
J	SACK, MN; RADER, DJ; CANNON, RO				SACK, MN; RADER, DJ; CANNON, RO			ESTROGEN AND INHIBITION OF OXIDATION OF LOW-DENSITY LIPOPROTEINS IN POSTMENOPAUSAL WOMEN	LANCET			English	Note							17-BETA ESTRADIOL	Oxidative modification of low-density lipoprotein (LDL) may be atherogenic. We studied the time of onset of LDL oxidation (lag) in 18 postmenopausal women before and after intraarterial infusion of 17beta-oestradiol, after 3 weeks' patch administration ir 12 of these women, and 1. month after discontinuation in 10. The lag increased from baseline after acute infusion (from 134 [SD 41] to 167 [36] min, p = 0.01) and after the patch (132 [31] to 178 [45] min, p = 0.009). After discontinuation of oestradiol, the lag returned to baseline. This study shows an antioxidant effect of physiological levels of 17beta-oestradiol, which may contribute to an anti-atherogenic action.	NHLBI,CARDIOL BRANCH,BLDG 10,ROOM 7B-15,BETHESDA,MD 20892; NHLBI,MOLEC DIS BRANCH,BETHESDA,MD 20892; GEORGETOWN UNIV HOSP,WASHINGTON,DC 20007	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Georgetown University								ADAMS MR, 1990, ARTERIOSCLEROSIS, V10, P1051, DOI 10.1161/01.ATV.10.6.1051; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CARR BR, 1992, WILLIAMS TXB ENDOCRI, P733; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOUGH JL, 1986, ARTERIOSCLEROSIS, V6, P57, DOI 10.1161/01.ATV.6.1.57; MAZIERE C, 1991, ATHEROSCLEROSIS, V89, P175, DOI 10.1016/0021-9150(91)90058-B; RIFICI VA, 1992, METABOLISM, V41, P1110, DOI 10.1016/0026-0495(92)90295-L; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499	9	483	493	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					269	270		10.1016/S0140-6736(94)91117-7	http://dx.doi.org/10.1016/S0140-6736(94)91117-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905101	hybrid			2022-12-28	WOS:A1994MT44000015
J	HOOTON, TM; ROBERTS, MC; KENNY, GE				HOOTON, TM; ROBERTS, MC; KENNY, GE			MYCOPLASMA-GENITALIUM AND NONGONOCOCCAL URETHRITIS	LANCET			English	Editorial Material											HOOTON, TM (corresponding author), UNIV WASHINGTON,HARBORVIEW MED CTR,MADISON CLIN,SEATTLE,WA 98104, USA.							BOWIE WR, 1981, ANN INTERN MED, V95, P306, DOI 10.7326/0003-4819-95-3-306; BOWIE WR, 1989, SEXUALLY TRANSMITTED, P627; HANDSFIELD H H, 1976, Journal of the American Venereal Disease Association, V2, P5; HOERNER PJ, 1993, LANCET, V342, P582; Hooton T M, 1987, Infect Dis Clin North Am, V1, P165; HOOTON TM, 1988, LANCET, V1, P266; TAYLORROBINSON D, 1985, BRIT J EXP PATHOL, V66, P95	7	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					69	69		10.1016/S0140-6736(94)90810-9	http://dx.doi.org/10.1016/S0140-6736(94)90810-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903773				2022-12-28	WOS:A1994MQ09200005
J	MARAN, A; CRANSTON, I; LOMAS, J; MACDONALD, I; AMIEL, SA				MARAN, A; CRANSTON, I; LOMAS, J; MACDONALD, I; AMIEL, SA			PROTECTION BY LACTATE OF CEREBRAL FUNCTION DURING HYPOGLYCEMIA	LANCET			English	Article							INSULIN-INDUCED HYPOGLYCEMIA; DEFECTIVE GLUCOSE COUNTERREGULATION; DEPENDENT DIABETES-MELLITUS; GLYCEMIC CONTROL; SYMPTOMS; CATECHOLAMINES; RESPONSES; HUMANS; BRAIN; IDDM	Severe hypoglycaemia with brain dysfunction limits intensified therapy in patients with insulin-dependent diabetes mellitus, despite evidence that such therapy reduces the risk of chronic complications of the disease. We have investigated the effect of infusing lactate (a potential non-glucose fuel for brain metabolism) on protective, symptomatic neurohumoral responses and on brain function during hypoglycaemia in seven healthy men. Elevation of lactate (within a physiological range) substantially diminished catecholamines, growth hormone, cortisol, and symptomatic responses to hypoglycaemia and lowered the glucose level at which these responses began. Glucagon responses were unaffected. Lactate was also associated with a significant lowering of the glucose level at which brain function deteriorated, suggesting that brain function was protected during the hypoglycaemia. The defect in counter-regulation is similar to that seen in hypoglycaemia-prone diabetic patients. Initiation of the protective responses to hypoglycaemia (except glucagon) can be delayed by supporting-metabolism with an alternative metabolic fuel. Cerebral cortical dysfunction of severe hypoglycaemia is also delayed. Our demonstration that higher brain function can be protected during hypoglycaemia may have therapeutic potential.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, GUYS HOSP, METAB MED UNIT, LONDON SE1 9RT, ENGLAND; UNIV NOTTINGHAM HOSP, QUEENS MED CTR, DEPT PHYSIOL & PHARMACOL, NOTTINGHAM NG7 2UH, ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Nottingham			Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285; Macdonald, Ian/0000-0002-7540-9850; MARAN, ALBERTO/0000-0002-7266-8486				AMIEL SA, 1991, CLIN SCI, V81, P189, DOI 10.1042/cs0810189; AMIEL SA, 1991, DIABETES CARE, V14, P109, DOI 10.2337/diacare.14.2.109; AMIEL SA, 1987, NEW ENGL J MED, V316, P1376, DOI 10.1056/NEJM198705283162205; BIGGERS DW, 1989, DIABETES, V38, P7, DOI 10.2337/diabetes.38.1.7; BOYLE PJ, 1988, NEW ENGL J MED, V318, P1487, DOI 10.1056/NEJM198806093182302; CLARKE WL, 1991, DIABETES, V40, P680, DOI 10.2337/diabetes.40.6.680; CUNNAH D, 1987, J ENDOCRINOL, V113, P123, DOI 10.1677/joe.0.1130123; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; FLETCHER P, 1986, BRIT J CLIN PHARMACO, V21, P691, DOI 10.1111/j.1365-2125.1986.tb05235.x; HELLER SR, 1987, LANCET, V2, P359; HELLER SR, 1991, DIABETES, V40, P223, DOI 10.2337/diabetes.40.2.223; HEPBURN DA, 1991, DIABETES CARE, V14, P949, DOI 10.2337/diacare.14.11.949; LIU D, 1992, DIABETOLOGIA, V35, P287, DOI 10.1007/BF00400932; MACDONALD IA, 1985, J NEUROSCI METH, V13, P239, DOI 10.1016/0165-0270(85)90072-X; MARAN A, 1993, BMJ-BRIT MED J, V306, P167, DOI 10.1136/bmj.306.6871.167; MARAN A, 1993, DIABETES, V42, pA17; MARCHETTI P, 1990, DIABETES METAB, V16, P473; MAZLAN M, 1989, THESIS U LONDON LOND; MCCALL AL, 1986, AM J PHYSIOL, V251, pE442, DOI 10.1152/ajpendo.1986.251.4.E442; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; OWEN OE, 1967, J CLIN INVEST, V46, P1589, DOI 10.1172/JCI105650; RIZZA RA, 1979, J CLIN INVEST, V64, P62, DOI 10.1172/JCI109464; RYDER RJ, 1990, BMJ-BRIT MED J, V310, P783; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; WIDOM B, 1990, ANN INTERN MED, V112, P904, DOI 10.7326/0003-4819-112-12-904; WIDOM B, 1992, DIABETES, V41, P1597, DOI 10.2337/diabetes.41.12.1597; WISE JK, 1973, NEW ENGL J MED, V288, P487, DOI 10.1056/NEJM197303082881003; YOUNG AA, 1993, LIFE SCI, V52, P1717, DOI 10.1016/0024-3205(93)90480-Q	28	197	198	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	1994	343	8888					16	20		10.1016/S0140-6736(94)90876-1	http://dx.doi.org/10.1016/S0140-6736(94)90876-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905041				2022-12-28	WOS:A1994MN93700012
J	HALLISSEY, MT; DUNN, JA; WARD, LC; ALLUM, WH; ARNOTT, S; BAKER, P; BROOKES, VS; CRAVEN, JL; ELLIS, DJ; FIELDING, JWL; FAGG, SL; HOCKEY, MS; LEVISON, D; JONES, BG; KELLY, K; MASON, MC; MINAWA, A; MCADAM, A; TIMOTHY, A; WATERHOUSE, JAH; WINSEY, S; WRIGLEY, PFM				HALLISSEY, MT; DUNN, JA; WARD, LC; ALLUM, WH; ARNOTT, S; BAKER, P; BROOKES, VS; CRAVEN, JL; ELLIS, DJ; FIELDING, JWL; FAGG, SL; HOCKEY, MS; LEVISON, D; JONES, BG; KELLY, K; MASON, MC; MINAWA, A; MCADAM, A; TIMOTHY, A; WATERHOUSE, JAH; WINSEY, S; WRIGLEY, PFM			THE 2ND BRITISH STOMACH-CANCER GROUP TRIAL OF ADJUVANT RADIOTHERAPY OR CHEMOTHERAPY IN RESECTABLE GASTRIC-CANCER - 5-YEAR FOLLOW-UP	LANCET			English	Article							MITOMYCIN-C; RANDOMIZED TRIAL; INTERIM-REPORT; 5-FLUOROURACIL; DOXORUBICIN; THERAPY	The overall survival in patients with gastric cancer is low, even among those undergoing resection. It has been hoped that the development of adjuvant therapy might improve survival in patients following surgery when tumour burden was minimal and both chemotherapy and radiotherapy have been proposed as suitable for use in gastric cancer. Their value has been evaluated by the British Stomach Cancer Group Second adjuvant therapy trial. 436 patients entered a prospective, randomised, controlled trial of adjuvant radiotherapy or cytotoxic chemotherapy with mitomycin, doxorubicin, and fluorouracil after gastrectomy for adenocarcinoma. After at least 5 years, there have been 372 deaths of which 7 were due to surgical complications and 327 from recurrent cancer. Following stratified randomisation, 145 patients were allocated to surgery alone, 153 to receive adjuvant radiotherapy, and 138 to adjuvant combination chemotherapy. The overall 2-year and 5-year survival were 33% (95% confidence interval 31-35%) and 17% (13-21%). No survival advantage has been shown for those patients receiving either adjuvant therapy compared to those undergoing surgery alone. The 5-year survival for surgery alone was 20%, for surgery plus radiotherapy 12%, and for surgery plus chemotherapy 19%. Surgery, therefore, remains the standard treatment for this condition and the use of adjuvant treatments should be restricted to controlled trials.	QUEEN ELIZABETH HOSP,CRC,TRIALS UNIT,BIRMINGHAM,W MIDLANDS,ENGLAND; EPSOM GEN HOSP,DEPT SURG,EPSOM,SURREY,ENGLAND	University of Birmingham	HALLISSEY, MT (corresponding author), QUEEN ELIZABETH HOSP,DEPT SURG,WARD W 6,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.		Hallissey, Mike T/AAW-6797-2021	Dunn, Janet/0000-0001-7313-4446				ALLUM WH, 1989, BRIT J CANCER, V60, P739, DOI 10.1038/bjc.1989.350; ALLUM WH, 1989, LANCET, V1, P571; ALLUM WH, 1989, BRIT J SURG, V76, P535, DOI 10.1002/bjs.1800760604; BITRAN JD, 1979, CANCER TREAT REP, V63, P2049; COOMBES RC, 1990, J CLIN ONCOL, V8, P1362, DOI 10.1200/JCO.1990.8.8.1362; CROCKER J, 1983, J CLIN PATHOL, V36, P24, DOI 10.1136/jcp.36.1.24; CUSCHIERI A, 1986, BRIT J SURG, V73, P513; FIELDING JWL, 1983, WORLD J SURG, V7, P390, DOI 10.1007/BF01658089; FINDLAY M, 1993, BR J CANCER S20, V67, P15; Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204; GUNDERSON LL, 1982, INT J RADIAT ONCOL, V8, P1, DOI 10.1016/0360-3016(82)90377-7; HALLISSEY MT, 1990, BRIT MED J, V301, P513, DOI 10.1136/bmj.301.6751.513; HOCKEY M S, 1984, British Medical Journal, V289, P601; JONES BG, 1980, LANCET, V1, P1275; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; MACDONALD JS, 1992, P AN M AM SOC CLIN, P168; PREUSSER P, 1988, CANCER TREAT REV, V15, P257, DOI 10.1016/0305-7372(88)90025-4; PRIESTMAN TJ, 1986, CANCER STOMACH, P231; SASAKO M, 1992, JPN J CLIN ONCOL, V22, P41; SCHEIN PS, 1981, ADV BIOSCI, V32, P139; TONNESEN H, 1988, LANCET, V2, P990; WILKE H, 1989, J CLIN ONCOL, V7, P1318, DOI 10.1200/JCO.1989.7.9.1318; 1981, JAP J SURG, V11, P127	23	225	236	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1309	1312		10.1016/S0140-6736(94)92464-3	http://dx.doi.org/10.1016/S0140-6736(94)92464-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910321				2022-12-28	WOS:A1994NN21700007
J	BURGAN, S; URBAN, P; CHEVROLET, J; UNGER, P; RUTISHAUSER, W				BURGAN, S; URBAN, P; CHEVROLET, J; UNGER, P; RUTISHAUSER, W			IMPACT OF A MULTICENTER RANDOMIZED TRIAL ON DOOR-TO-NEEDLE TIME FOR ACUTE MYOCARDIAL-INFARCTION	LANCET			English	Letter											BURGAN, S (corresponding author), UNIV HOSP GENEVA, CTR CARDIOL, MED INTENS CARE & MED POLICLIN, CH-1211 GENEVA 14, SWITZERLAND.							CHATELAIN P, 1992, REAN URG, V1, P241; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001	2	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 21	1994	343	8908					1300	1300		10.1016/S0140-6736(94)92192-X	http://dx.doi.org/10.1016/S0140-6736(94)92192-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910311				2022-12-28	WOS:A1994NM14400061
J	PAPANEK, PJ				PAPANEK, PJ			HOW CLEAN SHOULD THE OCEAN BE FOR SWIMMERS	LANCET			English	Editorial Material							WATER-QUALITY				PAPANEK, PJ (corresponding author), LOS ANGELES CTY DEPT HLTH SERV,LOS ANGELES,CA, USA.							CABELLI VJ, 1982, AM J EPIDEMIOL, V115, P606, DOI 10.1093/oxfordjournals.aje.a113342; CABELLI VJ, 1983, EPA800180031 HLTH EF; CHEUNG WHS, 1990, EPIDEMIOL INFECT, V105, P139, DOI 10.1017/S0950268800047737; CORBETT SJ, 1993, AM J PUBLIC HEALTH, V83, P1701, DOI 10.2105/AJPH.83.12.1701; FLEISHER JM, 1993, INT J EPIDEMIOL, V22, P698, DOI 10.1093/ije/22.4.698; FLEISHER JM, 1991, RES J WATER POLLUT C, V63, P259; GOLD M, 1990, ASSESSMENT INPUTS FE; HAILE RW, 1992, STUDY DESIGN INVESTI; KEBABJIAN R, 1994, J ENVIRON HEALTH, V56, P15; 1990, OCEAN HLTH STUDY STU	10	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1238	1239		10.1016/S0140-6736(94)92144-X	http://dx.doi.org/10.1016/S0140-6736(94)92144-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910268				2022-12-28	WOS:A1994NM14400002
J	PERTL, B; YAU, SC; SHERLOCK, J; DAVIES, AF; MATHEW, CG; ADINOLFI, M				PERTL, B; YAU, SC; SHERLOCK, J; DAVIES, AF; MATHEW, CG; ADINOLFI, M			RAPID MOLECULAR METHOD FOR PRENATAL DETECTION OF DOWNS-SYNDROME	LANCET			English	Note							PCR	We have evaluated a rapid method that allows prenatal detection of Down's syndrome in less than 24 hours. DNA from uncultured amniotic fluid, fetal blood, and tissue samples was amplified with the small tandem repeat (STR) marker D21S11. Quantitative analysis of fluorescent STR products with evaluation of their sizes provided clear evidence for trisomy 21. Whilst most normal samples showed two amplification peaks of equal size, Down's syndrome samples were characterised by either th ree STR peaks or two peaks with a ratio of 2:1. Co-amplification with a non-polymorphic sequence allowed analysis of Samples that were homozygous for the 21-derived STRs.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DIV MED & MOLEC GENET,LONDON SE1 9RT,ENGLAND; GRAZ UNIV,DEPT OBSTET & GYNECOL,GRAZ,AUSTRIA	University of London; King's College London; University of Graz			Mathew, Christopher G/G-3434-2015	Mathew, Christopher G/0000-0003-4178-1838; Sherlock, Jon/0000-0001-5475-2361				Ferre F, 1992, PCR Methods Appl, V2, P1; GIBSON RA, 1993, HUM MOL GENET, V2, P35, DOI 10.1093/hmg/2.1.35; LUBIN MB, 1991, MOL CELL PROBE, V5, P307, DOI 10.1016/0890-8508(91)90054-N; MANSFIELD ES, 1993, HUM MOL GENET, V2, P43, DOI 10.1093/hmg/2.1.43; PETERSEN MB, 1991, AM J HUM GENET, V48, P65; SHARMA V, 1992, HUM MOL GENET, V1, P67, DOI 10.1093/hmg/1.1.67-a	6	115	152	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1197	1198		10.1016/S0140-6736(94)92404-X	http://dx.doi.org/10.1016/S0140-6736(94)92404-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909872				2022-12-28	WOS:A1994NL17500013
J	JELLINEK, EH				JELLINEK, EH			TRAUMA AND MULTIPLE-SCLEROSIS	LANCET			English	Editorial Material																		BAMFORD C, 1978, CAN J NEUROL SCI, V5, P41, DOI 10.1017/S0317167100024732; BAMFORD CR, 1981, NEUROLOGY, V31, P1229, DOI 10.1212/WNL.31.10.1229; Dawson JW, 1916, EDINBURGH MED J, V17, DOI [10.1007/978-3-319-02735-7, DOI 10.1007/978-3-319-02735-7]; EBERS GC, 1994, LANCET, V343, P275, DOI 10.1016/S0140-6736(94)91119-3; ENGELL T, 1989, ACTA NEUROL SCAND, V79, P428, DOI 10.1111/j.1600-0404.1989.tb03811.x; GEORGI W, 1961, SCHWEIZ MED WSCHR, V91, P605; GILBERT JJ, 1983, ARCH NEUROL-CHICAGO, V40, P533, DOI 10.1001/archneur.1983.04050080033003; KELLY R, 1985, HDB CLIN NEUROLOGY, P49; KELLY RE, 1961, BRIT MED J, V2, P421, DOI 10.1136/bmj.2.5249.421; MATTHEWS WB, 1991, MCALPINES MULTIPLE S, P112; MILLER DH, 1993, BRAIN, V116, P1077, DOI 10.1093/brain/116.5.1077; POSER CM, 1993, J NEUROL SCI S, V115, P3; SIBLEY W, 1993, NEUROLOGY, V41, P1871; SIBLEY WA, 1985, LANCET, V1, P1313; SIBLEY WA, 1991, J NEUROL NEUROSUR PS, V54, P584, DOI 10.1136/jnnp.54.7.584; SIVA A, 1993, NEUROLOGY, V43, P1878, DOI 10.1212/WNL.43.10.1878; VOST A, 1964, J PATHOL BACTERIOL, V88, P463, DOI 10.1002/path.1700880209	17	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 30	1994	343	8905					1053	1054		10.1016/S0140-6736(94)90178-3	http://dx.doi.org/10.1016/S0140-6736(94)90178-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ694	7909097				2022-12-28	WOS:A1994NJ69400006
J	RIDKER, PM; HENNEKENS, CH; STAMPFER, MJ; MANSON, JE; VAUGHAN, DE				RIDKER, PM; HENNEKENS, CH; STAMPFER, MJ; MANSON, JE; VAUGHAN, DE			PROSPECTIVE-STUDY OF ENDOGENOUS-TISSUE PLASMINOGEN-ACTIVATOR AND RISK OF STROKE	LANCET			English	Article							MYOCARDIAL-INFARCTION; RAPID INHIBITOR; DISEASE; PLASMA; FIBRINOGEN	Few haematological or lipid risk factors have been identified for stroke, by contrast with coronary heart disease. To find out whether a marker of endogenous fibrinolytic function might be associated with stroke risk, we measured tissue plasminogen activator (tPA) antigen concentrations in baseline plasma samples from 88 healthy participants in the Physicians' Health Study who subsequently had first-ever strokes (71 thromboembolic, 12 haemorrhagic, 5 indeterminate) and from 471 participants who remained free of cardiovascular disease during 5 years of follow-up (controls). Mean baseline tPA concentrations were significantly higher among men who later had strokes than in the controls (11.14 [SE 0.80] vs 9.59 [0.27] ng/mL, p = 0.03). The difference was largely due to an excess of abnormally high values among stroke cases. The age-adjusted relative risk for stroke among men with baseline tPA concentrations above the 95th percentile of the control distribution was 3 51 (95% CI 1.72-7.17, p=0.0006) for total stroke and 3.89 (1.83-8.26, p-0.0004) for thromboembolic stroke.These findings did not change substantially in analyses that also controlled for stroke risk factors (high blood pressure, body-mass index, smoking, presence of diabetes, and parental history of myocardial infarction) or the plasma lipid profile. This prospective study shows that high concentrations of tPA antigen among apparently healthy men are independently associated with high risks of future stroke, especially thromboembolic stroke. This finding is consistent with the hypothesis that activation of the endogenous fibrinolytic system occurs years in advance of arterial vascular occlusion.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOL,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT MED,CTR RES THROBOLYSIS,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT MED,CHANNING LAB,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT AMBULATORY & PREVENT MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	RIDKER, PM (corresponding author), BRIGHAMS & WOMENS HOSP,DEPT MED,DIV PREVENT MED,900 COMMONWEALTH AVE E,BOSTON,MA 02215, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER; NCI NIH HHS [CA-34944] Funding Source: Medline; NHLBI NIH HHS [HL-34595, HL-26490] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREOTTI F, 1988, AM J CARDIOL, V62, P635, DOI 10.1016/0002-9149(88)90669-8; ANGLETON P, 1989, CIRCULATION, V79, P101, DOI 10.1161/01.CIR.79.1.101; [Anonymous], 1989, NEW ENGL J MED, V321, P129; ATKINS D, 1993, ANN INTERN MED, V119, P136, DOI 10.7326/0003-4819-119-2-199307150-00008; DYKEN ML, 1984, STROKE, V15, P1105; ELIASSON M, 1993, FIBRINOLYSIS, V7, P316, DOI 10.1016/0268-9499(93)90147-N; FEINBERG WM, 1989, STROKE, V20, P592, DOI 10.1161/01.STR.20.5.592; HAMSTEN A, 1987, LANCET, V2, P3; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HART RG, 1990, STROKE, V21, P1111, DOI 10.1161/01.STR.21.8.1111; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; LUCURE CL, 1991, CORONARY ARTERY DIS, V2, P157; MARMOT MG, 1992, LANCET, V339, P344, DOI 10.1016/0140-6736(92)91659-V; MARTINEZ HR, 1993, STROKE, V24, P19, DOI 10.1161/01.STR.24.1.19; MEADE TW, 1993, LANCET, V342, P1076, DOI 10.1016/0140-6736(93)92062-X; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; RANBY M, 1986, CLIN CHEM, V32, P2160; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; RIDKER PM, 1992, CURR OPIN LIPIDOL, V3, P285; SALOMAA VV, 1993, CIRCULATION, V87, P22; SHINTANI S, 1993, STROKE, V24, P965, DOI 10.1161/01.STR.24.7.965; SMOKOVITIS A, 1908, HAEMOSTASIS, V18, P146; UNDERWOOD MJ, 1993, CARDIOVASC RES, V27, P882, DOI 10.1093/cvr/27.5.882; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; ZENKER G, 1986, STROKE, V17, P942, DOI 10.1161/01.STR.17.5.942; 1993, EUR HEART J, V14, P8	26	281	286	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					940	943		10.1016/S0140-6736(94)90064-7	http://dx.doi.org/10.1016/S0140-6736(94)90064-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909008				2022-12-28	WOS:A1994NF70000008
J	FALLON, JF; LOPEZ, A; ROS, MA; SAVAGE, MP; OLWIN, BB; SIMANDL, BK				FALLON, JF; LOPEZ, A; ROS, MA; SAVAGE, MP; OLWIN, BB; SIMANDL, BK			FGF-2 - APICAL ECTODERMAL RIDGE GROWTH SIGNAL FOR CHICK LIMB DEVELOPMENT	SCIENCE			English	Article							SKELETAL-MUSCLE; FACTOR RECEPTOR; BUD; EXPRESSION	The apical ectodermal ridge permits growth and elongation of amniote limb buds; removal causes rapid changes in mesodermal gene expression, patterned cell death, and truncation of the limb. Ectopic fibroblast growth factor (FGF)-2 supplied to the chick apical bud mesoderm after ridge removal will sustain normal gene expression and cell viability, and allow relatively normal limb development. A bioassay for FGFs demonstrated that FGF-2 was the only detectable FGF in chick limb bud extracts. By distribution and bioactivity, FGF-2 is the prime candidate for the chick limb bud apical ridge growth signal.	UNIV WISCONSIN,NEUROSCI TRAINING PROGRAM,MADISON,WI 53706; UNIV CANTABRIA,DEPT ANAT & BIOL CELULAR,E-39011 SANTANDER,SPAIN; PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	University of Wisconsin System; University of Wisconsin Madison; Universidad de Cantabria; Purdue University System; Purdue University; Purdue University West Lafayette Campus	FALLON, JF (corresponding author), UNIV WISCONSIN,DEPT ANAT,1300 UNIV AVE,MADISON,WI 53706, USA.		Olwin, Bradley B/A-1333-2014; Ros, Maria A./K-8160-2014	Ros, Maria A./0000-0002-1224-7671	NICHD NIH HHS [HD20743] Funding Source: Medline; NIGMS NIH HHS [5T32GM07507] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD020743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007507] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON R, 1993, DEVELOPMENT, V117, P1423; AONO H, 1988, DEV BIOL, V128, P136, DOI 10.1016/0012-1606(88)90275-8; BOWEN J, 1989, ANAT EMBRYOL, V179, P269, DOI 10.1007/BF00326592; CAIRNS JM, 1975, J EMBRYOL EXP MORPH, V34, P155; FALLON JF, 1993, LIMB DEV REGENERAT B; FALLON JF, 1993, LIMB DEV REGENERAT A; FLOTTRAHMEL B, 1992, NEUROREPORT, V3, P1077, DOI 10.1097/00001756-199212000-00011; FOX JC, 1993, IN VITRO CELL DEV-AN, V29A, P228; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAYEK A, 1987, BIOCHEM BIOPH RES CO, V147, P876, DOI 10.1016/0006-291X(87)91011-4; IZPISUABELMONTE JC, 1992, EMBO J, V11, P1451, DOI 10.1002/j.1460-2075.1992.tb05189.x; KARDAMI E, 1985, P NATL ACAD SCI USA, V82, P8044, DOI 10.1073/pnas.82.23.8044; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; OLWIN BB, 1986, BIOCHEMISTRY-US, V25, P3487, DOI 10.1021/bi00360a001; OLWIN BB, 1990, J CELL BIOL, V110, P503, DOI 10.1083/jcb.110.2.503; RILEY BB, 1993, DEVELOPMENT, V118, P95; ROS MA, 1992, DEVELOPMENT, V116, P811; ROWE DA, 1982, DEV BIOL, V93, P83, DOI 10.1016/0012-1606(82)90241-X; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SAVAGE MP, 1993, DEV DYNAM, V198, P159, DOI 10.1002/aja.1001980302; SEED J, 1988, DEV BIOL, V128, P40, DOI 10.1016/0012-1606(88)90264-3; SEED J, 1988, DEV BIOL, V128, P50, DOI 10.1016/0012-1606(88)90265-5; SLACK JMW, 1993, MECH DEVELOP, V41, P91, DOI 10.1016/0925-4773(93)90040-5; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; TODT WL, 1984, J EMBRYOL EXP MORPH, V80, P21; WATANABE A, 1993, DEV BIOL, V159, P223, DOI 10.1006/dbio.1993.1235; ZWILLING E, 1956, J EXP ZOOL, V132, P219, DOI 10.1002/jez.1401320203; ZWILLING E, 1955, J EXP ZOOL, V128, P423, DOI 10.1002/jez.1401280304	30	416	425	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 1	1994	264	5155					104	107		10.1126/science.7908145	http://dx.doi.org/10.1126/science.7908145			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND536	7908145				2022-12-28	WOS:A1994ND53600041
J	DAVIS, M; ESPINER, E; RICHARDS, G; BILLINGS, J; TOWN, I; NEILL, A; DRENNAN, C; RICHARDS, M; TURNER, J; YANDLE, T				DAVIS, M; ESPINER, E; RICHARDS, G; BILLINGS, J; TOWN, I; NEILL, A; DRENNAN, C; RICHARDS, M; TURNER, J; YANDLE, T			PLASMA BRAIN NATRIURETIC PEPTIDE IN ASSESSMENT OF ACUTE DYSPNEA	LANCET			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; ENDOPEPTIDASE; INVIVO	Recognition of heart failure (HF) may be difficult in patients presenting with acute dyspnoea, particularly in the presence of chronic airways obstruction. Since increased secretion of the cardiac hormones atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) occurs early in the course of HF, we have assessed the value of measuring these hormones in plasma in the diagnosis of suspected HF in 52 elderly patients presenting with acute dyspnoea, and compared values with left-ventricular election fraction (LVEF), a standard measure of left-ventricular function, by radionuclide angiography. Patients were enrolled prospectively. On the basis of clinical findings, conventional tests, and response to specific treatment, 20 of the 52 patients were classified as having primary lung disorder(PLD), 12 as HF alone, and 20 as HF with underlying PLD (HF/PLD). Compared with findings in PLD patients, LVEF was significantly depressed in HF and HF/PLD patients (p<0.001), whereas both plasma ANP and BNP were significantly increased (p<0.001). Admission plasma BNP concentration more accurately reflected the final diagnosis of HF (93% sensitivity and 90% specificity when BNP greater than or equal to 22 pmol/L) than LVEF or plasma ANP concentration. When all patients were considered together, there were strong negative correlations between LVEF and log BNP (r=-0.7, p<0.001) and log ANP (r=-0.59, p<0.001). Our finding that plasma BNP is raised in dyspnoeic patients with HF but not in acutely breathless patients with PLD, suggests that rapid BNP assays may assist in the diagnosis of patients with acute dyspnoea.	CHRISTCHURCH HOSP,DEPT ENDOCRINOL,CHRISTCHURCH,NEW ZEALAND; CHRISTCHURCH HOSP,DEPT RESP MED,CHRISTCHURCH,NEW ZEALAND; CHRISTCHURCH HOSP,DEPT CARDIOL,CHRISTCHURCH,NEW ZEALAND; CHRISTCHURCH HOSP,DEPT NUCL MED,CHRISTCHURCH,NEW ZEALAND; CHRISTCHURCH HOSP,DEPT RADIOL,CHRISTCHURCH,NEW ZEALAND	Christchurch Hospital New Zealand; Christchurch Hospital New Zealand; Christchurch Hospital New Zealand; Christchurch Hospital New Zealand; Christchurch Hospital New Zealand				Yandle, Timothy/0000-0002-8848-8041				ANAND IS, 1992, CIRCULATION, V86, P12, DOI 10.1161/01.CIR.86.1.12; BAERTSCHI AJ, 1988, AM J PHYSIOL, V255, pH295, DOI 10.1152/ajpheart.1988.255.2.H295; BORSON DB, 1991, AM J PHYSIOL, V260, pL212, DOI 10.1152/ajplung.1991.260.4.L212; BUCKLEY MG, 1992, CLIN SCI, V83, P437, DOI 10.1042/cs0830437; HOLMES SJ, 1993, J CLIN ENDOCR METAB, V76, P91, DOI 10.1210/jc.76.1.91; HOSODA K, 1991, HYPERTENSION, V17, P1152, DOI 10.1161/01.HYP.17.6.1152; KILLIAN KJ, 1984, CLIN CHEST MED, V5, P99; LANG CC, 1992, CLIN SCI, V83, P529, DOI 10.1042/cs0830529; MOTWANI JG, 1993, LANCET, V341, P1109, DOI 10.1016/0140-6736(93)93126-L; MUKOYAMA M, 1991, J CLIN INVEST, V87, P1402, DOI 10.1172/JCI115146; MURPHY JM, 1987, ARCH GEN PSYCHIAT, V44, P550; NICHOLSON S, 1993, CLIN EXP PHARMACOL P, V20, P535, DOI 10.1111/j.1440-1681.1993.tb01737.x; PIMM FS, 1993, 24TH ANN SCI M AUSTR, P145; RUSKOAHO H, 1992, PHARMACOL REV, V44, P479; YANDLE T, 1992, CLIN CHEM, V38, P1785; YANDLE TG, 1993, J CLIN ENDOCR METAB, V76, P832, DOI 10.1210/jc.76.4.832; YANDLE TG, 1986, J CLIN ENDOCR METAB, V63, P72, DOI 10.1210/jcem-63-1-72; YOSHIMURA M, 1993, CIRCULATION, V87, P464, DOI 10.1161/01.CIR.87.2.464	18	398	418	4	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 19	1994	343	8895					440	444		10.1016/S0140-6736(94)92690-5	http://dx.doi.org/10.1016/S0140-6736(94)92690-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905953				2022-12-28	WOS:A1994MW69000008
J	MASTROGIACOMO, A; PARSONS, SM; ZAMPIGHI, GA; JENDEN, DJ; UMBACH, JA; GUNDERSEN, CB				MASTROGIACOMO, A; PARSONS, SM; ZAMPIGHI, GA; JENDEN, DJ; UMBACH, JA; GUNDERSEN, CB			CYSTEINE STRING PROTEINS - A POTENTIAL LINK BETWEEN SYNAPTIC VESICLES AND PRESYNAPTIC CA2+ CHANNELS	SCIENCE			English	Article							CALCIUM CHANNELS; BETA-SUBUNIT; RELEASE; CELLS	Presynaptic calcium channels are key regulators of neurotransmitter release. Oocyte expression studies suggest that cysteine string proteins are essential subunits or modulators of these channels. Subcellular fractionation revealed that cysteine string proteins copurify with synaptic vesicles. An average vesicle had eight protein monomers with both the amino and carboxyl termini detected on the cytoplasmic face. Thus, docked synaptic vesicles may regulate presynaptic calcium channels and neurotransmitter release.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MOLEC & MED PHARMACOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT ANAT & CELL BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF SANTA BARBARA, DEPT CHEM, SANTA BARBARA, CA 93106 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Santa Barbara				Parsons, Stanley/0000-0001-7097-8221				ANDERSON DC, 1986, J NEUROCHEM, V46, P1207, DOI 10.1111/j.1471-4159.1986.tb00639.x; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BERTOLINO M, 1992, ANNU REV PHARMACOL, V32, P399, DOI 10.1146/annurev.pa.32.040192.002151; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; GUNDERSEN CB, 1992, NEURON, V9, P527, DOI 10.1016/0896-6273(92)90190-O; GUNDERSEN CB, 1993, NEUR ABST, V19, P1329; HARLOW E, 1989, ANTIBODIES LABORATOR, P498; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; JENDEN DJ, 1973, ANAL BIOCHEM, V55, P483; Katz B., 1969, RELEASE NEURAL TRANS; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; MASTROGIACOMO A, IN PRESS J NEUROCHEM; MCCLESKEY EW, 1986, J EXP BIOL, V124, P177; MILLER RJ, 1990, FASEB J, V4, P3291, DOI 10.1096/fasebj.4.15.1979294; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; OCONNOR VM, 1993, FEBS LETT, V326, P255, DOI 10.1016/0014-5793(93)81802-7; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STANLEY EF, 1993, NEURON, V11, P1007, DOI 10.1016/0896-6273(93)90214-C; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; YAMAGATA SK, 1989, J NEUROCHEM, V53, P1354, DOI 10.1111/j.1471-4159.1989.tb08525.x; ZAMPIGHI GA, 1989, J CELL BIOL, V108, P2255, DOI 10.1083/jcb.108.6.2255; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150	28	161	162	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	1994	263	5149					981	982		10.1126/science.7906056	http://dx.doi.org/10.1126/science.7906056			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX165	7906056				2022-12-28	WOS:A1994MX16500040
J	CAPOVILLA, M; BRANDT, M; BOTAS, J				CAPOVILLA, M; BRANDT, M; BOTAS, J			DIRECT REGULATION OF DECAPENTAPLEGIC BY ULTRABITHORAX AND ITS ROLE IN DROSOPHILA MIDGUT MORPHOGENESIS	CELL			English	Article							HOMEODOMAIN RECOGNITION HELIX; DNA-SEQUENCE RECOGNITION; HOMEOTIC GENE-EXPRESSION; VISCERAL MESODERM; BITHORAX COMPLEX; HOMEOBOX GENE; ANTENNAPEDIA HOMEODOMAIN; ECTOPIC EXPRESSION; PATTERN-FORMATION; GERM LAYERS	Drosophila homeotic genes encode transcription factors thought to control segmental identity by regulating expression of largely unknown target genes. The formation of the second midgut constriction requires the Ultrabithorax (Ubx) and abdominal-A (abd-A) homeotic genes and decapentaplegic (dpp), a gene encoding a member of the TGF beta family of proteins. We identified a 674 bp enhancer of dpp controlling its expression in the second constriction domain of the visceral mesoderm (parasegment 7). Normal enhancer function requires positive regulation by Ubx and negative regulation by abd-A. This enhancer contains UBX- and ABD-A-binding sites defined in vitro. By generating complementary alterations of the binding sites and the binding specificity of UBX, we show that Ubx directly regulates dpp expression. These regulatory interactions are relevant to normal development, because a transgene made with this enhancer driving a dpp transcription unit rescues the second midgut constriction and larval lethality phenotypes of dpp(s) mutations.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine	CAPOVILLA, M (corresponding author), BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030, USA.		Capovilla, Maria/O-8483-2016	Capovilla, Maria/0000-0002-1308-7964				AFFOLTER M, 1990, P NATL ACAD SCI USA, V87, P4093, DOI 10.1073/pnas.87.11.4093; AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; ANDREW DJ, 1992, NEW BIOL, V4, P5; APPEL B, 1993, EMBO J, V12, P1099, DOI 10.1002/j.1460-2075.1993.tb05751.x; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BEACHY PA, 1988, CELL, V55, P1069, DOI 10.1016/0092-8674(88)90251-6; BENDER W, 1983, SCIENCE, V221, P23, DOI 10.1126/science.221.4605.23; BIENZ M, 1988, NATURE, V333, P576, DOI 10.1038/333576a0; Botas J, 1993, CURR OPIN CELL BIOL, V5, P1015, DOI 10.1016/0955-0674(93)90086-6; DAVIDSON EH, 1991, DEVELOPMENT, V113, P1; DESSAIN S, 1992, EMBO J, V11, P991, DOI 10.1002/j.1460-2075.1992.tb05138.x; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; EKKER SC, 1992, EMBO J, V11, P4059, DOI 10.1002/j.1460-2075.1992.tb05499.x; ERSELIUS JR, 1990, DEVELOPMENT, V110, P629; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GARCIABELLIDO A, 1977, AM ZOOL, V17, P613; GIBSON G, 1988, DEVELOPMENT, V102, P657; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HOFFMANN FM, 1987, GENE DEV, V1, P615, DOI 10.1101/gad.1.6.615; HURSH DA, 1993, DEVELOPMENT, V117, P1211; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; JONES B, 1993, GENE DEV, V7, P229, DOI 10.1101/gad.7.2.229; Kaufman T C, 1990, Adv Genet, V27, P309; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LOPEZ AJ, 1991, P NATL ACAD SCI USA, V88, P9924, DOI 10.1073/pnas.88.22.9924; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; MALLCKI J, 1990, CELL, V63, P961; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MORATA G, 1993, CURR OPIN GENET DEV, V3, P606, DOI 10.1016/0959-437X(93)90096-8; OHARA E, 1993, DEVELOPMENT, V117, P847; OLIVER G, 1988, EMBO J, V7, P3199, DOI 10.1002/j.1460-2075.1988.tb03187.x; OTTING G, 1988, EMBO J, V7, P4305, DOI 10.1002/j.1460-2075.1988.tb03329.x; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PERCIVALSMITH A, 1990, EMBO J, V9, P3967, DOI 10.1002/j.1460-2075.1990.tb07617.x; PERCIVALSMITH A, 1990, EMBO J, V11, P382; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; REUTER R, 1990, DEVELOPMENT, V109, P289; REUTER R, 1990, DEVELOPMENT, V110, P1031; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SANCHEZHERRERO E, 1985, NATURE, V313, P108, DOI 10.1038/313108a0; SCHLER AF, 1992, NATURE, V356, P804; SCHMID P, 1991, DEVELOPMENT, V111, P117; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; TREISMAN J, 1989, CELL, V59, P553; TREMML G, 1989, EMBO J, V8, P2677, DOI 10.1002/j.1460-2075.1989.tb08408.x; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; ZHAO JJ, 1993, GENE DEV, V7, P343, DOI 10.1101/gad.7.3.343	71	167	168	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 11	1994	76	3					461	475		10.1016/0092-8674(94)90111-2	http://dx.doi.org/10.1016/0092-8674(94)90111-2			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	7906203				2022-12-28	WOS:A1994MX20700008
J	CARR, T; STEVENS, RF				CARR, T; STEVENS, RF			MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA	LANCET			English	Editorial Material							MYELOID-LEUKEMIA				CARR, T (corresponding author), ROYAL MANCHESTER CHILDRENS HOSP,MANCHESTER M27 1HA,LANCS,ENGLAND.							BARTRAM CR, 1989, LANCET, V1, P1260; GERHARTZ HH, 1990, LEUKEMIA, V4, P508; Hagenbeek A, 1991, Baillieres Clin Haematol, V4, P609; VANDONGEN JJM, 1991, CLIN CHIM ACTA, V198, P93; YAMADA M, 1990, NEW ENGL J MED, V323, P448, DOI 10.1056/NEJM199008163230705	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 22	1994	343	8891					190	190		10.1016/S0140-6736(94)90986-5	http://dx.doi.org/10.1016/S0140-6736(94)90986-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT332	7904664				2022-12-28	WOS:A1994MT33200005
J	DEBONO, D				DEBONO, D			DIGOXIN IN EURHYTHMIC HEART-FAILURE - PROVED OR NOT PROVEN	LANCET			English	Editorial Material											DEBONO, D (corresponding author), UNIV LEICESTER,DEPT MED,DIV CARDIOL,LEICESTER LE1 7RH,ENGLAND.							NOBLE D, 1980, CARDIOVASC RES, V14, P495, DOI 10.1093/cvr/14.9.495; PACKER M, 1993, NEW ENGL J MED, V329, P1, DOI 10.1056/NEJM199307013290101; PUGH SE, 1989, BRIT HEART J, V61, P529; SMITH T W, 1988, New England Journal of Medicine, V318, P358; SMITH TW, 1993, NEW ENGL J MED, V329, P51, DOI 10.1056/NEJM199307013290111; URETSKY BF, 1993, J AM COLL CARDIOL, V22, P955, DOI 10.1016/0735-1097(93)90403-N; YUSUF S, 1992, AM J CARDIOL, V69, pG64, DOI 10.1016/0002-9149(92)91255-3; 1991, NEW ENGL J MED, V325, P293; 1987, NEW ENGL J MED, V316, P1429	9	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 15	1994	343	8890					128	129		10.1016/S0140-6736(94)90926-1	http://dx.doi.org/10.1016/S0140-6736(94)90926-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7903996				2022-12-28	WOS:A1994MQ86900002
J	NIJHAWAN, S; RAI, RR				NIJHAWAN, S; RAI, RR			DOES POST-LIGATION ESOPHAGEAL ULCER HEALING REQUIRE TREATMENT	LANCET			English	Letter											NIJHAWAN, S (corresponding author), SMS MED COLL & HOSP,DEPT GASTROENTEROL,JAIPUR,INDIA.							GIMSON AES, 1993, LANCET, V342, P391, DOI 10.1016/0140-6736(93)92812-8; STIEGMANN GV, 1988, AM SURGEON, V54, P105; YOUNG MF, 1993, GASTROINTEST ENDOSC, V39, P119, DOI 10.1016/S0016-5107(93)70049-8	3	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					116	117		10.1016/S0140-6736(94)90844-3	http://dx.doi.org/10.1016/S0140-6736(94)90844-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903747				2022-12-28	WOS:A1994MQ09200045
J	SUZUKI, S; NAKATOMI, Y; SATO, H; TSUKADA, H; ARAKAWA, M				SUZUKI, S; NAKATOMI, Y; SATO, H; TSUKADA, H; ARAKAWA, M			HAEMOPHILUS-PARAINFLUENZAE ANTIGEN AND ANTIBODY IN RENAL BIOPSY SAMPLES AND SERUM OF PATIENTS WITH IGA NEPHROPATHY	LANCET			English	Article							FC-RECEPTOR; VIRUS; DEPOSITION; PROTEINS	IgA nephropathy may be associated with colonisation with Haemophilus parainfluenzae. In patients with glomerular diseases, we examined renal-biopsy specimens for presence of bacterial antigen by immunofluorescence microscopy with rabbit antiserum against H parainfluenzae, and by enzyme-linked immunosorbent assay looked for IgA antibody against H parainfluenzae in patient sera. The rabbit antiserum recognised by immunoblotting four components of H parainfluenzae outer membranes (OMHP) of molecular weights 19.5, 30, 33, and 40 5 kDa. All 44 patients with IgA nephropathy and 2 of 3 9 patients with other glomerular diseases showed mesangial deposition of OMHP antigens (p<0.001). Patients with IgA nephropathy had significantly more IgA antibody against H parainfluenzae than did patients with other glomerular diseases. IgA antibody in the sera of patients with IgA nephropathy recognised by immunoblotting the same four components of OMHP as recognised by rabbit antiserum. Glomerular deposition of OMHP antigens and the presence of IgA antibody against OMHP in patients with IgA nephropathy suggest that H parainfluenzae has a role in the aetiology of this disease.	DENKA SELKEN CO LTD,DIV RES & DEV,NIIGATA,JAPAN		SUZUKI, S (corresponding author), NIIGATA UNIV,SCH MED,DEPT MED 2,ASAHIMACHI DORI,NIIGATA 951,JAPAN.							ANDRE PM, 1990, NEPHRON, V54, P185, DOI 10.1159/000185845; BERGER J, 1969, TRANSPL P, V1, P939; BORRADORI L, 1990, NEPHRON, V56, P35, DOI 10.1159/000186097; CLARKSON AR, 1984, CLIN NEPHROL, V21, P7; COPPO R, 1990, CLIN NEPHROL, V33, P72; DAMICO G, 1985, NEPHRON, V41, P1, DOI 10.1159/000183538; DAVIN JC, 1987, KIDNEY INT, V31, P1132, DOI 10.1038/ki.1987.119; GREGORY MC, 1988, LANCET, V1, P11; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI KN, 1988, CLIN NEPHROL, V29, P229; LAWRENCE S, 1983, CLIN NEPHROL, V16, P280; MORTON DJ, 1989, J GEN MICROBIOL, V135, P445; NICHOLLS K, 1984, AM J KIDNEY DIS, V4, P128, DOI 10.1016/S0272-6386(84)80060-8; ROCCATELLO D, 1985, CLIN NEPHROL, V23, P159; SATO M, 1988, CLIN EXP IMMUNOL, V73, P295; SUZUKI S, 1992, AM J NEPHROL, V12, P22, DOI 10.1159/000168413; TOMINO Y, 1987, NEPHRON, V47, P258, DOI 10.1159/000184520; WOODROFFE AJ, 1980, KIDNEY INT, V18, P366, DOI 10.1038/ki.1980.147	18	111	120	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					12	16		10.1016/S0140-6736(94)90875-3	http://dx.doi.org/10.1016/S0140-6736(94)90875-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905040				2022-12-28	WOS:A1994MN93700011
J	HENGARTNER, MO; HORVITZ, HR				HENGARTNER, MO; HORVITZ, HR			ACTIVATION OF C-ELEGANS CELL-DEATH PROTEIN CED-9 BY AN AMINO-ACID SUBSTITUTION IN A DOMAIN CONSERVED IN BCL-2	NATURE			English	Article							CAENORHABDITIS-ELEGANS; SEQUENCE SIMILARITY; FOLLICULAR LYMPHOMA; GENE; TRANSLOCATION; EXPRESSION; NEMATODE; CLONING	THE Caenorhabditis elegans gene ced-9 and the human protooncogene bcl-2 both of which protect cells from programmed cell death, are members of the same gene family(1-11). ced-9 and bcl-2 were discovered because of the effects of dominant gain-of-function mutations(12-14). Such bcl-2 mutations, which are commonly found in follicular lymphoma, are translocations that result in overexpression of a normal Bcl-2 protein in B cells(1,13-16) Here we report that, by contrast, the ced-9(n1950) gain-of-function mutation affects the open reading frame of ced-9 and results in a glycine-to-glutamate substitution in a region highly conserved among all ced-9/bcl-2 family members. We conclude that this glycine has an important function in ced-9 regulation, and we suggest that alteration of this glycine in other members of the ced-9/bcl-2 family might lead to oncogenic activation. We also present genetic evidence suggesting that the CED-9 protein might exist in two distinct forms that have opposite effects on cell death.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)			Hengartner, Michael O/E-6235-2011; Hengartner, Michael O/A-7058-2008	Hengartner, Michael/0000-0002-7584-596X				ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CAZALSHATEM DL, 1992, BIOCHIM BIOPHYS ACTA, V1132, P109, DOI 10.1016/0167-4781(92)90064-7; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FILES JG, 1983, J MOL BIOL, V164, P355, DOI 10.1016/0022-2836(83)90056-6; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HENGARTNER MO, IN PRESS CURR OPIN G; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LIN EY, 1993, J IMMUNOL, V151, P1979; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NEILAN JG, 1993, J VIROL, V67, P4391, DOI 10.1128/JVI.67.7.4391-4394.1993; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PEARSON GR, 1987, VIROLOGY, V160, P151, DOI 10.1016/0042-6822(87)90055-9; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUNIS JJ, 1982, NEW ENGL J MED, V307, P1231, DOI 10.1056/NEJM198211113072002	28	154	159	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 26	1994	369	6478					318	320		10.1038/369318a0	http://dx.doi.org/10.1038/369318a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN109	7910376				2022-12-28	WOS:A1994NN10900049
J	FENAUX, P; CHASTANG, C; CHOMIENNE, C; DEGOS, L				FENAUX, P; CHASTANG, C; CHOMIENNE, C; DEGOS, L			TRETINOIN WITH CHEMOTHERAPY IN NEWLY-DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA	LANCET			English	Letter							TRANS-RETINOIC ACID		HOP ST LOUIS,DBIM,PARIS,FRANCE; HOP ST LOUIS,BIOL CELLULAIRE HEMATOL LAB,PARIS,FRANCE; HOP ST LOUIS,SERV CLIN MALAD SANG,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	FENAUX, P (corresponding author), CHU LILLE,SERV MALAD SANG,F-59037 LILLE,FRANCE.			CHOMIENNE, Christine/0000-0001-5513-5752				CHOMIENNE C, 1990, BLOOD, V76, P1710; FENAUX P, 1993, BLOOD, V82, P3241; FENAUX P, 1992, BLOOD, V80, P2176; FRANKEL SR, 1994, ANN INTERN MED, V120, P278, DOI 10.7326/0003-4819-120-4-199402150-00004; OHNO R, 1993, LEUKEMIA, V7, P1722	5	41	41	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 23	1994	343	8904					1033	1033		10.1016/S0140-6736(94)90151-1	http://dx.doi.org/10.1016/S0140-6736(94)90151-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909058				2022-12-28	WOS:A1994NG68200031
J	JAMES, A				JAMES, A			MARINE POLLUTION AND LIMB REDUCTION DEFECTS	LANCET			English	Editorial Material																		FIRTH HV, 1991, LANCET, V337, P762, DOI 10.1016/0140-6736(91)91374-4; HOYME HE, 1982, J PEDIATR-US, V101, P839, DOI 10.1016/S0022-3476(82)80343-0; SHEPARD TH, 1991, LANCET, V337, P1092; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; WEBSTER WS, 1988, TERATOLOGY, V38, pA199	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 23	1994	343	8904					990	991		10.1016/S0140-6736(94)90121-X	http://dx.doi.org/10.1016/S0140-6736(94)90121-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909088				2022-12-28	WOS:A1994NG68200004
J	COHEN, FE; PAN, KM; HUANG, Z; BALDWIN, M; FLETTERICK, RJ; PRUSINER, SB				COHEN, FE; PAN, KM; HUANG, Z; BALDWIN, M; FLETTERICK, RJ; PRUSINER, SB			STRUCTURAL CLUES TO PRION REPLICATION	SCIENCE			English	Editorial Material							CREUTZFELDT-JAKOB DISEASE; TRANSGENIC MICE; PRP ISOFORMS; PROTEIN GENE; SCRAPIE; HAMSTERS; LINKAGE; CELLS		UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BESSEN RA, 1992, J GEN VIROL, V73, P329, DOI 10.1099/0022-1317-73-2-329; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BROWN P, 1990, P NATL ACAD SCI USA, V87, P7240, DOI 10.1073/pnas.87.18.7240; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CARLSON GA, 1989, P NATL ACAD SCI USA, V86, P7475, DOI 10.1073/pnas.86.19.7475; CARLSON GA, IN PRESS P NATL ACAD; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; DEARMOND SJ, 1993, P NATL ACAD SCI USA, V90, P6449, DOI 10.1073/pnas.90.14.6449; DICKINSON AG, 1968, J COMP PATHOL, V78, P293, DOI 10.1016/0021-9975(68)90005-4; DLOUHY SR, 1992, NAT GENET, V1, P64, DOI 10.1038/ng0492-64; GABIZON R, 1993, AM J HUM GENET, V33, P828; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; HUANG Z, IN PRESS P NATL ACAD; LIFSON S, 1980, PROTEIN FOLDING, P289; MCKINLEY MP, 1991, J VIROL, V65, P1440; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PETERSEN RB, 1992, NEUROLOGY, V42, P1859, DOI 10.1212/WNL.42.10.1859; POULTER M, 1992, BRAIN, V115, P675, DOI 10.1093/brain/115.3.675; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P2793, DOI 10.1073/pnas.90.7.2793; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; TARABOULOS A, 1992, EMBO J, V11, P863; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; WESTAWAY D, 1994, CELL, V76, P117, DOI 10.1016/0092-8674(94)90177-5; WESTAWAY D, IN PRESS P NATL ACAD	42	430	451	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 22	1994	264	5158					530	531		10.1126/science.7909169	http://dx.doi.org/10.1126/science.7909169			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH010	7909169				2022-12-28	WOS:A1994NH01000025
J	BESSLER, M; MASON, P; HILLMEN, P; LUZZATTO, L				BESSLER, M; MASON, P; HILLMEN, P; LUZZATTO, L			SOMATIC MUTATIONS AND CELLULAR-SELECTION IN PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA	LANCET			English	Note							RED-CELLS; HEMOGLOBINURIA	Patients with paroxysmal nocturnal haemoglobinuria (PNH) have in their blood two red-cell populations, one normal and one deficient in proteins anchored to the membrane through a glycan phosphatidylinositol (GPI) structure. The PNH abnormality is due to a somatic mutation in the PIG-A gene, whose product is required for an early step in GPI anchor biosynthesis. We show that in two patients, two PNH clones with different mutations co-exist, and must therefore have arisen independently. This finding supports the concept that PNH develops under the pressures of a positive selection mechanism whereby GPI-anchor-deficient haemopoietic cells have a survival advantage.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,LRF LEUKAEMIA UNIT,LONDON,ENGLAND	Imperial College London	BESSLER, M (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HAEMATOL,DU CANE RD,LONDON W12 ONN,ENGLAND.		Mason, Philip J/B-1087-2008		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARMSTRONG C, 1992, J BIOL CHEM, V267, P25347; BESSLER M, 1994, EMBO J, V13, P110, DOI 10.1002/j.1460-2075.1994.tb06240.x; DACIE JV, 1972, SER HAEMATOL, V3, P3; HILLMEN P, 1993, BLOOD, V81, P193; MIYATA T, 1994, NEW ENGL J MED, V330, P249, DOI 10.1056/NEJM199401273300404; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; ONI SB, 1970, BLOOD-J HEMATOL, V36, P145, DOI 10.1182/blood.V36.2.145.145; ROSSE WF, 1973, BRIT J HAEMATOL, V24, P327, DOI 10.1111/j.1365-2141.1973.tb01657.x; Rotoli B, 1989, Baillieres Clin Haematol, V2, P113, DOI 10.1016/S0950-3536(89)80010-1; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T	10	146	148	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					951	953		10.1016/S0140-6736(94)90068-X	http://dx.doi.org/10.1016/S0140-6736(94)90068-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909012				2022-12-28	WOS:A1994NF70000012
J	CASCINELLI, N; BUFALINO, R; MORABITO, A; MACKIE, R				CASCINELLI, N; BUFALINO, R; MORABITO, A; MACKIE, R			RESULTS OF ADJUVANT INTERFERON STUDY IN WHO MELANOMA PROGRAM	LANCET			English	Letter											CASCINELLI, N (corresponding author), UNIV GLASGOW,DEPT DERMATOL,ROBERTSON BLDG,GLASGOW G12 8QQ,SCOTLAND.								0	136	137	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 9	1994	343	8902					913	914		10.1016/S0140-6736(94)90030-2	http://dx.doi.org/10.1016/S0140-6736(94)90030-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF213	7908370				2022-12-28	WOS:A1994NF21300030
J	RAVINE, D; GIBSON, RN; WALKER, RG; SHEFFIELD, LJ; KINCAIDSMITH, P; DANKS, DM				RAVINE, D; GIBSON, RN; WALKER, RG; SHEFFIELD, LJ; KINCAIDSMITH, P; DANKS, DM			EVALUATION OF ULTRASONOGRAPHIC DIAGNOSTIC-CRITERIA FOR AUTOSOMAL-DOMINANT POLYCYSTIC KIDNEY DISEASE-1	LANCET			English	Article							CHROMOSOME-16; LOCUS; PKD1; MARKERS; GENE	Although ultrasound is commonly used for screening subjects at risk of polycystic kidney disease 1 (PKD1), there has been no evaluation of ultrasonographic diagnostic criteria. We used DNA linkage among subjects from 128 sibships within 18 PKD1 families as the basis for an assessment of ultrasound sensitivity. Positive and negative predictive values were calculated to allow assessment of different diagnostic cut-off points in previously undiagnosed cases. Currently used criteria (bilateral cysts with at least two in one kidney) provided good sensitivity (88.5% at age 15-29 years and 100% at 30 years and above) but performance could be improved by less stringent criteria in subjects aged 15-29 years and more stringent criteria in older family members, in whom simple renal cysts are frequent. The presence of at least two renal cysts (unilateral or bilateral) in individuals at risk and younger than 30 years may be regarded as sufficient to establish a diagnosis; among those aged 30-59 years, the presence of at least two cysts in each kidney may be required, and among those aged 60 years and above, at least four cysts in each kidney should be required.	ROYAL CHILDRENS HOSP,MURDOCH INST,PARKVILLE,VIC 3052,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT RADIOL,PARKVILLE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT NEPHROL,PARKVILLE,VIC 3050,AUSTRALIA	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Royal Melbourne Hospital; Royal Melbourne Hospital			Ravine, David/A-6797-2008					BEAR JC, 1984, AM J MED GENET, V18, P45, DOI 10.1002/ajmg.1320180108; BEAR JC, 1992, AM J MED GENET, V43, P548, DOI 10.1002/ajmg.1320430309; BENNETT WM, 1990, SEMIN NEPHROL, V10, P552; BREUNING MH, 1990, NUCLEIC ACIDS RES, V18, P3106, DOI 10.1093/nar/18.10.3106-a; BREUNING MH, 1987, LANCET, V2, P1359; COTO E, 1992, J MED GENET, V29, P243, DOI 10.1136/jmg.29.4.243; DISNEY APS, 1990, ANZDATA13TH QUEEN EL, P22; FICK GM, 1993, J AM SOC NEPHROL, V3, P1863; GERMINO GG, 1990, AM J HUM GENET, V46, P925; HOGEWIND BL, 1980, CLIN GENET, V18, P168; HYLAND VJ, 1990, HUM GENET, V84, P286; JARMAN AP, 1986, EMBO J, V5, P1857, DOI 10.1002/j.1460-2075.1986.tb04437.x; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; KIMBERLING WJ, 1988, NEW ENGL J MED, V319, P913, DOI 10.1056/NEJM198810063191405; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LATHROP GM, 1988, AM J HUM GENET, V42, P498; MCHUGH K, 1991, RADIOLOGY, V178, P383, DOI 10.1148/radiology.178.2.1987597; MILUTINOVIC J, 1980, LANCET, V1, P1203; MILUTINOVIC J, 1989, AM J KIDNEY DIS, V13, P340, DOI 10.1016/S0272-6386(89)80043-5; PARFREY PS, 1990, NEW ENGL J MED, V323, P1085, DOI 10.1056/NEJM199010183231601; PETERS DJM, 1993, NAT GENET, V5, P359, DOI 10.1038/ng1293-359; PETERS DJM, 1992, CONTRIB NEPHROL, V97, P128; RAVINE D, 1993, AM J KIDNEY DIS, V22, P803, DOI 10.1016/S0272-6386(12)70338-4; RAVINE D, 1992, LANCET, V340, P1300; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; ROMEO G, 1988, LANCET, V2, P8; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P88; SNIJDEWINT FGM, 1990, NUCLEIC ACIDS RES, V18, P3108, DOI 10.1093/nar/18.10.3108-a; THOMPSON AD, 1992, GENOMICS, V13, P402, DOI 10.1016/0888-7543(92)90260-Y; Tufveson G, 1989, NEPHROL DIAL TRAN S4, V4, P5	30	442	465	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					824	827		10.1016/S0140-6736(94)92026-5	http://dx.doi.org/10.1016/S0140-6736(94)92026-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908078				2022-12-28	WOS:A1994ND79200009
J	HORTON, R				HORTON, R			TRIALS OF WOMEN	LANCET			English	Editorial Material																		CASCHETTA MB, 1993, NEW ENGL J MED, V329, P1815; Mastroianni AC, 1994, WOMEN HLTH RES ETHIC	2	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 26	1994	343	8900					745	746		10.1016/S0140-6736(94)91831-7	http://dx.doi.org/10.1016/S0140-6736(94)91831-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907725				2022-12-28	WOS:A1994NC35100003
J	ARINAMI, T; ITOKAWA, M; ENGUCHI, H; TAGAYA, H; YANO, S; SHIMIZU, H; HAMAGUCHI, H; TORU, M				ARINAMI, T; ITOKAWA, M; ENGUCHI, H; TAGAYA, H; YANO, S; SHIMIZU, H; HAMAGUCHI, H; TORU, M			ASSOCIATION OF DOPAMINE D2 RECEPTOR MOLECULAR VARIANT WITH SCHIZOPHRENIA	LANCET			English	Note							GENE	We have examined a variant of the dopamine D2 receptor gene (Ser311-->Cys) in 156 Japanese schizophrenic patients and 300 controls. The allele frequency of Cys311 was significantly higher in the whole patient group (0.054), among patients with onset before age 25 (0.090), and among those with a family history (0.135) than in the controls (0.018). 3 patients were homozygous for Cys311. The patients with Cys311 showed significantly less severe thought disorder and negative symptoms of schizophrenia than those without Cys311. The Cys311 variant of the D2 receptor may be a genetic risk factor for some types of schizophrenia.	TOKYO MED & DENT UNIV,DEPT NEUROPSYCHIAT,TOKYO,TOKYO,JAPAN; HOKUSHIN GEN HOSP,DEPT PSYCHIAT,NAKANO,NAGANO,JAPAN	Tokyo Medical & Dental University (TMDU)	ARINAMI, T (corresponding author), UNIV TSUKUBA,INST BASIC MED SCI,DEPT MED GENET,TSUKUBA,IBARAKI 305,JAPAN.			Itokawa, Masanari/0000-0003-4433-8030				CATALANO M, 1992, NEUROPSYCHOBIOLOGY, V26, P1, DOI 10.1159/000118888; CROW TJ, 1980, BRIT MED J, V280, P66, DOI 10.1136/bmj.280.6207.66; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; ITOKAWA M, 1993, BIOCHEM BIOPH RES CO, V196, P1369, DOI 10.1006/bbrc.1993.2404; KRAWIECKA M, 1977, ACTA PSYCHIAT SCAND, V55, P299, DOI 10.1111/j.1600-0447.1977.tb00174.x; SARKAR G, 1991, GENOMICS, V11, P8, DOI 10.1016/0888-7543(91)90096-W; SEEMAN P, 1993, NEUROPSYCHOPHARMACOL, V8, P137, DOI 10.1038/npp.1993.15; SEEMAN P, 1992, NEUROPSYCHOPHARMACOL, V7, P261; SU Y, 1993, ARCH GEN PSYCHIAT, V50, P205	10	168	173	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					703	704		10.1016/S0140-6736(94)91581-4	http://dx.doi.org/10.1016/S0140-6736(94)91581-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907680				2022-12-28	WOS:A1994NB80900010
J	ABRAMS, DI; GOLDMAN, AI; LAUNER, C; KORVICK, JA; NEATON, JD; CRANE, LR; GRODESKY, M; WAKEFIELD, S; MUTH, K; KORNEGAY, S; COHN, DL; HARRIS, A; LUSKINHAWK, R; MARKOWITZ, N; SAMPSON, JH; THOMPSON, M; DEYTON, L				ABRAMS, DI; GOLDMAN, AI; LAUNER, C; KORVICK, JA; NEATON, JD; CRANE, LR; GRODESKY, M; WAKEFIELD, S; MUTH, K; KORNEGAY, S; COHN, DL; HARRIS, A; LUSKINHAWK, R; MARKOWITZ, N; SAMPSON, JH; THOMPSON, M; DEYTON, L			A COMPARATIVE TRIAL OF DIDANOSINE OR ZALCITABINE AFTER TREATMENT WITH ZIDOVUDINE IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIDS-RELATED COMPLEX; PHASE-I TRIAL; 2',3'-DIDEOXYINOSINE DDI; HIV; DIDEOXYCYTIDINE; MODELS	Background. Both didanosine and zalcitabine are commonly used to treat patients with human immunodeficiency virus (HIV) infection who cannot tolerate zidovudine treatment or who have had disease progression despite it. The relative efficacy and safety of these second-line therapies are not well defined. Methods. In this multicenter, open-label trial we randomly assigned 467 patients who previously received zidovudine and had 300 or fewer CD4 cells per cubic millimeter or a diagnosis of the acquired immunodeficiency syndrome (AIDS) to treatment with either didanosine (500 mg per day) or zalcitabine (2.25 mg per day). Results. After a median follow-up of 16 months, disease progression or death occurred in 157 of 230 patients assigned to didanosine and 152 of 237 patients assigned to zalcitabine, for a relative risk of 0.93 for the zalcitabine group as compared with the didanosine group (P = 0.56), which decreased to 0.84 (P = 0.15) after adjustment for the CD4 count, Karnofsky score, and presence of AIDS at base line. There were 100 deaths in the didanosine group and 88 in the zalcitabine group, for a relative risk of 0.78 (P = 0.09) and an adjusted relative risk of 0.63 (P = 0.003). A majority of patients in each group (66 percent) had at least one adverse event during treatment (153 patients taking didanosine and 157 taking zalcitabine). Peripheral neuropathy and stomatitis occurred more often with zalcitabine and diarrhea and abdominal pain more frequently with didanosine. Conclusions. For patients with HIV infection who have not responded to treatment with zidovudine, zalcitabine is at least as efficacious as didanosine in delaying disease progression and death.	NIAID,DIV AIDS,BETHESDA,MD 20892; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO COMMUNITY CONSORTIUM AIDS,SAN FRANCISCO,CA; UNIV MINNESOTA,DIV BIOSTAT,MINNEAPOLIS,MN; HARPER GRACE HOSP,COMPREHENS AIDS ALLIANCE DETROIT,DETROIT,MI 48201; CHICAGO COMMUNITY PROGRAMS CLIN RES AIDS,CHICAGO,IL; ROW SCI,ROCKVILLE,MD; ST JOSEPH HOSP & HLTH CARE CTR,DEPT MED,CHICAGO,IL 60657; HENRY FORD HOSP,DIV INFECT DIS,DETROIT,MI 48202; RES & EDUC GRP,PORTLAND,OR; AIDS RES CONSORTIUM ATLANTA,ATLANTA,GA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California San Francisco; University of Minnesota System; University of Minnesota Twin Cities; Henry Ford Health System; Henry Ford Hospital								ALLAN JD, 1993, 9TH INT C AIDS BERL; COOLEY TP, 1990, NEW ENGL J MED, V322, P1340, DOI 10.1056/NEJM199005103221902; COX DR, 1972, J R STAT SOC B, V34, P187; DARBYSHIRE JH, 1992, LANCET, V340, P1346, DOI 10.1016/0140-6736(92)92524-J; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; MERIGAN TC, 1989, ANN INTERN MED, V110, P189, DOI 10.7326/0003-4819-110-3-189; NAUSSKAROL C, 1992, AIDS S1, V6, pS29; PIKE IM, 1993, CLIN INFECT DIS, V16, pS63, DOI 10.1093/clinids/16.Supplement_1.S63; YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840; YARCHOAN R, 1988, LANCET, V1, P76; 1993, J ACQ IMMUN DEF SYND, V6, P46; 1987, MMWR S1, V36, pS1	16	197	199	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 10	1994	330	10					657	662		10.1056/NEJM199403103301001	http://dx.doi.org/10.1056/NEJM199403103301001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY575	7906384	Bronze			2022-12-28	WOS:A1994MY57500001
J	BARNETT, DB				BARNETT, DB			BETA-BLOCKERS IN HEART-FAILURE - A THERAPEUTIC PARADOX	LANCET			English	Editorial Material							IDIOPATHIC DILATED CARDIOMYOPATHY; CONGESTIVE CARDIOMYOPATHY; CARDIAC-FUNCTION; DOUBLE-BLIND; BLOCKADE; BUCINDOLOL; METOPROLOL				BARNETT, DB (corresponding author), UNIV LEICESTER, DEPT MED & THERAPEUT, LEICESTER, LEICS, ENGLAND.							COHN JN, 1984, NEW ENGL J MED, V31, P28; CURRIE PJ, 1984, J AM COLL CARDIOL, V3, P203, DOI 10.1016/S0735-1097(84)80449-0; ENGELMEIER RS, 1985, CIRCULATION, V72, P536, DOI 10.1161/01.CIR.72.3.536; FRANCIS GS, 1990, CIRCULATION, V82, P1724, DOI 10.1161/01.CIR.82.5.1724; GILBERT EM, 1990, AM J MED, V88, P223, DOI 10.1016/0002-9343(90)90146-5; IKRAM H, 1981, LANCET, V2, P490; LEVINE TB, 1982, AM J CARDIOL, V49, P1659, DOI 10.1016/0002-9149(82)90243-0; NEMANICH JW, 1990, AM J CARDIOL, V66, P843, DOI 10.1016/0002-9149(90)90362-5; POLLOCK SG, 1990, AM J CARDIOL, V66, P603, DOI 10.1016/0002-9149(90)90488-M; SWEDBERG K, 1980, BRIT HEART J, V44, P134; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; WAAGSTEIN F, 1975, BRIT HEART J, V37, P1022; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; WOODLEY SL, 1991, CIRCULATION, V84, P2426, DOI 10.1161/01.CIR.84.6.2426	14	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 5	1994	343	8897					557	558		10.1016/S0140-6736(94)91518-0	http://dx.doi.org/10.1016/S0140-6736(94)91518-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906326				2022-12-28	WOS:A1994MY84300006
J	BUTLER, C				BUTLER, C			OVERPOPULATION, OVERCONSUMPTION, AND ECONOMICS	LANCET			English	Editorial Material							HEALTH						Butler, Colin D./H-2267-2019	Butler, Colin D./0000-0002-2942-5294				[Anonymous], 1973, SMALL IS BEAUTIFUL; BARBIER E, 1986, LIVING EC NEW EC MAK, P7; BUTLER CD, 1991, MED J AUSTRALIA, V155, P351, DOI 10.5694/j.1326-5377.1991.tb142316.x; Dalai Lama XIV, 1990, D LAMA POLICY KINDNE; EHRLICH PR, 1991, HEALING PLANET, P42; FELLOWS L, 1992, LANCET, V340, P1330; GORE A, 1992, EARTH BALANCE; HAINES A, 1993, LANCET, V342, P1464, DOI 10.1016/0140-6736(93)92937-O; Henderson H., 1981, POLITICS SOLAR AGE; KELLY J, 1993, LANCET, V342, P808; KING M, 1990, LANCET, V336, P664, DOI 10.1016/0140-6736(90)92156-C; KING M, 1993, LANCET, V341, P669, DOI 10.1016/0140-6736(93)90431-F; LAST JM, 1993, LANCET, V342, P508, DOI 10.1016/0140-6736(93)91641-X; LEAF A, 1989, NEW ENGL J MED, V321, P1577, DOI 10.1056/NEJM198912073212305; LOVELOCK J, 1988, AGES GAIA, P181; OMRAN AR, 1993, LANCET, V342, P808, DOI 10.1016/0140-6736(93)91574-6; ONEILL P, 1993, BRIT MED J, V307, P1162; PEETERS MA, 1993, LANCET, V342, P808; REDDY AKN, 1990, SCI AM, V263, P64; TROUNSON A, 1994, LANCET, V343, P59, DOI 10.1016/S0140-6736(94)90916-4; TYLLESKAR T, 1992, LANCET, V339, P208, DOI 10.1016/0140-6736(92)90006-O; VERKUYL DAA, 1993, LANCET, V342, P473, DOI 10.1016/0140-6736(93)91597-F; 1993, 1993 WORLD BANK WORL; 1993, LANCET, V342, P1125; 1993, LANCET, V342, P447	25	11	11	1	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 5	1994	343	8897					582	584		10.1016/S0140-6736(94)91526-1	http://dx.doi.org/10.1016/S0140-6736(94)91526-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MY843	7906334				2022-12-28	WOS:A1994MY84300014
J	TESI, RJ; ELKHAMMAS, EA; DAVIES, EA; HENRY, ML; FERGUSON, RM				TESI, RJ; ELKHAMMAS, EA; DAVIES, EA; HENRY, ML; FERGUSON, RM			RENAL-TRANSPLANTATION IN OLDER-PEOPLE	LANCET			English	Article							65 YEARS OLD; KIDNEY-TRANSPLANTATION; CYCLOSPORINE; AGE	Renal transplantation in people 60 years old or more is controversial due to the morbidity associated with immunosuppression and the scarcity of renal allografts. We have reviewed the outcome of 1222 consecutive renal transplants done at a single institution with a uniform immunosuppressive protocol over 10 years. 5-year graft survival was the same in the under sixties as in the sixties and over. Patient survival was worse (p=0.0001), but there were immunological graft losses: 11% vs 31% (p=0.0009;relative risk [RR]=0.36 [95% confidence interval 0.19-0.66]). A majority of the deaths in both groups were secondary to cardiovascular disease, not due to complications of immunosuppression. We conclude that renal transplantation in people 60 and over has results equivalent to a younger population. Age 60 and over should not be a major factor in considering if a patient is eligible for renal transplantation.	OHIO STATE UNIV, DEPT SURG, DIV TRANSPLANTAT, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University			Elkhammas, Elmahdi A./E-3020-2011	Elkhammas, Elmahdi/0000-0002-0265-1865				BRUNNER FP, 1988, NEPHROL DIAL TRANSPL, V2, P109; FAUCHALD P, 1988, TRANSPLANT INT, V1, P131, DOI 10.1111/j.1432-2277.1988.tb01800.x; FEHRMAN I, 1989, TRANSPLANT P, V21, P2018; HENRY ML, 1988, TRANSPLANT P, V20, P419; HENRY ML, 1988, TRANSPLANTATION, V45, P73, DOI 10.1097/00007890-198801000-00017; HIROKAWA K, 1992, NUTR REV, V50, P361, DOI 10.1111/j.1753-4887.1992.tb02481.x; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; LINDHOLM A, 1993, TRANSPLANTATION, V56, P307, DOI 10.1097/00007890-199308000-00010; MAILLOUX LU, 1991, AM J KIDNEY DIS, V18, P326, DOI 10.1016/S0272-6386(12)80091-6; MATAS AJ, 1993, TRANSPLANT P, V25, P1309; MORRIS GE, 1991, NEPHROL DIAL TRANSPL, V6, P887, DOI 10.1093/ndt/6.11.887; OST L, 1980, TRANSPLANTATION, V30, P339; POWERS DC, 1987, POSTGRAD MED, V81, P355, DOI 10.1080/00325481.1987.11699769; ROZA AM, 1989, TRANSPLANTATION, V48, P689; SCHULAK JA, 1990, SURGERY, V108, P726; SIBLEY RK, 1983, SURGERY, V94, P225; SOMMER BG, 1987, TRANSPLANTATION, V43, P85, DOI 10.1097/00007890-198701000-00019; TESI RJ, 1993, CLIN TRANSPLANT, V7, P345; TESI RJ, 1994, IN PRESS TRANSPLANT; TESI RJ, 1993, IN PRESS CLIN TRANSP; VIVAS CA, 1992, J UROLOGY, V147, P990, DOI 10.1016/S0022-5347(17)37443-8; YUGE J, 1992, CLIN TRANSPLANTS 199, P257	22	132	136	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	1994	343	8895					461	464		10.1016/S0140-6736(94)92698-0	http://dx.doi.org/10.1016/S0140-6736(94)92698-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905959				2022-12-28	WOS:A1994MW69000015
J	DONALDSON, YK; BELL, JE; IRONSIDE, JW; BRETTLE, RP; ROBERTSON, JR; BUSUTTIL, A; SIMMONDS, P				DONALDSON, YK; BELL, JE; IRONSIDE, JW; BRETTLE, RP; ROBERTSON, JR; BUSUTTIL, A; SIMMONDS, P			REDISTRIBUTION OF HIV OUTSIDE THE LYMPHOID SYSTEM WITH ONSET OF AIDS	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DEFICIENCY SYNDROME AIDS; INFECTED INDIVIDUALS; CELLS; BRAIN; MACROPHAGES; DISEASE; RNA; DNA	The basis for many of the symptoms and pathological changes found in patients with the acquired immunodeficiency syndrome (AIDS) remains poorly understood. We have used a quantitative polymerase chain reaction technique to investigate the extent to which direct infection with human immunodeficiency virus (HIV) produces the disease manifestations of AIDS. In five patients who died with AIDS-defining illnesses (Centers for Disease Control and Prevention class IV), we found variable, but in many cases extensive, infection by HIV at various sites, including brain, lung, colon, and liver. By contrast, in three HIV-positive subjects who died without HIV-related disease (CDC class II), we found no evidence of significant infection of any non-lymphoid organ. In both groups of patients there were high levels of infection in cells of the spleen, lymph nodes, and peripheral blood. Pathological examination of tissues from the AIDS patients revealed many abnormalities, of which some, such as giant-cell encephalitis in the brain, were specifically associated with the presence of high levels of HIV infection. These findings suggest that spread of HIV outside cells of the immune system is a late event in HIV infection and is extremely sensitive to the degree of immunosuppression in the patient.	UNIV EDINBURGH,SCH MED,DEPT MED MICROBIOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT PATHOL,EDINBURGH,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,DEPT PATHOL,EDINBURGH,MIDLOTHIAN,SCOTLAND; CITY HOSP EDINBURGH,REG INFECT DIS UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND; MULRHOUSE GEN PRACTICE,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh; University of Edinburgh				Ironside, James/0000-0001-5869-2108; Simmonds, Peter/0000-0002-7964-4700				BELL JE, 1993, J INFECT DIS, V168, P819; Budka H, 1991, BRAIN PATHOL, V1, P143, DOI 10.1111/j.1750-3639.1991.tb00653.x; CAOY, 1992, AIDS, V6, P65; CLARKE JR, 1990, AIDS, V4, P1133, DOI 10.1097/00002030-199011000-00012; DAVIS LE, 1992, NEUROLOGY, V42, P1736, DOI 10.1212/WNL.42.9.1736; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FOX CH, 1989, J INFECT DIS, V159, P467, DOI 10.1093/infdis/159.3.467; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; GRAY F, 1988, BRAIN, V111, P245, DOI 10.1093/brain/111.2.245; HO DD, 1986, J CLIN INVEST, V77, P1712, DOI 10.1172/JCI112491; HO DD, 1987, NEW ENGL J MED, V317, P278; HOUSSET C, 1990, HUM PATHOL, V21, P404, DOI 10.1016/0046-8177(90)90202-G; LEVY JA, 1985, VIROLOGY, V147, P441, DOI 10.1016/0042-6822(85)90146-1; MACATONIA SE, 1990, IMMUNOLOGY, V71, P38; MOYER MP, 1990, AIDS RES HUM RETROV, V6, P1409, DOI 10.1089/aid.1990.6.1409; PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; SCHNEIDERMAN DJ, 1987, HEPATOLOGY, V7, P925, DOI 10.1002/hep.1840070522; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; SINCLAIR E, 1992, J NEUROL, V239, P469, DOI 10.1007/BF00856814; WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125; WILLEY CA, 1986, P NATL ACAD SCI USA, V83, P7089	23	90	91	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					382	385		10.1016/S0140-6736(94)91222-X	http://dx.doi.org/10.1016/S0140-6736(94)91222-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905551				2022-12-28	WOS:A1994MW28300008
J	GRIFFITH, MJ; GARRATT, CJ; MOUNSEY, P; CAMM, AJ				GRIFFITH, MJ; GARRATT, CJ; MOUNSEY, P; CAMM, AJ			VENTRICULAR-TACHYCARDIA AS DEFAULT DIAGNOSIS IN BROAD COMPLEX TACHYCARDIA	LANCET			English	Article							DIFFERENTIAL-DIAGNOSIS; ELECTROCARDIOGRAPHIC CRITERIA; MIS-DIAGNOSIS	In the differential diagnosis of broad complex tachycardia, the most important decision is whether or not the tachycardia is ventricular, since this type carries the worst prognosis. However, the rules for a diagnosis of ventricular tachycardia are so complex that they are not satisfied in many cases, and the default diagnosis, supraventricular tachycardia, is erroneously accepted. We sought to reverse this strategy; unless simple rules for a positive diagnosis of supraventricular tachycardia were satisfied, ventricular tachycardia was diagnosed by default. The criterion for a diagnosis of supraventricular tachycardia was electrocardiographic (ECG) findings typical of bundle branch block (left = rS or QS wave in leads V1 and V2, delay to S wave nadir < 70 ms, and R wave and no Q wave in lead V6; right = rSR' wave in lead V1 and an RS wave in lead V6, with R wave height greater than S wave depth). Twelve-lead ECGs were done for 102 consecutive patients with broad-complex tachycardia (QRS width > 110 ms). Two observers, who were unaware of definitive diagnoses validated by electrophysiology, by our diagnostic rules made correct diagnosis of ventricular tachycardia in 63 and 62 of 69 patients, respectively, and correct diagnoses of supraventricular tachycardia in 28 and 22 of 33 patients (sensitivity for ventricular tachycardia 90% and 91%, specificity 67% and 85%). One observer then sought independent P waves in cases diagnosed as supraventricular tachycardia; sensitivity for the diagnosis of ventricular tachycardia rose to 96%, with a specificity of 64%. These criteria, which require only knowledge of typical bundle branch block patterns, were highly sensitive for the important diagnosis of ventricular tachycardia.	FREEMAN RD HOSP,NEWCASTLE TYNE,TYNE & WEAR,ENGLAND; ST GEORGE HOSP,LONDON,ENGLAND; GROBY RD HOSP,LEICESTER,W YORKSHIRE,ENGLAND	Newcastle Freeman Hospital; St Georges University London	GRIFFITH, MJ (corresponding author), QUEEN ELIZABETH HOSP,DEPT CARDIAC,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.							BRUGADA P, 1991, CIRCULATION, V83, P1649, DOI 10.1161/01.CIR.83.5.1649; DANCY M, 1985, LANCET, V2, P320; DANCY M, 1985, BRIT MED J, V291, P1036, DOI 10.1136/bmj.291.6501.1036; GRIFFITH MJ, 1992, EUR HEART J, V13, P478, DOI 10.1093/oxfordjournals.eurheartj.a060200; GRIFFITH MJ, 1991, BRIT HEART J, V66, P166; GRIFFITH MJ, 1988, LANCET, V1, P672; KINDWALL KE, 1988, AM J CARDIOL, V61, P1279, DOI 10.1016/0002-9149(88)91169-1; Marriott H. J. L., 1966, PROG CARDIOVASC DIS, V9, P18; MARRIOTT HJ, 1970, GERIATRICS, V25, P91; STEWART RB, 1986, ANN INTERN MED, V104, P766, DOI 10.7326/0003-4819-104-6-766; TCHOU P, 1988, AM J MED, V84, P53, DOI 10.1016/0002-9343(88)90008-3; Wellens H J, 1987, Cardiol Clin, V5, P511	12	72	78	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					386	388		10.1016/S0140-6736(94)91223-8	http://dx.doi.org/10.1016/S0140-6736(94)91223-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905552				2022-12-28	WOS:A1994MW28300009
J	NEILD, GH				NEILD, GH			HEMOLYTIC-UREMIC SYNDROME IN PRACTICE	LANCET			English	Article							HEMOLYTIC-UREMIC SYNDROME; THROMBOTIC THROMBOCYTOPENIC PURPURA; ACUTE RENAL-FAILURE; CLINICAL-EXPERIENCE; ESCHERICHIA-COLI; PLASMA; ACTIVATION; INFECTION; ELASTASE; FEATURES		UNIV COLL HOSP LONDON, INST UROL & NEPHROL, DIV NEPHROL, LONDON, ENGLAND	University College London Hospitals NHS Foundation Trust; University of London; University College London	NEILD, GH (corresponding author), MIDDLESEX HOSP, MORTIMER ST, LONDON W1N 8AA, ENGLAND.							BELL WR, 1991, NEW ENGL J MED, V325, P398, DOI 10.1056/NEJM199108083250605; CIMOLAI N, 1992, PEDIATRICS, V90, P616; EKNOYAN G, 1986, AM J NEPHROL, V6, P117, DOI 10.1159/000167066; FITZPATRICK MM, 1992, PEDIATR NEPHROL, V6, P50, DOI 10.1007/BF00856833; GRIFFIN PM, 1988, ANN INTERN MED, V109, P705, DOI 10.7326/0003-4819-109-9-705; HAKIM RM, 1985, AM J KIDNEY DIS, V5, P170, DOI 10.1016/S0272-6386(85)80046-9; INNIGER R, 1987, 10TH INT C NEPHR LON, P17; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; KOSTER F, 1978, NEW ENGL J MED, V298, P927, DOI 10.1056/NEJM197804272981702; MILFORD DV, 1991, NEPHROL DIAL TRANSPL, V6, P232, DOI 10.1093/ndt/6.4.232; MILFORD DV, 1990, ARCH DIS CHILD, V65, P713, DOI 10.1136/adc.65.7.713; MOAKE JL, 1988, LAB INVEST, V59, P415; MORELMAROGER L, 1979, KIDNEY INT, V15, P548, DOI 10.1038/ki.1979.70; NEILD GH, 1992, OXFORD TXB CLIN NEPH, P1041; NEILD GH, IN PRESS OXFORD TXB; RARICK MU, 1992, AM J HEMATOL, V40, P103, DOI 10.1002/ajh.2830400206; REMUZZI G, 1987, KIDNEY INT, V32, P292, DOI 10.1038/ki.1987.206; RIZZONI G, 1986, HELV PAEDIATR ACTA, V41, P114; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; SCHIEPPATI A, 1992, J AM SOC NEPHROL, V2, P1640; TAYLOR CM, 1986, BRIT MED J, V292, P1513, DOI 10.1136/bmj.292.6534.1513; THOMPSON CE, 1992, BLOOD, V80, P1890; TROMPETER RS, 1983, ARCH DIS CHILD, V58, P101, DOI 10.1136/adc.58.2.101; VANDYCK M, 1988, CLIN NEPHROL, V29, P109; WALTERS MDS, 1988, KIDNEY INT, V33, P107, DOI 10.1038/ki.1988.17	25	81	87	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	1994	343	8894					398	401		10.1016/S0140-6736(94)91228-9	http://dx.doi.org/10.1016/S0140-6736(94)91228-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905557				2022-12-28	WOS:A1994MW28300014
J	BRAIG, HR; GUZMAN, H; TESH, RB; ONEILL, SL				BRAIG, HR; GUZMAN, H; TESH, RB; ONEILL, SL			REPLACEMENT OF THE NATURAL WOLBACHIA SYMBIONT OF DROSOPHILA-SIMULANS WITH A MOSQUITO COUNTERPART	NATURE			English	Article							CYTOPLASMIC INCOMPATIBILITY; REPRODUCTIVE ISOLATION; POPULATIONS	INHERITED rickettsial symbionts of the genus Wolbachia occur commonly in arthropods and have been implicated in the expression of parthenogenesis1,2, feminization2,3 and cytoplasmic incompatibility phenomena in their respective hosts4-7. Here we use purified Wolbachia from the Asian tiger mosquito, Aedes albopictus, to replace the natural infection of Drosophila simulans by means of embryonic microinjection techniques. The transferred Wolbachia infection behaves like a natural Drosophila infection with regard to its inheritance, cytoskeleton interactions and ability to induce incompatibility when crossed with uninfected flies. The trans-infected flies are bidirectionally incompatible with all other naturally infected strains of Drosophila simulans, however, and as such represent a unique crossing type. The successful transfer of this symbiont between distantly related hosts suggests that it may be possible to introduce this agent experimentally into arthropod species of medical and agricultural importance in order to manipulate natural populations genetically.			BRAIG, HR (corresponding author), YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,POB 3333,NEW HAVEN,CT 06510, USA.		Braig, Henk/I-5477-2013; O'Neill, Scott L/B-3568-2009; O'Neill, Scott/R-9560-2019	Braig, Henk/0000-0001-9592-1141; O'Neill, Scott L/0000-0002-4131-3615; O'Neill, Scott/0000-0002-4131-3615				BEARD CB, 1993, PARASITOL TODAY, V9, P179, DOI 10.1016/0169-4758(93)90142-3; BOYLE L, 1993, SCIENCE, V260, P1796, DOI 10.1126/science.8511587; Breeuwer J.A.J., 1992, Insect Molecular Biology, V1, P25, DOI 10.1111/j.1365-2583.1993.tb00074.x; BREEUWER JAJ, 1990, NATURE, V346, P558, DOI 10.1038/346558a0; BREEUWER JAJ, 1993, GENETICS, V135, P565; CURTIS CF, 1992, NATURE, V357, P450, DOI 10.1038/357450b0; HOFFMANN AA, 1986, EVOLUTION, V40, P692, DOI 10.1111/j.1558-5646.1986.tb00531.x; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; HSIAO C, 1985, J INVERTEBR PATHOL, V45, P244, DOI 10.1016/0022-2011(85)90016-3; JOST E, 1970, THEOR APPL GENET, V40, P251, DOI 10.1007/BF00282034; LAVEN H, 1959, COLD SPRING HARB SYM, V24, P166, DOI 10.1101/SQB.1959.024.01.017; MONTCHAMPMOREAU C, 1991, GENETICS, V129, P399; NIGRO L, 1991, HEREDITY, V66, P41, DOI 10.1038/hdy.1991.5; ONEILL SL, 1992, P NATL ACAD SCI USA, V89, P2699, DOI 10.1073/pnas.89.7.2699; ONEILL SL, 1990, NATURE, V348, P178, DOI 10.1038/348178a0; RIGAUD T, 1993, GENETICS, V133, P247; ROUSSET F, 1992, P ROY SOC B-BIOL SCI, V250, P91, DOI 10.1098/rspb.1992.0135; ROUSSET F, 1992, P ROY SOC B-BIOL SCI, V247, P163, DOI 10.1098/rspb.1992.0023; RYAN SL, 1968, MOL GEN GENET, V103, P29, DOI 10.1007/BF00271154; Simon C., 1991, MOL TECHNIQUES TAXON, P329; SOUTHAMER R, 1993, NATURE, V361, P66; TURELLI M, 1991, NATURE, V353, P440, DOI 10.1038/353440a0; WADE MJ, 1985, SCIENCE, V227, P527, DOI 10.1126/science.3966160; YEN JH, 1971, NATURE, V232, P657, DOI 10.1038/232657a0	24	127	143	2	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 3	1994	367	6462					453	455		10.1038/367453a0	http://dx.doi.org/10.1038/367453a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	7906391				2022-12-28	WOS:A1994MU67900052
J	OBRIEN, S; KANTARJIAN, H; ESTEY, E; KOLLER, C; ROBERTSON, B; BERAN, M; ANDREEFF, M; PIERCE, S; KEATING, M				OBRIEN, S; KANTARJIAN, H; ESTEY, E; KOLLER, C; ROBERTSON, B; BERAN, M; ANDREEFF, M; PIERCE, S; KEATING, M			LACK OF EFFECT OF 2-CHLORODEOXYADENOSINE THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA REFRACTORY TO FLUDARABINE THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HAIRY-CELL LEUKEMIA; PLASMA; AGENT	Background. Fludarabine and 2-chlorodeoxyadenosine are nucleoside analogues that have proved effective in patients with chronic lymphocytic leukemia (CLL). Although their mechanism of action is thought to be similar, a small number of patients who do not respond to fludarabine do respond to 2-chlorodeoxyadenosine. The extent to which 2-chlorodeoxyadenosine is effective in patients who do not respond to fludarabine is not known, however. Methods. We treated 28 patients with CLL refractory to fludarabine therapy with a continuous infusion of 2-chlorodeoxyadenosine at a daily dose of 4 mg per square meter of body-surface area for seven days. The treatment could be repeated monthly. The number of treatments ranged from one to five; patients who responded continued to receive treatment until the maximal response was achieved. Results. Two patients (7 percent) had partial remissions, but no patients had complete remissions. One other patient had a substantial response but had residual thrombocytopenia. The rate of response in most affected organs was 20 percent, but anemia or thrombocytopenia rarely improved. Myelosuppression was frequent, and 65 percent of the courses of 2-chlorodeoxyadenosine therapy were accompanied by febrile episodes or infections. Ten patients died within 60 days of starting therapy with 2-chlorodeoxyadenosine; eight deaths were related to infection. The median platelet count at the start of 2-chlorodeoxyadenosine therapy in these 10 patients was 24,000 per cubic millimeter, as compared with 109,000 per cubic millimeter in the other 18 patients. Five patients were alive after a median follow-up of 24 months. Conclusions. Patients with advanced CLL refractory to fludarabine therapy are unlikely to benefit from treatment with 2-chlorodeoxyadenosine. Although 20 percent of the patients have some response, thrombocytopenia and anemia are rarely corrected and may be made worse by 2-chlorodeoxyadenosine therapy.			OBRIEN, S (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,BOX 61,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							CHESON BD, 1988, AM J HEMATOL, V29, P152, DOI 10.1002/ajh.2830290307; DANHAUSER L, 1986, CANCER CHEMOTH PHARM, V18, P145; DELANNOY A, 1993, NEW ENGL J MED, V328, P812; ESTEY EH, 1992, BLOOD, V79, P882; GANDHI V, 1993, LEUKEMIA LYMPHOMA, V10, P49, DOI 10.3109/10428199309147356; JULIUSSON G, 1993, J CLIN ONCOL, V11, P679, DOI 10.1200/JCO.1993.11.4.679; JULIUSSON G, 1992, NEW ENGL J MED, V327, P1056, DOI 10.1056/NEJM199210083271504; KEATING MJ, 1989, BLOOD, V74, P19; LILIEMARK J, 1991, BLOOD S, V78, pA33; LILIEMARK JO, 1985, CANCER RES, V45, P5952; PIRO LD, 1990, NEW ENGL J MED, V322, P1117, DOI 10.1056/NEJM199004193221605; PIRO LD, 1988, BLOOD, V72, P1069; PLUNKETT W, 1993, CHRONIC LYMPHOCYTIC, V1, P197; ROBERTSON LE, 1993, BLOOD, V81, P143; SAVEN A, 1991, LEUKEMIA LYMPHOMA, V5, P133, DOI 10.3109/10428199109103394	15	82	84	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 3	1994	330	5					319	322		10.1056/NEJM199402033300504	http://dx.doi.org/10.1056/NEJM199402033300504			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU489	7904047				2022-12-28	WOS:A1994MU48900004
J	CALLEBAUT, C; KRUST, B; JACOTOT, E; HOVANESSIAN, AG				CALLEBAUT, C; KRUST, B; JACOTOT, E; HOVANESSIAN, AG			T-CELL ACTIVATION ANTIGEN, CD26, AS A COFACTOR FOR ENTRY OF HIV IN CD4+ CELLS	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DIPEPTIDYL PEPTIDASE-IV; PRINCIPAL NEUTRALIZING DETERMINANT; HUMAN LYMPHOCYTES-T; ENVELOPE GLYCOPROTEIN; V3 DOMAIN; MONOCLONAL-ANTIBODIES; CD4-MEDIATED FUSION; SYNTHETIC PEPTIDES; AMINOPEPTIDASE-IV	The CD4 molecule is essential for binding HIV particles, but is not sufficient for efficient viral entry and infection. The cofactor was shown to be dipeptidyl peptidase IV (DPP IV), also known as CD26. This serine protease cleaves its substrates at specific motifs; such motifs are also highly conserved in the V3 loops of HIV-1, HIV-2, and related simian isolates. Entry of HIV-1 or HIV-2 into T lymphoblastoid and monocytoid cell lines was inhibited by a specific monoclonal antibody against DPP IV or specific peptide inhibitors of this protease. Co-expression of human CD4 and CD26 in murine NIH 3T3 cells rendered them permissive to infection by HIV-1 and HIV-2. These observations could provide the basis for developing simple and specific inhibitors of HIV and open a possibility for vaccine development.	INST PASTEUR, CNRS, UA 1157, UNITE VIROL & IMMUNOL CELLULAIRE, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				/0000-0002-5301-1569				ARDMAN B, 1990, J ACQ IMMUN DEF SYND, V3, P206; ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; Barclay A.N., 1993, LEUCOCYTE ANTIGEN FA; BARNETT SW, 1993, J VIROL, V67, P1006, DOI 10.1128/JVI.67.2.1006-1014.1993; BAUVOIS B, 1988, BIOCHEM J, V252, P723, DOI 10.1042/bj2520723; BAUVOIS B, 1992, EUR J IMMUNOL, V22, P923, DOI 10.1002/eji.1830220407; BAUVOIS B, 1991, LYMPHATIC TISSUES IN; BLAZQUEZ MV, 1992, J IMMUNOL, V149, P3073; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; Brown A J, 1991, AIDS, V5 Suppl 2, pS35, DOI 10.1097/00002030-199101001-00005; CHESEBRO B, 1992, J VIROL, V66, P6547, DOI 10.1128/JVI.66.11.6547-6554.1992; CHOU SH, 1992, AIDS RES HUM RETROV, V8, P1611, DOI 10.1089/aid.1992.8.1611; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; CLEMENTS GJ, 1991, AIDS RES HUM RETROV, V7, P3, DOI 10.1089/aid.1991.7.3; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DANG NH, 1990, J IMMUNOL, V145, P3963; DEJONG JJ, 1992, J VIROL, V66, P6777, DOI 10.1128/JVI.66.11.6777-6780.1992; DEMEESTER I, 1992, CLIN CHIM ACTA, V210, P23, DOI 10.1016/0009-8981(92)90042-O; DEPASQUALE A, 1989, ACTA HAEMATOL-BASEL, V81, P19; DEROSSI A, 1991, VIROLOGY, V184, P187; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; EBENBICHLER CF, 1993, AIDS, V7, P489, DOI 10.1097/00002030-199304000-00006; EIDEN LE, 1992, IMMUNOL TODAY, V13, P201, DOI 10.1016/0167-5699(92)90154-Y; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; GOWDA SD, 1989, J IMMUNOL, V142, P773; GRIMAILA RJ, 1992, J VIROL, V66, P1875, DOI 10.1128/JVI.66.4.1875-1883.1992; HAFLER DA, 1989, J IMMUNOL, V142, P2590; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; HATTORI T, 1989, FEBS LETT, V248, P48, DOI 10.1016/0014-5793(89)80429-6; HEGEN M, 1990, J IMMUNOL, V144, P2908; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; HENDERSON LA, 1993, J BIOL CHEM, V268, P15291; HOLMBACK K, 1993, J VIROL, V67, P1612; HOVANESSIAN AG, 1987, EMBO J, V6, P1273, DOI 10.1002/j.1460-2075.1987.tb02364.x; KAMEOKA J, 1993, SCIENCE, V261, P466, DOI 10.1126/science.8101391; KENNY AJ, 1976, BIOCHEM J, V157, P169, DOI 10.1042/bj1570169; KIDO H, 1991, FEBS LETT, V286, P233, DOI 10.1016/0014-5793(91)80981-8; KIDO H, 1988, J BIOL CHEM, V263, P18104; KINNEYTHOMAS E, 1988, AIDS, V2, P25; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Koito A, 1989, Int Immunol, V1, P613, DOI 10.1093/intimm/1.6.613; KREUTZ R, 1992, AIDS RES HUM RETROV, V8, P1619, DOI 10.1089/aid.1992.8.1619; KUDO M, 1985, J BIOCHEM, V97, P1211, DOI 10.1093/oxfordjournals.jbchem.a135166; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LAURENTCRAWFORD AG, 1993, AIDS RES HUM RETROV, V9, P761, DOI 10.1089/aid.1993.9.761; LINSLEY PS, 1988, J VIROL, V62, P3695, DOI 10.1128/JVI.62.10.3695-3702.1988; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MASUDA T, 1990, J IMMUNOL, V145, P3240; MATTERN T, 1991, SCAND J IMMUNOL, V33, P737, DOI 10.1111/j.1365-3083.1991.tb02548.x; MCKEATING JA, 1992, VIROLOGY, V191, P732, DOI 10.1016/0042-6822(92)90249-O; MILICH L, 1993, J VIROL, V67, P5623, DOI 10.1128/JVI.67.9.5623-5634.1993; MORIMOTO C, 1989, J IMMUNOL, V143, P3430; MORRISON ME, 1993, J EXP MED, V177, P1135, DOI 10.1084/jem.177.4.1135; MUNOZ E, 1992, IMMUNOLOGY, V77, P43; MYERS G, 1992, HUMAN RETROVIRUSES A; NEHETE PN, 1993, J VIROL, V67, P6841, DOI 10.1128/JVI.67.11.6841-6846.1993; PAGE KA, 1992, J VIROL, V66, P524, DOI 10.1128/JVI.66.1.524-533.1992; PARDI R, 1992, IMMUNOL TODAY, V13, P224, DOI 10.1016/0167-5699(92)90159-5; QURESHI NM, 1990, AIDS, V4, P553, DOI 10.1097/00002030-199006000-00009; RAO PE, 1983, CELL IMMUNOL, V80, P310, DOI 10.1016/0008-8749(83)90119-3; REY MA, 1989, VIROLOGY, V173, P258, DOI 10.1016/0042-6822(89)90242-0; REYCUILLE MA, UNPUB; REYCUILLE MA, IN PRESS; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SCHON E, 1987, EUR J IMMUNOL, V17, P1821, DOI 10.1002/eji.1830171222; SCHON E, 1989, SCAND J IMMUNOL, V29, P127, DOI 10.1111/j.1365-3083.1989.tb01108.x; STEPHENS PE, 1990, NATURE, V343, P219, DOI 10.1038/343219b0; TANAKA T, 1993, P NATL ACAD SCI USA, V90, P4586, DOI 10.1073/pnas.90.10.4586; TANAKA T, 1992, J IMMUNOL, V149, P481; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; TORIMOTO Y, 1991, J IMMUNOL, V147, P2514; UMEZAWA H, 1984, J ANTIBIOT, V37, P422, DOI 10.7164/antibiotics.37.422; VANHAM G, 1993, J ACQ IMMUN DEF SYND, V6, P749; WEINER DB, 1991, PATHOBIOLOGY, V59, P361, DOI 10.1159/000163679; WEISS RA, 1992, SCIENCE CHALLENGING AIDS, P107; WERNER A, 1993, J VIROL, V67, P2566, DOI 10.1128/JVI.67.5.2566-2574.1993; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	79	234	241	2	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1993	262	5142					2045	2050		10.1126/science.7903479	http://dx.doi.org/10.1126/science.7903479			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	7903479				2022-12-28	WOS:A1993MN10800042
J	RAUTONEN, J; MAKELA, A; BOYD, H; APAJASALO, M; POHJAVUORI, M				RAUTONEN, J; MAKELA, A; BOYD, H; APAJASALO, M; POHJAVUORI, M			CRIB AND SNAP - ASSESSING THE RISK OF DEATH FOR PRETERM NEONATES	LANCET			English	Article								The performance of three scoring systems for assessing mortality risk for neonates-clinical risk index for babies (CRIB), score for neonatal acute physiology (SNAP), and SNAP's perinatal extension (SNAP-PE)-were tested in the same set of patients. In 222 neonates weighing less than 1500 g at birth, CRIB scores were significantly better for assessing mortality risk than SNAP (p=0.017) or SNAP-PE (p<0.001), areas under receiver operating characteristic curves being 0.89 (SE 0.02), 0.82 (0.03), and 0.79 (0.03), respectively. Male sex was independently associated with poor prognosis after ta king the CRIB score into account with a risk ratio of 2.75. We conclude that CRIB is the most useful score for comparing the performance of neonatal intensive-care units. New treatment methods, however, may require modifications to the system.			RAUTONEN, J (corresponding author), UNIV HELSINKI,CHILDRENS HOSP,STENBACKINKATU,SF-00290 HELSINKI,FINLAND.							BARD H, 1993, LANCET, V342, P449, DOI 10.1016/0140-6736(93)91587-C; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HORBAR JD, 1993, CRIT CARE MED, V21, P12, DOI 10.1097/00003246-199301000-00008; RICHARDSON DK, 1993, PEDIATRICS, V91, P969; RICHARDSON DK, 1993, PEDIATRICS, V91, P617; SCHWARTZ LS, 1991, GEN HOSP PSYCHIAT, V13, P19, DOI 10.1016/0163-8343(91)90005-H; 1993, LANCET, V342, P193	8	65	68	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1272	1273		10.1016/S0140-6736(94)92158-X	http://dx.doi.org/10.1016/S0140-6736(94)92158-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910282				2022-12-28	WOS:A1994NM14400016
J	BOLSHAKOV, VY; SIEGELBAUM, SA				BOLSHAKOV, VY; SIEGELBAUM, SA			POSTSYNAPTIC INDUCTION AND PRESYNAPTIC EXPRESSION OF HIPPOCAMPAL LONG-TERM DEPRESSION	SCIENCE			English	Article							RAT VISUAL-CORTEX; CALCIUM CHANNELS; AREA CA1; NITRIC-OXIDE; POTENTIATION; ENHANCEMENT; INVOLVEMENT; RECEPTORS; BLOCKADE; SLICES	Long-term depression (LTD) is an activity-dependent decrease in synaptic efficacy that together with its counterpart, long-term potentiation, is thought to be an important cellular mechanism for learning and memory in the mammalian brain. The induction of LTD in hippocampal CA1 pyramidal neurons in neonatal rats is shown to depend on postsynaptic calcium ion entry through L-type voltage-gated calcium channels paired with the activation of metabotropic glutamate receptors. Although induced postsynaptically, LTD is due to a long-term decrease in transmitter release from presynaptic terminals. This suggests that LTD is likely to require the production of a retrograde messenger.			BOLSHAKOV, VY (corresponding author), COLUMBIA UNIV,HOWARD HUGHES MED INST,CTR NEUROBIOL & BEHAV,DEPT PHARMACOL,NEW YORK,NY 10032, USA.							ABRAHAM WC, 1991, BRAIN RES, V546, P336, DOI 10.1016/0006-8993(91)91498-P; ARONIADOU VA, 1991, BRAIN RES, V562, P136, DOI 10.1016/0006-8993(91)91197-9; ARTOLA A, 1990, NATURE, V347, P69, DOI 10.1038/347069a0; BASHIR ZI, 1993, EUR J PHARMACOL, V239, P265, DOI 10.1016/0014-2999(93)91009-C; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BOLSHAKOV VY, UNPUB; CHRISTIE BR, 1992, SYNAPSE, V10, P1, DOI 10.1002/syn.890100102; DANIEL H, 1992, EXP BRAIN RES, V90, P327; Davies C. H., 1993, Society for Neuroscience Abstracts, V19, P276; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; DUDEK SM, 1993, J NEUROSCI, V13, P2910; EATON SA, 1993, EUR J PHARM-MOLEC PH, V244, P195, DOI 10.1016/0922-4106(93)90028-8; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; ELLIOT LS, 1993, NATURE, V361, P634; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; IZUMI Y, 1993, NEUROREPORT, V4, P1131; KATO N, 1993, P NATL ACAD SCI USA, V90, P3650, DOI 10.1073/pnas.90.8.3650; Kimura F, 1990, Neuroreport, V1, P65, DOI 10.1097/00001756-199009000-00018; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; MALENKA RC, 1993, P NATL ACAD SCI USA, V90, P3121, DOI 10.1073/pnas.90.8.3121; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; MORAD M, 1988, SCIENCE, V241, P842, DOI 10.1126/science.2457253; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; SAKURAI M, 1990, P NATL ACAD SCI USA, V87, P3383, DOI 10.1073/pnas.87.9.3383; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; STANTON PK, 1989, NATURE, V339, P215, DOI 10.1038/339215a0; STANTON PK, 1991, NEUROSCI LETT, V127, P61, DOI 10.1016/0304-3940(91)90895-Z; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; WICKENS JR, 1991, NEUROSCI LETT, V130, P128, DOI 10.1016/0304-3940(91)90244-N; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	40	414	424	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 20	1994	264	5162					1148	1152		10.1126/science.7909958	http://dx.doi.org/10.1126/science.7909958			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM146	7909958				2022-12-28	WOS:A1994NM14600033
J	JONGBLOETS, LMM; LENSING, AWA; KOOPMAN, MMW; BULLER, HR; TENCATE, JW				JONGBLOETS, LMM; LENSING, AWA; KOOPMAN, MMW; BULLER, HR; TENCATE, JW			LIMITATIONS OF COMPRESSION ULTRASOUND FOR THE DETECTION OF SYMPTOMLESS POSTOPERATIVE DEEP-VEIN THROMBOSIS	LANCET			English	Article							MOLECULAR-WEIGHT HEPARIN; ELECTIVE HIP-SURGERY; COLOR DOPPLER ULTRASOUND; B-MODE ULTRASONOGRAPHY; VENOUS THROMBOSIS; ROENTGENOGRAPHIC PHLEBOGRAPHY; IMPEDANCE PLETHYSMOGRAPHY; DIAGNOSIS; VENOGRAPHY; TIME	Compression ultrasonography is regarded as the non-invasive gold-standard to detect deep vein thrombosis (DVT) in patients presenting with symptoms. However, its use as a screening method in symptom-free postoperative patients at high risk of developing DVT remains controversial. In 100 consecutive patients who had undergone craniotomy, we compared the results of bilateral compression ultrasonic measurements of the entire legs with the outcomes of contrast venography. Proximal DVT was detected in 13 patients, 5 of whom also had an abnormal ultrasonic result (sensitivity 38%, 95% CI 8-69%). Only 5 of the 9 patients with an abnormal ultrasound result for the proximal veins had proximal DVT (positive predictive value, 56%, 18-94%). Calf sonograms were evaluable in 71 of the 91 patients with bilaterally normal ultrasound results for the proximal veins. Of the 16 patients with calf DVT, ultrasound was abnormal in 8 (sensitivity 50%, 25-75%). Overall, ultrasound detected 13 of the 26 patients with proximal or isolated calf DVT (sensitivity 50%, 29-71%). The positive predictive value for the whole leg examination was 41% (24-60%). Most thrombi missed by ultrasound were non-occlusive and smaller than 5 cm. We conclude that compression ultrasound is not useful for screening for DVT in symptom-free postoperative high-risk patients.	UNIV AMSTERDAM, ACAD MED CTR, DEPT NEUROL & NEUROSURG, 1105 AZ AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, ACAD MED CTR, CTR HEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & I, 1105 AZ AMSTERDAM, NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam								AGNELLI G, 1991, THROMB HAEMOSTASIS, V65, P1728; APPELMAN PT, 1987, RADIOLOGY, V163, P743, DOI 10.1148/radiology.163.3.3554343; BARNES RW, 1989, J VASC SURG, V9, P251, DOI 10.1067/mva.1989.vs0090251; BAXTER GM, 1990, CLIN RADIOL, V42, P32, DOI 10.1016/S0009-9260(05)81618-6; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; Borris L C, 1990, Eur J Vasc Surg, V4, P473, DOI 10.1016/S0950-821X(05)80786-8; BORRIS LC, 1989, THROMB HAEMOSTASIS, V61, P363; COMEROTA AJ, 1990, J VASC SURG, V11, P53, DOI 10.1067/mva.1990.16342; CRUICKSHANK MK, 1989, THROMB HAEMOSTASIS, V62, P830; DAVIDSON BL, 1992, ANN INTERN MED, V117, P735, DOI 10.7326/0003-4819-117-9-735; DORFMAN GS, 1990, AM J ROENTGENOL, V154, P851, DOI 10.2214/ajr.154.4.2107688; FRANCIS CW, 1983, JAMA-J AM MED ASSOC, V249, P374, DOI 10.1001/jama.249.3.374; FROEHLICH JA, 1989, J BONE JOINT SURG AM, V71A, P249, DOI 10.2106/00004623-198971020-00012; GINSBERG JS, 1991, RADIOLOGY, V181, P651, DOI 10.1148/radiology.181.3.1947076; HARRIS WH, 1976, J BONE JOINT SURG AM, V58, P939, DOI 10.2106/00004623-197658070-00008; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HIRSH J, 1988, BR J CLIN PRACT S43, V65, P2; JONGBLOETS LMM, 1992, THROMB RES S, V65, pC87; LENSING AWA, 1990, RADIOLOGY, V177, P503, DOI 10.1148/radiology.177.2.2217792; LENSING AWA, 1992, THROMB HAEMOSTASIS, V67, P8; LENSING AWA, 1993, THROMB HAEMOSTASIS, V69, P2; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LENSING AWA, 1994, HEMOSTASIS THROMBOSI, P1297; LEVINE MN, 1991, ANN INTERN MED, V114, P545, DOI 10.7326/0003-4819-114-7-545; LEYVRAZ PF, 1983, NEW ENGL J MED, V309, P954, DOI 10.1056/NEJM198310203091605; MATTOS MA, 1992, J VASC SURG, V15, P366, DOI 10.1016/0741-5214(92)90258-A; MOSER KM, 1981, ANN INTERN MED, V94, P439, DOI 10.7326/0003-4819-94-4-439; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; PAIEMENT G, 1988, AM J SURG, V155, P400, DOI 10.1016/S0002-9610(88)80099-0; POLAK JF, 1989, RADIOLOGY, V171, P481, DOI 10.1148/radiology.171.2.2649923; RAGHAVENDRA BN, 1984, RADIOLOGY, V152, P789, DOI 10.1148/radiology.152.3.6463262; ROSE SC, 1990, RADIOLOGY, V175, P639, DOI 10.1148/radiology.175.3.2188293; SAUTTER RD, 1979, ARCH INTERN MED, V139, P148, DOI 10.1001/archinte.139.2.148; TURPIE AGG, 1986, NEW ENGL J MED, V315, P925, DOI 10.1056/NEJM198610093151503; WOOLSON ST, 1990, J BONE JOINT SURG AM, V72A, P983, DOI 10.2106/00004623-199072070-00004; YUCEL EK, 1991, RADIOLOGY, V179, P443, DOI 10.1148/radiology.179.2.2014289	36	87	89	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 7	1994	343	8906					1142	1144		10.1016/S0140-6736(94)90240-2	http://dx.doi.org/10.1016/S0140-6736(94)90240-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK730	7910237				2022-12-28	WOS:A1994NK73000014
J	DONDERO, TJ; CURRAN, JW				DONDERO, TJ; CURRAN, JW			EXCESS DEATHS IN AFRICA FROM HIV - CONFIRMED AND QUANTIFIED	LANCET			English	Editorial Material							IVORY-COAST; ABIDJAN		CTR DIS CONTROL & PREVENT,OFF DIRECTOR,ATLANTA,GA	Centers for Disease Control & Prevention - USA	DONDERO, TJ (corresponding author), CTR DIS CONTROL & PREVENT,CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30341, USA.							DECOCK KM, 1991, AIDS, V5, P393, DOI 10.1097/00002030-199104000-00006; DECOCK KM, 1989, LANCET, V2, P408; RICHARDS SB, IN PRESS TUBERCULE L	3	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 23	1994	343	8904					989	990		10.1016/S0140-6736(94)90120-1	http://dx.doi.org/10.1016/S0140-6736(94)90120-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909087				2022-12-28	WOS:A1994NG68200003
J	GARRUTO, RM; BROWN, P				GARRUTO, RM; BROWN, P			TAU-PROTEIN, ALUMINUM, AND ALZHEIMERS-DISEASE	LANCET			English	Editorial Material											GARRUTO, RM (corresponding author), NIH,CENT NERVOUS SYST STUDIES LAB,BETHESDA,MD 20892, USA.							ABDELGHANY M, 1993, J BIOL CHEM, V268, P11976; EXLEY C, 1993, FEBS LETT, V324, P293, DOI 10.1016/0014-5793(93)80137-J; GARRUTO RM, 1991, NEUROTOXICOLOGY, V12, P347; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GUIROY DC, 1987, P NATL ACAD SCI USA, V84, P2073, DOI 10.1073/pnas.84.7.2073; HARRINGTON CR, 1991, P NATL ACAD SCI USA, V88, P5842, DOI 10.1073/pnas.88.13.5842; KAWAHARA M, 1994, BIOCHEM BIOPH RES CO, V198, P531, DOI 10.1006/bbrc.1994.1078; KAWAHARA M, 1992, BIOCHEM BIOPH RES CO, V189, P1317, DOI 10.1016/0006-291X(92)90217-9; MANTYH PW, 1993, J NEUROCHEM, V61, P1171, DOI 10.1111/j.1471-4159.1993.tb03639.x; MESCO ER, 1991, MOL CHEM NEUROPATHOL, V14, P199, DOI 10.1007/BF03159936; MUKAETOVALADINSKA EB, 1993, AM J PATHOL, V143, P565; SCOTT CW, 1993, BRAIN RES, V628, P77, DOI 10.1016/0006-8993(93)90940-O; SHIGEMATSU K, 1992, BRAIN RES, V593, P117, DOI 10.1016/0006-8993(92)91272-G	13	13	13	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 23	1994	343	8904					989	989		10.1016/S0140-6736(94)90119-8	http://dx.doi.org/10.1016/S0140-6736(94)90119-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909086				2022-12-28	WOS:A1994NG68200002
J	GOODALE, MA				GOODALE, MA			PERCEIVING THE WORLD AND GRASPING IT - IS THERE A DIFFERENCE	LANCET			English	Editorial Material							OPTIC ATAXIA; PERCEPTION; OBJECTS		UNIV WESTERN ONTARIO,GRAD PROGRAM NEUROSCI,LONDON N6A 3K7,ONTARIO,CANADA	Western University (University of Western Ontario)	GOODALE, MA (corresponding author), UNIV WESTERN ONTARIO,DEPT PSYCHOL,LONDON N6A 3K7,ONTARIO,CANADA.		Goodale, Melvyn A/M-5907-2013	Goodale, Melvyn A/0000-0001-6748-0561				BRIDGEMAN B, 1981, PERCEPT PSYCHOPHYS, V34, P149; BRIDGEMAN B, IN PRESS BEHAV BRAIN; Goodale M. A, 1988, COMPUTATIONAL PROCES, P262; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; GOODALE MA, 1991, NATURE, V349, P154, DOI 10.1038/349154a0; JAKOBSON LS, 1991, NEUROPSYCHOLOGIA, V29, P803, DOI 10.1016/0028-3932(91)90073-H; MILNER AD, 1991, BRAIN, V114, P405, DOI 10.1093/brain/114.1.405; PERENIN MT, 1988, BRAIN, V111, P643, DOI 10.1093/brain/111.3.643; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549	9	2	2	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					930	931		10.1016/S0140-6736(94)90061-2	http://dx.doi.org/10.1016/S0140-6736(94)90061-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NF700	7909006				2022-12-28	WOS:A1994NF70000005
J	KHAW, KT				KHAW, KT			GENETICS AND ENVIRONMENT - ROSE,GEOFFREY REVISITED	LANCET			English	Editorial Material							INDIVIDUALS				KHAW, KT (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,CLIN GERONTOL UNIT,CAMBRIDGE CB2 2QQ,ENGLAND.		Khaw, Kay-Tee/AAZ-3209-2021					DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; DOLL R, 1954, BMJ-BRIT MED J, V1, P1451, DOI 10.1136/bmj.1.4877.1451; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; ROSE G, 1990, BRIT MED J, V301, P1031, DOI 10.1136/bmj.301.6759.1031; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Rose G., 1992, STRATEGY PREVENTIVE; Stamler J, 1992, CORONARY HEART DIS E, P35; WOODHOUSE PR, 1993, J HYPERTENS, V11, P1267; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1	9	16	16	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					838	839		10.1016/S0140-6736(94)92031-1	http://dx.doi.org/10.1016/S0140-6736(94)92031-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908083				2022-12-28	WOS:A1994ND79200014
J	TAYLOR, CJ				TAYLOR, CJ			COLONIC STRICTURES IN CYSTIC-FIBROSIS	LANCET			English	Editorial Material											TAYLOR, CJ (corresponding author), UNIV SHEFFIELD,DEPT PAEDIAT,SHEFFIELD,ENGLAND.							BAXTER PS, 1988, ARCH DIS CHILD, V63, P1496, DOI 10.1136/adc.63.12.1496; HEIJERMAN HG, 1991, ANN INTERN MED, V114, P200, DOI 10.7326/0003-4819-114-3-200; SMYTH RL, 1994, LANCET, V343, P85, DOI 10.1016/S0140-6736(94)90817-6; 1994, LANCET, V343, P109; 1994, LANCET, V343, P599	5	32	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 12	1994	343	8898					615	616		10.1016/S0140-6736(94)92629-8	http://dx.doi.org/10.1016/S0140-6736(94)92629-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906805				2022-12-28	WOS:A1994NA09300002
J	ROBERTS, WM; RIVERA, GK; RAIMONDI, SC; SANTANA, VM; SANDLUND, JT; CRIST, WM; PUI, CH				ROBERTS, WM; RIVERA, GK; RAIMONDI, SC; SANTANA, VM; SANDLUND, JT; CRIST, WM; PUI, CH			INTENSIVE CHEMOTHERAPY FOR PHILADELPHIA-CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA	LANCET			English	Note							LEUKEMIA	Childhood acute lymphoblastic leukaemia with the classic Philadelphia chromosome translocation is fatal in patients treated with chemotherapy alone. We report probable cures in three adolescents and one child who received extensively reinforced, early chemotherapy followed by rotational treatment with pairs of non-cross-resistant drugs. The median duration of leukaemia-free survival in this subgroup is 6.5 years (range 6-8 years). The two patients with long-term bone marrow surveillance for residual disease showed no evidence of the Philadelphia chromosome at 31 and 53 months post-remission. Such intensive chemotherapy is a reasonable option for patients who are not able to undergo bone marrow transplantation.	ST JUDE CHILDRENS RES HOSP, DEPT PATHOL & LAB MED, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PATHOL, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	ROBERTS, WM (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, 332 N LAUDERDALE, POB 318, MEMPHIS, TN 38101 USA.		Raimondi, Susana C/N-8166-2018; Pui, Ching-Hon/N-8076-2018	Pui, Ching-Hon/0000-0003-0303-5658	NATIONAL CANCER INSTITUTE [P01CA020180, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA20180, P30 CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETT AJ, 1992, BLOOD, V79, P3067; CRIST W, 1990, BLOOD, V76, P489; DOW LW, 1989, BLOOD, V73, P1291; FLETCHER JA, 1992, LEUKEMIA LYMPHOMA, V8, P75, DOI 10.3109/10428199209049820; MIYAMURA K, 1993, BLOOD, V81, P1089; PRIEST JR, 1980, BLOOD, V56, P15; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; RIBEIRO RC, 1993, HEMATOL PATHOL, V7, P121; RIBEIRO RC, 1987, BLOOD, V70, P948; RIVERA GK, 1991, LANCET, V337, P61, DOI 10.1016/0140-6736(91)90733-6; SURYANARAYAN K, 1991, BLOOD, V77, P324	11	48	48	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 5	1994	343	8893					331	332		10.1016/S0140-6736(94)91166-5	http://dx.doi.org/10.1016/S0140-6736(94)91166-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905148				2022-12-28	WOS:A1994MU98500012
J	CLAES, G; DROTT, C				CLAES, G; DROTT, C			HYPERHIDROSIS	LANCET			English	Editorial Material											CLAES, G (corresponding author), BORAS HOSP,DEPT SURG,BORAS,SWEDEN.							BYRNE J, 1990, BRIT J SURG, V77, P1046, DOI 10.1002/bjs.1800770931; CLAES G, 1993, SCAND J PLAST RECONS, V27, P29, DOI 10.3109/02844319309080288; EDMONDSON RA, 1992, ANN SURG, V215, P289, DOI 10.1097/00000658-199203000-00015; Hughes J, 1942, Proc R Soc Med, V35, P585; Kotzareff A, 1920, REV MED SUISSE ROM, V40, P111; KUX E, 1954, THORAKOSKOPISCHE EIN	6	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					247	248		10.1016/S0140-6736(94)91105-3	http://dx.doi.org/10.1016/S0140-6736(94)91105-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905089				2022-12-28	WOS:A1994MT44000003
J	ROLLES, K; BURROUGHS, AK; DAVIDSON, BR; KARATAPANIS, S; PRENTICE, HG; HAMON, MD				ROLLES, K; BURROUGHS, AK; DAVIDSON, BR; KARATAPANIS, S; PRENTICE, HG; HAMON, MD			DONOR-SPECIFIC BONE-MARROW INFUSION AFTER ORTHOTOPIC LIVER-TRANSPLANTATION	LANCET			English	Note							SURVIVAL	Donor-specific bone marrow infusion after organ grafting can induce tolerance in animals. In this randomised controlled study we show it has no benefit in patients undergoing liver transplantation. Of 25 patients, 9 received bone marrow 5 days after a 10 day course of antithymocyte globulin. Immunosuppression was maintained with cyclosporin only. An average of 30 rejection episodes per patient was seen in the bone marrow group compared to 31 in the controls. Chimerism was not found in peripheral blood or bone marrow of recipients using erythrocyte antigen markers, PCR for donor class II DNA or Y-probe in-situ hybridisation in one female recipient of male liver and bone marrow.			ROLLES, K (corresponding author), UNIV LONDON,ROYAL FREE HOSP,DEPT SURG,POND ST,LONDON NW3 2QG,ENGLAND.		Burroughs, Andrew K/C-5645-2009	Burroughs, Andrew K/0000-0001-6527-457X				BARBER WH, 1991, TRANSPLANTATION, V51, P70, DOI 10.1097/00007890-199101000-00011; CARIDIS DT, 1973, TRANSPLANT P, V5, P671; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; THOMAS FT, 1983, ANN SURG, V198, P370, DOI 10.1097/00000658-198309000-00013; WOOD ML, 1971, TRANSPLANT P, V3, P676	5	55	55	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					263	265		10.1016/S0140-6736(94)91113-4	http://dx.doi.org/10.1016/S0140-6736(94)91113-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905097				2022-12-28	WOS:A1994MT44000011
J	KAUR, SR; HERXHEIMER, A				KAUR, SR; HERXHEIMER, A			RECOGNIZING PATIENTS RIGHTS - PATCHY PROGRESS	LANCET			English	Editorial Material									NHS,RES & DEV PROGRAM,UK COCHRANE CTR,OXFORD,ENGLAND	Cochrane Centre; Oxford University Hospitals NHS Foundation Trust	KAUR, SR (corresponding author), INT ORG CONSUMERS UNIONS,REG OFF ASIA & PACIFIC,GEORGE TOWN,MALAYSIA.								0	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 15	1994	343	8890					132	132		10.1016/S0140-6736(94)90930-X	http://dx.doi.org/10.1016/S0140-6736(94)90930-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7904000				2022-12-28	WOS:A1994MQ86900006
J	MACPHERSON, AJS; KHOO, UY; BJARNASON, I				MACPHERSON, AJS; KHOO, UY; BJARNASON, I			INFLAMMATORY BOWEL-DISEASE OF MICE - AND MEN	LANCET			English	Editorial Material							CYTOKINE PRODUCTION				MACPHERSON, AJS (corresponding author), UNIV LONDON KINGS COLL, SCH MED, DEPT MED, LONDON WC2R 2LS, ENGLAND.							FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; MACDERMOTT RP, 1988, ADV IMMUNOL, V42, P285, DOI 10.1016/S0065-2776(08)60848-2; MOMBAERTS P, 1993, CELL, V75, P275, DOI 10.1016/0092-8674(93)80069-Q; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5	8	6	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	1994	343	8890					130	131		10.1016/S0140-6736(94)90928-8	http://dx.doi.org/10.1016/S0140-6736(94)90928-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7903998				2022-12-28	WOS:A1994MQ86900004
J	LI, XL; NOLL, M				LI, XL; NOLL, M			EVOLUTION OF DISTINCT DEVELOPMENTAL FUNCTIONS OF 3 DROSOPHILA GENES BY ACQUISITION OF DIFFERENT CIS-REGULATORY REGIONS	NATURE			English	Article							SEGMENT POLARITY GENES; EVEN-SKIPPED PROTEIN; INT-1 PROTOONCOGENE; SPATIAL EXPRESSION; PAIRED GENE; POX-NEURO; EMBRYOS; PATTERN; DNA; EMBRYOGENESIS	IT is generally accepted that the specific function of a gene depends on its coding sequence. The three paired-box and homeobox genes paired (prd), gooseberry (gsb) and gooseberry neuro (gsbn) have distinct developmental functions in Drosophila embryogenesis1-5. During the syncytial blastoderm stage, the pair-rule gene prd4,6 activates segment-polarity genes, such as gsb7, wingless (wg), and engrailed (en), in segmentally repeated stripes8. After germ-band extension, gsb maintains the expression of wg, which in turn specifies the denticle pattern by repressing a default state of ubiquitous denticle formation in the ventral epidermis9. In addition, gsb activates gsbn5, which is expressed mainly in the central nervous system2,3, suggesting that gsbn is involved in neural development. Here we show that, despite the functional difference and the considerably diverged coding sequence of these genes, their proteins have conserved the same function. The finding that the essential difference between genes may reside in their cis-regulatory regions exemplifies an important evolutionary mechanism of how function diversifies after gene duplication.			LI, XL (corresponding author), UNIV ZURICH,INST MOLEC BIOL 2,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND.							BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BOPP D, 1989, EMBO J, V8, P3447, DOI 10.1002/j.1460-2075.1989.tb08509.x; COTE S, 1987, EMBO J, V6, P2793, DOI 10.1002/j.1460-2075.1987.tb02575.x; DAMBLYCHAUDIERE C, 1992, CELL, V69, P159, DOI 10.1016/0092-8674(92)90127-X; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; GUTJAHR T, 1993, DEVELOPMENT, V117, P609; GUTJAHR T, 1993, DEVELOPMENT, V118, P21; HIDALGO A, 1991, MECH DEVELOP, V35, P77, DOI 10.1016/0925-4773(91)90059-F; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; ISHHOROWICZ D, 1987, CELL, V51, P405, DOI 10.1016/0092-8674(87)90636-2; JACOB F, 1977, SCIENCE, V196, P1161, DOI 10.1126/science.860134; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KILCHHERR F, 1986, NATURE, V321, P493, DOI 10.1038/321493a0; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; LI XL, 1993, EMBO J, V12, P4499, DOI 10.1002/j.1460-2075.1993.tb06139.x; LI XL, 1993, EMBO J, V12, P1427, DOI 10.1002/j.1460-2075.1993.tb05786.x; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; MANOUKIAN AS, 1993, DEVELOPMENT, V118, P785; MANOUKIAN AS, 1992, GENE DEV, V6, P1740, DOI 10.1101/gad.6.9.1740; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MORRISSEY D, 1991, GENE DEV, V5, P1684, DOI 10.1101/gad.5.9.1684; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STRUHL G, 1985, NATURE, V318, P677, DOI 10.1038/318677a0; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; Wieschaus E., 1986, P199	36	123	129	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 6	1994	367	6458					83	87		10.1038/367083a0	http://dx.doi.org/10.1038/367083a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP865	7906390				2022-12-28	WOS:A1994MP86500065
J	CHILD, J				CHILD, J			BATS IN MY BELFRY	LANCET			English	Editorial Material											CHILD, J (corresponding author), DUDLEY RD GEN HOSP,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND.							AJELLO L, 1962, AM J TROP MED HYG, V11, P249, DOI 10.4269/ajtmh.1962.11.249; KING AA, 1993, J COMP PATHOL, V108, P1, DOI 10.1016/S0021-9975(08)80224-1; KLITE PD, 1965, AM J TROP MED HYG, V14, P433, DOI 10.4269/ajtmh.1965.14.433; LAFON M, 1986, LANCET, V2, P515; MEREDITH C D, 1971, South African Medical Journal, V45, P767; TAYLOR RL, 1962, AM J TROP MED HYG, V11, P790, DOI 10.4269/ajtmh.1962.11.790; 1990, RABIES B EUR, V14	7	4	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					5	6		10.1016/S0140-6736(94)90870-2	http://dx.doi.org/10.1016/S0140-6736(94)90870-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905056				2022-12-28	WOS:A1994MN93700006
J	SCHLITT, HJ; HUNDRIESER, J; HISANAGA, M; UTHOFF, K; KARCK, M; WAHLERS, T; WONIGEIT, K; PICHLMAYR, R				SCHLITT, HJ; HUNDRIESER, J; HISANAGA, M; UTHOFF, K; KARCK, M; WAHLERS, T; WONIGEIT, K; PICHLMAYR, R			PATTERNS OF DONOR-TYPE MICROCHIMERISM AFTER HEART-TRANSPLANTATION	LANCET			English	Note							ALLOGRAFTS; CHIMERISM; LIVER	Allogeneic microchimerism of donor-type has been demonstrated in stable patients in the long-term after organ transplantation. We have analysed microchimerism in shin and blood of 47 heart-transplanted patients after transplantation with polymerase-chain-reaction amplification specific for donor HLA-DRB1. Microchimerism was detectable in 50% of the patients in the first 6 months, in 100% between 6 months and 2 years, and in 58% in the third postoperative year or later. The state of chimerism was not related to acute or chronic rejections. Patterns of microchimerism after heart transplantation may be dynamic, but any association with clinical and immunological variables remains to be elucidated.	HANNOVER MED SCH,THORAX HERZ & GEFASSCHIRURG KLIN,D-30623 HANNOVER,GERMANY	Hannover Medical School	SCHLITT, HJ (corresponding author), HANNOVER MED SCH,ABDOMINAL & TRANSPLANTAT CHIRURG KLIN,D-30623 HANNOVER,GERMANY.		Schlitt, Hans J./ABG-4368-2020					BEIN G, 1992, TISSUE ANTIGENS, V39, P68, DOI 10.1111/j.1399-0039.1992.tb01909.x; CICCONE E, 1992, J EXP MED, V175, P709, DOI 10.1084/jem.175.3.709; DEMETRIS AJ, 1993, TRANSPL P, V25, P3337; LARSEN CP, 1990, ANN SURG, V212, P308, DOI 10.1097/00000658-199009000-00009; QIAN S, IN PRESS HEPATOLOGY; SCHLITT HJ, 1994, NEW ENGL J MED, V330, P646, DOI 10.1056/NEJM199403033300919; SCHLITT HJ, 1993, TRANSPLANTATION, V56, P951, DOI 10.1097/00007890-199310000-00033; SCHLITT HJ, 1992, TRANSPLANTATION, V56, P1001; STARZL TE, 1993, TRANSPLANTATION, V55, P1272, DOI 10.1097/00007890-199306000-00012; STARZL TE, 1992, LANCET, V340, P876, DOI 10.1016/0140-6736(92)93286-V	10	130	132	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1469	1471		10.1016/S0140-6736(94)92584-4	http://dx.doi.org/10.1016/S0140-6736(94)92584-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911180				2022-12-28	WOS:A1994NQ41500011
J	HORTON, R				HORTON, R			... ON THE BRINK OF HUMANITARIAN DISASTER	LANCET			English	Editorial Material																		MANN J, 1994, BOSNIA WAR PUBLIC HL	1	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 30	1994	343	8905					1053	1053		10.1016/S0140-6736(94)90177-5	http://dx.doi.org/10.1016/S0140-6736(94)90177-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NJ694	7909096				2022-12-28	WOS:A1994NJ69400005
J	JONES, PE; CAWLEY, JF				JONES, PE; CAWLEY, JF			PHYSICIAN ASSISTANTS AND HEALTH SYSTEM REFORM - CLINICAL CAPABILITIES, PRACTICE ACTIVITIES, AND POTENTIAL ROLES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NURSE PRACTITIONERS; CALIFORNIA; CARE		GEORGE WASHINGTON UNIV,DEPT HLTH CARE SCI,PHYSICIAN ASSISTANT PROGRAM,WASHINGTON,DC 20037	George Washington University	JONES, PE (corresponding author), UNIV TEXAS,SW MED CTR,DEPT HLTH CARE SCI,PHYSICIAN ASSISTANT PROGRAM,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.			Jones, P. Eugene/0000-0002-6481-3081				[Anonymous], 1994, REPORT ADVISORY GROU; CATON L, 1990, J AM ACAD PHYSICIAN, V3, P439; CAWLEY JF, 1993, ROLES PHYSICIAN ASSI, P21; CLAWSON DK, 1993, ROLES PHYSICIAN ASSI; EDWARDS JC, 1993, JUN ANN M ASS PHYS A; EVENHOUSE S, 1993, J AM ACAD PHYSICIAN, V6, P525; FASSER CE, 1992, J AM ACAD PHYSICIAN, V5, P663; FOWKES V, 1993, ASSESSMENT PHYSICIAN; FOWKES VK, 1990, WESTERN J MED, V153, P328; FRANKS P, 1993, JAMA-J AM MED ASSOC, V270, P1449, DOI 10.1001/jama.270.12.1449; FRARY TN, 1991, J AM ACAD PHYSICIAN, V4, P597; GARA N, 1992, AM ACAD PHYSICIAN AS, V13, P10; GOLDBERG H, 1984, MED CARE, V22, P760, DOI 10.1097/00005650-198408000-00008; HAFFERTY FW, 1986, HEALTH SERV RES, V21, P107; Hershey J C, 1978, J Med Syst, V2, P123, DOI 10.1007/BF02222313; Hooker RS., 1993, ROLES PHYS ASSISTANT, P51; HUDSON CL, 1961, JAMA-J AM MED ASSOC, V176, P839, DOI 10.1001/jama.1961.03040230005002; JOHNSON RE, 1985, PHYSICIAN ASSIST, V5, P159; JONES PE, 1993, J AM ACAD PHYS ASSIS, V6, P407; KASSIRER JP, 1994, NEW ENGL J MED, V330, P204, DOI 10.1056/NEJM199401203300310; KIMBALL HR, 1994, JAMA-J AM MED ASSOC, V271, P315, DOI 10.1001/jama.271.4.315; KINDIG DA, 1993, JAMA-J AM MED ASSOC, V270, P1109; KOLE ALA, 1991, J AM ACAD PHYSICIAN, V4, P542; MENDENHALL RC, 1980, MED CARE, V18, P609, DOI 10.1097/00005650-198006000-00004; MIEKLE TH, 1992, REPORT J MACY F; MILES SH, 1993, ACAD MED, V68, P648, DOI 10.1097/00001888-199309000-00002; Morgan W A, 1993, Nurse Pract, V18, P65; NELSON EC, 1975, NEW ENGL J MED, V293, P527, DOI 10.1056/NEJM197509112931104; NELSON EC, 1974, JAMA-J AM MED ASSOC, V228, P63, DOI 10.1001/jama.228.1.63; NICHOLS AW, 1980, J FAM PRACTICE, V11, P101; OLIVER D, 1983, ROLES PHYSICIAN ASSI, P85; OLIVER DR, 1993, 9TH ASS PHYS ASS PRO; OLIVER DR, 1991, 7TH ASS PHYS ASS PRO; OSTERWEIS M, 1993, ROLES PHYSICIAN ASSI, P1; PERRY HB, 1977, J MED EDUC, V52, P639; PERRY HB, 1981, PHYSICIAN ASSISTANTS; RECORD JC, 1980, J HEALTH POLIT POLIC, V5, P470; REGAN DM, 1991, MED GROUP MANAGE NOV, P446; SCHAFFT GE, 1987, PHYSICIAN ASSISTANTS; SHOWSTACK J, 1992, JAMA-J AM MED ASSOC, V267, P2497, DOI 10.1001/jama.267.18.2497; SOX HC, 1979, ANN INTERN MED, V91, P459, DOI 10.7326/0003-4819-91-3-459; STEAD EA, 1966, J AMER MED ASSOC, V198, P1108, DOI 10.1001/jama.198.10.1108; WILLIS J, 1993, J AM ACAD PHYSICIAN, V6, P115; Willis J., 1993, JAAPA, V6, P418; WILLIS JB, 1993, AM ACAD PHYSICIAN AS, V14, P6; Willis JB, 1992, JAAPA, V5, P280; 1993, PHYSICIAN ASSISTANT; 1993, OEI019002070 DEP HLT; 1993, GENERAL CENSUS DATA; 1991, PHS8TH US DEP HLTH H; 1993, 1993 PHYS PAYM REV C; 1986, OTAHCS37 US C OFF TE; 1990, GRANTS PROGRAMS PHYS; 1990, OTAH434 OFF TECHN AS; 1992, CHRON HIGHER ED S, V39, P37; 1993, RURAL HLTH TEXAS REP; 1993, AM ACAD PHYSICIAN AS, V14, P3; 1971, ESSENTIALS GUIDELINE	58	43	43	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 27	1994	271	16					1266	1272		10.1001/jama.271.16.1266	http://dx.doi.org/10.1001/jama.271.16.1266			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG362	7908706				2022-12-28	WOS:A1994NG36200027
J	WICKNER, RB				WICKNER, RB			[URE3] AS AN ALTERED URE2 PROTEIN - EVIDENCE FOR A PRION ANALOG IN SACCHAROMYCES-CEREVISIAE	SCIENCE			English	Article							SHUTTLE VECTORS; STRANDED-RNA; YEAST; DNA; MITOCHONDRIAL; POLYMERASE; SCRAPIE; GENES	A cytoplasmically inherited element, [URE3], allows yeast to use ureidosuccinate in the presence of ammonium ion. Chromosomal mutations in the URE2 gene produce the same phenotype. [URE3] depends for its propagation on the URE2 product (Ure2p), a negative regulator of enzymes of nitrogen metabolism. Saccharomyces cerevisiae strains cured of [URE3] with guanidium chloride were shown to return to the [URE3]-carrying state without its introduction from other cells. Overproduction of Ure2p increased the frequency with which a strain became [URE3] by 100-fold. In analogy to mammalian prions, [URE3] may be an altered form of Ure2p that is inactive for its normal function but can convert normal Ure2p to the altered form. The genetic evidence presented here suggests that protein-based inheritance, involving a protein unrelated to the mammalian prion protein, can occur in a microorganism.			WICKNER, RB (corresponding author), NIDDKD, BIOCHEM PHARMACOL LAB, GENET SIMPLE EUKARYOTES SECT, ROOM 207, BLDG 8, BETHESDA, MD 20892 USA.							AIGLE M, 1975, MOL GEN GENET, V136, P327, DOI 10.1007/BF00341717; AIGLE M, COMMUNICATION; BENTON BM, 1990, MOL CELL BIOL, V10, P353, DOI 10.1128/MCB.10.1.353; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; COURCHESNE WE, 1988, J BACTERIOL, V170, P708, DOI 10.1128/jb.170.2.708-713.1988; Cox Brian, 1993, P219; COX BS, 1988, YEAST, V4, P159, DOI 10.1002/yea.320040302; DRILLIEN R, 1972, J BACTERIOL, V109, P203, DOI 10.1128/JB.109.1.203-208.1972; DRILLIEN R, 1973, BIOCHEM BIOPH RES CO, V53, P367, DOI 10.1016/0006-291X(73)90671-2; FOURY F, 1989, J BIOL CHEM, V264, P20552; GAJDUSEK DC, 1991, EUR J EPIDEMIOL, V7, P567, DOI 10.1007/BF00143141; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KIM KH, 1988, J BIOL CHEM, V263, P833; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LACROUTE F, 1971, J BACTERIOL, V106, P519, DOI 10.1128/JB.106.2.519-522.1971; MAGASANIK B, 1992, MOL CELLULAR BIOL YE, V2, P283; MEAD DA, 1985, NUCLEIC ACIDS RES, V13, P1103, DOI 10.1093/nar/13.4.1103; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; RIDLEY SP, 1984, MOL CELL BIOL, V4, P761, DOI 10.1128/MCB.4.4.761; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0; WICKNER RB, 1992, ANNU REV MICROBIOL, V46, P347, DOI 10.1146/annurev.micro.46.1.347; WICKNER RB, UNPUB	29	1053	1080	0	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 22	1994	264	5158					566	569		10.1126/science.7909170	http://dx.doi.org/10.1126/science.7909170			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH010	7909170	Green Submitted			2022-12-28	WOS:A1994NH01000036
J	LIPSKY, JJ				LIPSKY, JJ			CONCORDE LANDS	LANCET			English	Editorial Material									MAYO CLIN & MAYO FDN,DEPT PHARMACOL,CLIN PHARMACOL UNIT,ROCHESTER,MN 55905	Mayo Clinic	LIPSKY, JJ (corresponding author), MAYO CLIN & MAYO FDN,DEPT MED,CLIN PHARMACOL UNIT,ROCHESTER,MN 55905, USA.							ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; BARTLETT JG, 1993, NEW ENGL J MED, V329, P351, DOI 10.1056/NEJM199307293290510; COHEN J, 1993, SCIENCE, V260, P157, DOI 10.1126/science.8469966; HIRSCH MS, 1993, NEW ENGL J MED, V328, P1686, DOI 10.1056/NEJM199306103282307; LENDERKING WR, 1994, NEW ENGL J MED, V330, P738, DOI 10.1056/NEJM199403173301102; LIPSKY JJ, 1993, LANCET, V341, P30, DOI 10.1016/0140-6736(93)92496-G; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; PETO R, 1993, LANCET, V341, P1022, DOI 10.1016/0140-6736(93)91109-Y; SANDE MA, 1993, JAMA-J AM MED ASSOC, V270, P2583, DOI 10.1001/jama.270.21.2583	9	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 9	1994	343	8902					866	867		10.1016/S0140-6736(94)90002-7	http://dx.doi.org/10.1016/S0140-6736(94)90002-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF213	7908352				2022-12-28	WOS:A1994NF21300002
J	TOPOL, EJ; CALIFF, RM; WEISMAN, HF; ELLIS, SG; TCHENG, JE; WORLEY, S; IVANHOE, R; GEORGE, BS; FINTEL, D; WESTON, M; SIGMON, K; ANDERSON, KM; LEE, KL; WILLERSON, JT; SMITH, CR; WEISMAN, H				TOPOL, EJ; CALIFF, RM; WEISMAN, HF; ELLIS, SG; TCHENG, JE; WORLEY, S; IVANHOE, R; GEORGE, BS; FINTEL, D; WESTON, M; SIGMON, K; ANDERSON, KM; LEE, KL; WILLERSON, JT; SMITH, CR; WEISMAN, H			RANDOMIZED TRIAL OF CORONARY INTERVENTION WITH ANTIBODY AGAINST PLATELET IIB/IIIA INTEGRIN FOR REDUCTION OF CLINICAL RESTENOSIS - RESULTS AT 6 MONTHS	LANCET			English	Article							ANGIOPLASTY; PREVENTION; FREQUENCY; PARADIGM; INJURY	Restenosis after coronary angioplasty occurs in at least 30% of patients in the first six months and, as yet, there is no known treatment to decrease this event. We tested a monoclonal antibody Feb fragment (c7E3) directed against the platelet glycoprotein IIb/IIIa integrin, the receptor mediating the final common pathway of platelet aggregation, to see whether it reduced the frequency of clinical restenosis. Patients who had unstable angina, recent or evolving myocardial infarction, or high-risk angiographic morphology, were randomised to receive c7E3 bolus and a 12 hour infusion of c7E3 (708 patients), c7E3 bolus and placebo infusion (695 patients), or placebo bolus and placebo infusion (696 patients). With maintenance of the double-blind state, patients were followed-up for at least 6 months to determine the need for repeat angioplasty or surgical coronary revascularisation and the occurrence of ischaemic events. By 30 days, 12.8% of placebo bolus/placebo infusion patients had had a major ischaemic event (death, myocardial infarcton, urgent revascularisation), compared with 8.3% of c7E3 bolus/c7E3 infusion patients, yielding a 4.5% difference (35% reduction, p = 0.008). At 6 months, the absolute difference in patients with a major ischaemic event or elective revascularisation was 8.1% between placebo bolus/ placebo infusion and c7E3 bolus/c7E3 infusion patients (35.1% vs 27.0%; 23% reduction p = 0.001). The favourable long-term effect was mainly due to less need for bypass surgery or repeat angioplasty in patients with an initial successful procedure, since need for repeat target vessel revascularisation was 26% less for c7E3 bolus/c7E3 infusion than for placebo treatment (16.5% vs 22.3%; p = 0.007). The c7E3 bolus/placebo infusion group had an intermediate outcome which was not significantly better than that of the placebo bolus/placebo infusion group. These results extend the benefit of c7E3 bolus/c7E3 infusion from reducing abrupt closure and acute-phase adverse outcomes to a diminished need for subsequent coronary revascularisation procedures. Because this therapy carries a risk of bleeding complications and has been studied only in high-risk angioplasty patients, further evaluation is needed before it can be applied to other patient groups.			TOPOL, EJ (corresponding author), CLEVELAND CLIN FDN,DEPT CARDIOL,F-25,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.			Topol, Eric/0000-0002-1478-4729				ADELMAN AG, 1993, NEW ENGL J MED, V329, P228, DOI 10.1056/NEJM199307223290402; BATES ER, 1992, CORONARY ARTERY DIS, V3, P67, DOI 10.1097/00019501-199201000-00010; CASSCELLS W, 1992, CIRCULATION, V86, P723, DOI 10.1161/01.CIR.86.3.723; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; COLLER BS, 1993, J CLIN INVEST, V92, P2796, DOI 10.1172/JCI116899; DEFEYTER PJ, 1991, CIRCULATION, V83, P927, DOI 10.1161/01.CIR.83.3.927; DETRE K M, 1989, Journal of the American College of Cardiology, V13, p230A; ELLIS SG, 1993, CORONARY ARTERY DIS, V4, P167, DOI 10.1097/00019501-199302000-00007; FORRESTER JS, 1991, J AM COLL CARDIOL, V17, P758, DOI 10.1016/S0735-1097(10)80196-2; GROVES HM, 1986, ARTERIOSCLEROSIS, V6, P189, DOI 10.1161/01.ATV.6.2.189; HERRMAN JR, 1993, DRUGS, V46, P259; HILLEGASS WB, 1994, TXB INTERVENTIONAL C, P415; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IP JH, 1991, J AM COLL CARDIOL, V17, pB77; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LINCOFE AM, 1992, J AM COLL CARDIOL, V19, P926, DOI 10.1016/0735-1097(92)90272-O; PLOW EF, 1988, PROG HEMOST THROMB, V296, P320; POPMA JJ, 1991, CIRCULATION, V84, P1426, DOI 10.1161/01.CIR.84.3.1426; SCHWARTZ L, 1988, NEW ENGL J MED, V318, P1714, DOI 10.1056/NEJM198806303182603; SCHWARTZ RS, 1992, J AM COLL CARDIOL, V20, P1284, DOI 10.1016/0735-1097(92)90389-5; SERRUYS PW, 1991, CIRCULATION, V84, P1568, DOI 10.1161/01.CIR.84.4.1568; SERRUYS PW, 1993, CIRCULATION, V88, P1588, DOI 10.1161/01.CIR.88.4.1588; SUTTON J, 1993, CLIN RES, V41, pA118; TCHENG JE, 1993, CIRCULATION, V88, P595; TCHENG JE, 1991, CIRCULATION S2, V84, P590; TOPOL EJ, 1993, CIRCULATION, V87, P1489, DOI 10.1161/01.CIR.87.5.1489; TOPOL EJ, 1993, MAYO CLIN PROC, V68, P88, DOI 10.1016/S0025-6196(12)60026-3; TOPOL EJ, 1993, NEW ENGL J MED, V329, P228; WILENTZ JR, 1987, CIRCULATION, V75, P636, DOI 10.1161/01.CIR.75.3.636; WILLERSON JT, 1991, P NATL ACAD SCI USA, V88, P10624, DOI 10.1073/pnas.88.23.10624; 1988, J AM COLL CARDIOL, V12, P529; 1994, NEW ENGL J MED, V330, P956; 1992, CIRCULATION, V86, P100	33	790	812	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 9	1994	343	8902					881	886		10.1016/S0140-6736(94)90007-8	http://dx.doi.org/10.1016/S0140-6736(94)90007-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF213	7908357				2022-12-28	WOS:A1994NF21300007
J	BOOTH, IW				BOOTH, IW			COSTING MALNUTRITION - ADD OR MULTIPLY	LANCET			English	Editorial Material							CHILDREN; RISK				BOOTH, IW (corresponding author), UNIV BIRMINGHAM,INST CHILD HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.							BRIEND A, 1987, LANCET, V2, P725; CHEN LC, 1980, AM J CLIN NUTR, V33, P1836, DOI 10.1093/ajcn/33.8.1836; FAWZI WW, 1993, JAMA-J AM MED ASSOC, V269, P898, DOI 10.1001/jama.269.7.898; PELLETIER DL, 1993, AM J PUBLIC HEALTH, V83, P1130, DOI 10.2105/AJPH.83.8.1130; VANDENBROECK J, 1993, LANCET, V341, P1491, DOI 10.1016/0140-6736(93)90632-Q; Waterlow JC, 1992, PROTEIN ENERGY MALNU	6	1	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 5	1994	343	8897					554	555		10.1016/S0140-6736(94)91514-8	http://dx.doi.org/10.1016/S0140-6736(94)91514-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906322				2022-12-28	WOS:A1994MY84300002
J	CHOO, V				CHOO, V			MATERNAL TRANSMISSION OF HIV	LANCET			English	Editorial Material																			0	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					533	533		10.1016/S0140-6736(94)91477-X	http://dx.doi.org/10.1016/S0140-6736(94)91477-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906769				2022-12-28	WOS:A1994MX88800024
J	VONGERSDORFF, H; MATTHEWS, G				VONGERSDORFF, H; MATTHEWS, G			DYNAMICS OF SYNAPTIC VESICLE FUSION AND MEMBRANE RETRIEVAL IN SYNAPTIC TERMINALS	NATURE			English	Article							TRANSMITTER RELEASE; NERVE-TERMINALS; CALCIUM INFLUX; BIPOLAR CELLS; CAPACITANCE MEASUREMENTS; INTRACELLULAR CALCIUM; GOLDFISH RETINA; AMINO-ACIDS; EXOCYTOSIS; CURRENTS	COMMUNICATION among neurons occurs at specialized synaptic junctions, where neurotransmitter is released via calcium-dependent exocytosis from the synaptic terminal of the presynaptic cell onto the postsynaptic target neuron. Here we exploit the unique properties of giant synaptic terminals1-4 of bipolar neurons from goldfish retina to establish the kinetics and calcium-dependence of exocytosis, and the characteristics of membrane retrieval following secretion in presynaptic terminals. Simultaneous patch-clamp, calcium-indicator dye and time-resolved capacitance measurements reveal that activation of calcium current drives secretion at a rapid rate of about 10,000 vesicles per s and the, calcium level necessary to drive secretion is locally greater than 50 muM. Two components of membrane retrieval were observed following secretory stimulation. After strong stimulation, capacitance returned to rest with a time constant of about 30 s, but after weaker stimuli recovery was much faster, with a time constant of about 2 s. Secretion in a vertebrate central nervous system neuron was thus found to differ substantially from that in other secretory cells in its rapid rate of vesicle fusion, requirement for high levels of intracellular calcium, and the high speed and completeness of membrane retrieval. These distinctive features reflect the specialization of neuronal synaptic terminals for rapid and focally directed release of neurotransmitter.			VONGERSDORFF, H (corresponding author), SUNY STONY BROOK,DEPT NEUROBIOL & BEHAV,STONY BROOK,NY 11794, USA.							ADLER EM, 1991, J NEUROSCI, V11, P1496; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P553, DOI 10.1113/jphysiol.1954.sp005128; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; HEIDELBERGER R, 1992, J PHYSIOL-LONDON, V447, P235, DOI 10.1113/jphysiol.1992.sp019000; HEUSER JE, 1981, J CELL BIOL, V88, P564, DOI 10.1083/jcb.88.3.564; ISHIDA AT, 1980, J COMP NEUROL, V191, P315, DOI 10.1002/cne.901910302; JAFFE LA, 1978, DEV BIOL, V67, P243, DOI 10.1016/0012-1606(78)90314-7; KANDEL ER, 1991, PRINCIPLES NEURAL SC, P200; KANEKO A, 1985, J PHYSIOL-LONDON, V358, P131, DOI 10.1113/jphysiol.1985.sp015544; KELLY RB, 1993, NEURON S, V10, P43; LIM NF, 1990, NATURE, V344, P449, DOI 10.1038/344449a0; LINDAU M, 1992, BIOPHYS J, V61, P19, DOI 10.1016/S0006-3495(92)81812-X; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; MARC RE, 1989, NATO ASI SERIES H, V31, P53; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; RYAN TA, 1993, NEURON, V11, P7132; SHERRY DM, 1993, J COMP NEUROL, V329, P188, DOI 10.1002/cne.903290204; SIMON SM, 1985, BIOPHYS J, V48, P485, DOI 10.1016/S0006-3495(85)83804-2; STERN MD, 1992, CELL CALCIUM, V13, P183, DOI 10.1016/0143-4160(92)90046-U; TACHIBANA M, 1991, J NEUROSCI, V11, P2199; TACHIBANA M, 1993, J NEUROSCI, V13, P2898; THOMAS P, 1993, EMBO J, V12, P303, DOI 10.1002/j.1460-2075.1993.tb05657.x; THOMAS P, 1990, NEURON, V5, P723, DOI 10.1016/0896-6273(90)90226-6; VERHAGE M, 1991, NEURON, V6, P517, DOI 10.1016/0896-6273(91)90054-4; ZUCKER RS, 1986, P NATL ACAD SCI USA, V83, P3032, DOI 10.1073/pnas.83.9.3032	30	383	389	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 24	1994	367	6465					735	739		10.1038/367735a0	http://dx.doi.org/10.1038/367735a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	7906397				2022-12-28	WOS:A1994MX63100058
J	TOFT, AD				TOFT, AD			IF I SHOULD LIVE TO BE 100	LANCET			English	Editorial Material											TOFT, AD (corresponding author), ROYAL INFIRM, EDINBURGH, SCOTLAND.							CUTLER RG, 1991, ANN NY ACAD SCI, V621, P1; MARRIOTTI S, 1993, J CLIN ENDOCR METAB, V77, P1130; MARTIN GR, 1993, ANNU REV MED, V44, P419, DOI 10.1146/annurev.me.44.020193.002223	3	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 19	1994	343	8895					434	434		10.1016/S0140-6736(94)92688-3	http://dx.doi.org/10.1016/S0140-6736(94)92688-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905952				2022-12-28	WOS:A1994MW69000006
J	AMIEL, SA				AMIEL, SA			GLUCAGON-LIKE PEPTIDE - A THERAPEUTIC GLIMMER	LANCET			English	Editorial Material											AMIEL, SA (corresponding author), GUYS HOSP,DIV MED,LONDON SE1 9RT,ENGLAND.							GERICH JE, 1989, NEW ENGL J MED, V321, P1231; GUTNIAK M, 1992, NEW ENGL J MED, V326, P1316, DOI 10.1056/NEJM199205143262003; HIROTA M, 1990, DIABETES RES CLIN PR, V9, P179, DOI 10.1016/0168-8227(90)90110-F; KREYMANN B, 1987, LANCET, V2, P1300; NAUCK MA, 1993, DIABETOLOGIA, V36, P741, DOI 10.1007/BF00401145; NAUCK MA, 1993, J CLIN ENDOCR METAB, V76, P912, DOI 10.1210/jcem.76.4.8473405; ORSKOV C, 1991, J CLIN INVEST, V87, P415, DOI 10.1172/JCI115012	7	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					4	5		10.1016/S0140-6736(94)90869-9	http://dx.doi.org/10.1016/S0140-6736(94)90869-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905051				2022-12-28	WOS:A1994MN93700005
J	ORLANDO, V; PARO, R				ORLANDO, V; PARO, R			MAPPING POLYCOMB-REPRESSED DOMAINS IN THE BITHORAX COMPLEX USING IN-VIVO FORMALDEHYDE CROSS-LINKED CHROMATIN	CELL			English	Article							POSITION-EFFECT VARIEGATION; HOMEOTIC GENE ULTRABITHORAX; ABDOMINAL-B DOMAIN; DROSOPHILA-MELANOGASTER; MOLECULAR-GENETICS; ANTENNAPEDIA GENE; CONTROL REGION; DNA-SEQUENCES; PROTEIN; EXPRESSION	The Polycomb group (Pc-G) proteins are responsible for keeping developmental regulators, like homeotic genes, stably and inheritably repressed during Drosophila development. Several similarities to a protein class involved in heterochromatin formation suggest that the Pc-G exerts its function at the higher order chromatin level. Here we have mapped the distribution of the Pc protein in the homeotic bithorax complex (BX-C) of Drosophila tissue culture cells. We have elaborated a method, based on the in vivo formaldehyde cross-linking technique, that allows a substantial enrichment for Pc-interacting sites by immunoprecipitation of the cross-linked chromatin with anti-Pc antibodies. We find that the Pc protein quantitatively covers large regulatory regions of repressed BX-C genes. Conversely, we find that the Abdominal-B gene is active in these cells and the region devoid of any bound Pc protein.			ORLANDO, V (corresponding author), UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,IM NEUENHEIMER FELD 282,D-69120 HEIDELBERG,GERMANY.							APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BENDER W, 1983, SCIENCE, V221, P23, DOI 10.1126/science.221.4605.23; BIENZ M, 1988, CELL, V53, P567, DOI 10.1016/0092-8674(88)90573-9; BLANCO J, 1985, BIOCHEMISTRY-US, V24, P8021, DOI 10.1021/bi00348a028; BOULET AM, 1988, GENE DEV, V2, P1600, DOI 10.1101/gad.2.12a.1600; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BUSTURIA A, 1993, EMBO J, V12, P1415, DOI 10.1002/j.1460-2075.1993.tb05785.x; CASANOVA J, 1986, CELL, V47, P627, DOI 10.1016/0092-8674(86)90627-6; CASTELLIGAIR J, 1992, DEVELOPMENT, V114, P877; CELNIKER SE, 1990, EMBO J, V9, P4277, DOI 10.1002/j.1460-2075.1990.tb07876.x; CELNIKER SE, 1989, GENE DEV, V3, P1424, DOI 10.1101/gad.3.9.1424; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DECAMILLIS M, 1992, GENE DEV, V6, P223, DOI 10.1101/gad.6.2.223; DELORENZI M, 1988, EMBO J, V7, P3223, DOI 10.1002/j.1460-2075.1988.tb03189.x; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; EISSENBERG JC, 1991, TRENDS GENET, V7, P335, DOI 10.1016/0168-9525(91)90424-O; ENGSTROM Y, 1992, ROUX ARCH DEV BIOL, V201, P65, DOI 10.1007/BF00420417; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; GALLONI M, 1993, EMBO J, V12, P1087, DOI 10.1002/j.1460-2075.1993.tb05750.x; GILMOUR DS, 1986, MOL CELL BIOL, V6, P3984, DOI 10.1128/MCB.6.11.3984; GOLDSCHMIDTCLERMONT M, 1980, NUCLEIC ACIDS RES, V8, P235, DOI 10.1093/nar/8.2.235; GOULD AP, 1990, NATURE, V348, P308, DOI 10.1038/348308a0; GYURKOVICS H, 1990, EMBO J, V9, P2579, DOI 10.1002/j.1460-2075.1990.tb07439.x; HARDING K, 1988, EMBO J, V7, P205, DOI 10.1002/j.1460-2075.1988.tb02801.x; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; IRISH VF, 1989, EMBO J, V8, P1527, DOI 10.1002/j.1460-2075.1989.tb03537.x; IRVINE KD, 1991, DEVELOPMENT, V111, P407; JACKSON V, 1978, CELL, V15, P945, DOI 10.1016/0092-8674(78)90278-7; JOHNSON DH, 1991, PCR PRACTICAL APPROA; JURGENS G, 1985, NATURE, V316, P153, DOI 10.1038/316153a0; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KARCH F, 1985, CELL, V43, P81, DOI 10.1016/0092-8674(85)90014-5; KENNISON JA, 1993, TRENDS GENET, V9, P75, DOI 10.1016/0168-9525(93)90227-9; KUZIORA MA, 1988, EMBO J, V7, P3233, DOI 10.1002/j.1460-2075.1988.tb03190.x; LAUGHON A, 1986, MOL CELL BIOL, V6, P4676, DOI 10.1128/MCB.6.12.4676; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LOCKE J, 1988, GENETICS, V120, P181; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MESSMER S, 1992, GENE DEV, V6, P1241, DOI 10.1101/gad.6.7.1241; MULLER J, 1991, EMBO J, V10, P3147, DOI 10.1002/j.1460-2075.1991.tb04876.x; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PARO R, 1983, EMBO J, V2, P853, DOI 10.1002/j.1460-2075.1983.tb01513.x; PEIFER M, 1987, GENE DEV, V1, P891, DOI 10.1101/gad.1.9.891; QIAN S, 1991, EMBO J, V10, P1415, DOI 10.1002/j.1460-2075.1991.tb07662.x; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; SAKONJU S, 1984, GENETICS, V107, P593; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZHERRERO E, 1991, DEVELOPMENT, V111, P437; SAUNDERS RDC, 1989, NUCLEIC ACIDS RES, V17, P9027, DOI 10.1093/nar/17.22.9027; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHNEUWLY S, 1986, EMBO J, V5, P733, DOI 10.1002/j.1460-2075.1986.tb04275.x; SCHOUTEN JP, 1985, J BIOL CHEM, V260, P9929; SIMON J, 1990, EMBO J, V9, P3945, DOI 10.1002/j.1460-2075.1990.tb07615.x; SIMON J, 1992, DEVELOPMENT, V114, P493; SOLOMON MJ, 1985, P NATL ACAD SCI USA, V82, P6470, DOI 10.1073/pnas.82.19.6470; SOLOMON MJ, 1988, CELL, V53, P937, DOI 10.1016/S0092-8674(88)90469-2; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; WHITE RAH, 1984, CELL, V39, P163, DOI 10.1016/0092-8674(84)90202-2; ZAVORTINK M, 1989, GENE DEV, V3, P1969, DOI 10.1101/gad.3.12a.1969; ZHANG CC, 1991, DEVELOPMENT, V113, P1171; ZHANG CC, 1992, P NATL ACAD SCI USA, V89, P7511, DOI 10.1073/pnas.89.16.7511; ZINK B, 1989, NATURE, V337, P468, DOI 10.1038/337468a0; ZINK B, 1991, EMBO J, V10, P153, DOI 10.1002/j.1460-2075.1991.tb07931.x	71	305	316	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 17	1993	75	6					1187	1198		10.1016/0092-8674(93)90328-N	http://dx.doi.org/10.1016/0092-8674(93)90328-N			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	7903220				2022-12-28	WOS:A1993MM89300017
J	DRUCKER, E; ALCABES, P; BOSWORTH, W; SCKELL, B				DRUCKER, E; ALCABES, P; BOSWORTH, W; SCKELL, B			CHILDHOOD TUBERCULOSIS IN THE BRONX, NEW-YORK	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INTRAVENOUS DRUG-USERS; INFECTION; RATES; RISK; AIDS	The resurgence of tuberculosis (TB) in New York City in the period 1978-92 has been closely linked to the AIDS epidemic but the increase of active TB in areas of urban poverty also implies increased community exposure. We have examined the ecological relation between community rates of AIDS and residential crowding and cases of active TB in Bronx children under age 5. Residential crowding was defined as the percent of households with more than 1 person per room. All childhood TB cases reported between 1986 and 1992 for the Bronx (n = 75) were included. Cumulative AIDS mortality rates for adult females through 1990 represented community HIV burden. All data were coded by the 64 health areas of the borough. We examined trends in these data and used Poisson regression to model the effect of HIV burden and residential crowding on TB risk. For the Bronx as a whole the two variables of TB and residential crowding showed a clear temporal correspondence for the period 1970-90. Residential crowding was associated with poverty and greater dependence on public assistance, large household size, Hispanic ethnicity, and a higher proportion of young children. The overall TB case rate increased with the proportion of crowded households, with a rise from 1.47 to over 8 cases per 10 000 children as the proportion of crowded households increased. At both the lowest and highest levels of AIDS mortality in these areas, the childhood TB risk increased as crowding increased. Children living in areas of the Bronx in which over 12 percent of homes are severely overcrowded were 5.6-fold more likely to develop active TB, even after holding constant the presumed HIV burden in each local community. While HIV infection, the newest risk factor for TB, appears to play a critical role in the resurgent epidemic, our findings show that the earliest known TB risk factors, poverty and household crowding, are still potent forces.	YALE UNIV,SCH MED,AIDS PROGRAM,NEW HAVEN,CT; CUNY HERBERT H LEHMAN COLL,DEPT POLIT SCI,BRONX,NY 10468; CUNY HERBERT H LEHMAN COLL,BRONX DATA CTR,BRONX,NY 10468	Yale University; City University of New York (CUNY) System; Lehman College (CUNY); City University of New York (CUNY) System; Lehman College (CUNY)	DRUCKER, E (corresponding author), MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10467, USA.							BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BATES B, 1992, BARGAINING LIFE; BELLIN E, 1993, JAMA-J AM MED ASSOC, V259, P2228; BRESLOW NE, 1980, STATISTICAL METHODS; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CHAPMAN JS, 1984, AM REV RESPIR DIS, V90, P48; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; DRUCKER E, 1989, AM J EPIDEMIOL, V130, P133, DOI 10.1093/oxfordjournals.aje.a115304; DRUCKER E, 1987, FRANKLIN AVE SHELTER; DRUCKER E, 1993, NY TIMES        0820, pA28; Dubos Rene, 1987, WHITE PLAGUE TUBERCU; DUGGER C, 1992, NY TIMES        0216, P1; DUGGER CW, 1993, NY TIMES        1116, pA1; DUGGER CW, 1993, NY TIMES        1116, pB4; NOVICK LF, 1991, AM J PUBLIC HEALTH, V81, P15, DOI 10.2105/AJPH.81.Suppl.15; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; STLOUIS ME, 1990, NEW ENGL J MED, V323, P213, DOI 10.1056/NEJM199007263230401; SUNDERAM G, 1986, JAMA-J AM MED ASSOC, V256, P362, DOI 10.1001/jama.256.3.362; WALLACE R, 1988, ENVIRON RES, V47, P1, DOI 10.1016/S0013-9351(88)80018-5; 1986, MMWR-MORBID MORTAL W, V28, P587; 1986, MMWR-MORBID MORTAL W, V35, P74; 1992, INFORMATION SUMMARY	25	86	90	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1482	1485		10.1016/S0140-6736(94)92588-7	http://dx.doi.org/10.1016/S0140-6736(94)92588-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911184				2022-12-28	WOS:A1994NQ41500015
J	EBELING, P; KOIVISTO, VA				EBELING, P; KOIVISTO, VA			PHYSIOLOGICAL IMPORTANCE OF DEHYDROEPIANDROSTERONE	LANCET			English	Note							HORMONE-BINDING GLOBULIN; BODY-FAT DISTRIBUTION; BREAST-CANCER; POSTMENOPAUSAL WOMEN; CARDIOVASCULAR MORTALITY; INSULIN SENSITIVITY; ADIPOSE TISSUES; NORMAL MEN; FOLLOW-UP; SULFATE	Dehydroepiandrosterone (DHEA), with its sulphate conjugate (DHEAS), is the most abundant steroid hormone in the circulation but its physiological importance is unclear. We propose that DHEA has either oestrogen-like or androgen-like effects depending on the hormonal milieu. In premenopausal women DHEA is either an oestrogen antagonist, perhaps through the competitive binding its metabolite of androstene-3 beta, 17 beta-diol (ADIOL) and oestradiol oestrogen receptor, or an androgen through its metabolism to androstenedione and testosterone. In women DHEA contributes to abdominal obesity and insulin resistance: in the premenopausal high oestrogen concentrations may counterbalance the androgenic effects of DHEA but in the postmenopausal metabolism to testosterone may increase the risk of cardiovascular disease, though this effect may be counterbalanced by the age-dependent decline in DHEA and also by the oestradiol-like effects of ADIOL. In some breast cancer cell lines in a low oestrogen milieu DHEA has an oestradiol-like effect, stimulating tumour growth, whereas in oestradiol abundance DHEA antagonises the growth-stimulating effect of oestradiol. In men, with an androgenic milieu, DHEA acts like an oestrogen and protects against cardiovascular disease.	HELSINKI UNIV HOSP,DEPT MED 2,SF-00290 HELSINKI,FINLAND	University of Helsinki; Helsinki University Central Hospital								ADAMS J, 1981, CANCER RES, V41, P4720; ADLERCREUTZ H, 1989, AM J CLIN NUTR, V49, P433, DOI 10.1093/ajcn/49.3.433; BARRETTCONNOR E, 1987, NEW ENGL J MED, V317, P711; BARRETTCONNOR E, 1986, NEW ENGL J MED, V315, P1519, DOI 10.1056/NEJM198612113152405; BIRD CE, 1978, J CLIN ENDOCR METAB, V47, P818, DOI 10.1210/jcem-47-4-818; BIRKELAND KI, 1993, J CLIN ENDOCR METAB, V76, P275, DOI 10.1210/jc.76.2.275; BJORNTORP P, 1991, DIABETES CARE, V14, P1132, DOI 10.2337/diacare.14.12.1132; BOCCUZZI G, 1992, ANTICANCER RES, V12, P1479; BOLINDER J, 1983, DIABETES, V32, P117, DOI 10.2337/diabetes.32.2.117; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; DRUCKER WD, 1972, J CLIN ENDOCR METAB, V35, P48, DOI 10.1210/jcem-35-1-48; FRIED SK, 1993, J CLIN INVEST, V92, P2191, DOI 10.1172/JCI116821; GORDON GB, 1990, CANCER RES, V50, P3859; KHAW KT, 1991, CLIN SCI, V80, P199, DOI 10.1042/cs0800199; MARIN P, 1992, METABOLISM, V41, P882, DOI 10.1016/0026-0495(92)90171-6; MORTOLA JF, 1990, J CLIN ENDOCR METAB, V71, P696, DOI 10.1210/jcem-71-3-696; NESTLER JE, 1988, J CLIN ENDOCR METAB, V66, P57, DOI 10.1210/jcem-66-1-57; ORENTREICH N, 1984, J CLIN ENDOCR METAB, V59, P551, DOI 10.1210/jcem-59-3-551; POORTMAN J, 1975, J CLIN ENDOCR METAB, V40, P373, DOI 10.1210/jcem-40-3-373; PREZIOSI P, 1993, J CLIN ENDOCR METAB, V76, P283, DOI 10.1210/jcem.76.2.8432770; REBUFFESCRIVE M, 1990, J CLIN ENDOCR METAB, V71, P1215, DOI 10.1210/jcem-71-5-1215; ROSANO GMC, 1993, LANCET, V342, P133, DOI 10.1016/0140-6736(93)91343-K; ROTTER JI, 1985, METABOLISM, V34, P731, DOI 10.1016/0026-0495(85)90023-X; SEIDELL JC, 1990, METABOLISM, V39, P897, DOI 10.1016/0026-0495(90)90297-P; SEYMOURMUNN K, 1982, ENDOCRINOLOGY, V112, P486; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; USISKIN KS, 1990, INT J OBESITY, V14, P457; WILLIAMS DP, 1993, J CLIN ENDOCR METAB, V77, P80, DOI 10.1210/jc.77.1.80; ZUMOFF B, 1988, ANTICANCER RES, V8, P627; ZUMOFF B, 1981, CANCER RES, V41, P3360; Zumoff B, 1988, Acta Med Scand Suppl, V723, P153	31	299	310	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1479	1481		10.1016/s0140-6736(94)92587-9	http://dx.doi.org/10.1016/s0140-6736(94)92587-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911183				2022-12-28	WOS:A1994NQ41500014
J	SARKANY, RPE; ALEXANDER, GJMA; COX, TM				SARKANY, RPE; ALEXANDER, GJMA; COX, TM			RECESSIVE INHERITANCE OF ERYTHROPOIETIC PROTOPORPHYRIA WITH LIVER-FAILURE	LANCET			English	Note							GENE; MUTATIONS	Erythropoietic protoporphyria is characterised by skin photosensitivity and deficiency of ferrochelatase; fatal liver disease occurs rarely. Transmission is considered to be dominant with incomplete penetrance. We investigated a family in which two siblings with erythropoietic protoporphyria developed hepatic failure that required transplantation. Their healthy parents had partial enzyme deficiency and were each heterozygous for a distinct mutation in a ferrochelatase gene. Both offspring were compound heterozygotes with ferrochelatase deficiency. Recessive transmission of protoporphyria predisposes to severe liver disease in this family. Patients with the recessive form of this disease may be at special risk of hepatic failure.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOULECHFAR S, 1993, GENOMICS, V16, P645, DOI 10.1006/geno.1993.1242; DAILEY HA, 1994, J BIOL CHEM, V269, P390; DOSS MO, 1989, CLIN BIOCHEM, V22, P223, DOI 10.1016/S0009-9120(89)80081-5; ELDER GH, 1993, J CLIN PATHOL, V46, P977, DOI 10.1136/jcp.46.11.977; GALLAGHER PG, 1991, J BIOL CHEM, V266, P15154; LAMORIL J, 1991, BIOCHEM BIOPH RES CO, V181, P594, DOI 10.1016/0006-291X(91)91231-Z; NAKAHASHI Y, 1993, HUM GENET, V91, P303; NUNN AVW, 1988, ANAL BIOCHEM, V174, P146, DOI 10.1016/0003-2697(88)90529-5; POLSON RJ, 1988, TRANSPLANTATION, V46, P386, DOI 10.1097/00007890-198809000-00010; SARKANY RPE, 1994, J INVEST DERMATOL, V102, P481, DOI 10.1111/1523-1747.ep12373073; STEINGRIMSDOTTIR H, 1992, NUCLEIC ACIDS RES, V20, P1201, DOI 10.1093/nar/20.6.1201	11	77	79	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1394	1396		10.1016/S0140-6736(94)92525-9	http://dx.doi.org/10.1016/S0140-6736(94)92525-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910885				2022-12-28	WOS:A1994NP95500011
J	LEES, C; CAMPBELL, S; JAUNIAUX, E; BROWN, R; RAMSAY, B; GIBB, D; MONCADA, S; MARTIN, JF				LEES, C; CAMPBELL, S; JAUNIAUX, E; BROWN, R; RAMSAY, B; GIBB, D; MONCADA, S; MARTIN, JF			ARREST OF PRETERM LABOR AND PROLONGATION OF GESTATION WITH GLYCERYL TRINITRATE, A NITRIC-OXIDE DONOR	LANCET			English	Note							INDOMETHACIN	13 women admitted consecutively in preterm labour were recruited to an observational study of the effect of glyceryl trinitrate (GTN) patches on uterine contractions and prolongation of pregnancy. All twenty episodes of preterm labour (at 23-33 weeks' gestation) responded. 1 patient delivered because of cervical incompetence despite cessation of uterine contractions. The mean prolongation of pregnancy was 34 days. 8 babies have been born so far, and are progressing well. GTN patches appear to be a safe, well-tolerated, and non-invasive method of suppressing uterine contractions in preterm labour.	UNIV LONDON KINGS COLL HOSP,SCH MED & DENT,DEPT OBSTET & GYNAECOL,LONDON SE5 8RX,ENGLAND; UNIV LONDON KINGS COLL HOSP,SCH MED & DENT,DEPT MED,LONDON SE5 8RX,ENGLAND; WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; GlaxoSmithKline; Wellcome Research Laboratories			Brown, Richard/I-3851-2019	Brown, Richard/0000-0002-5476-2698				BIVINS HA, 1993, AM J OBSTET GYNECOL, V169, P1065, DOI 10.1016/0002-9378(93)90055-N; BOOTSTAYLOR B, 1994, AM J OBSTET GYNECO S, V179, P281; GREENSPOON JS, 1991, LANCET, V338, P124, DOI 10.1016/0140-6736(91)90122-6; Hankins G.D.V., 1991, CRITICAL CARE OBSTET, P231; IZUMI H, 1993, AM J OBSTET GYNECOL, V169, P1327, DOI 10.1016/0002-9378(93)90301-X; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NORTON ME, 1993, NEW ENGL J MED, V329, P1602, DOI 10.1056/NEJM199311253292202; RAMSAY B, 1994, EUR J CLIN INVEST, V24, P76, DOI 10.1111/j.1365-2362.1994.tb02064.x; SLADEK SM, 1993, AM J OBSTET GYNECOL, V169, P1285, DOI 10.1016/0002-9378(93)90295-T; 1992, NEW ENGL J MED, V327, P308	10	176	183	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1325	1326		10.1016/S0140-6736(94)92468-6	http://dx.doi.org/10.1016/S0140-6736(94)92468-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910325				2022-12-28	WOS:A1994NN21700011
J	FINKEL, TH; TOROK, TJ; FERGUSON, PJ; DURIGON, EL; ZAKI, SR; LEUNG, DYM; HARBECK, RJ; GELFAND, EW; SAULSBURY, FT; HOLLISTER, JR; ANDERSON, LJ				FINKEL, TH; TOROK, TJ; FERGUSON, PJ; DURIGON, EL; ZAKI, SR; LEUNG, DYM; HARBECK, RJ; GELFAND, EW; SAULSBURY, FT; HOLLISTER, JR; ANDERSON, LJ			CHRONIC PARVOVIRUS B19 INFECTION AND SYSTEMIC NECROTIZING VASCULITIS - OPPORTUNISTIC INFECTION OR ETIOLOGIC AGENT	LANCET			English	Article							HUMANS; SERUM	We describe three patients who had infection with human parvovirus B19 in association with new-onset systemic necrotising vasculitis syndromes, two with features of polyarteritis nodosa and one with features of Wegener's granulomatosis. Chronic B19 infection, lasting 5 months to more than 3 years, was shown by enzyme immunoassay for IgG and IgM antibodies to B19 and polymerase chain reaction for B19 DNA in serum and tissue samples. The patients had atypical serological responses to the B19 infection, although none had a recognisable immunodeficiency disorder. Treatment with corticosteroids and cyclophosphamide did not control vasculitis. Intravenous immunoglobulin (IVIG) therapy led to rapid improvement of the systemic vascultis manifestations, clearing of the chronic parvovirus infection, and long-term remission. These observations suggest an aetiological relation between parvovirus B19 infection and systemic necrotising vasculitis in these patients and indicate a potentially curative role for IVIG in such disorders.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA; UNIV VIRGINIA,HLTH SCI CTR,DEPT PEDIAT,CHARLOTTESVILLE,VA; UNIV SAO PAULO,INST BIOMED SCI,SAO PAULO,BRAZIL; UNIV COLORADO,CHILDRENS HOSP,HLTH SCI CTR,DENVER,CO 80218	Centers for Disease Control & Prevention - USA; University of Virginia; Universidade de Sao Paulo; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	FINKEL, TH (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DENVER,CO 80206, USA.			Durigon, Edison/0000-0003-4898-6553	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037260, R37HL037260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029704] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37260] Funding Source: Medline; NIAID NIH HHS [R01 AI29704] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON LJ, 1988, CLIN PERINATOL, V15, P273, DOI 10.1016/S0095-5108(18)30712-7; ANDERSON MJ, 1985, J INFECT DIS, V152, P257, DOI 10.1093/infdis/152.2.257; BROWN KE, 1993, SCIENCE, V262, P114, DOI 10.1126/science.8211117; CORMAN LC, 1992, LANCET, V339, P491, DOI 10.1016/0140-6736(92)91096-Q; CORMAN LC, 1992, ARTHRITIS RHEUM, V35, pS165; COTMORE SF, 1986, J VIROL, V60, P548, DOI 10.1128/JVI.60.2.548-557.1986; DURIGON EL, 1993, J VIROL METHODS, V44, P155, DOI 10.1016/0166-0934(93)90051-R; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; ERDMAN DD, 1991, J MED VIROL, V35, P110, DOI 10.1002/jmv.1890350207; FADEN H, 1992, CLIN INFECT DIS, V15, P595, DOI 10.1093/clind/15.4.595; FRICKHOFEN N, 1989, MICROB PATHOGENESIS, V7, P319, DOI 10.1016/0882-4010(89)90035-1; JAYNE DRW, 1991, LANCET, V337, P1137, DOI 10.1016/0140-6736(91)92797-6; JOSEPH PR, 1986, NEW YORK STATE J MED, V86, P560; KAJIGAYA S, 1991, P NATL ACAD SCI USA, V88, P4646, DOI 10.1073/pnas.88.11.4646; KURTZMAN GJ, 1989, J CLIN INVEST, V84, P114; LEFRERE JJ, 1986, PEDIATRICS, V78, P183; MATHIESON PW, 1990, NEW ENGL J MED, V323, P250, DOI 10.1056/NEJM199007263230407; MCOMISH F, 1993, J CLIN MICROBIOL, V31, P323, DOI 10.1128/JCM.31.2.323-328.1993; MOREY AL, 1992, BRIT J OBSTET GYNAEC, V99, P566, DOI 10.1111/j.1471-0528.1992.tb13822.x; NEILD G, 1986, LANCET, V2, P1226; NIITSU H, 1990, JPN J CLIN HEMATOL, V31, P1566; PRYDE PG, 1992, OBSTET GYNECOL, V79, P859; SAVAGE COS, 1991, SYSTEMIC VASCULITIDE, P7; SHADE RO, 1986, J VIROL, V58, P921, DOI 10.1128/JVI.58.3.921-936.1986; Tijssen P, 1990, Handbook of parvoviruses, VII; TOROK TJ, 1992, ADV INTERNAL MED, V37, P431; YOUNG N, 1988, SEMIN HEMATOL, V25, P159	27	274	278	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1255	1258		10.1016/S0140-6736(94)92152-0	http://dx.doi.org/10.1016/S0140-6736(94)92152-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910276				2022-12-28	WOS:A1994NM14400010
J	MOULTON, C; PENNYCOOK, AG				MOULTON, C; PENNYCOOK, AG			RELATION BETWEEN GLASGOW COMA SCORE AND COUGH REFLEX	LANCET			English	Note								How unconscious does a patient need to be, to be intubated without drugs? In 76 comatose patients (Glasgow coma score [GCS] less than or equal to 8) who were treated consecutively in an emergency department, the integrity of the cough reflex was not related to GCS. All comatose patients must be treated as if their airway is compromised but even at the lowest coma scores, there are many patients whose airway reflexes are sufficiently intact to make procedures such as endotracheal intubation difficult and dangerous without drugs. The state of the airway should be assessed independently of conscious level.	MANCHESTER ROYAL INFIRM, DEPT ACCID & EMERGENCY MED, MANCHESTER M13 9WL, LANCS, ENGLAND; SOUTHAMPTON GEN HOSP, SOUTHAMPTON, HANTS, ENGLAND	University of Manchester; University of Southampton								[Anonymous], 1976, BMJ-BRIT MED J, V2, P1187; ATKINSON RS, 1987, SYNOPSIS ANAESTHESIA, P165; BRADLEY RD, 1987, OXFORD TXB MED, V2; KULIG K, 1982, LANCET, V1, P565; MOULTON C, 1991, BRIT MED J, V303, P1240, DOI 10.1136/bmj.303.6812.1240; MURPHY PJ, 1993, BRIT J ANAESTH, V70, P131, DOI 10.1093/bja/70.2.131; PONTOPPIDAN H, 1960, JAMA-J AM MED ASSOC, V174, P2209, DOI 10.1001/jama.1960.03030180029007; SEKIZAWA K, 1990, LANCET, V335, P1228, DOI 10.1016/0140-6736(90)92758-A; YATES DW, 1985, LECTURE NOTES ACCIDE, P8; 1989, ADV TRAUMA LIFE SUPP, P31	10	63	65	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 21	1994	343	8908					1261	1262		10.1016/S0140-6736(94)92155-5	http://dx.doi.org/10.1016/S0140-6736(94)92155-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910279				2022-12-28	WOS:A1994NM14400013
J	BLASZYK, H; VAUGHN, CB; HARTMANN, A; MCGOVERN, RM; SCHROEDER, JJ; CUNNINGHAM, J; SCHAID, D; SOMMER, SS; KOVACH, JS				BLASZYK, H; VAUGHN, CB; HARTMANN, A; MCGOVERN, RM; SCHROEDER, JJ; CUNNINGHAM, J; SCHAID, D; SOMMER, SS; KOVACH, JS			NOVEL PATTERN OF P53 GENE-MUTATIONS IN AN AMERICAN BLACK COHORT WITH HIGH MORTALITY FROM BREAST-CANCER	LANCET			English	Note								The pattern of acquired mutations in the p53 gene can be used to study differences in factors contributing to carcinogenesis. We investigated mutations in exons 5-9 and adjacent intronic regions in 47 breast cancers of black women from Michigan, a population with the highest breast-cancer mortality in the US. The 16 mutations detected differed from those of other populations. In particular, the black women had an excess of A:T-->G:C transitions compared with rural white US midwest women. While the causes of the different pattern of acquired mutation remain to be determined, this molecular epidemiological approach detects the consequences of mutagenic processes in specific populations. Mutation patterns will constrain hypotheses to mechanisms consistent with the observed biochemical alterations.	MAYO CLIN & MAYO FDN,DEPT ONCOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,ROCHESTER,MN 55905; SOUTHFIELD ONCOL INST,SOUTHFIELD,MI	Mayo Clinic; Mayo Clinic; Mayo Clinic					NATIONAL CANCER INSTITUTE [R01CA056881] Funding Source: NIH RePORTER; NCI NIH HHS [NCI 5 R01 CA56881-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIGGS PJ, 1993, MUTAGENESIS, V8, P275, DOI 10.1093/mutage/8.4.275; COLES C, 1992, CANCER RES, V52, P5291; GOSTOUT B, 1993, HUM MOL GENET, V2, P293, DOI 10.1093/hmg/2.3.293; HABUCHI T, 1993, CANCER RES, V53, P3795; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; JONES PA, 1991, CANCER RES, V51, P3617; RIES LAG, 1991, DHEW NIH912789 PUBL; SOMMER SS, 1990, NATURE, V346, P22, DOI 10.1038/346022b0; SOMMER SS, 1992, J NATL CANCER I, V84, P246, DOI 10.1093/jnci/84.4.246; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068	10	64	65	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1195	1197		10.1016/S0140-6736(94)92403-1	http://dx.doi.org/10.1016/S0140-6736(94)92403-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909871				2022-12-28	WOS:A1994NL17500012
J	SUTHERLAND, LR; VERHOEF, M; WALLACE, JL; VANROSENDAAL, G; CRUTCHER, R; MEDDINGS, JB				SUTHERLAND, LR; VERHOEF, M; WALLACE, JL; VANROSENDAAL, G; CRUTCHER, R; MEDDINGS, JB			A SIMPLE, NONINVASIVE MARKER OF GASTRIC DAMAGE - SUCROSE PERMEABILITY	LANCET			English	Article							CROHNS-DISEASE; INTESTINAL PERMEABILITY; MISOPROSTOL; SUGARS	Disaccharides do not cross intact gastrointestinal mucosa to any appreciable extent unless there is damage to the epithelium. Furthermore, since sucrose is rapidly broken down in the small intestine, the absorption of intact sucrose implies damage to proximal epithelium. We have reported that measurement of sucrose permeability detects gastric damage in animals. Whilst such a non-specific test could not replace endoscopy, it might represent a clinically useful technique to identify patients who would benefit from endoscopy. 189 patients underwent endoscopy and assessment of sucrose permeability to evaluate the effectiveness of increased sucrose permeability in the prediction of endoscopic findings. The endoscopist was blinded to results of the sucrose assay. Gastric damage, particularly ulcers and severe gastritis, was successfully detected with this technique. Increased sucrose permeability, however, did not reliably detect mild gastritis, oesophagitis, or duodenal disease. The sensitivity of the test for gastric ulceration was 84% and specificity in predicting an abnormal endoscopy was 96%. Measurement of sucrose permeability is a simple way of screening for gastric damage. It has a sensitivity similar to that for upper gastrointestinal radiology and provides a new way to effectively screen large populations at risk of gastric damage.	UNIV CALGARY, GASTROINTESTINAL RES GRP, CALGARY T2N 4N1, AB, CANADA	University of Calgary								DAWSON DJ, 1988, CLIN SCI, V74, P427, DOI 10.1042/cs0740427; GRAHAM DY, 1988, LANCET, V2, P1277; HERLINGER H, 1977, CLIN RADIOL, V28, P307, DOI 10.1016/S0009-9260(77)80187-6; LAUFER I, 1976, GASTROENTEROLOGY, V71, P874; MEDDINGS JB, 1993, GASTROENTEROLOGY, V104, P1619, DOI 10.1016/0016-5085(93)90637-R; MURPHY MS, 1989, ARCH DIS CHILD, V64, P321, DOI 10.1136/adc.64.3.321; ROTH S, 1989, ARCH INTERN MED, V149, P775, DOI 10.1001/archinte.149.4.775; UKABAM SO, 1983, DIGESTION, V27, P70, DOI 10.1159/000198932; VANELBURG RM, 1992, SCAND J GASTROENTERO, V27, P19, DOI 10.3109/00365529209096021	9	120	122	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 23	1994	343	8904					998	1000		10.1016/S0140-6736(94)90125-2	http://dx.doi.org/10.1016/S0140-6736(94)90125-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909091				2022-12-28	WOS:A1994NG68200008
J	ROBINSON, IA; MCKEE, G; NICHOLSON, A; DARCY, J; JACKSON, PA; COOK, MG; KISSIN, MW				ROBINSON, IA; MCKEE, G; NICHOLSON, A; DARCY, J; JACKSON, PA; COOK, MG; KISSIN, MW			PROGNOSTIC VALUE OF CYTOLOGICAL GRADING OF FINE-NEEDLE ASPIRATES FROM BREAST CARCINOMAS	LANCET			English	Article							TERM FOLLOW-UP; CANCER; INDEX	Because neoadjuvant therapy, including preoperative chemotherapy and tamoxifen, is becoming increasingly common for early breast cancer, it is desirable to grade tumours before surgery so that the most appropriate medical regimen can be selected. We have used a cytological grading system for ductal carcinoma of type not otherwise specified (NOS). Wet-fixed Papanicolaou-stained breast aspirates are examined for the extent of cell dissociation, cell size and uniformity, and the appearance of nucleoli, the nuclear margin, and chromatin. 377 invasive breast carcinomas were removed after preoperative diagnostic fine-needle aspiration. cytology (FNAC) during the 25 months of the study. 286 tumours were ductal carcinomas NOS on histology. We established three cytological grades and found that cytological grade corresponded well with the established histological grades (Elston's modified Bloom and Richardson method). All cytological features included in the score were equally important on regression analysis. This study shows that grading of breast cancer on FNAC is feasible and reproducible. Cytological grade may substitute for histological grade, so a combination of FNAC and mammography can provide information on tumour type, grade, and size before surgery. We recommend this grading system to centres that use FNAC for the diagnosis of breast cancers.	ROYAL SURREY CTY HOSP, DEPT CYTOPATHOL, EGERTON RD, GUILDFORD GU2 5XX, SURREY, ENGLAND; ROYAL SURREY CTY HOSP, DEPT SURG, GUILDFORD GU2 5XX, SURREY, ENGLAND; ROYAL SURREY CTY HOSP, DEPT HISTOPATHOL, GUILDFORD GU2 5XX, SURREY, ENGLAND	Royal Surrey County Hospital; Royal Surrey County Hospital; Royal Surrey County Hospital								BLACK MM, 1955, SURG GYNECOL OBSTET, V100, P543; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; CIATTO S, 1993, DIAGN CYTOPATHOL, V9, P160, DOI 10.1002/dc.2840090210; DOUSSAL V, 1989, CANCER, V64, P1914; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; Eichner W J, 1970, Nebr State Med J, V55, P405; ELLIS IO, 1992, HISTOPATHOLOGY, V20, P479; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; ELSTON CW, 1987, DIAGNOSTIC HISTOPATH, P300; FISHER E, 1984, SURG CLIN N AM, V64, P361; Fisher E R, 1980, Pathol Annu, V15, P239; HAYBITTLE JL, 1982, BRIT J CANCER, V45, P361, DOI 10.1038/bjc.1982.62; Hunt C M, 1990, Cytopathology, V1, P287, DOI 10.1111/j.1365-2303.1990.tb00362.x; MORGAN D, 1993, BREAST, V2, P206; MOSSLER JA, 1982, ACTA CYTOL, V26, P417; MOURIQUAND J, 1986, J CLIN PATHOL, V39, P489, DOI 10.1136/jcp.39.5.489; NIH, 1991, ONCOLOGY, V5, P120; Page DL, 1987, DIAGNOSTIC HISTOPATH; POWLES T, 1993, BREAST, V2, P187; SCHULTE E, 1987, DIAGN CYTOPATHOL, V3, P256, DOI 10.1002/dc.2840030316; SMITH IE, 1993, EUR J CANCER, V29A, P1796, DOI 10.1016/0959-8049(93)90133-Z; SNEIGE N, 1989, DIAGN CYTOPATHOL, V5, P371, DOI 10.1002/dc.2840050406; THOMAS JS, 1989, J CLIN PATHOL, V42, P28, DOI 10.1136/jcp.42.1.28; TODD JH, 1987, BRIT J CANCER, V56, P489, DOI 10.1038/bjc.1987.230; ZAJDELA A, 1984, ACTA CYTOL, V23, P75; ZAJICEK J, 1974, ASPIRATION BIOPSY CY, P166; ZURRIDA S, 1993, BREAST, V2, P187	28	137	140	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					947	949		10.1016/S0140-6736(94)90066-3	http://dx.doi.org/10.1016/S0140-6736(94)90066-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909010				2022-12-28	WOS:A1994NF70000010
J	CLARK, DA				CLARK, DA			MICROFILARIA, TOLERANCE, AND T-CELLS	LANCET			English	Editorial Material											CLARK, DA (corresponding author), MCMASTER UNIV,DEPT MED,HAMILTON,ON,CANADA.							ASHERSON GL, 1992, IMMUNOLOGY, V76, P427; Gill Thomas J. Iii, 1994, P783; GILL TJ, 1991, AM J REPROD IMMUNOL, V25, P69, DOI 10.1111/j.1600-0897.1991.tb01065.x; GREEN DR, 1993, IMMUNOL TODAY, V14, P523, DOI 10.1016/0167-5699(93)90180-S; HAQUE A, 1988, EUR J IMMUNOL, V18, P1167, DOI 10.1002/eji.1830180804; PETERSON JD, 1993, EUR J IMMUNOL, V23, P46, DOI 10.1002/eji.1830230109; SPRENT J, 1993, AUTOIMMUNITY, V15, P155, DOI 10.3109/08916939309043890; ZETTEL L, 1992, INT IMMUNOL, V4, P975, DOI 10.1093/intimm/4.9.975; ZHANG L, 1993, TRANSPLANTATION, V56, P918, DOI 10.1097/00007890-199310000-00027	9	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 9	1994	343	8902					868	869		10.1016/S0140-6736(94)90004-3	http://dx.doi.org/10.1016/S0140-6736(94)90004-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF213	7908354				2022-12-28	WOS:A1994NF21300004
J	WOODS, KL; FLETCHER, S				WOODS, KL; FLETCHER, S			LONG-TERM OUTCOME AFTER INTRAVENOUS MAGNESIUM-SULFATE IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - THE 2ND LEICESTER INTRAVENOUS MAGNESIUM INTERVENTION TRIAL (LIMIT-2)	LANCET			English	Article							ISOLATED RAT-HEART; REPERFUSION; CALCIUM; SULFATE; METAANALYSIS; MORTALITY; ISCHEMIA; AGENTS	The second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2) examined the effect of an intravenous regimen of magnesium sulphate in 2316 patients with suspected acute myocardial infarction. Treatment, according to a double-blind randomised protocol, was started with a loading injection, before any thrombolytic therapy, and continued with a maintenance infusion for a further 24 h. Cause-specific mortality of randomised patients has now been examined over 1.0-5.5 (mean 2.7) years of follow-up. Mortality rate from ischaemic heart disease was reduced by 21% (95% CI 5-35%, p=0.01) and all-cause mortality rate reduced by 16% (2-29%, p=0.03) in magnesium-treated patients. Magnesium protects the contractile function of the myocardium from reperfusion injury (''stunning'') in experimental models; this observation accords with the 25% (7-39%, p=0.009) reduction in early left ventricular failure in the magnesium group of LIMIT-2. For such protection to occur, magnesium must be raised by the time of reperfusion since the injury is immediate. In the clinical context the timing of magnesium treatment in relation to thrombolytic therapy or spontaneous reperfusion is likely to be critical. The early benefits of this simple and safe intervention are reflected in improved long-term survival.	UNIV LEICESTER,DEPT MED & THERAPEUT,LEICESTER LE1 7RH,ENGLAND	University of Leicester								ADAMS JH, 1979, THROMB HAEMOSTASIS, V42, P603; AHMAD EN, 1991, FASEB J, V5, pA1045; BOLLI R, 1989, CIRC RES, V65, P607, DOI 10.1161/01.RES.65.3.607; BOLLI R, 1990, CIRCULATION, V82, P723, DOI 10.1161/01.CIR.82.3.723; BORCHGREVINK PC, 1989, AM J PHYSIOL, V256, pH195, DOI 10.1152/ajpheart.1989.256.1.H195; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; DUTOIT EF, 1992, CIRC RES, V70, P960, DOI 10.1161/01.RES.70.5.960; FERRARI R, 1986, J MOL CELL CARDIOL, V18, P487, DOI 10.1016/S0022-2828(86)80914-2; Fibrinolytic 'Therapy Trialists' (FTT) Collaborative Group, 1994, LANCET, V343, P311; GERTZ SD, 1987, MAGNESIUM, V6, P225; HARA A, 1990, N-S ARCH PHARMACOL, V342, P100; HEARSE DJ, 1978, J THORAC CARDIOV SUR, V75, P877; HENNING H, 1979, CIRCULATION, V59, P1124, DOI 10.1161/01.CIR.59.6.1124; HORNER SM, 1992, CIRCULATION, V86, P774, DOI 10.1161/01.CIR.86.3.774; HWANG DL, 1992, AM J HYPERTENS, V5, P700, DOI 10.1093/ajh/5.10.700; LAREAU S, 1993, CARDIOVASC RES, V27, P1009, DOI 10.1093/cvr/27.6.1009; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; RASMUSSEN HS, 1986, LANCET, V1, P234; RASMUSSEN HS, 1988, CLIN CARDIOL, V11, P377, DOI 10.1002/clc.4960110604; ROFFE C, 1994, BRIT HEART J, V71, P141; SMITH LF, 1986, INT J CARDIOL, V12, P1755; STEVENSON R, 1993, BMJ-BRIT MED J, V307, P349, DOI 10.1136/bmj.307.6900.349; TEO KK, 1991, BMJ-BRIT MED J, V303, P1499, DOI 10.1136/bmj.303.6816.1499; VIGORITO C, 1991, AM J CARDIOL, V67, P1435, DOI 10.1016/0002-9149(91)90478-4; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V; YANO Y, 1985, J SURG RES, V39, P529, DOI 10.1016/0022-4804(85)90121-0; 1991, LANCET, V338, P667; 1993, CIRCULATION S, V4, P1559	28	166	173	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					816	819		10.1016/S0140-6736(94)92024-9	http://dx.doi.org/10.1016/S0140-6736(94)92024-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908076				2022-12-28	WOS:A1994ND79200007
J	OLDENHAVE, A; NETELENBOS, C				OLDENHAVE, A; NETELENBOS, C			PATHOGENESIS OF CLIMACTERIC COMPLAINTS - READY FOR THE CHANGE	LANCET			English	Article							ESTROGEN REPLACEMENT THERAPY; DOPPLER-DERIVED PARAMETERS; CORONARY HEART-DISEASE; POSTMENOPAUSAL WOMEN; LUTEINIZING-HORMONE; AORTIC FLOW; BONE MASS; MENOPAUSE; PREVENTION; OSTEOPOROSIS		FREE UNIV AMSTERDAM HOSP, DEPT ENDOCRINOL, AMSTERDAM, NETHERLANDS	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	OLDENHAVE, A (corresponding author), ACAD HOSP UTRECHT, DEPT OBSTET & GYNAECOL, POB 85500, 3508 GA UTRECHT, NETHERLANDS.							ALAZZAWI F, 1987, BRIT MED J, V294, P1261, DOI 10.1136/bmj.294.6582.1261-a; ARJANDI BH, 1993, BONE MINER, V21, P63; BRICK JF, 1988, SOUTHERN MED J, V81, P98, DOI 10.1097/00007611-198801000-00024; BUSH TL, 1991, OSTEOPOROSIS INT, V2, P5, DOI 10.1007/BF01627072; CHEN JT, 1993, LANCET, V342, P49, DOI 10.1016/0140-6736(93)91911-5; CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445; DAVIES MC, 1990, BRIT MED J, V301, P790, DOI 10.1136/bmj.301.6755.790; ELDERS PJM, 1988, BONE MINER, V5, P11, DOI 10.1016/0169-6009(88)90003-7; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; GINSBURG J, 1981, BRIT J OBSTET GYNAEC, V88, P925, DOI 10.1111/j.1471-0528.1981.tb02230.x; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; HOROWITZ MC, 1993, SCIENCE, V260, P626, DOI 10.1126/science.8480174; Hui S L, 1990, Osteoporos Int, V1, P30, DOI 10.1007/BF01880413; ILES S, 1989, BAILLIERE CLIN OB GY, V3, P375, DOI 10.1016/S0950-3552(89)80028-8; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; KRONENBERG F, 1990, ANN NY ACAD SCI, V592, P52; LINDSAY R, 1976, LANCET, V1, P1038; LOMAX P, 1993, PHARMACOL THERAPEUT, V57, P347, DOI 10.1016/0163-7258(93)90060-Q; METCALF MG, 1981, CLIN ENDOCRINOL, V14, P245, DOI 10.1111/j.1365-2265.1981.tb00193.x; NAESSEN T, 1992, OSTEOPOROSIS INT, V2, P225, DOI 10.1007/BF01624146; OLDENHAVE A, 1993, AM J OBSTET GYNECOL, V168, P765, DOI 10.1016/S0002-9378(12)90816-9; OLDENHAVE A, 1993, AM J OBSTET GYNECOL, V168, P772, DOI 10.1016/S0002-9378(12)90817-0; OLDENHAVE A, 1991, THESIS LEIDSCHENDAM; PINES A, 1992, CHEST, V102, P1496, DOI 10.1378/chest.102.5.1496; PINES A, 1992, AM J CARDIOL, V69, P1104, DOI 10.1016/0002-9149(92)90877-2; RAVNIKAR V, 1984, FERTIL STERIL, V41, P881; REYES FI, 1977, AM J OBSTET GYNECOL, V129, P557; ROSANO GMC, 1993, LANCET, V342, P133, DOI 10.1016/0140-6736(93)91343-K; SLOOTWEG MC, 1993, HORM METAB RES, V25, P335, DOI 10.1055/s-2007-1002115; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; SULLIVAN JM, 1990, ARCH INTERN MED, V150, P2557, DOI 10.1001/archinte.150.12.2557; TRELOAR AE, 1981, MATURITAS, V3, P249, DOI 10.1016/0378-5122(81)90032-3; VANBERESTEIJN ECH, 1993, AM J EPIDEMIOL, V137, P383, DOI 10.1093/oxfordjournals.aje.a116686; WILLIAMS JK, 1992, J AM COLL CARDIOL, V20, P452, DOI 10.1016/0735-1097(92)90116-5	34	42	42	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 12	1994	343	8898					649	653		10.1016/S0140-6736(94)92641-7	http://dx.doi.org/10.1016/S0140-6736(94)92641-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906816				2022-12-28	WOS:A1994NA09300014
J	OCONNOR, V; AUGUSTINE, GJ; BETZ, H				OCONNOR, V; AUGUSTINE, GJ; BETZ, H			SYNAPTIC VESICLE EXOCYTOSIS - MOLECULES AND MODELS	CELL			English	Review							PROTEIN-KINASE-II; TRANSMITTER RELEASE; SYNAPSIN-I; BINDING		DUKE UNIV,MED CTR,DEPT NEUROBIOL,DURHAM,NC 27710	Duke University	OCONNOR, V (corresponding author), MAX PLANCK INST BRAIN RES,DEPT NEUROCHEM,D-60528 FRANKFURT,GERMANY.		Augustine, George James/J-9228-2013					ALNAES E, 1975, J PHYSIOL-LONDON, V248, P285, DOI 10.1113/jphysiol.1975.sp010974; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; GARCIA E, 1994, IN PRESS P NATL ACAD; GENGYOANDO K, 1993, NEURON, V11, P703, DOI 10.1016/0896-6273(93)90080-B; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HESS SD, 1993, SCIENCE, V259, P1169, DOI 10.1126/science.8438167; HODEL A, 1994, IN PRESS J BIOL CHEM; HORIKAWA HPM, 1993, FEBS LETT, V330, P236, DOI 10.1016/0014-5793(93)80281-X; LEVEQUE C, 1994, IN PRESS J BIOL CHEM; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; MOLLARD GF, 1991, NATURE, V328, P814; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; OCONNOR VM, 1993, FEBS LETT, V326, P255, DOI 10.1016/0014-5793(93)81802-7; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; PEVSNER J, 1994, IN PRESS P NATL ACAD; POPOLI M, 1993, FEBS LETT, V317, P85, DOI 10.1016/0014-5793(93)81496-M; POPOV SV, 1993, CELL, V73, P1247, DOI 10.1016/0092-8674(93)90352-Q; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; SALZBERG A, 1993, DEVELOPMENT, V117, P1309; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; THOMAS P, 1993, NEURON, V11, P93, DOI 10.1016/0896-6273(93)90274-U	33	110	111	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 11	1994	76	5					785	787		10.1016/0092-8674(94)90352-2	http://dx.doi.org/10.1016/0092-8674(94)90352-2			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	7907278				2022-12-28	WOS:A1994NA89000003
J	ROBERTS, M; WILLISON, H; VINCENT, A; NEWSOMDAVIS, J				ROBERTS, M; WILLISON, H; VINCENT, A; NEWSOMDAVIS, J			SERUM FACTOR IN MILLER-FISHER VARIANT OF GUILLAIN-BARRE-SYNDROME AND NEUROTRANSMITTER RELEASE	LANCET			English	Note								Serum IgG autoantibodies to GQ1b ganglioside are associated with the acute phase of the Miller-Fisher syndrome (MFS). We investigated the effects of three anti-GQ1b-positive MFS sera in the mouse phrenic-nerve/diaphragm preparation. Miniature endplate potential frequencies increased eight-fold within 25 min, declined rapidly, and ceased altogether after 3 h, when nerve stimulation no longer evoked a response. One MFS convalescent serum (anti-GQ1b negative) and sera from healthy controls and from patients with other neurological diseases were without effect. Thus muscle weakness in MFS may be caused by a serum factor, likely to be GQ1b antibody, that leads to failure of acetylcholine release from motor nerve terminals.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,DEPT CLIN NEUROL,NEUROSCI GRP,OXFORD OX3 9DU,ENGLAND; UNIV GLASGOW,SO GEN HOSP,INST NEUROL SCI,DEPT NEUROL,GLASGOW G51 4TF,SCOTLAND	University of Oxford; University of Glasgow			willison, hugh/HCI-7819-2022					CHIBA A, 1992, ANN NEUROL, V31, P677, DOI 10.1002/ana.410310619; FISHER M, 1956, NEW ENGL J MED, V255, P57, DOI 10.1056/NEJM195607122550201; LANG B, 1981, LANCET, V2, P224; MONTECUCCO C, 1988, BIOCHEM J, V251, P379, DOI 10.1042/bj2510379; WILLISON HJ, 1993, J NEUROIMMUNOL, V46, P105, DOI 10.1016/0165-5728(93)90239-U; WILLISON HJ, 1993, J NEUROL NEUROSUR PS, V56, P204, DOI 10.1136/jnnp.56.2.204; WILLISON HJ, IN PRESS J NEUROIMMU; YUKI N, 1993, NEUROLOGY, V43, P414, DOI 10.1212/WNL.43.2.414	8	151	153	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 19	1994	343	8895					454	455		10.1016/S0140-6736(94)92694-8	http://dx.doi.org/10.1016/S0140-6736(94)92694-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905957				2022-12-28	WOS:A1994MW69000012
J	SCHIEVINK, WI; PRAKASH, UBS; PIEPGRAS, DG; MOKRI, B				SCHIEVINK, WI; PRAKASH, UBS; PIEPGRAS, DG; MOKRI, B			ALPHA(1) ANTITRYPSIN DEFICIENCY IN INTRACRANIAL ANEURYSMS AND CERVICAL ARTERY DISSECTION	LANCET			English	Note							ALPHA-1-ANTITRYPSIN	The pathogenesis of ruptured intracranial aneurysms and cervical artery dissections is poorly understood but may be similar in these two disorders. We report four patients with alpha(1)-antitrypsin deficiency who developed a ruptured intracranial aneurysm or spontaneous dissection of the cervical internal carotid artery. Three patients were heterozygous for the deficient allele (PiMZ or PiGZ) and one was homozygous (PiZZ). A deficiency of alpha(1)-antitrypsin or one of the other protease inhibitors could result in degradation of the arterial wall through an imbalance between proteolytic enzymes and their inhibitors, thereby predisposing the arterial wall to dissection or aneurysm formation.	MAYO CLIN & MAYO FDN,DIV THORAC DIS & INTERNAL MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT NEUROL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic	SCHIEVINK, WI (corresponding author), MAYO CLIN & MAYO FDN,DEPT NEUROL SURG,200 1ST ST SW,ROCHESTER,MN 55905, USA.							COHEN JR, 1990, J SURG RES, V49, P319, DOI 10.1016/0022-4804(90)90029-2; Cox Diane Wilson, 1993, P549; FOGELHOLM R, 1987, J NEUROL NEUROSUR PS, V50, P78, DOI 10.1136/jnnp.50.1.78; KUIVANIEMI H, 1993, NEUROLOGY, V43, P2652, DOI 10.1212/WNL.43.12.2652; MITCHELL MB, 1993, J VASC SURG, V17, P420, DOI 10.1016/0741-5214(93)90427-N; SCHIEVINK WI, 1991, STROKE, V22, P1426, DOI 10.1161/01.STR.22.11.1426; SCHIEVINK WI, 1992, J NEUROSURG, V76, P62, DOI 10.3171/jns.1992.76.1.0062; SCHIEVINK WI, IN PRESS N ENGL J ME; SMITH KC, 1989, J AM ACAD DERMATOL, V21, P1192, DOI 10.1016/S0190-9622(89)70328-5; WALLAERT B, 1993, AM REV RESPIR DIS, V147, P1537, DOI 10.1164/ajrccm/147.6_Pt_1.1537	10	126	130	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 19	1994	343	8895					452	453		10.1016/S0140-6736(94)92693-X	http://dx.doi.org/10.1016/S0140-6736(94)92693-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905956				2022-12-28	WOS:A1994MW69000011
J	LAFOND, AK				LAFOND, AK			WHEN THE MONEY RUNS OUT	LANCET			English	Editorial Material											LAFOND, AK (corresponding author), SAVE CHILDREN FUND,LONDON,ENGLAND.							CAMPBELL BB, 1988, PRIMARY HLTH CARE SY; LAFOND A, 1993, SUSTAINABILITY HLT 1; LAFOND A, 1993, SUSTAINABILITY HLT 2; Smith M. W. A., 1986, Literary & Linguistic Computing, V1, P202, DOI 10.1093/llc/1.4.202; 1990, POVERTY; 1993, INVESTING HLTH	6	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					371	371		10.1016/S0140-6736(94)91218-1	http://dx.doi.org/10.1016/S0140-6736(94)91218-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905547				2022-12-28	WOS:A1994MW28300004
J	THOMPSON, C				THOMPSON, C			IGE DECLARES WAR ON PARASITES	LANCET			English	Editorial Material							SCHISTOSOMIASIS; REINFECTION; RESISTANCE											BUTTERWORTH AE, 1975, NATURE, V256, P727, DOI 10.1038/256727a0; CAPRON A, 1992, MEM I OSWALDO CRUZ, V87, P19, DOI [10.1590/S0074-02761992000800003, 10.1016/S0171-2985(11)80480-8]; CAPRON M, 1986, Parasitology Today, V2, P69, DOI 10.1016/0169-4758(86)90158-4; DUNNE DW, 1992, EUR J IMMUNOL, V22, P1483, DOI 10.1002/eji.1830220622; GUONNI AS, 1994, NATURE, V67, P183; HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0; 1993, WHO TECH REP SER, V830, P86	7	2	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 5	1994	343	8893					309	310		10.1016/S0140-6736(94)91159-2	http://dx.doi.org/10.1016/S0140-6736(94)91159-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905141				2022-12-28	WOS:A1994MU98500005
J	EVAINBRION, D; PORQUET, D; THEROND, P; FJELLESTADPAULSEN, A; GRENECHE, MO; FRANCOIS, L; CZERNICHOW, P				EVAINBRION, D; PORQUET, D; THEROND, P; FJELLESTADPAULSEN, A; GRENECHE, MO; FRANCOIS, L; CZERNICHOW, P			VITAMIN-A-DEFICIENCY AND NOCTURNAL GROWTH-HORMONE SECRETION IN SHORT CHILDREN	LANCET			English	Note							ALPHA-TOCOPHEROL; RETINOL	In the growth hormone (GH) neurosecretory dysfunction syndrome affecting slowly growing children with delayed bone age, low nocturnal GH secretion is accompanied by normal responses to pharmacological stimuli. We compared plasma vitamin A with physiological nocturnal and stimulated GH secretion in 68 short prepubertal children. Fasting plasma vitamin A correlated with nocturnal GH secretion but not with stimulated GH secretion. Total dietary vitamin A intake was significantly lower in short children with abnormal nocturnal GH secretion than in normal children and in endocrinologically-normal short children. 9 of 12 children with low nocturnal GH secretion and normal stimulated GH peaks who were supplemented with vitamin A 3000 mug for 3 months had increased nocturnal GH secretion.	HOP ROBERT DEBRE,SERV BIOCHIM HORMONOL,F-75019 PARIS,FRANCE; HOP ROBERT DEBRE,DEPT DIETET,F-75019 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite	EVAINBRION, D (corresponding author), HOP ROBERT DEBRE,SERV ENDOCRINOL & DIABETOL INFANTILE,48 BLVD SERURIER,F-75019 PARIS,FRANCE.							AMEDEEMANESME O, 1985, HEPATOLOGY, V5, P1143, DOI 10.1002/hep.1840050614; DELEENHEER AP, 1979, J CHROMATOGR, V162, P408, DOI 10.1016/S0378-4347(00)81528-5; MALVY JMD, 1989, INT J VITAM NUTR RES, V59, P29; MERRIAM GR, 1982, AM J PHYSIOL, V243, pE310, DOI 10.1152/ajpendo.1982.243.4.E310; PORQUET D, 1992, CLIN CHEM, V38, P1717; PORQUET D, 1993, HORM RES, V39, P19; SOUCI SW, 1989, COMPOSITION ALIMENTS; SPILIOTIS BE, 1984, JAMA-J AM MED ASSOC, V251, P2223, DOI 10.1001/jama.251.17.2223; ZADIK Z, 1985, PEDIATRICS, V76, P355	9	35	37	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					87	88		10.1016/S0140-6736(94)90819-2	http://dx.doi.org/10.1016/S0140-6736(94)90819-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903782				2022-12-28	WOS:A1994MQ09200014
J	TAYLOR, JA; WATSON, MA; DEVEREUX, TR; MICHELS, RY; SACCOMANNO, G; ANDERSON, M				TAYLOR, JA; WATSON, MA; DEVEREUX, TR; MICHELS, RY; SACCOMANNO, G; ANDERSON, M			P53 MUTATION HOTSPOT IN RADON-ASSOCIATED LUNG-CANCER	LANCET			English	Note							TUMOR SUPPRESSOR GENE; JAPAN	Mutations in gene p53 are the most common defects in lung cancer and may be a pathway through which environmental carcinogens initiate cancer. We investigated p53 mutations in lung cancers from uranium miners with high radon exposure. 16 (31%) of 52 large-cell and squamous-cell cancers from miners contained the same AGG to ATG transversion at codon 249, including cancers from 3 or 5 miners who had never smoked. This specific mutation has been reported in only 1 of 241 published p53 mutations from lung cancers. The codon 249 mutation may be a marker for radon-induced lung cancer.	NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709; ST MARYS HOSP,GRAND JCT,CO	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	TAYLOR, JA (corresponding author), NIEHS,EPIDEMIOL BRANCH,POB 12233,RES TRIANGLE PK,NC 27709, USA.		taylor, jack a/C-7154-2019	taylor, jack a/0000-0001-5303-6398				DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; JABERABOANSARI A, 1991, RADIAT RES, V127, P202, DOI 10.2307/3577966; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; KONDO K, 1992, BIOCHEM BIOPH RES CO, V183, P1139, DOI 10.1016/S0006-291X(05)80309-2; MITSUDOMI T, 1992, ONCOGENE, V7, P171; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SOZZI G, 1992, CANCER RES, V52, P6079; SUZUKI H, 1992, CANCER RES, V52, P734; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2	10	139	149	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					86	87		10.1016/S0140-6736(94)90818-4	http://dx.doi.org/10.1016/S0140-6736(94)90818-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903781				2022-12-28	WOS:A1994MQ09200013
J	NOJI, EK				NOJI, EK			PROGRESS IN DISASTER MANAGEMENT	LANCET			English	Editorial Material							INJURIES				NOJI, EK (corresponding author), CTR DIS CONTROL & PREVENT,ATLANTA,GA, USA.							ARMENIAN HK, 1992, B WORLD HEALTH ORGAN, V70, P251; BINDER S, 1987, ANN EMERG MED, V16, P1081, DOI 10.1016/S0196-0644(87)80763-1; FRANKEL DH, 1994, LANCET, V343, P347, DOI 10.1016/S0140-6736(94)91173-8; FRENCH J, 1983, PUBLIC HEALTH REP, V98, P584; GLASS RI, 1980, SCIENCE, V207, P734, DOI 10.1126/science.207.4432.734; LECHAT MF, 1990, DISASTERS, V14, P1, DOI 10.1111/j.1467-7717.1990.tb00967.x; NOJI EK, 1992, 2ND P US JAP NAT DIS, P327; 1993, WORLD DISASTERS REPO; 1992, MMWR, V41, P696; 1994, MMWR, V43, P194; 1988, ARES42169; 1993, MMWR, V42, P243; 1987, CONFRONTING NATURAL, P1	13	7	7	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1239	1240		10.1016/S0140-6736(94)92145-8	http://dx.doi.org/10.1016/S0140-6736(94)92145-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910269				2022-12-28	WOS:A1994NM14400003
J	LALLEMANT, M; BAILLOU, A; LALLEMANTLECOEUR, S; NZINGOULA, S; MAMPAKA, M; MPELE, P; BARIN, F; ESSEX, M				LALLEMANT, M; BAILLOU, A; LALLEMANTLECOEUR, S; NZINGOULA, S; MAMPAKA, M; MPELE, P; BARIN, F; ESSEX, M			MATERNAL ANTIBODY-RESPONSE AT DELIVERY AND PERINATAL TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN AFRICAN WOMEN	LANCET			English	Article							TO-INFANT TRANSMISSION; VERTICAL TRANSMISSION; HIV-1; GP120; INFECTION; MOTHER; SEQUENCE; DOMAIN; PHENOTYPE; CHILDREN	Prospective cohort studies indicate that 13-45% of human immunodeficiency virus type 1 (HIV-1)-infected pregnant women transmit the virus to their infants. Although factors that influence perinatal transmission are not well understood, drug and immunotherapy trials to interrupt transmission are underway. The identification of women most at risk is essential for prevention, counselling, and medical intervention. We assessed 70 HIV-1-infected pregnant women enrolled in a prospective study of perinatal transmission in Brazzaville, Congo. The relations between maternal health status, antibody levels to selected HIV-1 structural antigens at delivery, and infant outcome were explored. Independent of clinical stage, higher maternal antibody titres to peptides corresponding to the V3 region of gp120 and the immunodominant domain of gp41 were correlated with a higher risk of perinatal transmission. In a logistic regression model, the predicted risk of transmission for symptom-free women whose antibody titres to V3 and gp41 were lowest was 0.02, whereas it was 0.88 for symptomatic women whose antibody titres to V3 and TMSP18 were highest. These associations may give new insight into the mechanisms of perinatal transmission and they may also provide a powerful means of identifying women who would most benefit from intervention trials to halt perinatal transmission.	BRETONNEAU HOSP, VIROL LAB, TOURS, FRANCE; MINIST HLTH, NATL PROGRAM AIDS, Brazzaville, REP CONGO; MINIST HLTH, DEPT MOTHER & CHILD HLTH, Brazzaville, REP CONGO	CHU Tours	LALLEMANT, M (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT CANC BIOL, FRENCH RES INST DEV COOPERAT, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.							ARENDRUP M, 1992, J ACQ IMMUN DEF SYND, V5, P303; BAILLOU A, 1991, J CLIN MICROBIOL, V29, P1387, DOI 10.1128/JCM.29.7.1387-1391.1991; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BORKOWSKY W, 1992, PEDIATRICS, V90, P133; CHIN J, 1990, LANCET, V336, P221, DOI 10.1016/0140-6736(90)91743-T; DABIS F, 1993, AIDS, V7, P1139, DOI 10.1097/00002030-199308000-00027; DEVASH Y, 1990, P NATL ACAD SCI USA, V87, P3445, DOI 10.1073/pnas.87.9.3445; EHRNST A, 1991, LANCET, V338, P203, DOI 10.1016/0140-6736(91)90347-R; FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992; GOEDERT JJ, 1989, LANCET, V2, P1351; HALSEY NA, 1992, J ACQ IMMUN DEF SYND, V5, P153; HIRA SK, 1989, BRIT MED J, V299, P1250, DOI 10.1136/bmj.299.6710.1250; LALLEMANT M, 1989, AIDS, V3, P643, DOI 10.1097/00002030-198910000-00004; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LINDGREN S, 1991, AIDS, V5, P1111, DOI 10.1097/00002030-199109000-00009; NEWELL ML, 1992, LANCET, V339, P1007; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; PAREKH BS, 1991, AIDS, V5, P1179, DOI 10.1097/00002030-199110000-00004; ROBERTSON CA, 1992, J INFECT DIS, V166, P704, DOI 10.1093/infdis/166.4.704; ROBINSON WE, 1990, P NATL ACAD SCI USA, V87, P3185, DOI 10.1073/pnas.87.8.3185; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; UKWU HN, 1992, OBSTET GYNECOL, V80, P458; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; WOLFS TFW, 1990, P NATL ACAD SCI USA, V87, P9938, DOI 10.1073/pnas.87.24.9938; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; 1986, WKLY EPIDEMIOL REC, V61, P69; 1992, J ACQUIR IMM DEFIC S, V5, P1019	30	42	42	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 23	1994	343	8904					1001	1005		10.1016/S0140-6736(94)90126-0	http://dx.doi.org/10.1016/S0140-6736(94)90126-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909048				2022-12-28	WOS:A1994NG68200009
J	BUSCH, ORC; HOP, WCJ; MARQUET, RL; JEEKEL, J				BUSCH, ORC; HOP, WCJ; MARQUET, RL; JEEKEL, J			AUTOLOGOUS BLOOD AND INFECTIONS AFTER COLORECTAL SURGERY	LANCET			English	Letter											BUSCH, ORC (corresponding author), ERASMUS UNIV ROTTERDAM,HOSP DIJKZIGT,DEPT SURG,3015 GD ROTTERDAM,NETHERLANDS.		Busch, Olivier/AAC-3650-2020					BUSCH ORC, 1993, NEW ENGL J MED, V328, P1372, DOI 10.1056/NEJM199305133281902; 1993, LANCET, V342, P1328	2	33	33	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 12	1994	343	8898					668	668		10.1016/S0140-6736(94)92660-3	http://dx.doi.org/10.1016/S0140-6736(94)92660-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906822				2022-12-28	WOS:A1994NA09300031
J	CASPARI, R; FRIEDL, W; MANDL, M; MOSLEIN, G; KADMON, M; KNAPP, M; JACOBASCH, KH; ECKER, KW; KREISSLERHAAG, D; TIMMERMANS, G; PROPPING, P				CASPARI, R; FRIEDL, W; MANDL, M; MOSLEIN, G; KADMON, M; KNAPP, M; JACOBASCH, KH; ECKER, KW; KREISSLERHAAG, D; TIMMERMANS, G; PROPPING, P			FAMILIAL ADENOMATOUS POLYPOSIS - MUTATION AT CODON-1309 AND EARLY-ONSET OF COLON-CANCER	LANCET			English	Article							GERM-LINE MUTATIONS; APC GENE; CHROMOSOME-5Q21; IDENTIFICATION; FAP	The clinical course of familial adenomatous polyposis (FAP) varies considerably between patients. Prediction of the severity of the disease is important in the interest of effective cancer prevention. We examined whether age at diagnosis of FAP due to gastrointestinal symptoms and age at death due to colorectal cancer are related to the site of mutation in the responsible gene. 225 families with FAP were screened for mutations. The deletion of 5 base pairs at codon 1309 within exon 15 (known to be the most common mutation) was identified in 20 families; other mutations within exons 7-15 were found in 49 families. In patients with the 5 base-pair deletion at codon 1309, gastrointestinal symptoms and death from colorectal cancer occurred about 10 years earlier than in patients with other mutations. The 1309 mutation leads to development of colonic polyps at a younger age, thus giving rise to an earlier malignant tranformation. This relationship should be taken into account in strategies for preventing cancer in patients with FAP.	UNIV BONN,INST HUMAN GENET,D-53111 BONN,GERMANY; UNIV DUSSELDORF,SURG CLIN,DUSSELDORF,GERMANY; UNIV HEIDELBERG,SURG CLIN,HEIDELBERG,GERMANY; UNIV BONN,INST MED STAT,BONN,GERMANY; UNIV CLIN RUDOLF VIRCHOW,BERLIN,GERMANY; UNIV HOMBURG SAAR,SURG CLIN,HOMBURG,GERMANY	University of Bonn; Heinrich Heine University Dusseldorf; Ruprecht Karls University Heidelberg; University of Bonn			Ecker, Karl-Wilhelm/ABF-6313-2020	Ecker, Karl-Wilhelm/0000-0002-9672-2504				CASPARI R, 1993, Z GASTROENTEROL, V31, P646; COTTRELL S, 1992, LANCET, V340, P626, DOI 10.1016/0140-6736(92)92169-G; FODDE R, 1992, GENOMICS, V13, P1162, DOI 10.1016/0888-7543(92)90032-N; FRIEDL W, 1993, HUM MOL GENET, V2, P1481, DOI 10.1093/hmg/2.9.1481; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GRODEN J, 1993, AM J HUM GENET, V52, P262; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KIRK RE, 1968, EXPT DESIGN PROCEDUR, P299; MANDL M, 1994, HUM MOL GENET, V3, P181, DOI 10.1093/hmg/3.1.181; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; Nagase Hiroki, 1992, Human Mutation, V1, P467, DOI 10.1002/humu.1380010603; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OLSCHWANG S, 1993, AM J HUM GENET, V52, P273; OLSCHWANG S, 1993, CELL, V75, P959, DOI 10.1016/0092-8674(93)90539-3; PAUL P, 1993, HUM MOL GENET, V2, P925, DOI 10.1093/hmg/2.7.925; PRESCIUTTINI S, 1993, ANN HUM GENET, V57, P105, DOI 10.1111/j.1469-1809.1993.tb00892.x; REED TE, 1955, AM J HUM GENET, V7, P236; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; UTSONOMIYA J, 1980, CANCER, V45, P198; VARESCO L, 1993, AM J HUM GENET, V52, P280; VEALE AMO, 1965, EUGEN LAB, V40, P1	26	191	196	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 12	1994	343	8898					629	632		10.1016/S0140-6736(94)92634-4	http://dx.doi.org/10.1016/S0140-6736(94)92634-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906810				2022-12-28	WOS:A1994NA09300007
J	CORMAN, ML				CORMAN, ML			UNDERSTANDING SURVEILLANCE COLONOSCOPY	LANCET			English	Editorial Material							ULCERATIVE-COLITIS; DYSPLASIA; CANCER; PROGRAM				CORMAN, ML (corresponding author), SANSUM MED CLIN,SANTA BARBARA,CA 93105, USA.							BERNSTEIN CN, 1994, LANCET, V343, P71; CHOI PM, 1993, GASTROENTEROLOGY, V105, P418, DOI 10.1016/0016-5085(93)90715-O; COLLINS RH, 1987, NEW ENGL J MED, V316, P1654, DOI 10.1056/NEJM198706253162609; KIRSNER JB, 1982, NEW ENGL J MED, V306, P775, DOI 10.1056/NEJM198204013061304; LASHNER BA, 1992, AM J GASTROENTEROL, V87, P168; LEIDENIUS M, 1991, GUT, V32, P1521, DOI 10.1136/gut.32.12.1521; LENNARDJONES JE, 1986, GUT, V27, P1403, DOI 10.1136/gut.27.12.1403; LORBERG R, 1990, GASTROENTEROLOGY, V99, P1021; MORSON BC, 1967, GUT, V8, P423, DOI 10.1136/gut.8.5.423; NUGENT FW, 1991, GASTROENTEROLOGY, V100, P1241, DOI 10.1016/0016-5085(91)70010-U; NUGENT FW, 1979, GASTROENTEROLOGY, V76, P1; NUGENT FW, 1984, GASTROENTEROLOGY, V86, P1197; RUBIO CA, 1984, DIS COLON RECTUM, V27, P283, DOI 10.1007/BF02555626	13	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 5	1994	343	8897					556	557		10.1016/S0140-6736(94)91517-2	http://dx.doi.org/10.1016/S0140-6736(94)91517-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906325				2022-12-28	WOS:A1994MY84300005
J	CHESTER, KA; BEGENT, RHJ; ROBSON, L; KEEP, P; PEDLEY, RB; BODEN, JA; BOXER, G; GREEN, A; WINTER, G; COCHET, O; HAWKINS, RE				CHESTER, KA; BEGENT, RHJ; ROBSON, L; KEEP, P; PEDLEY, RB; BODEN, JA; BOXER, G; GREEN, A; WINTER, G; COCHET, O; HAWKINS, RE			PHAGE LIBRARIES FOR GENERATION OF CLINICALLY USEFUL ANTIBODIES	LANCET			English	Note							MONOCLONAL-ANTIBODIES; AFFINITY	Insertion of antibody genes into filamentous bacteriophage makes it possible to generate and screen libraries of 10(7) or more antibodies. Each phage expresses an antibody on its surface and contains the corresponding antibody gene. Genes that encode antibodies with desired characteristics are readily selected and their antibodies expressed as soluble proteins in Escherichia coli. We used this system to produce an antibody to carcinoembryonic antigen with higher affinity and better tumour specificity than antibodies currently in use.	ROYAL FREE HOSP,SCH MED,LONDON NW3 2PF,ENGLAND; CTR PROT ENGN,CAMBRIDGE,CAMBS,ENGLAND; ADDENBROOKES HOSP,CTR PROT ENGN,CAMBRIDGE,CAMBS,ENGLAND; ADDENBROOKES HOSP,DEPT CLIN ONCOL,CAMBRIDGE,CAMBS,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			Chester, Kerry/AAE-2856-2020					BEGENT RHJ, 1990, SCI CANCER TREATMENT, V2, P161; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; HAWKINS RE, 1992, BRIT MED J, V305, P1348, DOI 10.1136/bmj.305.6865.1348; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; NAP M, 1992, CANCER RES, V52, P2329	6	164	175	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 19	1994	343	8895					455	456		10.1016/S0140-6736(94)92695-6	http://dx.doi.org/10.1016/S0140-6736(94)92695-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905958				2022-12-28	WOS:A1994MW69000013
J	WETTER, LA; HAMADEH, RM; GRIFFISS, JM; OESTERLE, A; AAGAARD, B; WAY, LW				WETTER, LA; HAMADEH, RM; GRIFFISS, JM; OESTERLE, A; AAGAARD, B; WAY, LW			DIFFERENCES IN OUTER-MEMBRANE CHARACTERISTICS BETWEEN GALLSTONE-ASSOCIATED BACTERIA AND NORMAL BACTERIAL-FLORA	LANCET			English	Article							ESCHERICHIA-COLI; POLYACRYLAMIDE GELS; HEMOLYSIN PRODUCTION; ANTI-GAL; STONES; HEMAGGLUTINATION; ERYTHROCYTES; RECOGNITION; MANNOSE; BILE	Previous studies with scanning electron microscopy (SEM) have suggested that pigment gallstones contain bacteria. We set out to culture these bacteria and to study their membrane characteristics. We studied gallstones from 54 patients (36 men, 18 women; mean age 55.4 years) admitted consecutively to two hospitals for cholecystectomy. SEM detected bacteria in all of 14 brown pigment stones, 2 of 14 black pigment stones, and in the pigmented centres of 9 of 19 mixed cholesterol stones; no bacteria were detected in 14 pure cholesterol stones or within the cholesterol portions of mixed stones. We were able to culture bacteria from all gallstones with bacteria seen on SEM and for which sufficient material was available (n=16). 20 bacterial species were recovered from these stones. Gallstones containing bacteria were associated with clinical sepsis and cholangitis. All bacteria obtained from gallstones agglutinated human O P1 erythrocytes, which reflects the presence of P1-specific fimbriae. 5 strains were positive for Forssman-antigen-specific fimbriae. None showed evidence of mannose-specific fimbriae. All of the organisms bound anti-Gal, a ubiquitous naturally occurring IgG specific for a-galactosyl residues. The presence of P1 fimbriae and alpha-galactosyl residues and the absence of mannose-specific fimbriae distinguish these organisms from gut flora. We postulate that possession of these unusual properties may enhance the ability of bacteria to colonise the biliary tree and initiate pigment gallstone formation.	UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR IMMUNOCHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIAID NIH HHS [AI 21171] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021171] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIYOSHI T, 1990, DIGEST DIS SCI, V35, P27, DOI 10.1007/BF01537218; BERNHOFT RA, 1984, AM J SURG, V148, P77, DOI 10.1016/0002-9610(84)90292-7; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CETTA F, 1991, ANN SURG, V213, P315, DOI 10.1097/00000658-199104000-00006; CETTA FM, 1986, HEPATOLOGY, V6, P482, DOI 10.1002/hep.1840060327; DONOVAN JM, 1991, GASTROENTEROL CLIN N, V20, P47; DUGUID JP, 1980, BACTERIAL ADHERENC B, V6, P185; EVANS DJ, 1979, INFECT IMMUN, V23, P336, DOI 10.1128/IAI.23.2.336-346.1979; GALILI U, 1984, J EXP MED, V160, P1519, DOI 10.1084/jem.160.5.1519; GALILI U, 1985, J EXP MED, V162, P573, DOI 10.1084/jem.162.2.573; GREEN CP, 1981, INFECT IMMUN, V31, P309, DOI 10.1128/IAI.31.1.309-315.1981; HAMADEH R, 1991, CLIN RES, V39, pA439; HAMADEH RM, 1990, J CLIN MICROBIOL, V28, P20, DOI 10.1128/JCM.28.1.20-26.1990; HAMADEH RM, 1992, J CLIN INVEST, V89, P1223, DOI 10.1172/JCI115706; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; KALLENIUS G, 1980, FEMS MICROBIOL LETT, V7, P297, DOI 10.1111/j.1574-6941.1980.tb01608.x; KIM JJ, 1989, INFECT IMMUN, V57, P602, DOI 10.1128/IAI.57.2.602-608.1989; KORHONEN TK, 1985, INFECT IMMUN, V48, P486, DOI 10.1128/IAI.48.2.486-491.1985; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKI T, 1966, ANN SURG, V164, P90, DOI 10.1097/00000658-196607000-00010; OHANLEY P, 1985, NEW ENGL J MED, V313, P414, DOI 10.1056/NEJM198508153130704; OKADA Y, 1988, J IMMUNOL METHODS, V112, P243, DOI 10.1016/0022-1759(88)90364-X; OLD DC, 1972, J GEN MICROBIOL, V71, P149, DOI 10.1099/00221287-71-1-149; SKAR V, 1988, SCAND J GASTROENTERO, V23, P83, DOI 10.3109/00365528809093853; SMITH AL, 1989, ARCH SURG-CHICAGO, V124, P629; STEWART L, 1987, ANN SURG, V206, P242, DOI 10.1097/00000658-198709000-00002; SUNG JY, 1992, DIGEST DIS SCI, V37, P689, DOI 10.1007/BF01296423; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; VAISANEN V, 1981, LANCET, V2, P1366	29	35	37	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 19	1994	343	8895					444	448		10.1016/S0140-6736(94)92691-3	http://dx.doi.org/10.1016/S0140-6736(94)92691-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905954				2022-12-28	WOS:A1994MW69000009
J	LEFRERE, JJ; MARIOTTI, M; THAUVIN, M				LEFRERE, JJ; MARIOTTI, M; THAUVIN, M			B19 PARVOVIRUS DNA IN SOLVENT DETERGENT-TREATED ANTI-HEMOPHILIA CONCENTRATES	LANCET			English	Note							INFECTION	A transfusional B19 parvovirus infection may have severe consequences in immunocompromised hosts. The presence of B19 DNA was investigated with a polymerase chain reaction (PCR) assay in 30 batches of solvent/detergent-treated clotting factor concentrates (12 batches of factor VIII, 16 batches of factor IX, 1 batch of factor VII, and 1 batch of PPSB). B19 DNA was detected in 6 (20%) batches, including 3 factor VIII and 3 factor IX concentrates. Because of the frequency of B19 DNA in batches of clotting factors, measures to prevent transfusional risk of B19 infection via these blood products are justified, especially in recipients immunocompromised by HIV infection.			LEFRERE, JJ (corresponding author), HOP ST ANTOINE,INST NATL TRANSFUS SANGUINE,53 BLVD DIDEROT,F-75571 PARIS 12,FRANCE.							AZZI A, 1992, AM J HEMATOL, V39, P228, DOI 10.1002/ajh.2830390315; CORSI OB, 1988, J MED VIROL, V25, P165, DOI 10.1002/jmv.1890250206; LEFRERE JJ, 1992, BRIT J HAEMATOL, V82, P467, DOI 10.1111/j.1365-2141.1992.tb06446.x; LEFRERE JJ, 1986, BRIT J HAEMATOL, V62, P653, DOI 10.1111/j.1365-2141.1986.tb04088.x; MCOMISH F, 1993, J CLIN MICROBIOL, V31, P323, DOI 10.1128/JCM.31.2.323-328.1993; MORFINI M, 1992, AM J HEMATOL, V39, P149, DOI 10.1002/ajh.2830390217; MORTIMER PP, 1983, LANCET, V2, P482; NAIDES SJ, 1993, J INFECT DIS, V168, P101, DOI 10.1093/infdis/168.1.101; SOL N, 1993, J GEN VIROL, V74, P2011, DOI 10.1099/0022-1317-74-9-2011; ZAKRZEWSKA K, 1992, BRIT J HAEMATOL, V81, P407, DOI 10.1111/j.1365-2141.1992.tb08248.x	10	81	82	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 22	1994	343	8891					211	212		10.1016/S0140-6736(94)90993-8	http://dx.doi.org/10.1016/S0140-6736(94)90993-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT332	7904670				2022-12-28	WOS:A1994MT33200012
J	CHADWICK, D				CHADWICK, D			GABAPENTIN	LANCET			English	Article							BRAIN; ACID				CHADWICK, D (corresponding author), WALTON HOSP,DEPT NEUROL SCI,LIVERPOOL L9 1AE,MERSEYSIDE,ENGLAND.							ANHUT H, IN PRESS EPILEPSIA; BROWNE TR, ROYAL SOC MED INT C, V198, P47; Hauser W, 1990, EPILEPSY FREQUENCY C; HILL DR, 1993, EUR J PHARM-MOLEC PH, V244, P303, DOI 10.1016/0922-4106(93)90156-4; LIPPERT B, 1977, EUR J BIOCHEM, V74, P441, DOI 10.1111/j.1432-1033.1977.tb11410.x; LOSCHER W, 1991, NEUROSCI LETT, V128, P150, DOI 10.1016/0304-3940(91)90249-S; RICHENS A, ROYAL SOC MED INT C, V198, P41; TAYLOR CP, 1993, EPILEPSY RES, V14, P11, DOI 10.1016/0920-1211(93)90070-N; TAYLOR CP, ROYAL SOC MED INT C, V198, P13; TWYMAN RE, 1991, GABA MECHANISMS EPIL, P89; 1990, LANCET, V335, P1114; IN PRESS NEUROLOGY	12	70	73	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					89	91		10.1016/S0140-6736(94)90820-6	http://dx.doi.org/10.1016/S0140-6736(94)90820-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903783				2022-12-28	WOS:A1994MQ09200015
J	SIMONS, FER; SIMONS, KJ				SIMONS, FER; SIMONS, KJ			DRUG-THERAPY - THE PHARMACOLOGY AND USE OF H-1-RECEPTOR-ANTAGONIST DRUGS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SEASONAL ALLERGIC RHINITIS; CHRONIC IDIOPATHIC URTICARIA; POLLEN-INDUCED RHINOCONJUNCTIVITIS; HISTAMINE H1-RECEPTOR ANTAGONIST; DOUBLE-BLIND; PHARMACOKINETIC PROPERTIES; PROPHYLACTIC TREATMENT; TERFENADINE SELDANE; HAY-FEVER; CETIRIZINE		UNIV MANITOBA, FAC MED, WINNIPEG, MB, CANADA; UNIV MANITOBA, FAC PHARM, WINNIPEG R3T 2N2, MB, CANADA; UNIV MANITOBA, FAC SCI, WINNIPEG, MB, CANADA	University of Manitoba; University of Manitoba; University of Manitoba								ADVENIER C, 1989, DRUGS, V38, P634, DOI 10.2165/00003495-198938040-00009; AFFRIME MB, 1993, J ALLERGY CLIN IMMUN, V91, P259; ALFORD C, 1992, HUM PSYCHOPHARM CLIN, V7, P25, DOI 10.1002/hup.470070104; BANTZ EW, 1987, ANN ALLERGY, V59, P341; BELAICH S, 1990, ANN ALLERGY, V64, P191; BERTHJONES J, 1989, BRIT J DERMATOL, V121, P635, DOI 10.1111/j.1365-2133.1989.tb08196.x; BHATTI JZ, 1989, CLIN EXP ALLERGY, V19, P609, DOI 10.1111/j.1365-2222.1989.tb02754.x; BLEEHEN SS, 1987, BRIT J DERMATOL, V117, P81, DOI 10.1111/j.1365-2133.1987.tb04095.x; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P881, DOI 10.1016/0091-6749(88)90094-2; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V86, P248, DOI 10.1016/S0091-6749(05)80072-7; BOUSQUET J, 1992, THERAPEUTIC INDEX AN, P57; BRADLEY CM, 1987, EUR J CLIN PHARMACOL, V32, P419, DOI 10.1007/BF00543979; BRIK A, 1987, J ALLERGY CLIN IMMUN, V80, P51, DOI 10.1016/S0091-6749(87)80190-2; BROGDEN RN, 1991, DRUGS, V41, P927, DOI 10.2165/00003495-199141060-00008; BROGDEN RN, 1991, DRUGS, V42, P639, DOI 10.1007/BF03259139; BROOKS CD, 1990, CLIN EXP ALLERGY, V20, P21, DOI 10.1111/j.1365-2222.1990.tb02770.x; BRUNET C, 1990, J ALLERGY CLIN IMMUN, V86, P787, DOI 10.1016/S0091-6749(05)80184-8; CAINELLI T, 1986, PHARMATHERAPEUTICA, V4, P679; CANTEKIN EI, 1983, NEW ENGL J MED, V308, P297, DOI 10.1056/NEJM198302103080601; CASY AF, 1991, HDB EXPT PHARM, V97, P549; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; CHOWDHURY BA, 1994, J ALLERGY CLIN IMMUN, V93, P215; CIMBURA G, 1982, J FORENSIC SCI, V27, P855; CLISSOLD SP, 1989, DRUGS, V37, P42, DOI 10.2165/00003495-198937010-00003; DEBACKER MD, 1993, BIOCHEM BIOPH RES CO, V197, P1601, DOI 10.1006/bbrc.1993.2662; DECHANT KL, 1991, DRUGS, V41, P202, DOI 10.2165/00003495-199141020-00006; DELCARPIO J, 1989, J ALLERGY CLIN IMMUN, V84, P741; DIJKMAN JH, 1990, CLIN EXP ALLERGY, V20, P483, DOI 10.1111/j.1365-2222.1990.tb03140.x; ESTELLE F, 1994, DRUG SAFETY, V10, P350, DOI 10.2165/00002018-199410050-00002; FALLIERS CJ, 1991, ANN ALLERGY, V66, P257; FROSTAD AB, 1993, CLIN EXP ALLERGY, V23, P406, DOI 10.1111/j.1365-2222.1993.tb00346.x; GAFFEY MJ, 1988, PEDIATR INFECT DIS J, V7, P223, DOI 10.1097/00006454-198803000-00032; GENGO FM, 1987, CLIN PHARMACOL THER, V42, P265, DOI 10.1038/clpt.1987.145; GIBBS TG, 1989, BRIT J CLIN PRACT, V43, P11; GOETZ DW, 1991, ANN ALLERGY, V67, P448; GOETZ DW, 1989, J ALLERGY CLIN IMMUN, V84, P316, DOI 10.1016/0091-6749(89)90414-4; GRANT JA, 1988, J ALLERGY CLIN IMMUN, V81, P563, DOI 10.1016/0091-6749(88)90197-2; GRANT SM, 1991, DRUGS, V41, P889, DOI 10.2165/00003495-199141060-00007; GRANT SM, 1990, DRUGS, V40, P412, DOI 10.2165/00003495-199040030-00006; HANRAHAN JP, 1992, POST MARKETING SURVE, V6, P23; HILL SJ, 1990, PHARMACOL REV, V42, P45; HOLLISTER LE, 1975, PSYCHOPHARMACOL COMM, V1, P61; HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P1513, DOI 10.1001/jama.269.12.1513; HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P2088; HOWARTH PH, 1984, BRIT J CLIN PHARMACO, V18, P1; HUXTABLE RF, 1963, AM J DIS CHILD, V106, P496, DOI 10.1001/archpedi.1963.02080050498019; JANSSENS MML, 1993, CLIN REV ALLERG, V11, P35; JUHLIN L, 1988, BRIT J DERMATOL, V119, P67, DOI 10.1111/j.1365-2133.1988.tb07103.x; JUNIPER EF, 1989, J ALLERGY CLIN IMMUN, V83, P627, DOI 10.1016/0091-6749(89)90075-4; JUNIPER EF, 1988, J ALLERGY CLIN IMMUN, V82, P670, DOI 10.1016/0091-6749(88)90981-5; KLEMENTSSON H, 1990, J ALLERGY CLIN IMMUN, V86, P466, DOI 10.1016/S0091-6749(05)80201-5; LABRECQUE M, 1993, CHEST, V103, P777, DOI 10.1378/chest.103.3.777; LANTIN JP, 1990, CURR THER RES CLIN E, V47, P683; LEVANDER S, 1991, EUR J CLIN PHARMACOL, V41, P435, DOI 10.1007/BF00626365; LEVI R, 1991, HDB EXPT PHARM, P347; LORENTZ W, 1990, J CLIN ANESTHH, V2, P3450; LORENZ W, 1991, J CLIN ANESTH, V3, P170; MALO JL, 1990, J ALLERGY CLIN IMMUN, V85, P729, DOI 10.1016/0091-6749(90)90191-6; MARSHALL C, 1989, J ALLERGY CLIN IMMUN, V83, P254; MATZKE GR, 1987, ANN ALLERGY, V59, P25; MCTAVISH D, 1990, DRUGS, V39, P552, DOI 10.2165/00003495-199039040-00006; MCTAVISH D, 1989, DRUGS, V38, P778, DOI 10.2165/00003495-198938050-00005; MEADOR KJ, 1989, J ALLERGY CLIN IMMUN, V84, P322, DOI 10.1016/0091-6749(89)90415-6; MELTZER EO, 1991, ANN ALLERGY, V67, P625; MICHEL L, 1988, J ALLERGY CLIN IMMUN, V82, P101, DOI 10.1016/0091-6749(88)90058-9; NACLERIO RM, 1990, AM REV RESPIR DIS, V142, P167, DOI 10.1164/ajrccm/142.1.167; NACLERIO RM, 1989, LARYNGOSCOPE, V99, P596; NICHOLSON AN, 1991, BRIT J PHARMACOL, V104, P270, DOI 10.1111/j.1476-5381.1991.tb12418.x; ORGEL HA, 1991, ANN ALLERGY, V66, P237; PATON DM, 1985, CLIN PHARMACOKINET, V10, P477, DOI 10.2165/00003088-198510060-00002; PAUL E, 1986, EUR J CLIN PHARMACOL, V31, P277, DOI 10.1007/BF00981123; PEARCE FL, 1991, AGENTS ACTIONS, V33, P4, DOI 10.1007/BF01993112; PRATT CM, 1994, AM J CARDIOL, V73, P346, DOI 10.1016/0002-9149(94)90006-X; RAFFERTY P, 1989, J ALLERGY CLIN IMMUN, V84, P144, DOI 10.1016/0091-6749(89)90317-5; RAFFERTY P, 1987, AM REV RESPIR DIS, V135, P181; RAFFERTY P, 1990, BRIT J CLIN PHARMACO, V30, P229, DOI 10.1111/j.1365-2125.1990.tb03769.x; RAMPE D, 1993, MOL PHARMACOL, V44, P1240; RIMMER SJ, 1990, CLIN EXP ALLERGY, V20, P3, DOI 10.1111/j.1365-2222.1990.tb02456.x; ROMBAUT N, 1991, ANN ALLERGY, V67, P75; RUAT M, 1990, J NEUROCHEM, V55, P379, DOI 10.1111/j.1471-4159.1990.tb04148.x; SALE ME, 1993, J ALLERGY CLIN IMMUN, V91, P258; SANDERS RL, 1992, J ALLERGY CLIN IMMUN, V89, P183; SCHATZ M, 1993, ALLERGY PRINCIPLES P, V2, P1301; SEIDEL WF, 1990, J ALLERGY CLIN IMMUN, V86, P1029, DOI 10.1016/S0091-6749(05)80249-0; Simons F E, 1991, Clin Pharmacokinet, V21, P372; SIMONS FER, 1990, J ALLERGY CLIN IMMUN, V86, P540; SIMONS FER, 1988, J ALLERGY CLIN IMMUN, V82, P1068; SIMONS FER, 1994, J ALLERGY CLIN IMMUN, V93, P222; SIMONS FER, 1993, ALLERGY PRINCIPLES P, V1, P856; SIMONS FER, IN PRESS J ALLERGY C; SMITH MBH, 1993, JAMA-J AM MED ASSOC, V269, P2258, DOI 10.1001/jama.269.17.2258; SPENCER CM, 1993, DRUGS, V46, P1055, DOI 10.2165/00003495-199346060-00008; STERN MA, 1990, BRIT J CLIN PRACT, V44, P359; STORMS WW, 1989, J ALLERGY CLIN IMMUN, V83, P1083, DOI 10.1016/0091-6749(89)90450-8; TERLAAK AM, 1993, EUR J PHARMACOL, V232, P199, DOI 10.1016/0014-2999(93)90774-C; TIMMERMAN H, 1992, THERAPEUTIC INDEX AN, P19; TOWN GI, 1990, J ALLERGY CLIN IMMUN, V86, P886, DOI 10.1016/S0091-6749(05)80151-4; WATSON WTA, 1989, J ALLERGY CLIN IMMUN, V84, P457, DOI 10.1016/0091-6749(89)90358-8; WEILER J M, 1991, Journal of Allergy and Clinical Immunology, V87, P219, DOI 10.1016/0091-6749(91)91602-P; WHITE MV, 1990, J ALLERGY CLIN IMMUN, V86, P599, DOI 10.1016/S0091-6749(05)80223-4; WOOSLEY RL, 1993, JAMA-J AM MED ASSOC, V269, P1532, DOI 10.1001/jama.269.12.1532; YANG W H, 1991, Journal of Allergy and Clinical Immunology, V87, P224, DOI 10.1016/0091-6749(91)91620-9; ZHANG MQ, 1993, EUR J MED CHEM, V28, P165, DOI 10.1016/0223-5234(93)90009-4	103	286	304	1	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 9	1994	330	23					1663	1670						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP220	7909915				2022-12-28	WOS:A1994NP22000007
J	PINI, P				PINI, P			SUPERBUG STARS IN MEDIA-MADE EPIDEMIC	LANCET			English	Editorial Material																		CLEARY PP, 1992, LANCET, V339, P518, DOI 10.1016/0140-6736(92)90339-5; SCHWARTZ B, 1990, LANCET, V336, P1167, DOI 10.1016/0140-6736(90)92777-F; SEPPALA H, 1992, NEW ENGL J MED, V326, P292, DOI 10.1056/NEJM199201303260503; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; 1994, COMMUNICAB DIS REP, V4, P97	5	15	16	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1376	1377		10.1016/S0140-6736(94)92518-6	http://dx.doi.org/10.1016/S0140-6736(94)92518-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910878				2022-12-28	WOS:A1994NP95500004
J	TAGGART, DP; PEPPER, J				TAGGART, DP; PEPPER, J			NORMOTHERMIC VERSUS HYPOTHERMIC CORONARY-BYPASS SURGERY	LANCET			English	Letter											TAGGART, DP (corresponding author), ROYAL BROMPTON NATL HEART & LUNG HOSP,LONDON SW3 6NP,ENGLAND.							LICHTENSTEIN SV, 1989, LANCET, V1, P1443; LOOP FD, 1992, J THORAC CARDIOV SUR, V104, P608; MARTIN TD, 1994, ANN THORAC SURG, V57, P298, DOI 10.1016/0003-4975(94)90987-3; TAGGART DP, 1994, BRIT HEART J, V71, P177; TAGGART DP, IN PRESS BR HEART J	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1994	343	8906					1156	1156						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK730	7910241				2022-12-28	WOS:A1994NK73000031
J	OSMOND, D; CHARLEBOIS, E; LANG, W; SHIBOSKI, S; MOSS, A				OSMOND, D; CHARLEBOIS, E; LANG, W; SHIBOSKI, S; MOSS, A			CHANGES IN AIDS SURVIVAL-TIME IN 2 SAN-FRANCISCO COHORTS OF HOMOSEXUAL MEN, 1983 TO 1993	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; CONTROLLED TRIAL; TRIMETHOPRIM SULFAMETHOXAZOLE; AEROSOLIZED PENTAMIDINE; INCUBATION PERIOD; HIV-INFECTION; ZIDOVUDINE; RISK; PROPHYLAXIS	Background.-During the first decade since the recognition of the acquired immunodeficiency syndrome (AIDS), new therapies have been introduced and the frequency of clinical manifestations has changed. The impact of these changes on AIDS survival, however, has not been well characterized. Design.-A prospective cohort study of the outcomes of human immunodeficiency virus (HIV) infection. Setting.-Homosexual and bisexual men residing in San Francisco, Calif, recruited in 1983 and 1984 for two prospective studies and followed up for more than 9 years with clinical examinations. Participants.-A total of 761 HIV-positive homosexual and bisexual men. MaIn Outcome Measures.-Survival time from a CD4 lymphocyte count at 0.20 x 10(9)/L (200/muL) and from a clinical AIDS diagnosis to death. Results.-Median survival time from a CD4 lymphocyte count at 0.20 x 10(9)/L increased from 28.4 months in the October 1983 to November 1986 period to 40.1 months in the November 1986 to November 1988 period and is estimated at 38.1 months in the November 1988 to February 1993 period. Patients diagnosed with Pneumocystis carinii pneumonia (PCP) accounted for most of this increase with a gain in median survival time of 9.7 months (P=.0009), compared with a nonsignificant decline in the survival time of those patients without a PCP diagnosis. Multivariate analysis showed that rate of CD4 lymphocyte loss (P<.001) and receipt of both PCP prophylaxis and antiretroviral therapy (P=.04) were significantly associated with longer survival time, whereas antiretroviral therapy alone was not (P=.81). Time to death from a clinical AIDS diagnosis was 14.7 months in the 1983 to 1986 period, 19.1 months in the 1986 to 1988 period, and an estimated 15.7 months in the 1988 to 1993 period. Conclusions.-Survival time from a CD4 lymphocyte count at 0.20 x 10(9)/L has improved significantly by about 1 year, yet survival time using the 1987 AIDS case definition has shown small improvement. The largest increase in survival time from a CD4 lymphocyte count at 0.20 x 10(9)/L was in patients diagnosed with PCP, suggesting that PCP prophylaxis and treatment were more important factors in longer survival time than antiretroviral therapy.	CALIF PACIFIC MED CTR,SAN FRANCISCO,CA	California Pacific Medical Center	OSMOND, D (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT EPIDEMIOL & BIOSTAT,DIV EPIDEMIOL & MED,SAN FRANCISCO,CA 94110, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI082515] Funding Source: NIH RePORTER; NIAID NIH HHS [NIAID N01-AI-82515] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; [Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BACCHETTI P, 1989, NATURE, V338, P251, DOI 10.1038/338251a0; BACCHETTI P, 1988, J INFECT DIS, V157, P104; CHAISSON RE, 1992, ARCH INTERN MED, V152, P2009, DOI 10.1001/archinte.152.10.2009; CREAGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009, DOI 10.1001/jama.260.20.3009; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCHL MA, 1990, NEW ENGL J MED, V323, P1090; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; LANG W, 1989, LANCET, V1, P1397; LANG W, 1987, JAMA-J AM MED ASSOC, V257, P326, DOI 10.1001/jama.257.3.326; LANGE N, 1992, J AM STAT ASSOC, V87, P615, DOI 10.2307/2290194; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LUI KJ, 1988, SCIENCE, V240, P1333, DOI 10.1126/science.3163848; LUNDGREN JD, 1993, 9TH INT C AIDS BERL; Miller R. G., 1981, SURVIVAL ANAL; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; MOSS AR, 1987, AM J EPIDEMIOL, V125, P1035, DOI 10.1093/oxfordjournals.aje.a114619; PHILLIPS AN, 1992, JAMA-J AM MED ASSOC, V268, P2662, DOI 10.1001/jama.268.19.2662; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; SEAGE GR, 1990, AM J PUBLIC HEALTH, V80, P835, DOI 10.2105/AJPH.80.7.835; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321; 1987, SAS STAT GUIDE PERSO; 1987, MMWR MORB MORTAL WKL, V34, P373; IN PRESS HIV AIDS SU	28	98	98	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	1994	271	14					1083	1087		10.1001/jama.271.14.1083	http://dx.doi.org/10.1001/jama.271.14.1083			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE228	7908703				2022-12-28	WOS:A1994NE22800029
J	WIEBERS, DO; LEANING, J; WHITE, RD				WIEBERS, DO; LEANING, J; WHITE, RD			ANIMAL PROTECTION AND MEDICAL SCIENCE	LANCET			English	Editorial Material							RIGHTS											COHEN C, 1986, NEW ENGL J MED, V315, P865, DOI 10.1056/NEJM198610023151405; DIXON B, 1976, WHAT IS SCI; GLUCK JP, 1991, ETHICS BEHAV, V2, P157; JOHNSON D, 1990, PSYCHOL SCI, V1, P213, DOI 10.1111/j.1467-9280.1990.tb00201.x; KULLBERG JF, 1991, NY TIMES        0129; LUBATON S, 1993, NY TIMES        0225; PARDES H, 1991, NEW ENGL J MED, V324, P1640, DOI 10.1056/NEJM199106063242306; RENNIE D, 1989, JAMA-J AM MED ASSOC, V261, P2543, DOI 10.1001/jama.261.17.2543; Russell WMS, 1959, PRINCIPLES HUMAN EXP; SMITH SJ, 1988, JAMA-J AM MED ASSOC, V259, P2007, DOI 10.1001/jama.259.13.2007; VANNOORDEN GK, 1991, AM J OPHTHALMOL, V111, P367; VISSCHER MB, 1966, JAMA-J AM MED ASSOC, V196, P101; WOOLSEY TA, 1988, CIRCULATION, V77, P1197, DOI 10.1161/01.CIR.77.6.1197	13	5	5	2	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 9	1994	343	8902					902	904		10.1016/S0140-6736(94)90013-2	http://dx.doi.org/10.1016/S0140-6736(94)90013-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF213	7908363	Green Submitted			2022-12-28	WOS:A1994NF21300013
J	PRENTICE, HG; GLUCKMAN, E; POWLES, RL; LJUNGMAN, P; MILPIED, NJ; RANADA, JMF; MANDELLI, F; KHO, P; KENNEDY, L; BELL, AR; HAMON, MD; COUMAR, A; HIRSCH, I; HANRAHAN, A; BURNETT, A; RUSSELL, N; HUNTER, A; CAHN, JY; FLESCH, M; FIERE, D; TIGAUD, J; ASHCAN, J; ARCESE, W; DINUCCI, G; GENTILE, G; DELAURENZI, A; PACILLI, L; ROSSIFERRINI, P; BOSI, A; MARTELLI, M; AVERSA, F; FELICINI, R; TURA, S; ROSTI, G; BERLARDINELLI, AR; BERNASCONI, C; ALLESSANDRINO, E; LUCARELLI, G; GALIMBERTI, M; KOLB, JH; CAMERA, R; BEESLEY, K; FIDDIAN, AP; GEFFRIER, C; PAPARATTI, U; PARKE, A; USAN, L				PRENTICE, HG; GLUCKMAN, E; POWLES, RL; LJUNGMAN, P; MILPIED, NJ; RANADA, JMF; MANDELLI, F; KHO, P; KENNEDY, L; BELL, AR; HAMON, MD; COUMAR, A; HIRSCH, I; HANRAHAN, A; BURNETT, A; RUSSELL, N; HUNTER, A; CAHN, JY; FLESCH, M; FIERE, D; TIGAUD, J; ASHCAN, J; ARCESE, W; DINUCCI, G; GENTILE, G; DELAURENZI, A; PACILLI, L; ROSSIFERRINI, P; BOSI, A; MARTELLI, M; AVERSA, F; FELICINI, R; TURA, S; ROSTI, G; BERLARDINELLI, AR; BERNASCONI, C; ALLESSANDRINO, E; LUCARELLI, G; GALIMBERTI, M; KOLB, JH; CAMERA, R; BEESLEY, K; FIDDIAN, AP; GEFFRIER, C; PAPARATTI, U; PARKE, A; USAN, L			IMPACT OF LONG-TERM ACYCLOVIR ON CYTOMEGALOVIRUS-INFECTION AND SURVIVAL AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION	LANCET			English	Article							SEVERELY IMMUNOCOMPROMISED PATIENTS; VIRUS INFECTIONS; CONTROLLED TRIAL; ORAL ACYCLOVIR; RECIPIENTS; GANCICLOVIR; PROPHYLAXIS; IMMUNOGLOBULIN; PREVENTION; PNEUMONIA	Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality after allogeneic bone marrow transplantation (BMT). Our aim was to study the prophylactic effect of high-dose intravenous acyclovir given around the time of BMT followed by oral acyclovir on CMV infection and survival. 310 BMT recipients at risk of developing CMV infection were randomised to one of three regimens in a double-blind and double-dummy design: intravenous acyclovir (500 mg/m(2), three times a day) for 1 month followed by oral acyclovir (800 mg four times a day for a further 6 months) (intravenous/oral group); intravenous acyclovir followed by oral placebo (intermediate group); or low-dose oral acyclovir (200 or 400 mg, four times a day) followed by placebo (''controls''). Analysis was by intention-to-treat. Intravenous acyclovir significantly reduced the probability of and delayed the onset of CMV infection. There was no further reduction in infection risk with the addition of long-term oral acyclovir. Time to CMV viraemia was delayed in the intravenous/oral acyclovir group compared with controls. Extending the prophylaxis with oral acyclovir significantly improved survival: 79 of 105 recipients were still alive at 7 months compared with 60 of 102 controls (p=0.012). Although the intravenous/oral acyclovir group did significantly better than controls in terms of survival, the difference between the intravenous/oral acyclovir group and the intermediate group was of borderline statistical significance (p=0.054). Adverse events that were possibly treatment related were similar in all three groups. The most commonly reported events were nausea, vomiting, elevated creatinine, and renal failure.	HOP ST LOUIS,SERV HEMATOL,PARIS,FRANCE; ROYAL MARSDEN HOSP,LEUKAEMIA UNIT,SUTTON,SURREY,ENGLAND; HUDDINGE SJUKHUS,MED KLIN,HUDDINGE,SWEDEN; CTR HOSP REG UNIV NANTES,HOTEL DIEU,SERV HEMATOL PR HAROUSSEAU & PR MLLPLED,NANTES,FRANCE; HOSP PRINCESA,MADRID,SPAIN; INST EMATOL,ROME,ITALY; WELLCOME RES LABS,BECKENHAM,KENT,ENGLAND; GLASGOW ROYAL HOSP,GLASGOW,LANARK,SCOTLAND; CITY HOSP,NOTTINGHAM,NOTTS,ENGLAND; HOP JEAN MINJOZ,BESANCON,FRANCE; HOP EDOUARD HERRIOT,LYON,FRANCE; OSPED DI CAREGGI,FLORENCE,ITALY; POLYCLIN MONTELUCE,PERUGIA,ITALY; OSPED S ORSOLA MALPIGHI,BOLOGNA,ITALY; OSPED SAN MATTEO,PAVIA,ITALY; OSPED PESARO,PASARO,ITALY; KLINIKUM GROSSHADERN,MUNICH,GERMANY; OSPED S CAMILLO ROMA,ROME,ITALY; WELLCOME FDN LTD,BECKENHAM,KENT,ENGLAND	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Royal Marsden NHS Foundation Trust; Nantes Universite; CHU de Nantes; Hospital de La Princesa; GlaxoSmithKline; Wellcome Research Laboratories; University of Nottingham; Universite de Franche-Comte; CHU Besancon; CHU Lyon; IRCCS Azienda Ospedaliero-Universitaria di Bologna; IRCCS Fondazione San Matteo; University of Munich; GlaxoSmithKline	PRENTICE, HG (corresponding author), ROYAL FREE HOSP,DEPT HAEMATOL,LONDON NW3 2QG,ENGLAND.		Ljungman, Per/M-4946-2019	Milpied, Noel/0000-0002-5177-014X				BALFOUR HH, 1989, NEW ENGL J MED, V320, P1381, DOI 10.1056/NEJM198905253202105; EMMANUEL D, 1988, ANN INTERN MED, V109, P777; GOODRICH JM, 1993, ANN INTERN MED, V118, P173, DOI 10.7326/0003-4819-118-3-199302010-00003; GUYOTAT D, 1987, J MED VIROL, V23, P393, DOI 10.1002/jmv.1890230412; LJUNGMAN P, 1992, CLIN INFECT DIS, V14, P831, DOI 10.1093/clinids/14.4.831; LJUNGMAN P, 1986, BONE MARROW TRANSPL, V1, P185; Meyers J D, 1984, Birth Defects Orig Artic Ser, V20, P101; MEYERS JD, 1988, NEW ENGL J MED, V318, P70, DOI 10.1056/NEJM198801143180202; OREILLY RJ, 1983, BLOOD, V62, P941; PAULIN T, 1985, TRANSPLANTATION, V39, P377, DOI 10.1097/00007890-198504000-00008; PRENTICE HG, 1983, J ANTIMICROB CHEMOTH, V12, P153, DOI 10.1093/jac/12.suppl_B.153; REED EC, 1988, ANN INTERN MED, V109, P783, DOI 10.7326/0003-4819-109-10-783; ROOK AH, 1985, CLIN RES, V33, pA560; SARAL R, 1981, NEW ENGL J MED, V305, P63, DOI 10.1056/NEJM198107093050202; SAWYER MH, 1993, AM J MED, V84, P1067; SCHMIDT GM, 1988, TRANSPLANTATION, V46, P905; SELBY PJ, 1989, BRIT J CANCER, V59, P434, DOI 10.1038/bjc.1989.88; SHEPP DH, 1986, NEW ENGL J MED, V314, P208, DOI 10.1056/NEJM198601233140404; SMITH PD, 1985, PHYSL METABOLIC IMMU, P319; TYMS AS, 1981, J ANTIMICROB CHEMOTH, V8, P65, DOI 10.1093/jac/8.1.65; WINSTON DJ, 1993, ANN INTERN MED, V118, P179, DOI 10.7326/0003-4819-118-3-199302010-00004	21	257	263	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 26	1994	343	8900					749	753		10.1016/S0140-6736(94)91835-X	http://dx.doi.org/10.1016/S0140-6736(94)91835-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907729				2022-12-28	WOS:A1994NC35100007
J	VANDERMAST, BJ; HORNSTRA, N; RUIGROK, MB; CLAAS, FHJ; VANROOD, JJ; LAGAAIJ, EL				VANDERMAST, BJ; HORNSTRA, N; RUIGROK, MB; CLAAS, FHJ; VANROOD, JJ; LAGAAIJ, EL			TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE IN IMMUNOCOMPETENT PATIENTS - A SELF-PROTECTIVE MECHANISM	LANCET			English	Article							NONIMMUNOCOMPROMISED HOSTS; BLOOD-TRANSFUSIONS; T-CELLS; RESISTANCE; TRANSPLANTATION; HEART; RATS	Transfusion-associated graft-versus-host disease (TA-GVHD) is a rare but hazardous complication caused by transfusion of leucocyte-containing blood. It is not clear why some patients are at risk for TA-GVHD, but others are not. We studied TA-GVHD in immunocompetent individuals by looking at donor-anti-host reactivity after transfusion of leucocyte-containing blood. We tested reactivity in 62 donor-recipient combinations in vitro before and at different times after blood transfusion with mixed lymphocyte culture. One patient was studied in more detail. Reactivity of blood donors against hosts gradually decreased after blood transfusion. This decrease significantly correlated with time (p<0.001). Studies in a single patient showed that absence of donor-host reactivity was due to host T cells that inhibited the response. These data indicate that an active mechanism exists in immunocompetent individuals which inhibits the graft-versus-host reaction of the donor against the host. This mechanism might be exploited in organ transplantation by pre-transplant blood transfer.	UNIV HOSP LEIDEN,DEPT IMMUNOHAEMATOL & BLOOD BANK,2333 AA LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)								ANDERSEN CB, 1992, HUM PATHOL, V23, P831, DOI 10.1016/0046-8177(92)90355-7; AVOY DR, 1990, TRANSFUSION, V30, P849, DOI 10.1046/j.1537-2995.1990.30991048795.x; BELGRAU DL, 1978, J EXP MED, V148, P103; BURDICK JF, 1988, NEW ENGL J MED, V318, P689, DOI 10.1056/NEJM198803173181107; DEGAST GC, 1991, BONE MARROW TRANSPL, V7, P293; DESFORGES JF, 1990, NEW ENGL J MED, V323, P315; GOULMY E, 1983, HLA TYPING METHODOLO, V2, P105; GREENBAUM BH, 1991, J CLIN ONCOL, V9, P1889, DOI 10.1200/JCO.1991.9.10.1889; KIMURA H, 1984, J EXP MED, V160, P652, DOI 10.1084/jem.160.3.652; KIMURA H, 1984, NATURE, V308, P463, DOI 10.1038/308463a0; KOSMATOPOULOS K, 1987, J IMMUNOL, V138, P1038; KOSMATOPOULOS K, 1988, TRANSPLANTATION, V46, P570, DOI 10.1097/00007890-198810000-00021; KOSMATOPOULOS K, 1987, TRANSPLANTATION, V44, P267, DOI 10.1097/00007890-198708000-00018; LAGAAIJ EL, 1989, NEW ENGL J MED, V321, P701, DOI 10.1056/NEJM198909143211101; LEHMANN PV, 1991, J EXP MED, V173, P333, DOI 10.1084/jem.173.2.333; MARCUS JN, 1989, NEW ENGL J MED, V322, P1004; OHTO H, 1992, TRANSFUSION, V32, P691, DOI 10.1046/j.1537-2995.1992.32792391051.x; OPELZ G, 1973, TRANSPLANT P, V5, P253; PIRENNE J, 1991, TRANSPLANTATION, V51, P51, DOI 10.1097/00007890-199101000-00007; SAKAKIBARA T, 1986, LANCET, V2, P1099; SAZAMA K, 1990, TRANSFUSION, V30, P583, DOI 10.1046/j.1537-2995.1990.30790385515.x; SHIVDASANI RA, 1993, NEW ENGL J MED, V328, P766, DOI 10.1056/NEJM199303183281105; SPITZER TR, 1990, CANCER-AM CANCER SOC, V66, P2346, DOI 10.1002/1097-0142(19901201)66:11<2346::AID-CNCR2820661116>3.0.CO;2-T; SUZUKI K, 1992, TRANSFUSION, V32, P358, DOI 10.1046/j.1537-2995.1992.32492263452.x; VOGELSANG GB, 1990, TRANSFUSION, V30, P101, DOI 10.1046/j.1537-2995.1990.30290162892.x; WILSON DB, 1989, IMMUNOL REV, V107, P159, DOI 10.1111/j.1600-065X.1989.tb00008.x; 1989, LANCET, V2, P529	27	32	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 26	1994	343	8900					753	757		10.1016/S0140-6736(94)91836-8	http://dx.doi.org/10.1016/S0140-6736(94)91836-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907730				2022-12-28	WOS:A1994NC35100008
J	FARRANT, M; FELDMEYER, D; TAKAHASHI, T; CULLCANDY, SG				FARRANT, M; FELDMEYER, D; TAKAHASHI, T; CULLCANDY, SG			NMDA-RECEPTOR CHANNEL DIVERSITY IN THE DEVELOPING CEREBELLUM	NATURE			English	Article							METHYL-D-ASPARTATE; NEURONS; RAT; GLUTAMATE; ACTIVATION; CURRENTS; ADULT; CELLS; DISTINCTION; RESPONSES	IN the cerebellum, NMDA (N-methyl-D-aspartate) receptors play an important role in neuronal differentiation(1,2) and excitatory synaptic transmission(3-5). During early cerebellar development, marked changes occur in the distribution of messenger RNAs encoding various NMDA-receptor subunits(6). To determine whether these changes result in the appearance of functionally distinct NMDA receptors(7-9), we have recorded single-channel currents in rat cerebellar granule cells during the period of their migration from the external germinal layer to the inner granular layer(10). Here we show that before synapse formation(10,11), pre-migratory and migrating granule cells express NMDA receptors possessing single-channel properties similar to those previously described for many central neurons(12,16). In contrast, mature post-migratory cells also express an atypical form of NMDA receptor that has a lower single-channel conductance and distinct kinetic behaviour. The properties of these 'low-conductance' channels correspond to those described(17) for recombinant NMDA receptors formed by coexpression of NR1 and NR2C subunits(8,9). The NR2C subunit appears postnatally and is found predominantly in the adult cerebellum(6-8). Our data demonstrate developmental changes in NMDA-receptor properties at the single-channel level, and suggest that is the cerebellum the expression of a specific subunit protein results in a distinct form of native receptor.	UNIV TOKYO, FAC MED,INST BRAIN RES,DEPT NEUROPHYSIOL,BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo	FARRANT, M (corresponding author), UCL, DEPT PHARMACOL, GOWER ST, LONDON WC1E 6BT, ENGLAND.		Feldmeyer, Dirk/H-5940-2013; Takahashi, Tomoyuki/G-5951-2015	Feldmeyer, Dirk/0000-0002-1716-8972; Takahashi, Tomoyuki/0000-0002-8771-7666; Farrant, Mark/0000-0002-9918-0376; Cull-Candy, Stuart G/0000-0002-0831-8326	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTMAN J, 1972, J COMP NEUROL, V145, P465, DOI 10.1002/cne.901450403; BLANTON MG, 1992, J NEUROPHYSIOL, V67, P1185, DOI 10.1152/jn.1992.67.5.1185; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; CULLCANDY SG, 1987, NATURE, V325, P525, DOI 10.1038/325525a0; DANGELO E, 1993, NEUROSCIENCE, V53, P121, DOI 10.1016/0306-4522(93)90290-V; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; GARTHWAITE G, 1987, DEV BRAIN RES, V36, P288, DOI 10.1016/0165-3806(87)90034-4; GARTHWAITE J, 1989, NEUROSCIENCE, V29, P401, DOI 10.1016/0306-4522(89)90067-5; GIBB AJ, 1992, J PHYSIOL-LONDON, V456, P143, DOI 10.1113/jphysiol.1992.sp019331; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAMORI J, 1983, J COMP NEUROL, V220, P365, DOI 10.1002/cne.902200402; HESTRIN S, 1992, NATURE, V357, P686, DOI 10.1038/357686a0; HOWE JR, 1991, J PHYSIOL-LONDON, V432, P143, DOI 10.1113/jphysiol.1991.sp018381; ISHII T, 1993, J BIOL CHEM, V268, P2836; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; RABACCHI S, 1992, SCIENCE, V256, P1823, DOI 10.1126/science.1352066; ROSSI DJ, 1993, NEUROPHARMACOLOGY, V32, P1239, DOI 10.1016/0028-3908(93)90018-X; SAH P, 1989, SCIENCE, V246, P815, DOI 10.1126/science.2573153; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; SILVER RA, 1992, NATURE, V355, P163, DOI 10.1038/355163a0; STERN P, 1992, P ROY SOC B-BIOL SCI, V250, P271, DOI 10.1098/rspb.1992.0159; TAKAHASHI T, 1992, NEURON, V9, P1155, DOI 10.1016/0896-6273(92)90073-M; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027	31	265	267	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 24	1994	368	6469					335	339		10.1038/368335a0	http://dx.doi.org/10.1038/368335a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB985	7907398				2022-12-28	WOS:A1994NB98500046
J	BERKLEY, S				BERKLEY, S			DIAGNOSTIC-TESTS FOR SEXUALLY-TRANSMITTED DISEASES - A CHALLENGE	LANCET			English	Editorial Material											BERKLEY, S (corresponding author), ROCKEFELLER FDN,DIV HLTH SCI,NEW YORK,NY 10036, USA.								0	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					685	686		10.1016/S0140-6736(94)91575-X	http://dx.doi.org/10.1016/S0140-6736(94)91575-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907675				2022-12-28	WOS:A1994NB80900004
J	MORTIMER, PP				MORTIMER, PP			A LURKING ENDEMIC	LANCET			English	Editorial Material											MORTIMER, PP (corresponding author), CENT PUBL HLTH LAB,HEPATITIS & RETROVIRUS LAB,DIV VIRUS REFERENCE,LONDON,ENGLAND.							CHANT K, 1993, LANCET, V342, P1548, DOI 10.1016/S0140-6736(05)80112-6; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; Flaum A., 1926, ACTA MED SCAND, V16, P544; HERSH S, 1993, AIDS, V7, P1617; Laird S. M., 1947, GLASGOW MED JOUR, V28, P199; MCNEE J, 1952, BMJ-BRIT MED J, V1, P1367, DOI 10.1136/bmj.1.4773.1367; PATRASCU IV, 1993, AIDS RES HUM RETROV, V9, P99, DOI 10.1089/aid.1993.9.99; POKROVSKY VV, 1989, 5 INT C AIDS MONTR; Salaman MH, 1944, LANCET, V2, P7; Sheehan HL, 1944, LANCET, V2, P8; VICKERS J, 1994, CDR REV, V4, P1; 1922, REPORTS SALVARSAN CO, V2; 1993, MMWR, V24, P969; 1943, LANCET, V1, P83	14	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					368	370		10.1016/S0140-6736(94)91216-5	http://dx.doi.org/10.1016/S0140-6736(94)91216-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905545				2022-12-28	WOS:A1994MW28300002
J	HOFSTRA, RMW; LANDSVATER, RM; CECCHERINI, I; STULP, RP; STELWAGEN, T; LUO, Y; PASINI, B; HOPPENER, JWM; VANAMSTEL, HKP; ROMEO, G; LIPS, CJM; BUYS, CHCM				HOFSTRA, RMW; LANDSVATER, RM; CECCHERINI, I; STULP, RP; STELWAGEN, T; LUO, Y; PASINI, B; HOPPENER, JWM; VANAMSTEL, HKP; ROMEO, G; LIPS, CJM; BUYS, CHCM			A MUTATION IN THE RET PROTOONCOGENE ASSOCIATED WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE-2B AND SPORADIC MEDULLARY-THYROID CARCINOMA	NATURE			English	Article							CHROMOSOME-10; LINKAGE; DOMAINS; KINASE	MULTIPLE endocrine neoplasia type 2 (MEN 2) comprises three clinically distinct, dominantly inherited cancer syndromes. MEN 2A patients develop medullary thyroid carcinoma (MTC) and phaeochromocytoma. MEN 2B patients show in addition ganglioneuromas of the gastrointestinal tract and skeletal abnormalities. In familial MTC, only the thyroid is affected. Germ-line mutations of the RET proto-oncogene have recently been reported in association with MEN 2A and familial MTC1,2. All mutations occurred within codons specifying cysteine residues in the transition point between the RET protein extracellular and transmembrane domains. We now show that MEN 2B is also associated with mutation of the RET proto-oncogene. A mutation in codon 664, causing the substitution of a threonine for a methionine in the tyrosine kinase domain of the protein, was found in all nine unrelated MEN 2B patients studied. The same mutation was found in six out of 18 sporadic tumours.	UNIV GRONINGEN,DEPT MED GENET,ANT DEUSINGLAAN 4,9713 AW GRONINGEN,NETHERLANDS; UNIV UTRECHT HOSP,CTR CLIN GENET,DEPT INTERNAL MED & PATHOL,3584 CX UTRECHT,NETHERLANDS; INST G GASLINI,GENET MOLEC LAB,I-16148 GENOA,ITALY	University of Groningen; Utrecht University; Utrecht University Medical Center; University of Genoa; IRCCS Istituto Giannina Gaslini			Pasini, Barbara/AHI-2004-2022; Ceccherini, Isabella/P-8195-2014	Pasini, Barbara/0000-0002-4373-1212; Ceccherini, Isabella/0000-0001-8732-1955; Hofstra, Robert/0000-0001-7498-3829				CECCHERINI I, 1993, BIOCHEM BIOPH RES CO, V196, P1288, DOI 10.1006/bbrc.1993.2392; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JACKSON CE, 1979, AM J HUM GENET, V101, P704; LANDSVATER RM, 1989, GENOMICS, V4, P246, DOI 10.1016/0888-7543(89)90327-3; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NELKIN BD, 1989, CANCER RES, V49, P4114; NORUM RA, 1990, GENOMICS, V8, P313, DOI 10.1016/0888-7543(90)90287-5; ORITA M, 1989, GENOMICS, V5, P873; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1992, COLD SPRING HARBOR M; SIMPSON NE, 1987, NATURE, V328, P528, DOI 10.1038/328528a0; TAKAHASHI M, 1988, ONCOGENE, V3, P571	14	955	980	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					375	376		10.1038/367375a0	http://dx.doi.org/10.1038/367375a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	7906866				2022-12-28	WOS:A1994MT54000069
J	BUCKLEY, NA; DAWSON, AH; WHYTE, IM; HENRY, DA				BUCKLEY, NA; DAWSON, AH; WHYTE, IM; HENRY, DA			GREATER TOXICITY IN OVERDOSE OF DOTHIEPIN THAN OF OTHER TRICYCLIC ANTIDEPRESSANTS	LANCET			English	Article							DRUGS; AMITRIPTYLINE; NEWCASTLE	Epidemiological studies have implicated dothiepin in a greater number of self-poisoning deaths than would be expected from its use. We have prospectively assessed the clinical toxicity of dothiepin and other tricyclic antidepressants (TCAs) in overdose. We followed-up consecutively admitted patients with TCA poisoning managed by our department between January, 1987, and August, 1992. 75 patients had taken dothiepin, 101 amitriptyline, 83 doxepin, and 61 other TCAs. Death after TCA poisoning is rare nowadays, so we used intermediate outcome measures-general seizures, tachyarrhythmias, sedation, and QRS width on the electrocardiogram. 15 patients had seizures and 7 tachyarrhythmias. When we excluded patients who had taken more than one TCA, general seizures were more likely after dothiepin than after other TCAs (9/67 vs 5/220) as were arrhythmias (4/67 vs 3/220). Rates of other complications were similar. The dothiepin group had ingested a larger dose, attributable to the larger average tablet strength, than patients who took other TCAs. The odds ratio for seizures with dothiepin versus other TCAs was 6.7 (95% Cl 2.2-20.7) unadjusted and 7.1 (2.2-23.2) after adjustment for sex, age, and ingested dose. The corresponding odds ratios for arrhythmias were 4.6 (1.0-21.1) and 3.4 (0.7-16.3). Dothiepin in overdose seems to be proconvulsant. Patients with only minor sedation and normal limb-lead QRS width may still have major complications. Consideration should be given to the use of other antidepressants in patients at risk of seizures or suicide. Regulatory authorities should review the need for a 75 mg strength tablet of any TCA.			BUCKLEY, NA (corresponding author), MATER MISERICORDIAE HOSP,DEPT CLIN PHARMACOL & TOXICOL,NEWCASTLE,NSW 2298,AUSTRALIA.		Dawson, Andrew/D-5085-2012; Whyte, Ian/A-1621-2010; Buckley, Nicholas A/D-4030-2012; Dawson, Andrew H/U-8041-2019; Henry, David/AAJ-4332-2020; Henry, David/AAU-4650-2020	Dawson, Andrew/0000-0002-8047-397X; Whyte, Ian/0000-0001-7693-3948; Buckley, Nicholas A/0000-0002-6326-4711; Dawson, Andrew H/0000-0002-8047-397X; Henry, David/0000-0003-2934-2242; Henry, David/0000-0001-7169-7704				BARNES RJ, 1968, BMJ-BRIT MED J, V3, P222, DOI 10.1136/bmj.3.5612.222; BOEHNERT MT, 1985, NEW ENGL J MED, V313, P474, DOI 10.1056/NEJM198508223130804; CALLAHAM M, 1985, ANN EMERG MED, V14, P29; CASSIDY S, 1987, BRIT MED J, V295, P1021, DOI 10.1136/bmj.295.6605.1021; FOULKE GE, 1986, AM J EMERG MED, V4, P496, DOI 10.1016/S0735-6757(86)80002-X; FROMMER DA, 1987, JAMA-J AM MED ASSOC, V257, P521, DOI 10.1001/jama.257.4.521; HARDWICKE C, 1986, MED J AUSTRALIA, V144, P453, DOI 10.5694/j.1326-5377.1986.tb101046.x; HOLLISTER LE, 1981, DRUGS, V22, P129, DOI 10.2165/00003495-198122020-00003; HULTEN BA, 1983, ACTA MED SCAND, V213, P275; JACOBSEN D, 1984, HUM TOXICOL, V3, P93, DOI 10.1177/096032718400300203; KING LA, 1983, MED SCI LAW, V23, P193, DOI 10.1177/002580248302300307; KOPPEL C, 1922, HUM EXP TOXICOL, V11, P458; LANCASTER SG, 1989, DRUGS, V38, P123, DOI 10.2165/00003495-198938010-00005; LEVITT MA, 1986, AM J EMERG MED, V4, P121, DOI 10.1016/0735-6757(86)90155-5; MONTGOMERY SA, 1987, PSYCHOPHARMACOLOGY, V92, P265; MONTGOMERY SA, 1989, ACTA PSYCHIAT SCAND, V80, P47, DOI 10.1111/j.1600-0447.1989.tb03046.x; MYERS JB, 1981, MED J AUSTRALIA, V2, P402, DOI 10.5694/j.1326-5377.1981.tb101028.x; NIEMANN JT, 1986, AM J CARDIOL, V57, P1154, DOI 10.1016/0002-9149(86)90691-0; PRESCOTT LF, 1985, BRIT MED J, V290, P1633, DOI 10.1136/bmj.290.6482.1633; STARKEY IR, 1980, Q J MED, V193, P33; STROM J, 1984, ACTA ANAESTH SCAND, V28, P666, DOI 10.1111/j.1399-6576.1984.tb02142.x; THORSTRAND C, 1976, ACTA MED SCAND, V199, P337; WEDIN GP, 1986, ANN EMERG MED, V14, P797; 1991, DATA AUSTR DRUG UTIL	24	78	78	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 15	1994	343	8890					159	162		10.1016/S0140-6736(94)90940-7	http://dx.doi.org/10.1016/S0140-6736(94)90940-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7904010				2022-12-28	WOS:A1994MQ86900016
J	LENG, GC				LENG, GC			DEPRESSION FOLLOWING MYOCARDIAL-INFARCTION	LANCET			English	Editorial Material							VARIABLES; MORTALITY				LENG, GC (corresponding author), UNIV EDINBURGH,WOLFSON UNIT PREVENT PERIPHERAL VASC DIS,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND.							AHERN DK, 1990, AM J CARDIOL, V66, P59, DOI 10.1016/0002-9149(90)90736-K; CARNEY RM, 1987, AM J CARDIOL, V60, P1273, DOI 10.1016/0002-9149(87)90607-2; CAY EL, 1972, J PSYCHOSOM RES, V16, P425, DOI 10.1016/0022-3999(72)90068-2; DALY LE, 1983, BMJ-BRIT MED J, V287, P324, DOI 10.1136/bmj.287.6388.324; LADWIG KH, 1991, EUR HEART J, V12, P959; LLOYD GG, 1978, BRIT MED J, V2, P1453, DOI 10.1136/bmj.2.6150.1453; SCHLEIFER SJ, 1989, ARCH INTERN MED, V149, P1785, DOI 10.1001/archinte.149.8.1785; STERN MJ, 1977, ARCH INTERN MED, V137, P1680, DOI 10.1001/archinte.137.12.1680; VERWOERDT A, 1964, GERIATRICS, V19, P856	9	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					2	3		10.1016/S0140-6736(94)90867-2	http://dx.doi.org/10.1016/S0140-6736(94)90867-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905042				2022-12-28	WOS:A1994MN93700003
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW DEVICE APPROVED FOR USE BY PARAPLEGICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	1994	271	23					1818	1818						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP959	7910857				2022-12-28	WOS:A1994NP95900006
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PACLITAXEL APPROVED FOR TREATMENT OF CERTAIN BREAST-CANCER PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	1994	271	23					1818	1818						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP959	7910857				2022-12-28	WOS:A1994NP95900005
J	SASIENI, P				SASIENI, P			ENDOMETRIOSIS DURING TAMOXIFEN TREATMENT	LANCET			English	Letter											SASIENI, P (corresponding author), IMPERIAL CANC RES FUND, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.			Sasieni, Peter/0000-0003-1509-8744				VANLEEUWEN FE, 1994, LANCET, V343, P448, DOI 10.1016/S0140-6736(94)92692-1	1	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 16	1994	343	8903					978	978		10.1016/S0140-6736(94)90103-1	http://dx.doi.org/10.1016/S0140-6736(94)90103-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909033				2022-12-28	WOS:A1994NF70000047
J	POWLES, TJ; ASHLEY, S				POWLES, TJ; ASHLEY, S			ENDOMETRIOSIS DURING TAMOXIFEN TREATMENT	LANCET			English	Letter											POWLES, TJ (corresponding author), ROYAL MARSDEN HOSP,SUTTON SM2 5PT,SURREY,ENGLAND.			Sasieni, Peter/0000-0003-1509-8744					0	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					978	978		10.1016/S0140-6736(94)90103-1	http://dx.doi.org/10.1016/S0140-6736(94)90103-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909033				2022-12-28	WOS:A1994NF70000049
J	HARDELL, L				HARDELL, L			ENDOMETRIOSIS DURING TAMOXIFEN TREATMENT	LANCET			English	Letter											HARDELL, L (corresponding author), OREBRO MED CTR HOSP, DEPT ONCOL, S-70185 OREBRO, SWEDEN.			Sasieni, Peter/0000-0003-1509-8744				HARDELL L, 1988, LANCET, V2, P1432	1	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 16	1994	343	8903					978	978		10.1016/S0140-6736(94)90103-1	http://dx.doi.org/10.1016/S0140-6736(94)90103-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909033				2022-12-28	WOS:A1994NF70000050
